{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "00feb670",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/leonardo/miniconda3/envs/rag_env/lib/python3.10/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "/home/leonardo/miniconda3/envs/rag_env/lib/python3.10/site-packages/torch/cuda/__init__.py:184: UserWarning: CUDA initialization: Unexpected error from cudaGetDeviceCount(). Did you run some cuda functions before calling NumCudaDevices() that might have already set an error? Error 804: forward compatibility was attempted on non supported HW (Triggered internally at /pytorch/c10/cuda/CUDAFunctions.cpp:119.)\n",
      "  return torch._C._cuda_getDeviceCount() > 0\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "from PyPDF2 import PdfReader\n",
    "import unicodedata\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "from langchain_core.documents import Document\n",
    "from langchain_community.document_loaders import PyPDFDirectoryLoader\n",
    "import os\n",
    "from get_embedding_function import get_embedding_function\n",
    "from langchain_chroma import Chroma\n",
    "pdf_path = \"/home/leonardo/Documents/python recap/guideline-170-en.pdf\"\n",
    "reader = PdfReader(pdf_path)\n",
    "def remove_punct(text):\n",
    "    return re.sub(r'[^\\w\\s]','', text)\n",
    "\n",
    "def to_lower(text):\n",
    "    return text.lower()\n",
    "\n",
    "from nltk.corpus import stopwords\n",
    "\n",
    "stop_words = set(stopwords.words(\"english\"))\n",
    "\n",
    "def remove_stopwords(text):\n",
    "    return \" \".join([word for word in text.split() if word not in stop_words])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "797cc875",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "text = \"\"\n",
    "for page in reader.pages:\n",
    "    text += page.extract_text()\n",
    "    text_1 = unicodedata.normalize(\"NFKD\", text)\n",
    "    text_1 = re.sub(r'Exported on: .*', '', text_1)\n",
    "    text_1 = remove_punct(text_1)\n",
    "    \n",
    "    text_2 = to_lower(text_1)\n",
    "    text_3 = remove_stopwords(text_2)\n",
    "    \n",
    "with open(\"clean_text\", 'w', encoding='unicode-escape') as f:\n",
    "    f.write(text_3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "112dac7c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "page_content='Page 1 / 409\n",
      "Exported on: 30/01/2025\n",
      "Clinical guidelines - Diagnosis and treatmentmanual\n",
      "For curative programmes in hospitals and dispensariesGuidance for prescribing\n",
      " \n",
      " \n",
      "© Médecins Sans Frontières\n",
      "All rights reserved for all countries. No reproduction, translation and adaptation may be done without the prior\n",
      "permission of the Copyright owner.\n",
      "We're working to ﬁx some technical issues in the MSF Guidelines app affecting ofﬂine access ×' metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 0, 'page_label': '1'}\n"
     ]
    }
   ],
   "source": [
    "\n",
    "DATA_PATH = \"data\"\n",
    "\n",
    "\n",
    "\n",
    "def load_documents():\n",
    "    document_loader = PyPDFDirectoryLoader(DATA_PATH)\n",
    "    return document_loader.load()\n",
    "\n",
    "docs = load_documents()\n",
    "print(docs[0])\n",
    "def split_documents(documents: list[Document]):\n",
    "    text_splitter = RecursiveCharacterTextSplitter(\n",
    "        chunk_size=800,\n",
    "        chunk_overlap=80,\n",
    "        length_function=len,\n",
    "        is_separator_regex=False,\n",
    "    )\n",
    "    return text_splitter.split_documents(documents)\n",
    "\n",
    "chunked_docs = split_documents(docs)\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4b5e9963",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "\n",
    "\n",
    "def add_to_chroma(chunks: list[Document]):\n",
    "    db = Chroma(\n",
    "        persist_directory=CHROMA_PATH, embedding_function=get_embedding_function()\n",
    "    )\n",
    "    db.add_documents(new_chunks, ids=new_chunk_ids)\n",
    "    db.persist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "1f747b66",
   "metadata": {},
   "outputs": [],
   "source": [
    "last_page_id = None\n",
    "current_chunk_index = 0\n",
    "for chunk in chunked_docs:\n",
    "    source = chunk.metadata.get(\"source\")\n",
    "    page = chunk.metadata.get(\"page\")\n",
    "    current_page_id = f\"{source}:{page}\"\n",
    "    if current_page_id == last_page_id:\n",
    "        current_chunk_index += 1\n",
    "    else:\n",
    "        current_chunk_index = 0\n",
    "\n",
    "    chunk_id = f\"{current_page_id}:{current_chunk_index}\"\n",
    "    last_page_id = current_page_id\n",
    "    chunk.metadata[\"id\"] = chunk_id\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "2087caaf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 0, 'page_label': '1', 'id': 'data/guideline-170-en.pdf:0:0'}, page_content=\"Page 1 / 409\\nExported on: 30/01/2025\\nClinical guidelines - Diagnosis and treatmentmanual\\nFor curative programmes in hospitals and dispensariesGuidance for prescribing\\n\\xa0\\n\\xa0\\n© Médecins Sans Frontières\\nAll rights reserved for all countries. No reproduction, translation and adaptation may be done without the prior\\npermission of the Copyright owner.\\nWe're working to ﬁx some technical issues in the MSF Guidelines app affecting ofﬂine access ×\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 1, 'page_label': '2', 'id': 'data/guideline-170-en.pdf:1:0'}, page_content='Page 2 / 409\\nISBN\\n\\xa0\\nMédecins Sans Frontières. Clinical guidelines - Diagnosis and treatment manual.\\nDecember 2024\\n978-2-37585-276-7'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 2, 'page_label': '3', 'id': 'data/guideline-170-en.pdf:2:0'}, page_content='Page 3 / 409\\nTable of contents\\nAuthors/Contributors\\nPreface\\nAbbreviations and acronyms\\nChapter 1: A few symptoms and syndromes\\nChapter 2: Respiratory diseases\\nChapter 3: Gastrointestinal disorders\\nChapter 4: Skin diseases\\nChapter 5: Eye diseases\\nChapter 6: Parasitic diseases\\nChapter 7: Bacterial diseases\\nChapter 8: Viral diseases\\nChapter 9: Genito-urinary diseases\\nChapter 10: Medical and minor surgical procedures\\nChapter 11: Mental disorders in adults\\nChapter 12: Other conditions\\nAppendices\\nMain references'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 3, 'page_label': '4', 'id': 'data/guideline-170-en.pdf:3:0'}, page_content='Page 4 / 409\\nAuthors/Contributors\\n\\xa0\\n\\xa0\\nThe Clinical guidelines\\xa0\\u202fhas\\u202fbeen developed by Médecins Sans Frontières.\\n\\xa0\\nMSF would like to express its sincere gratitude to\\xa0everyone who has contributed to developing these guidelines.\\xa0Co-authors: Grace Dubois, Blandine Vasseur-Binachon, Cedric Yoshimoto\\xa0Contributors: Gabriel Alcoba, Beatriz Alonso, Mohana Amirtharajah, Haydar Alwash, Catherine Bachy, Roberta\\nCaboclo, Severine Caluwaerts, Cristina Carreno, Arlene Chua, Kate Clezy, Anne-Sophie Coutin, Marcio da Fonseca,\\nMartin De Smet, Eva Deplecker, Carolina Echeverri, Sylvie Fagard-Sultan, Roopan Gill, Sonia Guinovart, Jarred Halton,\\nKerstin Hanson, Christian Heck, Caroline Henry-Ostian, Cathy Hewison, Yves-Laurent Jackson, Carolina Jimenez, John'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 3, 'page_label': '4', 'id': 'data/guideline-170-en.pdf:3:1'}, page_content='Johnson, Rupa Kanapathipillai, Mohamad Khalife, Nadia Lafferty, Amin Lamrous, James Lee, Helen McColl, Natasha\\nMlakar, Juno Min, Miguel Palma, Isabella Panunzi, Roberta Petrucci, Nicolas Peyraud, Ernestina Repetto, Jean Rigal,\\nKoert Ritmeijer, Julia Sander, Raghda Sleit, Erin Stratta, Alex Telnov, Malcolm Townsend, Clara Van Gulik.\\xa0Speciﬁc support has been given by the\\xa0International Guidelines Publication\\xa0team:\\nEditor: Véronique Grouzard\\nLanguage editors: Mohamed Elsonbaty Ramadan, Carolina López, Anna Romero\\nLay-out designer: Evelyne Laissu'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 4, 'page_label': '5', 'id': 'data/guideline-170-en.pdf:4:0'}, page_content='Page 5 / 409\\nPreface\\n\\xa0\\n\\xa0\\nThis\\xa0guide\\xa0is designed for use by medical professionals involved in curative care at the dispensary and\\xa0primary\\xa0hospital.\\xa0We have tried to respond in the simplest and most practical way possible to the questions and problems faced by ﬁeld\\nmedical staff, using the accumulated ﬁeld experience of Médecins Sans Frontières, the recommendations of reference\\norganizations such as the World Health Organization (WHO) and specialized works in each ﬁeld.\\xa0This edition touches on the curative and, to a lesser extent, the preventive aspects of the main diseases encountered\\nin the ﬁeld. The list is incomplete, but covers the essential needs.\\xa0This\\xa0guide\\xa0is used not only in programmes supported by Médecins Sans Frontières, but also in other programmes and in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 4, 'page_label': '5', 'id': 'data/guideline-170-en.pdf:4:1'}, page_content='other contexts. It is notably an integral part of the WHO Emergency Health Kit.\\nMédecins Sans Frontières has also issued French, Spanish and Arabic editions. Editions in other languages have also\\nbeen produced in the ﬁeld.\\xa0This\\xa0guide\\xa0is a collaborative effort of medical professionals from many disciplines, all with ﬁeld experience.\\xa0Despite all efforts, it is possible that certain errors may have been overlooked in this\\xa0guide. Please inform the authors\\nof any errors detected. It is important to remember, that if in doubt, it is the responsibility of the prescribing medical'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 4, 'page_label': '5', 'id': 'data/guideline-170-en.pdf:4:2'}, page_content='professional to ensure that the doses indicated in this manual conform to the manufacturer ’s speciﬁcations.\\xa0To ensure that this guide continues to evolve while remaining adapted to ﬁeld realities, please send any\\xa0comments or\\nsuggestions.\\xa0\\xa0As treatment protocols are regularly revised, please check the monthly\\xa0updates.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 5, 'page_label': '6', 'id': 'data/guideline-170-en.pdf:5:0'}, page_content='Page 6 / 409\\nAbbreviations and acronyms\\n\\xa0\\nLast update: October 2023'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 6, 'page_label': '7', 'id': 'data/guideline-170-en.pdf:6:0'}, page_content='Page 7 / 409\\nACE angiotensin converting enzyme\\nACT\\xa0 artemisinin-based combination therapy\\xa0\\nAFB acid-fast bacillus\\nALT alanine aminotransferase\\nARV antiretroviral\\nAST aspartate\\xa0aminotransferase\\nBCG\\xa0 bacillus Calmette-Guérin\\xa0\\nBMI body mass index\\nBP\\xa0 blood pressure\\xa0\\n°C\\xa0 degree Celsius\\xa0\\nco-amoxiclav amoxicillin + clavulanic acid\\nco-trimoxazole sulfamethoxazole + trimethoprim\\nCRT capillary reﬁll\\xa0time\\nCSF cerebrospinal ﬂuid\\nCMV cytomegalovirus\\nD1 (D2, D3, etc.)\\xa0 Day 1 or ﬁrst day (Day 2 or 2 \\xa0day, Day 3 or 3 \\xa0day, etc.)nd rd\\ndl\\xa0 decilitre\\xa0\\n(e)FAST (extended) focused assessment with sonography for trauma\\nFBC full blood count\\ng\\xa0 gram\\xa0\\nHBP high blood pressure (hypertension)\\nHF heart failure\\nHIV\\xa0 human immunodeﬁciency virus\\xa0\\nHR heart rate'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 7, 'page_label': '8', 'id': 'data/guideline-170-en.pdf:7:0'}, page_content='Page 8 / 409\\nIg immunoglobulin\\nIM\\xa0 intramuscular\\xa0\\nIO intraosseous\\nIU\\xa0 international unit\\xa0\\nIV\\xa0 intravenous\\nkcal kilocalorie\\nkg\\xa0 kilogram\\xa0\\nLP lumbar puncture\\nmg\\xa0 milligram\\xa0\\nMIU million international units\\nml\\xa0 millilitre\\xa0\\nmmHg\\xa0 millimetre of mercury\\xa0\\nmmol\\xa0 millimole\\xa0\\nMSF Médecins Sans Frontières\\nNSAID nonsteroidal anti-inﬂammatory drug\\nORS oral rehydration solution or salts\\nPCP pneumocystosis\\nPCR polymerase chain reaction\\nPO\\xa0 per os – oral administration\\xa0\\nPOCUS point-of-care ultrasound\\nPRBC packed-red blood cells\\nRR respiratory rate\\nSAM severe acute malnutrition\\nSC\\xa0 subcutaneous\\nSMX sulfamethoxazole'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 8, 'page_label': '9', 'id': 'data/guideline-170-en.pdf:8:0'}, page_content='Page 9 / 409\\n\\xa0\\nSMX + TMP sulfamethoxazole + trimethoprim = co-trimoxazole\\nSpO2 arterial\\xa0blood oxygen saturation\\xa0measured\\xa0by\\xa0pulse\\xa0oximetry\\ntab\\xa0 tablet\\xa0\\nTB\\xa0 tuberculosis\\xa0\\nTMP trimethoprim\\nWHO\\xa0 World Health Organization'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 9, 'page_label': '10', 'id': 'data/guideline-170-en.pdf:9:0'}, page_content='Page 10 / 409\\nChapter 1: A few symptoms and syndromes\\nShock\\nGeneralised tonic-clonic seizures and convulsive status epilepticus\\nHypoglycaemia\\nFever\\nPain\\nAnaemia\\nDehydration\\nSevere acute malnutrition'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 10, 'page_label': '11', 'id': 'data/guideline-170-en.pdf:10:0'}, page_content='Page 11 / 409\\nShock\\nLast updated: September 2023\\n\\xa0\\nShock is a condition of widespread reduced tissue perfusion and inadequate oxygen delivery. Prolonged shock can\\nresult in cellular dysfunction and\\xa0irreversible organ failure.\\xa0Mortality is high without early diagnosis and treatment.\\nClinical features\\nShock should be suspected in patients with:\\n\\xa0In children, accurate BP measurement is difﬁcult, and hypotension is a very late sign of shock. Therefore, critically ill\\nchildren should be treated for\\xa0shock if they present at least one of the following signs: lower limb temperature\\ngradient , CRT ≥ 3 seconds, weak radial pulse or severe tachycardia .\\xa0Clinical features may vary according to the type of shock :'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 10, 'page_label': '11', 'id': 'data/guideline-170-en.pdf:10:1'}, page_content='Sign(s) of hypotension: weak pulse, low or declining blood pressure (BP) , narrow pulse pressure a \\nAcute onset of signs of tissue hypoperfusion:\\nSkin: pallor, mottled skin, sweating, cold extremities or lower limb temperature gradient , capillary reﬁll time\\n(CRT)\\xa0≥ 3 seconds\\n b \\nLungs: tachypnea, dyspnoea\\nHeart: tachycardia, which often occurs before BP decreases\\nKidney: oliguria (urine output < 0.5 to 1 ml/kg/hour) or anuria\\nBrain: thirst, anxiety, agitation, confusional state, apathy, altered mental status\\n c \\n b  d [1] \\n [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 11, 'page_label': '12', 'id': 'data/guideline-170-en.pdf:11:0'}, page_content='Page 12 / 409\\nType Speciﬁc clinical features Risk factors\\nDistributive\\nSevere vasodilation\\nand increased capillary\\npermeability resulting\\nin\\xa0maldistribution of\\nblood ﬂow\\nAnaphylaxis: likely when either of the following 2\\ncriteria develop within minutes to hours : [3] \\nInvolvement of skin and/or mucous membranes (e.g.\\ngeneralised urticaria, itching, ﬂushing, swollen\\nlips/tongue/uvula) AND ≥ 1 of the following:\\nrespiratory symptoms (wheeze, dyspnoea);\\nlow BP or symptoms of end-organ dysfunction\\n(hypotonia, incontinence);\\nsevere gastrointestinal symptoms (abdominal\\npain, repetitive vomiting).\\nHypotension, bronchospasm or laryngeal\\ninvolvement (stridor, vocal changes, odynophagia)\\nafter exposure to known or probable allergen for\\nthat patient.\\nRecent exposure to an allergen'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 11, 'page_label': '12', 'id': 'data/guideline-170-en.pdf:11:1'}, page_content='that patient.\\nRecent exposure to an allergen\\n(e.g. food, sting, medicine) or\\nhistory of anaphylaxis\\n\\xa0\\n\\xa0\\nSeptic shock: signs of infection, fever or\\nhypothermia,\\xa0altered mental status, dyspnoea,\\npersisting hypotension despite ﬂuid resuscitation [4]\\nInfection, recent surgery,\\nimmunodeﬁciency\\nCardiogenic\\nCardiac pump failure\\nIschaemia: chest pain, dyspnoea\\nArrhythmia\\nMurmur of valvular heart disease\\nHistory of cardiac disease,\\nadvanced age\\nAcute heart failure: see\\xa0Heart failure in adults, Chapter\\n12.\\nHistory of cardiac disease, viral\\nillness, immunodeﬁciency\\nHypovolaemic\\nDirect blood/ﬂuid loss\\nor ﬂuid sequestration\\ninto the extravascular\\nspace\\xa0resulting in\\ndecreased\\nintravascular volume\\nHaemorrhagic: external bleeding, signs and symptoms\\nof internal bleeding, hypotension (a)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 11, 'page_label': '12', 'id': 'data/guideline-170-en.pdf:11:2'}, page_content='of internal bleeding, hypotension (a)\\nTrauma, recent surgery, obstetric\\nhaemorrhage\\nNon-haemorrhagic: dry mouth, absence of tears,\\nsunken eyes/fontanelle, low jugular venous pressure\\n(JVP), altered mental status\\nProfuse diarrhoea and/or\\nvomiting,\\xa0intestinal obstruction\\nObstructive\\nObstruction to blood\\nﬂow to, or from, the\\nheart or great vessels\\nPulmonary embolism (PE): chest pain, tachycardia,\\ntachypnoea, hypoxia\\xa0\\nDeep vein thrombosis (DVT): leg pain, swelling, warmth\\nRecent surgery or immobilisation,\\ncancer, history of PE or DVT\\nTension pneumothorax: decreased breath sounds,\\nraised JVP, weak radial pulse, tracheal deviation\\nTrauma, invasive medical\\nprocedure\\nCardiac tamponade: pulsus paradoxus , raised JVP,\\nnarrow pulse pressure, mufﬂed heart sounds\\n (b) Trauma, immunodeﬁciency'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 11, 'page_label': '12', 'id': 'data/guideline-170-en.pdf:11:3'}, page_content='narrow pulse pressure, mufﬂed heart sounds\\n (b) Trauma, immunodeﬁciency\\n(a) In children and young adults with hypovolaemic shock, BP may be maintained initially, but subsequently declines rapidly ifﬂuid loss is not replaced.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 12, 'page_label': '13', 'id': 'data/guideline-170-en.pdf:12:0'}, page_content=\"Page 13 / 409\\nManagement\\n\\xa0Primary objective of shock management is to restore adequate tissue perfusion, demonstrated by:\\n\\xa0After initial management:\\n\\xa0On-going care:\\nBasic Life Support\\n1) Manage airways and breathing\\n(b) Pulsus paradoxus is measured by taking the patient's BP during both expiration and inspiration. It is deﬁned as a decreaseof > 10 mmHg in the SBP during inspiration compared with expiration.\\nAttend to the patient immediately even if the type of shock is not known. Call for help. Move to critical care unit if\\npossible.\\nAssess and manage A (airway), B (breathing), and C (circulation) according to Basic Life Support (see below). If\\nanaphylaxis is suspected, immediately go to speciﬁc management.\\xa0\\xa0\\nTake a rapid history to try to determine underlying cause.\\nMonitor:\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 12, 'page_label': '13', 'id': 'data/guideline-170-en.pdf:12:1'}, page_content='Take a rapid history to try to determine underlying cause.\\nMonitor:\\nurine output hourly (insert a urinary catheter)\\nHR, RR, BP, temperature, CRT, SpO, and level of consciousness2\\nPerform the following tests:\\nhaemoglobin and blood glucose level\\nmalaria rapid diagnostic test in endemic area: see Malaria, Chapter 6\\nblood culture (if available) and blood group\\nIn children, administer ceftriaxone IV : one dose of 80 mg/kg. Reassess\\xa0need for further antibiotic treatment\\naccording to\\xa0underlying cause.\\n e \\nTreat pain: see Pain, Chapter 1.\\nReturning vital signs, CRT, SpO, mental status, etc. to normal.2\\nMaintaining mean arterial pressure (MAP) > 65 mmHg in adults (or higher if patient has pre-existing hypertension). f \\nMaintaining urine output > 0.5 to 1 ml/kg/hour.\\nTake a more detailed history.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 12, 'page_label': '13', 'id': 'data/guideline-170-en.pdf:12:2'}, page_content=\"Maintaining urine output > 0.5 to 1 ml/kg/hour.\\nTake a more detailed history.\\nPerform a comprehensive physical\\xa0examination.\\nIn case of dehydration: see Dehydration, Chapter 1.\\nIn case of blunt thoracic or abdominal trauma, perform POCUS :\\xa0(e)FAST exam to evaluate for pneumothorax or\\nfree ﬂuid in pleural, pericardial and/or peritoneal spaces. Refer to surgeon as required.\\n g \\nRe-evaluate patient’s condition and response to treatment every 10 minutes until patient is stable.\\nPerform a second comprehensive physical\\xa0examination.\\nInitiate nutritional support adapted to patient's needs as soon as possible and reassess regularly. Patients have high\\nprotein and energy requirements. Enteral route is preferred.\\xa0\\nLay the patient on their back. However:\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 12, 'page_label': '13', 'id': 'data/guideline-170-en.pdf:12:3'}, page_content='Lay the patient on their back. However:\\nif spinal trauma is suspected, do not move the patient;\\nin case of anaphylaxis, the patient may prefer a sitting position.\\nIn case of altered mental status:\\nbe prepared with mask and bag if needed for ventilation;\\nremove any airway obstruction (e.g. secretions, foreign body);\\nopen airway: stand at head of bed, place one hand on the forehead and gently tilt the head back.\\nSimultaneously, place the ﬁngertips of the other hand under the chin and lift the chin. If suspicion of spinal\\ntrauma, do not move the neck. Instead, place heels of both hands on patient’s parietal areas, and use index and\\nmiddle ﬁngers of both hands to push the angle of mandible anteriorly (jaw thrust)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 13, 'page_label': '14', 'id': 'data/guideline-170-en.pdf:13:0'}, page_content='Page 14 / 409\\n\\xa02) Maintain circulation\\nAnaphylaxis\\nRepeat after 5 minutes if no or poor clinical improvement (up to a total of 3 IM injections).\\xa0\\nRepeat bolus once if signs of poor perfusion persist after 15 minutes.\\nSeptic shock\\nLook for source of infection. If possible, take specimens for culture before starting antibiotic treatment.\\nif needed, insert an oropharyngeal airway.\\nAuscultate lungs to assess ventilation.\\nAdminister 10 to 15 litres/minute\\xa0of oxygen with mask to maintain SpO > 94%.2\\nIf SpOremains ≤ 94% with oxygen, see If resources allow.2 \\nControl bleeding:\\napply direct manual pressure and/or compression/haemostatic dressing to the wound;\\nin case of massive life-threatening bleeding from an extremity (e.g. leg) not controlled by direct pressure: apply a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 13, 'page_label': '14', 'id': 'data/guideline-170-en.pdf:13:1'}, page_content='windlass tourniquet . h [5] \\nInsert 2 peripheral IV lines (catheters 20-22G in children and 14-18G in adults) or an intraosseous (IO) needle.\\nAdminister Ringer lactate (RL) , glucose 5%-Ringer lactate (G5%-RL) , and/or blood, following speciﬁc\\nmanagement described below. Reassess before giving additional ﬂuid therapy. Monitor for ﬂuid overload ,\\nespecially in patients at risk, e.g. severely malnourished children;\\xa0patients with severe malaria, heart disease, severe\\nanaemia; older patients.\\xa0\\xa0\\n i  j \\n k \\nMaintain normal body temperature.\\nIf unable to maintain BP, see If resources allow.\\nRemove exposure to causal agent.\\nAdminister epinephrine\\xa0(adrenaline) IM into the mid-anterolateral thigh. Use undiluted solution and a 1 ml syringe\\ngraduated in 0.01 ml : [6]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 13, 'page_label': '14', 'id': 'data/guideline-170-en.pdf:13:2'}, page_content='graduated in 0.01 ml : [6] \\nChildren under 6 months: 0.1 to 0.15 ml\\nChildren 6 months to 5 years: 0.15 ml\\nChildren 6 to 12 years: 0.3 ml\\nChildren over 12 yearsand adults: 0.5 ml l \\nMonitor HR, BP, CRT and clinical response.\\nIn case of stridor, administer\\xa0nebulized epinephrine: 0.5 mg/kg/dose (max. 5 mg) in 5 ml of 0.9% sodium chloride\\nover 10 to 15 minutes\\nIf SpO is < 94%, ventilate with bag mask.2\\nAdminister a bolus of RL:\\nChildren: 10 ml/kg as quickly as possible\\nAdults: 500 ml as quickly as possible\\nIf shock persists after 3 IM injections of epinephrine, in particular if unable to maintain BP, see If ressources allow.\\nAfter initial treatment with epinephrine and IV ﬂuids, some patients (e.g. patients requiring continuing treatment after'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 13, 'page_label': '14', 'id': 'data/guideline-170-en.pdf:13:3'}, page_content='2 doses of epinephrine IM or patients with ongoing asthma or shock)\\xa0may beneﬁt from a short course of\\ncorticosteroid therapy. When the patient is stable,\\xa0prednisolone PO : 1 to 2 mg/kg (max. 50 mg) once daily in the\\nmorning for 3 to 5 days. Use an\\xa0IV corticosteroid only if the patient cannot take oral treatment.\\nFluid therapy:\\nChildren and adolescents under 15 years:\\xa0G5%-RL\\xa0solution as maintenance ﬂuids (see Appendix 1)\\nAdolescents 15 years and over and adults: one bolus of 250 to 500 ml of RL as quickly as possible\\nAntibiotic treatment:\\nStart antibiotics according to the suspected origin of infection within 1 hour of presentation (see\\xa0tables\\nbelow).\\n [7]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 14, 'page_label': '15', 'id': 'data/guideline-170-en.pdf:14:0'}, page_content='Page 15 / 409\\n\\xa0\\nIf source is unknown, administer a broad-spectrum antibiotic to cover gram-positive, gram-negative, and\\nanaerobic bacteria. If possible, take into account local epidemiology (rates and types of resistance).\\nDifferentiate community acquired sepsis and nosocomial sepsis as pathogens and rates of resistance may be\\ndifferent. Simplify the antibiotic treatment (to narrower spectrum) whenever possible.\\nReassess treatment daily:\\nIf culture results are available:\\xa0adapt treatment accordingly.\\nIf improvement after 24 to 48 hours: change to oral route, however some foci (e.g. meningitis) require\\nprolonged IV treatment.\\nIf no improvement after 48 to 96 hours: consider resistant pathogen , in particular in patients with'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 14, 'page_label': '15', 'id': 'data/guideline-170-en.pdf:14:1'}, page_content='immunodeﬁciency or recent (in the last month) hospitalisation or antibiotic use\\xa0and adapt treatment\\naccordingly.\\n m \\nOther measures to control infection:\\nIf suspected catheter-related infection, insert a new catheter in another site and remove the suspected\\ncatheter.\\nDrain soft-tissue abscess (see Cutaneous abscess, Chapter 10);\\xa0irrigate and debride traumatic wounds. Refer to\\nsurgeon if needed for debridement, drainage, relieving obstruction, etc.\\nTreatment of fever: see Fever, Chapter 1.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 15, 'page_label': '16', 'id': 'data/guideline-170-en.pdf:15:0'}, page_content='Page 16 / 409\\nOrigin\\xa0 Antibiotics Alternatives (c)\\nCutaneous\\nstaphylococci, streptococci (d)\\ncloxacillin\\n(+ vancomycin if risk factors\\nfor MRSA ) (e) \\ncefazolin\\n(or vancomycin if risk factors for\\nMRSA )\\n (f)\\n (e) \\nPulmonary\\npneumococci, H. inﬂuenzae\\nceftriaxone + azithromycin\\n(+ gentamicin if risk factors\\nfor MDR gram negative\\nbacteria ) (g) \\nclindamycin + ciproﬂoxacin +\\ndoxycyline\\nIntestinal or biliary\\nenterobacteria, anaerobic bacteria,\\nenterococci\\nceftriaxone +\\nmetronidazole\\n(+ gentamicin if risk factors\\nfor MDR gram negative\\nbacteria )\\n(+ ampicillin if biliary source)\\n (g) \\nclindamycin + ciproﬂoxacin\\nGynaecological \\nstreptococci, gonococci, anaerobic\\nbacteria, E. coli\\nceftriaxone +\\nmetronidazole +\\nazithromycin\\nclindamycin + gentamicin +\\nazithromycin\\nUrinary\\nenterobacteria, enterococci'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 15, 'page_label': '16', 'id': 'data/guideline-170-en.pdf:15:1'}, page_content='clindamycin + gentamicin +\\nazithromycin\\nUrinary\\nenterobacteria, enterococci\\nceftriaxone\\n(+ amikacin if risk factors\\nfor pseudomonas ) (h) \\nmeropenem\\n(+ amikacin if risk factors for\\npseudomonas ) (h) \\nCentral nervous system See Bacterial meningitis, Chapter 7.\\nOther or undetermined\\nampicillin + gentamicin in\\nchildren\\nceftriaxone\\nor cloxacillin + amikacin in children\\nceftriaxone\\n(+ amikacin if risk factors\\nfor pseudomonas ) in\\nadults\\n (h) \\nclindamycin + ciproﬂoxacin in adults\\n(c) Only if ﬁrst-line antibiotic is not available or in allergic patients.\\n(d) For necrotising infections, see Necrotising infection of skin and soft tissues, Chapter 10.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 15, 'page_label': '16', 'id': 'data/guideline-170-en.pdf:15:2'}, page_content='(e) Risk factors for MRSA: prior MRSA infection, recent hospitalisation or antibiotic use, recurrent skin infection, chronicwounds, invasive device, settings with high rates of MRSA.\\n(f) Do not administer if severe beta-lactam allergy\\n(g) Risk factors for multiresistant (MDR) gram negative bacteria: recent hospitalisation in intensive care unit or antibiotic use.\\n(h) Risk factors for pseudomonas: immunodeﬁciency, recent hospitalisation or antibiotic use, burns or presence of invasivedevice.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 16, 'page_label': '17', 'id': 'data/guideline-170-en.pdf:16:0'}, page_content='Page 17 / 409\\nAntibiotics Children over 1 month Adults\\namikacin IM or slow\\xa0IV injection\\nover 3 minutes\\n15 mg/kg (max. 1.5 g) once daily 15 mg/kg once daily\\nampicillin\\xa0IV infusion over\\n30 minutes\\n50 mg/kg (max. 2 g) every 8 hours 2 g every 6 to 8 hours\\n(2 g every 4 hours for meningitis)\\nazithromycin PO (by NGT)\\n\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\xa0\\n10 to 20 mg/kg (max. 500 mg) once\\ndaily\\n500 mg to 1 g once daily\\ncefazolin slow IV injection over 3\\nminutes or IV infusion over 30\\nminutes\\n25 mg/kg (max. 3 g) every 12 hours 2 g every 8 hours\\nceftriaxone\\xa0slow IV\\xa0injection\\nover 3 minutes or\\xa0IV infusion over\\n30 minutes\\n80 mg/kg (max. 4 g) once daily (100\\nmg/kg, max. 4 g, once daily for\\nmeningitis)\\n2 g once daily (2 g every 12 hours for\\nmeningitis)\\nciproﬂoxacin\\xa0PO (by NGT) 15 to 20 mg/kg (max. 750 mg) every'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 16, 'page_label': '17', 'id': 'data/guideline-170-en.pdf:16:1'}, page_content='meningitis)\\nciproﬂoxacin\\xa0PO (by NGT) 15 to 20 mg/kg (max. 750 mg) every\\n12 hours\\n500 to 750 mg every 12 hours\\nciproﬂoxacin IV infusion over\\n60 minutes\\n10 mg/kg (max. 400 mg) every 8\\nhours\\n400 mg every 8 to 12 hours\\n\\xa0\\nclindamycin\\xa0IV infusion over\\n30 minutes\\n10 mg/kg (max. 600 mg) every 8\\nhours\\n600 to 900 mg every 8 hours\\ncloxacillin\\xa0IV infusion over\\n60 minutes\\n25 to 50 mg/kg (max. 2 g) every 6\\nhours\\n2 g every 6 hours\\ndoxycycline PO (by NGT) 4.4\\xa0mg/kg (max. 200 mg) on D1 then\\n2.2 mg/kg (max. 100 mg) every 12\\nhours\\n200 mg on D1 then 100 mg every 12\\nhours\\ngentamicin\\xa0IM or slow IV\\ninjection over 3 minutes\\n7.5 mg/kg once daily\\n\\xa0\\n5 mg/kg once daily\\nmeropenem\\xa0IV infusion over\\n15 or 30 minutes\\n20 mg/kg (max. 2 g) every 8 hours 2 g every 8 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 16, 'page_label': '17', 'id': 'data/guideline-170-en.pdf:16:2'}, page_content='15 or 30 minutes\\n20 mg/kg (max. 2 g) every 8 hours 2 g every 8 hours\\nmetronidazole\\xa0PO (by NGT) 10 mg/kg (max. 500 mg) every 8\\nhours\\n500 mg every 8 hours\\nmetronidazole\\xa0IV infusion\\nover 30 minutes\\n10 mg/kg (max. 500 mg) every 8\\nhours\\n500 mg every 8 hours\\nvancomycin IV\\xa0infusion over 15 mg/kg (max. 500 mg) every 6 15 to 20 mg/kg (max. 2 g) every 12 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 17, 'page_label': '18', 'id': 'data/guideline-170-en.pdf:17:0'}, page_content='Page 18 / 409\\n\\xa0\\nCardiogenic shock\\nHypovolemic non-haemorrhagic shock\\nHypovolaemic haemorrhagic shock\\nIn order to prevent the “lethal trauma triad” of hypothermia, acidosis and coagulopathy:\\nRepeat if\\xa0needed.\\nWhen blood is available, stop RL and administer blood only.\\nThen immediately start a second dose, administered by IV infusion over 8 hours.\\nObstructive shock\\nThe management described up to this point will provide only temporary stabilization. Treat the cause or refer for\\naetiological treatment:\\n\\xa0\\n\\xa0\\n f\\n60 to 240\\xa0minutes hours\\xa0\\nAdminister RL with extreme caution and monitor closely for signs of ﬂuid overload:\\nAdults: 100 to 250 ml over 30 minutes\\nSubsequent ﬂuid administration should be based on thorough patient assessment, including urinary output,\\nmental status and SpO.2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 17, 'page_label': '18', 'id': 'data/guideline-170-en.pdf:17:1'}, page_content='mental status and SpO.2\\nVasopressors are often required to maintain BP, see If resources allow.\\nIn case of acute heart failure, see Heart failure in adults, Chapter 12.\\nArrhythmias should be managed according to Advanced Life Support techniques as appropriate and where\\navailable.\\nAdminister RL:\\nChildren under 1 year: 30 ml/kg over 1 hour then 70 ml/kg over 5 hours\\nChildren/adolescents 1 to 14 years: 30 ml/kg over 30 minutes then 70 ml/kg over 2.5 hours\\nAdolescents 15 years and over and adults: 250 to 500 ml as quickly as possible (to be repeated once if required)\\nthen adjusted to patient’s condition, providing up to 70 ml/kg over 2.5 hours\\nDetermine blood group and if needed transfuse, as quickly as possible:\\nChildren under 20 kg: 20 ml/kg of whole blood'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 17, 'page_label': '18', 'id': 'data/guideline-170-en.pdf:17:2'}, page_content='Children under 20 kg: 20 ml/kg of whole blood\\nChildren 20 kg and over and adults: an adult unit of whole blood\\nIf blood is not immediately available, administer a bolus of RL with caution (i.e.\\xa0minimize the use of RL) while waiting\\nfor blood:\\nChildren: 20 ml/kg as quickly as possible\\nAdults: 250 to 500 ml as quickly as possible\\nWarm the patient (blankets, warm room, warm IV ﬂuids).\\nIn case of trauma presenting within 3 hours, administer tranexamic acid slow IV (over 10 minutes):\\nChildren: 15 mg/kg (max. 1 g)\\nAdults: 1 g\\nIn case of postpartum haemorrhage, refer to the guide Essential obstetric and newborn care, MSF.\\nRefer to surgery if needed.\\nPulmonary embolism: anticoagulation +/- thrombolysis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 17, 'page_label': '18', 'id': 'data/guideline-170-en.pdf:17:3'}, page_content='Pulmonary embolism: anticoagulation +/- thrombolysis.\\nTension pneumothorax: needle decompression/ﬁnger thoracostomy, followed by insertion of chest tube.\\nCardiac tamponade: pericardial tap.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 18, 'page_label': '19', 'id': 'data/guideline-170-en.pdf:18:0'}, page_content=\"Page 19 / 409\\nIf resources allow:\\n\\xa0These protocols are for peripheral IV administration. Titrate according to patient's clinical situation. Refer to\\nmanagement objectives\\xa0(including BP)\\xa0under Management.\\xa0\\nManage airways and breathing:\\ncomplete airway obstruction: endotracheal intubation or cricothyroidotomy\\nrespiratory failure: non-invasive or invasive mechanical ventilation\\nMaintain circulation:\\nIf unable to achieve management objectives (in particular BP) using ﬂuid therapy (and no signs of ﬂuid\\noverload are present) or, in the case of anaphylaxis, if shock persists after 3 IM epinephrine injections,\\nvasopressors-inotropes (see below) can be used in the following conditions:\\nclose monitoring in a critical care unit;\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 18, 'page_label': '19', 'id': 'data/guideline-170-en.pdf:18:1'}, page_content='close monitoring in a critical care unit;\\na large peripheral IV catheter (proximal forearm or above), a central venous catheter or an IO line\\ndedicated to the infusion;\\n n \\nuse of an electric syringe or pump to control ﬂow rate ; o \\nintensive monitoring of drug administration, particularly during syringe changes.\\nAll infused volumes must be accounted for when recording ﬂuid balance.\\n\\xa0 Norepinephrine (NEP) tartrate (i) Epinephrine (EPN) (adrenaline)\\nIndication Children: 2 choice \\nAdults: 1  choice\\nnd \\nst\\nChildren: 1  choice \\nAdults: 2  choice\\nst\\nnd\\nPreparation\\nof\\ndiluted\\nsolution (j)\\nChildren:\\nAdd 1 ml (2 mg) of NEP tartrateto 39 ml\\nof 0.9% NaCl to obtain a 0.05 mg/ml (50\\nmicrograms/ml) solution.\\n\\xa0 \\nChildren:\\nAdd 2 ml (2 mg) of EPN to 38 ml of 0.9% NaCl'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 18, 'page_label': '19', 'id': 'data/guideline-170-en.pdf:18:2'}, page_content='Children:\\nAdd 2 ml (2 mg) of EPN to 38 ml of 0.9% NaCl\\nto\\xa0obtain a 0.05 mg/ml\\xa0(50 micrograms/ml)\\nsolution.\\nAdults:\\nAdd 2 ml (4 mg) of NEP tartrateto 38 ml\\nof 0.9% NaCl to obtain a 0.1 mg/ml (100\\nmicrograms/ml) solution.\\n\\xa0 \\nAdults:\\nAdd 4 ml (4 mg) of EPN to 36 ml of 0.9% NaCl\\nto\\xa0obtain a 0.1 mg/ml\\xa0(100 micrograms/ml)\\nsolution.\\nStarting\\nrate (k)\\n0.1 microgram/kg/minute\\nRate for\\nincreasing \\xa0 (k) \\nIncrease by 0.05 micrograms/kg/minute every 10 minutes for the ﬁrst hour, then every hour.\\nMax. 1 microgram/kg/minute.\\nRate for\\ndecreasing \\xa0 (k) \\nTaper down doses when management objectives are attained.\\xa0Do not stop abruptly.\\nDecrease by 0.05 micrograms/kg/minute every hour.\\n(i) 2 mg of NEP tartrate = 1 mg of NEP base.\\n(j) 0.9% sodium chloride or 5% glucose or RL can be used for dilution.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 18, 'page_label': '19', 'id': 'data/guideline-170-en.pdf:18:3'}, page_content='(j) 0.9% sodium chloride or 5% glucose or RL can be used for dilution.\\n(k) The infusion rate is\\xa0calculated as follows: [desired dose (microgram/kg/min) x weight (kg) x 60 min] ÷ concentration(microgram/ml).\\nOngoing care: measure serum potassium, magnesium, calcium and phosphate levels and correct any\\nabnormalities. Additional investigations (e.g. X-rays,\\xa0other laboratory tests) may be indicated, depending on\\naetiology suspected.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:0'}, page_content='Page 20 / 409\\n\\xa0\\nReferences\\nFootnotes\\n(a) Hypotension is based on systolic blood pressure (SBP) in adults: SBP < 90 mmHg or decrease in SBP\\xa0≥ 40 mmHg frombaseline or mean arterial pressure MAP < 65 mmHg.\\xa0Shock is often accompanied by hypotension but may also occur withnormal or elevated BP.\\n(b) Run the back of the hand from the toe to the knee. A notable temperature change from the cold foot to the warm knee is apositive temperature gradient, indicating distal hypoperfusion.\\n(c) Critically ill-appearing child: weak grunting or crying, drowsy and difﬁcult to arouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.\\n(d) Children under 1 year: > 180 bpm; Children 1 to 5 years: > 160 bpm; Children 5 years and over: > 140 bpm.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:1'}, page_content='(e) For IV administration of ceftriaxone, dissolve only in water for injection.\\n(f) MAP = diastolic BP (DBP) + 1/3 (SBP-DBP). A patient with BP 90/60 has a MAP = 60 + 1/3 (90-60) = 70.\\n(g) POCUS should only be performed and interpreted by trained clinicians.\\n(h) The patient should receive surgery within 1 hour of the application of a windlass tourniquet. After 1 hour, there is a risk ofischaemic injury of the limb. If surgery is not possible and the tourniquet is required to save the patient’s life, it should beleft in place. Any tourniquet that has been applied for more than 6 hours should be left in place until arrival at a facilitycapable of providing deﬁnitive surgical care.\\n(i) Crystalloids should be used. Colloids (e.g. modiﬁed ﬂuid gelatin, albumin) are not recommended.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:2'}, page_content='(j) Remove 50 ml of RL from a 500 ml RL bottle or bag, then add 50 ml of 50% glucose to the remaining 450 ml of RL to obtain500 ml of 5%\\xa0glucose-RL solution.\\n(k) In case of ﬂuid overload: sit the patient up, reduce the infusion rate to a minimum and administer furosemide IV (0.5 mg/kg inchildren; 40 mg in adults). Monitor the patient closely over 30 minutes and assess for underlying cardiorespiratory or renaldisease. Once the patient is stabilised, reassess the necessity of continuing IV ﬂuids. If IV ﬂuids are still required, re-start athalf the previous infusion rate and monitor closely.\\n(l) If small or prepubertal children, administer 0.3 ml of epinephrine.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:3'}, page_content='(l) If small or prepubertal children, administer 0.3 ml of epinephrine.\\n(m)For example: methicillin-resistant Staphylococcus aureus (MRSA), pseudomonas species, and gram-negative bacteria withextended-spectrum beta-lactamase (ESBL) activity.\\n(n) When using a peripheral vein, monitor infusion site closely for signs of extravasation, in particular in young children.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:4'}, page_content='(o) If no system to control volume delivery and ﬂow rate (e.g. syringe pump), an infusion using an infusion bag and standardpaediatric giving set can be considered in extreme situations as a temporary measure. However, it is important to considerthe risks related to this type of administration (accidental bolus or insufﬁcient dose). The infusion must be constantlymonitored to prevent any, even small, change from the prescribed rate.\\xa0\\n1. Houston KA, George EC, Maitland K. Implications for paediatric shock management in resource-limited settings: aperspective from the FEAST trial. Crit Care. 2018;22(1):119.https://doi.org/10.1186/s13054-018-1966-4'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 19, 'page_label': '20', 'id': 'data/guideline-170-en.pdf:19:5'}, page_content='2. Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of theEuropean Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795-1815.\\xa0https://doi.org/10.1007/s00134-014-3525-z\\n3. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 20, 'page_label': '21', 'id': 'data/guideline-170-en.pdf:20:0'}, page_content='Page 21 / 409\\n2020;13(10):100472. Published 2020 Oct 30.https://doi.org/10.1016/j.waojou.2020.100472\\n4. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Deﬁnitions for Sepsis and Septic Shock(Sepsis-3). JAMA. 2016;315(8):801-810.https://doi.org/10.1001/jama.2016.0288\\n5. Richey SL. Tourniquets for the control of traumatic hemorrhage: a review of the literature. World J Emerg Surg. 2007;2:28.Published 2007 Oct 24. \\xa0https://doi.org/10.1186/1749-7922-2-28\\n6. Emergency treatment of anaphylaxis. Guidelines for healthcare providers. Rescuscitation Council UK. Updated 2021[Accessed May 31 2023].https://www.resus.org.uk/sites/default/ﬁles/2021-05/Emergency%20Treatment%20of%20Anaphylaxis%20May%202021_0.pdf'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 20, 'page_label': '21', 'id': 'data/guideline-170-en.pdf:20:1'}, page_content='7. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis andseptic shock 2021. Intensive Care Med. 2021;47(11):1181-1247.\\xa0https://doi.org/10.1007/s00134-021-06506-y'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 21, 'page_label': '22', 'id': 'data/guideline-170-en.pdf:21:0'}, page_content='Page 22 / 409\\nGeneralised tonic-clonic seizures andconvulsive status epilepticus\\nLast updated:\\xa0October\\xa02024\\n\\xa0\\nGeneralised tonic-clonic\\xa0seizures are involuntary movements of both sides of the body associated with impaired or\\nloss of consciousness. They result from abnormal brain activity.\\xa0Most seizures are brief (less than 5 minutes) and resolve spontaneously. They may occur once or may recur.\\xa0In young children, seizures frequently occur in the context of fever, with no underlying causes. These are deﬁned as\\n\"febrile seizures\".\\xa0A seizure lasting longer than\\xa05\\xa0minutes\\xa0or 2 or more seizures in 5 minutes without complete restoration of baseline\\nconsciousness\\xa0between seizures is\\xa0deﬁned as \"status epilepticus\" .\\xa0Status epilepticus is a medical emergency'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 21, 'page_label': '22', 'id': 'data/guideline-170-en.pdf:21:1'}, page_content='requiring immediate management. The longer a seizure lasts, the more difﬁcult it is to stop, and the greater the risk\\nfor\\xa0permanent brain damage and death.\\xa0In pregnancy and the postpartum period, seizures\\xa0may be a manifestation of eclampsia. Refer to\\xa0Essential obstetric\\nand newborn care, MSF.\\xa0\\nClinical features\\nDuring a seizure\\nand\\nThese signs may be associated with loss of urine, breathing difﬁculty, and cyanosis.\\xa0Immediately after a seizure (postictal phase)\\nThe patient experiences fatigue and temporary symptoms such as confusional state, headache, memory loss, focal\\ndeﬁcits. Recovery usually occurs within 30 to 60 minutes but may be delayed.\\nFirst aid during a seizure\\nFebrile seizures\\n [1] [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 21, 'page_label': '22', 'id': 'data/guideline-170-en.pdf:21:2'}, page_content='First aid during a seizure\\nFebrile seizures\\n [1] [2] \\ncontraction of muscles, including respiratory muscles (tonic phase), followed by rhythmic jerking of the arms and\\nlegs (clonic phase)\\nloss of consciousness\\n [3] \\nNote the time. Call for help.\\nProtect from falls and trauma, loosen clothing.\\nMaintain airway, place patient in recovery position to avoid aspiration, do not put anything in the mouth.\\nTreat hypoglycaemia if present or administer glucose if unable to measure capillary blood glucose\\nimmediately\\xa0(see\\xa0Hypoglycaemia, Chapter 1).\\nDepending on the context:\\nAdminister oxygen if available.\\nIf febrile\\xa0seizures are likely, see Febrile seizures.\\nIn adults, thiamine\\xa0(100 mg by IV infusion in 100 ml 0.9% NaCl over 30 minutes) may be administered at the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 21, 'page_label': '22', 'id': 'data/guideline-170-en.pdf:21:3'}, page_content='same time as glucose if vitamin B deﬁciency is suspected (e.g. in case of alcohol-related seizures) .1  a \\nIf seizures stop\\xa0spontaneously in 5 minutes or less, see Postictal management.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 22, 'page_label': '23', 'id': 'data/guideline-170-en.pdf:22:0'}, page_content='Page 23 / 409\\nFebrile seizures frequently occur in children aged 6 months to 5 years with fever (usually due to viral infection) and no\\nsigns of central nervous system (CNS) infection, metabolic disturbances, or history of afebrile seizures . They may be\\neither \"simple\" or \"complex\".\\xa0\\xa0\\n\\xa0\\n\\xa0\\nStatus epilepticus\\nIn case of status epilepticus, start antiseizure medication (ASM).\\n\\xa0\\nStep 1 - First-line ASM treatment\\nStatus epilepticus in pre-hospital setting\\nStatus epilepticus in hospital setting\\n [4] \\nA simple febrile seizure is deﬁned\\xa0as a single generalised seizure, without focal signs, that lasts less than 15 minutes,\\nand does not recur within a 24-hour period . Most of these seizures last less than 5 minutes and if so,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 22, 'page_label': '23', 'id': 'data/guideline-170-en.pdf:22:1'}, page_content='no\\xa0antiseizure treatment is required. The risk of subsequent epilepsy is low after this type of\\xa0seizure. Observe the\\nchild at least until full recovery, and discharge\\xa0when child returns to neurological baseline. Give instructions for\\nhome-based management: symptomatic treatment of fever to make the child more comfortable (see Fever,\\nChapter 1) and of underlying viral infection if relevant.\\n [4] \\nA complex febrile seizure is a seizure meeting at least one the following criteria: presence of focal signs, a duration\\nmore than 15 minutes, or multiple seizures within a 24-hour period .\\xa0 [4] \\nIn all cases:\\nProvide\\xa0ﬁrst aid during a seizure.\\nAfter a seizure, see Postictal management.\\nIf a\\xa0seizure lasts more than 5 minutes or recurs within 5 minutes, start treatment for status epilepticus.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 22, 'page_label': '23', 'id': 'data/guideline-170-en.pdf:22:2'}, page_content='ASMs\\xa0may cause respiratory depression,\\xa0bradycardia, and hypotension, especially in children\\nand\\xa0older\\xa0patients.\\xa0\\nDuring and after ASM\\xa0administration:\\nhave ventilation equipment (Ambu and mask) and solutions for ﬂuid replacement ready for use,\\nmonitor RR, SpO, HR, and BP at least every 15 minutes until stable.2\\nNever administer ASMs by rapid IV injection. Reduce the administration rate in the event of\\xa0drop in RR,\\nHR, or BP.\\nAdminister one of the following benzodiazepines (BZD). The choice depends on the situation,\\xa0i.e. if seizures occur\\nin pre-hospital or hospital setting.\\nIn any case, do not administer more than 2 doses of BZD.\\nAdminister midazolam (5 mg/ml solution) by buccal or intranasalroute or diazepam (5 mg/ml solution) by rectal\\nroute.\\xa0For doses to be administered, see Table 1.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 22, 'page_label': '23', 'id': 'data/guideline-170-en.pdf:22:3'}, page_content='route.\\xa0For doses to be administered, see Table 1.\\n\\xa0\\nIf\\xa0seizures\\xa0do not stop 5\\xa0minutes after the ﬁrst dose of BZD, readminister\\xa0the same dose.\\xa0\\nIf\\xa0seizures\\xa0do not stop after the second\\xa0dose of BZD, refer urgently to hospital for treatment with second-line\\nASM(s).\\nIf\\xa0seizures\\xa0stop after 1 or 2 doses of BZD, refer to hospital for further management (aetiologic treatment and\\npotential maintenance treatment).\\nWhile awaiting transfer, monitor vital signs, administer oxygen if available to maintain SpO > 94%. If seizures stop,\\nsee Postictal management.\\n2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 23, 'page_label': '24', 'id': 'data/guideline-170-en.pdf:23:0'}, page_content='Page 24 / 409\\nCheck whether a BZD has been administered before arrival at the hospital\\xa0and the number of doses.\\xa0If one dose was\\nadministered, give a second dose. If 2 doses were administered, start\\xa0Step 2 - Second-line ASM treatment.\\xa0If no pre-hospital dose of BZD was administered:\\n\\xa0Table 1 - Dosage of benzodiazepines\\xa0\\nIf IV or IO\\xa0access: diazepam (5 mg/ml solution) by slow IV injection (over 3 to 5 minutes).\\xa0For doses to be\\nadministered, see Table 1.\\nIf no IV or IO access: midazolam (5 mg/ml solution) by buccal\\xa0or intranasalroute or\\xa0midazolam (1 mg/ml solution)\\nby IM route or\\xa0diazepam (5 mg/ml solution) by rectal route.\\xa0For doses to be administered, see Table 1.\\n\\xa0\\nIf\\xa0seizures\\xa0do not stop 5\\xa0minutes after the ﬁrst dose of BZD, readminister\\xa0the same dose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 23, 'page_label': '24', 'id': 'data/guideline-170-en.pdf:23:1'}, page_content='If\\xa0seizures\\xa0do not stop after the second\\xa0dose of BZD, start Step 2 - Second-line ASM treatment.\\nIf seizures recur:\\xa0\\n6 hours or more after seizures stop, restart treatment from Step 1 - First-line ASM treatment as for a new\\nseizure,\\nLess than 6 hours after seizures stop, continue treatment at the last point, e.g.:\\nif seizures recur < 6 hours after a ﬁrst dose of BZD, readminister\\xa0the same dose,\\nif seizures recur < 6 hours after 2 doses of BZD, start Step 2 - Second-line ASM treatment.\\nIf\\xa0seizures\\xa0stop after 1 or 2 doses of BZD and do not recur, see Postictal management and evaluate the need for\\nmaintenance ASM treatment.\\nAge 1 to < 4months 4 to < 12months 1 to < 3years 3 to < 5years 5 to < 9\\xa0years\\xa0 9\\xa0\\xa0to < 12years ≥ 12 years\\xa0adults'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 23, 'page_label': '24', 'id': 'data/guideline-170-en.pdf:23:2'}, page_content='Weight 3 to < 6kg 6 to < 10kg 10 to < 15kg 15 to < 20kg 20\\xa0to <\\xa030\\xa0kg 30 to <\\xa040\\xa0kg ≥ 40 kg\\nmidazolam buccal \\xa0or\\xa0intranasal route , dose in ml (5 mg/ml solution)\\xa0\\xa0 (a)  (b) \\n\\xa0 0.25 ml 0.4 ml 0.6 ml 1 ml 1.2 ml 2 ml 2 ml\\nmidazolam IM route, dose in ml (1 mg/ml solution)\\xa0\\xa0\\xa0\\n\\xa0 0.6 ml 1.2 ml 2 ml 3 ml 4 ml 6 ml 10 ml\\ndiazepam rectal route , dose in ml (5 mg/ml solution)\\xa0\\xa0\\xa0 (c) \\n\\xa0 0.4\\xa0ml 0.7\\xa0ml 1.2\\xa0ml 1.5 ml 2 ml 2 ml 2 to 4 ml (d)\\ndiazepam\\xa0slow IV route, dose in ml (5 mg/ml solution)\\xa0\\xa0\\n\\xa0 0.25 ml 0.4 ml 0.6 ml 1 ml 1.2 ml 2 ml 2 ml (d)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 23, 'page_label': '24', 'id': 'data/guideline-170-en.pdf:23:3'}, page_content='0.25 ml 0.4 ml 0.6 ml 1 ml 1.2 ml 2 ml 2 ml (d)\\n(a) Midazolam buccal route: lay the patient on their side. Withdraw the required dose using a 1 ml or 2 ml syringe. Remove theneedle.\\xa0Insert the tip of the syringe into the space between the gum and cheek. Administer the dose by slowly pushing thesyringe plunger.\\n(b) Midazolam intranasal route: lay the patient on their back or side. Withdraw the required dose using a 1 ml or 2 ml syringe(add an additional 0.1 ml to the calculated dose to account for the remaining liquid in the atomising device). Remove theneedle. Attach the intranasal atomisation device to the syringe.\\xa0Briskly push the syringe plunger to spray the dose into thenostril. The dose\\xa0can be split in both nostrils to reduce irritation.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 23, 'page_label': '24', 'id': 'data/guideline-170-en.pdf:23:4'}, page_content='(c) Diazepam rectal route: lay the patient on their side. For volumes up to 1 ml, use a 1 ml syringe. Withdraw the required dose.Remove the needle. Insert the syringe into the rectum for a length of 1 to 3 cm (depending on age) to administer the dose.For volumes greater than 1 ml, use a 2 ml syringe and attach\\xa0to the tip of the syringe\\xa0a nasogastric tube n°8 cut to a lengthof 2 to 3 cm to administer the dose. After administration, hold the buttocks together for at least one minute.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 24, 'page_label': '25', 'id': 'data/guideline-170-en.pdf:24:0'}, page_content='Page 25 / 409\\nStep 2 - Second-line ASM treatment\\nPatients with no known epilepsy\\nSecond-line ASMs are indicated for:\\nThe choice of the ASM depends on the patient’s characteristics: age, sex, pregnancy or breastfeeding status, and\\ncomorbidities. See Table 2.\\xa0\\nFor doses to be administered, see Table\\xa03\\xa0Table 2 - Choice of a second-line antiseizure medication\\xa0\\nPatients with known epilepsy\\n(d) In patients ≥ 65 years: for diazepam rectal, do not exceed 2 ml (= 10 mg) per dose; for diazepam IV, reduce the dose by half(1 ml = 5 mg per dose).\\nChildren, if seizures do not stop within 5 minutes of second\\xa0dose of BZD.\\nAll adults, even if seizures stop\\xa0after 1 or 2 doses of BZD, unless a reversible cause of seizure can be quickly\\ntreated (e.g. hypoglycaemia, electrolyte disturbances).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 24, 'page_label': '25', 'id': 'data/guideline-170-en.pdf:24:1'}, page_content='treated (e.g. hypoglycaemia, electrolyte disturbances).\\n\\xa0 Children 1 month to < 2 years\\nGirls ≥ 10 years and women\\nGirls 2 to < 10 years\\nBoys\\xa0≥ 2 years and men\\n\\xa0\\nFirst choice levetiracetam (LEV) (e) levetiracetam (LEV) or\\nvalproic acid (VPA)\\n (e) \\n (f)\\nSecond choice phenobarbital (PB) (g) phenobarbital (PB) (g)\\nThird choice phenytoin (PHT) (h) phenytoin (PHT) (h)\\n(e) LEV can be used in all patients but with caution in patients with renal impairment or heart disorders.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 24, 'page_label': '25', 'id': 'data/guideline-170-en.pdf:24:2'}, page_content='(f) VPA is contraindicated:• in children under 2 years and patients with hepatic disease;• in women and girls who are or may become pregnant. Every effort should be made to ﬁnd a safer alternative to VPA inpregnant women and girls. However, prolonged status epilepticus is a life-threatening condition both for the mother andthe unborn child. If VPA is the only ASM available, use the lowest possible dose.\\xa0\\n(g) PB is contraindicated in patients with\\xa0severe impairment of respiratory, renal or hepatic function. It should be administeredwith\\xa0caution in children, older patients and patients with mild to moderate impairment of respiratory, renal or hepaticfunction.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 24, 'page_label': '25', 'id': 'data/guideline-170-en.pdf:24:3'}, page_content='(h) PHT is contraindicated in patients with bradycardia, atrioventricular block. It should be administered with caution inpatients with hepatic impairment, heart failure, cardiac rhythm disorders, hypotension.\\nIf seizures do not stop after second-line ASM, change to another second-line ASM.\\nIf seizures do not stop or recur in < 6 hours despite 2 second-line ASMs, transfer the patient to an intensive care\\nunit for\\xa0treatment of refractory status epilepticus.\\nIf\\xa0seizures stop after 1 or 2 second-line ASM(s), see Postictal management and Maintenance ASM treatment.\\nHistory taking:\\nASM and dose taken, effectiveness.\\nMissed doses if any, and reason (e.g. forgetting, interruption due to adverse effects, shortage of medication).\\nManagement:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 24, 'page_label': '25', 'id': 'data/guideline-170-en.pdf:24:4'}, page_content='Management:\\nAdminister the IV loading dose of the medication that the patient should usually take or see Table 2.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 25, 'page_label': '26', 'id': 'data/guideline-170-en.pdf:25:0'}, page_content='Page 26 / 409\\nStep 3 - Maintenance ASM treatment\\xa0\\nSome patients may require maintenance treatment after the loading dose.\\xa0\\nUnless the child has already received a loading dose, start with a loading dose, see Table 3.\\xa0\\n\\xa0\\nPostictal management\\nFrequent causes of seizures\\nIf seizures do not stop,\\xa0continue treatment as for patients with no known epilepsy.\\nIf seizures stop after 1 or 2 second-line ASM(s), see Postictal management and Maintenance ASM treatment.\\nIn children, maintenance treatment is indicated when:\\na second-line ASM\\xa0has been used to control seizures,\\xa0unless a reversible cause of seizure can be quickly\\ntreated (e.g. hypoglycaemia, electrolyte disturbances),\\n3 or more seizures occur within a 24-hour period,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 25, 'page_label': '26', 'id': 'data/guideline-170-en.pdf:25:1'}, page_content='3 or more seizures occur within a 24-hour period,\\nfocal signs and/or impaired consciousness persist beyond expected postictal period,\\nthere is known or presumed traumatic brain injury (within 24 hours of injury),\\nthere is known or presumed epilepsy.\\nIn adults, maintenance treatment is indicated for all patients,\\xa0unless a reversible cause of seizure can be quickly\\ntreated (e.g. hypoglycaemia, electrolyte disturbances).\\nIf seizures do not recur, administer maintenance treatment for 48 to 72 hours\\xa0and then reassess. Use oral route (or\\nnasogastric tube).\\xa0For maintenance doses to be administered, see Table\\xa03.\\nFor seizures in the context of head trauma, maintenance treatment should last 7 days.\\nIn case of epilepsy, start or resume long-term treatment. See Epilepsy, Chapter 12.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 25, 'page_label': '26', 'id': 'data/guideline-170-en.pdf:25:2'}, page_content='Note time of end of seizure; keep patient in recovery position; maintain airway.\\nAdminister oxygen to all patients if available and especially to patients who received ASM(s). Maintain SpO > 94%.2\\nMonitor vital signs and SpO every 15 minutes until stable, then every hour.2\\nClosely monitor RR if the patient received BZD, PB or PHT; HR and BP (and ECG if available) if the patient\\nreceived PHT.\\nObserve for further seizures.\\nAs soon as possible, try to identify the underlying cause and treat it, even in patients with known epilepsy (see\\nFrequent causes of seizures):\\nTake a detailed history and perform a full clinical examination, looking particularly for general status and focal\\nsigns.\\nDepending on assessment, perform the following tests if available:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 25, 'page_label': '26', 'id': 'data/guideline-170-en.pdf:25:3'}, page_content='signs.\\nDepending on assessment, perform the following tests if available:\\ncapillary blood glucose, especially if not done during the seizure. Check regularly blood glucose if necessary.\\nrapid diagnostic test for malaria in endemic areas\\nCSF examination (lumbar puncture) and culture\\nwhite blood cell count, serum electrolytes and creatinine, liver enzymes and coagulation tests,\\xa0blood culture\\nNote if patient does not return to baseline status within 30 to 60 minutes of end of seizure.\\nFebrile seizures: in young children with fever, usually in a context of a respiratory or gastrointestinal viral infection.\\nCNS infections: e.g. any meningitis (for Bacterial meningitis, see Chapter 7); severe malaria, neurocysticercosis,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 25, 'page_label': '26', 'id': 'data/guideline-170-en.pdf:25:4'}, page_content='trypanosomiasis (see Chapter 6); cerebral toxoplasmosis, cryptococcal meningitis (see HIV infection and AIDS,\\nChapter 8).\\nMetabolic abnormalities: e.g. hypoglycaemia (Chapter 1), electrolyte disorders (hyponatremia, hypocalcaemia).\\nIntoxications: e.g. psychoactive drugs and alcohol, methanol, medications, neurotoxic pesticides and venoms,\\ncarbon monoxide.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 26, 'page_label': '27', 'id': 'data/guideline-170-en.pdf:26:0'}, page_content='Page 27 / 409\\nDosage of second-line antiseizure medications\\nTable 3 - Second-line antiseizure medications (loading doses and maintenance doses)\\xa0\\nWithdrawal from CNS depressants: e.g. alcohol (see Agitation and Acute confusional state, Chapter 11), opioids,\\nbenzodiazepines, barbiturates.\\nUse of seizure-provoking drugs: many drugs may be involved, e.g. antidepressants, antipsychotics, some\\nantimicrobials.\\nVitamin B deﬁciencies (thiamine and pyridoxine), particularly in patients with chronic alcohol consumption.\\nEpilepsy: undiagnosed epilepsy, poor adherence to treatment, ineffective treatment or abrupt\\xa0stop of ASM.\\nHead trauma, CNS tumour, stroke, sepsis, encephalopathy (e.g. hypertensive, hypoxic).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 27, 'page_label': '28', 'id': 'data/guideline-170-en.pdf:27:0'}, page_content='Page 28 / 409\\nASMs Loading dose Maintenance dose\\nlevetiracetam\\n= LEV\\n500 mg in 5 ml vial (100 mg/ml)\\nChildren ≥ 1 month:\\nUse diluted solution: add 3 ml\\n(300\\xa0mg) of LEV to 17 ml of 0.9%\\nNaCl to obtain 20 ml of\\nsolution\\xa0containing 15 mg of LEV\\nper ml.\\nAdminister 40 mg/kg (max. 3\\ng)\\xa0over 10\\xa0minutes\\xa0by IV infusion\\nusing a syringe pump or by very\\nslow IV injection.\\xa0\\nIf\\xa0seizures do not stop after\\xa0the\\nend of the ﬁrst dose,\\nreadminister\\xa0half-dose: 20 mg/kg\\n(max. 1.5 g) as above.\\nDo not exceed the total dose of\\n60 mg/kg or 4.5 g.\\nDo not exceed an infusion rate of\\n5 mg/kg/minute.\\n12 hours after the loading dose:\\n7 mg/kg every 12 hours\\xa0PO\\n10 mg/kg every 12 hours\\xa0PO\\nChildren 1 to 5 months:\\xa0\\nChildren\\xa06 months to 15 years:\\nAdults \\xa0: (i) \\n60 mg/kg (max. 4.5 g) single dose\\nover 15 minutes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 27, 'page_label': '28', 'id': 'data/guideline-170-en.pdf:27:1'}, page_content='Adults \\xa0: (i) \\n60 mg/kg (max. 4.5 g) single dose\\nover 15 minutes\\xa0\\nUse diluted solution as above (15\\nmg/ml) if administered by IV\\ninfusion using a syringe pump.\\nUse undiluted solution if\\nadministered by IV infusion in a bag\\nof 100 ml\\xa0of 0.9% NaCl.\\nDo not exceed an infusion rate of\\n5 mg/kg/minute\\n12 hours after the loading dose:\\nAdults: 1 to 1.5 g every 12\\nhours\\xa0PO\\nphenobarbital\\n= PB\\n200 mg in 1 ml ampoule (200\\nmg/ml)\\nChildren ≥ 1 month:\\nUse diluted solution: add 1 ml (200\\nmg)\\xa0of PB to 9 ml of 0.9% NaCl\\nto obtain 10 ml of\\nsolution\\xa0containing 20 mg of PB\\nper ml.\\nAdminister 20 mg/kg (max. 1 g)\\nover 20 minutes by IV infusion\\nusing a syringe pump (or only if not\\navailable, using a pediatric infusion\\nset).\\nIf seizures do not stop after the\\nend of the ﬁrst dose, readminister'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 27, 'page_label': '28', 'id': 'data/guideline-170-en.pdf:27:2'}, page_content='set).\\nIf seizures do not stop after the\\nend of the ﬁrst dose, readminister\\nhalf-dose: 10 mg/kg as above.\\nDo not exceed an infusion rate of\\n1 mg/kg/minute.\\n12 hours after the loading dose:\\nChildren 1 to 11 months:\\xa05 to 6\\nmg/kg\\xa0once daily\\xa0PO\\nChildren\\xa01 to 5 years: 6 to 8\\nmg/kg\\xa0once daily\\xa0PO\\nChildren 6 to 12 years: 4 to 6\\nmg/kg\\xa0once daily\\xa0PO\\nChildren >\\xa012 years: 1 to 3\\nmg/kg\\xa0once daily\\xa0PO'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 28, 'page_label': '29', 'id': 'data/guideline-170-en.pdf:28:0'}, page_content='Page 29 / 409\\nAdults:\\n15 mg/kg (max. 1 g) single dose\\nover 15 minutes\\xa0\\nUse diluted solution as above (20\\nmg/ml) if administered by IV\\ninfusion using a syringe pump.\\nUse undiluted solution if\\nadministered by IV infusion in a bag\\nof 100 ml\\xa0of 0.9% NaCl.\\xa0\\nDo not exceed an infusion rate of\\n100\\xa0mg/minute.\\n12 hours after the loading dose:\\nAdults: 60 to 180 mg once\\ndaily\\xa0PO\\nphenytoin\\n= PHT\\n250 mg in 5 ml\\nampoule\\xa0or\\xa0vial\\xa0(50 mg/ml)\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0  \\xa0\\n\\xa0\\nUse a large central or\\nperipheral vein.\\nUse a infusion set or line with\\na 0.2 micron ﬁlter.\\nBefore and after infusion,\\nﬂush the catheter with 0.9%\\nNaCl to limit venous irritation\\nand potential incompatibility\\nwith other drugs.\\nDO NOT DILUTE IN\\nGLUCOSE.\\xa0\\nDo not use a line used for\\nglucose solution.\\nChildren ≥ 1 month and ≤ 25 kg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 28, 'page_label': '29', 'id': 'data/guideline-170-en.pdf:28:1'}, page_content='Do not use a line used for\\nglucose solution.\\nChildren ≥ 1 month and ≤ 25 kg\\nUse diluted solution: add 1 ml (50\\nmg)\\xa0of PHT to 9 ml of\\xa00.9% NaCl\\nto obtain 10 ml of\\nsolution\\xa0containing 5 mg of PHT\\nper ml.\\xa0\\nAdminister 20 mg/kg (max. 2\\ng)\\xa0single dose over 20 minutes by\\nIV infusion using a syringe pump.\\nOnly if syringe pump is not\\navailable, use a paediatric infusion\\nset.\\nDo not exceed an infusion rate of\\n1\\xa0mg/kg/minute.\\n12 hours after the loading dose:\\nChildren: 2.5 mg/kg every 12 hours\\nPO\\nChildren > 25 kg\\xa0and adults (j)\\nAdd undiluted solution to a 100 ml\\nbag\\xa0of 0.9% NaCl.\\xa0\\nAdminister 20 mg/kg (max. 2 g)\\nsingle dose by IV infusion at the\\nfollowing rate:\\n≤ 1 g or\\xa0≤\\xa050 kg: 20 minutes\\n> 1 g and ≤ 1.5 g or\\xa0> 50 kg\\nand ≤\\xa075 kg: 30 minutes\\n> 1.5 g and ≤ 2 g or\\xa0> 75 kg\\nand ≤\\xa0100 kg: 40 minutes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 28, 'page_label': '29', 'id': 'data/guideline-170-en.pdf:28:2'}, page_content='and ≤\\xa075 kg: 30 minutes\\n> 1.5 g and ≤ 2 g or\\xa0> 75 kg\\nand ≤\\xa0100 kg: 40 minutes\\nDo not exceed an infusion rate of\\n50 mg/minute.\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n12 hours after the loading dose:\\n\\xa0\\nAdults:\\xa03 to 4 mg/kg once daily\\nPO\\nOlder patients (≥\\xa065 years)\\nand adults with cardiac disorders\\nAdd undiluted solution to a 100 ml\\nbag\\xa0of 0.9% NaCl.\\xa0\\nAdminister 20 mg/kg (max. 2 g)\\nsingle dose by IV infusion at the\\nfollowing rate:\\n≤ 1 g or\\xa0≤\\xa050 kg: 40 minutes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 29, 'page_label': '30', 'id': 'data/guideline-170-en.pdf:29:0'}, page_content='Page 30 / 409\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n> 1 g and ≤ 1.5 g or\\xa0> 50 kg\\nand ≤\\xa075 kg: 60 minutes\\n> 1.5 g and ≤ 2 g or\\xa0> 75 kg\\nand ≤\\xa0100 kg: 80 minutes\\nDo not exceed an infusion rate of\\n25 mg/minute.\\nvalproic acid\\n= VPA (or sodium valproate)\\n400 mg in 4 ml ampoule (100\\nmg/ml)\\n (k)\\nChildren ≥ 2 years:\\xa0\\nUse diluted solution:\\xa0add 4 ml (400\\nmg) of VPA to 6 ml of 0.9% NaCl\\nto obtain 10 ml\\nof\\xa0solution\\xa0containing 40 mg of\\nVPA per ml.\\nAdminister\\xa020 mg/kg (max. 1.5\\xa0g)\\nover 5 minutes\\xa0by IV infusion using\\na syringe pump or by slow IV\\ninjection.\\nIf\\xa0seizures do not stop after\\xa0the\\nend of the ﬁrst dose, readminister\\nthe same dose: 20 mg/kg (max.\\n1.5\\xa0g) as above.\\xa0\\nDo not exceed the total dose\\nof\\xa040 mg/kg or 3 g.\\xa0\\nDo not exceed an infusion rate of\\n6 mg/kg/minute\\n6 to 8 hours after the loading dose:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 29, 'page_label': '30', 'id': 'data/guideline-170-en.pdf:29:1'}, page_content='6 mg/kg/minute\\n6 to 8 hours after the loading dose:\\n5 to 7.5 mg/kg (max. 600 mg) 2 times\\ndaily\\xa0PO\\nChildren ≥\\xa02\\xa0years:\\nAdults : (i) \\n40 mg/kg\\xa0(max. 3\\xa0g) single dose\\nover 10 minutes\\xa0\\nUse diluted solution as above (40\\nmg/ml) if administered by IV\\ninfusion using a syringe pump.\\nUse undiluted solution if\\nadministered by IV infusion in a bag\\nof 100 ml\\xa0of 0.9% NaCl.\\xa0\\nDo not exceed an infusion rate of\\n6 mg/kg/minute.\\n12 hours after the loading dose:\\nAdults: 1 g 2 times daily PO\\xa0\\n(i) Reduce dosage in patients with renal impairment.\\n(j) Reduce dosage in patients with hepatic impairment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 29, 'page_label': '30', 'id': 'data/guideline-170-en.pdf:29:2'}, page_content='(j) Reduce dosage in patients with hepatic impairment.\\n(k) For a pregnant woman, if VPA is the only ASM available, use the lowest possible loading dose (an option could be toadminister 20 mg/kg over 5 minutes, then repeat the same dose only if seizures do not stop by the end of the ﬁrst dose).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 30, 'page_label': '31', 'id': 'data/guideline-170-en.pdf:30:0'}, page_content=\"Page 31 / 409\\nReferences\\nFootnotes\\n(a) Thiamine should be administered at the same time as glucose because glucose may precipitate\\xa0Wernicke's encephalopathyin patients with chronic alcohol consumption. Treatment should be continued for 3 to 5 days with thiamine PO (100 to 200mg once daily) or IM (100 mg once daily).\\n1. Lowenstein DH, Bleck T, Macdonald RL. It’s Time to Revise the Deﬁnition of Status Epilepticus.\\xa0Epilepsia. 1999;40(1):120-122.\\xa0https://doi.org/10.1111/j.1528-1157.1999.tb02000.x\\n2. Brophy GM, Bell R, Claassen J, et al. Guidelines for the Evaluation and Management of Status Epilepticus. Neurocrit Care.2012;17:3-23.https://higherlogicdownload.s3.amazonaws.com/NEUROCRITICALCARE/b8b3b384-bfb9-42af-bb55-45973d5054a4/UploadedImages/Documents/Guidelines/SE_Guidelines_NCS_0412.pdf\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 30, 'page_label': '31', 'id': 'data/guideline-170-en.pdf:30:1'}, page_content='3. Pottkämper JCM, Hofmeijer J, Van Waarde JA, Van Putten MJAM. The postictal state — What do we know? Epilepsia.2020;61(6):1045-1061.https://doi.org/10.1111/epi.16519\\n4. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures. Febrile Seizures: ClinicalPractice Guideline for the Long-term Management of the Child With Simple Febrile Seizures. Pediatrics. 2008;121(6):1281-1286.https://doi.org/10.1542/peds.2008-0939'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 31, 'page_label': '32', 'id': 'data/guideline-170-en.pdf:31:0'}, page_content='Page 32 / 409\\nHypoglycaemia\\nLast update: November 2023\\n\\xa0\\nHypoglycaemia is an abnormally low concentration of blood glucose. Severe hypoglycaemia\\xa0can be fatal or lead to\\nirreversible neurological damage.\\nBlood glucose levels should be measured whenever possible in patients presenting symptoms\\xa0of hypoglycaemia. If\\nhypoglycaemia is suspected but blood glucose measurement is not\\xa0available, glucose (or another available sugar)\\nshould be given empirically.\\nAlways consider hypoglycaemia in patients presenting impaired consciousness (lethargy, coma)\\xa0or seizures.\\nFor diagnosis and treatment of hypoglycaemia in neonates, refer to\\xa0the guide\\xa0Essential obstetric and\\xa0newborn care,\\nMSF.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 31, 'page_label': '32', 'id': 'data/guideline-170-en.pdf:31:1'}, page_content='MSF.\\nClinical features\\nRapid onset of non-speciﬁc signs, mild to severe depending on the degree of the\\xa0hypoglycaemia: sensation of hunger\\nand fatigue, tremors, tachycardia, pallor, sweats, anxiety,\\xa0blurred vision, difﬁculty speaking, confusion, convulsions,\\nlethargy, coma.\\nDiagnosis\\nCapillary blood glucose concentration (reagent strip test):\\n\\xa0If blood glucose measurement is not available, diagnosis is conﬁrmed when symptoms resolve\\xa0after the administration\\nof sugar or glucose.\\nSymptomatic treatment\\nSymptoms improve approximately 15 minutes after taking sugar by oral route.\\xa0\\nNeurological symptoms improve a few minutes after the injection.\\xa0Check blood glucose after 15 minutes. If it is still low, re-administer glucose by IV route or sugar\\xa0by oral route according'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 31, 'page_label': '32', 'id': 'data/guideline-170-en.pdf:31:2'}, page_content='to the patient’s clinical condition.\\nIf there is no clinical improvement, differential diagnoses should be considered: e.g. serious\\xa0infection (severe malaria,\\nmeningitis, etc.), epilepsy,\\xa0unintentional alcohol intoxication or adrenal insufﬁciency in children.\\nIn all cases, after stabilisation, give a meal or snack rich in complex carbohydrates and monitor\\xa0the patients for a few\\nhours.\\nNon-diabetic patients:\\nHypoglycaemia: < 3.3 mmol/litre\\xa0(< 60 mg/dl)\\nSevere hypoglycaemia: < 2.2 mmol/litre\\xa0(< 40 mg/dl)\\nDiabetic patients on home treatment: <\\xa03.9 mmol/litre\\xa0(<\\xa070 mg/dl) [1]\\nConscious patients:\\nChildren: a teaspoon of powdered sugar in a few ml of water or 50 ml of fruit juice, maternal\\xa0or therapeutic milk\\nor 10 ml/kg of 10% glucose by oral route or nasogastric tube.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 31, 'page_label': '32', 'id': 'data/guideline-170-en.pdf:31:3'}, page_content='or 10 ml/kg of 10% glucose by oral route or nasogastric tube.\\nAdults: 15 to 20 g of sugar (3 or 4 cubes) or sugar water, fruit juice, soda, etc.\\nPatients with impaired consciousness or prolonged convulsions:\\nChildren: 2 ml/kg of 10% glucose by slow IV (2 to 3 minutes) \\xa0 a \\nAdults: 1 ml/kg of\\xa050% glucose\\xa0by slow IV (3 to 5 minutes)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 32, 'page_label': '33', 'id': 'data/guideline-170-en.pdf:32:0'}, page_content='Page 33 / 409\\nIf patient does not return to full alertness after an episode of severe hypoglycaemia, monitor\\xa0blood glucose levels\\nregularly.\\nAetiological treatment\\n\\xa0\\nReferences\\nOther than diabetes:\\nTreat severe acute malnutrition, neonatal sepsis, severe malaria, acute alcohol intoxication, etc.\\nEnd prolonged fast.\\nReplace drugs inducing hypoglycaemia (e.g. quinine IV, pentamidine, ciproﬂoxacin,\\xa0enalapril, beta-blockers, high-\\ndose aspirin, tramadol), or anticipate hypoglycaemia (e.g.\\xa0administer quinine IV in a glucose infusion).\\nIn diabetic patients:\\nAvoid missing meals, increase intake of carbohydrates if necessary.\\nAdjust dosage of insulin according to blood glucose levels and physical activity.\\nAdjust dosage of oral antidiabetics, taking into account possible drug interactions.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 32, 'page_label': '33', 'id': 'data/guideline-170-en.pdf:32:1'}, page_content='Footnotes\\n(a) If ready-made 10% glucose solution is not available: remove 100 ml of 5% glucose from a 500 ml bottle or bag, then add 50ml of 50% glucose to the remaining 400 ml of 5% glucose to obtain 450 ml of 10% glucose solution.\\n1. American Diabetes Association. Standards of Care in Diabetes—2023 Abridged for Primary Care Providers. Clinical Diabetes.2022;41(1):4-31.https://doi.org/10.2337/cd23-as01'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 33, 'page_label': '34', 'id': 'data/guideline-170-en.pdf:33:0'}, page_content='Page 34 / 409\\nFever\\nLast updated: December 2023\\n\\xa0\\nFever is deﬁned as an\\xa0axillary temperature\\xa0higher than 37.5 °C.\\nFever is frequently due to infection. In a febrile patient, ﬁrst look for signs of serious illness\\xa0then, try to establish a\\ndiagnosis.\\nSigns of severity\\nInfectious causes of fever according to\\xa0signs and symptoms\\nPetechial or purpuric rash, meningeal signs, heart\\xa0murmur, severe abdominal pain, dehydration.\\nSigns of severe bacterial infection or sepsis: critically ill appearance , hypothermia, altered level of consciousness,\\nsevere tachycardia, hypotension, tachypnoea, respiratory distress, seizures; a bulging fontanel in\\xa0young children.\\n a \\nSigns of circulatory impairment or shock: see Shock, Chapter 1.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 34, 'page_label': '35', 'id': 'data/guideline-170-en.pdf:34:0'}, page_content='Page 35 / 409\\n\\xa0\\nLaboratory and other examinations\\nSigns or symptoms Possible aetiology\\nMeningeal signs, seizures Meningitis/meningoencephalitis/severe malaria\\nAbdominal pain or peritoneal signs Appendicitis/peritonitis/enteric fevers/amaebic liver abscess\\nDiarrhoea, vomiting Gastroenteritis/enteric fevers\\nJaundice, enlarged liver Viral hepatitis\\nCough Pneumonia/measles/tuberculosis if persistent\\nEyelid erythema, eye pain and oedema Orbital cellulitis\\nEar pain, red tympanic membrane Otitis media\\nTender swelling behind the ear Mastoiditis\\nSore throat, enlarged lymph nodes Streptococcal pharyngitis/diphtheria/retropharyngeal or tonsillar\\nabscess/epiglotittis\\nMultiple vesicles on the oral mucosa and lips Oral herpes\\nDysuria, urinary frequency, back pain Urinary tract infection'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 34, 'page_label': '35', 'id': 'data/guideline-170-en.pdf:34:1'}, page_content='Dysuria, urinary frequency, back pain Urinary tract infection\\nRed, warm, painful skin Erysipelas/cellulitis/necrotising infections of the skin and soft\\ntissues/abscess\\nLimp, difﬁculty walking Osteomyelitis/septic arthritis\\nRash Measles/dengue/viral haemorrhagic fevers/chikungunya\\nBleeding (petechiae, epistaxis, etc.) Dengue/viral haemorrhagic fevers/severe malaria\\nJoint pain Rheumatic fever/chikungunya/dengue\\nIf the patient is ill appearing and has a persistent fever, consider HIV infection and tuberculosis,\\xa0according to\\nclinical presentation.\\n a \\nMalaria rapid diagnostic test in endemic areas.\\nIn case of circulatory impairment or shock: see Shock, Chapter 1.\\xa0\\nChildren 1 to 3\\xa0months with fever\\xa0without a focus:\\nurine dipstick and urine culture, if available;\\nblood culture, if available;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 34, 'page_label': '35', 'id': 'data/guideline-170-en.pdf:34:2'}, page_content='urine dipstick and urine culture, if available;\\nblood culture, if available;\\nfull blood count (FBC), if available;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 35, 'page_label': '36', 'id': 'data/guideline-170-en.pdf:35:0'}, page_content='Page 36 / 409\\nAetiological\\xa0treatment\\nSymptomatic treatment\\nparacetamol\\xa0PO\\xa0\\nChildren 1 month and over: 15 mg/kg 3 to 4 times daily (max. 60 mg/kg daily)\\nAdults: 1 g 3 to 4 times daily (max. 4 g daily)\\nor\\nibuprofen\\xa0PO\\nChildren over 3 months and < 12 years: 5 to 10 mg/kg 3 to 4 times daily (max. 30 mg/kg daily)\\nChildren 12 years and over and adults: 200 to 400 mg 3 to 4 times daily (max. 1200 mg daily)\\nor\\nacetylsalicylic acid\\xa0(ASA) PO\\nChildren over 16 years and adults: 500 mg to 1 g 3 to 4 times daily\\xa0(max. 4 g daily)\\nlumbar puncture (LP) if meningeal signs or\\xa0signs of severe bacterial infection or sepsis, or\\xa0failure of prior\\nantibiotic treatment;\\nchest x-ray,\\xa0if available,\\xa0in case of signs of respiratory disease or severe infection or sepsis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 35, 'page_label': '36', 'id': 'data/guideline-170-en.pdf:35:1'}, page_content='Children >\\xa03 months to 2 years with fever\\xa0without a focus:\\nurine dipstick and urine culture, if available;\\nLP if meningeal signs or\\xa0signs of severe bacterial infection or sepsis;\\nchest x-ray, if available,\\xa0if fever > 72 hours or signs of severe bacterial infection or sepsis;\\nblood culture, if available, if fever > 72 hours or signs of severe bacterial infection or sepsis;\\nFBC, if available,\\xa0if fever > 72 hours or\\xa0signs of severe bacterial infection or sepsis;\\nother: according to clinical presentation.\\nChildren over 2 years with fever\\xa0without a focus:\\nurine dipstick and urine culture, if available,\\xa0if history of urinary tract infection or fever > 72 hours\\xa0or signs of\\nsevere bacterial infection or sepsis;\\nLP if meningeal signs or signs of severe bacterial infection or sepsis;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 35, 'page_label': '36', 'id': 'data/guideline-170-en.pdf:35:2'}, page_content='LP if meningeal signs or signs of severe bacterial infection or sepsis;\\nchest x-ray, if available,\\xa0if fever > 72 hours or signs of severe bacterial infection or sepsis;\\nblood culture, if available,\\xa0if fever > 72 hours or signs of severe bacterial infection or sepsis;\\nFBC, if available,\\xa0if fever > 72 hours or signs of severe bacterial infection or sepsis;\\nother: according to clinical presentation.\\nAdults:\\xa0according to clinical presentation.\\nTreat patients with a positive malaria test: see Malaria, Chapter 6.\\nIf the\\xa0source of infection has been found: administer antibiotic treatment accordingly.\\nIf severe infection, sepsis, circulatory impairment or shock:\\xa0hospitalise and immediately administer an empiric'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 35, 'page_label': '36', 'id': 'data/guideline-170-en.pdf:35:3'}, page_content='antibiotic treatment (see Shock, Chapter 1).\\xa0Continue this treatment until the source of infection is found and adapt\\nantibiotic treatment accordingly.\\nIf no source of infection is found, and there are no signs of severe infection, sepsis, circulatory impairment or\\nshock,\\xa0hospitalise for further investigations and monitoring:\\nChildren 1 to 3 months;\\nChildren > 3 months to < 2 years with negative urine dipstick (and negative urine culture if available).\\nFor malnourished children, see Severe acute malnutrition, Chapter 1.\\nFor patients with sickle cell disease, see\\xa0Sickle cell disease, Chapter 12.\\nUndress the patient. Do not wrap children in wet towels or cloths (not effective, increases\\xa0discomfort, risk of\\nhypothermia).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 35, 'page_label': '36', 'id': 'data/guideline-170-en.pdf:35:4'}, page_content='hypothermia).\\nAntipyretics may increase the patient’s comfort but they do not prevent febrile convulsions.\\xa0Do not treat for more\\nthan 3 days with antipyretics.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 36, 'page_label': '37', 'id': 'data/guideline-170-en.pdf:36:0'}, page_content='Page 37 / 409\\nPrevention of complications\\n\\xa0Notes:\\n\\xa0\\nEncourage oral hydration. Continue frequent breastfeeding in infants.\\nLook for signs of dehydration.\\nMonitor urine output.\\nIn pregnant or breast-feeding women use paracetamol only.\\nIn case of viral haemorrhagic fevers and dengue: acetylsalicylic acid and ibuprofen are contraindicated;\\xa0use\\nparacetamol with caution in the presence of hepatic dysfunction.\\nFootnotes\\n(a) Critically ill appearing child: weak grunting or crying, drowsiness, difﬁcult to arrouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 37, 'page_label': '38', 'id': 'data/guideline-170-en.pdf:37:0'}, page_content='Page 38 / 409\\nPain\\nPain results from a variety of pathological processes. It is expressed differently by each patient\\xa0depending on cultural\\nbackground, age, etc. It is a subjective experience meaning that\\xa0only the individual is able to assess his/her level of pain.\\nRegular assessment of the intensity of\\xa0pain is indispensable in establishing effective treatment.\\nClinical features\\nPain assessment\\nClinical examination\\nSynthesis\\nThe synthesis of information gathered during history taking and clinical examination allows\\xa0aetiological diagnosis and\\norients treatment. It is important to distinguish:\\nPain evaluation scales\\nSelf-evaluation scale - Children over 5 years and adults\\nSimple verbal scale (SVS)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 37, 'page_label': '38', 'id': 'data/guideline-170-en.pdf:37:1'}, page_content='Simple verbal scale (SVS)\\nIntensity: use a simple verbal scale in children over 5 years and adults, and NFCS or FLACC\\xa0scales in children less\\nthan 5 years (see\\xa0Pain evaluation scales).\\nPattern: sudden, intermittent, chronic; at rest, at night, on movement, during care\\xa0procedures, etc.\\nCharacter: burning, cramping, spasmodic, radiating, etc.\\nAggravating or relieving factors, etc.\\nOf the organ or area where the pain is located.\\nSpeciﬁc signs of underlying disease (e.g. bone or osteoarticular pain may be caused by a\\xa0vitamin C deﬁciency) and\\nreview of all systems.\\nAssociated signs (fever, weight loss, etc.).\\nNociceptive\\xa0pain: it presents most often as acute pain and the cause-effect relationship is\\xa0usually obvious (e.g.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 37, 'page_label': '38', 'id': 'data/guideline-170-en.pdf:37:2'}, page_content='acute post-operative pain, burns, trauma, renal colic, etc.). The pain\\xa0may be present in different forms, but\\nneurological exam is normal. Treatment is relatively\\xa0well standardized.\\nNeuropathic\\xa0pain, due to a nerve lesion (section, stretching, ischaemia): most often chronic\\xa0pain. On a background\\nof constant, more or less localized pain, such as paraesthesia or\\xa0burning, there are recurrent acute attacks such as\\nelectric shock-like pain, frequently\\xa0associated with disordered sensation (anaesthesia, hypo or hyperaesthesia).\\nThis type of\\xa0pain is linked to viral infections directly affecting the CNS (herpes simplex, herpes zoster),\\xa0neural\\ncompression by tumors, post- amputation pain, paraplegia, etc.\\nMixed\\xa0pain\\xa0(cancer, HIV) for which management requires a broader approach.\\nIntensity\\nof pain'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 37, 'page_label': '38', 'id': 'data/guideline-170-en.pdf:37:3'}, page_content='Intensity\\nof pain\\nNo \\npain\\nMild\\npain\\nModerate\\npain Severe pain\\nScoring 0 1 2 3\\nWrite down 0 + ++ +++'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 38, 'page_label': '39', 'id': 'data/guideline-170-en.pdf:38:0'}, page_content='Page 39 / 409\\n\\xa0\\nObservational evaluation scale - Children 2 months-5 years\\nFLACC scale (Face Limb Activity Cry Consolability)\\n\\xa0Each category is scored from 0 to 2, giving a ﬁnal score between 0 and 10.\\n0 to 3: mild pain, 4 to 7: moderate pain, 7 to 10: severe pain\\nObservational evaluation scale - Children under 2 months\\nNFCS scale (Neonatal Facial Coding System)\\n\\xa0A score of 2 or more signiﬁes signiﬁcant pain, requiring analgesic treatment.\\nTreatment\\nTreatment depends on the type and intensity of the pain. It may be both aetiological and\\xa0symptomatic if a treatable\\ncause is identiﬁed. Treatment is symptomatic only in other cases (no\\xa0cause found, non-curable disease).\\n \\nItems\\nScoring\\n0 1 2\\nFace No particular\\nexpression or smile\\nOccasional grimace or frown, withdrawn,\\ndisinterested'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 38, 'page_label': '39', 'id': 'data/guideline-170-en.pdf:38:1'}, page_content='expression or smile\\nOccasional grimace or frown, withdrawn,\\ndisinterested\\nFrequent to constant frown,\\nclenched jaw, quivering chin\\nLegs Normal position or\\nrelaxed\\nUneasy, restless, tense Kicking, or legs drawn up\\nActivity Lying quietly, normal\\nposition, moves easily\\nSquirming, shifting back and forth, tense Arched, rigid or jerking\\nCry No cry (awake or\\nasleep)\\nMoans or whimpers, occasional\\ncomplaint\\nCrying steadily, screams or\\nsobs, frequent complaints\\nConsolability Content, relaxed Reassured by occasional touching,\\nhugging or being talked to, distractible\\nDifﬁcult to console or comfort\\n \\nItems\\nScoring\\n0 1\\nBrow bulge no yes\\nEye squeeze no yes\\nNasolabial furrow no yes\\nOpen lips no yes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 39, 'page_label': '40', 'id': 'data/guideline-170-en.pdf:39:0'}, page_content='Page 40 / 409\\nNociceptive pain\\nThe WHO classiﬁes analgesics used for this type of pain on a three-step ladder:\\n\\xa0The treatment of pain is based on a few fundamental concepts:\\nTreatment of acute pain\\n\\xa0\\nStep 1: non-opioid analgesics such as paracetamol and nonsteroidal anti-inﬂammatory drugs\\xa0(NSAIDs).\\nStep 2: weak opioid analgesics such as codeine and tramadol. Their combination with one or\\xa0two Step 1 analgesics\\nis recommended.\\nStep 3: strong opioid analgesics, ﬁrst and foremost morphine. Their combination with one or\\xa0two Step 1 analgesics\\nis recommended.\\nPain can only be treated correctly if it is correctly evaluated. The only person who can\\xa0evaluate the intensity of pain\\nis the patient himself. The use of pain assessment scales is\\xa0invaluable.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 39, 'page_label': '40', 'id': 'data/guideline-170-en.pdf:39:1'}, page_content='is the patient himself. The use of pain assessment scales is\\xa0invaluable.\\nThe pain evaluation observations should be recorded in the patient chart in the same fashion\\xa0as other vital signs.\\nTreatment of pain should be as prompt as possible.\\nIt is recommended to administer analgesics in advance when appropriate (e.g. before painful\\xa0care procedures).\\nAnalgesics should be prescribed and administered at ﬁxed time intervals (not on demand).\\nOral forms should be used whenever possible.\\nThe combination of different analgesic drugs (multimodal analgesia) is advantageous.\\nStart with an analgesic from the level presumed most effective: e.g., in the event of a\\xa0fractured femur, start with a\\nStep 3 analgesic.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 39, 'page_label': '40', 'id': 'data/guideline-170-en.pdf:39:2'}, page_content='Step 3 analgesic.\\nThe treatment and dose chosen are guided by the assessment of pain intensity, but also by\\xa0the patient’s response\\nwhich may vary signiﬁcantly from one person to another.\\nMild pain Paracetamol + /- NSAID\\nModerate pain Paracetamol + /- NSAID + tramadol or codeine\\nSevere pain Paracetamol + /- NSAID + morphine'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 40, 'page_label': '41', 'id': 'data/guideline-170-en.pdf:40:0'}, page_content='Page 41 / 409\\n\\xa0\\nAnalgesics Children\\nAdults (except\\npregnant/breast-feeding\\nwomen)\\nRemarks\\nLevel\\n1\\nparacetamol\\nPO\\n< 1 month: 10 mg/kg\\nevery 6 to 8 hours (max.\\n40 mg/kg daily)\\n≥ 1 month: 15 mg/kg\\nevery 6 to 8 hours (max.\\n60 mg/kg daily)\\n\\xa0\\n1 g every 6 to 8 hours (max.\\n4 g daily)\\nThe efﬁcacy of IV paracetamol\\nis not superior to the efﬁcacy of\\noral paracetamol; the IV route is\\nrestricted to situations where\\noral administration is impossible.\\nparacetamol\\nIV\\n< 1 month: 7.5 mg/kg\\nevery 6 hours (max. 30\\nmg/kg daily)\\n≥ 1 month and < 10 kg: 10\\nmg/kg every 6 hours (max.\\n30 mg/kg daily)\\n≥ 10 kg: 15 mg/kg every 6\\nhours (max. 60 mg/kg\\ndaily)\\n< 50 kg: 15 mg/kg every 6\\nhours (max. 60 mg/kg daily)\\n≥ 50 kg: 1 g every 6 hours\\n(max. 4 g daily)\\nacetylsalicylic\\nacid (aspirin)\\nPO\\n– 300 mg to 1 g every 4 to 6'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 40, 'page_label': '41', 'id': 'data/guideline-170-en.pdf:40:1'}, page_content='(max. 4 g daily)\\nacetylsalicylic\\nacid (aspirin)\\nPO\\n– 300 mg to 1 g every 4 to 6\\nhours (max. 4 g daily)\\nAvoid in children less than 16\\nyears.\\ndiclofenac IM – 75 mg once daily Treatment must be as short as\\npossible.\\nRespect contra-indications.ibuprofen PO > 3 months: 5 to 10 mg/kg\\nevery 6 to 8 hours (max.\\n30 mg/kg daily)\\n> 12 years: as for adults\\n200 to 400 mg every 6 to 8\\nhours (max. 1200 mg daily)\\nLevel\\n2\\n\\xa0\\n\\xa0\\ncodeine PO > 12 years: 30 to 60 mg\\nevery 4 to 6 hours (max.\\n240 mg daily)\\n30 to 60 mg every 4 to 6\\nhours (max. 240 mg daily)\\nAdd a laxative if treatment > 48\\nhours.\\ntramadol PO > 12 years: 50 to 100 mg\\nevery 4 to 6 hours (max.\\n400 mg daily)\\n50 to 100 mg every 4 to 6\\nhours (max. 400 mg daily)\\n\\xa0\\n25 to 50 mg every 12 hours in\\nelderly patients and in patients\\nwith severe renal or hepatic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 40, 'page_label': '41', 'id': 'data/guideline-170-en.pdf:40:2'}, page_content='elderly patients and in patients\\nwith severe renal or hepatic\\nimpairment.\\n\\xa0\\ntramadol IM,\\nslow IV or\\ninfusion\\n> 12 years: 50 to 100 mg\\nevery 4 to 6 hours (max.\\n600 mg daily)\\n50 to 100 mg every 4 to 6\\nhours (max. 600 mg daily)\\nLevel\\n3\\nmorphine PO\\nimmediate\\nrelease (MIR)\\n> 6 months: 0.15 mg/kg\\nevery 4 hours, to be\\najusted in relation to pain\\nintensity\\n10 mg every 4 hours, to be\\najusted in relation to pain\\nintensity\\n• Reduce the dose by half in\\nelderly patients and patients\\nwith renal or hepatic impairment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 41, 'page_label': '42', 'id': 'data/guideline-170-en.pdf:41:0'}, page_content='Page 42 / 409\\n\\xa0Notes on the use of morphine and derivatives:\\nThe RR should remain equal to or greater than the thresholds indicated below:\\n\\xa0 Respiratory depression must be identiﬁed and treated quickly: verbal and physical stimulation of the patient;\\nadministration of oxygen; respiratory support (bag and mask) if necessary. If no improvement, administer naloxone\\n(antagonist of morphine) in bolus to be repeated every minute until RR normalises and the excessive drowsiness\\nresolves: 5 micrograms/kg in children and 1 to 3 micrograms/kg in adults.\\n• Add a laxative if treatment >\\n48 hours.\\nmorphine PO\\nsustained\\nrelease (MSR)\\nThe daily dose is\\ndetermined during the\\ninitial treatment with\\nimmediate release\\nmorphine (MIR).\\nIf treatment is initiated\\ndirectly with MSR:\\n> 6 months: 0.5 mg/kg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 41, 'page_label': '42', 'id': 'data/guideline-170-en.pdf:41:1'}, page_content='If treatment is initiated\\ndirectly with MSR:\\n> 6 months: 0.5 mg/kg\\nevery 12 hours, to be\\najusted in relation to pain\\nintensity\\nThe daily dose is\\ndetermined during the initial\\ntreatment with immediate\\nrelease morphine (MIR).\\nIf treatment is initiated\\ndirectly with MSR:\\n30 mg every 12 hours, to\\nbe ajusted in relation to\\npain intensity\\n• Do not initiate treatment with\\nthe MSR in elderly patients and\\npatients with renal or hepatic\\nimpairment. Begin treatment\\nwith MIR.\\n• Add a laxative if treatment >\\n48 hours.\\nmorphine SC,\\nIM\\n> 6 months: 0.1 to 0.2\\nmg/kg every 4 hours\\n0.1 to 0.2 mg/kg every 4\\nhours\\n• Reduce doses by half and\\nadminister less frequently,\\naccording to clinical response, in\\nelderly patients and patients\\nwith severe renal or hepatic\\nimpairment.\\n• Add a laxative if treatment >'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 41, 'page_label': '42', 'id': 'data/guideline-170-en.pdf:41:2'}, page_content='with severe renal or hepatic\\nimpairment.\\n• Add a laxative if treatment >\\n48 hours.\\nmorphine IV > 6 months: 0.1 mg/kg\\nadministered in\\nfractionated doses (0.05\\nmg/kg every 10 minutes)\\nevery 4 hours if necessary\\n0.1 mg/kg administered in\\nfractionated doses (0.05\\nmg/kg every 10 minutes)\\nevery 4 hours if necessary\\nMorphine is an effective treatment for many types of severe pain. Its analgesic effect is dosedependent.\\xa0Its\\nadverse effects have often been exaggerated and should not be an obstacle\\xa0to its use.\\nThe most serious adverse effect of morphine is respiratory depression, which may be fatal.\\xa0This adverse effect\\nresults from overdose. It is, therefore, important to increase doses\\xa0gradually. Respiratory depression is preceded by'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 41, 'page_label': '42', 'id': 'data/guideline-170-en.pdf:41:3'}, page_content='drowsiness, which is a warning to monitor\\xa0respiratory rate (RR).\\xa0\\nChildren 1 to 12 months RR ≥ 25 respirations/minute\\nChildren 1 to 2 years RR ≥ 20 respirations/minute\\nChildren 2 to 5 years RR ≥ 15 respirations/minute\\nChildren > 5 years and adults RR ≥ 10 respirations/minute\\nMorphine and codeine always cause constipation. A laxative should be prescribed if the\\xa0opioid treatment continues\\nmore than 48 hours.\\xa0Lactulose\\xa0PO is the drug of choice: children\\xa0< 1 year: 5 ml daily; children 1-6 years: 5 to 10 ml\\ndaily; children 7-14 years: 10 to 15 ml daily;\\xa0adults: 15 to 45 ml daily.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 42, 'page_label': '43', 'id': 'data/guideline-170-en.pdf:42:0'}, page_content='Page 43 / 409\\nIf the patient’s stools are soft, a stimulant laxative (bisacodyl\\xa0PO: children > 3 years: 5 to\\xa010 mg once daily; adults:\\n10 to 15 mg once daily) is preferred.\\nChildren:\\nondansetron\\xa0PO: 0.15 mg/kg (max. 4 mg per dose) up to 3 times daily\\nDo not use metoclopramide in children.\\nAdults:\\nhaloperidol\\xa0PO (2 mg/ml oral solution): 1 to 2 mg up to 6 times daily\\xa0or\\xa0metoclopramide\\xa0PO: 5 to 10 mg 3 times\\ndaily with an interval of at least 6 hours\\xa0between each dose\\nDo not combine haloperidol and metoclopramide.\\nTreatment of nociceptive pain in pregnant and breast-feeding women\\nNeuropathic pain\\nNausea and vomiting are common at the beginning of treatment.\\nFor chronic pain in late stage disease (cancer, AIDS etc.), morphine PO is the drug of choice.\\xa0It may be necessary to'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 42, 'page_label': '43', 'id': 'data/guideline-170-en.pdf:42:1'}, page_content='increase doses over time according to pain assessment. Do not\\xa0hesitate to give sufﬁcient and effective doses.\\nMorphine, tramadol and codeine have similar modes of action and should not be combined.\\nBuprenorphine, nalbuphine and pentazocine must not be combined with morphine,\\xa0pethidine, tramadol or codeine\\nbecause they have competitive action.\\nAnalgesics\\nPregnancy\\nBreast-feeding0-5\\nmonths\\nFrom 6  monthth\\n \\nLevel\\n1\\nparacetamol ﬁrst\\nchoice\\nﬁrst choice ﬁrst choice\\naspirin avoid contra-indicated avoid\\nibuprofen avoid contra-indicated possible\\n \\n \\n \\nLevel\\n2\\ncodeine possible The neonate may develop withdrawal\\nsymptoms, respiratory depression and\\ndrowsiness in the event of prolonged\\nadministration of large doses at the\\nend of the thirdtrimester. Closely\\nmonitor the neonate.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 42, 'page_label': '43', 'id': 'data/guideline-170-en.pdf:42:2'}, page_content='end of the thirdtrimester. Closely\\nmonitor the neonate.\\nUse with caution, for a short period\\n(2-3 days), at the lowest effective\\ndose. Monitor the mother and the\\nchild: in the event of excessive\\ndrowsiness, stop treatment.\\ntramadol possible The child may develop drowsiness when the mother receives tramadol at the\\nend of the thirdtrimester and during breast-feeding. Administer with caution, for\\na short period, at the lowest effective dose, and monitor the child.\\n \\nLevel\\n3\\nmorphine possible The child may develop withdrawal symptoms, respiratory depression and\\ndrowsiness when the mother receives morphine at the end of the third trimester\\nand during breast-feeding.\\nAdminister with caution, for a short period, at the lowest effective dose, and\\nmonitor the child.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 43, 'page_label': '44', 'id': 'data/guideline-170-en.pdf:43:0'}, page_content='Page 44 / 409\\nCommonly used analgesics are often ineffective in treating this type of pain.\\nTreatment of neuropathic pain is based on a combination of two centrally acting drugs:\\namitriptyline\\xa0PO\\nAdults:\\xa025 mg once daily at bedtime (Week 1); 50 mg once daily at bedtime (Week 2); 75 mg once daily at bedtime (as\\nof Week 3); max.150 mg daily. Reduce the dose by half in elderly patients.\\ncarbamazepine\\xa0PO\\nAdults: 200 mg once daily at bedtime (Week 1);\\xa0200 mg 2 times daily (Week 2);\\xa0200 mg\\xa03 times daily\\xa0(as of Week 3)\\nGiven its teratogenic risk, carbamazepine should only be used in women of childbearing age\\xa0when covered\\nby\\xa0effective\\xa0contraception (intrauterine device or injectable progestogen). It is not recommended in pregnant women.\\nMixed pain'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 43, 'page_label': '44', 'id': 'data/guideline-170-en.pdf:43:1'}, page_content='Mixed pain\\nIn mixed pain with a signiﬁcant component of nociceptive pain, such as in cancer or AIDS,\\xa0morphine is combined with\\nantidepressants and antiepileptics.\\nChronic pain\\nIn contrast to acute pain, medical treatment alone is not always sufﬁcient in controlling chronic\\xa0pain. A multidisciplinary\\napproach including medical treatment, physiotherapy, psychotherapy\\xa0and nursing is often necessary to allow good pain\\nrelief and encourage patient selfmanagement.\\nCo-analgesics\\nThe combination of certain drugs may be useful or even essential in the treatment of pain:\\xa0antispasmodics, muscle\\nrelaxants, anxiolytics, corticosteroids, local anaesthesia, etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 44, 'page_label': '45', 'id': 'data/guideline-170-en.pdf:44:0'}, page_content='Page 45 / 409\\nAnaemia\\nLast updated: January 2024\\n\\xa0\\nAnaemia is deﬁned as a haemoglobin (Hb) level below reference values , which vary depending on age,\\xa0sex, and\\npregnancy status (see\\xa0Table 2).\\xa0Anaemia may be caused by:\\n\\xa0The causes of anaemia are often interlinked.\\nClinical features\\nLaboratory\\n\\xa0Table 1\\xa0- Possible diagnoses with FBC\\xa0\\n [1] [2] \\nDecreased production of red blood cells: iron deﬁciency, nutritional deﬁciencies (folic acid, vitamin B , vitamin A),\\ndepressed bone marrow function, certain infections (HIV, visceral leishmaniasis), renal failure;\\n12\\nLoss of red blood cells: acute or chronic haemorrhage (gastrointestinal ulcer, ancylostomiasis, schistosomiasis,\\netc.);\\nIncreased destruction of red blood cells (haemolysis): parasitic (malaria), bacterial and viral (HIV) infections;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 44, 'page_label': '45', 'id': 'data/guideline-170-en.pdf:44:1'}, page_content='haemoglobinopathies (sickle cell disease, thalassaemia); intolerance to certain drugs (primaquine, dapsone, co-\\ntrimoxazole, nitrofurantoin, etc.) in patients with G6PD deﬁciency.\\nCommon signs: pallor of the conjunctivae, mucous membranes, palms of hands and soles of feet; fatigue,\\ndizziness, dyspnoea, tachycardia, heart murmur.\\nSigns of decompensation:\\xa0cold extremities, altered mental status,\\xa0oedema in the lower limbs, respiratory distress,\\nelevated jugular venous pressure, cardiac/coronary failure, shock.\\nSigniﬁcant signs: cheilosis and glossitis (nutritional deﬁciency), jaundice, hepatosplenomegaly, dark coloured urine\\n(haemolysis), bleeding (maelena, haematuria, etc.), signs of\\xa0malaria\\xa0(Chapter 6), etc.\\nHb levels'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 44, 'page_label': '45', 'id': 'data/guideline-170-en.pdf:44:2'}, page_content='Hb levels\\nRapid diagnostic test or thick and thin blood ﬁlms in areas where malaria is endemic.\\nUrinary dipstick: check for haemoglobinuria or haematuria.\\nIf sickle cell disease is suspected\\xa0(to be done before blood transfusion): rapid diagnostic test (Sickle SCAN®) or, if\\nnot available, Emmel test.\\nFull blood count\\xa0(FBC) if available to guide diagnosis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 45, 'page_label': '46', 'id': 'data/guideline-170-en.pdf:45:0'}, page_content='Page 46 / 409\\n\\xa0\\nAetiological treatment\\nAnaemia in itself is not an indication for transfusion. Most anaemias are well tolerated and can be corrected with simple\\naetiological treatment.\\nAetiological treatment may be given alone or together with transfusion.\\nferrous salts/folic acid\\xa0PO, or if not available,\\xa0ferrous salts PO, for 3 months\\nDoses are expressed in\\xa0elemental iron :\\n\\xa0\\n\\xa0\\nfolic acid\\xa0PO for 4 months:\\nCharacteristics Main diagnoses\\nMacrocytic\\xa0 Deﬁciency (folic acid, vitamin B ), chronic alcoholism12\\nMicrocytic Iron deﬁciency (malnutrition, chronic haemorrhage), chronic inﬂammation (HIV\\ninfection, cancer), thalassaemia\\nNormocytic\\xa0 Acute haemorrhage, renal failure, haemolysis\\nReduced number of\\nreticulocytes\\nDeﬁciency (iron, folic acid, vitamin B ), spinal tumour, renal failure12'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 45, 'page_label': '46', 'id': 'data/guideline-170-en.pdf:45:1'}, page_content='Deﬁciency (iron, folic acid, vitamin B ), spinal tumour, renal failure12\\nIncreased or normal number of\\nreticulocytes\\nHaemolysis, sickle cell disease, thalassaemia\\nEosinophilia Ancylostomiasis, trichuriasis, schistosomiasis, HIV infection, malignant\\nhaemopathies\\nIron deﬁciency\\n a \\nChildren 1 month to < 6 years: 1.5 to 3 mg/kg 2 times daily\\nChildren 6 to < 12 years: 65 mg 2 times daily\\nChildren ≥ 12 years and adults: 65 mg 2 to 3 times daily\\nAge Weight\\nTreatment\\n45 mg/5 ml syrup 60 or 65 mg tablet\\n1 month to < 1 year 4\\xa0to\\xa0< 10 kg 1.5 ml x 2 –\\n1\\xa0to\\xa0< 6\\xa0years 10\\xa0to\\xa0< 20 kg 2.5 ml x 2 –\\n6\\xa0to\\xa0< 12\\xa0years 20\\xa0to\\xa0< 40 kg – 1\\xa0tab\\xa0x 2\\n≥ 12\\xa0years\\xa0and adults \\xa0≥ 40 kg \\xa0 1\\xa0tab\\xa0x 2 or 3\\nHelminthic infections: see\\xa0Schistosomiasis\\xa0and\\xa0Nematode infections\\xa0(Chapter 6).\\nFolic acid deﬁciency (rarely isolated)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 45, 'page_label': '46', 'id': 'data/guideline-170-en.pdf:45:2'}, page_content='Folic acid deﬁciency (rarely isolated)\\nChildren under 1 year: 0.5 mg/kg once daily\\nChildren 1 year and over and adults: 5 mg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 46, 'page_label': '47', 'id': 'data/guideline-170-en.pdf:46:0'}, page_content='Page 47 / 409\\nBlood transfusion\\nIndications\\nTo decide whether to transfuse, several parameters should be taken into account:\\nIf transfusion is indicated, it should be carried out without delay . For transfusion thresholds, see\\xa0Table 2.\\nVolume to be transfused\\nIf presence of haemorrhagic shock: see Shock, Chapter 1. Otherwise:\\xa0\\nTransfusion volume is based on presence or absence of fever at\\xa0any point from the time of ordering blood to the\\ntime of transfusion:\\xa0\\n\\xa0\\n\\xa0Repeat if necessary, depending on clinical condition.\\nMonitoring\\nRepeat the injection (same dose) after 2 hours if necessary.\\nMalaria: see\\xa0Malaria\\xa0(Chapter 6).\\xa0In the event of associated iron deﬁciency, wait 4 weeks after malaria treatment\\nbefore prescribing iron supplements.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 46, 'page_label': '47', 'id': 'data/guideline-170-en.pdf:46:1'}, page_content='before prescribing iron supplements.\\nSuspected haemolytic anaemia: stop any drug that causes haemolysis in patients with (or that may possibly have)\\nG6PD deﬁciency.\\nClinical tolerance of anaemia\\nUnderlying conditions (cardiovascular disease, infection, etc.)\\nRate at which anaemia develops.\\nHb levels\\n b \\nChildren : [3] \\nIf no fever (axillary temperature ≤ 37.5 °C) : administer either\\xa015 ml/kg of packed red blood cells (PRBC)\\xa0over 3\\nhours or 30 ml/kg of whole blood over 4 hours\\n c \\nIf fever (axillary temperature > 37.5 °C) : administer either\\xa010 ml/kg of PRBC over 3 hours or 20 ml/kg of whole\\nblood over 4 hours\\n c \\nAdolescents and adults:\\xa0start with an adult unit of PRBC\\xa0or\\xa0whole blood; do not exceed a transfusion rate of 5\\nml/kg/hour.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 46, 'page_label': '47', 'id': 'data/guideline-170-en.pdf:46:2'}, page_content='ml/kg/hour.\\nMonitor the patient’s condition and vital signs (heart rate, blood pressure, respiratory rate, temperature):\\nDuring the transfusion: 5 minutes after the start of transfusion, then every 15 minutes during the ﬁrst hour, then\\nevery 30 minutes until the end of the transfusion.\\nAfter the transfusion: 4 to 6 hours after the end of the transfusion.\\nPay attention to signs of transfusion reaction, ﬂuid overload, decompensation or continuing blood loss.\\nFor children:\\xa0measure Hb once between 8 and 24 hours after\\xa0the end of the transfusion or if signs of\\ndecompensation\\xa0or\\xa0continuing blood loss.\\nIf signs of circulatory overload appear:\\nStop temporarily the transfusion.\\nSit the patient in an upright position.\\nAdminister\\xa0oxygen.\\nAdminister\\xa0furosemide\\xa0by slow IV injection:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 46, 'page_label': '47', 'id': 'data/guideline-170-en.pdf:46:3'}, page_content='Administer\\xa0oxygen.\\nAdminister\\xa0furosemide\\xa0by slow IV injection:\\nChildren: 0.5 to 1 mg/kg\\nAdults: 20 to 40 mg\\nOnce the patient has been stabilised, start the transfusion again after 30 minutes.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 47, 'page_label': '48', 'id': 'data/guideline-170-en.pdf:47:0'}, page_content='Page 48 / 409\\nPrevention\\nferrous salts/folic acid\\xa0PO, or if not available,\\xa0ferrous salts PO,\\xa0as long as the\\xa0risk of deﬁciency persists (e.g.\\npregnancy , malnutrition).\\nDoses are expressed in elemental iron :\\n\\xa0\\n\\xa0\\n\\xa0\\nTable 2\\xa0- Deﬁnition of anaemia and transfusion thresholds\\xa0\\nIron (and folic acid) deﬁciency:\\nDrug supplements:\\n [4] \\n a \\nChildren 1 month to < 12 years: 1 to 2 mg/kg once daily (max. 65 mg daily)\\nChildren ≥ 12 years and adults: 65 mg\\xa0once daily\\nAge Weight\\nPrevention\\n45 mg/5 ml syrup 60 or 65 mg tablet\\n1 month to < 1 year 4\\xa0to\\xa0< 10 kg 1 ml –\\n1\\xa0to\\xa0< 6\\xa0years 10\\xa0to\\xa0< 20 kg 2.5 ml –\\n6\\xa0to\\xa0< 12\\xa0years 20\\xa0to\\xa0< 40 kg 5 ml –\\n≥ 12\\xa0years\\xa0and adults ≥ 40 kg – 1 tab\\nNutritional supplements (if the basic diet is insufﬁcient).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 47, 'page_label': '48', 'id': 'data/guideline-170-en.pdf:47:1'}, page_content='Nutritional supplements (if the basic diet is insufﬁcient).\\nIn the event of sickle cell anaemia: see\\xa0Sickle cell disease (Chapter 12).\\nEarly treatment of malaria, helminthic infections, etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 48, 'page_label': '49', 'id': 'data/guideline-170-en.pdf:48:0'}, page_content='Page 49 / 409\\nReferences\\nPatients Hb levels deﬁning\\nanaemia Transfusion thresholds\\nChildren 2-6 months < 9.5 g/dl Hb < 4 g/dl, even if there are no signs of\\ndecompensation\\nHb ≥ 4 g/dl and < 6 g/dl if there are signs of\\ndecompensation or ongoing blood loss or severe\\nmalaria or serious bacterial infection or pre-existing\\nheart disease (a)\\nChildren 6 months-4\\xa0years < 11 g/dl\\nChildren 5-11 years < 11.5 g/dl\\nChildren 12-14 years < 12 g/dl\\nMen\\xa0(≥ 15 years) < 13 g/dl Hb < 7 g/dl if there are signs of decompensation or\\nongoing blood loss or severe malaria or serious bacterial\\ninfection or pre-existing heart diseaseWomen\\xa0(≥ 15 years) < 12\\xa0g/dl\\nPregnant women\\n\\xa0\\n< 11 g/dl\\n(1  and 3  trimester)\\xa0< 10.5 g/dl\\n(2  trimester)\\n\\xa0\\nst rd\\nnd\\n< 36 weeks\\nHb ≤ 5 g/dl, even if there are no signs of\\ndecompensation'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 48, 'page_label': '49', 'id': 'data/guideline-170-en.pdf:48:1'}, page_content='st rd\\nnd\\n< 36 weeks\\nHb ≤ 5 g/dl, even if there are no signs of\\ndecompensation\\nHb > 5 g/dl and < 7 g/dl if there are signs of\\ndecompensation or sickle cell disease or severe\\nmalaria or serious bacterial infection or pre-existing\\nheart disease\\n≥ 36 weeks\\nHb ≤ 6 g/dl, even if there are no signs of\\ndecompensation\\nHb > 6 g/dl and < 8 g/dl if there are signs of\\ndecompensation or sickle cell disease or severe\\nmalaria or serious bacterial infection or pre-existing\\nheart disease'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 48, 'page_label': '49', 'id': 'data/guideline-170-en.pdf:48:2'}, page_content='malaria or serious bacterial infection or pre-existing\\nheart disease\\n(a) Immediate transfusion is not required in children 2 months to 12 years with Hb ≥ 4 g/dl and < 6 g/dl and no sign ofdecompensation or ongoing blood loss, provided that:• they are closely monitored (including Hb measurements at 8, 24 and 48 hours), and• transfusion preparation (blood grouping, etc.) is carried out without delay in case the child needs to be transfused lateron.\\nFootnotes\\n(a) A coformulated tablet of ferrous salts/folic acid contains 185 mg of ferrous fumarate or sulfate (equivalent to 60 mg ofelemental iron) and 400 micrograms of folic acid.A 200 mg tablet of ferrous\\xa0fumarate or sulfate contains 65 mg of elemental iron.A 140 mg/5 ml syrup of ferrous fumarate contains 45 mg/5 ml of elemental iron.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 48, 'page_label': '49', 'id': 'data/guideline-170-en.pdf:48:3'}, page_content='(b) Before transfusing: determine the recipient’s and potential donors’ blood groups/rhesus and carry out screening tests onthe donor’s blood for HIV-1 and 2, hepatitis B and C, syphilis and, in endemic areas, malaria and Chagas disease.\\n(c) Axillary temperature should be taken at the time of ordering blood\\xa0and immediately prior to transfusion.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 49, 'page_label': '50', 'id': 'data/guideline-170-en.pdf:49:0'}, page_content='Page 50 / 409\\n1. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. WorldHealth Organization; 2011. [Accessed June 26, 2023]https://apps.who.int/iris/handle/10665/85839\\n2. World Health Organization. Educational Modules on Clinical Use of Blood. World Health Organization; 2021.\\xa0[Accessed June26, 2023]https://apps.who.int/iris/handle/10665/350246\\n3. Maitland K, Olupot-Olupot P, Kiguli S, et al. Transfusion Volume for Children with Severe Anemia in Africa. N Engl J Med.2019;381(5):420-431.https://doi.org/10.1056/NEJMoa1900100\\n4. Word Health Organization. Daily iron and folic acid supplementation in pregnant women. Word Health Organization. Geneva,2012.\\xa0[Accessed June 26, 2023]https://apps.who.int/iris/handle/10665/77770'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 50, 'page_label': '51', 'id': 'data/guideline-170-en.pdf:50:0'}, page_content='Page 51 / 409\\nDehydration\\nDehydration results from excessive loss of water and electrolytes from the body. If prolonged, dehydration can\\ncompromise organ perfusion, resulting in shock.\\nIt is principally caused by diarrhoea, vomiting and severe burns.\\nChildren are particularly susceptible to dehydration due to frequent episodes of gastroenteritis, high surface area to\\nvolume ratio and inability to fully communicate, or independently meet their ﬂuid needs.\\xa0The protocols below are focused on treatment of dehydration caused by diarrhoea and vomiting. Alternative treatment\\nprotocols should be used for children with malnutrition (see Severe acute malnutrition, Chapter 1) or in patients with\\nsevere burns (see Burns, Chapter 10).\\nClinical features and assessment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 50, 'page_label': '51', 'id': 'data/guideline-170-en.pdf:50:1'}, page_content='severe burns (see Burns, Chapter 10).\\nClinical features and assessment\\n\\xa0\\nClassiﬁcation of degree of dehydration (adapted from the WHO)\\xa0\\nTreatment of dehydration\\nHistory of diarrhoea and/or vomiting and concomitant reduced urine output.\\nClinical features depend on the degree of dehydration (see table below). Features such as dry mouth, absence of\\ntears may also be noted.\\nPatients with severe dehydration should be assessed for shock (tachycardia, low blood pressure and delayed\\ncapillary reﬁll time etc.).\\nElectrolyte disorders may cause tachypnoea, muscle cramps or weakness, cardiac arrhythmia (irregular heart rate,\\npalpitation), confusion and/or seizures.\\n [1] [2]\\n\\xa0\\n\\xa0\\nSevere dehydration\\nAt least 2 of the\\nfollowing signs:\\nSome dehydration\\nAt least 2 \\nof the following signs:\\nNo dehydration'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 50, 'page_label': '51', 'id': 'data/guideline-170-en.pdf:50:2'}, page_content='Some dehydration\\nAt least 2 \\nof the following signs:\\nNo dehydration\\nNo signs of \"severe\"\\nor \"some\" dehydration.\\nMental status Lethargic or\\nunconscious Restless or irritable Normal\\nRadial pulse Weak or absent Palpable Easily palpable\\nEyes (a) Sunken Sunken Normal\\nSkin pinch (b) Goes back very slowly \\n(> 2 seconds)\\nGoes back slowly\\n(< 2 seconds)\\nGoes back quickly\\n(< 1 second)\\nThirst Drinks poorly\\nor not able to drink\\nThirst, \\ndrinks quickly\\nNo thirst,\\ndrinks normally\\n(a) Sunken eyes may be a normal feature in some children. Ask the mother if the child\\'s eyes are the same as usual or if they aremore sunken than usual.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 50, 'page_label': '51', 'id': 'data/guideline-170-en.pdf:50:3'}, page_content='(b) Skin pinch is assessed by pinching the skin of the abdomen between the thumb and foreﬁnger without twisting. In olderpeople this sign is not reliable as normal aging diminishes skin elasticity.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 51, 'page_label': '52', 'id': 'data/guideline-170-en.pdf:51:0'}, page_content='Page 52 / 409\\nSevere dehydration\\n\\xa0\\nWHO Treatment Plan C\\xa0\\n\\xa0\\n\\xa0\\nSome dehydration\\n\\xa0\\nWHO Treatment Plan B\\nTreat shock if present (see Shock, Chapter 1).\\nIf able to drink, administer oral rehydration solution (ORS) PO whilst obtaining IV access.\\n\\xa0according to WHO Treatment Plan C, monitoring infusion rate closely:\\nInsert peripheral IV line using large caliber catheter (22-24G in children or 18G in adults) or intraosseous needle.\\nAdminister Ringer lactate (RL) a\\n [1] [2]\\nAge First, give 30 ml/kg over : (c) Then, give 70 ml/kg over:\\nChildren < 1 year 1 hour 5 hours\\nChildren ≥\\xa01 year and adults 30 minutes 2\\xa0½ hours\\n(c) Repeat once if radial pulse remains weak or absent after ﬁrst bolus.\\nIn case of suspected severe anaemia, measure haemoglobin and treat accordingly (see Anaemia, Chapter 1). b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 51, 'page_label': '52', 'id': 'data/guideline-170-en.pdf:51:1'}, page_content='As soon as the patient is able to drink safely (often within 2 hours), provide ORS as the patient tolerates. ORS\\ncontains glucose and electrolytes which prevent development of complications.\\nMonitor ongoing losses closely. Assess clinical condition and degree of dehydration at regular intervals to ensure\\ncontinuation of appropriate treatment.\\nIf over the course of treatment the patient:\\nremains or becomes lethargic: measure blood glucose level and/or treat hypoglycaemia (see Hypoglycaemia,\\nChapter 1).\\ndevelops muscle cramps/weakness and abdominal distention: treat for moderate hypokalaemia with 7.5%\\npotassium chloride syrup (1 mmol of K/ml) PO for 2 days:\\nChildren under 45 kg: 2 mmol/kg (2 ml/kg) daily (according to weight, the daily dose is divided into 2 or 3 doses)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 51, 'page_label': '52', 'id': 'data/guideline-170-en.pdf:51:2'}, page_content='Children 45 kg and over and adults: 30 mmol (30 ml) 3 times daily\\nThis treatment should only be given as an inpatient .\\n+\\n c \\ndevelops peri-orbital or peripheral oedema: reduce the infusion rate to a minimum, auscultate the lungs, re-\\nevaluate the stage of dehydration and the necessity of continuing IV rehydration. If IV rehydration is still required,\\ncontinue the infusion at a slower rate and observe the patient closely. If IV rehydration is no longer required,\\nchange to oral treatment with ORS.\\ndevelops dyspnoea, cough and bibasal crepitations are heard on auscultation of the lungs: sit the patient up,\\nreduce the infusion rate to a minimum and administer one dose of furosemide IV (1 mg/kg in children; 40 mg in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 51, 'page_label': '52', 'id': 'data/guideline-170-en.pdf:51:3'}, page_content='adults). Monitor the patient closely over 30 minutes and assess for underlying cardiorespiratory or renal disease.\\nOnce the patient is stabilised, reassess the degree of dehydration and the necessity of continuing IV rehydration.\\nIf IV rehydration is still required, re-start at half the previous infusion rate and monitor closely. If IV rehydration is\\nno longer required, change to oral treatment with ORS.\\nAdminister ORS according to WHO Treatment Plan B which equates to 75 ml/kg ORS given over 4 hours.\\n [1] d'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 52, 'page_label': '53', 'id': 'data/guideline-170-en.pdf:52:0'}, page_content=\"Page 53 / 409\\n\\xa0\\n\\xa0\\nNo dehydration\\nPrevent dehydration:\\n\\xa0\\nWHO Treatment Plan A\\xa0\\n\\xa0\\nTreatment of diarrhoea\\nIn addition to the WHO treatment plan corresponding to patient's degree of dehydration:\\n\\xa0\\nAge <\\xa04\\nmonths\\n4 to\\n11\\xa0months\\n12 to\\n23\\xa0months 2 to 4\\xa0years 5 to\\n14\\xa0years ≥\\xa015 years\\nWeight < 5 kg 5 to \\n7.9 kg\\n8 to \\n10.9 kg\\n11 to 15.9\\nkg\\n16 to 29.9\\nkg ≥\\xa030 kg\\nQuantity of ORS over\\n4 hours\\n200 to 400\\nml\\n400 to \\n600 ml\\n600 to \\n800 ml\\n800 to 1200\\nml\\n1200 to\\n2200 ml\\n2200 to\\n4000 ml\\nEncourage additional age-appropriate ﬂuid intake, including breastfeeding in young children. Give additional ORS\\nafter each loose stool (see below).\\nMonitor ongoing losses closely. Assess clinical condition and degree of dehydration at regular intervals to ensure\\ncontinuation of appropriate treatment.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 52, 'page_label': '53', 'id': 'data/guideline-170-en.pdf:52:1'}, page_content='continuation of appropriate treatment.\\nEncourage age-appropriate ﬂuid intake, including breastfeeding in young children.\\nAdminister ORS according to WHO Treatment Plan A after any loose stool.\\n [1] [2]\\nAge Quantity of ORS\\nChildren\\xa0< 2 years 50 to 100 ml\\xa0(10 to 20 teaspoons)\\nChildren 2 to 10 years 100 to 200 ml\\xa0(½ to 1 glass)\\nChildren\\xa0> 10 years and adults at least 250 ml (at least 1 glass)\\nAdminister aetiologic treatment if required.\\nAdminister zinc sulfate to children under 5 years (see Acute diarrhoea, Chapter 3).\\nFootnotes\\n(a) If RL not available, 0.9% sodium chloride can be used.\\n(b) If transfusion is required, it should be provided in parallel to IV ﬂuids, using a separate IV line. The blood volume administeredshould be deducted from the total volume of Plan C.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 52, 'page_label': '53', 'id': 'data/guideline-170-en.pdf:52:2'}, page_content='(c) If available, take blood tests to monitor urea and electrolyte levels.\\n(d) For more detailed information on ORS\\xa0recommendations by age and weight, refer to the guide Management of a choleraepidemic, MSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 53, 'page_label': '54', 'id': 'data/guideline-170-en.pdf:53:0'}, page_content='Page 54 / 409\\nReferences\\n1. World Health Organization. The treatment of diarrhoea : a manual for physicians and other senior health workers, 4threv.\\xa0World Health Organization. 2005.\\xa0https://apps.who.int/iris/handle/10665/43209\\n2. World Health Organization. Pocket book of Hospital Care for children. Guidelines for the Management of CommonChildhood Illnesses. 2013.https://apps.who.int/iris/bitstream/handle/10665/81170/9789241548373_eng.pdf?sequence=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 54, 'page_label': '55', 'id': 'data/guideline-170-en.pdf:54:0'}, page_content='Page 55 / 409\\nSevere acute malnutrition\\nLast updated: February 2024\\n\\xa0\\nSevere acute malnutrition (SAM) results from insufﬁcient energy (kilocalories), fat, protein and/or other nutrients\\n(vitamins and minerals, etc.) to cover individual needs.\\xa0SAM\\xa0is frequently associated with medical complications due to metabolic disturbances and compromised\\xa0immunity. It\\nis a major cause of morbidity and mortality in children globally.\\xa0The protocols below are focused on the diagnosis and management of SAM in children 6 to 59 months only.\\xa0For\\nfurther details regarding this age group, and guidance for other age groups, refer to national recommendations and/or\\nspecialised protocols.\\xa0\\nClinical assessment\\nCharacteristic physical signs\\nDiagnostic and admission criteria'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 54, 'page_label': '55', 'id': 'data/guideline-170-en.pdf:54:1'}, page_content='Characteristic physical signs\\nDiagnostic and admission criteria\\nDiagnostic criteria\\xa0for SAM are\\xa0both anthropometric and clinical:\\n\\xa0Admission criteria for SAM treatment programmes vary with context. Refer to national recommendations.\\nMedical complications\\nNutritional treatment\\nIn marasmus: skeletal appearance resulting from signiﬁcant loss of muscle mass and subcutaneous fat.\\nIn kwashiorkor:\\nBilateral oedema of the lower limbs sometimes extending to other parts of the body (e.g. arms and hands, face).\\nDiscoloured, brittle hair; shiny skin which may crack, weep, and become infected.\\nMid-upper arm circumference (MUAC) measures the degree of muscle wasting. MUAC < 115 mm indicates\\nSAM\\xa0and signiﬁcant mortality risk.\\n a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 54, 'page_label': '55', 'id': 'data/guideline-170-en.pdf:54:2'}, page_content='SAM\\xa0and signiﬁcant mortality risk.\\n a \\nWeight-for-height z-score (WHZ) indicates the degree of weight loss by comparing the weight of\\xa0the child with the\\nmedian weight of non-malnourished children of the same height and sex. SAM is deﬁned as WHZ < –3 with\\nreference to the WHO Child\\xa0Growth Standards . b \\nThe presence of bilateral pitting oedema of the lower limbs (when other causes of oedema have\\xa0been ruled out)\\nindicates SAM, regardless of MUAC and WHZ.\\nChildren with any of the following severe medical conditions should receive hospital-based medical management:\\nPitting oedema extending from the lower limbs up to the face;\\nAnorexia (observed during appetite test);\\nOther severe complications: persistent vomiting, shock, altered mental status, seizures, severe anaemia'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 54, 'page_label': '55', 'id': 'data/guideline-170-en.pdf:54:3'}, page_content='(clinically suspected or conﬁrmed), persistent hypoglycaemia, eye lesions due to vitamin A deﬁciency, frequent\\nor abundant diarrhoea, dysentery, dehydration, severe malaria, pneumonia, meningitis, sepsis, severe cutaneous\\ninfection, fever of unknown origin, etc.\\nIn the absence of these conditions, children should be treated as outpatients with regular follow-up.\\nAll children with SAM should receive nutritional treatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 55, 'page_label': '56', 'id': 'data/guideline-170-en.pdf:55:0'}, page_content='Page 56 / 409\\nRoutine medical management\\xa0\\nThe following should be provided to all inpatients and outpatients with SAM:\\xa0\\n\\xa0\\nNutritional treatment is based on the use of specialised nutritious foods enriched with vitamins and minerals: F-75\\nand F-100 therapeutic milks, and ready-to-use therapeutic food (RUTF).\\nNutritional treatment is organised into phases:\\nPhase 1 (inpatient) intends to restore metabolic functions and treat or stabilize medical complications. Children\\nreceive F-75 therapeutic milk. This phase may last 1 to 7 days, after which children usually enter transition\\nphase. Children with medical complications generally begin with phase 1.\\nTransition phase (inpatient) intends to ensure tolerance of increased food intake and continued improvement of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 55, 'page_label': '56', 'id': 'data/guideline-170-en.pdf:55:1'}, page_content='clinical condition. Children receive F-100 therapeutic milk and/or RUTF. This phase usually lasts 1 to 3 days, after\\nwhich children enter phase 2.\\nPhase 2 (outpatient or inpatient) intends to promote rapid weight gain and catch-up growth. Children receive\\nRUTF. This phase usually lasts 1 to 3 days when inpatient, after which children are discharged for outpatient\\ncare. Children without medical complications enter directly into this phase as outpatients. The outpatient\\ncomponent usually lasts several weeks.\\nBreastfeeding should be continued in breastfed children.\\nDrinking water should be given in addition to meals, especially if the\\xa0ambient temperature is high, or the child has a\\nfever or is receiving RUTF.\\nAntibiotic\\ntreatment\\nFrom D1, unless speciﬁc signs of infection are present:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 55, 'page_label': '56', 'id': 'data/guideline-170-en.pdf:55:2'}, page_content='Antibiotic\\ntreatment\\nFrom D1, unless speciﬁc signs of infection are present:\\namoxicillin PO: 50 mg/kg (max. 1 g) 2 times daily for 5 to 7 days\\nMalaria On D1, rapid diagnostic test in endemic areas and treatment for malaria according to results or if\\ntesting is not available (see Malaria, Chapter 6).\\nIntestinal\\nparasites\\nIn transition phase\\xa0or upon outpatient admission, albendazole PO:\\nChildren 12 to 23 months: 200 mg single dose\\nChildren 24 months and over: 400 mg single dose\\nVaccination\\nChildren vaccinated between 6 and 8 months should be re-vaccinated as above (i.e. with 2\\ndoses) once they reach 9 months of age, provided that an interval of 4 weeks from the ﬁrst dose\\nis respected.\\nIn transition phase or upon outpatient admission, measles vaccine for children 6 months to 5'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 55, 'page_label': '56', 'id': 'data/guideline-170-en.pdf:55:3'}, page_content='years, unless a document shows that the child received 2 doses of vaccine administered as\\nfollows: one dose at or after 9 months and one dose at least 4 weeks after the ﬁrst dose.\\u202f\\nOther vaccines included in the EPI: check vaccination status and refer the child to vaccination\\nservices at discharge.\\nTuberculosis\\n(TB)\\n\\xa0\\nAt D1 then regularly during treatment, screen for TB. For a child screening positive, perform\\ncomplete diagnostic evaluation.\\nFor more information, refer to the guide Tuberculosis, MSF.\\nHIV infection\\n\\xa0\\nPerform HIV counselling and testing (unless the mother explicitly declines testing).\\nChildren under 18 months: test the mother with rapid diagnostic tests. For a mother testing\\npositive, request PCR test for the child.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 55, 'page_label': '56', 'id': 'data/guideline-170-en.pdf:55:4'}, page_content='positive, request PCR test for the child.\\nChildren 18 months and over: test the child with rapid diagnostic tests.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 56, 'page_label': '57', 'id': 'data/guideline-170-en.pdf:56:0'}, page_content='Page 57 / 409\\nManagement of complications\\nInfections\\nSevere anaemia\\nDiarrhoea and dehydration\\n\\xa0\\nRespiratory, cutaneous and urinary infections are common. However, classic signs of infection, such as fever, may\\nbe absent . [1] \\nSevere infection or sepsis should be suspected in children\\xa0that are lethargic or apathetic or suffering from\\xa0an acute\\ncomplication\\xa0such as\\xa0hypothermia, hypoglycaemia, seizures, difﬁculty breathing, or shock. Immediately\\nadminister\\xa0ampicillin IV 50 mg/kg every 8 hours\\xa0+ gentamicin IV 7.5 mg/kg once daily. Continue this treatment\\nunless\\xa0the source of infection is identiﬁed and different antibiotic treatment is required.\\nIf circulatory impairment or shock, immediately administer\\xa0ceftriaxone IV, one dose of 80 mg/kg, then assess the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 56, 'page_label': '57', 'id': 'data/guideline-170-en.pdf:56:1'}, page_content=\"source of infection to determine further antibiotic treatment. See also Shock, Chapter 1. Transfuse urgently as for\\nsevere anaemia (see below) if haemoglobin (Hb)\\xa0 is < 6 g/dl.\\xa0\\nIn less severe infections, assess the source of infection (see Fever, Chapter 1) and treat accordingly.\\nIf fever is present and causes discomfort, undress the child.\\xa0If insufﬁcient, administer paracetamol PO in low dose:\\n10 mg/kg, up to 3 times maximum\\xa0per 24 hours. Encourage oral ﬂuids (including breast milk).\\nIf hypothermia is present, place the child skin-to-skin against the mother's body and cover with a warm blanket.\\nTreat for infection as above. Check blood glucose level and treat for hypoglycaemia if necessary (see\\nHypoglycaemia, Chapter 1).\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 56, 'page_label': '57', 'id': 'data/guideline-170-en.pdf:56:2'}, page_content='Hypoglycaemia, Chapter 1).\\nIn children with kwashiorkor, infection of cutaneous lesions is common and may progress to soft tissue or systemic\\ninfection. If cutaneous infection is present, stop amoxicillin and start amoxicillin/clavulanic acid PO. Use\\nformulations in a ratio of 8:1 or 7:1. The dose is expressed in amoxicillin: 50 mg/kg 2 times daily for 7 days.\\nChildren with Hb < 4 or < 6 with signs of decompensation (such as respiratory distress) or ongoing blood loss require\\ntransfusion within the ﬁrst 24 hours. See Anaemia (Chapter 1) for\\xa0volume to be transfused and patient\\xa0monitoring\\nduring and after transfusion.\\nPreferably use packed red blood cells (PRBC),\\xa0if available.\\xa0Monitor closely for signs of ﬂuid overload (see box\\nbelow).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 56, 'page_label': '57', 'id': 'data/guideline-170-en.pdf:56:3'}, page_content='below).\\xa0\\nDiarrhoea is common. Therapeutic foods facilitate the recovery of physiological function of the gastrointestinal\\ntract.\\xa0Amoxicillin administered as part of routine treatment reduces intestinal bacterial overgrowth.\\xa0Diarrhoea\\ngenerally resolves without additional treatment. If an aetiological treatment is necessary, see\\xa0Acute diarrhoea,\\nChapter 3.\\nZinc supplementation is not needed if children consume recommended amounts of therapeutic foods.\\nThe diagnosis of dehydration is based on history and clinical features.\\nClinical assessment is difﬁcult in children with SAM as delayed skin pinch test and sunken eyes are often present\\neven in the absence of dehydration.\\nFor classiﬁcation of degree of dehydration adapted for children with SAM, see table below:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 57, 'page_label': '58', 'id': 'data/guideline-170-en.pdf:57:0'}, page_content='Page 58 / 409\\n\\xa0\\nAcute diarrhoea with no dehydration (Plan A SAM)\\nAcute diarrhoea with some dehydration (Plan B SAM)\\nAcute diarrhoea with severe dehydration (Plan C SAM)\\nClinical features\\n(2 or more of the following signs)\\nNo\\ndehydration\\nSome\\ndehydration\\nSevere\\ndehydration\\nMental status Normal Restless, irritability Lethargic\\xa0or\\nunconscious\\nThirst No thirst, drinks\\nnormally Thirsty, drinks eagerly Unable to drink or drinks\\npoorly\\nUrine output Normal Reduced Absent for\\nseveral hours\\nRecent frequent watery\\ndiarrhoea and/or vomiting Yes Yes Yes\\nRecent obvious rapid weight\\nloss No Yes Yes\\nStools are neither frequent nor abundant (outpatient):\\xa0oral rehydration solution (ORS) PO: 5 ml/kg after each loose\\nstool to prevent dehydration.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 57, 'page_label': '58', 'id': 'data/guideline-170-en.pdf:57:1'}, page_content='stool to prevent dehydration.\\nStools are frequent and/or abundant (inpatient):\\xa0ReSoMal PO or by nasogastric tube (NGT):\\xa05 ml/kg after each\\nloose stool to\\xa0prevent dehydration.\\n c \\nIn all cases, continue feeding and breastfeeding, encourage oral ﬂuids.\\nDetermine the target weight (weight before the onset of diarrhoea) before starting rehydration. If not feasible (e.g.\\nnew admission), estimate target weight as current weight x 1.06.\\nReSoMal PO or by NGT: 20 ml/kg/hour for 2 hours. In addition, administer\\xa05 ml/kg of\\xa0ReSoMal after each loose\\nstool if tolerated.\\n c \\nAssess after 2 hours (clinical evaluation and weight):\\nIf improvement (diarrhoea and signs of dehydration regress):\\nReduce ReSoMal to 10 ml/kg/hour until the signs of dehydration and/or weight\\xa0loss (known or estimated)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 57, 'page_label': '58', 'id': 'data/guideline-170-en.pdf:57:2'}, page_content='have been corrected.\\nAssess every 2 hours.\\nOnce there are no signs of dehydration and/or the target weight is reached, change to Plan A SAM to\\nprevent dehydration.\\nIf no improvement after 2 to 4 hours or if oral rehydration cannot compensate for losses: change to Plan C SAM\\n\"with circulatory impairment\".\\nContinue feeding including breastfeeding.\\nMonitor for signs of ﬂuid overload (see box below).\\xa0Regardless of the target weight, stop rehydration if signs\\nof\\xa0ﬂuid overload appear.\\nIn all patients:\\nAssess for circulatory impairment (see Shock, Chapter 1).\\nEstimate target weight as current weight x 1.1.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 58, 'page_label': '59', 'id': 'data/guideline-170-en.pdf:58:0'}, page_content='Page 59 / 409\\n\\xa0\\nSigns of ﬂuid overload\\xa0include:\\nPlus any one of the following:\\n\\xa0\\nOther complications\\nFor other complications (to be treated as inpatient), see:\\nMeasure blood glucose level and treat hypoglycaemia\\xa0(Chapter 1) if necessary.\\nMonitor vital signs and signs of dehydration every 15 to 30 minutes.\\nMonitor urine output.\\nMonitor for signs of ﬂuid overload (see box below).\\nIf there is no circulatory impairment:\\nReSoMal PO or by NGT: 20 ml/kg over 1 hour\\nIf the child is alert, continue feeding including breastfeeding.\\nAssess after 1 hour:\\nIf improvement: change to Plan B SAM, but keep the same target weight.\\nIf rehydration PO/NGT not tolerated (e. g.\\xa0vomiting):\\nStop ReSoMal. Administer\\xa0glucose 5%-Ringer lactate\\xa0(G5%-RL) IV infusion: 10 ml/kg/hour for 2 hours. d'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 58, 'page_label': '59', 'id': 'data/guideline-170-en.pdf:58:1'}, page_content='Assess after 2 hours of IV ﬂuids:\\nIf improvement and/or not vomiting, stop G5%-RL IV infusion and change to Plan B SAM.\\nIf no improvement or still vomiting, continue G5%-RL IV infusion: 10 ml/kg/hour for 2 hours.\\nIf deterioration with circulatory impairment: see below.\\nIf there is circulatory impairment:\\nAdminister ceftriaxone IV,\\xa0one dose of 80 mg/kg. Subsequent antibiotic treatment depends on assessment of\\nunderlying cause.\\nAdminister G5%-RL\\xa0IV infusion: 10 ml/kg/hour for 2 hours. Stop ReSoMal if the child was taking it.\\nAssess after 1 hour of IV ﬂuids:\\nIf improvement and no vomiting: stop IV ﬂuid and change to Plan B SAM, but keep\\xa0the same target weight.\\nIf no improvement:\\nContinue G5%-RL\\xa0IV infusion: 10 ml/kg/hour.\\nPrepare for blood transfusion.\\nAssess after 2 hours of IV ﬂuids:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 58, 'page_label': '59', 'id': 'data/guideline-170-en.pdf:58:2'}, page_content='Prepare for blood transfusion.\\nAssess after 2 hours of IV ﬂuids:\\nIf improvement: change to Plan B SAM, but keep\\xa0the same target weight.\\nIf no improvement\\xa0or deterioration:\\nCheck Hb as baseline and administer blood transfusion using a separate IV line.\\xa0See Anaemia (Chapter 1)\\nfor\\xa0volume to be transfused and patient\\xa0monitoring during and after transfusion.\\nWhile transfusing, continue G5%-RL IV infusion 10 ml/kg/hour for another 2 hours.\\nRR ≥ 10 breaths/minute compared to initial RR, or\\nHR ≥ 20 beats/minute\\xa0compared to initial HR\\nNew or worsening hypoxia (decrease in SpO by > 5%)2\\nNew onset of rales and/or ﬁne crackles in lung ﬁelds\\nNew galloping heart rhythm\\nIncreased liver size (must have marked liver border with pen before rehydration)\\nNew peripheral or eyelid oedema'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 58, 'page_label': '59', 'id': 'data/guideline-170-en.pdf:58:3'}, page_content='New peripheral or eyelid oedema\\nHypoglycaemia, seizures, Chapter 1.\\nAcute pneumonia, Chapter 2.\\nStomatitis, Chapter 3.\\nXerophthalmia (vitamin A deﬁciency), Chapter 5.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 59, 'page_label': '60', 'id': 'data/guideline-170-en.pdf:59:0'}, page_content='Page 60 / 409\\nDischarge criteria\\nIn general:\\n\\xa0Discharge criteria vary with context. Refer to national recommendations.\\n\\xa0\\nReferences\\nChildren can be discharged from hospital and be treated as outpatients if the following criteria are met:\\nclinically well;\\nmedical complications controlled;\\xa0\\nable to eat RUTF (observed during appetite test);\\nreduction or absence of oedema;\\ncaregiver feels able to provide care as outpatient;\\nvaccinations up to date or referral to vaccination service organised.\\nChildren can be discharged from nutritional treatment\\xa0if the following criteria are met:\\nco-existing medical conditions stable and outpatient treatment organised if necessary (e.g. dressing changes,\\nfollow-up for chronic diseases);\\nvaccinations up to date or referral to vaccination service organised;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 59, 'page_label': '60', 'id': 'data/guideline-170-en.pdf:59:1'}, page_content='vaccinations up to date or referral to vaccination service organised;\\nabsence of oedema and WHZ > –2 or MUAC > 125 mm for at least 2 weeks.\\nFootnotes\\n(a) MUAC is measured at the mid-point of the left upper arm. The arm should be relaxed. The measuring tape should be incontact with the skin all around the arm, without exerting pressure.\\n(b) For WHZ, see WHO simpliﬁed ﬁeld tables in z-scores for girls and for boys:https://www.who.int/tools/child-growth-standards/standards/weight-for-length-height\\n(c) ReSoMal is a speciﬁc oral rehydration solution for malnourished children, containing less sodium and more potassium thanstandard ORS. It should be administered under medical supervision to avoid overdosing and hyponatremia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 59, 'page_label': '60', 'id': 'data/guideline-170-en.pdf:59:2'}, page_content='(d) Remove 50 ml of Ringer lactate (RL) from a 500 ml RL bottle or bag, then add 50 ml of 50% glucose to the remaining 450 mlof RL to obtain 500 ml of 5%\\xa0glucose-RL solution.\\n1. Jones KDJ, Berkley JA. Severe acute malnutrition and infection. Paediatrics and International Child Health 2014; 34(sup1):S1-S29.https://www.tandfonline.com/doi/full/10.1179/2046904714Z.000000000218 [Accessed 24 August 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 60, 'page_label': '61', 'id': 'data/guideline-170-en.pdf:60:0'}, page_content='Page 61 / 409\\nChapter 2: Respiratory diseases\\nAcute upper airway obstruction\\nRhinitis and rhinopharyngitis (common cold)\\nAcute sinusitis\\nAcute pharyngitis\\nDiphtheria\\nOther upper respiratory tract infections\\nCroup (laryngotracheitis and laryngotracheobronchitis)\\nEpiglottitis\\nBacterial tracheitis\\nOtitis\\nAcute otitis externa\\nAcute otitis media (AOM)\\nChronic suppurative otitis media (CSOM)\\nPertussis (whooping cough)\\nBronchitis\\nAcute bronchitis\\nChronic bronchitis\\nBronchiolitis\\nAcute pneumonia\\nPneumonia in children under 5 years of age\\nPneumonia in children over 5 years and adults\\nPersistent pneumonia\\nStaphylococcal pneumonia\\nAsthma\\nAcute asthma (asthma attack)\\nChronic asthma\\nPulmonary tuberculosis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 61, 'page_label': '62', 'id': 'data/guideline-170-en.pdf:61:0'}, page_content='Page 62 / 409\\nAcute upper airway obstruction\\nAcute upper airway obstruction can be caused by foreign body aspiration, viral or bacterial infections (croup,\\nepiglottitis, tracheitis), anaphylaxis, burns or trauma.\\nInitially stable and partial obstruction may worsen and develop into a life-threatening emergency, especially in young\\nchildren.\\nClinical features\\nClinical signs of the severity of obstruction:\\xa0\\n\\xa0\\nManagement in all cases\\nObstruction Signs Danger\\nsigns\\nComplete Respiratory distress followed by cardiac arrest\\nYes\\nImminent\\ncomplete\\nSevere respiratory distress with cyanosis or SpO < 90%2\\nAgitation or lethargy\\nTachycardia, capillary reﬁll time > 3 seconds\\nSevere Stridor (abnormal high pitched sound on inspiration) at rest\\nSevere respiratory distress:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 61, 'page_label': '62', 'id': 'data/guideline-170-en.pdf:61:1'}, page_content='Severe respiratory distress:\\nSevere intercostal and subcostal retractions\\nNasal ﬂaring\\nSubsternal retractions (inward movement of the breastbone during\\ninspiration)\\nSevere tachypnoea\\nModerate Stridor with agitation\\nModerate respiratory distress:\\nMild intercostal and subcostal retractions\\nModerate tachypnoea No\\nMild Cough, hoarse voice, no respiratory distress\\nExamine children in the position in which they are the most comfortable.\\nEvaluate the severity of the obstruction according to the table above.\\nMonitor SpO, except in mild obstruction.2\\nAdminister oxygen continuously:\\nto maintain the SpO\\xa0between 94 and 98% if it is ≤ 90%or if the patient has\\xa0cyanosis or respiratory distress;2  a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 61, 'page_label': '62', 'id': 'data/guideline-170-en.pdf:61:2'}, page_content='if pulse oxymeter is not available: at least 5 litres/minute or to relieve the hypoxia and\\xa0improve respiration.\\nHospitalize (except if obstruction is mild), in intensive care if danger signs.\\nMonitor mental status, heart and respiratory rate, SpO\\xa0and severity of obstruction.2\\nMaintain adequate hydration by mouth if possible, by IV if patient unable to drink.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 62, 'page_label': '63', 'id': 'data/guideline-170-en.pdf:62:0'}, page_content='Page 63 / 409\\nManagement of foreign body aspiration\\nAcute airway obstruction (the foreign body either completely obstructs the pharynx or acts as a valve on the laryngeal\\ninlet), no warning signs, most frequently in a child 6 months-5 years playing with a small object or eating. Conscience is\\ninitially maintained.\\xa0Perform maneuvers to relieve obstruction only if the patient cannot speak or cough or emit any sound:\\nHeimlich manoeuvre: stand behind the patient. Place a closed ﬁst in the pit of the stomach, above the navel and\\nbelow the ribs. Place the other hand over ﬁst and press hard into the abdomen with a quick, upward thrust. Perform\\none to ﬁve abdominal thrusts in order to compress the lungs from the below and dislodge the foreign body.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 62, 'page_label': '63', 'id': 'data/guideline-170-en.pdf:62:1'}, page_content='Place the infant face down across the forearm (resting the forearm on the leg) and support the infant’s head with\\nthe hand. With the heel of the other hand, perform one to ﬁve slaps on the back, between shoulder plates.\\nIf unsuccessful, turn the infant on their back. Perform ﬁve forceful sternal compressions as in cardiopulmonary\\nresuscitation: use 2 or 3 ﬁngers in the center of the chest just below the nipples. Press down approximately one-\\nthird the depth of the chest (about 3 to 4 cm).\\xa0Repeat until the foreign body is expelled and the patient resumes spontaneous breathing (coughing, crying, talking). If\\nthe patient loses consciousness ventilate and perform cardiopulmonary rescucitation. Tracheostomy if unable to\\nventilate.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 62, 'page_label': '63', 'id': 'data/guideline-170-en.pdf:62:2'}, page_content='ventilate.\\nDifferential diagnosis and management of airway obstructions ofinfectious origin\\n\\xa0\\nManagement of other causes\\n\\xa0\\nChildren over 1 year and adults:\\nChildren under 1 year:\\nInfections Symptoms Appearance Timing of\\nsymptoms\\nViral croup Stridor, cough and moderate respiratory\\ndifﬁculty\\nPrefers to sit Progressive\\nEpiglottitis Stridor, high fever and severe respiratory\\ndistress\\nPrefers to sit, drooling (cannot\\nswallow their own saliva)\\nRapid\\nBacterial tracheitis Stridor, fever, purulent secretions and severe\\nrespiratory distress\\nPrefers to lie ﬂat Progressive\\nRetropharyngeal or\\ntonsillar abscess\\nFever, sore throat and painful swallowing,\\nearache, trismus and hot potato voice\\nPrefers to sit, drooling Progressive'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 62, 'page_label': '63', 'id': 'data/guideline-170-en.pdf:62:3'}, page_content='earache, trismus and hot potato voice\\nPrefers to sit, drooling Progressive\\nCroup, epiglottitis, and tracheitis: see\\xa0Other upper respiratory tract infections.\\nAbscess: refer for surgical drainage.\\nAnaphylactic reaction (angioedema): see\\xa0Anaphylactic shock\\xa0(Chapter 1)\\nBurns to the face or neck, smoke inhalation with airway oedema: see\\xa0Burns\\xa0(Chapter 10).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 63, 'page_label': '64', 'id': 'data/guideline-170-en.pdf:63:0'}, page_content='Page 64 / 409\\nFootnotes\\n(a) If possible it is better to treat all patients with a SpO < 95% with oxygen.2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 64, 'page_label': '65', 'id': 'data/guideline-170-en.pdf:64:0'}, page_content='Page 65 / 409\\nRhinitis and rhinopharyngitis (common cold)\\nRhinitis (inﬂammation of the nasal mucosa) and rhinopharyngitis (inﬂammation of the nasal and pharyngeal mucosa) are\\ngenerally benign, self-limited and most often of viral origin. However, they may be an early sign of another infection (e.g.\\nmeasles or inﬂuenza) or may be complicated by a bacterial infection (e.g. otitis media or sinusitis).\\nClinical features\\nTreatment\\n\\xa0\\nNasal discharge or obstruction, which may be accompanied by sore throat, fever, cough, lacrimation, and diarrhoea\\nin infants. Purulent nasal discharge is not indicative of a secondary bacterial infection.\\nIn children under 5 years, routinely check the tympanic membranes to look for an associated otitis media.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 64, 'page_label': '65', 'id': 'data/guideline-170-en.pdf:64:1'}, page_content='Antibiotherapy is not recommended: it does not promote recovery nor prevent complications.\\nTreatment is symptomatic:\\nClear the nose with 0.9% sodium chloride . a \\nFever, throat soreness: paracetamol PO for 2 to 3 days (Fever, Chapter 1).\\nFootnotes\\n(a) For a child: place him on his back, head turned to the side, and instil 0.9% sodium chloride into each nostril.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 65, 'page_label': '66', 'id': 'data/guideline-170-en.pdf:65:0'}, page_content='Page 66 / 409\\nAcute sinusitis\\nAcute sinusitis is an inﬂammation of one or more of the sinus cavities, caused by an infection or allergy.\\nMost acute sinus infections are viral and resolve spontaneously in less than 10 days. Treatment is symptomatic.\\nAcute bacterial sinusitis may be a primary infection, a complication of viral sinusitis or of dental origin. The principal\\ncausative organisms are\\xa0Streptococcus pneumoniae,\\xa0Haemophilus inﬂuenzae\\xa0and\\xa0Moraxella catarrhalis.\\nIt is essential to distinguish between bacterial sinusitis and common rhinopharyngitis (see\\xa0Rhinitis and rhinopharyngitis).\\nAntibiotic therapy is required in case of bacterial sinusitis only.\\nWithout treatment, severe sinusitis in children may cause serious complications due to the spread of infection to the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 65, 'page_label': '66', 'id': 'data/guideline-170-en.pdf:65:1'}, page_content='neighbouring bony structures, orbits or the meninges.\\nClinical features\\nSinusitis in adults\\n\\xa0Sinusitis is likely if symptoms persist for longer than 10 to 14 days or worsen after 5 to 7 days or are severe (severe\\npain, high fever, deterioration of the general condition).\\nSinusitis in children\\nTreatment\\nSymptomatic treatment\\nAntibiotherapy\\n\\xa0\\nPurulent unilateral or bilateral discharge, nasal obstruction\\nand\\nFacial unilateral or bilateral pain that increases when bending over; painful pressure in maxillary area or behind the\\nforehead.\\nFever is usually mild or absent.\\nSame symptoms; in addition, irritability or lethargy or cough or vomiting may be present.\\nIn the event of severe infection: deterioration of the general condition, fever over 39 °C, periorbital or facial\\noedema.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 65, 'page_label': '66', 'id': 'data/guideline-170-en.pdf:65:2'}, page_content='oedema.\\nFever\\xa0and\\xa0pain\\xa0(Chapter 1).\\nClear the nose with 0.9% sodium chloride . a \\nIn adults:\\nAntibiotherapy is indicated if the patient meets the criteria of duration or severity of symptoms. Oral amoxicillin is\\nthe ﬁrst-line treatment.\\nIf the diagnosis is uncertain (moderate symptoms < 10 days) and the patient can be reexamined in the next few\\ndays, start with a symptomatic treatment, as for rhinopharyngitis or viral sinusitis.\\nIn children:\\nAntibiotic therapy is indicated if the child has severe symptoms or mild symptoms associated with risk factors (e.g.\\nimmunosuppression, sickle cell disease, asthma).\\nOral amoxicillin is the ﬁrst-line treatment.\\namoxicillin\\xa0PO for 7 to 10 days:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 66, 'page_label': '67', 'id': 'data/guideline-170-en.pdf:66:0'}, page_content='Page 67 / 409\\n\\xa0\\nOther treatments\\n\\xa0\\nChildren:\\xa030 mg/kg 3 times daily\\xa0(max. 3 g daily)\\nAdults: 1 g 3 times daily\\nIn the event of failure to respond within 48 hours of therapy:\\namoxicillin/clavulanic acid\\xa0PO for 7 to 10 days.\\xa0Use formulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose\\nis expressed in amoxicillin:\\nChildren < 40 kg: 25 mg/kg 2 times daily\\nChildren ≥ 40 kg and adults:\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times\\xa0daily)\\nIn penicillin-allergic patients:\\nerythromycin\\xa0PO for 7 to 10 days:\\nChildren: 30 to 50 mg/kg daily\\nAdults: 1 g 2 to 3 times daily\\n b \\nIn infants with ethmoiditis, see\\xa0Periorbital and orbital cellulitis\\xa0(Chapter 5).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 66, 'page_label': '67', 'id': 'data/guideline-170-en.pdf:66:1'}, page_content='For sinusitis secondary to dental infection: dental extraction while under antibiotic treatment.\\nIn the event of ophthalmologic complications (ophthalmoplegia, mydriasis, reduced visual acuity, corneal\\nanesthesia), refer for surgical drainage.\\nFootnotes\\n(a) For a child: place him on his back, head turned to the side, and instil 0.9% sodium chloride into each nostril.\\n(b) For dosage according to age or weight, see erythromycin in the guide Essential drugs, MSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 67, 'page_label': '68', 'id': 'data/guideline-170-en.pdf:67:0'}, page_content='Page 68 / 409\\nAcute pharyngitis\\nLast updated: November 2020\\n\\xa0\\nAcute inﬂammation of the tonsils and pharynx. The majority of cases are of viral origin and do not require antibiotic\\ntreatment. Group A streptococcus (GAS) is the main bacterial cause, and mainly affects children aged 3 to 14 years.\\nAcute rheumatic fever (ARF), a serious late complication of GAS pharyngitis, can be prevented with antibiotic\\ntreatment.\\nOne of the main objectives of assessing acute pharyngitis is to identify patients requiring antibiotic treatment.\\nClinical features\\n\\xa0\\n\\xa0Common forms:\\nCentor criteria\\n\\xa0In patients over 14 years, the probability of GAS pharyngitis is low. Infectious mononucleosis (IM) due to the\\nEpstein-Barr virus should be suspected in adolescents and young adults with extreme fatigue, generalized'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 67, 'page_label': '68', 'id': 'data/guideline-170-en.pdf:67:1'}, page_content=\"adenopathy and often splenomegaly.\\nErythematous or exudative pharyngitis may also be associated with gonococcal or primary HIV infection. In\\nthese cases, the diagnosis is mainly prompted by the patient's history.\\n\\xa0 Other forms of pharyngitis:\\nFeatures common to all types of pharyngitis: throat pain, dysphagia (difﬁculty swallowing), inﬂammation of the\\ntonsils and pharynx, tender anterior cervical lymph nodes, with or without fever.\\nSpeciﬁc features, depending on the cause:\\nErythematous\\xa0(red throat) or\\xa0exudative\\xa0(red throat and whitish exudate) pharyngitis: this appearance is\\ncommon to both viral and GAS pharyngitis. Centor criteria help assessment and decrease the empirical use of\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 67, 'page_label': '68', 'id': 'data/guideline-170-en.pdf:67:2'}, page_content='antibiotics in settings where rapid testing for GAS is not available. A Centor score of less than 2 rules out GAS\\ninfection . Nevertheless, in patients with risk factors (immunosuppression, personal or family history of ARF)\\nfor poststreptococcal complications, or for local or general complications, do not use Centor score and\\nprescribe empirical antibiotic treatment.\\n [1] [2] \\nCriteria Score\\nTemperature > 38 °C 1\\nAbsence of cough 1\\nTender anterior cervical lymph node(s) 1\\nTonsillar swelling or exudate 1\\nPseudomembranous pharyngitis\\xa0(red tonsils/pharynx covered with an adherent greyish white false membrane):\\nsee\\xa0Diphtheria, Chapter 2.\\nVesicular pharyngitis\\xa0(clusters of tiny blisters or ulcers on the tonsils): always viral (coxsackie virus or primary\\nherpetic infection).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 67, 'page_label': '68', 'id': 'data/guideline-170-en.pdf:67:3'}, page_content='herpetic infection).\\nUlcero-necrotic pharyngitis: hard and painless syphilitic chancre of the tonsil; tonsillar ulcer soft on palpation in\\na patient with poor oral hygiene and malodorous breath (Vincent tonsillitis).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 68, 'page_label': '69', 'id': 'data/guideline-170-en.pdf:68:0'}, page_content='Page 69 / 409\\n\\xa0\\nPeritonsillar, retropharyngeal or lateral pharyngeal abscess: fever, intense pain, dysphagia, hoarse voice, trismus\\n(limitation of mouth opening), unilateral deviation of the uvula.\\xa0\\n\\xa0\\nTreatment\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nSpots on oral mucosa (Koplik’s spots) accompanied by conjunctivitis and skin rash (see Measles, Chapter 8).\\n“Strawberry” (red and bumpy) tongue accompanied by a skin rash: scarlet fever caused by GAS.\\nLocal complications:\\nGeneral complications:\\nComplications due to the toxin: diphtheria (see Diphtheria, Chapter 2).\\nPoststreptococcal complications: ARF, acute glomerulonephritis.\\nSigns of serious illness in children: severe dehydration, severe difﬁculty swallowing, upper airway compromise,\\ndeterioration of general condition.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 68, 'page_label': '69', 'id': 'data/guideline-170-en.pdf:68:1'}, page_content='deterioration of general condition.\\nDifferential diagnosis: epiglottitis (see Epiglottitis, Chapter 2).\\nSymptomatic treatment (fever and pain): paracetamol or ibuprofen PO (Fever, Chapter 1).\\nCentor score ≤ 1: viral pharyngitis, which typically resolves within a few days (or weeks, for IM): no antibiotic\\ntreatment.\\nCentor score ≥ 2 or scarlet fever: antibiotic treatment for GAS infections : [3] \\nIf single-use injection equipment is available, benzathine benzylpenicillin is the drug of choice as streptococcus\\nA resistance to penicillin remains rare; it is the only antibiotic proven effective in reducing the incidence of\\nrheumatic fever; and the treatment is administered as a single dose.\\nbenzathine benzylpenicillin\\xa0IM\\nChildren under 30 kg (or under 10 years): 600 000 IU single dose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 68, 'page_label': '69', 'id': 'data/guideline-170-en.pdf:68:2'}, page_content='Children under 30 kg (or under 10 years): 600 000 IU single dose\\nChildren 30 kg and over (or 10 years and over) and adults: 1.2 MIU single dose\\nPenicillin V is the oral reference treatment, but poor adherence is predictable due to the length of treatment.\\nphenoxymethylpenicillin (penicillin V)\\xa0PO for 10 days\\nChildren 1 to\\xa0<\\xa06 years:\\xa0250 mg\\xa02 times daily\\nChildren 6 to\\xa0<\\xa012 years:\\xa0500 mg\\xa02 times daily\\nChildren\\xa012 years and over\\xa0and adults:\\xa01 g\\xa02 times daily\\nChildren under 1 year:\\xa0125 mg 2 times daily\\nAmoxicillin is an alternative and the treatment has the advantage of being relatively short. However, it can\\ncause adverse skin reactions in patients with undiagnosed IM and thus should be avoided when IM has not been\\nexcluded\\namoxicillin\\xa0PO for 6 days\\nChildren: 25 mg/kg\\xa02 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 68, 'page_label': '69', 'id': 'data/guideline-170-en.pdf:68:3'}, page_content='excluded\\namoxicillin\\xa0PO for 6 days\\nChildren: 25 mg/kg\\xa02 times daily\\nAdults: 1 g 2 times daily\\nMacrolides should be reserved for penicillin allergic patients as resistance to macrolides is frequent and their\\nefﬁcacy in the prevention of rheumatic fever has not been studied.\\xa0\\nazithromycin\\xa0PO for 3 days\\nChildren: 20 mg/kg once daily (max. 500 mg daily)\\nAdults: 500 mg once daily\\nGonococcal or syphilitic pharyngitis: as for\\xa0genital gonorrhoea\\xa0(Chapter 9) and\\xa0syphilis\\xa0(Chapter 9).\\nDiphtherial pharyngitis: see\\xa0Diphtheria (Chapter 2).\\nVincent tonsillitis: metronidazole or amoxicillin.\\nPeritonsillar retropharyngeal or lateral pharyngeal abscess: refer for surgical drainage.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 69, 'page_label': '70', 'id': 'data/guideline-170-en.pdf:69:0'}, page_content='Page 70 / 409\\n\\xa0\\nReferences\\nIf signs of serious illness or epiglottitis are present in children: hospitalise.\\n1. Fine AM, Nizet V, Mandl KD. Large-scale validation of the Centor and McIsaac scores to predict group A streptococcalpharyngitis. Arch Intern Med. 2012;172(11):847-852.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627733/ [Accessed\\xa020 October\\xa02020]\\n2. National Institute for Health and Care Excellence. Sore throat (acute): antimicrobial prescribing. 2018.http://www.nice.org.uk/ng84 [Accessed 20 October\\xa02020]\\n3. Group A Streptococcal Disease, Centers for Disease Control and Prevention. Atlanta (GA): CDC; 2020.\\xa0https://www.cdc.gov/groupastrep/diseases-hcp/strep-throat.html\\xa0[Accessed 20 October 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 70, 'page_label': '71', 'id': 'data/guideline-170-en.pdf:70:0'}, page_content='Page 71 / 409\\nDiphtheria\\nLast updated: October 2022\\n\\xa0\\n\\xa0\\nDiphtheria is a bacterial infection due to Corynebacterium diphtheriae, spread from person to person through\\ninhalation of infected respiratory droplets of symptomatic or asymptomatic individuals, or direct contact with\\ncontaminated objects or diphtheria skin lesions .\\nAfter infection, C. diphtheriae has an incubation period of 1 to 5 days (max. 10 days) during which time it multiplies in\\nthe upper respiratory tract. The bacteria secretes a toxin which causes severe local as well as systemic effects. Death\\ncan occur from airway obstruction or as a result of systemic complications, including damage to the myocardium and\\nnervous system, caused by the toxin.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 70, 'page_label': '71', 'id': 'data/guideline-170-en.pdf:70:1'}, page_content='nervous system, caused by the toxin.\\xa0\\nCases can remain infectious up to 8 weeks after initial infection . Antibiotic treatment can reduce infectiousness to 6\\ndays .\\nVaccination is the key to prevention and control of diphtheria. It protects individuals from severe disease (fewer and\\nless severe symptoms) but does not prevent the spread of C. diphtheriae. Clinical disease does not confer protective\\nimmunity and vaccination is an integral part of case management.\\nClinical features\\nLaboratory\\nTreatment\\n [1] [2] a \\n [1] \\n [2] \\n [3] \\nDuring clinical examination respect standard, contact, and droplet precautions (handwashing, gloves, gown, mask,\\netc.). Conduct a careful examination of the throat.\\nSigns of respiratory diphtheria : a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 70, 'page_label': '71', 'id': 'data/guideline-170-en.pdf:70:2'}, page_content='Signs of respiratory diphtheria : a \\npharyngitis, rhinopharyngitis, tonsillitis or laryngitis with tough, greyish, ﬁrmly adherent pseudo-membranes of the\\npharynx, nasopharynx, tonsils, or larynx;\\ndysphagia and cervical adenitis, at times progressing to massive swelling of the neck;\\nairway obstruction and possible suffocation when the infection extends to the nasal passages, larynx, trachea\\nand bronchi;\\nfever is generally low-grade . [2] \\nGeneralised signs due to effects of the toxin:\\ncardiac dysfunction (tachycardia, arrhythmias), severe myocarditis with heart failure and possibly cardiogenic\\nshock (see Shock, Chapter 1) 3 to 7 days or 2 to 3 weeks after onset of the disease;\\nneuropathies in 2 to 8 weeks after the onset of disease leading to nasal voice and difﬁculty with swallowing'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 70, 'page_label': '71', 'id': 'data/guideline-170-en.pdf:70:3'}, page_content='(paralysis of the soft palate), vision (ocular motor paralysis), breathing (paralysis of respiratory muscles) and\\nambulation (limb paralysis);\\noliguria, anuria and acute renal failure.\\nDifferential diagnoses: Epiglottitis and Acute pharyngitis, Chapter 2, Stomatitis, Chapter 3.\\nDiagnosis is conﬁrmed by isolation of toxigenic C. diphtheriae by culture (and antibiotic susceptibility test) of swab\\nspecimens collected from the affected areas: throat (tonsils, pharyngeal mucosa, soft palate, exudate, ulcer, etc.),\\nnasopharynx.\\nThe presence of the toxin is conﬁrmed by PCR testing (detection of diphtheria toxin gene).\\nIsolation of patients; standard, droplet, and contact precautions for medical staff.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 71, 'page_label': '72', 'id': 'data/guideline-170-en.pdf:71:0'}, page_content='Page 72 / 409\\nThere is a risk of anaphylactic reaction, especially in patients with asthma. Close monitoring of the patient is\\nessential, with immediate availability of equipment for manual ventilation (Ambu bag, face mask) and\\nintubation, Ringer lactate and epinephrine (see Shock, Chapter 1).\\nBesredka method: inject 0.1 ml SC and wait 15 minutes. If there is no allergic reaction (no erythema at the injection\\nsite or a ﬂat erythema of less than 0.5 cm in diameter), inject a further 0.25 ml SC. If there is no reaction after 15\\nminutes, inject the rest of the product IM or IV depending on the volume to be administered.\\nDoses are given as a function of the severity of illness, and the delay in treatment:\\n\\xa0\\nNever administer procaine benzylpenicillin by IV injection or infusion.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 71, 'page_label': '72', 'id': 'data/guideline-170-en.pdf:71:1'}, page_content='Never administer procaine benzylpenicillin by IV injection or infusion.\\nIn penicillin-allergic patients, use erythromycin IV .\\nDiphtheria antitoxin (DAT) derived from horse serum:\\xa0\\nAdminister DAT as soon as possible after disease onset. Do not wait for bacteriological conﬁrmation ; administer\\nDAT under close monitoring in a hospital setting, according to the Besredka method to assess possibility of allergy.\\nAny delay can diminish efﬁcacy.\\n b \\n [1] \\n\\xa0\\n\\xa0\\nClinical signs Dose in units Administration route\\nLaryngitis or pharyngitis\\nor duration < 48 hours 20 to 40 000\\nIM or IV infusion in 250 ml of 0.9% sodium\\nchloride in 2 to 4 hours for doses of more\\nthan 20 000 units.\\nRhinopharyngitis 40 to 60 000\\nSevere disease (respiratory distress,\\nshock), cervical oedema or duration ≥ 48\\nhours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 71, 'page_label': '72', 'id': 'data/guideline-170-en.pdf:71:2'}, page_content='shock), cervical oedema or duration ≥ 48\\nhours\\n80 to 100 000\\nAntibiotic treatment (as soon as possible without waiting for bacteriological conﬁrmation ) for 14 days or according\\nto length of treatment recommended by the national protocol:\\nif the patient can swallow:\\nazithromycin PO (ﬁrst-line)\\nChildren: 10 to 12 mg/kg once daily (max. 500 mg daily)\\nAdults: 500 mg once daily\\nor\\nerythromycin PO\\nChildren under 40 kg: 10 to 15 mg/kg (max. 500 mg) 4 times daily\\nChildren 40 kg and over and adults: 500 mg 4 times daily\\nor\\nphenoxymethylpenicillin (penicillin V) PO\\nChildren under 40 kg: 10 to 15 mg/kg (max. 500 mg) 4 times daily\\nChildren 40 kg and over and adults: 500 mg\\xa04 times daily\\nIf the patient cannot swallow, start with one of the treatments below and change as soon as possible to oral'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 71, 'page_label': '72', 'id': 'data/guideline-170-en.pdf:71:3'}, page_content=\"route with one of the oral treatments\\xa0above to complete 14 days of treatment:\\nprocaine benzylpenicillin\\xa0IM\\nChildren under 25 kg: 50 000 IU/kg (= 50 mg/kg) once daily (max. 1.2 MIU = 1.2 g daily)\\nChildren 25 kg and over and adults: 1.2 MIU (= 1.2 g) once daily\\n\\xa0\\n\\xa0\\n c \\nIntubation/tracheotomy if necessary (airway obstruction, respiratory failure, etc.).\\nIf the event of shock, see\\xa0Shock, Chapter 1, for complementary treatment.\\nUpdate every patient's vaccination status before hospital discharge (or during ﬁrst visit, if receiving home-based\\ncare). If the patient has been administered DAT and can receive adequate home-based follow up after hospital\\ndischarge, wait 3 weeks after administration of DAT before vaccination.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 72, 'page_label': '73', 'id': 'data/guideline-170-en.pdf:72:0'}, page_content='Page 73 / 409\\nManagement of close contacts\\xa0\\nClose contacts include household members living under the same roof and people who were directly exposed (less than\\none metre) to nasopharyngeal secretions of the patient on a regular basis (e.g. family or close friends, children in the\\nsame class, medical personnel) during the 5 days or nights prior to onset of symptoms of the case .\\nBenzathine benzylpenicillin should never be administered by IV route.\\nor azithromycin PO or erythromycin PO as above for 7 days.\\nOutbreak surveillance measures\\nAND\\xa0\\nPrevention\\xa0\\nAdminister 2 subsequent booster doses containing d at least 4 weeks apart .       \\n\\xa0\\n [4] \\nCollect nasal and pharyngeal swabs for culture before starting antibiotic prophylaxis; temperature and throat'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 72, 'page_label': '73', 'id': 'data/guideline-170-en.pdf:72:1'}, page_content='examination daily (10 days); exclusion from school or work until 48 hours after starting antibiotic prophylaxis. If\\nsymptoms of respiratory infection appear: treat immediately as a case of diphtheria.\\nAntibiotic prophylaxis:\\nbenzathine benzylpenicillin IM\\nChildren under 30 kg: 600 000 IU single dose\\nChildren 30 kg and over and adults: 1.2 MIU single dose\\n\\xa0\\n\\xa0\\nCheck vaccination status:\\nif less than 3 injections received: complete vaccination schedule (see Prevention below);\\nif 3 injections received, with the last injection over one year ago: administer a booster dose immediately;\\nif 3 injections received, with the last injection less than one year ago: a booster dose is not immediately\\nnecessary.\\nA suspected case of diphtheria is deﬁned as a person with:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 72, 'page_label': '73', 'id': 'data/guideline-170-en.pdf:72:2'}, page_content='necessary.\\nA suspected case of diphtheria is deﬁned as a person with:\\npharyngitis, rhinopharyngitis, tonsillitis and/or laryngitis\\nan adherent pseudo-membrane of the pharynx, nose, tonsils and/or larynx . [1] \\nIsolate and treat suspect cases without delay. Collect swab samples before starting antibiotic treatment. Submit\\ncase notiﬁcation to the public health authorities within 24 hours . [1] \\nRoutine vaccination (EPI), for information: 3 doses of conjugate vaccine containing the higher potency (D)\\nformulation of diphtheria toxoid as soon as possible as of 6 weeks of age and at 4 week intervals; D booster\\nbetween 12 and 23 months, then between 4 and 7 years; booster with a vaccine containing a reduced dose (d) of\\ndiphtheria toxoid between 9 and 15 years . [5]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 72, 'page_label': '73', 'id': 'data/guideline-170-en.pdf:72:3'}, page_content='diphtheria toxoid between 9 and 15 years . [5] \\nCatch-up vaccination (individuals who have not received routine vaccination), for information:\\nchildren 1 to 6 years: 3 doses of conjugate vaccine containing\\xa0the higher potency (D) formulation of diphtheria\\ntoxoid at least 4 weeks apart;\\nchildren 7 years and over and adults (including medical staff): 3 doses of conjugate vaccine containing a reduced\\ndose (d) of diphtheria toxoid. Administer with a minimum interval of 4 weeks between ﬁrst and second dose and\\nan interval of at least 6 months between second and third dose (in the event of an outbreak this interval may be\\nreduced to 4 weeks to achieve protection quicker).\\n [5] \\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 72, 'page_label': '73', 'id': 'data/guideline-170-en.pdf:72:4'}, page_content='reduced to 4 weeks to achieve protection quicker).\\n [5] \\nFootnotes\\n(a) This guide focuses on respiratory diphtheria and signs due to the toxin. It should be noted that cutaneous diphtheria is stilla signiﬁcant reservoir of\\xa0C. diphtheriae.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 73, 'page_label': '74', 'id': 'data/guideline-170-en.pdf:73:0'}, page_content='Page 74 / 409\\nReferences\\n(b) DAT reduces mortality and should be given to all diphtheria patients. However, as supply is very limited, it may be necessaryto deﬁne criteria and reserve DAT for the treatment of patients who will beneﬁt the most from it. DAT can be administeredto pregnant women.\\n(c) erythromycin IV infusion (60 minutes)Children: 12.5 mg/kg every 6 hours (max. 2 g daily); adults: 500 mg every 6 hoursErythromycin powder (1 g) should be reconstituted in 20 ml of water for injection only. Then, dilute each dose oferythromycin in 10 ml/kg of 0.9% sodium chloride in children less than 20 kg and in a bag of 250 ml of 0.9% sodium chloridein children 20 kg and over and in adults. Do not dilute in glucose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 73, 'page_label': '74', 'id': 'data/guideline-170-en.pdf:73:1'}, page_content='1. World Health Organization. Diphtheria. Vaccine-Preventable Diseases Surveillance Standards. 2018.https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_04_Diphtheria_R2.pdf?ua=1\\xa0[Accessed 11 August 2020]\\n2. Tiwari TSP, Wharton M. Chapter 19: Diphtheria Toxoid. In: Plotkin SA, Orenstein WA, Ofﬁt PA, editors. Vaccines. 7th ed.Philadelphia, PA: Elsevier; 2018. p. 261–275.\\n3. Truelove SA, Keegan LT, Moss WJ, Chaisson LH, Macher E, Azman AS, Lessler J. Clinical and Epidemiological Aspects ofDiphtheria: A Systematic Review and Pooled Analysis. Clin Infect Dis. 2020 Jun 24;71(1):89-97.\\xa0https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312233/\\xa0[Accessed 24 November 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 73, 'page_label': '74', 'id': 'data/guideline-170-en.pdf:73:2'}, page_content='4. Pan American Health Organization, World Health Organization. Diphtheria in the Americas - Summary of the situation 2018.Epidemiological Update Diphtheria. 16 April 2018.https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=diphtheria-%098968&alias=44497-16-april-2018-diphtheria-epidemiological-update-497&Itemid=270&lang=en [Accessed 11 August2020]\\n5. World Health Organization. Diphtheria vaccine: WHO position paper - August 2017.\\xa0Weekly epidemiological record 2017;92/(31):417–436.https://www.who.int/immunization/policy/position_papers/wer_31_diphtheria_updated_position_paper.pdf?ua=1 [Accessed11 August 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 74, 'page_label': '75', 'id': 'data/guideline-170-en.pdf:74:0'}, page_content='Page 75 / 409\\nOther upper respiratory tract infections\\n\\xa0\\n\\xa0\\n\\xa0\\nCroup (laryngotracheitis and laryngotracheobronchitis)\\nEpiglottitis\\nBacterial tracheitis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 75, 'page_label': '76', 'id': 'data/guideline-170-en.pdf:75:0'}, page_content='Page 76 / 409\\nCroup (laryngotracheitis andlaryngotracheobronchitis)\\nLast updated: October\\xa02024\\n\\xa0\\nCommon viral respiratory infection with peak incidence amongst children between 6 months and 3 years.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0\\nTypical barking cough, hoarse voice or cry.\\nInspiratory stridor (abnormal high pitched sound on inspiration):\\nCroup is considered mild if the stridor only occurs with agitation;\\nCroup is considered severe if there is stridor at rest, especially when it is accompanied by respiratory distress.\\nWheezing may also be present if the bronchi are involved.\\nIn the absence of inspiratory stridor or intercostal,\\xa0subcostal or sternal retractions, treat symptomatically: ensure'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 75, 'page_label': '76', 'id': 'data/guideline-170-en.pdf:75:1'}, page_content='adequate hydration, seek medical attention if symptoms worsen (e.g. respiratory difﬁculty, noisy breathing, inability\\nto tolerate oral ﬂuids).\\nIf stridor is only present with agitation (mild croup) : [1] \\nAssure adequate hydration.\\nCorticosteroids:\\ndexamethasone\\xa0PO: 0.15 to 0.6 mg/kg (max. 16 mg) single dose a \\nor, if not available, prednisolone PO: 1 mg/kg\\xa0single dose\\nKeep the child under observation at least 30 minutes after oral corticosteroid. Consider hospitalisation or longer\\nobservation (> 4 hours) if the child is less than 6 months old, or is dehydrated, or lives far from health facility.\\nIf danger signs are present (stridor at rest, respiratory distress, hypoxia) or the child is unable to drink, admit\\nto\\xa0hospital : [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 75, 'page_label': '76', 'id': 'data/guideline-170-en.pdf:75:2'}, page_content='to\\xa0hospital : [1] \\nAdminister oxygen continuously if respiratory distress or SpO < 92%:\\xa0maintain\\xa0SpO\\xa0between\\xa094 and 98%\\xa0(or\\xa0if\\nSpO cannot be determined,\\xa0at least 5 litres/minute).\\n2 2\\n2\\nInsert a peripheral IV line and provide IV hydration.\\nEpinephrine (adrenaline)\\xa0via nebulizer : 0.5 mg/kg (max. 5 mg) to be repeated every 20 minutes if danger\\nsigns persist (see table below).\\nMonitor heart rate during nebulization (if heart rate greater than 200, stop the\\xa0nebulization).\\n [2] b \\nWeight 6 kg 7 kg 8 kg 9 kg 10-17 kg\\nDose in mg 3 mg 3.5 mg 4 mg 4.5 mg 5 mg\\nDose in ml\\xa0(1 mg/ml, 1 ml ampoule) 3 ml 3.5 ml 4 ml 4.5 ml 5 ml\\nNaCl 0.9% (a) 1 ml 1 ml – – –\\n(a) Add sufﬁcient NaCl 0.9% to obtain a total volume of 4 to 4.5 ml in the nebulizing chamber.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 76, 'page_label': '77', 'id': 'data/guideline-170-en.pdf:76:0'}, page_content='Page 77 / 409\\nEpinephrine is intended exclusively for nebulized administration and should not be given IV or IM in croup.\\n\\xa0\\n\\xa0\\n\\xa0\\xa0\\n\\xa0\\nReferences\\n\\xa0\\n\\xa0\\nCorticosteroids:\\ndexamethasone \\xa0PO (or IM or IV if the child is vomiting): 0.6 mg/kg (max. 16 mg) single dose (see table\\nbelow)\\n c \\nor, if not available, prednisolone PO: 1 mg/kg single dose\\nWeight 6-8\\xa0kg 9-11\\xa0kg 12-14\\xa0kg 15-17 kg\\nDose in mg 4 mg 6\\xa0mg 8\\xa0mg 10 mg\\nDose in 2 mg tablet 2 tab 3 tab 4 tab 5 tab\\nDose in ml\\xa0(4 mg/ml, 1 ml ampoule) 1 ml 1.5\\xa0ml 2\\xa0ml 2.5 ml\\nSuspect bacterial tracheitis in a critically ill appearing child with croup who does not improve with the above\\ntreatment.\\n d \\nIf the patient has a complete airway obstruction, intubation if possible or emergency tracheotomy.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 76, 'page_label': '77', 'id': 'data/guideline-170-en.pdf:76:1'}, page_content='Footnotes\\n(a) If children can easily return to hospital in case of deterioration or return of symptoms, administer 0.15 mg/kg ofdexamethasone. Otherwise, the dose of 0.6 mg/kg should be used.\\xa0\\n(b) Although not licensed for this indication, epinephrine 1:1000 (1 mg/ml) should be used for nebulisation.\\n(c) Administer orally if possible in order to avoid causing agitation in the child as this may worsen symptoms.\\n(d) Critically ill appearing child: weak grunting or crying, drowsiness, difﬁcult to arouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 76, 'page_label': '77', 'id': 'data/guideline-170-en.pdf:76:2'}, page_content='1. Pocket book of primary health care for children and adolescents: guidelines for health promotion, disease prevention andmanagement from the newborn period to adolescence. Copenhagen: WHO Regional Ofﬁce for Europe; 2022. Licence: CCBY-NCSA 3.0 IGO.https://www.who.int/europe/publications/i/item/9789289057622\\n2. Bjornson C, Russell K, Vandermeer B, Klassen TP, Johnson DW. Nebulized epinephrine for croup in children. Cochrane AcuteRespiratory Infections Group, ed. Cochrane Database Syst Rev. Published online October 10, 2013.https://doi.org/10.1002/14651858.CD006619.pub3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 77, 'page_label': '78', 'id': 'data/guideline-170-en.pdf:77:0'}, page_content='Page 78 / 409\\nEpiglottitis\\nBacterial infection of the epiglottis in young children caused by\\xa0Haemophilus inﬂuenzae\\xa0(Hib), it is rare when Hib\\nvaccine coverage is high. It can be caused by other bacteria and occur in adults.\\nClinical features\\n\\xa0 Allow the child to sit in a comfortable position or on the parent’s lap. Do not force them\\xa0to lie down (may\\nprecipitate airway obstruction). Avoid any examination that will upset\\xa0the child including examination of the\\nmouth and throat.\\nTreatment\\n\\xa0\\nRapid (less than 12-24 hours) onset of high fever.\\nTypical “tripod or snifﬁng” position, preferring to sit, leaning forward with an open mouth, anxious appearing.\\nDifﬁculty swallowing, drooling, and respiratory distress.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 77, 'page_label': '78', 'id': 'data/guideline-170-en.pdf:77:1'}, page_content='Difﬁculty swallowing, drooling, and respiratory distress.\\nStridor may be present (as opposed to croup, hoarse voice and cough are usually absent).\\nCritically ill appearing . a \\n\\xa0\\n\\xa0\\nIn case of imminent airway obstruction, emergency intubation or tracheotomy is indicated. The intubation is\\ntechnically difﬁcult and should be performed under anaesthesia by a physician familiar with the procedure. Be\\nprepared to perform a tracheotomy if intubation is unsuccessful.\\nIn all cases:\\nInsert a peripheral IV line and provide IV hydration.\\nAntibiotherapy:\\nceftriaxone\\xa0slow IV (3 minutes) or IV infusion (30 minutes) . Avoid IM route (may agitate the child and precipitate\\na respiratory arrest).\\nChildren: 50 mg/kg once daily\\nAdults: 1 g once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 77, 'page_label': '78', 'id': 'data/guideline-170-en.pdf:77:2'}, page_content='a respiratory arrest).\\nChildren: 50 mg/kg once daily\\nAdults: 1 g once daily\\nThe IV treatment is administered for at least 5 days then, if the clinical condition has improved and oral\\ntreatment can be tolerated, change to:\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav)\\xa0PO to complete a total of 7 to 10 days of treatment. Use\\nformulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose is expressed in amoxicillin:\\nChildren < 40 kg: 50 mg/kg 2 times daily\\nChildren ≥ 40 kg and adult:\\nRatio 8:1: 3000 mg daily (2 tablets of 500/62.5 mg 3 times\\xa0daily)\\nRatio 7:1: 2625 mg daily (1 tablet of 875/125 mg 3 times\\xa0daily)\\n b \\n c \\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 77, 'page_label': '78', 'id': 'data/guideline-170-en.pdf:77:3'}, page_content='b \\n c \\nFootnotes\\n(a) Critically ill appearing child: weak grunting or crying, drowsiness, difﬁcult to arrouse, does not smile, unconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.\\n(b) For administration by IV route, ceftriaxone powder should to be reconstituted in water for injection only. For administrationby IV infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kgand in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.\\n(c) Improvement criteria include: fever reduction, diminished respiratory distress, improved SpO, improved appetite and/oractivity.\\n2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 78, 'page_label': '79', 'id': 'data/guideline-170-en.pdf:78:0'}, page_content='Page 79 / 409\\nBacterial tracheitis\\nBacterial infection of the trachea in children, occurring as a complication of a previous viral infection (croup, inﬂuenza,\\nmeasles, etc.).\\nClinical features\\nTreatment\\n\\xa0\\nFever in a critically ill appearing child . a \\nStridor, cough and respiratory distress.\\nCopious purulent secretions.\\nAs opposed to epiglottitis the onset of symptoms is gradual and the child prefers to lie ﬂat.\\nIn severe cases there is a risk of complete airway obstruction, especially in very young children.\\nSuction purulent secretions.\\nInsert a peripheral IV line and provide IV hydration.\\nAntibiotherapy:\\nceftriaxone\\xa0slow IV (3 minutes) or IV infusion (30 minutes).\\xa0Do not administer by IM route (may agitate the child and\\nprecipitate a respiratory arrest).\\nChildren: 50 mg/kg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 78, 'page_label': '79', 'id': 'data/guideline-170-en.pdf:78:1'}, page_content='precipitate a respiratory arrest).\\nChildren: 50 mg/kg once daily\\nAdults: 1 g once daily\\n+\\ncloxacillin\\xa0IV infusion (60 minutes)\\nChildren less than 12 years: 25 to 50 mg/kg every 6 hours\\nChildren 12 years and over\\xa0and adults: 2 g\\xa0every 6 hours\\nThe IV treatment is administered for at least 5 days then, if the clinical condition has improved and oral treatment\\ncan be tolerated, change to :\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav)\\xa0PO to complete 7 to 10 days of treatment, as in epiglottitis.\\n b \\n c \\nIf the event of complete airway obstruction, intubation if possible or emergency tracheotomy.\\nFootnotes\\n(a) Critically ill appearing child: weak grunting or crying, drowsiness, difﬁcult to arrouse, does not smile, unconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 78, 'page_label': '79', 'id': 'data/guideline-170-en.pdf:78:2'}, page_content='(b) For administration by IV route, ceftriaxone powder should to be reconstituted in water for injection only. For administrationby IV infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kgand in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.\\n(c) Improvement criteria include: fever reduction, diminished respiratory distress, improved SpO, improved appetite and/oractivity.\\n2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 79, 'page_label': '80', 'id': 'data/guideline-170-en.pdf:79:0'}, page_content='Page 80 / 409\\nOtitis\\n\\xa0\\n\\xa0\\n\\xa0\\nAcute otitis externa\\nAcute otitis media (AOM)\\nChronic suppurative otitis media (CSOM)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 80, 'page_label': '81', 'id': 'data/guideline-170-en.pdf:80:0'}, page_content='Page 81 / 409\\nAcute otitis externa\\nDiffuse inﬂammation of the external ear canal, due to bacterial or fungal infection. Common precipitants of otitis\\nexterna are maceration, trauma of the ear canal or presence of a foreign body or dermatologic diseases (such as\\neczema, psoriasis).\\xa0\\nClinical features\\nTreatment\\nEar canal pruritus or ear pain, often severe and exacerbated by motion of the pinna; feeling of fullness in the ear;\\nclear or purulent ear discharge or no discharge\\nOtoscopy (remove skin debris and secretions from the auditory canal by gentle dry mopping (use a dry cotton bud\\nor a small piece of dry cotton wool):\\ndiffuse erythema and edema, or infected eczema, of the ear canal\\nlook for a foreign body'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 80, 'page_label': '81', 'id': 'data/guideline-170-en.pdf:80:1'}, page_content='look for a foreign body\\nif visible, the tympanic membrane is normal (swelling and pain very often prevent adequate visualization of the\\ntympanic membrane)\\nRemove a foreign body, if present.\\nTreatment of pain: paracetamol PO (Chapter 1,\\xa0Pain).\\nLocal treatment:\\nRemove secretions from the auditory canal by gentle dry mopping (use a dry cotton bud or a small piece of dry\\ncotton wool). Consider ear irrigation (0.9% sodium chloride, using a syringe) only if the tympanic membrane can\\nbe fully visualised and is intact (no perforation). Otherwise, ear irrigation is contra-indicated.\\nApply\\xa0ciproﬂoxacin\\xa0ear drops in the\\xa0affected ear(s) for 7 days:\\nChildren ≥ 1 year: 3 drops 2 times daily\\nAdults: 4 drops 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 81, 'page_label': '82', 'id': 'data/guideline-170-en.pdf:81:0'}, page_content='Page 82 / 409\\nAcute otitis media (AOM)\\nAcute inﬂammation of the middle ear, due to viral or bacterial infection, very common in children under 3 years, but\\nuncommon in adults.\\nThe principal causative organisms of bacterial otitis media are\\xa0Streptococcus pneumoniae, Haemophilus inﬂuenzae,\\nMoraxella catarrhalis\\xa0and in older children,\\xa0Streptococcus pyogenes.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0\\namoxicillin\\xa0PO\\xa0for 5 days\\nChildren:\\xa030 mg/kg 3 times daily\\xa0(max. 3 g daily)\\nAdults: 1 g 3 times daily\\nRapid onset of ear pain (in infants: crying, irritability, sleeplessness, reluctance to nurse) and ear discharge\\n(otorrhoea) or fever.\\nOther signs such as rhinorrhoea, cough, diarrhoea or vomiting are frequently associated, and may confuse the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 81, 'page_label': '82', 'id': 'data/guideline-170-en.pdf:81:1'}, page_content='diagnosis, hence the necessity of examining the tympanic membranes.\\nOtoscopy: bright red tympanic membrane (or yellowish if rupture is imminent) and presence of pus, either\\nexternalised (drainage in ear canal if the tympanic membrane is ruptured) or internalised (opaque or bulging tympanic\\nmembrane). The combination of these signs with ear pain or fever conﬁrms the diagnosis of AOM.\\nNote:\\nThe following otoscopic ﬁndings are not sufﬁcient to make the diagnosis of AOM:\\nA red tympanic membrane alone, with no evidence of bulging or perforation, is suggestive of viral otitis in a\\ncontext of upper respiratory tract infection, or may be due to prolonged crying in children or high fever.\\nThe presence of air bubbles or ﬂuid behind an intact tympanic membrane, in the absence of signs and symptoms'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 81, 'page_label': '82', 'id': 'data/guideline-170-en.pdf:81:2'}, page_content='of acute infection, is suggestive of otitis media with effusion (OME).\\nComplications, particularly in high-risk children (malnutrition, immunodeﬁciency, ear malformation) include chronic\\nsuppurative otitis media, and rarely, mastoiditis, brain abscess or meningitis.\\nIn all cases:\\nTreatment of\\xa0fever\\xa0and\\xa0pain: paracetamol PO (Chapter 1).\\nEar irrigation is contra-indicated if the tympanic membrane is ruptured, or when the tympanic membrane cannot\\nbe fully visualised. Ear drops are not indicated.\\nIndications for antibiotic therapy:\\nAntibiotics are prescribed in children less than 2 years, children whose assessment suggests severe infection\\n(vomiting, fever > 39 °C, severe pain) and children at risk of unfavourable outcome (malnutrition,\\nimmunodeﬁciency, ear malformation).\\nFor other children:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 81, 'page_label': '82', 'id': 'data/guideline-170-en.pdf:81:3'}, page_content='immunodeﬁciency, ear malformation).\\nFor other children:\\nIf the child can be re-examined within 48 to 72 hours: it is preferable to delay antibiotic prescription.\\nSpontaneous resolution is probable and a short symptomatic treatment of fever and pain may be sufﬁcient.\\nAntibiotics are prescribed if there is no improvement or worsening of symptoms after 48 to 72 hours.\\nIf the child cannot be re-examined: antibiotics are prescribed.\\nFor children treated with antibiotics: advise the mother to bring the child back if fever and pain persist after 48\\nhours.\\nChoice of antibiotherapy:\\nAmoxicillin is the ﬁrst-line treatment:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 82, 'page_label': '83', 'id': 'data/guideline-170-en.pdf:82:0'}, page_content='Page 83 / 409\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO for 5 days\\nUse formulations in a ratio of 8:1 or 7:1.\\xa0The dose is expressed in amoxicillin:\\nChildren < 40 kg: 25 mg/kg 2 times daily\\nChildren ≥ 40 kg and adult:\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times\\xa0daily)\\nPersistence of a ear drainage alone, without fever and pain, in a child who has otherwise improved (reduction in\\nsystemic symptoms and local inﬂammation) does not warrant a change in antibiotic therapy. Clean ear canal by\\ngentle dry mopping until no more drainage is obtained.\\nazithromycin\\xa0PO\\nChildren over 6 months: 10 mg/kg once daily for 3 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 82, 'page_label': '83', 'id': 'data/guideline-170-en.pdf:82:1'}, page_content='azithromycin\\xa0PO\\nChildren over 6 months: 10 mg/kg once daily for 3 days\\nAmoxicillin/clavulanic acid is used as second-line treatment, in the case of treatment\\xa0failure. Treatment failure is\\ndeﬁned as persistence of fever and/or ear pain after 48 hours\\xa0of antibiotic treatment.\\nMacrolides should be reserved for very rare penicillin-allergic patients, as treatment failure (resistance to\\nmacrolides) is frequent.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 83, 'page_label': '84', 'id': 'data/guideline-170-en.pdf:83:0'}, page_content='Page 84 / 409\\nChronic suppurative otitis media (CSOM)\\nChronic bacterial infection of the middle ear with persistent purulent discharge through a perforated tympanic\\nmembrane.\\nThe principal causative organisms are\\xa0Pseudomonas aeruginosa, Proteus\\xa0sp, staphylococcus, other Gram negative\\nand anaerobic bacteria.\\nClinical features\\nTreatment\\nChildren 1 year and over: 3 drops 2 times daily\\nAdults: 4 drops 2 times daily\\nPurulent discharge for more than 2 weeks, often associated with hearing loss or even\\xa0deafness; absence of pain\\nand fever\\nOtoscopy: perforation of the tympanic membrane and purulent exudate\\nComplications:\\nConsider a superinfection (AOM) in the case of new onset of fever with ear pain, and treat accordingly.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 83, 'page_label': '84', 'id': 'data/guideline-170-en.pdf:83:1'}, page_content='Consider mastoiditis in the case of new onset of high fever, severe ear pain and/or tender swelling behind the\\near, in a patient who appears signiﬁcantly unwell.\\nConsider brain abscess or meningitis in the case of impaired consciousness, neck stiffness and focal\\nneurological signs (e.g. facial nerve paralysis).\\nRemove secretions from the auditory canal by gentle dry mopping (use a dry cotton bud or a small piece of dry\\ncotton wool).\\nApply\\xa0ciproﬂoxacin\\xa0ear drops\\xa0until no more drainage is obtained (approximately 2 weeks, max. 4 weeks):\\nComplications:\\nChronic mastoiditis is a medical emergency that requires prompt hospitalisation, prolonged antibiotherapy that\\ncovers the causative organisms of CSOM (ceftriaxone\\xa0IM for 10 days +\\xa0ciproﬂoxacin\\xa0PO for 14 days),'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 83, 'page_label': '84', 'id': 'data/guideline-170-en.pdf:83:2'}, page_content='atraumatic cleaning of the ear canal; surgical treatment may be required. Before transfer to hospital, if the\\npatient needs to be transferred, administer the ﬁrst dose of antibiotics.\\nMeningitis\\xa0(Chapter 7).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 84, 'page_label': '85', 'id': 'data/guideline-170-en.pdf:84:0'}, page_content='Page 85 / 409\\nPertussis (whooping cough)\\nLast updated: December 2024\\n\\xa0\\nPertussis is a highly contagious infection of the respiratory tract caused by the bacterium Bordetella pertussis.\\nIt is transmitted via airborne droplets spread by infected people (by coughing and/or sneezing), particularly within 3\\nweeks of the onset of cough . Despite the development of effective vaccines, it remains an important cause of\\nmorbidity and mortality, particularly in infants.\\xa0This disease is endemic worldwide and outbreaks are common.\\xa0 It most commonly affects children < 5 years, but can\\naffect any age group. Reported incidence in adolescents and adults has been increasing in some regions .\\xa0Pertussis is a notiﬁable disease in many countries, and cases should be reported to local or national public health'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 84, 'page_label': '85', 'id': 'data/guideline-170-en.pdf:84:1'}, page_content='authorities. Pertussis immunization is part of all vaccination schedules and is included in the Expanded Programme on\\nImmunization (EPI).\\nClinical features\\nAfter an incubation period of 7 to 10 days (up to 21 days), the illness evolves in 3 stages :\\xa0\\n\\xa0\\n\\xa0Complications may include secondary bacterial pneumonia (new-onset fever can be an indicator), dehydration and\\nmalnutrition triggered by feeding difﬁculty due to cough and vomiting, seizures, encephalopathy, sudden death,\\nintracranial bleeding, petechiae, rib fracture, hernia, rectal prolapse.\\xa0\\n\\xa0The disease is most severe, with a high risk of death, in infants. Adolescents and adults commonly have milder\\nsymptoms, but older adults, immunocompromised persons, and people with underlying respiratory conditions are at risk'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 84, 'page_label': '85', 'id': 'data/guideline-170-en.pdf:84:2'}, page_content='of severe disease and hospitalisation .\\xa0Pertussis is most contagious and antibiotic treatment is most beneﬁcial during the catarrhal stage of the illness. Since\\nthis is also the period during which clinical symptoms and signs are non-speciﬁc, it is necessary to maintain a high index\\nof suspicion with clues from the context. These include patients with any compatible symptoms and close contact with\\na suspected case or in a pertussis outbreak setting.\\nManagement\\nSuspected cases\\nAntibiotic treatment\\n [1] \\n [2] \\n [3] \\nCatarrhal stage (1 to 2 weeks, but may be shorter in infants < 6 months):\\nRunny nose, mild cough, no or low-grade fever.\\nDuring this stage, the disease is indistinguishable from other non-speciﬁc respiratory infections.\\nParoxysmal stage (1 to 6 weeks):'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 84, 'page_label': '85', 'id': 'data/guideline-170-en.pdf:84:3'}, page_content='Paroxysmal stage (1 to 6 weeks):\\nCough of increasing severity, occuring in characteristic bouts\\xa0(paroxysms) of a series of coughs during one\\nexhalation, followed by a laboured inspiration causing a distinctive gasping sound (whoop), and/or post-tussive\\nvomiting.\\xa0\\nNo or low-grade fever.\\xa0\\nApnoea and cyanosis (in infants).\\nProlonged cough, sometimes without paroxysms or whoop (particularly in older children and adults).\\nConvalescent stage (weeks to months):\\nParoxysms of cough gradually decrease in frequency and severity.\\n [4]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 85, 'page_label': '86', 'id': 'data/guideline-170-en.pdf:85:0'}, page_content='Page 86 / 409\\nAntibiotic treatment is indicated for the following patients and should be started as soon as pertussis is suspected:\\n\\xa0\\n\\xa0Admit the following patients to hospital\\n\\xa0Infection prevention and control measures\\nPatients with pertussis are considered infectious until they have completed 5 days of appropriate antibiotics, or if not\\ntreated, until 21 days after the start of the paroxysmal cough . During this infectious period, these measures should\\nbe followed:\\n\\xa0\\n [5] \\nAll patients 1 year of age and older, within 3 weeks of the onset of cough.\\nInfants and pregnant women, within 6 weeks of the onset of cough.\\nFirst line\\nazithromycin PO\\nfor 5 days\\nChildren < 6 months: 10 mg/kg once daily\\nChildren ≥ 6 months: 10 mg/kg (max. 500 mg) on D1 then 5 mg/kg (max.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 85, 'page_label': '86', 'id': 'data/guideline-170-en.pdf:85:1'}, page_content='Children ≥ 6 months: 10 mg/kg (max. 500 mg) on D1 then 5 mg/kg (max.\\n250 mg) once daily from D2 to D5\\nAdults: 500 mg on D1 then 250 mg once daily from D2 to D5\\nAlternatives\\nerythromycin\\xa0PO\\nfor 7 days\\n (a) Children: 15 mg/kg 3 times daily\\nAdults: 1 g 3 times daily\\nco-trimoxazole PO\\nfor 14 days\\n (b) Children ≥ 6 weeks: 20 mg SMX/4 mg TMP/kg (max. 800 mg SMX/160\\nmg TMP) 2 times daily\\nAdults: 800 mg SMX/160 mg TMP 2 times daily\\n(a) Erythromycin is an alternative, but azithromycin is better tolerated and simpler to administer (shorter treatment duration,fewer daily doses).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 85, 'page_label': '86', 'id': 'data/guideline-170-en.pdf:85:2'}, page_content='(b) Use co-trimoxazole only if macrolides are contra-indicated, not tolerated, or not available.Avoid:- during the ﬁrst trimester of pregnancy (risk of congenital malformations),- after 36 weeks of pregnancy and in women breastfeeding neonates (0 to 4 weeks), or breastfeeding infants that arepremature, low birth weight, jaundiced, or ill (risk of\\xa0haemolysis and jaundice in the child).Advise patients to seek immediate medical attention if there are signs of anaemia or jaundice, especially in regions with highprevalence of G6PD deﬁciency.\\nPatients with severe illness\\xa0(e.g. respiratory distress, apnoea, cyanosis, pneumonia, seizures or impaired\\nconsciousness)\\nInfants up to\\xa03 months of age (with\\xa0monitoring 24 hours per day due to the risk of apnoea)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 85, 'page_label': '86', 'id': 'data/guideline-170-en.pdf:85:3'}, page_content='Patients with difﬁculty in feeding or drinking\\n [1] \\nIn hospital: single room if possible, or grouping pertussis cases together away from other patients\\n(cohorting);\\xa0standard precautions and droplet precautions (including, for the patient, cough etiquette and wearing a\\nsurgical mask if outside the room) [6]\\nAll patients: avoid contact with young children and pregnant women; avoid congregate settings including childcare,\\nschool, and work'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 86, 'page_label': '87', 'id': 'data/guideline-170-en.pdf:86:0'}, page_content='Page 87 / 409\\nSupportive care\\nHydration and nutrition: if child is breastfeeding, continue; ensure adequate ﬂuid and calorie intake, give frequent small\\nfeedings including after coughing bouts and post-tussive vomiting; some patients may require nasogastric tube feeding\\nor IV maintenance ﬂuids; be aware that NG tube placement might provoke paroxysmal coughing, so it should be\\ninserted by experienced medical staff with minimal manipulation. If weight loss occurred during illness, consider food\\nsupplements for several weeks during convalescent stage when child is able to eat comfortably.\\xa0Respiratory measures\\n\\xa0For children\\xa0treated as outpatients,\\xa0teach\\xa0the parents about signs that\\xa0require immediate medical attention\\xa0(e.g.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 86, 'page_label': '87', 'id': 'data/guideline-170-en.pdf:86:1'}, page_content='respiratory difﬁculty, apnoea, cyanosis, increasing\\xa0fever,\\xa0seizures or impaired consciousness,\\xa0dehydration,\\xa0feeding\\ndifﬁculty).\\nContacts\\xa0\\nPrevention\\n\\xa0\\n\\xa0\\nPlace the patient in a semi-reclining position (± 30°).\\nIn case of apnoea, stimulate the patient, but be prepared to ventilate if necessary (keep bag and mask accessible).\\nAdminister oxygen if SpO < 92%, for severe respiratory distress, or for recurrent apnoea.\\xa0Perform gentle\\noropharyngeal suctioning if required\\xa0but avoid deep suctioning (may provoke\\xa0paroxysmal coughing).\\n2\\nPost-exposure\\xa0prophylaxis (same\\xa0antibiotic\\xa0treatment as for suspect cases) is recommended,\\xa0regardless of\\nvaccination status, for:\\nAsymptomatic close contacts (having face-to-face exposure or direct contact with oral, nasal, or other'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 86, 'page_label': '87', 'id': 'data/guideline-170-en.pdf:86:2'}, page_content='respiratory secretions )\\xa0of a person with suspected pertussis within 3 weeks of onset of paroxysmal cough [7] \\nAsymptomatic exposed people\\xa0at high risk of complications or who will come into contact with people at high\\nrisk : [4] [8] \\npregnant women in the third trimester (risk to neonate),\\ninfants under 1 year,\\npeople with\\xa0immunodepression,\\xa0moderate to severe asthma, and consider for people with other underlying\\nrespiratory conditions and adults ≥ 65 years.\\nIsolation of\\xa0asymptomatic\\xa0contacts is not necessary.\\nSymptomatic contacts should be treated as suspected pertussis.\\nAssess whether the person is up-to-date with pertussis vaccination according to national protocol (see\\nPrevention).\\nPertussis vaccination provides substantial immunity that wanes over time . [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 86, 'page_label': '87', 'id': 'data/guideline-170-en.pdf:86:3'}, page_content='Pertussis vaccination provides substantial immunity that wanes over time . [1] \\nIn all cases (suspected cases and contacts) who are not up-to-date with pertussis vaccination, begin or refer for\\nvaccination.\\nRoutine vaccination\\xa0with a 3-dose primary series of\\xa0polyvalent vaccine containing pertussis antigen(s) from the age\\nof 6 weeks or according to national protocol.\\xa0A booster dose is recommended, preferably during the second year\\nof life . Based on local epidemiology, further booster doses may be required\\xa0later in life to reinforce immunity and\\nreduce the risk of developing pertussis.\\n [1] \\nIf the pertussis primary vaccination series has been interrupted, it should be completed rather than restarted from\\nthe beginning.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 86, 'page_label': '87', 'id': 'data/guideline-170-en.pdf:86:4'}, page_content=\"the beginning.\\nIn general, vaccinations are deferred for patients with moderate to severe illness, but the vaccine should be\\nadministered as soon as\\xa0the patient's condition has improved.\\xa0\\nVaccination will probably not prevent disease in a person who is already infected by\\xa0B. pertussis. It is not a\\nsubstitute for post-exposure prophylaxis . [7] [9]\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 87, 'page_label': '88', 'id': 'data/guideline-170-en.pdf:87:0'}, page_content='Page 88 / 409\\nReferences\\n1. Pertussis vaccines: WHO position paper – August 2015. Wkly Epidemiol Rec. 2015;(35):433-458.https://iris.who.int/bitstream/handle/10665/242413/WER9035_433-458.PDF [Accessed May 17, 2024].\\n2. Güris D, Strebel PM, Bardenheier B, et al. Changing Epidemiology of Pertussis in the United States: Increasing ReportedIncidence Among Adolescents and Adults, 1990‐1996. Clin Infect Dis. 1999;28(6):1230-1237.https://doi.org/10.1086/514776 [Accessed September 10, 2024].\\n3. Daniels HL, Sabella C. Bordetella pertussis (Pertussis). Pediatr Rev. 2018;39(5):247-257.https://doi.org/10.1542/pir.2017-0229 [Accessed September 11, 2024].'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 87, 'page_label': '88', 'id': 'data/guideline-170-en.pdf:87:1'}, page_content='4. Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis.2019;69(2):218-226.https://doi.org/10.1093/cid/ciy889\\xa0[Accessed September 13, 2024]\\n5. Centers for Disease Control and Prevention. For Clinicians: Pertussis Treatment. Published online August 4, 2022.https://www.cdc.gov/pertussis/clinical/treatment.html\\xa0[Accessed April 28, 2024].\\n6. Siegel J, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee. 2007Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Published onlineJuly 2023.https://www.cdc.gov/infection-control/media/pdfs/Guideline-Isolation-H.pdf [Accessed April 28,2024].'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 87, 'page_label': '88', 'id': 'data/guideline-170-en.pdf:87:2'}, page_content='7. World Health Organization. Pertussis: Vaccine-Preventable Diseases Surveillance Standards. Published online September 5,2018.https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-pertussis [Accessed May 19,2024].\\n8. Centers for Disease Control and Prevention. Pertussis and Postexposure Antimicrobial Prophylaxis (PEP). Published onlineAugust 4, 2022.https://www.cdc.gov/pertussis/php/postexposure-prophylaxis/index.html [Accessed April 29, 2024].\\n9. Blain A, Skoff T, Cassiday P, Tondella ML, Acosta A. Pertussis. In: Manual for the Surveillance of Vaccine-Preventable Diseases.Centers for Disease Control and Prevention; 2020:Chapter\\xa010.https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-10-pertussis.html\\xa0[Accessed May 19, 2024].'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 88, 'page_label': '89', 'id': 'data/guideline-170-en.pdf:88:0'}, page_content='Page 89 / 409\\nBronchitis\\n\\xa0\\n\\xa0\\n\\xa0\\nAcute bronchitis\\nChronic bronchitis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 89, 'page_label': '90', 'id': 'data/guideline-170-en.pdf:89:0'}, page_content='Page 90 / 409\\nAcute bronchitis\\nAn acute inﬂammation of the bronchial mucosa, most commonly of viral origin. In older children it can be caused\\nby\\xa0Mycoplasma pneumoniae. In children over 2 years of age with repetitive acute bronchitis or ‘wheezing’ bronchitis,\\nconsider asthma (see\\xa0Asthma). In children under 2 years of age, consider bronchiolitis (see\\xa0Bronchiolitis).\\nClinical features\\nOften begins with a rhinopharyngitis that descends progressively: pharyngitis, laryngitis, tracheitis.\\nTreatment\\namoxicillin\\xa0PO\\nChildren:\\xa030 mg/kg 3 times daily\\xa0(max.\\xa03 g daily)\\xa0for 5 days\\nAdults: 1 g 3 times daily\\xa0for 5 days\\nHeavy cough, dry at the beginning then becoming productive\\nLow-grade fever\\nNo tachypnoea, no dyspnoea\\nOn pulmonary auscultation: bronchial wheezing\\nFever: paracetamol PO (Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 89, 'page_label': '90', 'id': 'data/guideline-170-en.pdf:89:1'}, page_content='Fever: paracetamol PO (Chapter 1).\\nKeep the patient hydrated, humidify air (with a bowl of water or a wet towel).\\nChildren: nasal irrigation with 0.9% sodium chloride or Ringer lactate, 4 to 6 times daily to clear the airway.\\nAntibiotherapy is not useful for patients in good overall condition with rhinopharyngitis or inﬂuenza.\\nAntibiotherapy is indicated only if:\\nthe patient is in poor general condition: malnutrition, measles, rickets, severe anaemia, cardiac disease, elderly\\npatient etc.\\nif the patient has dyspnoea, fever greater than 38.5 °C and purulent expectorations: a secondary infection\\nwith\\xa0Haemophilus inﬂuenzae\\xa0or with pneumococcus is probable.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 90, 'page_label': '91', 'id': 'data/guideline-170-en.pdf:90:0'}, page_content='Page 91 / 409\\nChronic bronchitis\\nA chronic inﬂammation of the bronchial mucosa due to irritation (tobacco, pollution), allergy (asthma) or infection\\n(repetitive acute bronchitis). It may develop into chronic obstructive pulmonary disease.\\nClinical features\\n\\xa0A patient with an acute exacerbation of chronic bronchitis presents with:\\nTreatment\\nProductive cough for 3 consecutive months per year for 2 successive years.\\nNo dyspnoea at onset. Dyspnoea develops after several years, ﬁrst on exertion, then becoming persistent.\\nOn pulmonary auscultation: bronchial wheeze (always exclude tuberculosis).\\nOnset or increase of dyspnoea.\\nIncreased volume of sputum.\\nPurulent sputum.\\nAntibiotic treatment is not useful in treating simple chronic bronchitis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 90, 'page_label': '91', 'id': 'data/guideline-170-en.pdf:90:1'}, page_content='Antibiotic treatment is not useful in treating simple chronic bronchitis.\\nAntibiotic treatment may be useful, for patients in a poor general condition only, for acute exacerbations of chronic\\nbronchitis (see\\xa0Acute bronchitis).\\nDiscourage smoking and other irritating factors.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 91, 'page_label': '92', 'id': 'data/guideline-170-en.pdf:91:0'}, page_content='Page 92 / 409\\nBronchiolitis\\nLast updated: October 2023\\n\\xa0\\nBronchiolitis is an epidemic and seasonal viral infection of the lower respiratory tract in children less than 2 years of\\nage, characterised by bronchiolar obstruction.\\nRespiratory syncytial virus (RSV) is responsible for 70% of cases of bronchiolitis. Transmission of RSV is direct,\\nthrough inhalation of droplets (coughing, sneezing), and indirect, through contact with hands or materials contaminated\\nby infected secretions.\\nIn the majority of cases, bronchiolitis is benign, resolves spontaneously (relapses are possible), and can be treated on\\nan outpatient basis.\\nSevere cases may occur, which put the child at risk due to exhaustion or secondary bacterial infection. Hospitalisation'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 91, 'page_label': '92', 'id': 'data/guideline-170-en.pdf:91:1'}, page_content='is necessary when signs/criteria of severity are present (10 to 20% of cases).\\nClinical features\\nRhinopharyngitis, with dry cough, precedes these features by 24 to 72 hours; fever is absent or moderate.\\xa0\\nTreatment\\nTreatment is symptomatic. Obstructive signs and symptoms last for about 10 days; cough may persist for 2 weeks or\\nlonger.\\xa0Hospitalise children with one of the following criteria:\\n\\xa0Consider hospitalisation on a case-by-case basis in the following situations:\\n\\xa0In all other cases, the child may be treated at home, provided the parents are taught how to carry out treatment, and\\nwhat signs of severity should lead to re-consultation.\\nTachypnoea, dyspnoea, wheezing, cough; profuse, frothy, obstructive secretions.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 91, 'page_label': '92', 'id': 'data/guideline-170-en.pdf:91:2'}, page_content='Tachypnoea, dyspnoea, wheezing, cough; profuse, frothy, obstructive secretions.\\nOn auscultation: prolonged expiration with diffuse, bilateral wheezes; sometimes diffuse ﬁne, end-inspiratory\\ncrackles.\\nSigns of severity:\\nSigniﬁcant deterioration in general condition, toxic appearance (pallor, greyish colouration)\\nApnoea, cyanosis (check lips, buccal mucosa, ﬁngernails)\\nRespiratory distress (nasal ﬂaring, sternal and chest wall indrawing)\\nAnxiety and agitation (hypoxia), altered level of consciousness\\nRespiratory rate > 60/minute\\nDecreased signs of respiratory distress (exhaustion)\\xa0and decline of respiratory rate\\xa0(< 30/minute below the age\\nof 1 year and < 20/minute below the age of 3 years). Exercise caution in interpreting these signs as indicators of\\nclinical improvement.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 91, 'page_label': '92', 'id': 'data/guideline-170-en.pdf:91:3'}, page_content='clinical improvement.\\nSpO persistently < 92%2\\nSweats, tachycardia at rest and in the absence of fever\\nSilence on auscultation (severe bronchospasm)\\nDifﬁculty drinking or sucking (reduced tolerance for exertion)\\nPresence of any sign of severity\\nPre-existing pathology (cardiac or pulmonary disease, malnutrition, HIV infection, etc.)\\nAssociated acute pathology (viral gastro-enteritis, bacterial infection, etc.)\\nAge less than 3 months'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 92, 'page_label': '93', 'id': 'data/guideline-170-en.pdf:92:0'}, page_content='Page 93 / 409\\nOutpatient treatment\\nHospitalisation\\n\\xa0\\nPrevention and control\\nThe risk of transmission of the virus is increased in hospital settings:\\n\\xa0\\nNasal irrigation with 0.9% NaCl before each feeding (demonstrate the technique to the mother) . a \\nSmall, frequent feedings to reduce vomiting triggered by bouts of coughing.\\nIncreased ﬂuids if fever and/or signiﬁcant secretions are present.\\nTreat\\xa0fever\\xa0(Chapter 1).\\nHandle the patient the patient as little as possible and avoid unnecessary procedures.\\nIn all cases:\\nPlace the infant in a semi-reclining position (± 30°).\\nNasal irrigation, small, frequent feeds, treatment of fever: as for outpatient treatment.\\nGentle oro-pharyngeal suction if needed.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 92, 'page_label': '93', 'id': 'data/guideline-170-en.pdf:92:1'}, page_content='Gentle oro-pharyngeal suction if needed.\\nMonitor ﬂuid intake: normal requirements are 80 to 100 ml/kg/day + 20 to 25 ml/kg/day with high fever or very\\nprofuse secretions.\\nAccording to symptoms:\\nHumidiﬁed nasal oxygen if respiratory distress or\\xa0SpO < 92%.2\\nWhen there is vomiting or signiﬁcant fatigue when sucking, ﬂuid requirements may be administered by\\nnasogastric tube (small volumes on a frequent basis) or the IV route, for the shortest possible time. Avoid\\nbreastfeeding or oral feeds in children with severe tachypnoea, but do not prolong NG feeds (respiratory\\ncompromise) or IV infusions any longer than necessary.\\nBronchodilator therapy\\xa0is not indicated but a trial treatment may be given in case of severe respiratory distress'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 92, 'page_label': '93', 'id': 'data/guideline-170-en.pdf:92:2'}, page_content='(salbutamol\\xa0metered-dose inhaler, 100 micrograms/puff: 2 to 3 puffs with spacer, repeated\\xa02 times at an\\ninterval of 30 minutes). If inhaled salbutamol appears effective in relieving symptoms, the treatment is continued\\n(2 to 3 puffs every 6 hours in the acute phase, then gradual reduction as recovery takes place). If the trial is\\nineffective, the treatment is discontinued.\\nAntibiotics are not indicated unless there is concern about complications such as secondary bacterial\\npneumonia.\\nChildren with bronchiolitis should be grouped together, away from other children (cohorting).\\nAs infection is most commonly transmitted by the hands, the most important prevention measure is hand-washing'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 92, 'page_label': '93', 'id': 'data/guideline-170-en.pdf:92:3'}, page_content='after any contact with patients, and objects or surfaces in contact with patients on which the virus may survive for\\nseveral hours.\\nIn addition, staff should wear gowns, gloves and surgical masks when in contact with patients.\\nFootnotes\\n(a) Lie the child on his back, head turned to the side and instil 0.9% NaCl into the nose, one nostril at a time.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 93, 'page_label': '94', 'id': 'data/guideline-170-en.pdf:93:0'}, page_content='Page 94 / 409\\nAcute pneumonia\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nAcute pneumonia is a viral, bacterial (pneumococcus, Haemophilus inﬂuenzae, staphylococcus, atypical bacteria) or\\nparasitic (pneumocystosis) infection of the pulmonary alveoli.\\nPneumonia in children under 5 years of age\\nPneumonia in children over 5 years and adults\\nPersistent pneumonia'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 94, 'page_label': '95', 'id': 'data/guideline-170-en.pdf:94:0'}, page_content='Page 95 / 409\\nPneumonia in children under 5 years of age\\nThe most common causes are viruses, pneumococcus and\\xa0Haemophilus inﬂuenzae.\\nClinical features\\n\\xa0Clinical examination must be done on a calm child in order to correctly count the respiratory rate and look for signs of\\nseverity.\\xa0\\nRR ≥ 60 breaths/minute in children under 1 months\\nRR ≥ 50 breaths/minute in children from 1 to\\xa011 months\\nRR ≥ 40 breaths/minute in children from 12 months to 5 years\\n\\xa0Notes:\\n\\xa0Consider also:\\nTreatment\\nSevere pneumonia (inpatient treatment)\\nCough or difﬁculty breathing\\nFever often high (> 39 °C), but the child may present with low-grade fever or may have no fever (often a sign of\\nserious illness)\\nA child has tachypnoea (increased respiratory rate) if:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 94, 'page_label': '95', 'id': 'data/guideline-170-en.pdf:94:1'}, page_content='serious illness)\\nA child has tachypnoea (increased respiratory rate) if:\\nOn pulmonary auscultation: dullness with diminished vesicular breath sounds, crepitations and sometimes bronchial\\nbreathing or normal pulmonary auscultation.\\nSigns of severity\\xa0(severe pneumonia):\\nChest indrawing: the inferior thoracic wall depresses on inspiration as the superior abdomen expands\\nCyanosis (lips, oral mucosa, ﬁngernails) or SpO\\xa0< 90%2\\nNasal ﬂaring\\nAltered consciousness (child is abnormally sleepy or difﬁcult to wake)\\nStridor (hoarse noise on inspiration)\\nGrunting (a short repetitive noise produced by a partial closure of the vocal cords) on expiration\\nRefusal to drink or feed\\nChildren under 2 months\\nSevere malnutrition'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 94, 'page_label': '95', 'id': 'data/guideline-170-en.pdf:94:2'}, page_content='Refusal to drink or feed\\nChildren under 2 months\\nSevere malnutrition\\nIn malnourished children, the RR thresholds should be decreased by 5 breaths/minute from those listed above.\\nChest indrawing is signiﬁcant if it is clearly visible and present at all times. If it is observed when a child is upset or\\nfeeding and is not visible when the child is resting, there is no chest indrawing.\\nIn children under 2 months of age, moderate chest indrawing is normal as the thoracic wall is ﬂexible.\\nIf only the soft tissues between the ribs or above the clavicles depress, there is no chest indrawing.\\nMalaria in endemic areas, as it may also cause cough and tachypnoea.\\nStaphylococcal pneumonia\\xa0in patients with empyema or painful abdominal swelling and diarrhoea.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 94, 'page_label': '95', 'id': 'data/guideline-170-en.pdf:94:3'}, page_content='Pneumocystosis in children with conﬁrmed or suspected HIV infection (see\\xa0HIV infection and AIDS, Chapter 8).\\nTuberculosis:\\nin a child with cough, fever and poor weight gain and a history of close contact with a tuberculous patient . For\\nthe diagnosis, refer to the MSF handbook,\\xa0Tuberculosis.\\n a \\xa0\\nin the event of pneumonia complicated with empyema (pus in the pleural space).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 95, 'page_label': '96', 'id': 'data/guideline-170-en.pdf:95:0'}, page_content=\"Page 96 / 409\\nChildren under 2 months\\xa0\\nThe ﬁrst line treatment is the combination\\xa0ampicillin\\xa0slow IV (3 minutes) for 10 days +\\xa0gentamicin\\xa0slow IV (3 minutes)\\nor IM for 5 days:\\xa0\\n\\xa0For ampicillin, IV route is preferred but IM route may be an alternative.\\xa0If ampicillin is not available, alternatives may be\\xa0cefotaxime\\xa0slow IV (3 minutes) or infusion (20 minutes) or IM for 10\\ndays (for doses, see\\xa0Meningitis, Chapter 7), or, as a last resort:\\xa0ceftriaxone\\xa0slow IV (3 minutes) or infusion (30 minutes;\\n60 minutes in neonates) or IM: 50 mg/kg once daily for 10 days.\\xa0If the child's condition does not improveafter 48 hours of well administered treatment, add\\xa0cloxacillin\\xa0IV for 10 to 14\\ndays:\\xa0\\n\\xa0\\nChildren from 2 months to 5 years\\nThe ﬁrst line treatment is:\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 95, 'page_label': '96', 'id': 'data/guideline-170-en.pdf:95:1'}, page_content=\"days:\\xa0\\n\\xa0\\nChildren from 2 months to 5 years\\nThe ﬁrst line treatment is:\\nceftriaxone\\xa0IM or slow IV (3 minutes): 50 mg/kg once daily\\nor\\nampicillin\\xa0slow IV (3 minutes) or IM: 50 mg/kg every 6 hours\\n+\\xa0gentamicin\\xa0slow IV (3 minutes) or IM: 6 mg/kg once daily\\nAmpicillin is preferably administered in 4 divided doses. If the context does not permit it, the daily dose must be divided\\nin at least 3 doses.\\xa0The treatment is administered by parenteral route for at least 3 days then, if the clinical condition has improved and\\noral treatment can be tolerated, switch to\\xa0amoxicillin\\xa0PO: 30 mg/kg 3 times daily to complete 10 days of treatment.\\xa0If the child's condition deteriorates or does not improve after 48 hours of correct administration, add\\xa0cloxacillin\\xa0IV: 25\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 95, 'page_label': '96', 'id': 'data/guideline-170-en.pdf:95:2'}, page_content='to 50 mg/kg every 6 hours. After clinical improvement and 3 days with no fever, switch to\\xa0amoxicillin/clavulanic\\nacid\\xa0(co-amoxiclav) PO to complete 10 to 14 days of treatment.\\xa0Use formulations in a ratio of 8:1 or 7:1\\nexclusively.\\xa0The dose is expressed in amoxicillin:\\xa050 mg/kg 2 times daily.\\n\\xa0\\nChildren\\n0 - 7 days\\n\\xa0\\n< 2 kg ampicillin 50 mg/kg every 12 hours\\n+ gentamicin 3 mg/kg once daily\\n≥ 2 kg ampicillin 50 mg/kg every 8 hours\\n+ gentamicin 5 mg/kg once daily\\nChildren\\n8 days - < 1 month\\nampicillin 50 mg/kg every 8 hours\\n+ gentamicin 5 mg/kg once daily\\nChildren\\n1 month - < 2 months\\nampicillin 50 mg/kg every 6 hours\\n+ gentamicin 6 mg/kg once daily\\n b \\n c \\nChildren 0 - 7 days\\n< 2 kg cloxacillin 50 mg/kg every 12 hours\\n≥ 2 kg cloxacillin 50 mg/kg every 8 hours\\nChildren > 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 95, 'page_label': '96', 'id': 'data/guideline-170-en.pdf:95:3'}, page_content='≥ 2 kg cloxacillin 50 mg/kg every 8 hours\\nChildren > 7 days\\n< 2 kg cloxacillin 50 mg/kg every 8 hours\\n≥ 2 kg cloxacillin 50 mg/kg every 6 hours\\n b \\n c'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 96, 'page_label': '97', 'id': 'data/guideline-170-en.pdf:96:0'}, page_content=\"Page 97 / 409\\n\\xa0If the child's condition does not improve after 48 hours with ceftriaxone + cloxacillin, consider tuberculosis. For the\\ndiagnosis, refer to the guide\\xa0Tuberculosis,\\xa0MSF.\\nIf tuberculosis is unlikely, continue with ceftriaxone + cloxacillin and add azithromycin (see\\xa0Atypical pneumonia).\\nNotes:\\nAdjuvant therapy\\nUse a nasogastric tube only if an IV line cannot be established: children under 12 months: 5 ml/kg/hour; children\\nover 12 months: 3 to 4 ml/kg/hour; alternate milk and water. Resume normal oral feeding as soon as possible.\\nPneumonia with no signs of severity\\nChildren under 2 months\\nAdmit the child for inpatient care and treat for\\xa0severe pneumonia.\\nChildren from 2 months to 5 years\\nTreat as outpatient, except infants.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 96, 'page_label': '97', 'id': 'data/guideline-170-en.pdf:96:1'}, page_content='Children from 2 months to 5 years\\nTreat as outpatient, except infants.\\namoxicillin\\xa0PO: 30 mg/kg 3 times daily for 5 days\\xa0Follow-up in 48 to 72 hours or sooner if the child’s condition deteriorates:\\n\\xa0\\nFor malnourished children, refer to speciﬁc protocol.\\nIn the event of moderate-large empyema, assess if drainage is required. Administer antibiotics active against\\npneumococci and staphylococci (see\\xa0Staphylococcal pneumonia).\\nFever: paracetamol PO (Chapter 1).\\nInfants: keep warm.\\nInstall on an incline (head elevated) or in semi-sitting position.\\nClear the airway (nasal irrigation with 0.9% sodium chloride if needed).\\nOxygen at the ﬂow rate required to maintain SpO\\xa0≥ 90% or, if pulse oxymeter is not available, minimum 1\\nlitre/minute.\\n2\\nMaintain adequate hydration and nutrition:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 96, 'page_label': '97', 'id': 'data/guideline-170-en.pdf:96:2'}, page_content='litre/minute.\\n2\\nMaintain adequate hydration and nutrition:\\nIn children with severe respiratory difﬁculty: place an IV line and give 70% of normal maintenance ﬂuids. Resume\\noral feeding as soon as possible (no severe respiratory difﬁculty, ability to eat normally).\\nIn the absence of severe respiratory difﬁculty: breastfeed on demand; milk/food and water by spoon on\\ndemand.\\nORS when required (Dehydration, Chapter 1).\\nIf the condition is improving : continue with the same antibiotic to complete treatment. c \\nIf there is no improvement after 3 days of correct administration: add azithromycin (see\\xa0Atypical pneumonia).\\nIf the condition is deteriorating: hospitalise and treat as severe pneumonia.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 96, 'page_label': '97', 'id': 'data/guideline-170-en.pdf:96:3'}, page_content='Footnotes\\n(a) Contact is deﬁned as living in the same household, or in close and regular contact with any known or suspected tuberculouscase within the last 12 months.\\n(b) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.\\xa0\\n(c) Improvement criteria include: fever reduction, diminished respiratory distress, improved SpO, improved appetite and/oractivity.\\xa0\\n2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 97, 'page_label': '98', 'id': 'data/guideline-170-en.pdf:97:0'}, page_content='Page 98 / 409\\nPneumonia in children over 5 years and adults\\nThe most common causes are viruses, pneumococcus, and\\xa0Mycoplasma pneumoniae.\\nClinical features\\n\\xa0Sudden onset with high fever (higher than 39 °C), thoracic pain and oral herpes are suggestive of pneumococcal\\ninfection. Symptoms may be confusing, particularly in children with\\xa0abdominal pain, meningeal syndrome, etc.\\xa0Signs of severity (severe pneumonia) include:\\n\\xa0Patients at risk include the older patients, patients with heart failure, sickle cell disease or severe chronic bronchitis;\\nimmunocompromised patients (severe malnutrition, HIV infection with CD4 < 200).\\nTreatment\\nSevere pneumonia (inpatient treatment)\\nceftriaxone\\xa0IM or slow IV (3 minutes)\\nChildren: 50 mg/kg once daily\\nAdults: 1 g once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 97, 'page_label': '98', 'id': 'data/guideline-170-en.pdf:97:1'}, page_content='Children: 50 mg/kg once daily\\nAdults: 1 g once daily\\nThe treatment is given by parenteral route for at least 3 days then, if the clinical condition has improved and oral\\ntreatment can be tolerated, switch to\\xa0amoxicillin\\xa0PO to complete 7 to 10 days of treatment:\\nChildren:\\xa030 mg/kg 3 times daily\\xa0(max. 3 g daily)\\nAdults: 1 g 3 times daily\\nor\\nampicillin\\xa0slow IV (3 minutes) or IM\\nChildren: 50 mg/kg every 6 hours\\nAdults: 1 g every 6 to 8 hours\\nAmpicillin is preferably administered in 4 divided doses. If the context does not permit it, the daily dose must be divided\\nin at least 3 doses.\\nThe treatment is given by parenteral route for at least 3 days then, if the clinical condition has improved and oral'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 97, 'page_label': '98', 'id': 'data/guideline-170-en.pdf:97:2'}, page_content='treatment can be tolerated, switch to the oral route with amoxicillin PO as above, to complete 7 to 10 days of\\ntreatment.\\xa0\\nCough, with or without purulent sputum, fever, thoracic pain, tachypnoea\\nOn pulmonary auscultation: decreased vesicular breath sounds, dullness, localised foci of crepitations, sometimes\\nbronchial wheeze.\\nCyanosis (lips, oral mucosa, ﬁngernails)\\nNasal ﬂaring\\nIntercostal or subclavial indrawing\\nRR > 30 breaths/minute\\nHeart rate > 125 beats/minute\\nAltered level of consciousness (drowsiness, confusion)\\n a \\n b \\n b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 98, 'page_label': '99', 'id': 'data/guideline-170-en.pdf:98:0'}, page_content='Page 99 / 409\\nIf the clinical condition deteriorates or does not improve after 48 hours of correct administration, administer\\nceftriaxone as above +\\xa0cloxacillin\\xa0IV infusion:\\nChildren: 25 to 50 mg/kg every 6 hours\\nAdults: 2 g\\xa0every 6 hours\\nAfter clinical improvement and 3 days with no fever, switch to\\xa0amoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO to\\ncomplete 10 to 14 days of treatment.\\xa0Use formulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose is expressed in\\namoxicillin:\\nChildren < 40 kg: 50 mg/kg\\xa02 times daily\\nChildren\\xa0≥\\xa040 kg and\\xa0adults:\\nRatio 8:1: 3000 mg daily (2 tablets of 500/62.5 mg 3 times daily)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 98, 'page_label': '99', 'id': 'data/guideline-170-en.pdf:98:1'}, page_content=\"Ratio 8:1: 3000 mg daily (2 tablets of 500/62.5 mg 3 times daily)\\nRatio 7:1: 2625 mg daily (1 tablet of 875/125 mg 3 times daily)\\xa0If the clinical condition does not improve after 48 hours with ceftriaxone + cloxacillin, consider tuberculosis. For the\\ndiagnosis, refer to the guide\\xa0Tuberculosis, MSF.\\xa0If tuberculosis is unlikely, continue with ceftriaxone + cloxacillin and add azithromycin (see\\xa0Atypical pneumonia).\\nAdjuvant therapy\\nPneumonia without signs of severity (outpatient treatment)\\namoxicillin\\xa0PO\\nChildren:\\xa030 mg/kg 3 times daily\\xa0(max. 3\\xa0g daily)\\xa0for 5 days\\nAdults: 1 g 3 times daily\\xa0for 5 days\\xa0Follow-up in 48 to 72 hours or sooner if the patient's condition deteriorates:\\n\\xa0\\nFever: paracetamol PO (Chapter 1).\\nClear the airway (nasal irrigation with 0.9% sodium chloride if needed).\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 98, 'page_label': '99', 'id': 'data/guideline-170-en.pdf:98:2'}, page_content='Clear the airway (nasal irrigation with 0.9% sodium chloride if needed).\\nOxygen at the ﬂow rate required to maintain SpO\\xa0≥ 90% or, if pulse oxymeter is not available, minimum 1\\nlitre/minute.\\n2\\nMaintain adequate hydration and nutrition.\\nIf the condition is improving : continue with the same antibiotic to complete treatment. b \\nIf there is no improvement after 3 days of correct administration: add azithromycin (see\\xa0Atypical pneumonia).\\nIf the condition is deteriorating: hospitalise and treat as severe pneumonia.\\nFootnotes\\n(a) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 98, 'page_label': '99', 'id': 'data/guideline-170-en.pdf:98:3'}, page_content='(b) Improvement criteria include: fever reduction, diminished respiratory distress, improved SpO, improved appetite and/oractivity.\\xa0\\n2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 99, 'page_label': '100', 'id': 'data/guideline-170-en.pdf:99:0'}, page_content='Page 100 / 409\\nPersistent pneumonia\\n\\xa0\\n\\xa0\\nLast update: November 2022\\n\\xa0\\nIn patients not responding to therapy, consider atypical pneumonia, tuberculosis, pneumocystosis (HIV infection and\\nAIDS, Chapter 8).\\xa0Bacteria responsible for atypical pneumonia are mainly\\xa0Mycoplasma pneumoniae\\xa0and\\xa0Chlamydophila pneumoniae. If\\nsuspected, one of the following antibiotics may be used:\\xa0First choice,\\xa0azithromycin\\xa0PO\\nChildren: 10 mg/kg (max. 500 mg)\\xa0once daily for 5 days\\nAdults: 500 mg on D1 then, 250 mg once daily from D2 to D5\\xa0If not available,\\nerythromycin\\xa0PO\\nChildren: 10 mg/kg (max. 500 mg) 4 times daily for 10 to 14 days\\nAdults: 500 mg 4 times daily\\xa0for 10 to 14 days\\nor\\ndoxycycline PO (except in pregnant or breastfeeding women)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 99, 'page_label': '100', 'id': 'data/guideline-170-en.pdf:99:1'}, page_content='or\\ndoxycycline PO (except in pregnant or breastfeeding women)\\nChildren under 45 kg: 2 to 2.2 mg/kg (max. 100 mg) 2 times daily\\xa0for 10 to 14 days\\nChildren 45 kg and over and adults: 100 mg 2 times daily\\xa0for 10 to 14 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 100, 'page_label': '101', 'id': 'data/guideline-170-en.pdf:100:0'}, page_content='Page 101 / 409\\nStaphylococcal pneumonia\\nPneumonia due to\\xa0Staphylococcus aureus\\xa0affecting young children, often those in a poor general condition\\n(malnutrition, skin lesions, etc.). Staphylococcal pneumonia is a classic complication of measles.\\nClinical features\\nParaclinical investigations\\nTreatment\\nTreatment is urgent as patients deteriorate quickly: hospitalise.\\xa0\\nceftriaxone\\xa0IM or slow IV (at least 3 minutes): 50 mg/kg once daily\\n+\\xa0cloxacillin\\xa0IV infusion (60 minutes)\\nNeonates 0 to 7 days (< 2 kg):\\xa050 mg/kg every 12 hours\\nNeonates 0 to 7 days (≥ 2 kg):\\xa050 mg/kg every 8 hours\\nNeonates 8 days to < 1 month (< 2 kg):\\xa050 mg/kg every 8 hours\\nNeonates 8 days to < 1 month (≥ 2 kg):\\xa050 mg/kg every 6 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 100, 'page_label': '101', 'id': 'data/guideline-170-en.pdf:100:1'}, page_content='Neonates 8 days to < 1 month (≥ 2 kg):\\xa050 mg/kg every 6 hours\\nChildren 1 month and over:\\xa025 to 50 mg/kg every 6 hours\\xa0(max. 8 g daily)\\xa0After clinical improvement , 3 days with no fever, and drain removal if any, switch to\\xa0amoxicillin/clavulanic\\nacid\\xa0PO to complete 10 to 14 days.\\xa0Use formulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose is expressed in\\namoxicillin: 50 mg/kg 2 times daily\\xa0In the event of large empyema: same treatment but switch to the oral route after 7 days with no fever and treat for\\n3 weeks.\\xa0Clindamycin\\xa0IV may be an alternative to cloxacillin: 10 mg/kg every 8 hours then switch to clindamycin PO at the\\nsame dose, according to the criteria above.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 100, 'page_label': '101', 'id': 'data/guideline-170-en.pdf:100:2'}, page_content='same dose, according to the criteria above.\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nGeneral signs: change in overall condition, pallor, high fever or hypothermia, frequently signs of shock; presence of\\nskin lesions (point of bacterial entry), however, skin lesions may be absent.\\nGastrointestinal signs: nausea, vomiting, diarrhoea, painful abdominal distention.\\nRespiratory signs: dry cough, tachypnoea, signs of distress (nasal ﬂaring, chest indrawing).\\xa0Pulmonary auscultation is\\noften normal; sometimes dullness indicating pleural effusion.\\nChest x-ray (if available): may show multilobar consolidation, cavitation, pneumatoceles, spontaneous\\npneumothorax.\\nAntibiotic treatment: if staphylococcal aetiology cannot be conﬁrmed or while waiting for conﬁrmation, a broad\\nspectrum antibiotic therapy is recommended:\\n a \\n b \\n c'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 100, 'page_label': '101', 'id': 'data/guideline-170-en.pdf:100:3'}, page_content='spectrum antibiotic therapy is recommended:\\n a \\n b \\n c \\nFever: paracetamol (Chapter 1).\\nHydration\\xa0by oral route or infusion or nasogastric tube depending on clinical condition.\\nOxygen at the ﬂow rate required to maintain SpO\\xa0≥ 90% or, if pulse oxymeter is not available, minimum 1\\nlitre/minute.\\n2\\nLocal disinfection of skin lesions.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 101, 'page_label': '102', 'id': 'data/guideline-170-en.pdf:101:0'}, page_content='Page 102 / 409\\nClinical evolution\\n\\xa0\\nIf there is signiﬁcant pleural effusion: pleural tap with drainage (for pyopneumothorax; insert 2 drains, one anterior\\nand one posterior) or without drainage (for suppurative pleurisy, make repetitive taps with an IV catheter).\\nThere is a serious risk of decompensation from pneumothorax or suppurative pleurisy or pyopneumothorax.\\nOn a paediatric ward, adequate equipment for urgent pleural drainage should always be available.\\nFootnotes\\n(a) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 101, 'page_label': '102', 'id': 'data/guideline-170-en.pdf:101:1'}, page_content='(b) Cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. Then dilute each dose of cloxacillin in5 ml/kg of 0.9% sodium chloride or 5 % glucose in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or5% glucose in children 20 kg and over and in adults.\\n(c) Improvement criteria include: fever reduction, diminished respiratory distress, improved SpO2, improved appetite and/oractivity.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 102, 'page_label': '103', 'id': 'data/guideline-170-en.pdf:102:0'}, page_content='Page 103 / 409\\nAsthma\\n\\xa0\\nLast updated: June 2023\\n\\xa0\\n\\xa0\\n\\xa0\\nAsthma is a chronic inﬂammatory disorder of the airways associated with airway hyperresponsiveness that leads to\\nrecurrent episodes of wheezing, breathlessness, chest tightness and coughing. These episodes are usually associated\\nwith airﬂow obstruction within the lung, often reversible, either spontaneously or with treatment.\\xa0Factors that precipitate/aggravate asthma include: allergens, infection, exercise, drugs (aspirin), tobacco,\\netc.\\xa0Symptoms are sometimes worse at night.\\xa0In children up to 5 years, most initial episodes of asthma-like symptoms are associated with a respiratory tract\\ninfection, with no symptoms between infections. Wheezing episodes usually become less frequent with time; most of\\nthese children do not develop asthma.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 102, 'page_label': '103', 'id': 'data/guideline-170-en.pdf:102:1'}, page_content='these children do not develop asthma.\\nAcute asthma (asthma attack)\\nChronic asthma'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 103, 'page_label': '104', 'id': 'data/guideline-170-en.pdf:103:0'}, page_content='Page 104 / 409\\nAcute asthma (asthma attack)\\nLast updated: June 2023\\n\\xa0\\nAsthma attack is a substantial worsening of asthma symptoms. The severity and duration of attacks are variable and\\nunpredictable.\\nAssessment of the severity of asthma attack\\nThe severity of the asthma attack must be rapidly evaluated by the following clinical criteria. Not all signs are\\nnecessarily present.\\xa0\\nAssessment of severity in children over 2 years and adults\\xa0\\n\\xa0\\nTreatment\\nReassure the patient. Treatment and follow-up depend on the severity of the attack and the patient’s response:\\nMild to moderate attack\\n [1] [2] [3]\\nMild or moderate attack Severe or life-threatening attack\\nAble to talk in sentences Cannot complete sentences in one breath\\nor\\nToo breathless to talk or feed\\nMild or moderate increase of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 103, 'page_label': '104', 'id': 'data/guideline-170-en.pdf:103:1'}, page_content='or\\nToo breathless to talk or feed\\nMild or moderate increase of\\nrespiratory rate (RR)\\nVery high RR\\nChildren 2-5 years: > 40/minute\\nChildren > 5 years and adults: > 30/minute\\nNormal or mild increase of heart rate (HR)\\nChildren 2-3 years: ≤ 180/minute\\nChildren 4-5 years: ≤ 150/minute\\nChildren > 5 years and adults: ≤ 120/minute\\xa0\\nVery high HR\\nChildren 2-3 years: > 180/minute\\nChildren 4-5 years: > 150/minute\\nChildren > 5 years and adults: > 120/minute\\nSpO ≥ 90% (≥ 92% for children 2-5 years)2 SpO < 90% (< 92% for children 2-5 years)2\\nand\\nNo criteria of severe or\\xa0life-threatening attack\\n\\xa0\\nSigns of life-threatening attack:\\nAltered level of consciousness (drowsiness, confusion, coma)\\nExhaustion\\nSilent chest\\nCyanosis\\nArrhythmia or hypotension in adults\\nPlace the patient\\xa0in a 1/2 sitting position.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 103, 'page_label': '104', 'id': 'data/guideline-170-en.pdf:103:2'}, page_content='Place the patient\\xa0in a 1/2 sitting position.\\nAdminister:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 104, 'page_label': '105', 'id': 'data/guideline-170-en.pdf:104:0'}, page_content='Page 105 / 409\\nSevere attack\\nThe two solutions should be mixed in the drug reservoir of the nebuliser. Assess symptoms at the end of each\\nnebulisation.\\nIf there is no nebuliser, use salbutamol MDI (same dose as for mild to moderate attack) and ipratropium MDI\\n20 micrograms/puff,\\xa04 to 8 puffs every 20 minutes for the ﬁrst hour.\\nsalbutamol metered-dose inhaler (MDI)\\xa0100 micrograms/puff: 2 to 10 puffs every 20 minutes during the ﬁrst\\nhour. In children, use a spacer \\xa0(use face mask in children under 3 years). Single puffs should be given one at a\\ntime, let the child breathe 4 to 5 times from the spacer before repeating the procedure.\\xa0A spacer can also be\\nused in adults to increase effectiveness.\\n a \\nprednisolone\\xa0PO: one dose of 1 to 2 mg/kg (max. 50 mg) for children over 5 years and adults'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 104, 'page_label': '105', 'id': 'data/guideline-170-en.pdf:104:1'}, page_content='oxygen if\\xa0SpO < 94%.2  b \\nIf the attack is completely resolved:\\nObserve the patient for 1 hour (4 hours if they live far from the health centre) then give outpatient\\ntreatment:\\xa0salbutamol\\xa0MDI for 24 to 48 hours (2 to 4 puffs every 4 to 6 hours depending on clinical evolution)\\nand\\xa0prednisolone\\xa0PO (same dose\\xa0as above\\xa0once daily)\\xa0to complete 5 days of treatment.\\xa0\\nReassess after 1 to 2 days: address any identiﬁed risk factor, reassess need for salbutamol and long-term\\ntreatment. If the patient is already receiving long-term treatment, reevaluate the severity of the asthma (see\\nChronic asthma), review compliance and correct use of medications and adjust treatment if necessary.\\nIf the attack is only partially resolved, continue with\\xa0salbutamol\\xa0MDI (2 to 10 puffs every 1\\xa0to 4 hours)\\xa0until'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 104, 'page_label': '105', 'id': 'data/guideline-170-en.pdf:104:2'}, page_content='symptoms subside. For children up to\\xa05 years, administer one dose of prednisolone PO as above if symptoms\\nrecur within 3 to 4 hours.\\xa0When the attack is completely resolved, proceed as above.\\nIf symptoms worsen or do not improve, treat as\\xa0severe attack.\\nHospitalise; place the patient in a 1/2 sitting position. c \\nAdminister:\\noxygen\\xa0to maintain SpO\\xa0between 94 and 98%.2  b \\nsalbutamol + ipratropium\\xa0nebuliser solutions using a nebuliser (continue oxygen via nasal cannula during\\nnebulisation):\\nChildren < 5 years salbutamol 2.5 mg (1.25 ml) + ipratropium 0.25 mg (1 ml) every 20 minutes for the\\nﬁrst hour\\nChildren 5 to 11 years salbutamol 2.5 to 5 mg (1.25 to 2.5\\xa0ml)\\xa0+ ipratropium 0.5 mg (2 ml) every 20\\nminutes for the ﬁrst hour\\nChildren 12 years and over\\nand adults'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 104, 'page_label': '105', 'id': 'data/guideline-170-en.pdf:104:3'}, page_content='minutes for the ﬁrst hour\\nChildren 12 years and over\\nand adults\\nsalbutamol 5 mg (2.5 ml) + ipratropium 0.5 mg (2 ml) every 20 minutes for the ﬁrst\\nhour\\nprednisolone\\xa0PO: one dose of 1 to 2 mg/kg\\xa0(max. 50 mg)\\nIf prednisolone is not available, or if the patient cannot take oral treatment, administer:\\nChildren: dexamethasone PO/IV/IM, one dose of 0.15 to 0.6 mg/kg (max. 16 mg)\\nAdults: hydrocortisone IV, 4 mg/kg (max. 100 mg) every 6 hours for 24 hours\\nIf symptoms do not improve after one hour:\\ntransfer to intensive care unit\\ninsert an IV line\\noxygen to maintain SpO\\xa0between 94 and 98%2  b\\ncontinue salbutamol (solution for nebuliser) without ipratropium, and corticosteroids as above.\\nadminister one dose of magnesium sulfate by IV infusion in 0.9% sodium chloride over 20 minutes, monitoring'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 104, 'page_label': '105', 'id': 'data/guideline-170-en.pdf:104:4'}, page_content='blood pressure:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 105, 'page_label': '106', 'id': 'data/guideline-170-en.pdf:105:0'}, page_content='Page 106 / 409\\n\\xa0\\nNotes:\\n\\xa0\\nReferences\\nChildren: 40 mg/kg (max. 2 g)\\nAdults: 2 g\\nIf symptoms improve: continue salbutamol (solution for nebuliser) every 1 to 4 hours (depending on symptoms) and\\noxygen as above. Assess symptoms at the end of each nebulisation. When possible, switch to salbutamol MDI\\nand continue as for mild to moderate attack.\\nIf the attack is completely resolved, observe the patient for at least 4 hours. Continue the treatment with\\nsalbutamol (MDI) and prednisolone PO and reassess as for a mild to moderate attack.\\nIn pregnant women, treatment is the same as for adults. In mild or moderate asthma attacks, administering oxygen\\nreduces the risk of foetal hypoxia.\\nFor all patients, irrespective of the severity of the asthma attack, look for underlying lung infection and treat'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 105, 'page_label': '106', 'id': 'data/guideline-170-en.pdf:105:1'}, page_content='accordingly.\\nFootnotes\\n(a) If a conventional spacer is not available, use a 500 ml plastic bottle: insert the mouthpiece of the inhaler into a hole made inthe bottom of the bottle (the seal should be as tight as possible). The patient breathes from the mouth of the bottle in thesame way as they would with a spacer. The use of a plastic cup instead of a spacer is not recommended (ineffective).\\n(b) If pulse oxymetry is not available, administer oxygen continuously in case of moderate, severe or life-threatening attack.\\n(c) If signs of life-threatening attack, transfer to intensive care unit as soon as possible.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 105, 'page_label': '106', 'id': 'data/guideline-170-en.pdf:105:2'}, page_content='1. British guideline on the management of asthma. A national clinical guideline First published 2003. Revised edition publishedJuly 2019.https://www.sign.ac.uk/our-guidelines/british-guideline-on-the-management-of-asthma/ [Accessed 12 January 2023]\\n2. Global INitiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022 update.https://ginasthma.org/gina-reports/ [Accessed 12 January 2023]\\n3. WHO Pocket book of primary health care for children and adolescents: guidelines for health promotion, disease preventionand management from the newborn period to adolescence. WHO Regional Ofﬁce for Europe; 2022.https://www.who.int/europe/publications/i/item/9789289057622 [Accessed 12 January 2023]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 106, 'page_label': '107', 'id': 'data/guideline-170-en.pdf:106:0'}, page_content='Page 107 / 409\\nChronic asthma\\nLast updated: June 2023\\nClinical features\\nTreatment\\nThe mainstay of long-term treatment are\\xa0inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA). LABAs\\nshould never be used alone but always in combination with an ICS. Combination inhalers are preferred, when available.\\nIn addition to long-term treatment, salbutamol (short-acting beta-2 agonist, SABA) and combination inhalers can be\\nused to reduce bronchoconstriction if the patient is symptomatic.\\nTreatment is started at the step most appropriate to initial severity then, re-evaluated and adjusted according to\\nclinical response. An intervening severe asthma attack or loss of control necessitates treatment reassessment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 106, 'page_label': '107', 'id': 'data/guideline-170-en.pdf:106:1'}, page_content='The inhaler is chosen according to age. In children, a spacer should be used. Instructions on inhaler technique and\\ninformation on asthma attack symptoms should be provided.\\xa0\\nLong-term treatment of asthma according to severity in children 6 years and over and adults\\xa0\\nAsthma should be suspected in patients with recurrent respiratory symptoms (wheezing, chest tightness, shortness\\nof breath and/or cough) of variable frequency, severity and duration, disturbing sleep, and causing the patient to sit\\nup to breathe. These symptoms may appear during or after exercise.\\nChest auscultation may be normal or demonstrate diffuse sibilant wheezes.\\nA personal or family history of atopy (eczema, allergic rhinitis/conjunctivitis) or a family history of asthma increases'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 106, 'page_label': '107', 'id': 'data/guideline-170-en.pdf:106:2'}, page_content='probability of asthma but their absence does not exclude asthma.\\nPatients with typical symptoms of asthma and a history of disease that is characteristic of asthma should be\\nconsidered as having asthma after exclusion of other diagnoses.\\nAny identiﬁed asthma risk factor (e.g. allergen, pollution, tobacco smoke exposure) should be eliminated where\\npossible. The assessment of the frequency of symptoms and limitations of daily activities determines the\\ntreatment.\\n [1] [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 107, 'page_label': '108', 'id': 'data/guideline-170-en.pdf:107:0'}, page_content='Page 108 / 409\\nSymptoms Children 6 to\\xa011 years Children\\xa0≥ 12 years and adults\\nIntermittent asthma\\nDaytime symptoms < 2\\ntimes monthly\\nNormal daily activities\\nsalbutamol when symptomatic beclometasone/formoterol when\\nsymptomatic\\n\\xa0 OR\\nbeclometasone + salbutamol\\xa0when\\nsymptomatic (a)\\nMild persistent asthma\\nDaytime symptoms ≥ 2\\ntimes monthly\\nSymptoms may affect\\ndaily activities\\nbeclometasone\\xa0(low dose) daily\\nAND\\nsalbutamol when symptomatic\\nbeclometasone/formoterol when\\nsymptomatic\\n\\xa0 OR\\nbeclometasone (low dose)\\xa0daily\\xa0\\nAND\\nsalbutamol\\xa0when symptomatic\\nModerate persistent\\nasthma\\nDaytime symptoms most\\ndays\\xa0OR nighttime\\nsymptoms ≥ once weekly\\nSymptoms affect daily\\nactivities\\nbeclometasone (low dose)\\n+ salmeterol\\xa0daily\\nAND\\nsalbutamol when symptomatic\\n (b)\\nbeclometasone/formoterol (low dose)\\ndaily\\nAND'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 107, 'page_label': '108', 'id': 'data/guideline-170-en.pdf:107:1'}, page_content='salbutamol when symptomatic\\n (b)\\nbeclometasone/formoterol (low dose)\\ndaily\\nAND\\nbeclometasone/formoterol when\\nsymptomatic\\nOR\\nbudesonide/formoterol (very low\\ndose)\\xa0daily\\nAND\\nbudesonide/formoterol when\\nsymptomatic\\nOR\\nbeclometasone (low dose)\\n+ salmeterol\\xa0daily\\nAND\\nsalbutamol when symptomatic\\n (b)\\nSevere persistent asthma\\nDaily daytime symptoms\\nOR very frequent\\nnighttime symptoms\\nDaily activities very\\nlimited by symptoms\\nbeclometasone (medium dose)\\n+ salmeterol\\xa0daily\\nAND\\nsalbutamol when symptomatic\\nbeclometasone/formoterol (medium\\ndose)\\xa0daily\\nAND\\nbeclometasone/formoterol when\\nsymptomatic\\nOR\\nbudesonide/formoterol\\xa0(low dose)\\ndaily\\nAND\\nbudesonide/formoterol\\xa0when\\nsymptomatic\\nOR\\nbeclometasone (medium dose)\\n+ salmeterol daily\\nAND\\nsalbutamol when symptomatic\\n\\xa0\\n (c)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 107, 'page_label': '108', 'id': 'data/guideline-170-en.pdf:107:2'}, page_content='+ salmeterol daily\\nAND\\nsalbutamol when symptomatic\\n\\xa0\\n (c)\\n(a) Salbutamol should be taken just before beclometasone, or together if a combination inhaler is available.\\n(b) If salmeterol is not available, use beclometasone medium-dose.\\n(c) If salmeterol is not available, use beclometasone high-dose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 108, 'page_label': '109', 'id': 'data/guideline-170-en.pdf:108:0'}, page_content='Page 109 / 409\\nThe doses vary according to the severity of asthma. Find the lowest possible effective dose necessary to both\\nrelieve\\xa0symptoms and avoid local and systemic adverse effects.\\xa0beclometasone MDI (ICS):\\xa0\\n\\xa0In all cases, do not exceed 2000 micrograms daily.\\xa0 The number of puffs of beclometasone depends on its concentration in the inhaled aerosol: 50, 100 or 250\\nmicrograms per puff.\\n\\xa0\\nsalbutamol MDI 100 micrograms/puff (SABA):\\n\\xa0salmeterol MDI 25 micrograms/puff (LABA):\\n\\xa0budesonide/formoterol MDI 80/4.5 micrograms/puff (ICS/LABA combination):\\nIn all cases, do not exceed 8 puffs daily.\\xa0beclometasone/formoterol MDI 100/6 micrograms/puff (ICS/LABA combination):\\nIn all cases, do not exceed 8 puffs daily.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 108, 'page_label': '109', 'id': 'data/guideline-170-en.pdf:108:1'}, page_content='In all cases, do not exceed 8 puffs daily.\\n\\xa0\\nDo not restrict exercise. If exercise is a trigger for asthma attacks, administer 1 or 2 puffs of salbutamol or\\nbeclometasone/formoterol 10 minutes beforehand.\\xa0In pregnant women, poorly controlled asthma increases the risk of pre-eclampsia, eclampsia, haemorrhage, in utero\\ngrowth retardation, premature delivery, neonatal hypoxia and perinatal mortality. Long-term treatment should be\\ncontinued under close monitoring.\\n\\xa0 Children 6 to 11 years Children ≥ 12 years and adults\\nWhen symptomatic – 200 to 500 micrograms\\nLong-term treatment\\nLow dose 50 to 100 micrograms\\n2 times daily\\n100 to 250 micrograms\\n2 times daily\\nMedium dose\\xa0 150 to 200 micrograms\\n2 times daily\\n300 to 500 micrograms\\n2 times daily\\nHigh dose – > 500 micrograms\\n2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 108, 'page_label': '109', 'id': 'data/guideline-170-en.pdf:108:2'}, page_content='2 times daily\\nHigh dose – > 500 micrograms\\n2 times daily\\n\\xa0\\n\\xa0\\nChildren and adults: 2 to 4 puffs up to 4 times daily if necessary\\nChildren 6 to 11 years: 2 puffs 2 times daily (max. 4 puffs daily)\\nChildren 12 years and over and adults: 2 to 4 puffs 2 times daily (max. 8 puffs daily)\\nChildren 6 to 11 years:\\nwhen symptomatic: 1 puff\\nlong-term treatment, very low-dose: 1 puff once daily\\nlong-term treatment, low-dose: 1 puff 2 times daily\\nChildren 12 years and over and adults:\\nwhen symptomatic: 1 puff\\nlong-term treatment, low-dose: 1 puff 2 times daily\\nlong-term treatment, medium-dose: 2 puffs 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 109, 'page_label': '110', 'id': 'data/guideline-170-en.pdf:109:0'}, page_content='Page 110 / 409\\n\\xa0If symptoms have not been well controlled for a period of 2 to\\xa03 months, check inhalation technique and adherence\\nbefore changing to a stronger treatment.\\xa0If symptoms have been well controlled for a period of at least 3 months (the patient is asymptomatic or the asthma\\nattacks\\xa0are well controlled): try a step-wise reduction in medication.\\n\\xa0\\nReferences\\n1. Global INitiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022 update.https://ginasthma.org/gina-reports/ [Accessed 23 January 2023]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 109, 'page_label': '110', 'id': 'data/guideline-170-en.pdf:109:1'}, page_content='2. WHO Pocket book of primary health care for children and adolescents: guidelines for health promotion, disease preventionand management from the newborn period to adolescence. WHO Regional Ofﬁce for Europe; 2022.https://www.who.int/europe/publications/i/item/9789289057622 [Accessed 23 January 2023]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 110, 'page_label': '111', 'id': 'data/guideline-170-en.pdf:110:0'}, page_content='Page 111 / 409\\nPulmonary tuberculosis\\nPulmonary tuberculosis is a bacterial infection due to Mycobacterium tuberculosis, spread\\xa0from person to person\\nthrough inhalation of infected respiratory droplets.\\nAfter\\xa0infection, M. tuberculosis multiplies slowly in the lungs and is usually eliminated spontaneously or lies dormant.\\nOnly 10% of cases\\xa0develop active tuberculosis. The risk of progressing to active tuberculosis is higher in\\nimmunocompromised patients.\\xa0In certain countries, half of newly diagnosed tuberculosis patients are co-infected with\\nHIV .\\xa0For more information on tuberculosis, refer to the guide Tuberculosis, MSF.\\nClinical features\\n\\xa0In an endemic area, the diagnosis of tuberculosis is to be considered,\\xa0in any patient consulting for respiratory'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 110, 'page_label': '111', 'id': 'data/guideline-170-en.pdf:110:1'}, page_content='symptoms for over 2 weeks who does not respond to non-speciﬁc antibacterial treatment.\\nLaboratory\\nTreatment\\nFor pulmonary tuberculosis, the standard treatment is a combination of four\\xa0antituberculosis drugs (isoniazid,\\nrifampicin, pyrazinamide, ethambutol). The regimen is organised into 2 phases (initial phase and continuation phase)\\xa0and\\nlasts 6 months.\\xa0If the strain is drug-resistant, the treatment is longer and different drug combinations are used.\\xa0It takes signiﬁcant investment to cure tuberculosis, both from the patient and the medical team. Only uninterrupted\\ntreatment\\xa0will lead to cure and prevent the development of resistance. It is essential that the patient understands the\\nimportance of treatment adherence and has access to correct case management until treatment is completed.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 110, 'page_label': '111', 'id': 'data/guideline-170-en.pdf:110:2'}, page_content='Prevention\\n\\xa0\\nReferences\\n [1] \\nProlonged cough (> 2 weeks) with or without sputum production and/or haemoptysis, prolonged fever, night sweats,\\nanorexia, weight loss, chest pain and fatigue.\\nDifferential diagnosis includes pneumonia, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary\\ndistomatosis (Flukes, Chapter 6) and melioidosis (Southeast Asia).\\nIn the general population: Xpert® MTB/RIF\\xa0test which simultaneously detects M. tuberculosis (MTB) in sputum and\\nresistance to rifampicin (RIF). If not available perform sputum smear microscopy . [2] \\nIf HIV co-infection suspected or diagnosed: Xpert® MTB/RIF test and point-of-care, urine LF-LAM (lateral ﬂow\\nurine lipoarabinomannan assay) . [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 110, 'page_label': '111', 'id': 'data/guideline-170-en.pdf:110:3'}, page_content='urine lipoarabinomannan assay) . [2] \\nBCG vaccination in neonates: provides 59% protection against pulmonary tuberculosis . [3] \\nInfection control in healthcare settings: standard precautions and airborne precautions for conﬁrmed or suspected\\ncases.\\nClose contacts: isoniazid preventive therapy for 6 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 111, 'page_label': '112', 'id': 'data/guideline-170-en.pdf:111:0'}, page_content='Page 112 / 409\\n1. World Health\\xa0Organization. Global tuberculosis report 2018.\\xa0https://apps.who.int/iris/handle/10665/274453\\xa0[Accessed 21 October 2019]\\n2. Global Laboratory Initiative. GLI model TB diagnostic algorithms. 2018.\\xa0http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf\\xa0[Accessed 21 October 2019]\\n3. World Health Organization.\\xa0Weekly epidemiological record/Relevé épidémiologique hebdomadaire 23rd\\xa0February 2018,93rd\\xa0year/23 Février 2018, 93e\\xa0année. No 8, 2018, 93, 73–96.https://www.who.int/immunization/policy/position_papers/bcg/en/\\xa0[Accessed 21 October 2019]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 112, 'page_label': '113', 'id': 'data/guideline-170-en.pdf:112:0'}, page_content='Page 113 / 409\\nChapter 3: Gastrointestinal disorders\\nAcute diarrhoea\\nShigellosis\\nAmoebiasis\\nDisorders of the stomach and duodenum\\nGastro-oesophageal reﬂux\\nGastric and duodenal ulcers in adults\\nDyspepsia\\nStomatitis\\nOral and oropharyngeal candidiasis\\nOral herpes\\nOther infectious causes\\nStomatitis from scurvy (vitamin C deﬁciency)\\nOther lesions resulting from a nutritional deﬁciency'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 113, 'page_label': '114', 'id': 'data/guideline-170-en.pdf:113:0'}, page_content='Page 114 / 409\\nAcute diarrhoea\\nAcute diarrhoea is deﬁned as at least 3 liquid stools per day for less than 2 weeks.\\nClinical features\\nTreatment\\nGeneral principles:\\nPrevention and treatment of dehydration\\xa0\\nSee Dehydration, Chapter 1.\\nAdapted treatment protocols are recommended for children with malnutrition (see Severe acute malnutrition, Chapter\\n1).\\nPrevention of malnutrition\\nContinue unrestricted normal diet. In breastfed children, increase the frequency of feeds. Breast milk does not replace\\nORS. ORS should be given between feeds.\\nZinc supplementation\\nThere are 2 clinical types of acute diarrhoea:\\nDiarrhoea\\xa0without blood, caused by viruses in 60% of cases (rotavirus, enterovirus), bacteria (Vibrio cholerae,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 113, 'page_label': '114', 'id': 'data/guideline-170-en.pdf:113:1'}, page_content='enterotoxigenic\\xa0Escherichia coli, non Typhi\\xa0Salmonella,\\xa0Yersinia\\xa0enterocolitica) or parasites (giardiasis).\\nDiseases, such as malaria, acute otitis media, respiratory tract infections, etc. can be accompanied by this type\\nof diarrhoea.\\nDiarrhoea with blood, caused by bacteria (Shigella\\xa0in 50% of cases,\\xa0Campylobacter\\xa0jejuni, enteroinvasive or\\nenterohaemorrhagic\\xa0Escherichia\\xa0coli,\\xa0Salmonella) or parasites (intestinal amoebiasis).\\nInfectious diarrhoeas are transmitted by direct (dirty hands) or indirect (ingestion of contaminated water or food)\\ncontact.\\nThe high mortality rate from diarrhoeal diseases, even benign, is due to acute dehydration and malnutrition. This can\\nbe prevented by adequate rehydration and nutrition.\\nFirst assess for signs of dehydration (see Dehydration, Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 113, 'page_label': '114', 'id': 'data/guideline-170-en.pdf:113:2'}, page_content='First assess for signs of dehydration (see Dehydration, Chapter 1).\\nThen look for other signs:\\nprofuse watery diarrhoea (cholera, enterotoxigenic\\xa0E. coli),\\nrepeated vomiting (cholera),\\nfever (salmonellosis, viral diarrhoea),\\npresence of red blood in stools: see\\xa0also\\xa0Shigellosis\\xa0and\\xa0Amoebiasis\\xa0(Chapter 3).\\nIn a patient over 5 years with severe and rapid onset of dehydration, suspect cholera.\\nPrevent or treat dehydration: rehydration consists of prompt replacement of ﬂuid and electrolyte losses as\\nrequired, until the diarrhoea stops.\\nAdminister zinc sulfate to children under 5 years.\\nPrevent malnutrition.\\nDo not systematically administer antimicrobials: only certain diarrhoeas require antibiotics (see\\xa0Antimicrobial\\ntreatment).\\nDo not administer anti-diarrhoeal drugs or antiemetics.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 113, 'page_label': '114', 'id': 'data/guideline-170-en.pdf:113:3'}, page_content='treatment).\\nDo not administer anti-diarrhoeal drugs or antiemetics.\\nTreat the underlying condition if any (malaria, otitis, respiratory infection, etc.).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 114, 'page_label': '115', 'id': 'data/guideline-170-en.pdf:114:0'}, page_content='Page 115 / 409\\nZinc sulfate is given in combination with oral rehydration solution in order to reduce the duration and severity of\\ndiarrhoea, as well as to prevent further occurrences in the 2 to 3 months after treatment:\\nzinc sulfate\\xa0PO\\nChildren under 6 months: 10 mg\\xa0(½ tablet)\\xa0once daily\\xa0for 10 days\\nChildren from 6 months to 5 years: 20 mg (1 tablet) once daily\\xa0for 10 days\\xa0Place the half-tablet or full tablet in a teaspoon, add a bit of water to dissolve it, and give the entire spoonful to the\\nchild.\\nAntimicrobial treatment\\nDiarrhoea without blood\\nMost acute diarrhoeas are caused by viruses unresponsive to antimicrobials. Antimicrobials can be beneﬁcial in the\\nevent of cholera or giardiasis.\\nDiarrhoea with blood\\nPrevention\\n\\xa0\\n\\xa0\\nReferences'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 114, 'page_label': '115', 'id': 'data/guideline-170-en.pdf:114:1'}, page_content='event of cholera or giardiasis.\\nDiarrhoea with blood\\nPrevention\\n\\xa0\\n\\xa0\\nReferences\\nCholera: the most important part of treatment is rehydration. In the absence of resistance (perform antibiotic-\\nsensitivity testing\\xa0at the beginning of an outbreak), antibiotic treatment shortens the duration of diarrhoea.\\xa0See the\\nguide\\xa0Management of a cholera epidemic, MSF.\\nGiardiasis: see\\xa0Intestinal protozoan infections, Chapter 6.\\nShigellosis\\xa0is the most frequent cause of\\xa0bloody diarrhoea (amoebiasis\\xa0is much less common). If there is no\\nlaboratory diagnosis to conﬁrm the presence of amoebae, ﬁrst line treatment is for\\xa0shigellosis\\xa0(Chapter 3).\\nAmoebiasis: antiparasitic treatment only if motile Entamoeba histolytica\\xa0amoebae\\xa0are found in stools or if a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 114, 'page_label': '115', 'id': 'data/guideline-170-en.pdf:114:2'}, page_content='correct shigellosis treatment has been ineffective (see\\xa0Amoebiasis, Chapter 3).\\nBreastfeeding reduces infant morbidity and mortality from diarrhoea and the severity of diarrhoea episodes.\\nWhen the child is weaned preparation and storage of food are associated with the risk of contamination by faecal\\nmicro-organisms: discourage bottle-feeding; food must be cooked well; milk or porridge must never be stored at\\nroom temperature.\\nAccess to sufﬁcient amounts of clean water and personal hygiene (washing hands with soap and water before food\\npreparation and before eating, after defecation etc.) are effective methods of reducing the spread of diarrhoea.\\nIn countries with a high rotavirus diarrhoea fatality rate, the WHO recommends routine rotavirus vaccination in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 114, 'page_label': '115', 'id': 'data/guideline-170-en.pdf:114:3'}, page_content='children between 6 weeks and 24 months of age . [1] \\n1. Weekly epidemiological record/Relevé épidémiologique hebdomadaire 1st\\xa0February 2013, 88th\\xa0year/1er\\xa0Février 2013, 88eannée No. 5, 2013, 88, 49–64.https://www.who.int/wer/2013/wer8805.pdf\\xa0[Accessed 02 January 2019]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 115, 'page_label': '116', 'id': 'data/guideline-170-en.pdf:115:0'}, page_content='Page 116 / 409\\nShigellosis\\nShigellosis is a\\xa0highly\\xa0contagious bacterial infection resulting in bloody diarrhoea. There are 4 serogroups of shigella:\\xa0S.\\ndysenteriae,\\xa0S. sonnei,\\xa0S. ﬂexneri,\\xa0S. boydii.\\nS. dysenteriae\\xa0type 1 (Sd1) is the only strain that causes large scale outbreaks. It has the highest case fatality rate (up\\nto 10%).\\xa0\\nPatients at risk of death are children under 5 years, malnourished patients, children after measles, adults over 50 years.\\nClinical features\\nLaboratory\\nShigellosis in an epidemic context:\\nTreatment\\n\\xa0\\n\\xa0\\n\\xa0 If resistance or contra-indication to ciproﬂoxacin or\\xa0if no improvement within 48 hours of starting ﬁrst-line\\ntreatment:\\nDiarrhoea with bright red blood visible in stool , with or without fever\\xa0 a \\nAbdominal and rectal pain frequent'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 115, 'page_label': '116', 'id': 'data/guideline-170-en.pdf:115:1'}, page_content='Abdominal and rectal pain frequent\\nSigns of serious illness: fever above 39 °C; severe dehydration; seizures, altered\\xa0mental status\\nComplications (more frequent with Sd1): febrile seizures (5 to 30% of children), rectal prolapse (3%), septicaemia,\\nintestinal obstruction or perforation, moderate to severe haemolytic uraemic syndrome\\nConﬁrm the causal agent (stool culture) and perform antibiotic sensitivity tests.\\nPerform monthly culture and sensitivity tests (antibiotic resistance can develop rapidly, sometimes during the course\\nof an outbreak).\\nPatients\\xa0with signs of serious illness or with life-threatening risk factors must be admitted as inpatients.\\nTreat patients with neither signs of serious illness nor risk factors as outpatients.\\nAntibiotherapy:\\nFirst-line treatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 115, 'page_label': '116', 'id': 'data/guideline-170-en.pdf:115:2'}, page_content='Antibiotherapy:\\nFirst-line treatment\\nciproﬂoxacin PO for 3 days\\nChildren: 15 mg/kg 2 times daily\\n(max. 1 g daily)\\nAdults: 500 mg 2 times daily\\nif the strain is sensitive\\nif there is no antibiotic sensitivity test\\nif oral administration is possible\\nceftriaxone IM for 3 days\\nChildren: 50 to 100 mg/kg once daily\\n(max. 1 g daily)\\nAdults: 1 to 2 g once daily\\nin patients with severe infection and/or oral\\nadministration is not possible\\nin pregnant women b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 116, 'page_label': '117', 'id': 'data/guideline-170-en.pdf:116:0'}, page_content='Page 117 / 409\\nazithromycin\\xa0PO\\xa0for 5 days\\nChildren: one dose of 12 mg/kg on D1 then 6 mg/kg once daily from D2 to D5\\nAdults: one dose of 500 mg on D1 then 250 mg once daily from D2 to D5\\nor\\nceﬁxime\\xa0PO for 5 days\\nChildren: 8 mg/kg once daily (max. 400 mg daily)\\nAdults: 400 mg once daily\\xa0If there is no improvement 48 hours after starting second-line treatment, treat for\\xa0amoebiasis .\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nShigellosis in an epidemic context\\xa0\\n\\xa0\\nReferences\\n [1] [2] \\nFor pain and/or fever:\\nparacetamol\\xa0PO (see\\xa0Pain, Chapter 1). All opioid analgesics are contra-indicated as they slow peristalsis.\\nSupportive therapy:\\nnutrition: nutritional supplement with frequent meals\\xa0\\n+ 2500 kcal daily during hospitalisation\\xa0\\n+ 1000 kcal daily as outpatients'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 116, 'page_label': '117', 'id': 'data/guideline-170-en.pdf:116:1'}, page_content='+ 2500 kcal daily during hospitalisation\\xa0\\n+ 1000 kcal daily as outpatients\\xa0\\nrehydration:\\xa0administration of ORS according to WHO protocols (see Dehydration, Chapter 1).\\nzinc supplement in children under 5 years (see\\xa0Acute diarrhoea, Chapitre 3).\\nNever give loperamide or any other antidiarrhoeal.\\nManagement of complications: rectal prolapse\\xa0reduction, septicaemia (see\\xa0Septic shock, Chapter 1), etc.\\nIsolation of hospitalised patients; school exclusion of children treated as outpatients.\\nHygiene (handwashing, hygienic preparation and storage of food, home hygiene, etc.).\\nManagement if signs worsen or bloody diarrhoea in entourage (seek medical attention).\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 116, 'page_label': '117', 'id': 'data/guideline-170-en.pdf:116:2'}, page_content='Footnotes\\n(a) This deﬁnition excludes: blood detected on microscope examination; stool containing digested blood (melaena); streaks ofblood on the surface of normal stool (haemorrhoids, anal or rectal lesion, etc.).\\n(b) Ciproﬂoxacin should be avoided in pregnant women. Nevertheless, if ceftriaxone is not available, the other antibiotics canbe used, including ciproﬂoxacin if necessary.\\xa0\\n1. Karen L. Kotloff et al. Seminar: Shigellosis. The Lancet, Volume 391, ISSUE 10122, P801-812, February 24, 2018.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 116, 'page_label': '117', 'id': 'data/guideline-170-en.pdf:116:3'}, page_content='2. Word Health Organization. Pocket book for hospital care in children: guidelines for the management of common childhoodillnesses, 2013.http://apps.who.int/iris/bitstream/handle/10665/81170/9789241548373_eng.pdf;jsessionid=CE5C46916607EF413AA9FCA89B84163F?sequence=1\\xa0[Accessed 20 September 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 117, 'page_label': '118', 'id': 'data/guideline-170-en.pdf:117:0'}, page_content='Page 118 / 409\\nAmoebiasis\\nAmoebiasis is a parasitic infection due to the intestinal protozoa\\xa0Entamoeba histolytica. Transmission is faecal-oral,\\nby ingestion of amoebic cysts from food or water contaminated with faeces. Usually, ingested cysts release non-\\npathogenic amoebae and 90% of carriers are asymptomatic.\\nIn 10% of infected patients, pathogenic amoebae penetrate the mucous of the colon: this is the intestinal amoebiasis\\n(amoebic dysentery). The clinical picture is similar to that of shigellosis, which is the principal cause of dysentery.\\nOccasionally, the pathogenic amoebae migrate via the blood stream and form peripheral abscesses. Amoebic liver\\nabscess is the most common form of extra-intestinal amoebiasis.\\nClinical features\\nInvestigations\\nTreatment\\nAmoebic dysentery'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 117, 'page_label': '118', 'id': 'data/guideline-170-en.pdf:117:1'}, page_content='Clinical features\\nInvestigations\\nTreatment\\nAmoebic dysentery\\ndiarrhoea containing red blood and mucus\\nabdominal pain, tenesmus\\nno fever or moderate fever\\npossibly signs of dehydration\\nAmoebic liver abscess\\npainful hepatomegaly; mild jaundice may be present\\nanorexia, weight loss, nausea, vomiting\\nintermittent fever, sweating, chills; change in overall condition\\nAmoebic dysentery: identiﬁcation of mobile trophozoites (E. histolytica histolytica) in fresh stool samples\\nAmoebic liver abscess: indirect haemoagglutination and ELISA\\nPOCUS : perform an EFAST (extended focused assessment with sonography for trauma) examination, with\\nadditional views of the liver and spleen to evaluate for signs of amoebic lesions. Contact an expert (local or via'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 117, 'page_label': '118', 'id': 'data/guideline-170-en.pdf:117:2'}, page_content='telemedicine services) to help interpret the images and differentiate amoebic abscesses from other pathologies\\nwith similar characteristics.\\n a \\nAmoebic\\xa0dysentery\\nThe presence of cysts alone should not lead to the treatment of amoebiasis.\\nAmoebiasis conﬁrmed with a parasitological stool examination:\\xa0\\ntinidazole\\xa0PO\\nChildren: 50 mg/kg once daily for 3 days (max. 2 g daily)\\nAdults: 2 g once daily for 3 days\\nor\\xa0metronidazole\\xa0PO\\nChildren: 15 mg/kg 3 times daily for 5 days\\nAdults: 500 mg 3 times daily\\xa0for 5 days\\nIf there is no laboratory, ﬁrst line treatment for dysentery is for\\xa0shigellosis. Treat for amoebiasis if correct\\ntreatment for shigellosis has been ineffective.\\nOral rehydration salts (ORS) if there is risk of, or if there are signs of dehydration (see\\xa0Dehydration, Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 117, 'page_label': '118', 'id': 'data/guideline-170-en.pdf:117:3'}, page_content='Amoebic liver abscess\\ntinidazole\\xa0PO: same treatment for 5 days\\nmetronidazole\\xa0PO: same treatment for 5 to 10 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 118, 'page_label': '119', 'id': 'data/guideline-170-en.pdf:118:0'}, page_content='Page 119 / 409\\n\\xa0\\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 119, 'page_label': '120', 'id': 'data/guideline-170-en.pdf:119:0'}, page_content='Page 120 / 409\\nDisorders of the stomach and duodenum\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nGastro-oesophageal reﬂux\\nGastric and duodenal ulcers in adults\\nDyspepsia'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 120, 'page_label': '121', 'id': 'data/guideline-170-en.pdf:120:0'}, page_content='Page 121 / 409\\nGastro-oesophageal reﬂux\\nClinical features\\nBurning stomachache or heartburn, generally relieved by antacids; acid regurgitation (often postural: while sitting\\nforward or lying down). In the absence of dysphagia (oesophageal stenosis), these signs are benign.\\nTreatment\\nFirst instance: encourage the patient to avoid alcohol and tobacco use.\\nGive aluminium hydroxide/magnesium hydroxide PO (400 mg/400 mg tablet) : 1 to 2 tablets\\xa03 times daily 20\\nminutes to one hour after meals, or 1 tablet\\xa0during painful attacks.\\n a \\nIf antacids are insufﬁcient:\\nomeprazole PO: 20 mg once daily in the morning for 3 days\\nIn\\xa0young children: no drug treatment, rest and sleep on an incline (30° to 45°).\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 120, 'page_label': '121', 'id': 'data/guideline-170-en.pdf:120:1'}, page_content='Footnotes\\n(a) Aluminium hydroxide/magnesium hydroxide may decrease intestinal absorption of drugs taken at the same time:•\\xa0 atazanavir,\\u202fchloroquine,\\xa0digoxin,\\xa0doxycycline,\\xa0iron\\xa0 salts,\\xa0gabapentin,\\xa0itraconazole,\\xa0levothyroxine (take\\xa0at least 2 hoursapart).•\\xa0 ciproﬂoxacin\\xa0(take\\xa0ciproﬂoxacin\\xa02\\xa0hours\\xa0before or 4 hours after antacids), dolutegravir (take\\xa0dolutegravir\\xa02\\xa0hours\\xa0beforeor 6 hours after antacids),\\xa0velpatasvir\\xa0(take 4 hours apart).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 121, 'page_label': '122', 'id': 'data/guideline-170-en.pdf:121:0'}, page_content='Page 122 / 409\\nGastric and duodenal ulcers in adults\\nClinical features\\nBurning epigastric pain or epigastric cramps between meals, that wake the patient at night. Recurrent episodes\\ncharacteristically last a few days and are often accompanied by nausea\\xa0and even vomiting.\\nThe most common complications are perforation and bleeding.\\nTreatment of non-complicated ulcers\\nTreatment of complicated ulcers\\nPerforation\\nPerforation should be considered in patients presenting with sudden onset intense epigastric pain, particularly if there is\\nrigidity of the abdominal wall. The risk of peritonitis is increased if the perforation occurs on a full stomach.\\nGastrointestinal bleeding\\nPassing of black stool (maelena) and/or vomiting blood (haematemesis). In 80% of cases the bleeding stops\\nspontaneously.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 121, 'page_label': '122', 'id': 'data/guideline-170-en.pdf:121:1'}, page_content='spontaneously.\\nFor an isolated episode:\\xa0\\nidentify patients taking NSAID or acetylsalicylic acid; stop treatment;\\nencourage patients to avoid alcohol and tobacco use;\\nomeprazole PO: 20 mg once daily in the morning for 7 to 10 days. In severe or recurrent cases, dose can be\\nincreased to 40 mg once daily and the treatment can be prolonged for up to 8 weeks.\\nIf the patient has frequent recurrences unrelated to NSAID use, that require repeated treatment with antiulcer drugs:\\nsee\\xa0eradication of\\xa0Helicobacter pylori.\\nTo start:\\xa0\\nplace the patient on a strict fast (NPO); insert a nasogastric tube and aspirate if possible;\\ninsert an intravenous line and hydrate (Ringer lactate);\\ntreat acute pain (see Pain, Chapter 1);\\nomeprazole IV infusion: 40 mg once daily over 20 to 30 minutes\\nRefer to a surgeon.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 121, 'page_label': '122', 'id': 'data/guideline-170-en.pdf:121:2'}, page_content=\"Refer to a surgeon.\\nIf referral not possible, risk of mortality is high:\\nContinue conservative management including maintenance ﬂuid (alternate 5% glucose and Ringer lactate).\\nStart IV antibiotics (see Shock, Chapter 1).\\nIf after 3 days, the patient's clinical condition has improved, cautiously restart oral feeding, remove the\\nnasogastric tube and start PO treatment to eradicate Helicobacter pylori\\xa0(see\\xa0eradication of\\xa0Helicobacter\\npylori).\\nInsert a nasogastric tube for aspiration and insert an IV line (16G).\\nIf the haemodynamic state is stable\\xa0(pulse and blood pressure are normal):\\nHydrate (Ringer lactate), monitor, keep NPO for 12 hours.\\nIf there is no active haemorrhage, restart oral feeding after 12 hours.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 121, 'page_label': '122', 'id': 'data/guideline-170-en.pdf:121:3'}, page_content='If there is no active haemorrhage, restart oral feeding after 12 hours.\\nGastric lavage with cold water is not essential, but may help evaluate persistence of bleeding.\\nIf the haemorrhage continues\\xa0(haematemesis) and/or\\xa0if the haemodynamic state deteriorates\\xa0(pulse increases, BP\\ndrops):'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 122, 'page_label': '123', 'id': 'data/guideline-170-en.pdf:122:0'}, page_content='Page 123 / 409\\nEradication of Helicobacter pylori\\nMost peptic ulcers are caused by Helicobacter pylori infection. If a diagnosis of ulcer is probable, treatment to\\neradicate H. pylori should be considered\\xa0if\\xa0the patient has frequent attacks requiring repeated and/or prolonged\\ntreatments with antiulcer drugs over 8 weeks or in cases of complicated ulcers (perforation or gastrointestinal\\nbleeding).\\xa0Infection should be conﬁrmed with a test where possible.\\xa0H. pylori resistance to antibiotics varies globally, follow national recommendations where available. If not, for\\ninformation, administer a\\xa0triple\\xa0therapy for 7 days:\\nomeprazole PO 20 mg 2 times daily + clarithromycin PO 500 mg 2 times daily + amoxicillin PO 1 g 2 times daily .'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 122, 'page_label': '123', 'id': 'data/guideline-170-en.pdf:122:1'}, page_content='In immunocompromised patients, consider mycobacterium avium complex (MAC) infection or other nontuberculous\\nmycobacterium (NTM) infection prior to starting a\\xa0clarithromycin-containing\\xa0triple\\xa0therapy.\\xa0If symptoms continue despite treatment, consider the differential diagnosis of gastric cancer. Refer for investigations\\nif possible.\\n\\xa0\\nNotes:\\n\\xa0\\nIntensive care and transfusion according to the severity of the bleeding (see\\xa0haemorrhagic\\xa0shock, Chapter 1).\\nEmergency surgical intervention.\\n a \\nAcetylsalicylic acid (aspirin) and NSAID (ibuprofen, diclofenac, etc.) are contra-indicated in patients suffering from\\nor with a history of ulcers.\\nOmeprazole is as effective PO as IV.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 122, 'page_label': '123', 'id': 'data/guideline-170-en.pdf:122:2'}, page_content='or with a history of ulcers.\\nOmeprazole is as effective PO as IV.\\nFootnotes\\n(a) In penicillin-allergic patients, amoxicillin PO can be substituted with metronidazole PO 500 mg 2 times daily.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 123, 'page_label': '124', 'id': 'data/guideline-170-en.pdf:123:0'}, page_content='Page 124 / 409\\nDyspepsia\\nLast updated: December 2020\\xa0\\nClinical features\\nEpigastric pain or discomfort following meals, often accompanied by bloating, sensation of fullness and nausea.\\nDyspepsia is most commonly functional.\\xa0The diagnosis of functional dyspepsia is based on clinical assessment after\\nruling out organic causes (Gastro-oesophageal reﬂux, Gastric and duodenal ulcers, drug-induced symptoms, gastric\\ncancer). If possible, test for Helicobacter pylori.\\nTreatment\\nIn adults:\\n\\xa0\\xa0Note: consider and treat possible intestinal parasites (see Intestinal protozoan infections, Cestodes,\\xa0Nematode\\ninfections, Chapter 6; Amoebiasis,\\xa0Chapter 3).\\n\\xa0\\nReferences\\nIn case of patients who test positive for\\xa0H. pylori,\\xa0see\\xa0Eradication of Helicobacter pylori . [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 123, 'page_label': '124', 'id': 'data/guideline-170-en.pdf:123:1'}, page_content='Omeprazole PO (10 mg once daily) for 4 weeks may help even in H. pylori-negative patients . [2] [3] \\n1. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. 2020 Nov 21;396(10263):1689-1702.\\n2. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol.2017 Jul;112(7):988-1013.http://www.cag-acg.org/images/publications/CAG_CPG_Dyspepsia_AJG_Aug2017.pdf [Accessed 24 November 2020]\\n3. National Institute for Health and Care Excellence. Gastro-oesophageal reﬂux disease and dyspepsia in adults: investigationand management. Sept 2014.\\xa0\\xa0https://www.nice.org.uk/guidance/CG184/chapter/1-Recommendations#interventions-for-functional-dyspepsia\\xa0[Accessed\\xa024\\xa0November\\xa02020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 124, 'page_label': '125', 'id': 'data/guideline-170-en.pdf:124:0'}, page_content='Page 125 / 409\\nStomatitis\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nStomatitis is an inﬂammation of the mucous membranes of the mouth caused by a fungal, viral or bacterial infection, a\\nvitamin deﬁciency, an injury, etc.\\nProlonged or painful stomatitis may contribute to dehydration or may cause loss of appetite with denutrition,\\nparticularly in children.\\nIn infants, examine routinely the mouth in the event of breast refusal or difﬁculties in sucking.\\n\\xa0\\nIn all cases:\\nOral and oropharyngeal candidiasis\\nOral herpes\\nOther infectious causes\\nStomatitis from scurvy (vitamin C deﬁciency)\\nOther lesions resulting from a nutritional deﬁciency\\nMaintain adequate hydration and feeding; offer foods that will not irritate the mucosa (soft, non-acidic). Use a\\nnasogastric tube for a few days if pain is preventing the patient from eating.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 124, 'page_label': '125', 'id': 'data/guideline-170-en.pdf:124:1'}, page_content='nasogastric tube for a few days if pain is preventing the patient from eating.\\nKeep the mouth clean to prevent complications and recurrence.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 125, 'page_label': '126', 'id': 'data/guideline-170-en.pdf:125:0'}, page_content='Page 126 / 409\\nOral and oropharyngeal candidiasis\\nInfection due to Candida albicans, common in infants, immunocompromised or diabetic patients. Other risk factors\\ninclude treatment with oral antibiotics or high-dose inhaled corticosteroids.\\nClinical features\\nTreatment\\nnystatin oral suspension for 7 days\\nChildren and adults: 400 000 IU daily, i.e. 1 ml of the oral suspension (100 000 IU) 4 times daily\\nor \\nmiconazole oral gel for 7 days\\nChildren 6 months to 2 years: 1.25 ml 4 times daily\\nChildren over 2 years and adults: 2.5 ml 4 times daily\\xa0Apply the oral suspension of nystatin or the oral gel of miconazole between meals; keep in the mouth for 2 to 3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 125, 'page_label': '126', 'id': 'data/guideline-170-en.pdf:125:1'}, page_content='minutes,\\xa0then swallow. In young children, apply\\xa0to the tongue and inside of each cheek.\\xa0Show the mother how to treat since, in most cases, candidiasis will be treated at home.\\xa0In immunocompromised patients: see HIV infection and AIDS, Chapter 8.\\nWhite patches on the tongue, inside the cheeks, that may spread to the pharynx.\\nIn patients with frequent recurrences or extensive forms invading the esophagus (swallowing difﬁculty and pain),\\nconsider HIV infection.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 126, 'page_label': '127', 'id': 'data/guideline-170-en.pdf:126:0'}, page_content='Page 127 / 409\\nOral herpes\\nInfection due to the\\xa0herpes simplex\\xa0virus. Primary infection typically occurs in children aged 6 months to 5 years and\\nmay cause acute gingivostomatitis, sometimes severe. After primary infection, the virus remains in the body and\\ncauses in some individuals periodic recurrences which are usually benign (herpes labialis).\\nClinical features\\nMultiple vesicles on the oral mucosa and lips which rupture to form painful, yellowish, at times extensive ulcers.\\nLocal lesions are usually associated with general malaise, regional lymphadenopathy and fever.\\nClusters of vesicles at the junction between the lip and the skin.\\xa0In patients with frequent recurrences or extensive forms, consider HIV infection (see\\xa0HIV infection and AIDS, Chapter\\n8).\\nTreatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 126, 'page_label': '127', 'id': 'data/guideline-170-en.pdf:126:1'}, page_content='8).\\nTreatment\\nPrimary herpetic gingivostomatitis\\n\\xa0In immunocompromised patients: see\\xa0HIV infection and AIDS, Chapter 8.\\nRecurrent herpes labialis\\nSpontaneous resolution within 7 to 10 days. An antiseptic (chlorhexidine or povidone iodine) may be applied;\\nparacetamol PO if necessary.\\n\\xa0\\nBoth forms of herpes are contagious: do not touch lesions (or wash hands afterwards); avoid oral contact.\\nPrimary herpetic gingivostomatitis\\nRecurrent herpes labialis\\nTreat\\xa0pain: paracetamol or ibuprofen PO (Chapter 1)\\nIn the event of severe lesions, inability to drink and signiﬁcant pain:\\nAdmit the child to hospital (high risk of dehydration).\\nIf the child presents within the ﬁrst 96 hours of symptoms onset,\\xa0aciclovir\\xa0PO for 5 to 7 days:\\nChildren under 2 years: 200 mg 5 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 126, 'page_label': '127', 'id': 'data/guideline-170-en.pdf:126:2'}, page_content='Children under 2 years: 200 mg 5 times daily\\nChildren 2 years and over and adults: 400 mg 5 times daily\\nIn the event of secondary bacterial infection: amoxicillin PO 7 days.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 127, 'page_label': '128', 'id': 'data/guideline-170-en.pdf:127:0'}, page_content='Page 128 / 409\\nOther infectious causes\\n\\xa0\\n\\xa0\\nSee\\xa0Pharyngitis\\xa0(Chapter 2),\\xa0Diphtheria\\xa0(Chapter 2),\\xa0Measles\\xa0(Chapter 8).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 128, 'page_label': '129', 'id': 'data/guideline-170-en.pdf:128:0'}, page_content='Page 129 / 409\\nStomatitis from scurvy (vitamin C deﬁciency)\\nClinical features\\nBleeding gums, associated in infants with lower limb pain caused by subperiosteal haemorrhage. It is common in\\ncontexts of poor food quality or in populations completely dependent on food aid (refugee camps).\\nTreatment\\nascorbic acid\\xa0(vitamin C) PO\\nThe optimal dose has not been established. For information:\\nChildren 1 month to 11 years: 100 mg 3 times daily\\xa0\\nChildren 12 years and over and adults: 250 mg\\xa03 times daily\\xa0\\nor\\nChildren 1 month to 3 years: 100 mg 2\\xa0times daily\\nChildren 4 to 11 years: 250 mg 2\\xa0times daily\\xa0\\nChildren 12 years and over and adults: 500 mg\\xa02\\xa0times daily\\xa0\\xa0Treatment is administred at least 2 weeks or longer (until symptoms resolve), then preventive treatment is'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 128, 'page_label': '129', 'id': 'data/guideline-170-en.pdf:128:1'}, page_content='given\\xa0(children and adults: 50 mg daily as long as the situation requires).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 129, 'page_label': '130', 'id': 'data/guideline-170-en.pdf:129:0'}, page_content='Page 130 / 409\\nOther lesions resulting from a nutritionaldeﬁciency\\n\\xa0\\n\\xa0\\nOther vitamin deﬁciencies may provoke mouth lesions: angular stomatitis of the lips and glossitis from vitamin\\nB\\xa0(riboﬂavin), niacin (see\\xa0Pellagra, Chapter 4) or vitamin B\\xa0(pyridoxine) deﬁciencies.\\xa0Iron deﬁciency may also provoke angular stomatitis (see\\xa0Anaemia, Chapter 1).\\xa0Give the corresponding vitamins at curative doses. Multivitamins are insufﬁcient to treat true vitamin deﬁciencies.\\n2 6'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 130, 'page_label': '131', 'id': 'data/guideline-170-en.pdf:130:0'}, page_content='Page 131 / 409\\nChapter 4: Skin diseases\\nDermatology\\nScabies\\nLice (pediculosis)\\nSuperﬁcial fungal infections\\nBacterial skin infections\\nImpetigo\\nFuruncles and carbuncles\\nErysipelas and cellulitis\\nCutaneous anthrax\\nEndemic treponematoses\\nLeprosy\\nHerpes simplex and herpes zoster\\nHerpes simplex\\nHerpes zoster (shingles)\\nOther skin disorders\\nEczema\\nSeborrheic dermatitis\\nUrticaria\\nPellagra'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 131, 'page_label': '132', 'id': 'data/guideline-170-en.pdf:131:0'}, page_content='Page 132 / 409\\nDermatology\\n\\xa0\\n\\xa0\\nSkin diseases, particularly infectious skin diseases, are very common. They must be treated individually or collectively,\\nbut must also be considered as indicators of the sanitary condition of a population. A high prevalence of infectious skin\\ndiseases may reﬂect a problem of insufﬁcient water quantity and lack of hygiene in a population.\\nDermatological examination\\n\\xa0\\nPatients with skin disease often present late. At this stage, primary lesions and speciﬁc signs may be masked by\\nsecondary infection. In these cases, it is necessary to re-examine the patient, after treating the secondary infection, in\\norder to identify and treat the underlying skin disease.\\nObserve the type of lesion:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 131, 'page_label': '132', 'id': 'data/guideline-170-en.pdf:131:1'}, page_content='Observe the type of lesion:\\nMacule: ﬂat, non palpable lesion that is different in colour than the surrounding skin\\nPapule: small (< 1 cm) slightly elevated, circumscribed, solid lesion\\nVesicle\\xa0(< 1 cm), bulla (> 1 cm): clear ﬂuid-ﬁlled blisters\\nPustule: vesicle containing pus\\nNodule: ﬁrm, elevated palpable lesion (> 1 cm) that extend into the dermis or subcutaneous tissue\\nErosion: loss of the epidermis that heals without leaving a scar\\nExcoriation: erosion caused by scratching\\nUlcer: loss of the epidermis and at least part of the dermis that leaves a scar\\nScale: ﬂake of epidermis that detaches from the skin surface\\nCrust: dried serum, blood, or pus on the skin surface\\nAtrophy: thinning of the skin\\nLicheniﬁcation: thickening of the skin with accentuation of normal skin markings'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 131, 'page_label': '132', 'id': 'data/guideline-170-en.pdf:131:2'}, page_content='Look at the distribution of the lesions over the body; observe their arrangement: isolated, clustered, linear, annular\\n(in a ring). Ask if the lesions are itchy.\\nLook for a possible cause: insect bites; scabies, lice, other parasitic skin infections; contact with plants, animals,\\njewellery, detergents, etc.\\nAsk about any\\xa0past or\\xa0ongoing treatment: topical, oral or parenteral.\\nLook for local or regional signs (secondary infection, lymphangitis, adenopathy, erysipelas) and/or systemic signs\\n(fever, septicaemia,\\xa0secondary focus).\\nConsider the sanitary conditions of the family, particularly for contagious skin diseases (scabies, scalp ringworm,\\nlice).\\nCheck tetanus vaccination status.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 132, 'page_label': '133', 'id': 'data/guideline-170-en.pdf:132:0'}, page_content='Page 133 / 409\\nScabies\\nScabies is a cutaneous parasitosis due to the presence of the mite Sarcoptes scabiei hominis within the epidermis. It\\nexists in two forms: ordinary scabies, relatively benign and moderately contagious; and crusted scabies, favoured by\\nimmune deﬁciency, extremely contagious and refractory to conventional treatment.\\nPerson to person transmission takes place chieﬂy through direct skin contact, and sometimes by indirect contact\\n(sharing clothing, bedding). The challenge in management is that it must include simultaneous treatment of both the\\npatient and close contacts, and at the same time, decontamination of clothing and bedding of all persons undergoing\\ntreatment, in order to break the transmission cycle.\\nClinical features\\nOrdinary scabies\\nIn older children and adults'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 132, 'page_label': '133', 'id': 'data/guideline-170-en.pdf:132:1'}, page_content='Clinical features\\nOrdinary scabies\\nIn older children and adults\\nand\\nand/or\\n\\xa0Typical lesions and secondary lesions may co-exist, or speciﬁc lesions may be entirely masked by secondary lesions.\\nIn infants and young children\\nCrusted (Norwegian) scabies\\nThick, scaly, erythematous plaques, generalised or localised, resembling psoriasis, with or without itching (50% of\\ncases). Delay in diagnosis may lead to a scabies epidemic.\\nTreatment\\nIn all cases\\nOrdinary scabies\\nItching, worse at night, very suggestive of scabies if close contacts have the same symptom\\nTypical skin lesions:\\nScabies burrows (common): ﬁne wavy lines of 5 to 15 mm, corresponding to the tunnels made by the parasite\\nwithin the skin. Burrows are most often seen in the interdigital spaces of the hand and ﬂexor aspect of the wrist,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 132, 'page_label': '133', 'id': 'data/guideline-170-en.pdf:132:2'}, page_content='but may be present on the areolae, buttocks, elbows, axillae. The back and the face are spared. Burrows may\\nbe associated with vesicles, corresponding to the entry point of the parasite in the skin.\\nScabies nodules (less common): reddish-brown nodules, measuring 2 to 20 mm, on the genitals in men, persisting\\nafter effective treatment (they are not necessarily indicative of active infection).\\nSecondary skin lesions: resulting from scratching (excoriations, crusts) or super-infection (impetigo).\\nVesicular eruption; often involving palms and soles, back, face, and limbs. Secondary infection or eczematisation is\\nfrequent. Isolated scabies nodules in the axillae may be the only manifestation.\\nExamination of the mother’s hands may support the diagnosis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 132, 'page_label': '133', 'id': 'data/guideline-170-en.pdf:132:3'}, page_content='Examination of the mother’s hands may support the diagnosis.\\xa0\\nClose contacts of the patient are treated simultaneously, even in the absence of symptoms.\\nClothing and bedding (including that of contacts) are changed after each treatment. They are washed at ≥ 60 °C\\nthen dried in the sun, or exposed to sunlight for 72 hours, or sealed in a plastic bag for 72 hours.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 133, 'page_label': '134', 'id': 'data/guideline-170-en.pdf:133:0'}, page_content='Page 134 / 409\\nTopical treatment\\nTopical scabicides are applied over the entire body (including the scalp, post-auricular areas, umbilicus, palms and\\nsoles), avoiding mucous membranes and face, and the breasts in breastfeeding women. Particular attention should be\\npaid to common infestation sites. The recommended contact time should not be shortened or exceeded; the patient\\nmust not wash his hands while the product is in use (or the product should be reapplied if the hands are washed). In\\nchildren under 2 years, the hands must be wrapped to prevent accidental ingestion of the product and contact with\\neyes. Topical scabicides should not be applied to broken or inﬂamed skin. Treatment of secondary bacterial infection,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 133, 'page_label': '134', 'id': 'data/guideline-170-en.pdf:133:1'}, page_content='if present, should be initiated 24 to 48 hours before use of topical scabicides (see Impetigo).\\xa0The preferred treatment is 5% permethrin\\xa0cream:\\nChildren 2 months and over and adults: one application, with a contact time of 8 hours, then rinse thoroughly. Repeat\\nthe application after 7 days.\\xa0or, if not available, 25% benzyl benzoate lotion:\\nSee the table below for dilution (depending on age), contact time and number of applications.\\n\\xa0\\nOral treatment\\nTreatment with ivermectin PO (200 micrograms/kg single dose) is an alternative: it is more practical than topical\\ntreatment (e.g. in the case of an epidemic or for treating contacts) and can be started right away in the case of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 133, 'page_label': '134', 'id': 'data/guideline-170-en.pdf:133:2'}, page_content='secondary infection. A single dose may be sufﬁcient; a second dose 7 days later reduces the risk of treatment failure.\\xa0Ivermectin is not recommended for children < 15 kg or pregnant women (safety not established) .\\nAdministration of ivermectin to patients with loiasis carries a risk of severe neurological complications when signiﬁcant\\nLoa loa microﬁlaraemia is present (see Filariasis, Chapter 6) .\\xa0ivermectin PO single dose:\\n\\xa0 Children\\n< 2 years\\nChildren\\n2 to 12 years\\nChildren\\n> 12 years\\nand adults\\nPregnant\\nwomen\\nDilution\\nLotion must be\\ndiluted before use:\\n1 part 25% lotion +\\n3 parts water\\nLotion must be\\ndiluted before\\nuse:\\n1 part 25%\\nlotion + 1 part\\nwater\\nUse undiluted\\n25% lotion\\nUse undiluted\\n25% lotion\\nContact time\\n12 hours (6 hours\\nfor infants\\n< 6 months)\\nthen rinse\\nthoroughly'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 133, 'page_label': '134', 'id': 'data/guideline-170-en.pdf:133:3'}, page_content='Contact time\\n12 hours (6 hours\\nfor infants\\n< 6 months)\\nthen rinse\\nthoroughly\\n24 hours\\xa0then\\nrinse\\xa0thoroughly\\n24 hours\\xa0then\\nrinse\\xa0thoroughly\\n12 hours then\\nrinse\\xa0thoroughly\\nNumber of applications One application\\nTwo applications (e.g. 24 hours\\napart, with a rinse between the 2\\napplications; or 2 successive\\napplications, 10 minutes apart,\\nwhen the ﬁrst application has dried\\nwith a rinse after 24 hours)\\xa0\\nOne application\\n a \\n b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 134, 'page_label': '135', 'id': 'data/guideline-170-en.pdf:134:0'}, page_content='Page 135 / 409\\n\\xa0Treatment effectiveness is judged on clinical grounds. Itching may persist for 1 to 3 weeks after elimination of the\\nparasite.\\xa0Persistence of typical burrows beyond 4 weeks should lead to suspicion of treatment failure (insufﬁcient treatment,\\ne.g. the scalp was not included in topical treatment or the patient washed his hands during the treatment period), or\\nearly re-infestation (contacts and environment not treated). In these cases, patient and contacts should be retreated.\\xa0Persistent itching may be due to another condition, initially masked by scabies.\\nCrusted scabies\\nTreatment combines simultaneous administration of oral ivermectin and topical scabicide at regular intervals, e.g. every'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 134, 'page_label': '135', 'id': 'data/guideline-170-en.pdf:134:1'}, page_content='week for 2 to 3 weeks or more, according to severity and clinical response.\\xa0Crusts should be softened (salicylic acid ointment) and removed before applying local treatment (otherwise, local\\ntreatment is ineffective).\\xa0As exfoliated skin scales may spread the parasite, the patient should be isolated during the treatment, staff should use\\nprotection (gloves, gowns and hand washing after contact), and environment (bedding, ﬂoors and surfaces) should be\\ndecontaminated.\\n\\xa0\\nWeight 15 to 24 kg 25 to 35 kg 36 to 50 kg 51 to 65 kg\\nIvermectin 3 mg tab 1 tab 2 tab 3 tab 4 tab\\nFootnotes\\n(a) Treatment with ivermectin in these patients is reserved for severe cases for which no alternative exists (see\\xa0Crustedscabies).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 134, 'page_label': '135', 'id': 'data/guideline-170-en.pdf:134:2'}, page_content='(b) In areas where loiasis is endemic, certain precautions are recommended before administering ivermectin: e.g. measure theLoa loa microﬁlaraemia, if possible, or ensure that the patient has no history of loiasis (migration of an adult worm under theconjunctiva or transient « Calabar » swellings), nor history of severe adverse reactions following a previous treatment withivermectin, or if in doubt, use topical treatment in preference to oral.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 135, 'page_label': '136', 'id': 'data/guideline-170-en.pdf:135:0'}, page_content='Page 136 / 409\\nLice (pediculosis)\\nPediculosis is a benign contagious parasitic infection due to 3 species of lice speciﬁc to humans: head lice, body lice\\nand pubic lice. Transmission from person to person occurs through direct or indirect contact.\\nBody lice are potential vectors of\\xa0relapsing fever\\xa0(Chapter 7), typhus (Eruptive rickettsioses, Chapter 7) and trench\\nfever.\\nClinical features\\nTreatment\\nHead lice\\nBody lice\\nMass treatment (outbreak)\\nApply 30 to 60 g (2 to 4 heaped soup spoons) of\\xa00.5% permethrin\\xa0powder to the inside of the clothes and\\nunderclothes in contact with the skin (front and back, neck and waistline, sleeves and socks) in a fully clothed patient,\\nthen rub in the powder by hand. Leave for 12 to 24 hours.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 135, 'page_label': '136', 'id': 'data/guideline-170-en.pdf:135:1'}, page_content='then rub in the powder by hand. Leave for 12 to 24 hours.\\nTreat other clothing (including headwear) and bedding in a plastic bag with\\xa00.5% permethrin\\xa0powder. Repeat in 8 to 10\\ndays if the infestation persists.\\nHead lice mainly affect children: itching and scratch marks (nape of neck and around the ears), which may become\\nsecondarily infected (impetigo) in prolonged infestation; presence of live lice and/or live (shiny, grey) nits attached to\\nthe hair shaft within 5 mm of the scalp.\\nBody lice mainly affect populations living under poor conditions (refugees, prisoners, the homeless): itching and\\nscratch marks (back, belt line and armpits), often inﬂamed and infected; presence of lice and nits in the clothing\\n(parasites are not found on the body).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 135, 'page_label': '136', 'id': 'data/guideline-170-en.pdf:135:2'}, page_content='(parasites are not found on the body).\\nPubic lice are considered to be a sexually transmitted infection (STI): itching and scratch marks (pubic and perianal\\narea), but other hairy areas may also be affected (armpits, thighs, eyelashes); lice and nits at the base of the hair\\nshaft, rarely visible.\\nExamine contacts; check for associated systemic infection (body lice) or STI (pubic lice).\\nApply lotion to scalp and dry hair, paying particular attention to the areas behind the ears and around the nape of the\\nneck. Do not reduce or exceed the recommended duration of application.\\n4% dimeticone lotion\\nChildren 6 months and over and adults: leave on hair for 8 hours, then rinse thoroughly.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 135, 'page_label': '136', 'id': 'data/guideline-170-en.pdf:135:3'}, page_content='Keep away from ﬂames and/or intense heat sources (including cigarettes) during application and until rinsing (risk of\\nignition).\\nor, if dimeticone is not available or in children 2 to 6 months:\\n1% permethrin lotion.\\xa0\\nChildren 2 months and over and adults: leave on hair for 10 minutes, then rinse thoroughly.\\nRepeat application of either treatment after 7 days.\\nDecontaminate combs, headwear and bedding (wash ≥ 60 °C/30 minutes, iron or dry in the sun or, if not feasible,\\nseal in a plastic bag for 2 weeks).\\nTreat as above contacts with live lice and/or live nits. Do not treat those with dead nits alone (dull, white, > 1 cm\\nfrom scalp).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 136, 'page_label': '137', 'id': 'data/guideline-170-en.pdf:136:0'}, page_content='Page 137 / 409\\nIndividual treatment\\nDisinfection of clothing and bedding as above or as for head lice.\\nPubic lice\\nShave and/or apply\\xa01% permethrin\\xa0lotion to hairy areas (as for head lice). Treat the partner at the same time.\\nDecontaminate clothing and bedding (as for head lice). Repeat the application after 7 days.\\nTreatment of secondary bacterial infection, if present, should begin 24 to 48 hours before local antiparasitic treatment\\n(see\\xa0Impetigo); local treatment is applied later when tolerated.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 137, 'page_label': '138', 'id': 'data/guideline-170-en.pdf:137:0'}, page_content='Page 138 / 409\\nSuperﬁcial fungal infections\\nSuperﬁcial fungal infections are benign infections of the skin, scalp and nails caused by\\xa0Candida albicans\\xa0or\\ndermatophytes.\\nClinical features and treatment\\nCandidiasis\\nCandidal diaper dermatitis\\nErythema of the perianal area with peripheral desquamation and sometimes pustules. Secondary infection may\\ndevelop.\\nOther candidiasis\\nDermatophytoses\\nDermatophytes cause various clinical lesions, depending on the anatomic site involved: scalp, glabrous (hairless) skin,\\nfolds or nails.\\xa0\\nButtocks must be kept clean (ordinary soap and water) and dry.\\nAvoid humidity: according to the context, expose the buttocks to air or change diapers more frequently; remove\\nplastic pants.\\nProtect the skin with\\xa0zinc oxide ointment\\xa0if diarrhoea is present.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 137, 'page_label': '138', 'id': 'data/guideline-170-en.pdf:137:1'}, page_content='Protect the skin with\\xa0zinc oxide ointment\\xa0if diarrhoea is present.\\nIf diaper dermatitis is severe and persistent despite these measures, consider an intestinal infection (nystatin\\xa0PO:\\n100 000 IU 4 times daily for 20 days).\\nCandidiasis of skin folds:\\xa0miconazole 2%\\xa0cream, one application 2 times daily for 2 to 4 weeks\\nOral candidiasis: see\\xa0Stomatitis, Chapter 3.\\nVulvovaginal candidiasis: see\\xa0Abnormal vaginal discharge, Chapter 9.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 138, 'page_label': '139', 'id': 'data/guideline-170-en.pdf:138:0'}, page_content='Page 139 / 409\\nAnatomic\\nsite (a) Clinical features Treatment\\nScalp\\nScalp ringworm\\nTinea capitis\\nCommon in children. Depending on the species:\\n• One or more round, scaly, erythematous plaques with\\nthe ends of broken hairs.\\n• Inﬂammation, suppuration, crusting and peripheral\\nlymphadenopathy (kerion).\\n• Permanent hair loss (favus).\\nSome scalp ringworms are contagious:\\nsimultaneously examine (and treat) symptomatic\\ncontacts.\\n•\\xa0Shave or cut hair short on and around\\nthe lesions.\\n• Local treatment: 2 times daily, clean\\nwith soap and water, dry and apply\\nmiconazole 2% cream or Whitﬁeld’s\\nointment for 2 weeks or longer if\\nnecessary.\\n• Administer systemic treatment as\\nlocal treatment alone does not cure\\nscalp ringworm:\\ngriseofulvin PO for 6 weeks minimum\\n(up to 8 to 12 weeks)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 138, 'page_label': '139', 'id': 'data/guideline-170-en.pdf:138:1'}, page_content='scalp ringworm:\\ngriseofulvin PO for 6 weeks minimum\\n(up to 8 to 12 weeks)\\nChildren 1 to 12 years: 10 to 20 mg/kg\\nonce daily (max. 500 mg daily)\\nChildren ≥ 12 years and adults: 500 mg\\nto 1 g once daily, depending on\\nseverity\\nor itraconazole PO\\nChildren: 3 to 5 mg/kg once daily for 4\\nto 6 weeks (max. 200 mg daily)\\nAdults: 200 mg once daily for 2 to 4\\nweeks\\n• Suppurative lesions: treat\\nsuperinfection (see Impetigo) before\\napplying local antifungal treatment.\\n• For painful kerion: paracetamol PO.\\nIn pregnant lactating/breastfeeding\\nwomen: oral antifungals are\\ncontraindicated. Apply a topical\\ntreatment (miconazole 2% cream or\\nWhitﬁeld’s ointment) to limit the\\nspread of infection until it is possible\\nto treat orally.\\nGlabrous skin\\nRingworm of the\\nbody\\nTinea corporis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 138, 'page_label': '139', 'id': 'data/guideline-170-en.pdf:138:2'}, page_content='to treat orally.\\nGlabrous skin\\nRingworm of the\\nbody\\nTinea corporis\\nErythematous, scaly, pruritic macule with a well-\\ndemarcated, raised, vesicular border and central\\nhealing.\\n• For non widespread, localised tinea:\\nLocal treatment: 2 times daily, clean\\nwith soap and water, dry and apply\\nmiconazole 2% cream or Whitﬁeld’s\\nointment for 2 to 4 weeks or for 2\\nweeks after clinical resolution.\\n• Reserve oral antifungals for\\nparticularly extensive lesions:\\ngriseofulvin PO for 4 to 6 weeks or\\nitraconazole for 2 weeks.\\nFolds • Interdigital spaces (Tinea pedis): Topical treatment as above. If oozing'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 139, 'page_label': '140', 'id': 'data/guideline-170-en.pdf:139:0'}, page_content='Page 140 / 409\\nTinea pedis\\n(athlete’s foot)\\nTinea cruris\\nPruritus, ﬁssure and whitish scales in the 3 and/or 4\\ninterdigital spaces .\\n• Groin (Tinea cruris):\\nCircumscribed, pruritic, erythematous plaque, with a\\npale centre surrounded by vesiculo- pustules, extending\\noutward from the groin.\\nrd th\\n (b) \\xa0\\nlesions, use miconazole 2% cream\\nonly (do not use Whitﬁeld’s ointment).\\n(a) Dermatophytosis may affect the nails (Tinea unguium, onychomycosis). Treatment is prolonged (12 to 18 months withgriseofulvin) thus, in practice, difﬁcult. Failures and relapses are frequent.\\n(b) In candidal intertrigo, lesions are usually located in the 1st and 2nd interdigital spaces.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 140, 'page_label': '141', 'id': 'data/guideline-170-en.pdf:140:0'}, page_content='Page 141 / 409\\nBacterial skin infections\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nImpetigo\\nFuruncles and carbuncles\\nErysipelas and cellulitis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 141, 'page_label': '142', 'id': 'data/guideline-170-en.pdf:141:0'}, page_content='Page 142 / 409\\nImpetigo\\nImpetigo is a benign, contagious infection of the epidermis due to group A ß-haemolytic streptococcus\\nand\\xa0Staphylococcus aureus. Co-infection is common. Transmission is by direct contact. Lack of water, and poor\\nhygiene, increase spread.\\nPrimary infections are most common in children. Secondary infections complicating preexisting pruritic dermatoses\\n(lice, scabies, eczema, herpes, chickenpox, etc.) are more common in adults.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0\\nNon bullous impetigo (classic form): ﬂaccid vesicle on erythematous skin which becomes pustular and forms a\\nyellowish crust. Different stages o the infection may be present simultaneously. The lesion does not leave a scar.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 141, 'page_label': '142', 'id': 'data/guideline-170-en.pdf:141:1'}, page_content='The most common sites of infection are around the nose and mouth, on the limbs or on the scalp.\\nBullous impetigo: large ﬂaccid bullae and erosions of the skin in the ano-genital region in newborns and infants.\\nEcthyma: an ulcerative form of impetigo that leaves scars. This form is most common in the immunocompromised\\n(e.g. HIV infection, malnutrition), diabetics and alcoholics.\\nRegardless of the type of impetigo: absence of fever or systemic signs.\\nPossible complications:\\nabscess, pyodermitis, cellulitis, lymphangitis, osteomyelitis, septicaemia;\\nacute glomerulonephritis (routinely look for signs of glomerulonephritis).\\nLocalised non bullous impetigo\\xa0(max. 5 lesions in a single skin area):\\nClean with soap and water and dry before applying mupirocin.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 141, 'page_label': '142', 'id': 'data/guideline-170-en.pdf:141:2'}, page_content='Clean with soap and water and dry before applying mupirocin.\\n2% mupirocin\\xa0ointment: one application 3 times daily for 7 days. Reassess after 3 days. If there is no response,\\nswitch to oral antibiotic therapy (see below).\\nKeep ﬁngernails short. Avoid touching the lesions, keep them covered with gauze if possible.\\nExtensive non bullous impetigo\\xa0(more than 5 lesions or impetigo involving more than one skin area), bullous\\nimpetigo, ecthyma, impetigo with abscess; immunocompromised patient; topical treatment failure:\\nClean with soap and water and dry 2 to 3 times daily.\\nKeep ﬁngernails short. Avoid touching the lesions, keep them covered with gauze if possible.\\nIncise abscesses if present.\\nAdminister oral antibiotic therapy :\\xa0\\ncefalexin\\xa0PO for 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 141, 'page_label': '142', 'id': 'data/guideline-170-en.pdf:141:3'}, page_content='Administer oral antibiotic therapy :\\xa0\\ncefalexin\\xa0PO for 7 days\\nNeonates under 7 days:\\xa025 mg/kg 2 times daily\\nNeonates 7 to 28 days:\\xa025 mg/kg\\xa03 times daily\\nChildren 1 month to 12 years:\\xa025 mg/kg\\xa02 times daily\\nChildren 12 years and over and adults:\\xa01 g\\xa02 times daily\\nor\\ncloxacillin\\xa0PO for 7 days\\nChildren over 10 years: 15 mg/kg\\xa03 times daily (max. 3 g daily)\\nAdults:\\xa01 g\\xa03 times daily\\nNote: in newborns with\\xa0lesions located around the umbilicus, administer cloxacilllin IV.\\n a \\nFor all patients:\\nQuarantine from school (children can return to school after 24 to 48 hours of antibiotic therapy).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 142, 'page_label': '143', 'id': 'data/guideline-170-en.pdf:142:0'}, page_content='Page 143 / 409\\n\\xa0\\nLook for and treat any underlying dermatosis:\\xa0lice,\\xa0scabies,\\xa0eczema,\\xa0herpes,\\xa0scalp ringworm, or an ENT\\ninfection.\\nTrace and treat contacts.\\nCheck for proteinuria (use urine dipstick) 3 weeks after the infection.\\nFootnotes\\n(a) In penicillin-allergic patients only (resistance to macrolides is common), azithromycin PO for 3 days (children: 10 mg/kg oncedaily; adults: 500 mg once daily).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 143, 'page_label': '144', 'id': 'data/guideline-170-en.pdf:143:0'}, page_content='Page 144 / 409\\nFuruncles and carbuncles\\nNecrotising perifollicular infection, usually due to\\xa0Staphylococcus aureus. Risk factors include: nasal carriage of\\xa0S.\\naureus, maceration, breaks in the skin, poor hygiene; diabetes mellitus, malnutrition, iron deﬁciency or\\nimmunodeﬁciency.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0\\n\\xa0\\nFuruncle: red, warm, painful nodule with a central pustule, usually around a hair follicle. It becomes ﬂuctuant,\\ndischarges a core of purulent exudate, and leaves a depressed scar. It occurs most frequently on the thighs, groin,\\nbuttocks, armpits, neck and back. There is no fever.\\nCarbuncle: a cluster of interconnected furuncles, sometimes with fever and peripheral lymphadenopathy. It leaves a\\ndepressed scar.\\nSingle furuncle:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 143, 'page_label': '144', 'id': 'data/guideline-170-en.pdf:143:1'}, page_content='depressed scar.\\nSingle furuncle:\\nClean with soap and water 2 times daily and cover with a dry dressing.\\nApply warm moist compresses to the furuncle in order to encourage it to drain.\\nAfter drainage, clean and apply a dry dressing until the lesion has healed.\\nFuruncle on the face, multiple furuncles, carbuncles or in immunocompromised patients:\\nSame local care.\\nAdd systematically an antibiotic for 7 days:\\xa0\\ncefalexin\\xa0PO\\nNeonates under 7 days:\\xa025 mg/kg 2 times daily\\nNeonates 7 to 28 days:\\xa025 mg/kg\\xa03 times daily\\nChildren 1 month to 12 years:\\xa025 mg/kg\\xa02 times daily\\nChildren 12 years and over and adults:\\xa01 g\\xa02 times daily\\nor\\xa0\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO.\\xa0Use formulations in a ratio of 8:1 or 7:1.\\xa0The dose is expressed\\nin amoxicillin:\\nChildren < 40\\xa0kg: 25 mg/kg 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 143, 'page_label': '144', 'id': 'data/guideline-170-en.pdf:143:2'}, page_content='in amoxicillin:\\nChildren < 40\\xa0kg: 25 mg/kg 2 times daily\\nChildren ≥ 40 kg and adults:\\xa0\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio\\xa07:1: 1750 mg daily (1 tablet of 875/125 mg 2 times daily)\\n a \\nIn all cases: wash hand frequently, wash bedding.\\nFootnotes\\n(a) For penicillin-allergic patients:clindamycin PO (children: 10 mg/kg 3 times daily; adults: 600 mg 3 times daily)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 144, 'page_label': '145', 'id': 'data/guideline-170-en.pdf:144:0'}, page_content='Page 145 / 409\\nErysipelas and cellulitis\\nLast updated: October 2020\\n\\xa0\\n\\xa0\\nAcute skin infections, due to bacteria (usually Group A beta-haemolytic streptococcus and sometimes\\nStaphylococcus aureus, including methicillin resistant S. aureus–MRSA) that enter through a break in the skin.\\nThe main risk factors are: venous insufﬁciency, obesity, oedema or lymphoedema, history of erysipelas or cellulitis,\\nimmunosuppression and cutaneous inﬂammation (e.g. dermatosis, wound).\\nErysipelas is a superﬁcial infection (affecting the dermis and superﬁcial lymph vessels), while cellulitis affects the deeper\\ntissues (deep dermis layers and subcutaneous fat).\\nGenerally, these infections affect the lower extremities and sometimes the face. If the orbital and periorbital tissues'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 144, 'page_label': '145', 'id': 'data/guideline-170-en.pdf:144:1'}, page_content='are infected, see Periorbital and orbital cellulitis, Chapter 5. If the infection is perifollicular, see Furuncles and\\ncarbuncles, Chapter 4.\\nClinical signs\\nParaclinical investigations\\nTreatment\\n\\xa0\\nWarm, tender, swollen well–demarcated erythematous plaque.\\nFever, lymphadenopathy and lymphangitis.\\nLook for a portal of entry (bite, ulcer, wound, intertrigo, eczema, fungal infection, etc.).\\nIn case of intense pain disproportionate to the skin lesion, hypoesthesia, rapidly progressing local signs, crepitation,\\nskin necrosis or critically ill appearing patient, consider necrotising fasciitis that is a surgical emergency\\n(see\\xa0Necrotising infections of the skin and soft tissues, Chapter 10).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 144, 'page_label': '145', 'id': 'data/guideline-170-en.pdf:144:2'}, page_content='(see\\xa0Necrotising infections of the skin and soft tissues, Chapter 10).\\nOther complications: septicaemia (see Septic shock, Chapter 1), acute glomerulonephritis, osteomyelitis, septic\\narthritis.\\nThe main differential diagnoses include: contact dermatitis, stasis dermatitis due to venous insufﬁciency, venous\\nthrombosis and erythema migrans characteristic of Lyme disease.\\nUltrasound: can detect signs of cellulitis and rule out an underlying abscess, deep vein thrombosis or a foreign body.\\nRadiography: can detect a foreign body, underlying osteomyelitis (or gas in the subcutaneous tissue in case of a\\nnecrotising infection, nevertheless the absence of gas does not rule out this diagnosis).\\nTest for proteinuria with urine dipstick 3 weeks after infection to look for glomerulonephritis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 144, 'page_label': '145', 'id': 'data/guideline-170-en.pdf:144:3'}, page_content='In all cases:\\nOutline the area of erythema with a pen in order to follow the infection . a \\nBed rest, elevation of affected area (e.g. leg).\\xa0\\nTreatment of pain (Chapter 1). Avoid NSAIDs that may increase the risk of necrotising fasciitis.\\nAdminister antibiotics: either orally or IV depending on severity.\\nTreat portal of entry and comorbidities.\\nCheck and/or catch up tetanus vaccination (see Tetanus, Chapter 7).\\nIn case of necrotising fasciitis, septic arthritis or osteomyelitis: urgent transfer to a surgical centre, initiate IV\\nantibiotic treatment while awaiting transfer.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 145, 'page_label': '146', 'id': 'data/guideline-170-en.pdf:145:0'}, page_content='Page 146 / 409\\n\\xa0\\n\\xa0 In the event of worsening clinical signs after 48 hours of antibiotic treatment, consider IV route.\\xa0\\nIf there is clinical improvement after 48 hours (afebrile and erythema and oedema have improved) switch to\\ncefalexin or amoxicillin/clavulanic acid PO at the doses indicated above to complete 7 to 10 days of treatment.\\nAfter 48 hours, change to clindamycin PO at the doses indicated above to complete 7 to 10 days of treatment.\\n\\xa0\\nHospitalize for the following: children younger than 3 months, critically ill appearing patient , local complications,\\ndebilitated patient (chronic conditions, the elderly) or if there is a risk of non-compliance with or failure of outpatient\\ntreatment. Treat other patients as outpatients.\\n b \\nOutpatient antibiotherapy :'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 145, 'page_label': '146', 'id': 'data/guideline-170-en.pdf:145:1'}, page_content='b \\nOutpatient antibiotherapy :\\xa0\\ncefalexin PO for 7 to 10 days\\nChildren 1 month to under 12 years: 25 mg/kg 2\\xa0times daily\\nChildren 12 years and over and adults: 1 g\\xa02\\xa0times daily\\nor\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO for 7 to 10 days.\\xa0\\nUse formulations in a ratio of 8:1 or 7:1.\\xa0The dose is expressed in amoxicillin:\\nChildren < 40\\xa0kg: 25 mg/kg 2 times daily\\nChildren ≥ 40 kg and adults:\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times daily)\\n c \\xa0\\nInpatient antibiotherapy : d \\nFirst line therapy:\\xa0\\ncloxacillin IV infusion over 60 minutes\\nChildren 1 month to under 12 years: 12.5 to 25 mg/kg every 6 hours\\nChildren 12 years and over and adults: 1 g every 6 hours\\xa0\\nor'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 145, 'page_label': '146', 'id': 'data/guideline-170-en.pdf:145:2'}, page_content='Children 12 years and over and adults: 1 g every 6 hours\\xa0\\nor\\namoxicillin/clavulanic acid (co-amoxiclav) by slow IV injection (3 minutes) or IV infusion (30 minutes). The dose\\nis expressed in amoxicillin:\\nChildren under 3 months:\\xa030\\xa0mg/kg every 12 hours\\xa0\\nChildren 3 months and over:\\xa020 to 30 mg/kg every 8 hours\\xa0(max. 3 g\\xa0daily)\\nAdults:\\xa01 g every 8 hours\\n e \\nIf there is no clinical improvement after 48 hours, consider MRSA:\\xa0\\nclindamycin IV infusion over 30 minutes\\nChildren 1 month and over: 10 mg/kg every 8 hours\\nAdults: 600 mg\\xa0every 8 hours\\n f \\nFootnotes\\n(a) The erythema will regress if the treatment is effective. If the erythema spreads consider a treatment failure (MRSA or anecrotising infection).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 145, 'page_label': '146', 'id': 'data/guideline-170-en.pdf:145:3'}, page_content='(b) Critically ill appearing child: weak grunting or crying, drowsy and difﬁcult to arouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.\\n(c) For penicillin-allergic patients, clindamycin PO for 7 to 10 days (children: 10 mg/kg 3 times daily; adults: 600 mg 3 times daily).\\n(d) For penicillin-allergic patients, clindamycin IV infusion (children: 10 mg/kg 3 times daily; adults: 600 mg 3 times daily).\\n(e) Cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. Then dilute each dose of cloxacillin in5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or5% glucose in children 20 kg and over and in adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 146, 'page_label': '147', 'id': 'data/guideline-170-en.pdf:146:0'}, page_content='Page 147 / 409\\n(f) Dilute each dose of clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of100 ml of 0.9% sodium chloride or 5% glucose in children 20 kg and over and in adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 147, 'page_label': '148', 'id': 'data/guideline-170-en.pdf:147:0'}, page_content='Page 148 / 409\\nCutaneous anthrax\\nLast updated: September 2022\\n\\xa0\\n\\xa0\\nAnthrax is caused by the bacterium\\xa0Bacillus anthracis\\xa0that primarily affects herbivores (sheep, goats, cows, camels,\\nhorses, etc.). Humans may become infected through contact of broken skin with a dead or sick animal. People at risk\\ninclude livestock farmers and those that manipulate skins, wool or carcasses of infected animals.\\nThe disease is found in Eastern Europe, Central Asia, the Mediterranean Basin, Africa and South America.\\nPulmonary (acquired by inhalation) and intestinal (acquired by eating infected meat) forms also exist.\\nClinical features\\nLaboratory\\nTreatment\\nUncomplicated cutaneous anthrax\\xa0\\ndoxycycline PO (except in\\xa0pregnant or breastfeeding\\xa0women)\\nChildren under 45 kg: 2 to 2.2 mg/kg (max. 100 mg) 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 147, 'page_label': '148', 'id': 'data/guideline-170-en.pdf:147:1'}, page_content='Children under 45 kg: 2 to 2.2 mg/kg (max. 100 mg) 2 times daily\\nChildren 45 kg and over and adults: 100 mg 2 times daily\\nclindamycin\\xa0PO (in\\xa0patients allergic to ﬁrst-line antibiotics)\\nChildren: 10 mg/kg (max. 600 mg) 3 times daily\\nAdults: 600 mg 3 times daily\\nor\\nPapule, then pruritic vesicle on uncovered skin surfaces (face, neck, arms, legs). The vesicle ulcerates and becomes\\na painless black eschar surrounded by oedema, often associated with with lymphangitis and regional\\nlymphadenopathy.\\nThe following are criteria of severity:\\nlesion located on the head or neck, or\\npresence of systemic symptoms (fever, malaise, headache, tachycardia, tachypnoea, hypotension,\\nhyper/hypothermia), or\\npresence of extensive oedema, or\\nmultiple, extensive or bullous lesions.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 147, 'page_label': '148', 'id': 'data/guideline-170-en.pdf:147:2'}, page_content='presence of extensive oedema, or\\nmultiple, extensive or bullous lesions.\\nFrom vesicular ﬂuid : culture and drug susceptibility testing (rarely available) or Gram stain for microscopic\\nexamination.\\n a \\nPCR testing (reference laboratory).\\nDo not excise the eschar; daily dry dressings.\\nAntibiotic\\xa0treatment for 7 to 10 days:\\nFirst-line antibiotics:\\nciproﬂoxacin\\xa0PO\\xa0(including in\\xa0pregnant or breastfeeding women and children)\\nChildren: 15 mg/kg (max. 500 mg) 2 times daily\\nAdults: 500 mg 2 times daily\\nor\\nAlternatives include:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 148, 'page_label': '149', 'id': 'data/guideline-170-en.pdf:148:0'}, page_content='Page 149 / 409\\namoxicillin\\xa0PO, if penicillins are effective\\xa0(documented susceptibility)\\nChildren: 30 mg/kg (max. 1 g) 3 times daily\\nAdults: 1 g\\xa03 times daily\\nSevere cutaneous anthrax\\nDo not mix the two antibiotics in the same infusion bag (incompatibility).\\nampicillin\\xa0IV\\xa0infusion over 30 minutes\\nChildren 1 month and over: 50 mg/kg (max. 3 g) every 6 hours or\\xa065 mg/kg\\xa0(max. 4 g) every 8 hours\\xa0\\nAdults: 3 g\\xa0every 6 hours\\xa0or\\xa04 g\\xa0every 8 hours\\n+\\xa0clindamycin\\xa0IV infusion as above.\\nChange to oral treatment as soon as possible to complete 14 days of treatment with ciproﬂoxacin + clindamycin or\\namoxicillin + clindamycin as for uncomplicated cutaneous anthrax.\\nPrevention\\n\\xa0\\nCombined\\xa0antibiotic\\xa0treatment for 14 days:\\n\\xa0\\n\\xa0\\nFirst-line:\\nciproﬂoxacin\\xa0IV infusion over 60 minutes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 148, 'page_label': '149', 'id': 'data/guideline-170-en.pdf:148:1'}, page_content='First-line:\\nciproﬂoxacin\\xa0IV infusion over 60 minutes\\nChildren: 10 mg/kg (max. 400 mg) every 8 hours\\xa0\\nAdults: 400 mg\\xa0every 8 hours\\xa0\\n+\\xa0clindamycin\\xa0IV infusion over 30 minutes\\nChildren 1 month and over: 10 to 13 mg/kg (max. 900 mg) every 8 hours\\nAdults: 900 mg every 8 hours\\n b \\n b \\nAlternative, if penicillins are effective (documented susceptibility):\\n b \\nIntensive care: symptomatic treatment of shock (see\\xa0Shock, Chapter 1); tracheostomy and ventilatory support may\\nbe necessary.\\nAntibiotic prophylaxis in case of known skin exposure: treat for 10 days PO as for uncomplicated cutaneous\\nanthrax.\\nLivestock vaccination; burial or burning of animal carcasses.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 148, 'page_label': '149', 'id': 'data/guideline-170-en.pdf:148:2'}, page_content='Livestock vaccination; burial or burning of animal carcasses.\\nFootnotes\\n(a) Samples can be stored (including transport time) for 7 days max. in cold chain (if not available, at a temperature < 30 °C).\\n(b) Dilute each dose of ciproﬂoxacin, clindamycin or ampicillin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children lessthan 20 kg and in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children 20 kg and above and in adults.Administer ciproﬂoxacin more slowly than clindamycin or ampicillin.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 149, 'page_label': '150', 'id': 'data/guideline-170-en.pdf:149:0'}, page_content='Page 150 / 409\\nEndemic treponematoses\\n\\xa0Endemic treponematoses are bacterial infections caused by 3 different types of treponema (other than\\xa0Treponema\\npallidum). Human-to-human transmission may be direct or indirect.\\nThe 3 endemic treponematoses result in positive syphilis serology (TPHA-VDRL), but these tests are not necessary as\\ndiagnosis is clinical. There is no laboratory test that can distinguish between the different treponematoses.\\nFor the diagnosis and treatment of syphilis, see\\xa0Genital infections, Chapter 9.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 150, 'page_label': '151', 'id': 'data/guideline-170-en.pdf:150:0'}, page_content='Page 151 / 409\\n\\xa0\\n\\xa0 Yaws Pinta Bejel\\nPathogen Treponema pertenue Treponema carateum Treponema pallidum type M\\nGeographic\\ndistribution\\nTropical and humid\\nforests\\nTropical zones of Latin America Arid areas, semi-desert of the Middle\\nEast and Africa\\nPopulation Children between 4 and\\n14\\u2008years\\nChildren and adults Nomadic populations, particularly\\nchildren\\nFirst stage Yaws chancre: skin\\ncoloured lesion, non-\\nindurated, itchy, on the\\nlower limbs in 95% of\\ncases, with peripheral\\nadenopathy.\\nSpontaneous healing or\\ndevelopment of a large\\nyaw surrounded by\\nsmaller yaws.\\nAnnular, erythematous, scaly\\nplaques, usually on uncovered\\nbody parts (face, extremities),\\nresemble dermatophytes.\\nLesions heal sponta- neously\\nleaving scars.\\nDiscrete chancre: moist papule, most\\ncommonly on the mucous membranes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 150, 'page_label': '151', 'id': 'data/guideline-170-en.pdf:150:1'}, page_content='Discrete chancre: moist papule, most\\ncommonly on the mucous membranes\\nor in dermal folds, with peripheral\\nadenopathy.\\nSecond\\nstage\\nLesions appear 3\\nweeks after the initial\\nchancre, occur in crops\\nand heal spontaneously:\\n• Frambesioma\\n(papillomatous lesion,\\nvegetal, very\\ncontagious)\\n• Isolated or associated\\nwith yaws (round,\\nsquamous papules, not\\nvery contagious)\\n• Osteoperiostitis of the\\nlong bones (phalanges,\\nnasal process of the\\nmaxilla, tibia)\\nPintids: plaques of various\\ncolours (bluish, reddish, whitish).\\nMay occur anywhere on the\\nbody.\\n• Mucous patches of the mouth\\ncommon: very contagious ulcerated,\\nround in form, indurated, with white\\ncoating, bleed easily, usually occur on\\nthe inside of the lips, cheek and tongue\\nor labial folds\\n• Condyloma in the anogenital region\\n(rare)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 150, 'page_label': '151', 'id': 'data/guideline-170-en.pdf:150:2'}, page_content='or labial folds\\n• Condyloma in the anogenital region\\n(rare)\\n• Cutaneous lesions are rare: vegetal\\naspect, in dermal folds\\n• Bone destruction identical to that of\\nyaws, in the legs and forearms\\nLate stage After some years of\\nlatency:\\n• Periostitis; painful,\\ndebilitating osteitis\\n• Ulcerating and\\ndisﬁguring\\nrhinopharyngitis\\n• Juxta-articular nodules\\nSymmetrical white patches on\\nthe limbs.\\u2008The depigmentation is\\npermanent, remaining after\\ntreatment.\\nAfter several years of latency:\\n• Gummatous lesions of skin and long\\nbones\\n• Plantar and palmar keratosis\\n• Juxta-articular nodules\\n• Hyper- and hypo-pigmented patches\\n(as in pinta)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 151, 'page_label': '152', 'id': 'data/guideline-170-en.pdf:151:0'}, page_content='Page 152 / 409\\nTreatment\\nYaws\\nazithromycin\\xa0PO\\nChildren and adults: 30 mg/kg single dose (max. 2 g)\\nor, if not available,\\nbenzathine benzylpenicillin\\xa0IM\\nChildren under 10 years:\\xa01.2 MIU single dose\\nChildren 10 years and over and adults: 2.4 MIU single dose\\nPinta and bejel\\nbenzathine benzylpenicillin\\xa0IM.\\nAs for yaws.\\xa0For patients allergic to penicillin:\\ndoxycycline PO (except in children under 8 years and pregnant or lactating women)\\nChildren 8 years and over: 50 mg 2 times daily for 14 days\\nAdults: 100 mg 2 times daily\\xa0for 14 days\\xa0Notes:\\nTreatment of contacts and latent cases\\nThe same treatment should be administered to all symptomatic and asymptomatic contacts and to all latent cases\\n(asymptomatic individuals with positive serologic test for syphilis) in endemic zones.\\xa0\\n\\xa0\\nReferences\\n [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 151, 'page_label': '152', 'id': 'data/guideline-170-en.pdf:151:1'}, page_content='References\\n [1] \\n [2] [3] \\nAntibiotic treatment will cure early stage cases and may relieve the pain of osteitis. It may be ineffective for late\\nstage infections.\\nSyphilis serology will remain positive despite clinical cure.\\n1. World Health Organization\\xa0( 2012) .\\xa0Yaws: recognition booklet for communities. Reprinted with changes, 2014.\\xa0http://www.who.int/iris/handle/10665/75360\\xa0[Accessed 15\\xa0May 2018]\\n2. Oriol Mitjà,\\xa0David Mabey.\\xa0Yaws, bejel, and pinta\\xa0(last updated.\\xa0May 07, 2018).\\xa0UpToDate\\xa0[Accessed 15\\xa0May 2018].\\n3. Michael Marks, Anthony W Solomon, David C Mabey. Endemic treponemal diseases.\\xa0Transactions of The Royal Society ofTropical Medicine and Hygiene, Volume 108, Issue 10, 1 October 2014, Pages 601–607.https://doi.org/10.1093/trstmh/tru128\\xa0[Accessed 15\\xa0May 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 152, 'page_label': '153', 'id': 'data/guideline-170-en.pdf:152:0'}, page_content='Page 153 / 409\\nLeprosy\\nLeprosy is a chronic bacterial infection due to\\xa0Mycobacterium leprae.\\nIt is transmitted by frequent close contact, mainly between household members.\\nIt mainly affects young adults. 94% of reported cases globally were in Bangladesh, Brazil, Democratic Republic of\\nCongo, Ethiopia, India, Indonesia, Madagascar, Myanmar, Nepal, Nigeria, the Philippines, Sri Lanka and the United\\nRepublic of Tanzania.\\nClinical features\\nLeprosy should be considered in any patient presenting with:\\n\\xa0There are different clinical forms and classiﬁcation systems of leprosy.\\nRidley-Jopling classiﬁcation\\xa0\\nThis classiﬁcation differentiates 5 forms based on the bacteriological index. These forms correlate with the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 152, 'page_label': '153', 'id': 'data/guideline-170-en.pdf:152:1'}, page_content='immunological response to \\xa0M. leprae.\\xa0Patients\\xa0with\\xa0tuberculoid leprosy (TT) are resistant to the bacillus and infection\\nis localised. Patients with lepromatous leprosy (LL) are extremely sensitive to the bacillus and the infection is\\ndisseminated. Borderline forms (BT, BB, BL) are between the two ends of the spectrum (TT and LL).\\xa0\\n\\xa0\\nWHO classiﬁcation\\nIn order to simplify diagnosis and to promote rapid implementation of treatment, the WHO has simpliﬁed clinical\\nclassiﬁcation of leprosy and differentiates only 2 forms:\\n\\xa0Multibacillary leprosy includes LL, BL and BB forms and paucibacillary leprosy includes the TT and BT forms of the\\nRidley-Jopling classiﬁcation system.\\nLaboratory\\n [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 152, 'page_label': '153', 'id': 'data/guideline-170-en.pdf:152:2'}, page_content='Ridley-Jopling classiﬁcation system.\\nLaboratory\\n [1]\\nHypopigmented or erythematous skin lesion(s) with\\xa0partial or complete\\xa0loss\\xa0of sensation to touch, pain, heat;\\xa0\\nInﬁltrated pigmented nodules, initially with no sensory loss, on the face, ear lobes and the upper and lower limbs;\\nTender, inﬁltrated and hypertrophied peripheral nerve\\xa0(ulnar, radial, median, popliteal, tibial etc.) with possible\\nparaesthesia of the extremities, trophic changes (perforating ulcer of the\\xa0foot) or paralysis (steppage gait,\\ndeformaties of hands and feet, facial nerve paralysis).\\nPaucibacillary forms \\n(least contagious forms)\\nMultibacillary forms \\n(most contagious forms)\\nTuberculoid Borderline\\nTuberculoid\\nBorderline Borderline\\nLepromatous\\nLepromatous\\nT.T. B.T. B.B. B.L. L.L.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 152, 'page_label': '153', 'id': 'data/guideline-170-en.pdf:152:3'}, page_content='Borderline Borderline\\nLepromatous\\nLepromatous\\nT.T. B.T. B.B. B.L. L.L.\\nMultibacillary leprosy: more than 5 skin lesions\\nPaucibacillary leprosy: 1 to 5 skin lesions\\nLaboratory diagnosis is based on the detection of acid-fast bacilli in a Ziehl-Neelsen stained nasal smear and skin-\\nsplit smear taken from the ear lobe or from a skin lesion. In TT leprosy bacilli are not found.\\nIn practice, in most endemic countries diagnosis is based on the WHO clinical classiﬁcation (number of lesions).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 153, 'page_label': '154', 'id': 'data/guideline-170-en.pdf:153:0'}, page_content='Page 154 / 409\\nTreatment\\nCountries where leprosy is endemic have a control programme. Check national recommendations.\\xa0First-line treatment regimens recommended by the WHO\\xa0\\n\\xa0Note: the monthly doses of rifampicin and clofazimine are administered under direct observation by medical staff\\nwhereas the daily doses of clofazimine and dapsone are taken by the patient at home. Rifampicin should be taken on\\nan empty stomach to\\xa0improve\\xa0absorption.\\xa0Teach the patient to recognise and quickly report a lepra reaction or relapse in order to modify or restart treatment.\\nLeprosy reactions\\nThese reactions usually occur during the course of treatment in patients with multibacillary leprosy (BL and LL). They'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 153, 'page_label': '154', 'id': 'data/guideline-170-en.pdf:153:1'}, page_content='are associated with the immunological response\\xa0to\\xa0M.\\xa0leprae\\xa0antigens. Urgent treatment is required to avoid\\nirreversible disability.\\xa0Do not interrupt ongoing leprosy treatment.\\xa0\\nClinical features\\n\\xa0\\nTreatment\\n\\xa0Age Multibacillary leprosy \\n(more than 5 skin lesions)\\nPaucibacillary leprosy  \\n(1 to 5 skin lesions)\\nChildren 10 to 14 years rifampicin PO: 450 mg once monthly\\n+ clofazimine PO: 150 mg once monthly\\nand 50 mg on alternate days\\n+ dapsone PO: 50 mg once daily\\nrifampicin PO: 450 mg once monthly\\n+ clofazimine PO: 150 mg once monthly\\nand 50 mg on alternate days\\n+ dapsone PO: 50 mg once daily\\nChildren 15 years and\\nover and adults\\nrifampicin PO: 600 mg once monthly\\n+ clofazimine PO: 300 mg once monthly\\nand 50 mg once daily\\n+ dapsone PO: 100 mg once daily\\nrifampicin PO: 600 mg once monthly'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 153, 'page_label': '154', 'id': 'data/guideline-170-en.pdf:153:2'}, page_content='+ dapsone PO: 100 mg once daily\\nrifampicin PO: 600 mg once monthly\\n+ clofazimine PO: 300 mg once monthly\\nand 50 mg once daily\\n+ dapsone PO: 100 mg once daily\\nDuration 12 months 6 months\\nReversal reactions:\\xa0\\nExacerbation\\xa0of the\\xa0skin lesions\\xa0that become\\xa0erythematous and\\xa0oedematous\\xa0and risk or ulceration.\\xa0Onset or\\nworsening of numbness\\xa0of skin lesions;\\xa0\\nOnset of acute painful\\xa0hypertrophic\\xa0neuritis.\\nErythema nodosum leprosum:\\nFever, asthenia,\\xa0alteration of the general state;\\nCrops of\\xa0purplish-red,\\xa0tender\\xa0subcutaneous nodules, warmer than the surrounding skin.\\xa0\\nReversal reactions:\\xa0\\nprednisolone\\xa0(or\\xa0prednisone) PO: 0.5 to 1 mg/kg once daily for 2 weeks. Re-examine the patient every 2 weeks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 153, 'page_label': '154', 'id': 'data/guideline-170-en.pdf:153:3'}, page_content='and decrease the dosage if the neurological signs recede. According to clinical response, treatment may last 3 to 6\\nmonths.\\nFor example, for an adult:\\nWeek 1 and 2: 40 mg once daily\\xa0\\n [2] \\n [3]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 154, 'page_label': '155', 'id': 'data/guideline-170-en.pdf:154:0'}, page_content='Page 155 / 409\\n\\xa0\\n\\xa0\\nReferences\\nWeek 3 and 4: 30 mg once daily\\xa0\\nWeek 5 and 6: 20 mg once daily\\xa0\\nWeek 7 and 8: 15 mg once daily\\xa0\\nWeek 9 and 10: 10 mg once daily\\xa0\\nWeek 11 and 12: 5 mg once daily\\nErythema nodosum leprosum:\\nprednisolone\\xa0(or\\xa0prednisone) PO as for reversal reactions, for 3 months. \\xa0 [2] \\nFever:\\xa0paracetamol\\xa0PO (see\\xa0Fever, Chapter 1)\\n1. World Health Organization. Global Leprosy Programme. Global leprosy strategy 2016-2020. Accelerating towards a leprosy-free world, 2016.http://apps.who.int/iris/bitstream/handle/10665/208824/9789290225096_en.pdf?sequence=14&isAllowed=y\\xa0[Accessed 17October 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 154, 'page_label': '155', 'id': 'data/guideline-170-en.pdf:154:1'}, page_content='2. World Health Organization. WHO Expert Committee on Leprosy. Eighth report. WHO technical report series, n° 968. Geneva,2012.http://www.searo.who.int/entity/global_leprosy_programme/publications/8th_expert_comm_2012.pdf\\xa0[Accessed 17 October2018]\\n3. World Health Organization.\\xa0A guide to eliminating leprosy as a public health problem.\\xa0Leprosy Elimination Group, 2000.http://apps.who.int/iris/bitstream/handle/10665/66612/WHO_CDS_CPE_CEE_2000.14.pdf?sequence=1\\xa0[Accessed 17October 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 155, 'page_label': '156', 'id': 'data/guideline-170-en.pdf:155:0'}, page_content='Page 156 / 409\\nHerpes simplex and herpes zoster\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nHerpes simplex\\nHerpes zoster (shingles)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 156, 'page_label': '157', 'id': 'data/guideline-170-en.pdf:156:0'}, page_content='Page 157 / 409\\nHerpes simplex\\nRecurrent viral infection of the skin and mucous membranes due to the\\xa0Herpes simplex\\xa0virus. Recurrent lesions have a\\ndifferent presentation than primary infection.\\nClinical features\\nTreatment\\nRecurrent herpes labialis: tingling feeling followed by an eruption of vesicles on an erythematous base, located on\\nthe lips (‘fever blisters’) and around the mouth, they may extend onto the face. Recurrence corresponds to a\\nreactivation of the latent virus after a primary infection. No associated malaise, adenopathy or fever.\\nCarefully consider other sites: buccal (Stomatitis, Chapter 3), genital (Genital ulcers, Chapter 9), ophthalmic, and\\nsecondary bacterial infections.\\nClean with soap and water 2 times daily until the lesions have healed.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 156, 'page_label': '157', 'id': 'data/guideline-170-en.pdf:156:1'}, page_content='Clean with soap and water 2 times daily until the lesions have healed.\\nFor patients with secondary bacterial infections: antibiotic treatment as for\\xa0impetigo.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 157, 'page_label': '158', 'id': 'data/guideline-170-en.pdf:157:0'}, page_content='Page 158 / 409\\nHerpes zoster (shingles)\\nAcute viral infection due to the varicella-zoster virus. Chickenpox is the primary infection and herpes zoster the\\nreactivation of the latent virus.\\nClinical features\\nTreatment\\nUnilateral neuralgic pain followed by an eruption of vesicles on a erythematous base, that follow the distribution of a\\nnerve pathway.\\nLesions most commonly occur on the thorax, but herpes zoster may also develop on the face with a risk of\\nophthalmic complications.\\nHerpes zoster is more common in adults than in children.\\nSimilar to that of herpes simplex, with the addition of systematic analgesics: paracetamol PO (see\\xa0Pain, Chapter 1).\\nAciclovir PO given within the ﬁrst 48 hours after the eruption of lesions is only indicated for severe forms: necrotic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 157, 'page_label': '158', 'id': 'data/guideline-170-en.pdf:157:1'}, page_content='or extensive lesions or lesion on the face which may spread to the eyes (see\\xa0HIV infection and AIDS, Chapter 8).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 158, 'page_label': '159', 'id': 'data/guideline-170-en.pdf:158:0'}, page_content='Page 159 / 409\\nOther skin disorders\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nEczema\\nSeborrheic dermatitis\\nUrticaria\\nPellagra'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 159, 'page_label': '160', 'id': 'data/guideline-170-en.pdf:159:0'}, page_content='Page 160 / 409\\nEczema\\nAcute eczema: erythematous plaque, pruritic, vesicular, oozing, with poorly demarcated and crumbly borders.\\nChronic eczema: erythematous plaque, scaly, dry, poorly demarcated and pruritic.\\nLook for a cause (contact allergic dermatitis, fungal or bacterial infection with a distant focus, malnutrition) and ask\\nabout family history.\\nTreatment\\nClean with soap and water 2 times daily.\\nThen:\\nfor acute eczema:\\xa0calamine\\xa0lotion, one application 2 times daily\\xa0\\nfor chronic eczema:\\xa0zinc oxide\\xa0ointment, one application 2 times daily\\nLook for and treat any pre-existing condition (scabies, lice etc.).\\nFor patients with secondary infections: treat as\\xa0impetigo.\\nFor patients with intense pruritus, antihistamines\\xa0for a few days\\xa0(see\\xa0Urticaria).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 160, 'page_label': '161', 'id': 'data/guideline-170-en.pdf:160:0'}, page_content='Page 161 / 409\\nSeborrheic dermatitis\\nSeborrheic dermatitis is an inﬂammatory chronic dermatosis that can be localized on areas rich with sebaceous glands.\\nThis dermatosis is more common in infected patients with HIV.\\nClinical features\\nTreatment\\nErythematous plaques covered by greasy yellow scales that can be localized on the scalp, the face (nose wings,\\neyebrows, edge of the eyelids), sternum, spine, perineum, and skin folds.\\nClean with soap and water 2 times daily; shampooing the scalp.\\nHydrocortisone 1%\\xa0cream:\\xa0one application once daily or 2 times daily to the affected area only, in thin layer, for 7\\ndays maximum\\nDo not apply if pre-existing bacterial infection; treat ﬁrst the infection (see\\xa0Impetigo).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 161, 'page_label': '162', 'id': 'data/guideline-170-en.pdf:161:0'}, page_content='Page 162 / 409\\nUrticaria\\nLast updated: July 2022\\n\\xa0\\nPapules: transient, erythematous, oedematous, pruritic, resembling nettle stings.\\nLook for a cause: food or drug (particularly antibiotic) allergy, insect bites; the invasive stage of a bacterial or parasitic\\ninfection (ascariasis, strongylodiasis, ancylostomiasis, schistosomiasis, loiasis), viral infection (hepatitis B or C);\\ngeneralised disease (cancer, lupus, dysthyroidism, vasculitis).\\nTreatment\\nIf the pruritus is intense, antihistamines\\xa0for a few days:\\nloratadine\\xa0PO\\nChildren over 2 years and under 30 kg: 5 mg (5 ml) once daily\\nChildren over 30 kg and adults: 10 mg (1 tab) once daily\\nIn the event of anaphylactic reaction, see\\xa0Shock\\xa0(Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 162, 'page_label': '163', 'id': 'data/guideline-170-en.pdf:162:0'}, page_content='Page 163 / 409\\nPellagra\\nPellagra is a dermatitis resulting from niacin and/or tryptophane deﬁciency (in persons whose staple food is sorghum;\\npatients with malabsorption, or during famine).\\nClinical features\\nClassically, disease of the ‘three Ds’: dermatitis, diarrhoea and dementia.\\nTreatment\\nChildren and adults: 100 mg 3 times daily, give with a diet rich in protein until the patient is fully cured.\\n\\xa0\\nReferences\\nDark red plaques, well demarcated, symmetric, located on exposed areas of the body (forehead, neck, forearms,\\nlegs). The skin becomes very scaly, pigmented, sometimes with haemorrhagic bullae.\\nGastrointestinal (glossitis, stomatitis and diarrhoea) and neuropsychiatric symptoms are seen in more serious forms.\\nnicotinamide\\xa0(vitamin PP) PO [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 162, 'page_label': '163', 'id': 'data/guideline-170-en.pdf:162:1'}, page_content='nicotinamide\\xa0(vitamin PP) PO [1]\\nIn the event of an epidemic of pellagra, for example in a refugee camp, it is vital that the food ration be modiﬁed\\n(add groundnuts or dry vegetables) in order to meet the daily requirements (approximately 15 mg daily for adults).\\n1. World Health Organization, United Nations High Commissions for Refugees.\\xa0Pellagra and its prevention and control in majoremergencies.\\xa0World Health Organization, 2000.http://www.who.int/nutrition/publications/en/pellagra_prevention_control.pdf [Accessed 23\\xa0May 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 163, 'page_label': '164', 'id': 'data/guideline-170-en.pdf:163:0'}, page_content='Page 164 / 409\\nChapter 5: Eye diseases\\nXerophthalmia (vitamin A deﬁciency)\\nConjunctivitis\\nNeonatal conjunctivitis\\nViral epidemic keratoconjunctivitis\\nTrachoma\\nPeriorbital and orbital cellulitis\\nOther pathologies\\nOnchocerciasis (river blindness)\\nLoiasis\\nPterygium\\nCataract'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 164, 'page_label': '165', 'id': 'data/guideline-170-en.pdf:164:0'}, page_content='Page 165 / 409\\nXerophthalmia (vitamin A deﬁciency)\\nThe term xerophthalmia covers all the ocular manifestations of vitamin A deﬁciency. Xerophthalmia can progress to\\nirreversible blindness if left untreated.\\xa0In endemic areas, vitamin A deﬁciency and xerophthalmia affect mainly children (particularly those suffering from\\nmalnutrition or measles) and pregnant women.\\xa0Disorders due to vitamin A deﬁciency can be prevented by the routine administration of retinol.\\nClinical features\\nTreatment\\nTreat early symptoms to avoid the development of severe complications. Vision can be saved provided that\\nulcerations affect less than a third of the cornea and the pupil is spared. Even if deﬁciency has already led to'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 164, 'page_label': '165', 'id': 'data/guideline-170-en.pdf:164:1'}, page_content='keratomalacia and irreversible loss of sight, it is imperative to administer treatment, in order to save the other eye and\\nthe life of the patient.\\xa0retinol (vitamin A) PO:\\nThe ﬁrst sign is hemeralopia (crepuscular blindness): the child cannot see in dim light, may bump into objects and/or\\nshow decreased mobility.\\nThen, other signs appear gradually:\\nConjunctival xerosis: bulbar conjunctiva appears dry, dull, thick, wrinkled and insensitive\\nBitot’s spots: greyish foamy patches on the bulbar conjunctiva, usually in both eyes (speciﬁc sign, however not\\nalways present)\\nCorneal xerosis: cornea appears dry and dull\\nCorneal ulcerations\\nKeratomalacia (the last and most severe sign of xerophthalmia): softening of the cornea, followed by'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 164, 'page_label': '165', 'id': 'data/guideline-170-en.pdf:164:2'}, page_content='perforation of the eyeball and blindness (extreme care must be taken during ophthalmic examination due to risk\\nof rupturing cornea)\\nTreatment is the same regardless of the clinical stage, except in pregnant women.\\nAge 200 000 IU capsule (a)\\nChildren < 6 months (b) 50 000 IU (2 drops) once daily\\xa0on D1, D2 and D8\\nChildren 6 months to < 1 year 100 000 IU (4 drops) once daily\\xa0on D1, D2 and D8\\nChildren\\xa0≥ 1 year and adults 200 000 IU (one capsule) once daily\\xa0on D1, D2 and D8\\n(a) Capsules must not be swallowed whole. Cut the end of the capsule and deliver the dose directly into the mouth.\\n(b) Vitamin A deﬁciency is rare in breastfed infants under 6 months.\\nIn pregnant women, treatment varies according to the stage of illness:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 164, 'page_label': '165', 'id': 'data/guideline-170-en.pdf:164:3'}, page_content=\"In pregnant women, treatment varies according to the stage of illness:\\nHemeralopia or Bitot's spots: 10 000 IU once daily or 25 000 IU once weekly for at least 4 weeks. Do not\\nexceed indicated doses (risk of foetal malformations).\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 165, 'page_label': '166', 'id': 'data/guideline-170-en.pdf:165:0'}, page_content='Page 166 / 409\\n\\xa0Corneal lesions are a medical emergency. In addition to the immediate administration of retinol, treat or prevent\\nsecondary bacterial infections with\\xa01% tetracycline eye ointment,\\xa0one application\\xa02 times daily (do not apply eye\\ndrops containing corticosteroids) and protect the eye with an eye-pad after each application.\\nPrevention\\nTo avoid excessive dosage, record any doses administered on the health/immunisation card and do not exceed\\nindicated doses. Vitamin A overdose may cause raised intracranial pressure (bulging fontanelle in infants; headache,\\nnausea, vomiting) and, in severe cases, impaired consciousness and convulsions. These adverse effects are transient;\\nthey require medical surveillance and symptomatic treatment if needed.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 165, 'page_label': '166', 'id': 'data/guideline-170-en.pdf:165:1'}, page_content='they require medical surveillance and symptomatic treatment if needed.\\n\\xa0\\nIf the cornea is affected, risk of blindness outweighs teratogenic risk. Administer 200 000 IU once daily on D1,\\nD2 and D8.\\nSystematically administer retinol PO to children suffering from measles (one dose on D1 and D2).\\nIn areas where vitamin A deﬁciency is endemic , routine supplementation of retinol PO: a \\nAge 200 000 IU capsule (c)\\nChildren < 6 months 50 000 IU (2 drops) single dose\\nChildren 6 months to < 1 year 100 000 IU (4 drops) every 4 to 6 months\\nChildren 1 to < 5 years 200 000 IU (one capsule) every 4 to 6 months\\nWomen after delivery 200 000 IU (one capsule) single dose\\n(c) Capsules must not be swallowed whole. Cut the end of the capsule and deliver the dose directly into the mouth.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 165, 'page_label': '166', 'id': 'data/guideline-170-en.pdf:165:2'}, page_content='Footnotes\\n(a) For more information country-speciﬁc prevalence of vitamin A deﬁciency, see:https://www.thelancet.com/action/showPdf?pii=S2214-109X%2815%2900039-X'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 166, 'page_label': '167', 'id': 'data/guideline-170-en.pdf:166:0'}, page_content='Page 167 / 409\\nConjunctivitis\\n\\xa0\\n\\xa0\\nConjunctivitis is an acute inﬂammation of the conjunctiva due to a bacterial or viral infection, allergy, or irritation.\\nConjunctivitis may be associated with measles or rhinopharyngitis in children.\\nIn the absence of hygiene and effective treatment, secondary bacterial infections may develop, affecting the cornea\\n(keratitis).\\nClinical features\\nTreatment\\nBacterial conjunctivitis\\nViral conjunctivitis\\nAllergic conjunctivitis\\n\\xa0\\nNote: in the event of a foreign body, check tetanus immunisation status.\\nNeonatal conjunctivitis\\nViral epidemic keratoconjunctivitis\\nClinical signs of all conjuctivites include: redness of the eye and irritation. Visual acuity is not affected.\\nDepending on the cause:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 166, 'page_label': '167', 'id': 'data/guideline-170-en.pdf:166:1'}, page_content='Depending on the cause:\\nabundant and purulent secretions, eyelids stuck together on waking, unilateral infection at onset: bacterial\\nconjunctivitis;\\nwatery (serous) secretions, no itching: viral conjunctivitis;\\nexcessive lacrimation, eyelid oedema, intense itching: allergic conjunctivitis.\\nIn endemic areas, turn both upper eyelids up to check for signs of trachoma (see\\xa0Trachoma).\\nSuspect keratitis if patient reports intense pain (more than is usually associated with conjunctivitis) and\\nphotophobia. Instill one drop of\\xa00.5% ﬂuorescein\\xa0to check for possible ulcerations.\\nAlways check for foreign bodies (subconjunctival or corneal) and remove after administering\\xa00.4%\\noxybuprocaine\\xa0anaesthetic eye drops. Never give bottle of eye drops to the patient.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 166, 'page_label': '167', 'id': 'data/guideline-170-en.pdf:166:2'}, page_content='Clean eyes 4\\xa0times daily with boiled water or 0.9% sodium chloride.\\nApply into both eyes\\xa01% tetracycline eye ointment:\\xa0one application\\xa02 times daily for 7 days\\nNever use corticosteroid drops or ointment.\\nClean eyes\\xa04\\xa0times daily with boiled water or 0.9% sodium chloride.\\nApply local antibiotics if there is a (risk of) secondary bacterial infection (see above).\\nLocal treatment as for viral conjunctivitis.\\nAntihistamines PO for one to 3 days (see\\xa0Urticaria, Chapter 4).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 167, 'page_label': '168', 'id': 'data/guideline-170-en.pdf:167:0'}, page_content='Page 168 / 409\\nNeonatal conjunctivitis\\nConjunctivitis due to Neisseria gonorrhoeae and/or Chlamydia trachomatis in neonates born to mothers with genital\\ngonococcal and/or chlamydial infections at the time of delivery.\\nNeonatal conjunctivitis is a medical emergency. Without prompt treatment, risk of corneal lesions and visual\\nimpairment.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0 If symptoms persist 48 hours after parenteral treatment alone, administer azithromycin PO (or erythromycin PO\\nas above).\\xa0Notes:\\nPrevention\\nApply as soon as possible and preferably within one hour after birth:\\n1% tetracycline eye ointment: application of 1 cm in each eye.\\n\\xa0\\nReferences\\nUnilateral or bilateral purulent conjunctivitis in the ﬁrst 28 days of life.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 167, 'page_label': '168', 'id': 'data/guideline-170-en.pdf:167:1'}, page_content='Unilateral or bilateral purulent conjunctivitis in the ﬁrst 28 days of life.\\nClean eyes with isotonic sterile solution (0.9% sodium chloride or Ringer lactate) 4 times daily to remove secretions.\\nAntibiotic treatment:\\nfor all neonates with conjunctivitis in the ﬁrst 28 days of life\\nfor all neonates born to mothers with a genital infection\\xa0(purulent cervical discharge) at the time of delivery\\xa0\\n\\xa0 0 to 7 days 8 to 28 days\\nFirst line\\n\\xa0\\nceftriaxone IM: 50 mg/kg single dose\\n(max. 125 mg)\\n\\xa0\\nceftriaxone IM: 50 mg/kg single dose\\n(max. 125 mg)\\n+\\nazithromycin PO: 20 mg/kg once daily for\\n3 days\\nAlternatives If ceftriaxone contra-indicated:\\ncefotaxime IM: 100 mg/kg single dose\\nIf azithromycin unavailable:\\nerythromycin PO: 12.5 mg/kg 4 times daily for\\n14 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 167, 'page_label': '168', 'id': 'data/guideline-170-en.pdf:167:2'}, page_content='erythromycin PO: 12.5 mg/kg 4 times daily for\\n14 days\\nWhen systemic treatment is not immediately available, clean both eyes and apply 1% tetracycline eye\\nointment\\xa0every hour, until systemic treatment is available.\\nIn all cases, treat the genital infection of the mother and partner (see Genital infections, Chapter 9).\\nAzithromycin and erythromycin are associated with an increased risk of pyloric stenosis in neonates. The risk is\\nhigher\\xa0with erythromycin . Adverse effects should be monitored. [1] [2] [3]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 168, 'page_label': '169', 'id': 'data/guideline-170-en.pdf:168:0'}, page_content='Page 169 / 409\\n1. Lund M et al. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohortstudy. BMJ. 2014; 348: g1908.https://www.bmj.com/content/348/bmj.g1908 [Accessed 16 April 2021]\\n2. Murchison L et al. Post-natal erythromycin exposure and risk of infantile hypertrophic pyloric stenosis: a systematic reviewand meta-analysis. Pediatr Surg Int. 2016 Dec; 32(12): 1147-1152.\\xa0https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106491/ [Accessed 16 April 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 168, 'page_label': '169', 'id': 'data/guideline-170-en.pdf:168:1'}, page_content='3. Almaramhy HH et al. The association of prenatal and postnatal macrolide exposure with subsequent development ofinfantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. Ital J Pediatr. 2019 Feb 4; 45(1)20.\\xa0https://ijponline.biomedcentral.com/articles/10.1186/s13052-019-0613-2 [Accessed 16 April 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 169, 'page_label': '170', 'id': 'data/guideline-170-en.pdf:169:0'}, page_content='Page 170 / 409\\nViral epidemic keratoconjunctivitis\\n\\xa0\\nCorneal and conjunctival lesions\\n\\xa0\\nTreat as viral conjunctivitis. If possible, refer to an ophthalmologist.\\nProtect the eye with a compress as long as photophobia lasts. Remove as soon as possible.\\nIf necessary, administer a preventive dose of\\xa0vitamin A.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 170, 'page_label': '171', 'id': 'data/guideline-170-en.pdf:170:0'}, page_content='Page 171 / 409\\nTrachoma\\nTrachoma is a highly contagious keratoconjunctivitis due to Chlamydia trachomatis. The disease is endemic in the\\npoorest rural areas of Africa, Asia, Central and South America and the Middle East.\\nInfection is usually ﬁrst contracted early in childhood by direct or indirect contact (dirty hands, contaminated towels,\\nﬂies). In the absence of hygiene and effective treatment, the inﬂammation intensiﬁes with successive infections,\\ncausing scars and deformities on the upper tarsal conjunctiva. The resulting ingrowing eyelashes (trichiasis) cause\\ncorneal lesions followed by permanent blindness, usually in adulthood.\\nThe WHO classiﬁes trachoma into 5 stages. Early diagnosis and treatment of ﬁrst stages is essential to avoid the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 170, 'page_label': '171', 'id': 'data/guideline-170-en.pdf:170:1'}, page_content='development of trichiasis and associated complications.\\nClinical features\\nSeveral stages can occur simultaneously :\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nTreatment\\n\\xa0\\n\\xa0\\n [1] [2] \\nStage 1: trachomatous inﬂammation - follicular (TF)\\nPresence of ﬁve or more follicles in the upper tarsal conjunctiva. Follicles are whitish, grey or yellow elevations,\\npaler than the surrounding conjunctiva.\\nStage 2: trachomatous inﬂammation - intense (TI)\\nThe upper tarsal conjunctiva is red, rough and thickened. The blood vessels, normally visible, are masked by a\\ndiffuse inﬂammatory inﬁltration or follicles.\\nStage 3: trachomatous scarring (TS)\\nFollicles disappear, leaving scars: scars are white lines, bands or patches in the tarsal conjunctiva.\\nStage 4: trachomatous trichiasis (TT)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 170, 'page_label': '171', 'id': 'data/guideline-170-en.pdf:170:2'}, page_content='Stage 4: trachomatous trichiasis (TT)\\nDue to multiple scars the margin of the eyelid, usually the upper lid, turns inwards (entropion); the eyelashes rub\\nagainst the cornea and cause ulcerations and chronic inﬂammation.\\nStage 5: corneal opacity (CO)\\nCornea gradually loses its transparency, leading to visual impairment and blindness.\\nStages 1 and 2:\\nClean eyes and face several times per day.\\nAntibiotic treatment :\\nThe treatment of choice is azithromycin PO:\\nChildren: 20 mg/kg single dose\\nAdults: 1 g single dose\\nFailing the above, 1% tetracycline eye ointment: one application 2 times daily for 6 weeks, or, as a last resort,\\nerythromycin PO: 20 mg/kg (max. 1 g) 2 times daily for 14 days.\\n [3] \\nStage 3: no treatment\\nStage 4: surgical treatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 170, 'page_label': '171', 'id': 'data/guideline-170-en.pdf:170:3'}, page_content='[3] \\nStage 3: no treatment\\nStage 4: surgical treatment\\nWhile waiting for surgery, if regular patient follow-up is possible, taping eyelashes to the eyelid is a palliative\\nmeasure that can help protect the cornea. In certain cases, this may lead to permanent correction of the trichiasis\\nwithin a few months.\\nThe method consists in sticking the ingrowing eyelashes to the external eyelid with a thin strip of sticking-plaster,\\nmaking sure that the eyelid can open and close perfectly. Replace the plaster when it starts to peel off (usually once\\na week); continue treatment for 3 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 171, 'page_label': '172', 'id': 'data/guideline-170-en.pdf:171:0'}, page_content='Page 172 / 409\\n\\xa0\\nPrevention\\nCleaning of the eyes, face and hands with clean water reduces direct transmission and the development of secondary\\nbacterial infections.\\n\\xa0\\nReferences\\nNote: epilation of ingrowing eyelashes is not recommended since it offers only temporary relief and regrowing\\neyelashes are more abrasive to the cornea.\\nStage 5: no treatment\\n1. Solomon AW et al. The simpliﬁed trachoma grading system, amended.\\xa0Bull World Health Organ. 2020;98(10):698-705.\\xa0https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652564/\\xa0[Accessed 20 April 2021]\\n2. Thylefors B et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ.1987;65(4):477–83.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491032/\\xa0[Accessed 20 April 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 171, 'page_label': '172', 'id': 'data/guideline-170-en.pdf:171:1'}, page_content='3. Evans JR et al. Antibiotics for trachoma. Cochrane Database Syst Rev. 2019 Sep 26;9:CD001860.\\xa0https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001860.pub4/full\\xa0[Accessed 20 April 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 172, 'page_label': '173', 'id': 'data/guideline-170-en.pdf:172:0'}, page_content='Page 173 / 409\\nPeriorbital and orbital cellulitis\\nPeriorbital cellulitis is a common, usually benign, bacterial infection of the eyelids. It arises principally following trauma\\nto the eyelids (insect bite or abrasion).\\nOrbital cellulitis is a serious infection involving the contents of the orbit (fat and ocular muscles) that may lead to loss of\\nvision or a brain abscess. It usually arises secondary to spread from sinusitis (e.g. as a complication of ethmoid\\nsinusitis).\\nPeriorbital and orbital cellulitis are more common in children than in adults.\\nThe most common organisms causing periorbital and orbital cellulitis are\\xa0Staphylococcus aureus, Streptococcus\\npneumoniae\\xa0and other streptococci, as well as\\xa0Haemophilus inﬂuenzae type b\\xa0(Hib) in children living in countries where'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 172, 'page_label': '173', 'id': 'data/guideline-170-en.pdf:172:1'}, page_content='rates of immunisation with Hib remain low.\\nClinical features\\nTreatment\\n\\xa0\\n\\xa0\\nSigns common to both periorbital and orbital cellulitis: acute eyelid erythema and oedema; the oedema has a\\nviolaceous hue if secondary to\\xa0H. inﬂuenzae.\\nIn case of orbital cellulitis only:\\nPain with eye movements;\\nOphthalmoplegia (paralysis of eye movements) often with diplopia (double vision);\\nProtrusion of the eye (eye bulges out of the socket);\\nHigh fever, systemic signs.\\nHospitalize for the following: orbital cellulitis, children younger than 3 months, critically ill appearing patient , local\\ncomplications, debilitated patient (chronic conditions, the elderly), if there is a risk of non-compliance with or failure\\nof outpatient treatment. Treat the other patients as outpatients.\\n a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 172, 'page_label': '173', 'id': 'data/guideline-170-en.pdf:172:2'}, page_content='of outpatient treatment. Treat the other patients as outpatients.\\n a \\nOutpatient antibiotic therapy :\\ncefalexin\\xa0PO for 7 to 10 days\\nNeonates 0 to 7 days: 25 mg/kg 2 times daily\\xa0\\nNeonates 8 days to 1 month:\\xa025 mg/kg 3 times daily\\xa0\\nChildren over 1 month: 25 mg/kg 2 times daily\\xa0(max. 2 g daily)\\nChildren ≥ 40 kg and adults: 1 g\\xa02 times daily\\nor\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO for 7 to 10 days\\nUse formulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose is expressed in amoxicillin:\\nChildren < 40 kg: 50 mg/kg 2 times daily\\nChildren ≥ 40 kg and adults:\\nRatio 8:1: 3000 mg daily (2 tab of 500/62.5 mg 3 times daily)\\nRatio 7:1: 2625 mg daily (1 tab of 875/125 mg 3 times\\xa0daily)\\n b \\nInpatient antibiotic therapy :'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 172, 'page_label': '173', 'id': 'data/guideline-170-en.pdf:172:3'}, page_content='b \\nInpatient antibiotic therapy :\\nceftriaxone\\xa0slow IV (3 minutes) or IV infusion (30 minutes; 60 minutes in neonates) for at least 5 days\\nChildren: one dose of 100 mg/kg on the ﬁrst day, then 50 mg/kg 2 times daily\\nAdults: 1 to 2 g once daily\\n+\\ncloxacillin\\xa0IV infusion (60 minutes)\\nNeonates 0 to 7 days (< 2 kg): 50 mg/kg every 12 hours\\n c \\n d \\n e'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 173, 'page_label': '174', 'id': 'data/guideline-170-en.pdf:173:0'}, page_content='Page 174 / 409\\n\\xa0 If there is no improvement in the ﬁrst 48 hours (suspicion of methicillin resistant S. aureus), replace cloxacillin with:\\nclindamycin\\xa0IV infusion (30 minutes)\\nNeonates 0 to 7 days (< 2 kg): 5 mg/kg\\xa0every 12 hours\\nNeonates 0 to 7 days (≥ 2 kg): 5 mg/kg\\xa0every 8 hours\\nNeonates 8 days to < 1 month (< 2 kg):\\xa05 mg/kg\\xa0every 8 hours\\nNeonates 8 days to < 1 month (≥ 2 kg): 10 mg/kg\\xa0every 8 hours\\nChildren 1 month and over: 10 mg/kg\\xa0every 8 hours\\xa0(max. 1800 mg daily)\\nAdults:\\xa0600 mg every 8 hours\\nAfter 5 days, change to clindamycin PO at the same doses to complete 7 to 10 days of treatment.\\xa0\\n\\xa0\\nNeonates 0 to 7 days (≥ 2 kg):\\xa050 mg/kg every 8 hours\\nNeonates 8 days to < 1 month (< 2 kg):\\xa050 mg/kg every 8 hours\\nNeonates 8 days to < 1 month (≥ 2 kg):\\xa050 mg/kg every 6 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 173, 'page_label': '174', 'id': 'data/guideline-170-en.pdf:173:1'}, page_content='Neonates 8 days to < 1 month (≥ 2 kg):\\xa050 mg/kg every 6 hours\\nChildren 1 month and over: 25 to 50 mg/kg every 6 hours\\xa0(max. 8 g daily)\\nChildren ≥ 40 kg and adults: 2 g\\xa0every 6 hours\\nIf there is clinical improvement (patient afebrile and erythema and oedema have improved) after 5 days, change to\\namoxicillin/clavulanic acid PO at the doses indicated above to complete 7 to 10 days of treatment.\\n f \\nIf orbital cellulitis is unresponsive to IV antibiotics, consider an abscess. Transfer patient to a surgical centre for\\ndrainage.\\nFootnotes\\n(a) Critically ill appearing child: weak grunting or crying, drowsy and difﬁcult to arrouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 173, 'page_label': '174', 'id': 'data/guideline-170-en.pdf:173:2'}, page_content='(b) For penicillin-allergic patients, clindamycin PO for 7 to 10 days:Children: 10 mg/kg 3 times daily; adults: 600 mg 3 times daily\\n(c) For penicillin-allergic patients, clindamycin IV infusion (doses as above).\\n(d) For administration by IV route, ceftriaxone powder should to be reconstituted in water for injection only. For administrationby IV infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kgand in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 173, 'page_label': '174', 'id': 'data/guideline-170-en.pdf:173:3'}, page_content='(e) Cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. Then dilute each dose of cloxacillin in5 ml/kg of 0.9% sodium chloride or 5 % glucose in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or5% glucose in children over 20 kg and in adults.\\n(f) Dilute each dose of clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of100 ml of 0.9% sodium chloride or 5% glucose in children over 20 kg and in adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 174, 'page_label': '175', 'id': 'data/guideline-170-en.pdf:174:0'}, page_content='Page 175 / 409\\nOther pathologies\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nOnchocerciasis\\nLoiasis\\nPterygium\\nCataract'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 175, 'page_label': '176', 'id': 'data/guideline-170-en.pdf:175:0'}, page_content='Page 176 / 409\\nOnchocerciasis (river blindness)\\nOcular lesions result from the invasion of the eye by microﬁlariae. They generally develop in adults and progress to\\nblindness in the absence of early treatment.\\nClinical features and treatment\\nOcular lesions are always associated with onchocercal skin lesions (see Onchocerciasis, Chapter 6).\\n\\xa0For treatment, see Onchocerciasis, Chapter 6. Ivermectin treatment may improve anterior segment lesions (sclerosing\\nkeratitis, iridocyclitis) and visual acuity. Severe lesions (chorioretinal lesions, optic atrophy) continue to progress despite\\ntreatment.\\nPruritus, hemeralopia (crepuscular blindness), decrease in visual acuity, narrowing of the visual ﬁeld, awareness of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 175, 'page_label': '176', 'id': 'data/guideline-170-en.pdf:175:1'}, page_content='microﬁlariae in the visual ﬁeld (the patient sees “little wiggling worms before his eyes”).\\nLesions of the cornea (punctuate, then sclerosing, keratitis), iris (iridocyclitis) or posterior segment\\n(chorioretinopathy and optic atrophy); microﬁlariae within the anterior chamber or vitreous humor (slit lamp).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 176, 'page_label': '177', 'id': 'data/guideline-170-en.pdf:176:0'}, page_content='Page 177 / 409\\nLoiasis\\nClinical features and treatment\\nMigration of an adult worm under the palpebral or bulbar conjunctiva (white, ﬁliform worm, measuring 4 to 7 cm in\\nlength, mobile) and ocular pruritus, lacrimation, photophobia or eyelid oedema.\\xa0For treatment, see\\xa0Loiais, Chapter 6. The migration of the worm is often of very brief duration. Do not attempt to\\nextract it, or administer anaesthetic drops; simply reassure the patient, the event is harmless. Surgical removal is\\nlikewise futile if the worm is dead/calciﬁed.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 177, 'page_label': '178', 'id': 'data/guideline-170-en.pdf:177:0'}, page_content='Page 178 / 409\\nPterygium\\nA whitish, triangular growth of ﬁbrovascular tissue extending slowly from the conjunctiva to the cornea. It occurs most\\nfrequently in patients who are exposed to wind, dust, or arid climates and never disappears spontaneously.\\nClinical features and treatment\\nTwo stages:\\nBenign pterygium develops slowly, does not reach the pupil: no treatment.\\nProgressive vascularized pterygium: red and inﬂamed growth covers the pupil and may impair vision:\\nClean eye with sterile water or 0.9% sodium chloride.\\nSurgical removal if facilities are available.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 178, 'page_label': '179', 'id': 'data/guideline-170-en.pdf:178:0'}, page_content='Page 179 / 409\\nCataract\\n\\xa0\\n\\xa0\\nOpacity of the lens that causes a progressive loss of visual acuity. Cataract is common in the tropics and can occur at\\na younger age than in Europe. The presence of cataract in both eyes leads to blindness. Surgery is the only treatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 179, 'page_label': '180', 'id': 'data/guideline-170-en.pdf:179:0'}, page_content='Page 180 / 409\\nChapter 6: Parasitic diseases\\nMalaria\\nHuman African trypanosomiasis (sleeping sickness)\\nAmerican trypanosomiasis (Chagas disease)\\nLeishmaniases\\nIntestinal protozoan infections (parasitic diarrhoea)\\nFlukes\\nSchistosomiases\\nCestodes\\nNematode infections\\nFilariasis\\nOnchocerciasis (river blindness)\\nLoiasis\\nLymphatic ﬁlariasis (LF)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 180, 'page_label': '181', 'id': 'data/guideline-170-en.pdf:180:0'}, page_content='Page 181 / 409\\nMalaria\\nMalaria is a parasitic infection due to protozoa of the genus Plasmodium, transmitted to humans by the bite of\\nAnopheles mosquitoes. Transmission by transfusion of parasite infected blood and transplacental transmission are\\nalso possible.\\n5 species of Plasmodium cause malaria in humans: P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. All\\nspecies may cause uncomplicated malaria. Severe malaria (deﬁned by the presence of complications) is almost always\\ndue to P. falciparum. and, less frequently, P. vivax and P. knowlesi.\\nUncomplicated malaria can rapidly progress to severe malaria, and severe malaria may cause death within a few hours\\nif left untreated.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 180, 'page_label': '181', 'id': 'data/guideline-170-en.pdf:180:1'}, page_content='if left untreated.\\nClinical features\\nMalaria should always be considered in patients living in or coming from, an endemic area, who presents with fever (or\\nhistory of fever in the previous 48 hours).\\xa0\\nUncomplicated malaria\\nFever is frequently associated with chills, sweating, headache, muscular ache, malaise, anorexia or nausea. In children,\\nfever may be associated with abdominal pain, diarrhoea and vomiting. Mild to moderate anaemia is frequent in children\\nand pregnant women.\\nSevere malaria\\nIn addition to the above, patients presenting with one or more of the following complications \\xa0should be hospitalised\\nimmediately:\\nLaboratory\\nParasitological diagnosis\\nDiagnosis of malaria should be conﬁrmed, whenever possible. If testing is not available, treatment of suspected malaria'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 180, 'page_label': '181', 'id': 'data/guideline-170-en.pdf:180:2'}, page_content='should not be delayed.\\xa0\\xa0Rapid diagnostic tests (RDTs)\\nRapid tests detect parasite antigens. They give only a qualitative result (positive or negative) and may remain positive\\nseveral days or weeks following elimination of parasites.\\xa0\\n [1] \\nImpaired consciousness, including coma.\\nSeizures: more than 2 episodes of generalised or focal (e.g. abnormal eye movements) seizures within 24 hours.\\nProstration:\\xa0extreme weakness; in children: inability to sit or drink/suck.\\nRespiratory distress: rapid, laboured breathing or slow, deep breathing.\\nShock: cold extremities, weak or absent pulse, capillary reﬁll time ≥ 3 seconds, cyanosis.\\nJaundice:\\xa0yellow discolouration of mucosal surfaces of the mouth, conjunctivae and palms.\\nHaemoglobinuria: dark red urine.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 180, 'page_label': '181', 'id': 'data/guideline-170-en.pdf:180:3'}, page_content='Haemoglobinuria: dark red urine.\\nAbnormal bleeding: skin (petechiae), conjunctivae, nose, gums; blood in stools.\\nAcute renal failure: oliguria (urine output < 12 ml/kg/day in children and < 400 ml/day in adults) despite adequate\\nhydration.\\n [2]\\n a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 181, 'page_label': '182', 'id': 'data/guideline-170-en.pdf:181:0'}, page_content='Page 182 / 409\\nMicroscopy\\nThin and thick blood ﬁlms enable parasite detection, species identiﬁcation, quantiﬁcation and monitoring of\\nparasitaemia.\\nBlood ﬁlms may be negative due to sequestration of the parasitized erythrocytes in peripheral capillaries in severe\\nmalaria, as well as in placental vessels in pregnant women.\\xa0Note: even with positive diagnostic results, rule out other causes of fever.\\nAdditional examinations\\nHaemoglobin (Hb) level\\nTo be measured routinely in all patients with clinical anaemia, and in all patients with severe malaria.\\xa0Blood glucose level\\nTo be measured routinely to detect hypoglycaemia in patients with severe malaria and those with malnutrition (see\\nHypoglycaemia, Chapter 1).\\nTreatment of malaria due to P. vivax, P. ovale, P. malariae, P. knowlesi'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 181, 'page_label': '182', 'id': 'data/guideline-170-en.pdf:181:1'}, page_content='Treatment of malaria due to P. vivax, P. ovale, P. malariae, P. knowlesi\\nchloroquine (CQ) PO\\nChildren and adults:\\nDay 1: 10 mg base/kg\\nDay 2: 10 mg base/kg \\nDay 3: 5 mg base/kg\\xa0In general P. vivax remains sensitive to CQ but resistance is found in several countries. Where such resistance is high\\n(>10%), or in countries which have de-registered CQ due to P. falciparum resistance, an artemisinin-based combination\\ntherapy (ACT) \\xa0should be used instead .\\xa0For dosing information, see Treatment of uncomplicated falciparum malaria.\\xa0Relapses can occur with P. vivax and P. ovale\\xa0due to activation of dormant parasites in the liver.\\xa0Primaquine PO for 14\\ndays (0.25 to 0.5 mg/kg once daily in children\\xa0≥ 15 kg; 15 mg once daily in adults)\\xa0can be given to eliminate these'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 181, 'page_label': '182', 'id': 'data/guideline-170-en.pdf:181:2'}, page_content='parasites, after the initial treatment with CQ or an ACT.\\xa0However, this treatment is only recommended for patients living\\nin areas where reinfection is unlikely, i.e. non-endemic,\\xa0low transmission areas or in countries aiming for elimination of\\nmalaria.\\xa0This treatment is contra-indicated in individuals with G6PD deﬁciency. If G6PD deﬁciency cannot be tested\\nindividually, the decision to prescribe primaquine must take into account the prevalence of deﬁciency in the population.\\nTreatment of uncomplicated falciparum malaria\\nAntimalarial treatment\\nDuring pregnancy, see Antimalarial treatment in pregnant women.\\xa0Treatment is an artemisinin-based combination therapy (ACT) given by the oral route for 3 days .\\xa0The ﬁrst-line ACT'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 181, 'page_label': '182', 'id': 'data/guideline-170-en.pdf:181:3'}, page_content='is chosen according to therapeutic efﬁcacy in the area where the patient is living.\\xa0If the ﬁrst line ACT is unavailable,\\ncontra-indicated or has failed despite being correctly administered, use another ACT. For dosing information, see table\\nbelow.\\xa0\\n b \\n c  [1] \\n c \\xa0  [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 182, 'page_label': '183', 'id': 'data/guideline-170-en.pdf:182:0'}, page_content='Page 183 / 409\\nTreatment of uncomplicated falciparum malaria\\nIn low malaria endemic areas, in addition to ACT, all individuals (except in children < 30 kg,\\xa0 pregnant women or\\nbreastfeeding women of infants aged < 6 months) diagnosed with P. falciparum malaria, should be given a single dose\\nof 0.25 mg/kg primaquine to reduce the risk of transmission .\\xa0Notes:\\n\\xa0Quinine PO is not recommended as standard treatment, however still remains in some national protocols:\\nquinine PO\\xa0for 7 days\\nChildren and adults under 50 kg: 10 mg/kg 3 times daily\\nAdults 50 kg and over: 600 mg\\xa03 times daily\\nSymptomatic treatment\\nParacetamol PO in the event of high fever only (Fever, Chapter 1).\\nTreatment of severe malaria\\nThe patient must be hospitalised.\\nAntimalarial treatment\\n b \\n [3]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 182, 'page_label': '183', 'id': 'data/guideline-170-en.pdf:182:1'}, page_content='The patient must be hospitalised.\\nAntimalarial treatment\\n b \\n [3] \\nIn infants below the age/weight mentioned in the table above, there is little data on efﬁcacy and safety of ACTs.\\nThe combinations AL, AS/AQ and DHA/PPQ can be used. The dose should be calculated so as to correspond to\\n10-16 mg/kg/dose of lumefantrine; 10 mg/kg daily of amodiaquine; 20 mg/kg daily of piperaquine.\\nClinical condition of young children can deteriorate rapidly; it may be preferable to start parenteral treatment\\nstraight away (see below).\\n b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 183, 'page_label': '184', 'id': 'data/guideline-170-en.pdf:183:0'}, page_content='Page 184 / 409\\nDuring pregnancy, see Antimalarial treatment in pregnant women.\\nPre-referral treatment\\nIf the patient needs to be transferred,\\xa0administer\\xa0before transfer:\\nor\\n\\xa0In either case, provide patients, especially children, with some sugar prior to or during transfer.\\nInpatient treatment\\nThe drug of choice is artesunate, preferably IV, or if not possible\\xa0IM.\\nFor patients in shock: IM route is not appropriate, use artesunate IV only.\\xa0\\xa0artesunate slow IV injection (3 to 5 minutes) or, if not possible, slow IM injection, into the anterior thigh:\\nChildren under 20 kg: 3 mg/kg/dose\\nChildren 20 kg and over and adults: 2.4 mg/kg/dose\\nTreat parenterally for at least 24 hours (3 doses), then, if the patient can tolerate the oral route, change to a complete'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 183, 'page_label': '184', 'id': 'data/guideline-170-en.pdf:183:1'}, page_content='3-day course of an ACT.\\xa0If not, continue parenteral treatment once daily until the patient can change to oral route\\n(without exceeding 7 days of parenteral treatment).\\xa0If artesunate is not unavailable, artemether may be an alternative: \\nartemether IM into the anterior thigh (never administer by IV route)\\nChildren and adults: 3.2 mg/kg on admission (D1) then 1.6 mg/kg once daily\\nTreat parenterally for at least 24 hours (2 doses), then, if the patient can tolerate the oral route, change to\\xa0a complete\\n3-day course of\\xa0an ACT.\\xa0If not, continue parenteral treatment once daily until the patient can change to oral route\\n(without exceeding 7 days of parenteral treatment).\\xa0Note:\\xa0if patient is still on parenteral treatment on Day 5, continue on the same treatment until Day 7. In this case it is'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 183, 'page_label': '184', 'id': 'data/guideline-170-en.pdf:183:2'}, page_content='not necessary to start an ACT.\\n\\xa0\\nQuinine IV is still recommended in some national protocols. It may be used in treatment of malaria with shock if\\nartesunate IV is not available. The dose is expressed in quinine salt:\\nFor adults, administer each dose of quinine in 250 ml of glucose. For children under 20 kg, administer each dose of\\nquinine in a volume of 10 ml/kg of glucose.\\nDo not administer a loading dose to patients who have received oral quinine, or meﬂoquine within the previous 24\\nhours: start with maintenance dose.\\nTreat\\xa0parenterally for at least 24 hours, then, if the patient can tolerate the oral route, change to\\xa0a complete 3-day\\ncourse of\\xa0an ACT (or if not available, oral quinine to complete 7 days of quinine treatment).\\xa0If not, continue parenteral'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 183, 'page_label': '184', 'id': 'data/guideline-170-en.pdf:183:3'}, page_content='treatment until the patient can change to oral route (without exceeding 7 days of parenteral treatment).\\nAt community level,\\xa0for children under 6 years: one dose of rectal artesunate \\xa0(10 mg/kg) d \\nChildren 2 months to < 3 years (≤ 10 kg): 1 rectal capsule (100 mg)\\nChildren 3 to\\xa0< 6 years (≤ 20 kg): 2 rectal capsules (200 mg)\\nAt dispensary level,\\xa0for children and adults:\\xa0the ﬁrst dose of artesunate or, if\\xa0unavailable, the ﬁrst dose of\\nartemether. For dosing information, see below.\\nOne dose on admission (H0)\\nOne dose 12 hours after admission (H12)\\nOne dose 24 hours after admission (H24)\\nThen one dose once daily\\nLoading dose: 20 mg/kg to be administered over 4 hours, then, keep the vein open with an infusion of 5% glucose\\nover 4 hours; then'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 183, 'page_label': '184', 'id': 'data/guideline-170-en.pdf:183:4'}, page_content='over 4 hours; then\\nMaintenance dose: 8 hours after the start of the loading dose, 10 mg/kg every 8 hours (alternate quinine over 4\\nhours and 5% glucose over 4 hours).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 184, 'page_label': '185', 'id': 'data/guideline-170-en.pdf:184:0'}, page_content='Page 185 / 409\\nSymptomatic treatment and management of complications\\nHydration\\nMaintain adequate hydration. As a guide, for volume to be administered per 24 hours by oral or IV route,\\xa0see Appendix\\n1.\\nAdjust the volume according to clinical condition in order to avoid dehydration or ﬂuid overload (risk of pulmonary\\noedema).\\nFever\\nParacetamol in the event of high fever only (Fever, Chapter 1).\\nSevere anaemia\\nFor treatment, see Anaemia, Chapter 1.\\nHypoglycaemia\\nFor treatment, see\\xa0Hypoglycaemia, Chapter 1.\\xa0Notes:\\xa0\\nComa\\nCheck/ensure the airway is clear, measure blood glucose level and assess level of consciousness.\\nIn the event of hypoglycaemia or if blood glucose level cannot be measured, administer glucose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 184, 'page_label': '185', 'id': 'data/guideline-170-en.pdf:184:1'}, page_content='If the patient does not respond to administration of glucose, or if hypoglycaemia is not detected:\\nSeizures\\nSee Seizures, Chapter 1. Address possible causes (e.g. hypoglycaemia; fever in children).\\nRespiratory distress\\n\\xa0\\nOliguria and acute renal failure\\nIn an unconscious or prostrated patient, in case of emergency or when venous access is unavailable or awaited, use\\ngranulated sugar by the sublingual route to correct hypoglycaemia . e \\nThe risk of hypoglycaemia is higher in patients receiving IV quinine.\\xa0\\nInsert a urinary catheter; place the patient in the recovery position.\\nMonitor vital signs, blood glucose level, level of consciousness, ﬂuid balance (urine output and ﬂuid input) hourly until\\nstable, then every 4 hours.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 184, 'page_label': '185', 'id': 'data/guideline-170-en.pdf:184:2'}, page_content='stable, then every 4 hours.\\nRule out meningitis (lumbar puncture) or proceed directly to administration of an antibiotic (see Meningitis, Chapter\\n7).\\nReposition the patient every 2 hours; ensure eyes and mouth are kept clean and moist, etc.\\nRapid laboured breathing:\\nCheck for pulmonary oedema (crepitations on auscultation), which may occur with or without ﬂuid overload: reduce\\nIV infusion rate if the patient is receiving IV therapy, nurse semi-sitting, oxygen, furosemide IV: 1 mg/kg in children,\\n40 mg in adults. Repeat after 1 to 2 hours if necessary.\\nAssociated pneumonia should also be considered (see Acute pneumonia, Chapter 2).\\nSlow, deep breathing (suspected metabolic acidosis):\\nLook for dehydration (and correct if present), decompensated anaemia (and transfuse if present).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 185, 'page_label': '186', 'id': 'data/guideline-170-en.pdf:185:0'}, page_content='Page 186 / 409\\nLook ﬁrst for dehydration (Dehydration, Chapter 1), especially due to inadequate ﬂuid intake or excessive ﬂuid losses\\n(high fever, vomiting, diarrhoea). Treat dehydration if present. Be aware of the risk of ﬂuid overload and acute\\npulmonary oedema. Monitor for the return of urine output.\\xa0Acute renal failure (ARF) is found almost exclusively in adults and is more common in Asia than Africa. Insert a urinary\\ncatheter, measure output. Restrict ﬂuids to 1 litre/day (30 ml/kg/day in children), plus additional volume equal to urine\\noutput. Renal dialysis is often necessary.\\nAntimalarial treatment in pregnant women\\nUncomplicated P. vivax, P. ovale, P. malariae, P. knowlesi malaria\\nAs other patients.\\nPrimaquine should not be given in pregnancy.\\nUncomplicated falciparum malaria'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 185, 'page_label': '186', 'id': 'data/guideline-170-en.pdf:185:1'}, page_content='Primaquine should not be given in pregnancy.\\nUncomplicated falciparum malaria\\nAll ACT\\xa0included in the table\\xa0Treatment of uncomplicated falciparum malaria\\xa0can be used in all trimesters.\\nIf ACTs are not available, quinine PO (for dosing, see\\xa0Treatment of uncomplicated falciparum malaria)\\ncombined\\xa0with\\xa0clindamycin PO\\xa0if possible\\xa0(10 mg/kg 2 times daily for 7 days) may be an alternative to ACT.\\nPrimaquine should not be given in pregnancy.\\nSevere malaria\\nArtesunate, or if unavailable artemether, is recommended in all trimesters.\\nQuinine IV is not recommended as standard treatment, however\\xa0it still remains\\xa0in some national protocols.\\nPrevention\\n\\xa0\\nFor pregnant women in areas with high risk of infection with P. falciparum, refer to the guide Essential obstetric and\\nnewborn care, MSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 185, 'page_label': '186', 'id': 'data/guideline-170-en.pdf:185:2'}, page_content='newborn care, MSF.\\nIn areas with seasonal malaria transmission (in particular across the Sahel sub-region), seasonal malaria\\nchemoprevention in children < 5 years reduces mortality: administer amodiaquine + SP at monthly intervals for 4\\nmonths during the transmission period . [4] \\nIn malaria endemic areas and in epidemic-prone contexts, all in-patient facilities (including HIV treatment centres\\nand feeding centres), should be furnished with long-lasting insecticidal nets (LLINs). For more information, refer to\\nthe guide Public health engineering, MSF.\\nSee\\xa0specialised literature for information regarding anti-vector measures and prevention in travellers.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 185, 'page_label': '186', 'id': 'data/guideline-170-en.pdf:185:3'}, page_content='Footnotes\\n(a) Most rapid tests detect the following antigens alone or in combination: HRP2 protein speciﬁc to P. falciparum; an enzyme(Pf pLDH) speciﬁc to P. falciparum; an enzyme (pan pLDH) common to all 4 plasmodium species. HRP2 may continue to bedetectable for\\xa06\\xa0weeks or more after parasite clearance; pLDH remains detectable for several days (up to 2 weeks) afterparasite clearance.Use pan pLDH tests as ﬁrst choice in hyper and holo-endemic areas, as well as in areas of intense seasonal transmission andduring outbreaks or complex emergencies. In other contexts, HRP2 tests (P. falciparum > 95%) or HRP2 + pLDH combinationtests (P. falciparum < 95%) are preferred.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 185, 'page_label': '186', 'id': 'data/guideline-170-en.pdf:185:4'}, page_content='(b) If the patient vomits within 30 minutes after\\xa0administration: re-administer the full dose.\\xa0If the patient vomits between 30minutes and 1 hour after administration,\\xa0re-administer half of the dose. If severe vomiting precludes oral therapy, manage assevere malaria, see Treatment of severe malaria.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 186, 'page_label': '187', 'id': 'data/guideline-170-en.pdf:186:0'}, page_content='Page 187 / 409\\nReferences\\n(c) ACT: a combination of artemisinin or one of its derivatives (e.g. artesunate, artemether) with another antimalarial of adifferent class.\\n(d) If it is impossible to refer a patient to a center capable of providing parenteral treatment, rectal artesunate should be givenaccording to the same schedule as artesunate slow IV injection (H0, H12, H24, then once daily).\\n(e) Place a level teaspoon of sugar, moistened with a few drops of water, under the tongue, then place the patient in therecovery position. Repeat after 15 minutes if the patient has not regained consciousness. As with other methods fortreating hypoglycaemia, maintain regular sugar intake, and monitor.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 186, 'page_label': '187', 'id': 'data/guideline-170-en.pdf:186:1'}, page_content='1. World Health Organization. Guidelines for the treatment of malaria, 3rd\\xa0ed. World Health Organization. 2015.https://apps.who.int/iris/handle/10665/162441\\n2. World Health Organization. Compendium of WHO malaria guidance: prevention, diagnosis, treatment, surveillance andelimination. 2019.https://apps.who.int/iris/handle/10665/312082\\n3. World Health Organization. WHO policy brief on single-dose primaquine as gametocytocide in Plasmodium falciparummalaria. 2015.https://www.who.int/malaria/publications/atoz/who_htm_gmp_2015.1.pdf?ua=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 186, 'page_label': '187', 'id': 'data/guideline-170-en.pdf:186:2'}, page_content='4. World Health Organization. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodiumfalciparum\\xa0malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. 2012.https://www.who.int/malaria/publications/atoz/smc_policy_recommendation_en_032012.pdf?ua=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 187, 'page_label': '188', 'id': 'data/guideline-170-en.pdf:187:0'}, page_content='Page 188 / 409\\nHuman African trypanosomiasis (sleepingsickness)\\nHuman African trypanosomiasis (HAT) is a zoonosis caused by protozoa (trypanosomes), transmitted to humans\\nthrough the bite of a tsetse ﬂy (Glossina). Transmission by contaminated blood transfusion and transplacental\\ntransmission are also possible.\\nThe disease is found only in sub-Saharan Africa. There are two forms:\\xa0Trypanosoma brucei gambiense\\xa0HAT in western\\nand central Africa and\\xa0Trypanosoma brucei rhodesiense\\xa0HAT in eastern and southern Africa.\\nClinical features\\nInoculation may be followed by an immediate local reaction (trypanosomal chancre). This chancre arises in about 50%\\nof all rhodesiense but rarely in gambiense.\\nGambiense HAT\\nRhodesiense HAT'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 187, 'page_label': '188', 'id': 'data/guideline-170-en.pdf:187:1'}, page_content='of all rhodesiense but rarely in gambiense.\\nGambiense HAT\\nRhodesiense HAT\\nThe ﬁrst stage is the same as above, but the incubation period is shorter (< 3 weeks), the disease evolves more rapidly\\nand symptoms are more severe. Patients often die of myocarditis in 3 to 6 months without having developed signs of\\nthe meningo-encephalitic stage.\\nIn practice, gambiense and rhodesiense HAT can be difﬁcult to differentiate: e.g., there exist cases of acute\\ngambiense infection and others of chronic rhodesiense infection.\\nLaboratory\\nIncubation lasts from a few days to several years.\\nThe ﬁrst stage (haemolymphatic stage) corresponds to the haematogenous and lymphatic dissemination of the\\nparasite. Signs include intermittent fever, joint pain, lymphadenopathy (ﬁrm, mobile, painless lymph nodes, mainly'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 187, 'page_label': '188', 'id': 'data/guideline-170-en.pdf:187:2'}, page_content='cervical), hepatosplenomegaly and skin signs (facial oedema, pruritus).\\nThe second stage (meningoencephalitic stage) corresponds to the invasion of the central nervous system. Signs of\\nthe haemolymphatic stage recede or disappear and varying neurological signs progressively develop: sensory\\ndisturbances (deep hyperaesthesia), psychiatric disorders (apathy or agitation), disturbance of the sleep cycle (with\\ndaytime somnolence alternating with insomnia at night), impaired motor functions (paralysis, seizures, tics) and\\nneuroendocrine disorders (amenorrhoea, impotence).\\nIn the absence of treatment: cachexia, lethargy, coma and death.\\nDiagnosis involves 3 steps for gambiense HAT (screening test, diagnostic conﬁrmation and stage determination)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 187, 'page_label': '188', 'id': 'data/guideline-170-en.pdf:187:3'}, page_content='and 2 steps for rhodesiense HAT (diagnostic conﬁrmation and stage determination).\\nThe recommended screening test for\\xa0T.b. gambiense\\xa0infection is the CATT (Card Agglutination Test for\\nTrypanosomiasis). It detects the presence of speciﬁc antibodies in the patient’s blood or serum.\\nDiagnostic conﬁrmation: presence of trypanosomes in lymph node aspirates or in blood using concentration\\ntechniques: capillary tube centrifugation technique (Woo test), quantitative buffy coat (QBC), mini-anion exchange\\ncentrifugation technique (mAEC).\\nStage determination: detection of trypanosomes (after centrifugation) and white cell count in the cerebrospinal ﬂuid\\n(lumbar puncture):\\nHaemolymphatic stage: no trypanosomes AND ≤ 5 white cells/mm3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 188, 'page_label': '189', 'id': 'data/guideline-170-en.pdf:188:0'}, page_content='Page 189 / 409\\nTreatment (except in pregnant women)\\nHaemolymphatic stage (Stage I)\\nGambiense HAT\\npentamidine isetionate\\xa0deep IM\\nChildren and adults: 4 mg/kg once daily for 7 to 10 days\\nPatients should receive a source of glucose (meal, sweet tea) one hour before injection (risk of hypoglycaemia); they\\nshould remain supine during administration and one hour after injection (risk of hypotension).\\nRhodesiense HAT\\nsuramin\\xa0slow IV\\nChildren and adults:\\nD1: test dose of 4 to 5 mg/kg\\nD3, D10, D17, D24, D31: 20 mg/kg (max. 1 g per injection)\\nSuramin may cause anaphylactic reactions, a test dose is recommended prior to starting treatment. In the event of an\\nanaphylactic reaction after the test dose, the patients must not be given suramin again.\\nMeningoencephalitic stage (Stage II)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 188, 'page_label': '189', 'id': 'data/guideline-170-en.pdf:188:1'}, page_content='Meningoencephalitic stage (Stage II)\\nBefore administrating trypanocides, the priority is to improve the patient’s general condition (rehydration, treatment of\\nmalaria, intestinal worms, malnutrition, bacterial infections). It is nonetheless recommended not to postpone the\\ntrypanocidal treatment for more than 10 days.\\nGambiense HAT\\n\\xa0\\nMeningoencephalitic stage: evidence of trypanosomes OR > 5 white cells/mm3\\nDue to the toxicity of trypanocides, detection of the parasite is essential before initiating treatment. In the absence\\nof parasitological conﬁrmation, treatment may nevertheless be justiﬁed in certain cases: very strong clinical\\nsuspicion, patients in life-threatening condition, strong serological suspicion (CATT 1:16 positive) in a population'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 188, 'page_label': '189', 'id': 'data/guideline-170-en.pdf:188:2'}, page_content='where the disease is highly prevalent (> 2%).\\nSeveral treatment regimens exist. Check national recommendations and local resistance levels.\\nTreatment must be administered under close medical supervision. Patients receiving pentamidine can be treated as\\noutpatients but those receiving suramin, eﬂornithine (with or without nifurtimox) or melarsoprol should be\\nhospitalised.\\nAfter treatment, patients should be checked every 6 months (clinical examination, lumbar puncture and examination\\nfor trypanosomes) over 24 months, to look for relapse.\\nFirst choice: nifurtimox-eﬂornithine combination therapy (NECT)\\nnifurtimox\\xa0PO\\nChildren and adults: 5 mg/kg 3 times daily for 10 days\\n+\\xa0eﬂornithine\\xa0IV infusion over 2 hours\\nChildren and adults: 200 mg/kg every 12 hours for 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 188, 'page_label': '189', 'id': 'data/guideline-170-en.pdf:188:3'}, page_content='Children and adults: 200 mg/kg every 12 hours for 7 days\\nThe catheter must be handled with great attention to avoid local or general bacterial infections: thoroughly disinfect\\nthe insertion site, ensure secure catheter ﬁxation, protect the insertion site with a sterile dressing, systematically\\nchange the catheter every 48 hours or earlier in case of signs of phlebitis.\\nSecond choice:\\neﬂornithine\\xa0IV infusion over 2 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 189, 'page_label': '190', 'id': 'data/guideline-170-en.pdf:189:0'}, page_content='Page 190 / 409\\n\\xa0\\nRhodesiense HAT\\nmelarsoprol\\xa0slow IV\\nChildren and adults: 2.2 mg/kg once daily for 10 days\\nPrednisolone\\xa0PO (1 mg/kg once daily) is frequently combined throughout the duration of treatment.\\nTreatment in pregnant women\\nAll trypanocides are potentially toxic for the mother and the foetus (risk of miscarriage, malformation, etc.). However,\\ndue to the life-threatening risk for the mother and the risk of mother-to-child transmission, treatment must be initiated\\nas follows:\\xa0\\n\\xa0\\nPrevention and control\\nChildren under 12 years: 150 mg/kg every 6 hours for 14 days\\nChildren 12 years and over and\\xa0adults: 100 mg/kg every 6 hours for 14 days\\nIn the event of a relapse after NECT or eﬂornithine:\\nmelarsoprol\\xa0slow IV\\nChildren and adults: 2.2 mg/kg once daily for 10 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 189, 'page_label': '190', 'id': 'data/guideline-170-en.pdf:189:1'}, page_content=\"melarsoprol\\xa0slow IV\\nChildren and adults: 2.2 mg/kg once daily for 10 days\\nMelarsoprol is highly toxic: reactive encephalopathy (coma, or recurrent or prolonged seizures) in 5 to 10% of\\ntreated patients, fatal in around 50% of cases; peripheral neuropathy, invasive diarrhoea, severe skin rash, phlebitis,\\netc.\\nPrednisolone\\xa0PO (1 mg/kg once daily) is frequently combined throughout the duration of treatment.\\nHaemolymphatic stage:\\npentamidine for gambiense HAT as of the second trimester and suramin for rhodesiense HAT.\\nMeningoencephalitic stage: treatment depends on the mother's condition:\\nIf in immediately life-threatening condition: treatment with NECT or eﬂornithine cannot be deferred until after\\ndelivery.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 189, 'page_label': '190', 'id': 'data/guideline-170-en.pdf:189:2'}, page_content='delivery.\\nIf not immediately life-threatening condition: pentamidine for gambiense HAT and suramin for rhodesiense HAT.\\nTreatment with NECT or eﬂornithine is to be administered after delivery.\\nIndividual protection against tsetse ﬂy bites: long sleeves and trousers, repellents, keeping away from risk areas\\n(e.g. near rivers).\\nDisease control: mass screening and treatment of patients (T.b. gambiense), trypanocide treatment of cattle (T.b.\\nrhodesiense), vector control using tsetse ﬂy traps or insecticides.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 190, 'page_label': '191', 'id': 'data/guideline-170-en.pdf:190:0'}, page_content='Page 191 / 409\\nAmerican trypanosomiasis (Chagas disease)\\nChagas\\xa0disease is a zoonosis caused by the protozoa\\xa0Trypanosoma cruzi. It is transmitted to humans by contact of\\ntriatomine bug faeces with a break in the skin (often caused by a bite from the triatomine bug), or with mucous\\nmembranes. Transmission by contaminated blood transfusion, accidental exposure to blood, mother-to-child (during\\npregnancy or childbirth) or consumption of contaminated food and water is also possible.\\xa0\\nChagas disease has two phases: an acute phase, which lasts approximately 4 to 6 weeks, and a chronic phase, which\\nis lifelong if left untreated.\\nThe disease is primarily found on the American continent . It is signiﬁcantly underdiagnosed.\\nClinical features\\nAcute phase\\nChronic phase\\nDiagnosis\\nLaboratory'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 190, 'page_label': '191', 'id': 'data/guideline-170-en.pdf:190:1'}, page_content=\"Clinical features\\nAcute phase\\nChronic phase\\nDiagnosis\\nLaboratory\\nOther investigations\\nTreatment\\n a  [1]\\nMost cases are asymptomatic.\\nIf transmitted through a break in the skin: a red swelling on the skin\\xa0(chagoma) or unilateral painless purplish\\nperiorbital oedema (Romaña's sign) with local lymphadenopathy, headache and fever.\\nRarely: multiple lymphadenopathies, hepatosplenomegaly, myocarditis (chest pain,\\xa0dyspnoea), meningoencephalitis\\n(seizures, paralysis).\\nMany cases remain asymptomatic (indeterminate phase).\\nUp to 30% of cases develop organ damage: [2]\\ncardiac lesions (conduction disorders, dilated cardiomyopathy): arrhythmia, dyspnoea, chest pain, heart failure;\\ngastrointestinal lesions (dilation of the oesophagus or colon i.e. megaoesophagus, megacolon): difﬁculty\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 190, 'page_label': '191', 'id': 'data/guideline-170-en.pdf:190:2'}, page_content='swallowing, severe constipation.\\nIndividuals with immunosuppression have a higher risk of developing organ damage than the general population.\\n [1]\\nAcute phase:\\nIdentiﬁcation of Trypanosoma cruzi by direct microscopy of fresh blood or blood concentrated by\\nmicrohematocrit method.\\nIn case of strong clinical suspicion despite no deﬁnitive diagnosis from direct microscopy, perform serologic\\ntests after a delay of approximately 1 month (see \"Chronic phase\").\\nChronic phase:\\nIdentiﬁcation of anti-Trypanosoma cruzi antibodies by serologic tests,\\xa0e.g. enzyme-linked immunosorbent assay\\n(ELISA), hemagglutination inhibition assay (HAI), indirect immunoﬂuorescence (IIF) or rapid diagnostic test (RDT).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 190, 'page_label': '191', 'id': 'data/guideline-170-en.pdf:190:3'}, page_content='For a deﬁnitive diagnosis, two different serological tests should be performed simultaneously; in case of\\nconﬂicting results, a third test is recommended. b\\nECG may demonstrate conduction disorders.\\nChest or abdominal x-ray may demonstrate cardiomegaly, megaoesophagus or megacolon.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 191, 'page_label': '192', 'id': 'data/guideline-170-en.pdf:191:0'}, page_content='Page 192 / 409\\nAetiologic treatment\\nFor information:\\nSymptomatic treatment\\nSee Seizures (Chapter 1), Pain (Chapter 1) and Heart failure (Chapter 12).\\nPrevention\\n\\xa0\\nReferences\\nAcute or chronic Chagas disease can be treated with either benznidazole or nifurtimox. However, treatment is not\\nrecommended if patient has already developed cardiac or digestive complications.\\nClose clinical monitoring should be provided due to the frequent occurrence of adverse effects. Where available,\\nblood tests (complete blood count, liver and renal function tests) should be performed before, during and after\\ntreatment.\\nProtocols vary according to the country, follow national recommendations.\\n\\xa0 Age Dose and duration\\nbenznidazole\\nPO( (a)\\n2 to 12 years [3] 5 to 8 mg/kg daily in 2 divided doses for 60 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 191, 'page_label': '192', 'id': 'data/guideline-170-en.pdf:191:1'}, page_content='PO( (a)\\n2 to 12 years [3] 5 to 8 mg/kg daily in 2 divided doses for 60 days\\n> 12 years and adults [4] 5 to 7 mg/kg daily in 2 divided doses for 60 days\\nnifurtimox\\nPO (b) [3]\\n≤ 10 years 15 to 20 mg/kg daily in 3 to 4 divided doses for 90 days\\n11 to 16 years 12.5 to 15 mg/kg daily in 3 to 4 divided doses for 90 days\\n≥ 17 years and adults 8 to 10 mg/kg daily in 3 to 4 divided doses for 90 days\\n(a) Benznidazole is contra-indicated in pregnancy, breastfeeding and in patient with severe hepatic/renal impairment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 191, 'page_label': '192', 'id': 'data/guideline-170-en.pdf:191:2'}, page_content='(b) Nifurtimox is contra-indicated in pregnancy, breastfeeding, patients with severe hepatic/renal impairment or history ofsevere mental disorders or seizures. Adverse effects (gastrointestinal disturbances, agitation, sleeping disorders, seizure)are frequent and reversible and should not necessarily result in discontinuation of treatment. Avoid alcohol and fatty mealsduring treatment.\\nIndividual protection against bite from triatomine bugs: use of long-lasting insecticidal net.\\nIn healthcare settings: standard precautions to avoid contamination with soiled materials or potentially infected\\nbody ﬂuids.\\nBlood transfusions: advise patients with Chagas disease not to donate blood. In endemic areas, screen donor\\nblood for Trypanosoma cruzi antibodies.\\xa0\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 191, 'page_label': '192', 'id': 'data/guideline-170-en.pdf:191:3'}, page_content='blood for Trypanosoma cruzi antibodies.\\xa0\\nFootnotes\\n(a) For more information on geographical distribution of cases of\\xa0T. cruzi\\xa0infection:http://gamapserver.who.int/mapLibrary/Files/Maps/Global_chagas_2009.png\\n(b) If resources are limited, ELISA alone can be performed. If the result is positive, a second serologic test should then beperformed to conﬁrm the diagnosis before starting treatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 192, 'page_label': '193', 'id': 'data/guideline-170-en.pdf:192:0'}, page_content='Page 193 / 409\\n1. Pan American Health Organization. Guidelines for diagnosis and treatment of Chagas disease. Washington, D.C. 2019.http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275120439_eng.pdf?sequence=6&isAllowed=y\\n2. Rassi A, Marin-Neto J. Seminar: Chagas disease. The Lancet, Volume 375, ISSUE 9723, P1388-1402, April 17, 2010.\\n3. Centers for Disease Control and Prevention. Parasites - American Trypanosomiasis.https://www.cdc.gov/parasites/chagas/\\xa0[Accessed 17 February 2020]\\n4. World Health Organization. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition. Geneva.1995.\\xa0https://apps.who.int/iris/handle/10665/41765\\xa0[Accessed 6 May 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 193, 'page_label': '194', 'id': 'data/guideline-170-en.pdf:193:0'}, page_content='Page 194 / 409\\nLeishmaniases\\nThe leishmaniases are a group of parasitic diseases caused by protozoa of the genus\\xa0Leishmania, transmitted by the\\nbite of a sandﬂy. Over 20 species cause disease in man.\\nClinical features\\nCutaneous and mucocutaneous leishmaniasis\\nVisceral leishmaniasis\\nVisceral leishmaniasis (kala azar) is a systemic disease, resulting in pancytopenia, immunosuppression, and death if left\\nuntreated.\\nPost-kala azar dermal leishmaniasis\\nMacular, nodular or papular skin rash of unknown aetiology, particularly on the face, and typically occurring after\\napparent cure of visceral leishmaniasis.\\nLaboratory\\nCutaneous and mucocutaneous leishmaniasis\\nVisceral leishmaniasis\\nCutaneous\\xa0leishmaniasis is endemic in more than 70 countries in South and Central America, Middle East, Central'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 193, 'page_label': '194', 'id': 'data/guideline-170-en.pdf:193:1'}, page_content='Asia, and Africa.\\nMucocutaneous\\xa0leishmaniasis occurs in Latin America and, more rarely, in Africa (Ethiopia, Sudan).\\nVisceral\\xa0leishmaniasis occurs in more than 60 countries in East and North Africa, South and Central Asia, Southern\\nEurope, and South and Central America.\\nSingle or multiple lesions on the uncovered parts of the body: an erythematous papule begins at the sandﬂy bite,\\nenlarges to a nodule and extends in surface and depth to form a scabbed ulcer. Ulcers are painless, unless there is\\nsecondary bacterial or fungal infection.\\nUsually, lesions heal spontaneously, leaving a scar, and result in lifelong protection from disease.\\nLesions may also spread to the mucosa (mouth, nose, conjunctiva) giving rise to the mucocutaneous form, which\\nmay cause severe disﬁgurement.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 193, 'page_label': '194', 'id': 'data/guideline-170-en.pdf:193:2'}, page_content='may cause severe disﬁgurement.\\nProlonged (> 2 weeks) irregular fever, splenomegaly, and weight loss are the main signs.\\nOther signs include: anaemia, diarrhoea, epistaxis, lymphadenopathy, moderate hepatomegaly.\\nBacterial diarrhoea, pneumonia, and tuberculosis may develop due to immunosuppression.\\nParasitological diagnosis: identiﬁcation of Giemsa-stained parasites in smears of tissue biopsy from the edge of\\nthe ulcer.\\nNo useful serological tests.\\nParasitological diagnosis: identiﬁcation of Giemsa-stained parasites in smears of splenic, bone marrow, or lymph\\nnode aspiration-biopsy. Splenic aspiration is the most sensitive technique but carries a theoretical risk of potentially\\nfatal haemorrhage.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 193, 'page_label': '194', 'id': 'data/guideline-170-en.pdf:193:3'}, page_content='fatal haemorrhage.\\nSerological diagnosis: rK39 dipstick test and direct agglutination test (DAT) can be used for diagnosis of primary\\nvisceral leishmaniasis in clinically suspect cases. Diagnosis of relapse is only by parasitological conﬁrmation.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 194, 'page_label': '195', 'id': 'data/guideline-170-en.pdf:194:0'}, page_content='Page 195 / 409\\nTreatment\\nThe various species of\\xa0Leishmania\\xa0respond differently to drugs. Follow national recommendations.\\nFor information:\\nCutaneous and mucocutaneous leishmaniasis\\nVisceral leishmaniasis\\nVisceral leishmaniasis in East Africa\\n\\xa0\\n\\xa0\\nVisceral leishmaniasis in South Asia\\n\\xa0\\n\\xa0For all patients with visceral leishmaniasis, hydration, nutritional support and treatment of intercurrent infections\\n(malaria, dysentery, pneumonia, etc.) are essential.\\nTuberculosis and/or HIV infection may also be present and should be suspected if relapse occurs more than once or in\\nthe event of treatment failure.\\nCutaneous lesions generally heal spontaneously in 3 to 6 months. Treatment is only indicated if lesions are\\npersistent (> 6 months), disﬁguring, ulcerating, or disseminated.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 194, 'page_label': '195', 'id': 'data/guideline-170-en.pdf:194:1'}, page_content='persistent (> 6 months), disﬁguring, ulcerating, or disseminated.\\nForms with a single lesion or few lesions: start with local treatment with a pentavalent antimonial:\\xa0sodium\\nstibogluconate\\xa0or\\xa0meglumine\\xa0antimoniate, 1 to 2 ml inﬁltrated into the lesion if it is a nodule and into the edges\\nand base around the crust if it is an ulcer.\\nIt should be repeated every 3 to 7 days for 2 to 4 weeks. Once healing begins, the treatment can be stopped and\\nhealing will continue.\\nIM treatment with a pentavalant antimonial (20 mg/kg daily for 10 to 20 days) is restricted to severe cases and must\\nbe administered under close medical supervision.\\nMiltefosine PO (as for visceral leishmaniasis) for 28 days is effective in many forms of cutaneous leishmaniasis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 194, 'page_label': '195', 'id': 'data/guideline-170-en.pdf:194:2'}, page_content='Ulcers are often secondarily infected with streptococci and staphylococci: administer suitable antibiotics.\\nMucocutaneous forms: as for visceral leishmaniasis.\\nFirst-line treatment:\\na\\xa0pentavalent antimonial\\xa0IM or slow IV: 20 mg/kg daily for 17 days\\n+\\xa0paromomycin\\xa0IM: 15 mg (11 mg base)/kg daily for 17 days\\nSecond-line treatment for relapse and for speciﬁc vulnerable groups: severe disease, pregnant women, patients\\nover 45 years:\\nliposomal amphotericin B\\xa0IV infusion: 3 to 5 mg/kg once daily for 6 to 10 days up to a total dose of 30 mg/kg\\nTreatment in HIV co-infected patients:\\nliposomal amphotericin B\\xa0IV infusion: 3 to 5 mg/kg once daily for 6 to 10 days up to a total dose of 30 mg/kg\\n+\\xa0miltefosine\\xa0PO for 28 days:\\nChildren 2 to 11 years: 2.5 mg/kg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 194, 'page_label': '195', 'id': 'data/guideline-170-en.pdf:194:3'}, page_content='+\\xa0miltefosine\\xa0PO for 28 days:\\nChildren 2 to 11 years: 2.5 mg/kg once daily\\nChildren\\xa0≥ 12 years and < 25 kg: 50 mg once daily\\nChildren ≥\\xa012 years and adults 25 to 50 kg: 50 mg 2 times daily\\nAdults > 50 kg: 50 mg 3 times daily\\nFirst-line treatment:\\nliposomal amphotericin B\\xa0IV infusion: 3 to 5 mg/kg once daily for 3 to 5 days up to a total dose of 15 mg/kg\\nor\\nliposomal amphotericin B\\xa0IV infusion: 10 mg/kg single dose\\nSecond-line treatment for relapse:\\nliposomal amphotericin B\\xa0IV infusion: 3 to 5 mg/kg once daily for 5 to 8 days up to a total dose of 25 mg/kg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 195, 'page_label': '196', 'id': 'data/guideline-170-en.pdf:195:0'}, page_content='Page 196 / 409\\nPost-kala azar dermal leishmaniasis (PKDL)\\nOnly patients with severe or disﬁguring disease or with lesions remaining for > 6 months, and young children with oral\\nlesions that interfere with feeding, are treated.\\nPKDL in East Africa\\na\\xa0pentavalent antimonial\\xa0IM or slow IV: 20 mg/kg daily for 17 to 60 days\\n+\\xa0paromomycin\\xa0IM: 15 mg (11 mg base)/kg daily for 17 days\\nor\\nliposomal amphotericin B\\xa0IV infusion: 2.5 mg/kg once daily for 20 days\\nor\\nmiltefosine\\xa0PO for 28 days (as for visceral leishmaniasis) may be beneﬁcial in HIV co-infected patients\\nPKDL in South Asia\\nliposomal amphotericin B\\xa0IV infusion: 5 mg/kg 2 times weekly up to a total dose of 30 mg/kg\\nPrevention\\nInsecticide-treated mosquito nets.\\nVector control and elimination of animal reservoir hosts.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 196, 'page_label': '197', 'id': 'data/guideline-170-en.pdf:196:0'}, page_content='Page 197 / 409\\nIntestinal protozoan infections (parasiticdiarrhoea)\\nThe most important intestinal protozoan infections are amoebiasis (Entamoeba histolytica), giardiasis (Giardia\\nlamblia), cryptosporidiosis (Cryptosporidium sp), cyclosporiasis (Cyclospora cayetanensis) and isosporiasis (Isospora\\nbelli).\\xa0Intestinal protozoa are transmitted by the faecal-oral route (soiled hands, ingestion of food or water contaminated\\nwith faeces) and may cause both individual cases of diarrhoea and epidemic diarrhoea outbreaks.\\nClinical features\\n\\xa0\\nLaboratory\\nDeﬁnitive diagnosis relies on parasite identiﬁcation in stool specimens (trophozoites and cysts for giardia; oocysts for\\ncryptosporidium, cyclospora, isospora). Two to three samples, collected 2 to 3 days apart are necessary, as'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 196, 'page_label': '197', 'id': 'data/guideline-170-en.pdf:196:1'}, page_content='pathogens are shed intermittently.\\nTreatment\\n\\xa0\\nAmoebiasis gives rise to bloody diarrhoea (see\\xa0Amoebiasis, Chapter 3).\\nClinical presentation of giardiasis, cryptosporidiosis, cyclosporiasis and isosporiasis is very similar:\\nDiarrhoea is usually mild and self-limiting, except in children and patients with advanced HIV disease (CD4 < 200).\\nThese patients are likely to develop severe, intermittent or chronic diarrhoea that may be complicated by\\nmalabsorption with signiﬁcant wasting (or failure to gain weight in children) or severe dehydration.\\nStools are usually watery, but steatorrhoea (pale, bulky, fatty stools) may be found in the event of secondary fat\\nmalabsorption; stools may contain mucus.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 196, 'page_label': '197', 'id': 'data/guideline-170-en.pdf:196:2'}, page_content='malabsorption; stools may contain mucus.\\nDiarrhoea is usually associated with non-speciﬁc gastrointestinal symptoms (abdominal distension and cramps,\\nﬂatulence, nausea, anorexia), but patients have low-grade fever or no fever.\\nCorrect dehydration if present (for clinical features and management, see Dehydration, Chapter 1).\\nIf the causal agent has been identiﬁed in the stool:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 197, 'page_label': '198', 'id': 'data/guideline-170-en.pdf:197:0'}, page_content='Page 198 / 409\\n\\xa0\\n\\xa0\\nGiardiasis tinidazole PO single dose\\nChildren: 50 mg/kg (max. 2 g)\\xa0\\nAdults: 2 g\\nor\\nmetronidazole PO for 3 days\\nChildren: 30 mg/kg once daily\\nAdults: 2 g once daily\\nCryptosporidiosis In immunocompetent patients, no aetiological treatment; spontaneous\\nresolution in 1 to 2 weeks.\\nCyclosporiasis co-trimoxazole PO for 7 days\\nChildren: 25 mg SMX + 5 mg TMP/kg 2 times daily\\nAdults: 800 mg SMX + 160 mg TMP 2 times daily\\nIn immunocompetent patients, symptoms\\xa0usually\\xa0resolve\\xa0spontaneous in 1 to 3\\nweeks. Treatment is given in case of severe or prolonged symptoms.\\nIsoporiasis co-trimoxazole PO for 7 to 10 days\\nAdults: 800 mg SMX + 160 mg TMP 2 times daily\\nIn immunocompetent patients,\\xa0symptoms\\xa0usually resolve\\xa0spontaneous\\xa0in 2 to 3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 197, 'page_label': '198', 'id': 'data/guideline-170-en.pdf:197:1'}, page_content='In immunocompetent patients,\\xa0symptoms\\xa0usually resolve\\xa0spontaneous\\xa0in 2 to 3\\nweeks. Treatment is given in case of severe or prolonged symptoms.\\nIf reliable stool examination cannot be carried out: parasitic diarrhoeas cannot be differentiated on clinical grounds,\\nnor is it possible to distinguish these from non- parasitic diarrhoeas. An empirical treatment (using tinidazole or\\nmetronidazole and co-trimoxazole as above, together or in succession) may be tried in the case of prolonged\\ndiarrhoea or steatorrhoea. In patients with HIV infection, see empirical treatment (HIV infections and AIDS, Chapter\\n8).\\nIn patients with advanced HIV disease, cryptosporidiosis, cyclosporiasis and isosporiasis are opportunistic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 197, 'page_label': '198', 'id': 'data/guideline-170-en.pdf:197:2'}, page_content='infections; the most effective intervention is the treatment of the underlying HIV infection with antiretrovirals.\\nPatients remain at high risk for dehydration/death until immunity is restored.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 198, 'page_label': '199', 'id': 'data/guideline-170-en.pdf:198:0'}, page_content='Page 199 / 409\\nFlukes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 199, 'page_label': '200', 'id': 'data/guideline-170-en.pdf:199:0'}, page_content='Page 200 / 409\\nInfection/Epidemiology Clinical features/Diagnosis Treatment\\nLung ﬂukes\\nParagonimus sp\\nDistribution: South-East\\nAsia, China, parts of\\nCameroon, Nigeria,\\nGabon, Congo, Colombia,\\nPeru\\nTransmission: eating raw\\nfreshwater crustaceans\\nThe two most prominent symptoms are prolonged (> 2 weeks)\\nproductive cough and intermittent haemoptysis (rusty-brown sputum).\\nIn endemic areas, paragonimosis should be considered whenever\\npulmonary tuberculosis is suspected as the clinical and radiological\\nfeatures overlap. Paragonimosis is conﬁrmed when eggs are\\ndetected in sputum (or possibly in stools).\\npraziquantel\\nPO\\nChildren 4 years\\nand over and\\nadults:\\n25 mg/kg 3\\ntimes daily for 2\\ndays\\nHepatobiliary ﬂukes\\nFasciola hepatica and\\ngigantica\\nDistribution: worldwide, in\\nareas where sheep and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 199, 'page_label': '200', 'id': 'data/guideline-170-en.pdf:199:1'}, page_content='gigantica\\nDistribution: worldwide, in\\nareas where sheep and\\ncattle are raised\\nTransmission: eating\\nuncooked aquatic plants\\n\\xa0\\nDuring migration phase: asthenia, prolonged fever, myalgia, right\\nupper quadrant pain, mild hepatomegaly; sometimes, allergic signs\\n(e.g. pruritus). At this stage, the diagnosis is rarely considered and can\\nonly be conﬁrmed through serology; parasitological examination of\\nstools is always negative.\\nOnce adult ﬂukes are present in the biliary tract: presentation\\nresembles cholelithiasis: right upper quadrant pain, recurrent episodes\\nof obstructive jaundice/ febrile cholangitis. The diagnosis is\\nconﬁrmed when parasite eggs are detected in stools (or ﬂukes are\\nseen in the biliary tract with sonography).\\n\\xa0\\ntriclabendazole\\nPO\\nChildren and\\nadults:\\n10 mg/kg single\\ndose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 199, 'page_label': '200', 'id': 'data/guideline-170-en.pdf:199:2'}, page_content='triclabendazole\\nPO\\nChildren and\\nadults:\\n10 mg/kg single\\ndose\\nMay repeat in\\n24 hours in the\\nevent of severe\\ninfection\\nOpisthorchis felineus\\n(Asia, Eastern Europe)\\nOpisthorchis viverrini\\n(Cambodia, Laos,\\nVietnam, Thailand)\\nClonorchis sinensis\\n(China, Koera, Vietnam)\\nTransmission: eating\\nraw/undercooked\\nfreshwater ﬁsh\\nAbdominal pain and diarrhoea. With heavy infection, hepatobiliary\\nsymptoms: hepatomegaly, right upper quadrant pain, jaundice or\\nepisodes of febrile cholangitis. The diagnosis is conﬁrmed when\\nparasite eggs are detected in stools.\\npraziquantel\\nPO\\nChildren 4 years\\nand over and\\nadults:\\n25 mg/kg 3\\ntimes daily for 2\\ndays\\nIntestinal ﬂukes\\nFasciolopsis buski\\n(India, Bangladesh,\\nSouth-East Asia)\\nHeterophyes\\nheterophyes\\n(South-East Asia, Nile\\ndelta)\\nMetagonimus yokogawai'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 199, 'page_label': '200', 'id': 'data/guideline-170-en.pdf:199:3'}, page_content='Heterophyes\\nheterophyes\\n(South-East Asia, Nile\\ndelta)\\nMetagonimus yokogawai\\n(Siberia, China, Korea)\\nTransmission: eating\\nuncooked aquatic plants\\n(F. buski),\\nSymptoms are limited to diarrhoea and epigastric or abdominal pain.\\nWith massive infection, F. buski can cause oedematous allergic\\nreactions (including ascites, anasarca).\\nThe diagnosis is conﬁrmed when parasite eggs are detected in\\nstools.\\npraziquantel\\nPO\\nChildren 4 years\\nand over and\\nadults:\\n25 mg/kg 3\\ntimes daily, 1\\nday'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 200, 'page_label': '201', 'id': 'data/guideline-170-en.pdf:200:0'}, page_content='Page 201 / 409\\n\\xa0\\n\\xa0\\n\\xa0\\nraw/undercooked ﬁsh\\n(other species)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 201, 'page_label': '202', 'id': 'data/guideline-170-en.pdf:201:0'}, page_content='Page 202 / 409\\nSchistosomiases\\nSchistosomiases are acute or chronic visceral parasitic diseases due to 5 species of trematodes (schistosomes). The\\nthree main species infecting humans are Schistosoma haematobium, Schistosoma mansoni and Schistosoma\\njaponicum. Schistosoma mekongi and Schistosoma intercalatum have a more limited distribution.\\xa0Humans are infected while wading/bathing in fresh water infested with schistosome larvae. Symptoms occurring during\\nthe phases of parasite invasion (transient localized itching as larvae penetrate the skin) and migration (allergic\\nmanifestations and gastrointestinal symptoms during migration of schistosomules) are frequently overlooked. In\\ngeneral, schistosomiasis is suspected when symptoms of established infection become evident. Each species gives'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 201, 'page_label': '202', 'id': 'data/guideline-170-en.pdf:201:1'}, page_content='rise to a speciﬁc clinical form: genito-urinary schistosomiasis due to S. haematobium, intestinal schistosomiasis due S.\\nmansoni, S. japonicum, S. mekongi and S. intercalatum.\\xa0The severity of the disease depends on the parasite load. Heavily infected patients are prone to visceral lesions with\\npotentially irreversible sequelae. Children aged 5 to 15 years are particularly at risk: prevalence and parasite load are\\nhighest in this age group.\\xa0An antiparasitic treatment should be administered to reduce the risk of severe lesions, even if there is a likelihood of re-\\ninfection.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 202, 'page_label': '203', 'id': 'data/guideline-170-en.pdf:202:0'}, page_content='Page 203 / 409\\n\\xa0 Parasite/Epidemiology a Clinical features/Diagnosis\\n(established infection)\\nGenito-urinary\\nschistosomiasis\\nS. haematobium\\nDistribution: Africa,\\nMadagascar and the\\nArabian peninsula\\nUrinary manifestations:\\nIn endemic areas, urinary schistosomiasis should be\\nsuspected in any patients who complain of macroscopic\\nhaematuria (red coloured urine throughout, or at the end of,\\nmicturition). Haematuria is frequently associated with\\npolyuria/dysuria (frequent and painful micturition).\\nIn patients, especially children and adolescents, with urinary\\nsymptoms, visual inspection of the urine (and dipstick test\\nfor microscopic haematuria if the urine appears grossly\\nnormal) is indispensible.\\nPresumptive treatment is recommended in the presence of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 202, 'page_label': '203', 'id': 'data/guideline-170-en.pdf:202:1'}, page_content='Presumptive treatment is recommended in the presence of\\nmacro- or microscopic haematuria, when parasitological\\nconﬁrmation (parasite eggs detected in urine) cannot be\\nobtained.\\nGenital manifestations:\\nIn women, symptoms of genital infection (white-yellow or\\nbloody vaginal discharge, itching, lower abdominal pain,\\ndyspareunia) or vaginal lesions resembling genital warts or\\nulcerative lesions on the cervix; in men, haematospermia\\n(blood in the semen).\\nIf left untreated: risk of recurrent urinary tract infections,\\nﬁbrosis/calciﬁcation of the bladder and ureters, bladder\\ncancer; increased susceptibility to sexually transmitted\\ninfections and risk of infertility.\\nIn endemic areas, genito-urinary schistosomiasis may be a\\ndifferential diagnosis to the genito-urinary tuberculosis, and in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 202, 'page_label': '203', 'id': 'data/guideline-170-en.pdf:202:2'}, page_content='differential diagnosis to the genito-urinary tuberculosis, and in\\nwomen, to the sexually transmitted infections (especially in\\nwomen with an history of haematuria).\\nIntestinal\\nschistosomiasis\\nS. mansoni\\nDistribution: tropical\\nAfrica, Madagascar, the\\nArabian peninsula, South\\nAmerica (especially Brazil)\\nS. japonicum\\nDistribution: China,\\nIndonesia, the Philippines\\nS. mekongi\\nDistribution: parts of Lao\\nPDR, Cambodia (along the\\nMekong River)\\nS. intercalatum\\nDistribution: parts of DRC,\\nCongo, Gabon, Cameroon,\\nChad\\nNon-speciﬁc digestive symptoms (abdominal pain; diarrhoea,\\nintermittent or chronic, with or without blood) and\\nhepatomegaly.\\nFor S. intercalatum: digestive symptoms only (rectal pain,\\ntenesmus, rectal prolapse, bloody diarrhoea).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 202, 'page_label': '203', 'id': 'data/guideline-170-en.pdf:202:3'}, page_content='tenesmus, rectal prolapse, bloody diarrhoea).\\nIf left untreated: risk of hepatic ﬁbrosis, portal hypertension,\\ncirrhosis, gastrointestinal haemorrhage (hematemesis, melena,\\netc.), except with S. intercalatum (less pathogenic than other\\nintestinal schistosomes, no severe hepatic lesions).\\nThe diagnosis is conﬁrmed when parasite eggs are detected\\nin stools.\\nIn the absence of reliable parasitological diagnosis: in areas\\nwhere intestinal schistosomiasis is common, diarrhoea\\n(especially bloody diarrhoea) with abdominal pain and/or\\nhepatomegaly may be a basis for presumptive diagnosis and\\ntreatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 203, 'page_label': '204', 'id': 'data/guideline-170-en.pdf:203:0'}, page_content='Page 204 / 409\\n\\xa0\\nTreatment\\npraziquantel PO\\nChildren 4\\xa0years and over and adults :\\n\\xa0\\nReferences\\n [1] [2] \\n b \\xa0\\nS. haematobium, S. mansoni, S. intercalatum: 40 mg/kg single dose or 2 doses of 20 mg/kg administered 4 hours\\napart\\nS. japonicum, S. mekongi: 2 doses of 30 mg/kg or 3 doses of 20 mg/kg administered 4 hours apart\\nFootnotes\\n(a) For more information on geographic distribution of schistosomiasis:https://www.who.int/schistosomiasis/Schistosomiasis_2012-01.png?ua=1\\n(b) For the treatment of schistosomiasis, praziquantel may me administered to pregnant women.\\n1. Treatment Guidelines from The Medical Letter. Vol. 11 (Suppl). Drugs for Parasitic Infections. 2013.https://www.uab.edu/medicine/gorgas/images/docs/syllabus/2015/03_Parasites/RxParasitesMedicalLetter2013.pdf\\xa0[Accessed 25 May 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 203, 'page_label': '204', 'id': 'data/guideline-170-en.pdf:203:1'}, page_content='2. Centers for Disease Control and Prevention (CDC). Schistosomiasis. Resources for Health Professionals. 2018.https://www.cdc.gov/parasites/schistosomiasis/health_professionals/index.html#tx\\xa0[Accessed 25 May 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 204, 'page_label': '205', 'id': 'data/guideline-170-en.pdf:204:0'}, page_content='Page 205 / 409\\nCestodes\\nCestodes (adult forms)\\nCestodes (larvae)\\nParasites Clinical\\nfeatures/Laboratory Treatment Transmission/Prevention\\nTaeniasis\\nTaenia saginata\\nTaenia solium\\n(worldwide)\\nOften asymptomatic\\nSegments expelled in the\\nstools, sometimes\\ngastrointestinal disturbances\\n(epigastric or abdominal\\npain, nausea, diarrhoea)\\nLaboratory: eggs in stools\\nor collected from perianal\\nskin (scotch tape method),\\nsegments in stools\\npraziquantel PO\\nChildren 4 years and\\nover and adults:\\n5 to 10 mg/kg single\\ndose\\n (a) Transmission by eating\\nraw or under-cooked meat:\\nPrevention:\\nbeef for T. saginata\\npork for T. solium\\nindividual: cook meat\\nthoroughly\\ncollective:\\nslaughterhouse\\nmonitoring\\nDiphyllobothriasis\\nDiphyllobothrium latum\\n(temperate or cold lake\\nareas)\\nOften asymptomatic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 204, 'page_label': '205', 'id': 'data/guideline-170-en.pdf:204:1'}, page_content='Diphyllobothrium latum\\n(temperate or cold lake\\nareas)\\nOften asymptomatic\\nIn the event of heavy\\ninfection: mild\\ngastrointestinal\\ndisturbances, anaemia due\\nto vitamin B deﬁciency\\nassociated with (rare)\\nneurological sequelae\\nLaboratory: eggs in stools\\n12 \\npraziquantel PO\\nChildren\\xa04 years and\\nover and adults:\\n5 to 10\\xa0mg/kg single\\ndose\\nIf anaemia: vitamin B\\n+ folic acid\\n (a) \\n12\\nTransmission by eating\\nraw or under- cooked\\nfreshwater ﬁsh\\nPrevention:\\nindividual: cook ﬁsh\\nthoroughly\\nHymenolepiasis\\nHymenolepis nana\\n(worldwide)\\nOften asymptomatic\\nIn the event of heavy\\ninfection: gastrointestinal\\ndisturbances (epigastric\\npain)\\nLaboratory: eggs in stools\\npraziquantel PO\\nChildren\\xa04 years and\\nover and adults:\\n15 to 25 mg/kg single\\ndose\\n (a) Transmission by faecal-\\noral route or auto-infection'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 204, 'page_label': '205', 'id': 'data/guideline-170-en.pdf:204:2'}, page_content='dose\\n (a) Transmission by faecal-\\noral route or auto-infection\\nPrevention:\\nindividual: hand washing,\\nnail cutting\\ncollective: hygiene and\\nsanitation (water,\\nlatrines, etc.)\\n(a) Praziquantel may be administered to pregnant women with\\xa0T. solium\\xa0taeniasis. For the other indications, treatment canusually be deferred until after delivery.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 205, 'page_label': '206', 'id': 'data/guideline-170-en.pdf:205:0'}, page_content='Page 206 / 409\\nParasites Clinical features/Laboratory Treatment Transmission/Prevention\\nCysticercosis\\nTaenia solium\\n(worldwide)\\nLaboratory: hypereosinophilia in\\nblood and cerebrospinal ﬂuid\\nMuscular: asymptomatic or\\nmyalgia\\nSubcutaneous: nodules\\nNeurological\\n(neurocysticercosis):\\xa0headache,\\nconvulsions, coma, etc.\\nOcular: exophthalmia,\\nstrabismus, iritis, etc.\\nNeurological and ocular\\ncysticercosis should be\\nmanaged in specialized\\nfacilities.\\nAntiparasitic treatment\\nwithout diagnosis of\\nlocation by\\ncomputerirsed\\ntomography and/or\\nmagnetic resonance\\nimaging can worsen the\\nsymptoms even threat\\nthe life. Neurosurgical\\ntreatment can be\\nrequired.\\nTransmission by eating\\nfood contaminated with T.\\nsolium eggs or auto-\\ninfection\\nPrevention:\\nindividual: treat T. solium\\ncarriers, hygiene, cook'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 205, 'page_label': '206', 'id': 'data/guideline-170-en.pdf:205:1'}, page_content='infection\\nPrevention:\\nindividual: treat T. solium\\ncarriers, hygiene, cook\\nmeat thoroughly\\nHydatid cyst\\nEchinococcus\\ngranulosus\\n(South America,\\nNorth, East and South\\nAfrica, Western\\nEurope)\\nCysts located in the liver (60% of\\ncases); lungs (30% of cases), and,\\nless frequently, in other sites\\nincluding the brain.\\nLong asymptomatic period. The\\ncyst becomes symptomatic when\\ncomplications develop (biliary\\nobstruction; anaphylactic shock in\\nthe event of rupture into peritoneal\\ncavity, vessels or an organ; febrile\\npainful jaundice in the event of\\nrupture into the biliary tree, etc.).\\nFirst-line treatment:\\nsurgical excision\\nalbendazole PO \\xa0is\\nuseful in addition to, or\\ninstead of, surgery:\\nChildren over 2 years\\nand adults under 60 kg:\\n7.5 mg/kg 2 times daily\\nAdults over 60 kg:\\n400 mg 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 205, 'page_label': '206', 'id': 'data/guideline-170-en.pdf:205:2'}, page_content='7.5 mg/kg 2 times daily\\nAdults over 60 kg:\\n400 mg 2 times daily\\nTreatment duration:\\nIn addition to surgery\\n(pre-operatively or\\npost- operatively):\\ncontinuous course of\\nminimum 2 months or at\\nleast two 28-day\\ncourses with a drug-\\nfree interval of 14 days.\\nInoperable cases: 28-\\nday courses with drug-\\nfree intervals of 14\\ndays, for 3 to 6 months\\n(on average), possibly\\nup to 1 year.\\n (b) \\nTransmission:\\nPrevention:\\ndirect: contact with\\ndogs\\nindirect: water and food\\ncontaminated by dog\\nfaeces\\nindividual: avoid contact\\nwith dogs\\ncollective: eliminate\\nstray dogs, monitor\\nslaughterhouses\\n(b) Albendazole is contra-indicated during the ﬁrst trimester of pregnancy.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 206, 'page_label': '207', 'id': 'data/guideline-170-en.pdf:206:0'}, page_content='Page 207 / 409\\nNematode infections'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 207, 'page_label': '208', 'id': 'data/guideline-170-en.pdf:207:0'}, page_content='Page 208 / 409\\nInfection/Epidemiology Clinical features/Diagnosis Treatment\\nAscariasis\\xa0(roundworms)\\nAscaris lumbricoides\\nDistribution: worldwide,\\nmainly in tropical and\\nsubtropical\\nTransmission: ingestion of\\nascaris eggs\\n(a) During larval migration\\nLoefﬂer ’s syndrome: transient pulmonary\\nsymptoms (dry cough, dyspnoea, wheezing) and\\nmild fever.\\nOnce adult worms are present in the intestine\\nAbdominal pain and distension. In general, the\\ndiagnosis is made when adult worms are\\nexpelled from the anus (or occasionally from the\\nmouth). Ascaris are large (15-30 cm), cylindrical\\nworms, pinkish-white, with slightly tapered ends.\\nComplications\\nAscariasis is usually benign, but massive\\ninfestation may cause intestinal obstruction\\n(abdominal pain, vomiting, constipation),'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 207, 'page_label': '208', 'id': 'data/guideline-170-en.pdf:207:1'}, page_content='(abdominal pain, vomiting, constipation),\\nespecially in children < 5 years. Worms may\\naccidentally migrate to gall bladder, liver or\\nperitoneum, causing jaundice, liver abscess, or\\nperitonitis.\\nAscaris eggs may be detected through\\nparasitological examination of stools.\\nalbendazole PO single dose\\nChildren > 6 months and adults:\\n400 mg\\n(200 mg in children > 6 months\\nbut < 10 kg)\\nor\\nmebendazole PO for 3 days\\nChildren > 6 months and adults:\\n100 mg 2 times daily\\n(50 mg 2 times daily in children\\n> 6 months but < 10 kg)\\nTrichuriasis\\xa0(whipworms)\\nTrichuris trichiura\\nDistribution and\\ntransmission:\\nas for A. lumbricoides\\n(a) In heavy infection: abdominal pain and diarrhoea.\\nIn massive infection: chronic bloody diarrhea,\\ntenesmus, rectal prolapse due to frequent'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 207, 'page_label': '208', 'id': 'data/guideline-170-en.pdf:207:2'}, page_content='tenesmus, rectal prolapse due to frequent\\nattempts to defecate, especially in children.\\nWorms may sometimes be seen on the rectal\\nmucosa when prolapsed: these are grayish-\\nwhite, 3-5 cm in length, in the shape of a whip,\\nwith a thickened body and a long, threadlike\\nextremity.\\nTrichuris eggs may be detected through\\nparasitological examination of stools.\\nalbendazole PO for 3 days\\nChildren > 6 months and adults:\\n400 mg once daily\\n(200 mg once daily in children >\\n6 months but < 10 kg)\\nor\\nmebendazole PO for 3 days,\\nas for ascariasis.\\nA single dose of albendazole\\nor mebendazole is often\\ninsufﬁcient.\\nAnkylostomiase\\nAncylostoma duodenale\\nNecator americanus\\nDistribution: tropical and\\nsubtropical regions\\nTransmission: larval skin\\npenetration following\\ncontact (feet, hands) with\\ncontaminated soil'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 207, 'page_label': '208', 'id': 'data/guideline-170-en.pdf:207:3'}, page_content='penetration following\\ncontact (feet, hands) with\\ncontaminated soil\\n(a) During larval penetration/migration\\nCutaneous signs (pruritic papulo-vesicular rash\\nat the site of penetration, usually the feet) and\\npulmonary symptoms (similar to ascariasis).\\nOnce adult worms are present in the intestine\\nMild abdominal pain. Attachment of the parasite\\nto the mucosa leads to chronic blood loss and\\nanaemia (in endemic areas, antihelminthic\\ntreatment is recommended for patients with\\niron-deﬁciency anaemia).\\nHookworm eggs may be detected through\\nparasitological examination of stools.\\nalbendazole single dose (as\\nfor ascariasis) is much more\\neffective than mebendazole\\nsingle dose.\\nWhen using mebendazole, a 3-\\nday treatment (as for\\nascariasis) is recommended.\\nTreatment of anaemia\\n(Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 207, 'page_label': '208', 'id': 'data/guideline-170-en.pdf:207:4'}, page_content='ascariasis) is recommended.\\nTreatment of anaemia\\n(Chapter 1).\\nStrongyloidiasis Acute strongyloidiasis First line treatment is:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 208, 'page_label': '209', 'id': 'data/guideline-170-en.pdf:208:0'}, page_content='Page 209 / 409\\nStrongyloides stercoralis\\nDistribution: humid tropical\\nregions\\nTransmission: larval skin\\npenetration and auto-\\ninfection\\nDuring larval penetration/migration:\\ncutaneous signs (erythema and pruritus at the\\nsite of penetration, which may persist several\\nweeks) and pulmonary symptoms (similar to\\nascariasis).\\nOnce larvae are present in the intestine:\\ngastrointestinal symptoms (bloating,\\nabdominal and epigastric pain, vomiting,\\ndiarrhoea).\\nChronic strongyloidiasis\\nIntestinal larvae may re-infect their host (auto-\\ninfection) by penetrating through the intestinal\\nwall or by migrating transcutaneously from\\nperianal skin. Chronic infections result in\\nprolonged or recurrent pulmonary and\\ngastrointestinal symptoms. Transcutaneous\\nmigration of intestinal larvae gives rise to a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 208, 'page_label': '209', 'id': 'data/guideline-170-en.pdf:208:1'}, page_content='migration of intestinal larvae gives rise to a\\ntypical rash (larva currens), mainly in the anal\\nregion and on the trunk: sinuous, raised, linear,\\nmigrating lesion, intensely pruritic, moving rapidly\\n(5 to 10 cm/hour) and lasting several hours or\\ndays.\\nComplications\\nHyperinfection (massive infestation) results in\\nexacerbation of pulmonary and gastrointestinal\\nsymptoms, and possible dissemination of larvae\\nto atypical locations, (CNS, heart, etc.). This\\nform occurs mainly in patients receiving\\nimmunosuppressive therapy (e.g.\\ncorticosteroids).\\nStrongyloides larvae may be detected through\\nparasitological examination of stools.\\nivermectin PO \\xa0single dose\\nChildren > 15 kg and adults:\\n200 micrograms/kg, on an\\nempty stomach\\nWhile less effective, a 3-day\\ntreatment with albendazole'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 208, 'page_label': '209', 'id': 'data/guideline-170-en.pdf:208:2'}, page_content='empty stomach\\nWhile less effective, a 3-day\\ntreatment with albendazole\\nPO (as for trichuriasis) may be\\nan alternative.\\nHyperinfections are refractory\\nto conventional therapy.\\nProlonged or intermittent\\nmultiple-dose regimens are\\nrequired.\\n(b)\\nEnterobiasis (pinworms)\\nEnterobius vermicularis\\nDistribution: worldwide\\nTransmission: faecal-oral\\nroute or auto-infection\\nAnal pruritus, more intense at night, vulvovaginitis\\nin girls (rare). In practice, the diagnosis is most\\noften made when worms are seen on the\\nperianal skin (or in the stool in heavy infestation).\\nPinworms are small (1 cm), mobile, white,\\ncylindrical worms with slightly tapered ends.\\nPinworm eggs may be collected from the anal\\narea (scotch tape method) and detected under\\nthe microscope.\\nalbendazole PO single dose,\\nas for ascariasis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 208, 'page_label': '209', 'id': 'data/guideline-170-en.pdf:208:3'}, page_content='the microscope.\\nalbendazole PO single dose,\\nas for ascariasis\\nor\\nmebendazole PO single dose\\nChildren > 6 months and adults:\\n100 mg\\n(50 mg in children > 6 months\\nbut < 10 kg)\\nA second dose may be given\\nafter 2 to 4 weeks.\\nTrichinellosis\\nTrichinella sp\\nDistribution: worldwide,\\nparticularly frequent in Asia\\n(Thailand, Laos, China, etc.)\\nEnteric phase (1 to 2 days after ingestion of\\ninfected meat)\\nSelf-limited episode of diarrhoea and abdominal\\npain lasting several days.\\nalbendazole PO for 10 to 15\\ndays\\nChildren > 2 years:\\n5 mg/kg 2 times daily\\nAdults:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 209, 'page_label': '210', 'id': 'data/guideline-170-en.pdf:209:0'}, page_content='Page 210 / 409\\n\\xa0\\n\\xa0Roundworms, whipworms and hookworms frequently co-infect the same host. This should be taken into account\\nwhen prescribing antihelminthic treatment.\\xa0 \\xa0The migrating larvae of\\xa0Ancylostoma braziliense\\xa0and\\xa0caninum\\xa0(hookworms of cats and dogs) also present as a\\npruritic, inﬂammatory, creeping eruption in humans (cutaneous larva migrans) but with a slower rate of progression and a\\nlonger duration (several weeks or months). Treatment is with\\xa0albendazole\\xa0(400 mg single dose or once daily for 3 days\\nin children > 6 months and adults; 200 mg in children > 6 months but < 10 kg) or\\xa0ivermectin\\xa0(200 micrograms/kg single\\ndose).\\nTransmission: consumption\\nof raw or undercooked\\nmeat containing trichinella\\nlarvae (pork, wart-hog, bear,\\ndog, etc.)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 209, 'page_label': '210', 'id': 'data/guideline-170-en.pdf:209:1'}, page_content='meat containing trichinella\\nlarvae (pork, wart-hog, bear,\\ndog, etc.)\\nMuscular phase (about 1 week after ingestion)\\nHigh fever; muscular pain (ocular [pain on eye\\nmovement], masseters [limitation of mouth\\nopening], throat and neck [pain with swallowing\\nand speech], trunk and limbs); facial or bilateral\\nperi-orbital oedema; conjunctival haemorrhage,\\nsubungual haemorrhage; headache. Typical\\nfeatures are not always present and the patient\\nmay present with a non-speciﬁc ﬂu-like\\nsyndrome.\\nOther features, such as dietary habits\\n(consuming pork/raw meat), suggestive\\nsymptoms (fever > 39 °C and myalgia and facial\\noedema) in several individuals who have shared\\nthe same meal (e.g. ceremony) or\\nhypereosinophilia > 1000/mm, reinforce the\\nclinical suspicion.\\n3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 209, 'page_label': '210', 'id': 'data/guideline-170-en.pdf:209:2'}, page_content='hypereosinophilia > 1000/mm, reinforce the\\nclinical suspicion.\\n3\\nDeﬁnitive diagnosis: muscle biopsy; serology\\n(ELISA, Western Blot).\\n400 mg 2 times daily\\nor\\nmebendazole PO for 10 to 15\\ndays\\nChildren > 2 years:\\n2.5 mg/kg 2 times daily\\nAdults:\\n200 mg 2 times daily\\nplus, regardless of which anti-\\nhelminthic is chosen:\\nprednisolone PO\\n0.5 to 1 mg/kg once daily for\\nthe duration of treatment\\n(a)\\n(b)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 210, 'page_label': '211', 'id': 'data/guideline-170-en.pdf:210:0'}, page_content='Page 211 / 409\\nFilariasis\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nFilariases are helminthiases due to tissue-dwelling nematode worms (ﬁlariae). Human to human transmission takes\\nplace through the bite of an insect vector.\\xa0The most important pathogens are outlined in the table below. Mixed infections are common in co-endemic regions.\\xa0Each ﬁlarial species is found in 2 principal developmental stages: macroﬁlariae (adult worms) and microﬁlariae (larval\\noffspring). The treatment depends on the pathogenic stage of the species considered and targets microﬁlariae for\\xa0O.\\nvolvulus\\xa0and macroﬁlariae for the other species.\\xa0\\nClassical antiﬁlarial agents include diethylcarbamazine (DEC), ivermectin and albendazole. Doxycycline is used solely in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 210, 'page_label': '211', 'id': 'data/guideline-170-en.pdf:210:1'}, page_content='the treatment of\\xa0O. volvulus\\xa0and lymphatic ﬁlarial worms, which harbour an endosymbiotic bacterium (Wolbachia)\\nsensitive to doxycycline.\\nOnchocerciasis (river blindness)\\nLoiasis.\\nLymphatic ﬁlariasis (LF)\\n\\xa0\\nSpecies/Infections Location of\\nmacroﬁlariae\\nLocation of \\nmicroﬁlariae\\nPathogenic \\nstage\\nPresence\\nof Wolbachia\\nOnchocerca volvulus\\n(onchocerciasis)\\nSubcutaneous\\nnodules Skin and eye Microﬁlariae Yes\\nLoa loa\\n(loiasis)\\nSubcutaneous\\ntissue Blood Macroﬁlariae No\\nWuchereria bancrofti, Brugia\\nmalayi and Brugia timori\\n(lymphatic ﬁlariasis)\\nLymph vessels Blood Macroﬁlariae Yes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 211, 'page_label': '212', 'id': 'data/guideline-170-en.pdf:211:0'}, page_content='Page 212 / 409\\nOnchocerciasis (river blindness)\\nThe distribution of onchocerciasis is linked to that of its vector (Simulium), which reproduces near rapidly ﬂowing rivers\\nin intertropical Africa (99% of cases), Latin America (Guatemala, Mexico, Ecuador, Colombia, Venezuela, Brazil) and\\nYemen.\\nClinical features\\nIn endemic areas, the following signs, alone or in combination, are suggestive of onchocerciasis:\\nLaboratory\\nTreatment\\nAntiparasitic treatment\\nOnchocercomas: painless subcutaneous nodules containing adult worms, usually found over a bony prominence\\n(iliac crest, trochanters, sacrum, rib cage, skull, etc.), measuring several mm or cm in size, ﬁrm, smooth, round or\\noval, mobile or adherent to underlying tissue; single, or multiple and clustered.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 211, 'page_label': '212', 'id': 'data/guideline-170-en.pdf:211:1'}, page_content='Acute papular onchodermatitis: papular rash, sometimes diffuse but often conﬁned to the buttocks or lower\\nextremities, intensely itchy, associated with scratch marks, often superinfected (“ﬁlarial scabies”) . This arises from\\ndermal invasion by microﬁlariae.\\n a \\nLate chronic skin lesions: patchy depigmentation on the shins (“leopard skin”), skin atrophy or areas of dry,\\nthickened, peeling skin (licheniﬁcation; “lizard skin”).\\nVisual disturbances and ocular lesions: see\\xa0Onchocerciasis, Chapter 5.\\nDetection of the microﬁlariae in the skin (skin snip biopsy, iliac crest).\\nIf the skin biopsy is positive, look for loiasis in regions where loiasis is co-endemic (mainly in Central Africa).\\nDiethylcarbamazine is contra-indicated (risk of severe ocular lesions).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 211, 'page_label': '212', 'id': 'data/guideline-170-en.pdf:211:2'}, page_content='Diethylcarbamazine is contra-indicated (risk of severe ocular lesions).\\nDoxycycline\\xa0PO (200 mg once daily for 4 weeks; if possible 6 weeks) kills a signiﬁcant percentage of adult worms\\nand progressively reduces the number of\\xa0O. volvulus\\xa0microﬁlariae . It is contraindicated in children < 8 years and\\npregnant or breast-feeding women.\\n b \\nIvermectin\\xa0PO is the drug of choice: 150 micrograms/kg single dose; a 2 \\xa0dose should be administered after 3\\nmonths if clinical signs persist. Repeat the treatment every 6 or 12 months to maintain the parasite load below the\\nthreshold at which clinical signs appear . Ivermectin is not recommended in children < 5 years or < 15 kg and\\npregnant women.\\nnd\\n c'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 211, 'page_label': '212', 'id': 'data/guideline-170-en.pdf:211:3'}, page_content='pregnant women.\\nnd\\n c \\nIn case of co-infection with\\xa0Loa loa\\xa0or in regions where loiasis is co-endemic, ivermectin should be administered\\nwith caution (risk of severe adverse reactions in patients with high\\xa0L. loa\\xa0microﬁlarial load):\\nIf it is possible to test for\\xa0Loa loa\\xa0(thick blood ﬁlm):\\nConﬁrm and quantify the microﬁlaraemia. Administer the appropriate treatment according to the microﬁlarial\\nload (see\\xa0Loiasis).\\nIf it is not possible to perform a thick ﬁlm examination, take a history from the patient:\\nIf the patient has received a previous treatment with ivermectin without developing serious adverse reactions\\n(see\\xa0Loiasis), administer the treatment.\\nIf the patient has never received ivermectin nor developed signs of loiasis (migration of an adult worm under the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 211, 'page_label': '212', 'id': 'data/guideline-170-en.pdf:211:4'}, page_content='conjunctiva, or « Calabar » swellings), administer the treatment.\\nIf the patient already has developed signs of loiaisis and if onchocerciasis has a signiﬁcant clinical impact,\\nadminister ivermectin under close supervision (see\\xa0Loiasis) or use an alternative (doxycycline, as above).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 212, 'page_label': '213', 'id': 'data/guideline-170-en.pdf:212:0'}, page_content='Page 213 / 409\\nNodulectomy (surgical removal of onchocercomas)\\nNodules are benign, often deep, and their ablation does not treat onchocerciasis. Thus, nodulectomy is reserved for\\ncranial nodules (their proximity to the eye is a risk factor for visual compromise) or nodules which are cosmetically\\nunacceptable. In other cases, refrain from nodulectomy. Nodulectomy is performed under local anaesthesia, in an\\nappropriately equipped facility.\\n\\xa0\\nIn the case of concomitant lymphatic ﬁlariasis: administer ivermectin ﬁrst then start treatment for lymphatic\\nﬁlariasis with doxycycline PO (see\\xa0Lymphatic ﬁlariasis) one week later.\\nFootnotes\\n(a) Differential diagnosis is sarcoptic scabies (Scabies, Chapter 4).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 212, 'page_label': '213', 'id': 'data/guideline-170-en.pdf:212:1'}, page_content='Footnotes\\n(a) Differential diagnosis is sarcoptic scabies (Scabies, Chapter 4).\\n(b) Elimination of Wolbachia reduces the longevity and fertility of the macroﬁlariae, and thus the production of new microﬁlariaewithin the organism.\\n(c) Ivermectin kills microﬁlariae and disrupts production of microﬁlariae by adult worms. However the treatment must beadministered at regular intervals since it does not kill adult worms.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 213, 'page_label': '214', 'id': 'data/guideline-170-en.pdf:213:0'}, page_content='Page 214 / 409\\nLoiasis\\nThe distribution of loiasis is linked to that of its vector (Chrysops) in forests or savannah with gallery forests in West or\\nCentral Africa (limits West: Benin; East: Uganda; North: Sudan and South: Angola).\\nClinical features\\nLaboratory\\nTreatment\\nAntiparasitic treatment\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa01)\\xa0 L. loa microﬁlaraemia is < 1,000-2,000 mf/ml\\nA 28-day treatment of\\xa0DEC\\xa0may be started using a small dose: 6 mg on D1, i.e.\\xa01/8 of a 50 mg tablet 2 times\\ndaily.\\nDouble the dose every day up to 200 mg 2 times daily in adults (1.5 mg/kg 2 times daily in children).\\nIf microﬁlaraemia or symptoms persist, a second treatment is given 4 weeks later.\\nIf DEC is contra-indicated due to possible or conﬁrmed co-infection with\\xa0O. volvulus,\\xa0ivermectin\\xa0(150'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 213, 'page_label': '214', 'id': 'data/guideline-170-en.pdf:213:1'}, page_content='microgams/kg single dose) treats onchocerciasis, and reduces pruritus and frequency of Calabar swellings.\\nThe treatment may be repeated every month or every 3 months.\\xa0\\nThe subconjunctival migration of an adult worm is pathognomonic of\\xa0Loa loa\\xa0infection.\\xa0\\nLocalised subcutaneous swellings, allergic in origin, transient (several hours or days), painless, non-pitting, appearing\\nanywhere on the body, frequently the upper extremities and face, often associated with localised or generalised\\npruritus (« Calabar swellings »).\\nOnset of pruritus, in the absence of other signs.\\nSubcutaneous migration of an adult worm: pruritic, palpable red cord-like linear lesion, sinuous, advancing (1\\ncm/hour), disappearing rapidly with no trace . Such migration generally arises following treatment with'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 213, 'page_label': '214', 'id': 'data/guideline-170-en.pdf:213:2'}, page_content='diethylcarbamazine, rarely spontaneously.\\n a \\nDetection of microﬁlariae in the peripheral blood (thick ﬁlm, stained with Giemsa). Blood specimens should be\\ncollected between 10 am and 5 pm. Quantify microﬁlaraemia even if the diagnosis is certain, since treatment is\\ndetermined by the intensity of the parasite load.\\nIf the thick ﬁlm is positive, look for onchocerciasis in regions where onchocerciasis is coendemic (mainly in Central\\nAfrica).\\nDiethylcarbamazine (DEC) is the only macroﬁlaricide available but is contra-indicated in:\\nPatients with microﬁlaraemia > 2000 mf/ml (risk of severe encephalopathy, with poor prognosis).\\nPatients co-infected with\\xa0O. volvulus\\xa0(risk of severe eye lesions).\\nPregnant women, infants, and patients in poor general condition.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 213, 'page_label': '214', 'id': 'data/guideline-170-en.pdf:213:3'}, page_content='Pregnant women, infants, and patients in poor general condition.\\nIvermectin (and possibly albendazole) is used to reduce microﬁlaraemia before administration of DEC; however,\\nivermectin administration may trigger encephalopathy in patients with very high\\xa0Loa loa\\xa0microﬁlaraemia (> 30 000\\nmf/ml).\\nDoxycycline is not indicated since\\xa0Loa loa\\xa0does not harbour\\xa0Wolbachia.\\nManagement:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 214, 'page_label': '215', 'id': 'data/guideline-170-en.pdf:214:0'}, page_content='Page 215 / 409\\n2)\\xa0 L. loa microﬁlaraemia is between 2,000 and 8,000 mf/ml\\nReduce microﬁlaraemia with\\xa0ivermectin\\xa0(150 micrograms/kg single dose); repeat the treatment every month if\\nnecessary; administer DEC when the microﬁlaraemia is < 2000 mf/ml.\\xa03)\\xa0 L. loa microﬁlaraemia is between 8,000 and 30,000 mf/ml\\nTreatment with\\xa0ivermectin\\xa0(150 micrograms/kg single dose) may cause marked functional impairment for\\nseveral days. Close supervision and support from family member(s) are necessary . Prescribe paracetamol as\\nwell for 7 days.\\xa04)\\xa0 L. loa microﬁlaraemia is > 30,000 mf/ml\\nExtraction of macroﬁlariae\\nSubcutaneous migration of a microﬁlaria usually results from treatment with DEC; the worm will die beneath the skin'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 214, 'page_label': '215', 'id': 'data/guideline-170-en.pdf:214:1'}, page_content='and extracting it serves no purpose.\\xa0Removal of an adult worm from the conjunctiva: see\\xa0Loasis, Chapter 5.\\n\\xa0\\n b \\nIf the loiasis is well tolerated, it is preferable to refrain from treatment: the disease is benign and treatment\\nwith ivermectin may cause very severe adverse reactions (encephalopathy), albeit rarely.\\nIf loiasis has a signiﬁcant clinical impact and/or the patient presents with symptomatic onchocerciasis\\nrequiring treatment,\\xa0ivermectin\\xa0(150 micrograms/kg single dose) is administered for 5 days under supervision\\nin hospital . An attempt to ﬁrst reduce\\xa0L. loa\\xa0microﬁlaraemia using\\xa0albendazole\\xa0(200 mg 2 times daily for 3\\nweeks) is an option. When\\xa0L. loa\\xa0microﬁlaraemia is < 30 000 mf/ml, treat with ivermectin under close'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 214, 'page_label': '215', 'id': 'data/guideline-170-en.pdf:214:2'}, page_content='supervision and support, then DEC when the microﬁlaraemia is < 2000 mf/ml.\\n c \\nFootnotes\\n(a) For differential diagnosis, see cutaneous larva migrans.\\n(b) Patients may present with various pain syndromes, be unable to move without help or unable to move at all. Monitoring isnecessary to determine whether the patient can manage activities of daily living, and provide assistance if necessary. If thepatient remains bedridden for several days, ensure pressure sores do not develop (mobilisation, repositioning).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 214, 'page_label': '215', 'id': 'data/guideline-170-en.pdf:214:3'}, page_content='(c) A severe reaction may occur on D2-D3. It is usually preceded by haemorrhages of the palpebral conjunctiva on D1-D2.Routinely check for this sign by turning back the eyelids. Symptoms of post ivermectin encephalopathy are reversible andthe prognosis favourable, if the patient is correctly managed; the treatment is symptomatic until symptoms resolve. Avoidthe use of steroids due to adverse effects.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 215, 'page_label': '216', 'id': 'data/guideline-170-en.pdf:215:0'}, page_content='Page 216 / 409\\nLymphatic ﬁlariasis (LF)\\nThe distribution of LF is linked to that of its mosquito vectors (Anopheles, Culex, Aedes, etc.):\\n90% of LF is due to\\xa0W. bancrofti\\xa0and 10% to\\xa0Brugia\\xa0spp.\\nClinical features\\n\\xa0\\nLaboratory\\nTreatment\\nAntiparasitic treatment\\nW. bancrofti: sub-Saharan Africa, Madagascar, Egypt, India, South East Asia, Paciﬁc region, South America, The\\nCaribbean\\nB. malayi: South East Asia, China, India, Sri Lanka\\nB. timori: Timor\\nAcute recurrent inﬂammatory manifestations\\nAdenolymphangitis: lymph node(s) and red, warm, tender oedema along the length of a lymphatic channel, with or\\nwithout systemic signs (e.g. fever, nausea, vomiting). The inﬂammation may involve the lower limbs, external\\ngenitalia and breast.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 215, 'page_label': '216', 'id': 'data/guideline-170-en.pdf:215:1'}, page_content='genitalia and breast.\\n\\xa0In men: acute inﬂammation of the spermatic cord (funiculitis), epididymis and testicle (epididymo-orchitis).\\nAttacks resolve spontaneously within a week and recur regularly in patients with chronic disease.\\nChronic manifestations\\nLymphoedema: oedema of the lower extremity or external genitalia or breast, secondary to obstruction of the\\nlymphatics by macroﬁlariae. The oedema is reversible initially but then becomes chronic and increasingly severe:\\nhypertrophy of the area affected, progressive thickening of the skin (ﬁbrous thickening with formation of\\ncreases, initially superﬁcial, but then deep, and verrucous lesions). The ﬁnal stage of lymphoedema is\\nelephantiasis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 215, 'page_label': '216', 'id': 'data/guideline-170-en.pdf:215:2'}, page_content='elephantiasis.\\nIn men: increase in volume of ﬂuid due to accumulation within the tunica vaginalis (hydrocoele, lymphocoele,\\nchylocoele); chronic epididymo-orchitis.\\nChyluria: milky or rice-water urine (disruption of a lymphatic vessel in the urinary tract).\\nIn patients parasitized by\\xa0Brugia\\xa0spp, genital lesions and chyluria are rare: lymphoedema is usually conﬁned to\\nbelow the knee.\\nDetection of microﬁlariae in the peripheral blood (thick ﬁlm) ; blood specimens should be collected between 9 pm\\nand 3 am.\\n a \\nIn regions where loiasis and/or onchocerciasis are co-endemic, check for co-infection if the LF diagnosis is\\npositive.\\nTreatment is not administered during an acute attack.\\nDoxycycline\\xa0PO, when administered as a prolonged treatment, eliminates the majority of macroﬁlariae and reduces'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 215, 'page_label': '216', 'id': 'data/guideline-170-en.pdf:215:3'}, page_content='lymphoedema: 200 mg once daily for 4 weeks minimum. It is contraindicated in children < 8 years and pregnant or\\nbreast-feeding women.\\nDiethylcarbamazine\\xa0PO single dose (400 mg in adults; 3 mg/kg in children) may be an alternative but eliminates a\\nvariable proportion of adult worms (up to 40%) and does not relieve symptoms; a prolonged treatment is no more\\neffective than single dose therapy. In addition, DEC is contra-indicated in patients with onchocerciasis or\\xa0Loa\\nloa\\xa0microﬁlarial load > 2000 mf/ml and in pregnant and breast-feeding women.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 216, 'page_label': '217', 'id': 'data/guideline-170-en.pdf:216:0'}, page_content='Page 217 / 409\\nControl/prevention of inﬂammatory manifestations and infectious complications\\nSurgery\\nMay be indicated in the treatment of chronic manifestations: advanced lymphoedema (diversion-reconstruction),\\nhydrocoele and its complications, chyluria.\\n\\xa0\\nIvermectin (weak or absent macroﬁlaricidal effect) and albendazole should not be used for the treatment of\\nindividual cases (no effect on symptoms).\\nIn the case of conﬁrmed or probable co-infection with\\xa0O. volvulus: treat\\xa0onchocerciasis\\xa0ﬁrst, then administer\\ndoxycycline.\\nAcute attacks: bed rest, elevation of the affected limb without bandaging, cooling of the affected limb (wet cloth,\\ncold bath) and analgesics; antibacterial or antifungal cream if necessary; antipyretics if fever (paracetamol) and\\nhydration.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 216, 'page_label': '217', 'id': 'data/guideline-170-en.pdf:216:1'}, page_content='hydration.\\nPrevention of episodes of lymphangitis and lymphoedema: hygiene of the affected extremity , comfortable\\nfootwear, immediate attention to secondary bacterial/fungal infections and wounds.\\n b \\nEstablished lymphoedema: bandaging of the affected limb by day, elevation of the affected extremity (after\\nremoval of the bandage) when at rest, simple exercises (ﬂexion-extension of the feet when recumbent or upright,\\nrotation of the ankles); skin hygiene, as above.\\nFootnotes\\n(a) When test results are negative in a clinically suspect case, consider detection of antigens (ICT rapid test) and/or ultrasoundof the inguinal area in search of the « ﬁlarial dance sign ».'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 216, 'page_label': '217', 'id': 'data/guideline-170-en.pdf:216:2'}, page_content='(b) Wash at least once daily (soap and water at room temperature), paying special attention to folds and interdigital areas;rinse thoroughly and dry with a clean cloth; nail care.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 217, 'page_label': '218', 'id': 'data/guideline-170-en.pdf:217:0'}, page_content='Page 218 / 409\\nChapter 7: Bacterial diseases\\nBacterial meningitis\\nTetanus\\nEnteric (typhoid and paratyphoid) fevers\\nBrucellosis\\nPlague\\nLeptospirosis\\nRelapsing fever (borreliosis)\\nLouse-borne relapsing fever (LBRF)\\nTick-borne relapsing fever (TBRF)\\nEruptive rickettsioses'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 218, 'page_label': '219', 'id': 'data/guideline-170-en.pdf:218:0'}, page_content='Page 219 / 409\\nBacterial meningitis\\nMeningitis is an acute bacterial infection of the meninges, which may affect the brain and lead to irreversible\\nneurological damage and auditory impairment.\\nBacterial meningitis is a medical emergency. The treatment is based on early parenteral administration of antibiotics\\nthat penetrates well into the cerebrospinal ﬂuid (CSF). Empiric antibiotic therapy is administered if the pathogen cannot\\nbe identiﬁed or while waiting for laboratory results.\\nThe main bacteria responsible vary depending on age and/or context:\\nMeningitis in a non-epidemic context\\nL. monocytogenes\\xa0is occasionally responsible for meningitis during this period.\\n\\xa0Special conditions:\\nMeningitis in an epidemic context'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 218, 'page_label': '219', 'id': 'data/guideline-170-en.pdf:218:1'}, page_content=\"Special conditions:\\nMeningitis in an epidemic context\\nIn the Sahelian region (but not exclusively, e.g. Rwanda, Angola, Brazil),\\xa0during the dry season, epidemics of\\nmeningococcal meningitis (Neisseria meningitidis\\xa0A or C or W135) affect children from 6 months of age, adolescents\\nand adults. In these regions, whether during epidemics or not, all the above pathogens can be found, especially in young\\nchildren.\\nClinical features\\nThe clinical presentation depends on the patient's age.\\nChildren over 1 year and adults\\nChildren under 1 year\\nThe classic signs of meningitis are usually absent.\\nChildren 0 to 3 months:\\nChildren ≤ 7 days: Gram-negative bacilli (Klebsiella\\xa0spp,\\xa0E. coli,\\xa0S.\\nmarcescens,\\xa0Pseudomona\\xa0spp,\\xa0Salmonella\\xa0spp) and group B streptococcus\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 218, 'page_label': '219', 'id': 'data/guideline-170-en.pdf:218:2'}, page_content=\"marcescens,\\xa0Pseudomona\\xa0spp,\\xa0Salmonella\\xa0spp) and group B streptococcus\\nChildren > 7 days:\\xa0S. pneumoniae\\xa0accounts for 50% of all bacterial meningitis\\nChildren 3 months-5 years:\\xa0S. pneumoniae,\\xa0H. inﬂuenza B\\xa0and\\xa0N. meningitidis\\nChildren > 5 years and adults:\\xa0S. pneumoniae\\xa0and\\xa0N. meningitidis\\nImmunodepressed patients (HIV, malnourished): high percentage of Gram- negative bacilli (specially\\xa0Salmonella\\xa0spp)\\nand also\\xa0M. tuberculosis.\\nSickle cell anaemia:\\xa0Salmonella\\xa0spp\\xa0and\\xa0Staphylococcus aureus\\xa0are frequent causes.\\nMeningitis may be related to\\xa0S. aureus\\xa0when associated with skin infection or skull fracture.\\nFever, severe headache, photophobia, neck stiffness\\nBrudzinski's sign (neck ﬂexion in a supine patient results in involuntary ﬂexion of the knees) and Kernig's sign\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 218, 'page_label': '219', 'id': 'data/guideline-170-en.pdf:218:3'}, page_content='(attempts to extend the knee from the ﬂexed-thigh position are met with strong passive resistance).\\nPetechial or ecchymotic purpura (usually in meningococcal infections)\\nIn severe forms: coma, seizures, focal signs, purpura fulminans\\nThe child is irritable, appears sick with fever or hypothermia, poor feeding or vomiting.\\nOther features include: seizures, apnoea, altered consciousness, bulging fontanelle (when not crying); occasionally,\\nneck stiffness and purpuric rash.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 219, 'page_label': '220', 'id': 'data/guideline-170-en.pdf:219:0'}, page_content='Page 220 / 409\\nLaboratory\\n\\xa0\\n\\xa0Note: in an endemic area, it is essential to test for severe malaria (rapid test or thin/thick ﬁlms).\\nTreatment in a non-epidemic context\\nAntibiotic therapy\\nFor the choice of antibiotic therapy and dosages according to age, see table below.\\xa0\\nLumbar puncture (LP):\\nMacroscopic examination of CSF: antibiotic therapy should be initiated immediately if the LP yields a turbid CSF.\\nMicroscopic examination: Gram stain (but a negative examination does not exclude the diagnosis) and white\\nblood cell count (WBC).\\nIn an epidemic context, once the meningococcal aetiology has been conﬁrmed, there is no need for routine LP\\nfor new cases.\\n\\xa0 Pressure Aspect WBC\\n(leucocytes/mm)3 Protein Other\\ntests\\nNormal CSF \\xa0 Clear < 5 Pandy–\\n< 40 mg/dl –'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 219, 'page_label': '220', 'id': 'data/guideline-170-en.pdf:219:1'}, page_content='(leucocytes/mm)3 Protein Other\\ntests\\nNormal CSF \\xa0 Clear < 5 Pandy–\\n< 40 mg/dl –\\nBacterial meningitis ++++ Cloudy, turbid\\n100-20 000 \\nmainly neutrophiles\\nIn neonates: \\n> 20\\nIn\\nimmunocompromised, \\nthe WBC may be < 100\\nPandy+\\n100-500\\nmg/dl\\nGram stain +\\nViral meningitis Normal to\\n+ Clear 10-700\\nmainly lymphocytes Pandy– –\\nTB meningitis +++ Clear or\\nyellowish\\n< 500 \\nmainly lymphocytes Pandy+ AFB\\nCryptococcal\\nmeningitis ++++ Clear < 800 \\nmainly lymphocytes Pandy– India ink\\nRapid test for detection of bacterial antigens.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 220, 'page_label': '221', 'id': 'data/guideline-170-en.pdf:220:0'}, page_content='Page 221 / 409\\n\\xa0 No associated skin infection Associated skin infection (including umbilical\\ncord infection)\\n\\xa0 First line Alternative First line Alternative\\n0 to 7\\ndays\\n< 2 kg\\nampicillin IV\\n100 mg/kg every 12 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 12 hours\\nampicillin IV\\n100 mg/kg\\nevery 12\\nhours\\n+\\ngentamicin\\nIV\\n3 mg/kg\\nonce daily\\ncloxacillin IV\\n50 mg/kg every 12 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 12 hours\\ncloxacillin\\nIV\\n50 mg/kg\\nevery 12\\nhours\\n+\\ngentamicin\\nIV\\n3 mg/kg\\nonce daily\\n0 to 7\\ndays\\n≥ 2 kg\\nampicillin IV\\n100 mg/kg every 8 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 8 hours\\nampicillin IV\\n100 mg/kg\\nevery 8\\nhours\\n+\\ngentamicin\\nIV\\n5 mg/kg\\nonce daily\\ncloxacillin IV\\n50 mg/kg every 8 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 8 hours\\ncloxacillin\\nIV\\n50 mg/kg\\nevery 8\\nhours\\n+\\ngentamicin\\nIV\\n5 mg/kg\\nonce daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 220, 'page_label': '221', 'id': 'data/guideline-170-en.pdf:220:1'}, page_content='cloxacillin\\nIV\\n50 mg/kg\\nevery 8\\nhours\\n+\\ngentamicin\\nIV\\n5 mg/kg\\nonce daily\\n8 days\\nto\\n< 1\\nmonth\\n≥ 2 kg\\nampicillin IV\\n100 mg/kg every 8 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 8 hours\\nampicillin IV\\n100 mg/kg\\nevery 8\\nhours\\n+\\ngentamicin\\nIV\\n5 mg/kg\\nonce daily\\ncloxacillin IV\\n50 mg/kg every 6 hours\\n+\\ncefotaxime IV\\n50 mg/kg every 8 hours\\ncloxacillin\\nIV\\n50 mg/kg\\nevery 6\\nhours\\n+\\ngentamicin\\nIV\\n5 mg/kg\\nonce daily\\n1 to 3\\nmonths\\nampicillin IV\\n100 mg/kg every 8 hours\\n+\\nceftriaxone IV 100 mg/kg on D1\\nthen starting on D2: 100 mg/kg once\\ndaily or 50 mg/kg every 12 hours\\nampicillin IV\\n100 mg/kg\\nevery 8\\nhours\\n+\\ngentamicin\\nIV\\n2.5 mg/kg\\nevery 8\\nhours\\ncloxacillin IV\\n50 mg/kg every 6 hours\\n+\\nceftriaxone IV 100 mg/kg on D1\\nthen starting on D2: 100 mg/kg once\\ndaily or 50 mg/kg every 12 hours\\ncloxacillin\\nIV\\n50 mg/kg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 220, 'page_label': '221', 'id': 'data/guideline-170-en.pdf:220:2'}, page_content='daily or 50 mg/kg every 12 hours\\ncloxacillin\\nIV\\n50 mg/kg\\nevery 6\\nhours\\n+\\ngentamicin\\nIV\\n2.5 mg/kg\\nevery 8\\nhours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 221, 'page_label': '222', 'id': 'data/guideline-170-en.pdf:221:0'}, page_content='Page 222 / 409\\nDuration of antibiotherapy:\\xa01) According to the pathogen:\\n\\xa02) If the pathogen is unknown:\\nAdditional treatment\\nTreatment in an epidemic context\\nAntibiotic therapy\\nIn this context,\\xa0N. meningitidis\\xa0is the most likely pathogen.\\xa0\\n> 3\\nmonths\\nceftriaxone IV\\nChildren: 100 mg/kg on D1 then starting on D2: 100\\nmg/kg once daily or 50 mg/kg every 12 hours (max.\\n4 g daily)\\ncloxacillin IV\\nChildren < 40 kg: 50 mg/kg every 6 hours\\nChildren ≥ 40 kg: 2 g every 6 hours\\n+\\nceftriaxone IV\\nChildren: 100 mg/kg on D1 then starting on D2: 100\\nmg/kg once daily or 50 mg/kg every 12 hours (max.\\n4 g daily)\\nAdults ceftriaxone IV: 4 g once daily or 2 g every 12 hours cloxacillin IV: 2 g every 6 hours\\n+\\nceftriaxone IV: 4 g once daily or 2 g every 12 hours\\nHaemophilus inﬂuenzae: 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 221, 'page_label': '222', 'id': 'data/guideline-170-en.pdf:221:1'}, page_content='Haemophilus inﬂuenzae: 7 days\\nStreptococcus pneumonia: 10-14 days\\nGroup B streptococcus and\\xa0Listeria: 14-21 days\\nGram-negative bacilli: 21 days\\nNeisseria meningitidis: see antibiotherapy in an epidemic context\\nChildren < 3 months: 2 weeks beyond the ﬁrst sterile CSF culture or 21 days\\nChildren > 3 months and adults: 10 days. Consider extending treatment or alternative diagnoses if fever persists\\nbeyond 10 days. On the other hand, a 7-day course of ceftriaxone is sufﬁcient in patients who are making an\\nuncomplicated recovery.\\nDexamethasone reduces the risk of hearing loss in patients with\\xa0H. inﬂuenzae\\xa0or\\xa0S. pneumoniae.\\nEarly administration is indicated in meningitis caused by these pathogens or when the pathogen is unknown, except'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 221, 'page_label': '222', 'id': 'data/guideline-170-en.pdf:221:2'}, page_content='in neonates (and in presumed meningococcal meningitis in an epidemic context).\\ndexamethasone\\xa0IV\\nChildren > 1 month: 0.15 mg/kg (max. 10 mg)\\xa0every 6 hours for 2 to 4 days\\nAdults: 10 mg\\xa0every 6 hours for 2 to 4 days\\nThe treatment should be started before or with the ﬁrst dose of antibiotic, otherwise, the treatment offers no\\nbeneﬁt.\\n [1] [2] \\nEnsure that the patient is well fed and well hydrated (infusions or nasogastric tube if necessary).\\nSeizures\\xa0(Chapter 1).\\nComa: prevention of bed sores, care of the mouth and eyes, etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 222, 'page_label': '223', 'id': 'data/guideline-170-en.pdf:222:0'}, page_content='Page 223 / 409\\nNote:\\nA short treatment with a single dose of ceftriaxone IM can be used in children 2 years and older and in adults\\xa0during a\\nmeningococcal meningitis epidemic if 1) conﬁrmed by a reliable laboratory\\xa02) the number of cases exceeds\\nmanagement capacities with the 5-day treatment. Check national recommendations. Nevertheless, it is essential to\\nensure a monitoring of cases after 24 hours.\\nceftriaxone\\xa0IM\\nChildren 2 to < 12 years: 100 mg/kg single dose\\nChildren ≥ 12 years and adults: 4 g single dose\\nIf there is no clinical improvement (fever > 38.5 °C, repeated seizures, appearance or aggravation of a reduced level of\\nconsciousness or of neurological signs) 24 hours after the injection, continue the treatment with ceftriaxone for 5 days.\\nAdditional treatment\\n\\xa0\\nReferences'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 222, 'page_label': '223', 'id': 'data/guideline-170-en.pdf:222:1'}, page_content='Additional treatment\\n\\xa0\\nReferences\\nAge Treatment [3]\\nChildren\\n< 2 months\\nceftriaxone\\xa0IV or IM \\xa0for 7 days\\n100 mg/kg once daily\\xa0\\n (a) \\xa0  (b) \\nChildren ≥ 2 months\\nand adults\\nceftriaxone\\xa0IV or IM \\xa0or 5 days\\nChildren 2 months to < 5 years: 100 mg/kg once daily (max. 2 g daily)\\nChildren ≥ 5 years and adults: 2 g once daily\\n (a) \\xa0  (b) \\n(a) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.\\n(b) For IM administration, divide the dose into 2 injections if needed, half-dose in each buttock.\\n a \\nEnsure that the patient is well fed and well hydrated (infusions or nasogastric tube if necessary).\\nSeizures\\xa0(Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 222, 'page_label': '223', 'id': 'data/guideline-170-en.pdf:222:2'}, page_content='Seizures\\xa0(Chapter 1).\\nComa: prevention of bed sores, care of the mouth and eyes, etc.\\nDexamethasone in not indicated.\\nFootnotes\\n(a) For IM administration, divide the dose into 2 injections if needed, half-dose in each buttock.\\n1. D. van de Beek, C. Cabellos, O. Dzupova, S. Esposito, M. Klein, A. T. Kloek, S. L. Leib, B. Mourvillier, C. Ostergaard, P. Pagliano,H.W. Pﬁster, R. C. Read, O. Resat Sipahi, M.C. Brouwer.\\xa0ESCMID guideline: diagnosis and treatment of acute bacterialmeningitis, 2016.https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(16)00020-3/pdf\\n2. Sheldon L Kaplan, MD.\\xa0Bacterial meningitis in children: Dexamethasone and other measures to prevent neurologiccomplications. UpToDate\\xa0[Accessed 25 February 2019].'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 222, 'page_label': '223', 'id': 'data/guideline-170-en.pdf:222:3'}, page_content='3. World Health Organization. Managing meningitis epidemics in Africa. A quick reference guide for health authorities andhealth-care workers. 2015.https://apps.who.int/iris/bitstream/handle/10665/154595/WHO_HSE_GAR_ERI_2010.4_Rev1_eng.pdf?sequence=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 223, 'page_label': '224', 'id': 'data/guideline-170-en.pdf:223:0'}, page_content='Page 224 / 409\\nTetanus\\nLast updated: August 2022\\n\\xa0\\nTetanus is a severe infection due to the bacillus\\xa0Clostridium tetani, found in soil, and human and animal waste. The\\ninfection is noncontagious.\\nClostridium tetani\\xa0is introduced into the body through a wound and produces a toxin whose action on the central\\nnervous system is responsible for the symptoms of tetanus.\\nTetanus is entirely preventable by vaccination. It occurs in people who have not been fully vaccinated before exposure\\nor have not received adequate post-exposure prophylaxis. In these individuals, most breaks in the skin or mucous\\nmembranes carry a risk of tetanus, but the wounds with the greatest risk are: the stump of the umbilical cord in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 223, 'page_label': '224', 'id': 'data/guideline-170-en.pdf:223:1'}, page_content='neonates, puncture wounds, wounds with tissue loss or contamination with foreign material or soil, avulsion and crush\\ninjuries, sites of non-sterile injections, chronic wounds (e.g. lower extremity ulcers), burns and bites. Surgical or\\nobstetrical procedures performed under non-sterile conditions also carry a risk of tetanus.\\nClinical features\\nGeneralised tetanus is the most frequent and severe form of the infection. It presents as muscular rigidity, which\\nprogresses rapidly to involve the entire body, and muscle spasms, which are very painful. Level of consciousness is not\\naltered.\\nChildren and adults\\nNeonates\\nTreatment\\nHospitalisation is needed and usually lasts 3 to 4 weeks. Correct management can reduce mortality even in hospitals\\nwith limited resources.\\nGeneral measures'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 223, 'page_label': '224', 'id': 'data/guideline-170-en.pdf:223:2'}, page_content='with limited resources.\\nGeneral measures\\nAverage time from exposure to onset of symptoms is 7 days (3 to 21 days).\\nMuscular rigidity begins in the jaw muscles (difﬁculty with then inability to open mouth [trismus] preventing the patient\\nfrom speaking, eating), spreading to the face (ﬁxed smile), neck (difﬁculty with swallowing), to the trunk (restriction\\nof respiratory muscles; hyperextension of spine [opisthotonus]), to the abdomen (guarding) and to the limbs (ﬂexion\\nof the upper limbs and extension of the lower limbs).\\nMuscle spasms, which are very painful, appear at the onset or when muscular rigidity becomes generalised. They\\nare triggered by stimuli (noise, light, touch) or arise spontaneously. Spasms of the thoracic and laryngeal muscles\\nmay cause respiratory distress or aspiration.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 223, 'page_label': '224', 'id': 'data/guideline-170-en.pdf:223:3'}, page_content='may cause respiratory distress or aspiration.\\nIn 90% of cases, initial symptoms appear within 3 to 14 days of birth.\\nThe ﬁrst signs are signiﬁcant irritability and difﬁculty sucking (rigidity of the lips, trismus) then rigidity becomes\\ngeneralised, as in adults. Any neonate, who initially sucked and cried normally, presenting with irritability and difﬁculty\\nsucking 3 to 28 days after birth and demonstrating rigidity and muscle spasms should be assumed to have neonatal\\ntetanus.\\nEnsure intensive nursing care.\\nThe patient should be in a dark, quiet room. Blindfold neonates with a cloth bandage.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 224, 'page_label': '225', 'id': 'data/guideline-170-en.pdf:224:0'}, page_content='Page 225 / 409\\nNeutralisation of toxin\\nhuman tetanus immunoglobulin\\xa0IM\\nNeonates, children and adults: 500 IU single dose, injected into 2 separate sites\\nInhibition of toxin production\\nmetronidazole IV infusion (30 minutes; 60 minutes in neonates) for 7 days\\nControl of rigidity and spasms, and sedation of the patient\\nDiazepam should decrease the frequency and intensity of spams without causing respiratory depression. The dose and\\nfrequency of administration depend on the patient’s clinical response and tolerance.\\xa0\\n\\xa0\\nHandle the patient carefully, while sedated and as little as possible; change position every 3 to 4 hours to avoid\\nbedsores.\\nTeach family the danger signs and instruct them to call the nurse for the slightest respiratory symptom (cough,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 224, 'page_label': '225', 'id': 'data/guideline-170-en.pdf:224:1'}, page_content='difﬁculty breathing, apnoea, excessive secretions, cyanosis, etc.).\\nEstablish IV access for hydration, IV injections.\\nGentle suction of secretions (mouth, oropharynx).\\nInsert a nasogastric tube for hydration, feeding and administration of oral medications.\\nProvide hydration and nutrition in feeds divided over 24 hours. In neonates, give expressed breast milk every 3 hours\\n(risk of hypoglycaemia).\\n\\xa0 a \\nNeonates:\\n0 to 7 days: 15 mg/kg on D1 then, after 24 hours, 7.5 mg/kg every 12 hours\\n8 days to < 1 month (< 2 kg): same doses\\n8 days to < 1 month (≥ 2 kg): 15 mg/kg every 12 hours\\nChildren 1 month and over: 10 mg/kg every 8 hours (max. 1500 mg daily)\\nAdults: 500 mg every 8 hours\\n\\xa0\\n\\xa0\\nThere is a high risk of respiratory depression and hypotension when using diazepam, especially in children and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 224, 'page_label': '225', 'id': 'data/guideline-170-en.pdf:224:2'}, page_content='elderly patients. Constant and close monitoring of the patient‘s respiratory rate (RR) and oxygen saturation\\n(SpO) is essential, with immediate availability of equipment for manual ventilation (Ambu bag, face mask) and\\nintubation, suction (electric if possible) and Ringer lactate.\\n2\\nA continuous IV infusion of diazepam requires the use of a dedicated vein (no other infusion/injection in this\\nvein); avoid the antecubital fossa if possible.\\nDo not stop treatment abruptly; an abrupt stop can cause spasms.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 225, 'page_label': '226', 'id': 'data/guideline-170-en.pdf:225:0'}, page_content='Page 226 / 409\\nCount the volume of the infusion of diazepam as part of the patient’s daily ﬂuid intake.\\xa0\\nNeonates diazepam emulsion for injection (10 mg ampoule, 5 mg/ml, 2 ml)\\n\\xa0Example:\\nNeonate weighing 3 kg (administration by electric syringe)\\n0.1 mg/kg/hour x 3 kg = 0.3 mg/hour\\nDilute one 10 mg\\xa0ampoule of diazepam emulsion for injection in 50 ml of 10% glucose to obtain a\\nsolution containing 0.2 mg of diazepam per ml.\\nAdminister 1.5 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour i.e. 0.3 (mg/hour) ÷ 0.2\\n(mg/ml) = 1.5 ml/hour].\\xa0If an electric syringe is not available, diluting the diazepam emulsion in an infusion bag for continuous\\ninfusion may be considered. Weigh the risks associated with this mode of administration (accidental'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 225, 'page_label': '226', 'id': 'data/guideline-170-en.pdf:225:1'}, page_content='bolus or insufﬁcient dose). The infusion should be monitored closely to avoid any change, however\\nsmall, of the prescribed rate.\\n0.1 to 0.3 mg/kg by slow IV injection (3 to 5 minutes) every 1 to 4 hours depending on the severity\\nand the persistence of the spasms as long as the RR is ≥ 30.\\nIf despite hourly diazepam the spasms persist, start a continuous infusion of diazepam with an\\nelectric syringe: 0.1 to 0.5 mg/kg/hour (2.4 to 12 mg/kg every\\xa024 hours). Start with 0.1 mg/kg/hour\\nand if symptoms persist, increase by 0.1 mg/kg/hour as long as RR is ≥ 30.\\nIf in spite of 0.5 mg/kg/hour symptoms persist, the dose can be increased up to 0.8 mg/kg/hour as\\nlong as the RR ≥ 30.\\nDiluted diazepam emulsion does not keep for more than 6 hours.\\nChildren\\n> 1\\nmonth\\nand\\nadults'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 225, 'page_label': '226', 'id': 'data/guideline-170-en.pdf:225:2'}, page_content='Children\\n> 1\\nmonth\\nand\\nadults\\nSame doses and protocol as in neonates but:\\n\\xa0Examples:\\nUse diazepam solution for injection 5 mg/ml: (10 mg ampoule, 5 mg/ml, 2 ml). (a)\\nThese doses can be administered as long as the RR is:\\n≥ 30 in children under 1 year\\n≥ 25 in children 1 to 4 years\\n≥ 20 in children 5 to 12 years\\n≥ 14 in children over 12 years\\n≥ 12 in adults\\nChild weighing 6 kg (continuous IV infusion using a pediatric infusion set; 1 ml = 60 drops)\\n0.1 mg/kg/hour x 6 kg = 0.6 mg/hour\\nDilute one 10 mg\\xa0ampoule of diazepam solution for injection in 50 ml of 5% glucose (10%\\nglucose if child < 3 months) to obtain a solution containing 0.2 mg of diazepam per ml.\\nAdminister 3 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour i.e. 0.6 (mg/hour) ÷ 0.2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 225, 'page_label': '226', 'id': 'data/guideline-170-en.pdf:225:3'}, page_content='(mg/ml) = 3 ml/hour] or 3 drops/minute (in a paediatric infusion set ml/hour = drops/minute).\\nAdult weighing 60 kg (standard adult infusion set, 1 ml = 20 drops)\\n0.1 mg/kg/hour x 60 kg = 6 mg/hour\\nDilute 5\\xa0ampoules of 10 mg of diazepam solution (50 mg) in 250 ml of 0.9% sodium chloride or\\n5% glucose to obtain a solution containing 0.2 mg of diazepam per ml.\\nAdminister 30 ml/hour [dose (in mg/hour) ÷ dilution (in mg/ml) = dose in ml/hour e.g. 6 (mg/hour) ÷ 0.5\\n(mg/ml) = 30 ml/hour] or 10 drops/minute.\\n(a) Administer the ﬁrst dose rectally if an IV cannot be placed immediately.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 226, 'page_label': '227', 'id': 'data/guideline-170-en.pdf:226:0'}, page_content='Page 227 / 409\\nWhen the frequency and severity of the spasms have decreased, start weaning the diazepam (gradually decrease the\\nrate of infusion):\\n\\xa0Notes:\\nTreatment of pain\\nmorphine\\xa0PO (via\\xa0nasogastric tube) if necessary (see\\xa0Pain, Chapter 1).\\nWhen morphine is administered with diazepam the risk of respiratory depression is increased, thus closer monitoring is\\nrequired. When morphine is no longer required, wean the same way as diazepam.\\nTreatment of the entry point and associated infections\\nTetanus vaccination\\nAs tetanus does not confer immunity, vaccination against tetanus must be administered once the patient has\\nrecovered.\\nIn case of neonatal tetanus, initiate the vaccination of the mother.\\nPrevention\\nOf critical importance, given the difﬁculty of treating tetanus once established.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 226, 'page_label': '227', 'id': 'data/guideline-170-en.pdf:226:1'}, page_content='1) Post-exposure prophylaxis\\nCalculate the total daily dose of IV diazepam and administer it orally in 4 divided doses, 6 hours apart, via\\nnasogastric (NG) tube. b \\xa0\\nGive ﬁrst NG dose and decrease rate of IV infusion by 50%.\\nGive second NG dose and stop IV diazepam infusion.\\nIf withdrawal signs appear, wean more slowly. c \\nOnce on diazepam PO, wean by 10 to 20% of the original dose daily, until at a dose of 0.05 mg/kg every 6 hours.\\nThen increase the interval from every 6 hours to every 8 hours for 24 hours as tolerated (wean more slowly if\\nwithdrawal signs appear).\\nContinue to increase the interval between the doses from every 8 hours to every 12 hours and then to every 24\\nhours before stopping the diazepam.\\nEach step should be for 24 hours or more if withdrawal signs appear.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 226, 'page_label': '227', 'id': 'data/guideline-170-en.pdf:226:2'}, page_content='Each step should be for 24 hours or more if withdrawal signs appear.\\nIt is often at these smaller doses that it is difﬁcult to wean diazepam. If this is the case, slow the wean further:\\ndropping the % wean (e.g. 5% wean every 24 hours instead of 10% wean) or increasing the interval between weans\\n(e.g. going from every 24 hours to every 48 hours).\\nIf the patient is also receiving morphine, wean diazepam ﬁrst then, wean morphine.\\nNon-pharmacological measures to reduce withdrawal: reduce environmental stimuli; swaddle infants, frequent\\nfeedings.\\nInfants who have had tetanus remain hypertonic, even when they are no longer having spams.\\nSearch systematically the entry wound. Provide local treatment under sedation: cleansing and for deep wounds,\\nirrigation and debridement.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 226, 'page_label': '227', 'id': 'data/guideline-170-en.pdf:226:3'}, page_content='irrigation and debridement.\\nCord infection: do not excise or debride; treat bacterial omphalitis and sepsis, add to metronidazole IV: cloxacillin IV\\n+ cefotaxime IV or cloxacillin IV + gentamicin IV (for doses, see\\xa0Bacterial meningitis).\\nIn all cases:\\nCleansing and disinfection of the wound, and removal of any foreign body.\\nAntibiotics are not prescribed routinely for prophylaxis. The decision to administer an antibiotic (metronidazole\\nor penicillin) is made on a case-by-case basis, according to the patient’s clinical status.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 227, 'page_label': '228', 'id': 'data/guideline-170-en.pdf:227:0'}, page_content='Page 228 / 409\\n\\xa0\\n\\xa0tetanus vaccine\\xa0IM\\nChildren and adults: 0.5 ml per dose\\nIf no vaccination or unknown vaccination status: administer at least 2 doses at an interval of 4 weeks.\\nIf incomplete vaccination: administer one dose.\\nThen, to ensure long-lasting protection, administer additional doses to complete a total of 5 doses, as indicated in\\nthe table below.\\xa0human anti-tetanus immunoglobulin\\xa0IM\\nChildren and adults: 250 IU single dose; 500 IU for wounds more than 24 hours old.\\nInject the vaccine and the immunoglobulin in 2 different sites, using a separate syringe for each.\\n2) Routine vaccination (pre-exposure prophylaxis)\\nDepending on pre-exposure vaccination status:\\nTetanus vaccine (TV) \\xa0and immunoglobulin: see indications below. d \\nType of wound\\nComplete vaccination (3 or more doses)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 227, 'page_label': '228', 'id': 'data/guideline-170-en.pdf:227:1'}, page_content='Type of wound\\nComplete vaccination (3 or more doses) \\nTime since administration of last dose:\\nIncomplete vaccination \\n(less than 3 doses) \\nor no vaccination\\nor unknown status< 5 years 5-10 years > 10 years\\nMinor, clean None None\\nTV\\n1 booster\\ndose\\nInitiate or complete TV\\nOther None TV \\n1 booster dose\\nTV\\n1 booster\\ndose\\nInitiate or complete TV\\nand administer tetanus immunoglobulin\\nChildren:\\xa06\\xa0doses in total: a ﬁrst series of 3 doses of DTP or DTP + HepB or DTP +\\xa0HepB + Hib\\xa0before the age of\\n1 year, administered at an interval of 1 month (e.g. at the age of 6, 10 and 14 weeks), then a dose of\\xa0a vaccine\\ncontaining tetanus toxoid between the age\\xa0of 12 and 23 months, a dose between the age\\xa0of 4 to 7 years, then\\xa0a\\ndose between the age of 12 and 15 years.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 227, 'page_label': '228', 'id': 'data/guideline-170-en.pdf:227:2'}, page_content='dose between the age of 12 and 15 years.\\nWomen of childbearing age: 5 doses during the reproductive years: a series of 3 doses of Td\\xa0with an interval of at\\nleast one month between the ﬁrst\\xa0and second\\xa0dose and an interval of at least 6 months between the second\\xa0and\\nthird\\xa0dose, then two other doses, each at minimum interval of one year, e.g. during pregnancies (see table below).\\nPregnant women: if a woman has never been vaccinated or if her vaccination status is unknown: 2 doses of\\nTdduring the pregnancy to reduce the risk of tetanus in mother and\\xa0 neonate: the ﬁrst as soon as possible during\\nthe pregnancy and the second at least 4 weeks later and at least 2 weeks before delivery. This vaccination\\nschedule protects more than 80% of neonates from tetanus. A single dose offers no protection'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 228, 'page_label': '229', 'id': 'data/guideline-170-en.pdf:228:0'}, page_content='Page 229 / 409\\n\\xa0\\nDose Vaccination schedule in adults Degree and duration of protection\\nTV1 On ﬁrst contact with the health care system\\nor as soon as possible during pregnancy No protection\\nTV2 At least 4 weeks after TV1 80% \\n1 to 3 years\\nTV3 6 months to 1 year after TV2\\nor during the following pregnancy\\n95% \\n5 years\\nTV4 1 to 5 years after TV3\\nor during the following pregnancy\\n99% \\n10 years\\nTV5 1 to 10 years after TV4\\nor during the following pregnancy\\n99% \\nThroughout the reproductive years\\nFootnotes\\n(a) Clindamycin IV for 7 days is an alternative (for doses, see Periorbital and orbital cellulitis, Chapter 5).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 228, 'page_label': '229', 'id': 'data/guideline-170-en.pdf:228:1'}, page_content='(b) Administration of oral diazepam tablets to infants: calculate the exact dose of diazepam, e.g. to obtain 0.5 mg of diazepam,cut a scored diazepam 2 mg tablet in half along scoring then split in half again. Crush quarter tablet and dissolve inexpressed breast milk or infant formula.\\n(c) Withdrawal signs: excessive irritability, tremors, increased muscle tone, frequent yawning, poor feeding, watery stools andsweating.\\n(d) Tetanus-containing vaccine, such as Td or DTP or DTP + HepB or DTP + HepB + Hib according to availability and patient’sage.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 229, 'page_label': '230', 'id': 'data/guideline-170-en.pdf:229:0'}, page_content='Page 230 / 409\\nEnteric (typhoid and paratyphoid) fevers\\nLast updated: March 2024\\n\\xa0\\n\\xa0\\nEnteric fevers include typhoid fever,\\xa0due to\\xa0Salmonella enterica\\xa0serotype Typhi (S. Typhi) and paratyphoid fever,\\xa0due\\nto\\xa0Salmonella enterica\\xa0serotype Paratyphi A, B or C (S. Paratyphi).\\nEnteric fevers are acquired by the ingestion of water or food contaminated with excreta of symptomatic or\\nasymptomatic carriers or by direct contact (dirty hands).\\nEnteric fevers are endemic in South, Central\\xa0and Southeast Asia, sub-saharan Africa, Oceania and, to a lesser extent, in\\nLatin America.\\nEffective treatment signiﬁcantly reduces the risk of complications and death.\\nClinical features\\nClinical manifestations of typhoid and paratyphoid fevers are the same.\\xa0Enteric fevers have insidious onset and vary'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 229, 'page_label': '230', 'id': 'data/guideline-170-en.pdf:229:1'}, page_content='from mild to severe.\\xa0\\n\\xa0Clinical diagnosis is difﬁcult as enteric fevers resembles other infections present in regions where they\\xa0are\\nendemic.\\xa0The main differential diagnoses are:\\xa0malaria, brucellosis, leptospirosis, typhus, rickettsiosis,\\nsepsis\\xa0and\\xa0dengue.\\nLaboratory\\nTreatment\\nIn all cases\\nThe characteristic sign is prolonged fever, which gradually increases during the ﬁrst week, plateaus the second\\nweek then decreases between the third and fourth week. \\xa0\\nNon-speciﬁc signs and symptoms are frequently associated: gastrointestinal disturbances (abdominal pain,\\nconstipation or diarrhoea, vomiting), headache, malaise, chills, fatigue, non productive cough and/or\\nhepatosplenomegaly.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 229, 'page_label': '230', 'id': 'data/guideline-170-en.pdf:229:2'}, page_content='hepatosplenomegaly.\\xa0\\nErythematous maculopapular rash on the trunk extreme fatigue and/or relative bradycardia (heart rate-temperature\\ndissociation) may be present.\\nSerious complications affect about 27% of hospitalised patients and usually occur during the second or third\\nweek of illness.\\xa0These may incude\\xa0decreased level of consciousness,\\xa0intestinal haemorrhage or perforation\\nor\\xa0peritonitis, shock, or nephritis. In pregnant women, severe infection may lead to foetal complications\\n(miscarriage, preterm delivery, intrauterine death).\\n [1] \\nRelapse may occur 2 to 3 weeks after recovery. It is usually not due to antibiotic resistance, and re-treatment is\\nrequired.\\nCulture of\\xa0S.\\xa0Typhi or\\xa0Paratyphi\\xa0and drug susceptibility test (blood and stool specimens).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 229, 'page_label': '230', 'id': 'data/guideline-170-en.pdf:229:3'}, page_content='In all cases, rapid test for malaria in endemic regions (and antimalarial treatment if needed, see Malaria, Chapter 6).\\xa0\\nWidal agglutination test, other serologic tests, and rapid diagnostic tests are not recommended (low sensitivity and\\nspeciﬁcity).\\xa0\\nHydrate and treat\\xa0fever\\xa0(Chapter 1).\\xa0Fever usually resolves 4 to 5 days after starting effective antibiotic treatment.\\nChoice of antibiotic treatment depends on the susceptibility of the strain, or when susceptibility\\xa0is unknown, on\\nrecent data on susceptibility of strains in the region. Check national recommendations. For information:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 230, 'page_label': '231', 'id': 'data/guideline-170-en.pdf:230:0'}, page_content='Page 231 / 409\\nUncomplicated cases (outpatients)\\nUncomplicated cases (the vast majority of cases) can be treated with an oral antibiotic treatment.\\nSevere cases (inpatients)\\nThese cases should be treated under close monitoring. Antibiotic treatment is initially parenteral, then oral when\\nthere is decreasing fever,\\xa0clinical improvement and the patient can tolerate oral treatment.\\nAdditional measures\\nPrevention\\nStrains resistant to chloramphenicol, ampicillin/amoxicillin and co-trimoxazole (multidrug-resistant, MDR\\nstrains)\\xa0are present in most parts of the world.\\xa0\\nCiproﬂoxacin is used as ﬁrst-line treatment in some countries, however ﬂuoroquinolone resistance is endemic in\\nAsia and is increasing in several parts of the world . [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 230, 'page_label': '231', 'id': 'data/guideline-170-en.pdf:230:1'}, page_content='Asia and is increasing in several parts of the world . [2] \\nCeftriaxone resistance has been identiﬁed in several regions . [2] \\nMDR strains also resistant to ﬂuoroquinolones and third-generation cephalosporins (extensively drug-resistant,\\nXDR strains) have developed .    [3] \\nFirst-line antibiotics:\\nazithromycin PO for 7 days (including for MDR and XDR cases, and pregnant women)\\nChildren: 10 to 20 mg/kg (max. 1 g)\\xa0once daily\\xa0\\nAdults: 500 mg to 1 g once daily or 1 g on D1 then 500 mg once daily\\nor\\nceﬁxime PO for 10 to 14 days (except for third-generation cephalosporin resistance and XDR cases)\\nChildren: 10 mg/kg (max. 200 mg) 2 times daily\\nAdults: 200 mg 2 times daily\\nAlternatives include, only if recent data show susceptibility of strains to these antibiotics in the region:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 230, 'page_label': '231', 'id': 'data/guideline-170-en.pdf:230:2'}, page_content='amoxicillin PO for 14 days\\nChildren: 30 mg/kg\\xa0(max. 1 g) 3 times daily\\xa0\\nAdults: 1 g 3 times daily \\nor\\nco-trimoxazole PO for 14 days\\nChildren: 20 mg SMX + 4 mg TMP/kg (max. 800 mg SMX + 160 mg TMP)\\xa02 times daily\\xa0\\nAdults: 800 mg SMX + 160 mg TMP 2 times daily\\nSevere cases include:\\ntoxic appearance or decreased level of consciousness or medical or surgical complication;\\noral administration not possible due to persistent vomiting.\\nStart with ceftriaxone\\xa0IV (including for pregnant women)\\nChildren: 50 to 100 mg/kg (max.\\xa04 g)\\xa0once daily\\nAdults: 2 g once daily or 2 times daily\\nThen change to azithromycin PO (as above) to complete at least 7 days of treatment.\\n a \\nFor suspected or conﬁrmed ceftriaxone resistance or XDR stains, use\\xa0meropenem IV,\\xa0including for pregnant'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 230, 'page_label': '231', 'id': 'data/guideline-170-en.pdf:230:3'}, page_content='women, then change to azithromycin PO to complete at least 7 days of treatment.\\nIn case of decreased level of consciousness or shock, dexamethasone IV: a loading dose of\\xa01\\xa0mg/kg\\xa0followed by\\n0.25\\xa0mg/kg\\xa0every 6 hours for 48 hours\\xa0(total of 8 doses).\\nTreat in intensive care unit patients with shock, signiﬁcant\\xa0intestinal haemorrhage or suspected\\nperforation/peritonitis. If suspected perforation/peritonitis,\\xa0get urgent surgical review\\xa0and add metronidazole to\\nceftriaxone for anaerobic bacterial coverage . b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 231, 'page_label': '232', 'id': 'data/guideline-170-en.pdf:231:0'}, page_content='Page 232 / 409\\n\\xa0\\nReferences\\nHygiene measures common to all diarrhoeas: handwashing; consumption of treated water (chlorinated, boiled,\\nbottled, etc.); washing/cooking of food, etc.\\nIn hospitals: for patients with watery diarrhoea, consider disinfection of excreta with chlorinated solution, if stools\\nare collected in buckets.\\nVaccination with the\\xa0typhoid\\xa0conjugate vaccine\\xa0in endemic regions .\\xa0This vaccine\\xa0can be used to control typhoid\\noutbreaks. It does not protect against paratyphoid fever.\\n c \\nFootnotes\\n(a) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must NEVER beadministered by IV route. For IV administration, water for injection must always be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 231, 'page_label': '232', 'id': 'data/guideline-170-en.pdf:231:1'}, page_content='(b) Do not add metronidazole if the patient receives meropenem (meropenem already covers anaerobic bacteria).\\n(c) For more information, see Typhoid vaccines: WHO position paper:http://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1\\n1. Cruz Espinoza LM, McCreedy E, Holm M, et al. Occurrence of typhoid fever complications and their relation to duration ofillness preceding hospitalization: a systematic literature review and meta-analysis. Clin Infect Dis 2019;69(Suppl 6):S435-48.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821330/\\xa0[Accessed 28 June 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 231, 'page_label': '232', 'id': 'data/guideline-170-en.pdf:231:2'}, page_content='2. Browne AJ, Hamadani BHK, Kumaran EAP, Rao P, et al. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematicreview and meta-analysis. BMC Medicine 2020;18:1+22.https://doi.org/10.1186/s12916-019-1443-1 [Accessed 23 February 2022]\\n3. Klemm EJ, Shakoor S, Page AJ, Qamar FN, et al. Emergence of an Extensively Drug-Resistant Salmonella enterica SerovarTyphi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-GenerationCephalosporins. mBio. 2018 Jan-Feb; 9(1): e00105-18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821095/ [Accessed 26June 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 232, 'page_label': '233', 'id': 'data/guideline-170-en.pdf:232:0'}, page_content='Page 233 / 409\\nBrucellosis\\nLast updated: September 2022\\n\\xa0\\nBrucellosis is a zoonosis that mainly affects livestock animals.\\xa0\\xa0The main routes of transmission to humans are:\\xa0\\n\\xa0Brucellosis is caused by bacteria of the genus Brucella,\\xa0particularly\\xa0B. melitensis\\xa0(sheep and goats),\\xa0B.\\nabortus\\xa0(cattle),\\xa0B. suis\\xa0(pigs).\\xa0The disease is found worldwide and mainly in rural areas.\\xa0\\nAfter primary infection relapses may occur (5 to 15% of cases, even months after end of initial treatment) or the\\ninfection may become chronic.\\nClinical features\\nAcute form (primary infection)\\n\\xa0Diagnosis is difﬁcult because of the broad spectrum of ﬂuctuating and non-speciﬁc\\xa0clinical manifestations. In patients'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 232, 'page_label': '233', 'id': 'data/guideline-170-en.pdf:232:1'}, page_content='with unexplained fever, brucellosis should be\\xa0considered when\\xa0risk factors are present: consumption of unpasteurized\\nmilk products; exposure to livestock (e.g. livestock farmers, veterinarians, butchers, slaughterhouse workers).\\nLocalised form\\xa0\\nPrimary infection may progress to localised infection (even several months or years later), mainly:\\nParaclinical investigations\\nLaboratory\\ndigestive, by ingestion of unpasteurized milk (or unpasteurized milk products) from an infected animal;\\ncutaneous, by direct contact with infected animals or carcasses of infected animals.\\xa0\\nRemittent or intermittent fever (39-40 °C), associated with several signs or symptoms: chills, night sweats, joint and\\nmuscle pain, weight loss, fatigue, malaise, headache; adenopathies (particularly in children).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 232, 'page_label': '233', 'id': 'data/guideline-170-en.pdf:232:2'}, page_content='May be associated with: non-speciﬁc gastrointestinal disorders, cough, hepato and/or splenomegaly, arthritis\\n(knee), orchitis.\\nosteoarticular: sacroiliac joint and\\xa0often particularly lower limbs joints;\\xa0\\xa0spine (intervertebral disk infection, vertebral\\nosteomyelitis)\\ngenito-urinary: orchitis, epididymitis\\xa0\\npulmonary: bronchitis, pneumonia, pleurisy\\xa0\\nneurological : meningitis, encephalitis, polyneuritis\\nBlood culture is the gold standard for diagnosis. It is positive only in the acute phase. The bacteria grow slowly (7 to\\n21 days).\\nSerological tests (Rose Bengal, Wright agglutination test, indirect immunoﬂuorescence, ELISA, etc.) provide\\npresumptive diagnoses.\\nIn the event of neurological signs or meningitis, lumbar puncture\\xa0shows clear\\xa0cerebrospinal ﬂuid (CSF) that may'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 232, 'page_label': '233', 'id': 'data/guideline-170-en.pdf:232:3'}, page_content='contain\\xa0high white blood cell count; high protein concentration in CSF; low CSF glucose.\\nRule out\\xa0malaria in endemic regions (rapid test).\\nExclude tuberculosis if cough > 2 weeks (sputum smear microscopy).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 233, 'page_label': '234', 'id': 'data/guideline-170-en.pdf:233:0'}, page_content='Page 234 / 409\\nRadiography\\xa0\\nTreatment\\nCheck national recommendations on antibiotic therapy. For information:\\xa0\\nco-trimoxazole PO for 6 weeks\\nChildren < 8 years: 20 mg SMX + 4 mg TMP/kg (max. 800 mg SMX + 160 mg TMP) 2 times daily\\xa0doxycycline PO\\xa0for 6 weeks\\xa0\\nChildren ≥\\xa08 years and < 45 kg: 2 to 2.2 mg/kg (max. 100 mg) 2 times daily\\nChildren ≥ 45 kg and adults: 100 mg 2 times daily\\xa0\\xa0rifampicin PO for 6 weeks\\nChildren: 15 to 20 mg/kg (max. 600 mg) once daily\\nAdults: 600 to 900 mg once daily\\xa0gentamicin IM for 2 weeks\\nChildren and adults: 5 mg/kg once daily\\xa0streptomycin IM for 2 weeks\\nAdults: 1 g once daily\\xa0For localised forms of the infection, same treatment but for a period of 6 weeks to 4 months depending on the focus.\\nPrevention'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 233, 'page_label': '234', 'id': 'data/guideline-170-en.pdf:233:1'}, page_content='Prevention\\nJoint pain (hips, knees, ankles, vertebrae, sacroiliac joint): small erosions or destruction or joint space narrowing.\\nOften involves the spine, particularly the lumbar spine, causing spondylodiskitis.\\nPulmonary signs: chest x-ray often normal.\\xa0There may be consolidation, nodules, lymphadenopathy, or pleural\\neffusion.\\n\\xa0\\nChildren under 8 years co-trimoxazole + rifampicin\\nor co-trimoxazole + gentamicin\\nChildren 8 years and over doxycycline + rifampicin\\nor doxycycline + gentamicin\\nAdults doxycycline + rifampicin\\nor doxycycline + streptomycin or gentamicin\\nPregnant/breast-feeding women rifampicin\\nWashing of hands and clothing if in contact with animals.\\nBoil milk, avoid ingestion of unpasteurized milk products, cook offal thoroughly.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 234, 'page_label': '235', 'id': 'data/guideline-170-en.pdf:234:0'}, page_content='Page 235 / 409\\nPlague\\nLast updated: September 2022\\n\\xa0\\n\\xa0\\nPlague is a zoonosis caused by the Gram-negative bacillus\\xa0Yersinia pestis\\xa0that affects many wild and domestic\\nmammals, particularly\\xa0rodents.\\nPlague is transmitted to man by infected animals (direct contact or inhalation of their respiratory secretions), the bite\\nof a ﬂea of infected animals, or inhalation of respiratory secretions of individuals with pneumonic plague.\\nNatural foci of infection include Africa, Asia, North and South America, and parts of Europe.\\xa0Bubonic plague\\xa0is the most common form, usually resulting from the bite of an infected ﬂea. Without prompt\\ntreatment, the bacteria may be disseminated by haematogenous route, producing a more severe form (see below) with\\na high mortality rate.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 234, 'page_label': '235', 'id': 'data/guideline-170-en.pdf:234:1'}, page_content='a high mortality rate.\\nThe following forms of plague may be primary or secondary to bubonic plague:\\nClinical features\\xa0\\nSee table below.\\xa0Main differential diagnoses include:\\nLaboratory\\nManagement\\nPneumonic plague can rapidly progress to respiratory distress, shock, and death without prompt treatment.\\nSepticaemic plague\\xa0is a fulminant illness that can progress to disseminated intravascular coagulation, respiratory\\ndistress, shock, and death.\\nPlague meningitis\\xa0is a rare but very severe form of plague.\\nOther causes of lymphadenitis (e.g. some\\xa0bacterial skin infections, tularemia, lymphogranuloma\\nvenereum,\\xa0chancroid)\\nAcute pneumonia\\xa0(Chapter 2)\\nOther causes of septicaemia (see Shock, Chapter 1) or meningitis (see Bacterial meningitis, Chapter 7)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 234, 'page_label': '235', 'id': 'data/guideline-170-en.pdf:234:2'}, page_content='Collect pre-treatment specimens: lymph node aspirate (bubonic plague), sputum (pneumonic plague), blood\\n(septicaemic plague), or cerebrospinal ﬂuid (plague meningitis).\\nSend specimens to reference laboratory for: a \\nRapid diagnostic test for detection of F1 capsular antigen of Y. pestis\\nPCR\\xa0\\nCulture of Y. pestis and drug suceptibility test\\nIn all cases, rapid test for malaria in endemic regions (and antimalarial treatment if needed, see Malaria, Chapter 6).\\nStart empiric antibiotic treatment for 10 to 14 days as soon as plague is suspected, before results of diagnosis\\ntests are available.\\xa0\\nA combination of 2 antibiotics from different classes is recommended in severe disease, plague meningitis, and\\npregnant women.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 234, 'page_label': '235', 'id': 'data/guideline-170-en.pdf:234:3'}, page_content='pregnant women.\\nFollow national recommendations according to antibiotic resistance patterns if known.\\xa0For information: see table\\nbelow.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 235, 'page_label': '236', 'id': 'data/guideline-170-en.pdf:235:0'}, page_content='Page 236 / 409\\nTreatment of suspected cases'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 236, 'page_label': '237', 'id': 'data/guideline-170-en.pdf:236:0'}, page_content='Page 237 / 409\\nForms of plague Clinical features Antibiotic treatment [1]\\nBubonic\\nAND\\xa0\\nFever, chills, malaise,\\nheadache\\xa0\\nLymph node (bubo), painful,\\nusually inguinal, (one or\\nmore)\\xa0\\nChildren (including < 8 years) and adults:\\ndoxycycline PO:\\nor\\ngentamicin IM or IV:\\nor\\nciproﬂoxacin PO:\\nUnder 45 kg: 4.4 mg/kg (max. 200 mg) on D1, then\\n2.2 mg/kg (max. 100 mg) 2 times daily\\n45 kg and over: 200 mg on D1, then 100 mg 2 times\\ndaily\\n (a)\\nChildren: 4.5 to 7.5 mg/kg once daily\\nAdults: 5 mg/kg once daily\\nChildren: 15 mg/kg 2 to 3 times daily (max. 750 mg 2\\ntimes daily\\xa0or\\xa0500 mg 3 times daily)\\nAdults: 750 mg 2 times daily\\nPneumonic\\nAND\\xa0\\xa0\\nFever, chills, malaise,\\nheadache\\xa0\\nDyspnea, chest pain,\\nproductive cough with\\npurulent or blood-stained\\nsputum\\xa0\\nRespiratory distress or\\nfailure and sepsis in severe'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 236, 'page_label': '237', 'id': 'data/guideline-170-en.pdf:236:1'}, page_content='sputum\\xa0\\nRespiratory distress or\\nfailure and sepsis in severe\\nor advanced, untreated\\ndisease\\nChildren and adults:\\xa0If mild disease:\\ngentamicin IM or IV (as above)\\nor\\nciproﬂoxacin PO (as above) or IV\\xa0If severe disease:\\ngentamicin + ciproﬂoxacin\\xa0(as above)\\nor, if not available,\\xa0gentamicin + doxycycline (as\\nabove)\\xa0After clinical improvement, change to ciproﬂoxacin or\\ndoxycycline PO (as above).\\n (a) \\n (b)\\nSepticaemic Frequently no localizing\\nsymptoms or signs\\nGastrointestinal\\ndisturbances (abdominal\\npain, vomiting, diarrhoea,\\netc.) often present\\nAs severe pneumonic plague\\nMeningitis (c) Signs of meningitis. Children and adults:\\nchloramphenicol IV:\\n+ ciproﬂoxacin PO or IV (as above)\\nor, if not available,\\ngentamicin + ciproﬂoxacin\\xa0(as above)\\nChildren 1 to 12 years: 25 mg/kg (max. 1 g) every 8'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 236, 'page_label': '237', 'id': 'data/guideline-170-en.pdf:236:2'}, page_content='Children 1 to 12 years: 25 mg/kg (max. 1 g) every 8\\nhours \\xa0\\nChildren 13 years and over and adults: 1 g every 8\\nhours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 237, 'page_label': '238', 'id': 'data/guideline-170-en.pdf:237:0'}, page_content='Page 238 / 409\\nTreatment in pregnant women\\nInfection prevention and control (in hospitals)\\nPost-exposure prophylaxis of contacts\\nIn the event of contact (distance less than 2 meters without appropriate personal protective equipment) with a\\npneumonic plague patient\\xa0or direct contact with infected body ﬂuids or tissues of any plague patient and within one\\nweek after the end of exposure:\\ndoxycycline\\xa0PO for 7 days\\nChildren: 2.2 mg/kg (max.\\xa0100 mg)\\xa02 times daily\\nAdults (including pregnant women): 100 mg 2 times daily\\nor\\nciproﬂoxacin\\xa0PO\\xa0for 7 days\\nChildren:\\xa020 mg/kg (max. 750 mg) 2 times daily\\nAdults: 500 to 750 mg\\xa02 times daily\\xa0\\nPregnant women: 500 mg 3 times daily\\nPrevention'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 237, 'page_label': '238', 'id': 'data/guideline-170-en.pdf:237:1'}, page_content='Pregnant women: 500 mg 3 times daily\\nPrevention\\n\\xa0\\n(a) Streptomycin IM may be an alternative to gentamicin (except in pregnant women):Children: 15 mg/kg (max. 1 g) every 12 hoursAdults: 1 g\\xa0every 12 hours\\n(b) Use\\xa0ciproﬂoxacin IV when oral route is not possible:Children: 10 mg/kg (max. 400 mg) every 8 or 12 hoursAdults: 400 mg every 8 hours\\n(c) If plague meningitis develops, add chloramphenicol to the existing regimen, and continue the combined regimen for anadditional 10 days.\\nBubonic, pneumonic, and septicaemic plague: gentamicin IM or IV\\xa0(as above) + ciproﬂoxacin PO (500 mg 3 times\\ndaily) or IV\\xa0(as above)\\nPlague meningitis: chloramphenicol IV + ciproﬂoxacin PO (500 mg 3 times daily) or IV (as above)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 237, 'page_label': '238', 'id': 'data/guideline-170-en.pdf:237:2'}, page_content='Bubonic plague: no isolation, standard precautions (handwashing, gowns, gloves, eye protection, etc.) with respect\\nto lymph node aspiration or discharge and other body ﬂuids.\\nPneumonic plague: isolation (in single room if possible), standard precautions, plus,\\xa0for 48 hours after the start of\\nantibiotic treatment, droplet precautions (medical mask for healthcare workers and for patients during\\ncontact).\\xa0Only for aerosol-generating procedures, airborne precautions (FFP2 or N95 respirators) for health\\nworkers exposed to aerosols.\\nElimination of ﬂeas (e.g. bedding, clothing, corpse): refer to the guide\\xa0Public health engineering, MSF.\\nFlea vector control,\\xa0sanitation and rodent reservoir\\xa0control, refer to the guide\\xa0Public health engineering, MSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 237, 'page_label': '238', 'id': 'data/guideline-170-en.pdf:237:3'}, page_content='Vaccination against plague is indicated for laboratory technicians handling rodents or working with\\xa0Y. pestis and is\\nnot a method for controlling an epidemic.\\nFootnotes\\n(a) Transportation of specimens in 0.9% sodium chloride requires a cold chain (failing that, a temperature below 30 °C), triplepackaging and UN3373 label.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 238, 'page_label': '239', 'id': 'data/guideline-170-en.pdf:238:0'}, page_content='Page 239 / 409\\nReferences\\n1. Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, et al. Antimicrobial treatment and prophylaxis of plague:recommendations for naturally acquired infection and bioterrorism response. MMWR Recomm Rep 2021;70(No. RR-3):1-27.https://www.cdc.gov/mmwr/volumes/70/rr/rr7003a1.htm?s_cid=rr7003a1_w [Accessed 25 January 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 239, 'page_label': '240', 'id': 'data/guideline-170-en.pdf:239:0'}, page_content='Page 240 / 409\\nLeptospirosis\\nLast update: October 2022\\n\\xa0\\n\\xa0\\nLeptospirosis is a zoonosis that affects many domestic and wild animals, mainly rodents (particularly rats) but also\\ndogs and cattle, etc.\\xa0It is transmitted to humans by contact through skin lesions or mucous membranes (e.g. eyes, mouth) with:\\n\\xa0It is caused by bacteria (spirochetes) of the genus\\xa0Leptospira.\\xa0Leptospirosis occurs worldwide, particularly in tropical and subtropical regions. There are often outbreaks after heavy\\nrainfall or ﬂooding.\\nClinical features\\nApproximately\\xa090% of cases are asymptomatic or\\xa0mild with a favourable outcome. 5 to 15% of cases present a\\nsevere form with multiple organ dysfunction and a high mortality rate without prompt treatment.\\nMild\\xa0form\\xa0\\nSevere or\\xa0ictero-haemorrhagic\\xa0form'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 239, 'page_label': '240', 'id': 'data/guideline-170-en.pdf:239:1'}, page_content='Mild\\xa0form\\xa0\\nSevere or\\xa0ictero-haemorrhagic\\xa0form\\xa0\\nThe onset is the same but a few days later the symptoms worsen: renal disorders (oliguria or polyuria), hepatic disorder\\n(jaundice), widespread haemorrhages\\xa0(purpura, ecchymoses, epistaxis, haemoptysis, etc.), pulmonary signs (chest pain)\\nor cardiac signs (myocarditis, pericarditis).\\xa0\\n\\xa0Other conditions to consider include a wide range of acute febrile illnesses, e.g.:\\u202f\\u202f\\nfreshwater or moist soil contaminated with urine of an infected animal (indirect contact);\\nurine, blood and other body ﬂuids or tissues of an infected animal (direct contact).\\nAcute phase (septicaemic):\\xa0\\nSudden onset of high fever with chills, headache, myalgia\\xa0(especially calf and lumbar pain), photophobia, ocular'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 239, 'page_label': '240', 'id': 'data/guideline-170-en.pdf:239:2'}, page_content='pain.\\xa0Bilateral\\xa0conjunctival suffusion affecting the bulbar conjunctiva (redness without discharge) is a\\ncharacteristic sign, but not always present.\\nMay be associated with: gastrointestinal symptoms (anorexia, abdominal pain, nausea, vomiting), non-\\nproductive cough, lymphadenopathy,\\xa0hepatomegaly, and sometimes, skin rash.\\nImmune phase:\\nThe signs of the acute phase regress after 5 to 7 days then reappear for a few days usually in a milder form\\n(milder fever, less severe myalgia) then disappear.\\xa0\\nSigns of meningitis (thought to be of immune origin) are however very common\\xa0during this phase.\\nDiagnosis is difﬁcult because of the broad spectrum of clinical manifestations. Patients that present the following\\nshould be considered as suspected cases of leptospirosis :\\nand\\n [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 239, 'page_label': '240', 'id': 'data/guideline-170-en.pdf:239:3'}, page_content='should be considered as suspected cases of leptospirosis :\\nand\\n [1] \\nabrupt onset of fever, chills, conjunctival suffusion, headache, myalgia and jaundice\\none or more risk factors for infection: exposure to contaminated freshwater (e.g. swimming, ﬁshing, rice ﬁelds,\\nﬂooding) or infected animals (e.g. crop and livestock farmers, veterinarians, butchers and slaughterhouse\\nworkers).\\nViral haemorrhagic fevers,\\xa0dengue, chikungunya, Zika, inﬂuenza,\\xa0measles, viral hepatitis, other causes of meningitis'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 240, 'page_label': '241', 'id': 'data/guideline-170-en.pdf:240:0'}, page_content='Page 241 / 409\\nLaboratory\\nDiagnosis\\nOther investigations\\n(if available)\\nTreatment\\nStart empiric antibiotic treatment as soon as leptospirosis suspected, before results of diagnosis tests are available.\\nMild form (outpatients)\\nSymptomatic treatment\\n\\xa0Antibiotic treatment\\nChildren under 45 kg: 2 to 2.2 mg/kg (max. 100 mg) 2 times daily\\nChildren 45 kg and over and adults: 100 mg 2 times daily\\nor, particularly in pregnant women:\\nChildren: 10 mg/kg (max. 500 mg) on D1 then 5 mg/kg (max. 250 mg) once daily on D2 and D3\\nAdults : 1 g on D1 then 500 mg once daily on D2 and D3\\xa0\\nor, if\\xa0not available,\\nChildren: 25 mg/kg (max. 1 g) 2 times daily\\xa0\\nAdults: 1 g 2 times daily\\xa0 Antibiotic treatment\\xa0can trigger a Jarisch-Herxheimer reaction (high fever, chills, fall in blood pressure and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 240, 'page_label': '241', 'id': 'data/guideline-170-en.pdf:240:1'}, page_content='sometimes shock). It is recommended to monitor the patient for 2 hours after the ﬁrst dose of antibiotic for\\noccurrence and management of severe Jarisch-Herxheimer reaction (symptomatic treatment of shock).\\n\\xa0\\nSevere form\\xa0(inpatients)\\nSymptomatic treatment\\nMalaria\\nTyphoid fever,\\xa0brucellosis,\\xa0rickettsioses\\nCollect pre-treatment specimens\\xa0and send them to reference laboratory:\\nAcute phase (ﬁrst week\\xa0of illness): blood and/or serum for IgM screening, PCR, and acute specimen for\\nmicroscopic agglutination test (MAT);\\nImmune phase (second week of illness): serum for IgM screening and convalescent specimen\\xa0for MAT, and urine\\nfor PCR.\\nIn all cases, rapid test for malaria in endemic regions (and antimalarial treatment if needed, see\\xa0Malaria, Chapter 6).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 240, 'page_label': '241', 'id': 'data/guideline-170-en.pdf:240:2'}, page_content='Serum creatinine: elevated if renal dysfunction.\\nFull blood count: possible\\xa0neutrophilia and thrombocytopenia (acute phase), or anaemia secondary to haemorrhage\\n(immune phase).\\nCerebrospinal ﬂuid (immune phase): features of aseptic meningitis in CSF (see viral meningitis, Chapter 7).\\nUrine: mild proteinuria, leukocyturia, possible microscopic haematuria (acute phase).\\nRest and treatment of pain and\\xa0fever: paracetamol PO (Chapter 1).\\nAcetylsalicylic acid (aspirin) is contra-indicated (risk of haemorrhage).\\ndoxycycline PO for 7 days\\nazithromycin\\xa0PO for 3 days\\namoxicillin\\xa0PO for 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 241, 'page_label': '242', 'id': 'data/guideline-170-en.pdf:241:0'}, page_content='Page 242 / 409\\n\\xa0Antibiotic treatment\\nChildren: 80 to 100 mg/kg (max. 2 g) once daily\\nAdults: 2 g once daily\\nor\\nChildren: 50 000 IU (30 mg)/kg\\xa0(max. 2 MIU or 1200 mg)\\xa0every 6 hours\\nAdults: 1 to 2 MIU (600 to 1200 mg) every 6 hours\\nPrevention\\n\\xa0\\nReferences\\nSpeciﬁc management according to organs affected.\\xa0Oliguria generally responds to correction of hypovolaemia.\\nRest and treatment of pain and\\xa0fever: paracetamol PO (Chapter 1).\\xa0Avoid or use paracetamol with caution in\\npatients with hepatic involvement.\\nceftriaxone\\xa0IV for 7 days a\\nbenzylpenicillin\\xa0IV for 7 days\\nAvoid bathing in freshwater in endemic areas.\\nDisinfect laundry and objects soiled by urine\\xa0of infected\\xa0animal or patient.\\xa0\\nVaccination and protective\\xa0clothing (only for professionals at risk of exposure).\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 241, 'page_label': '242', 'id': 'data/guideline-170-en.pdf:241:1'}, page_content='Footnotes\\n(a) For IV administration of ceftriaxone, dilute with water for injection only.\\n1. World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. World Health Organization,2003.https://apps.who.int/iris/bitstream/handle/10665/42667/WHO_CDS_CSR_EPH_2002.23.pdf?%20sequence=1&isAllowed=y[Accessed 5 September 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 242, 'page_label': '243', 'id': 'data/guideline-170-en.pdf:242:0'}, page_content='Page 243 / 409\\nRelapsing fever (borreliosis)\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nRelapsing fever (FR) is caused by spirochetes of the genus Borrelia, transmitted to humans by arthropod vectors.\\nLouse-borne relapsing fever (LBRF)\\nTick-borne relapsing fever (TBRF)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 243, 'page_label': '244', 'id': 'data/guideline-170-en.pdf:243:0'}, page_content='Page 244 / 409\\nLouse-borne relapsing fever (LBRF)\\nLast updated: October 2022\\n\\xa0\\n\\xa0\\nLBRF is caused by\\xa0Borrelia recurrentis. It occurs in epidemic waves when conditions favourable to the transmission of\\nbody lice are met: cold climate/season, overcrowding and very poor sanitation (e.g. refugee camps, prisons). Endemic\\nfoci of LBRF are mainly the Sudan and the Horn of Africa (especially Ethiopia). LBRF can be associated with louse-\\nborne typhus (see\\xa0Eruptive rickettsioses). The mortality rate for untreated LBRF ranges from 15 to 40%.\\nClinical features\\n\\xa0In practice, in an applicable epidemiological setting (see above), a suspect case of LBRF is, according to WHO,\\xa0a\\npatient with high fever and two of the following symptoms: severe joint pain, chills, jaundice or signs of bleeding (nose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 243, 'page_label': '244', 'id': 'data/guideline-170-en.pdf:243:1'}, page_content='or other bleeding) or a patient with high fever who is responding poorly to antimalarial drugs. Clothing should be\\nchecked for the presence of body lice and nits.\\nLaboratory\\nThe diagnosis is conﬁrmed by detection of\\xa0Borrelia\\xa0in thick or thin blood ﬁlms (Giemsa stain). Blood samples must be\\ncollected during febrile periods. Spirochetes are not found in the \\xa0peripheral blood during afebrile periods. In addition,\\nthe number of circulating spirochetes tends to decrease with each febrile episode.\\nTreatment\\nRelapsing fever is characterized by febrile episodes separated by afebrile periods of approximately 7 days (4 to 14\\ndays).\\nThe initial febrile episode lasts up to 6 days:\\nSudden onset of high fever (axillary temperature > 39 °C), severe headache and asthenia, diffuse pain (muscle,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 243, 'page_label': '244', 'id': 'data/guideline-170-en.pdf:243:2'}, page_content='joint, back pain), often associated with gastrointestinal disturbances (anorexia, abdominal pain, vomiting,\\ndiarrhoea).\\nSplenomegaly is common; bleeding signs (e.g. petechiae, subconjunctival haemorrhage, epistaxis, bleeding\\ngums), jaundice or neurological symptoms may be observed.\\nThe febrile episode terminates in a crisis with an elevation in temperature,\\xa0heart rate and blood pressure,\\nfollowed by a fall in temperature and blood pressure, which may last for several hours.\\nFollowing the initial febrile episode, the cycle usually reccurs; each episode is less severe than the previous one and\\nthe patient develops temporary immunity.\\nComplications:\\ncollapse during defervescence, myocarditis, cerebral haemorrhage;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 243, 'page_label': '244', 'id': 'data/guideline-170-en.pdf:243:3'}, page_content='collapse during defervescence, myocarditis, cerebral haemorrhage;\\nduring pregnancy: abortion, preterm delivery, in utero foetal death, neonatal death.\\nAntibiotic treatment (suspect or conﬁrmed cases and close contacts):\\ndoxycycline PO\\nChildren: 4 mg/kg (max. 100 mg)\\xa0single dose\\xa0\\nAdults: 200 mg single dose\\nor\\nerythromycin\\xa0PO\\nChildren under\\xa05 years: 250 mg single dose\\nChildren 5 years and over and adults: 500 mg single dose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 244, 'page_label': '245', 'id': 'data/guideline-170-en.pdf:244:0'}, page_content='Page 245 / 409\\nor\\nazithromycin PO\\nChildren: 10 mg/kg (max. 500 mg) single dose\\nAdults:\\xa0500 mg single dose\\nTreatment of pain and\\xa0fever\\xa0(paracetamol PO) and prevention or treatment of dehydration in the event of\\nassociated diarrhoea.\\nElimination of body lice is essential in control of epidemics (see\\xa0Pediculosis, Chapter 4).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 245, 'page_label': '246', 'id': 'data/guideline-170-en.pdf:245:0'}, page_content='Page 246 / 409\\nTick-borne relapsing fever (TBRF)\\nLast update: October 2022\\n\\xa0\\n\\xa0\\nTBRFs are caused by different\\xa0Borrelia\\xa0species. They are endemic in temperate and warm regions of the word,\\nespecially in Africa (Tanzania, DRC, Senegal, Mauritania, Mali, the Horn of Africa) and mainly in rural areas. TBRF is a\\nmajor cause of morbidity and mortality in children and pregnant women. The mortality rate for untreated TBRF ranges\\nfrom 2 to 15%.\\nClinical features\\nThe clinical manifestations and complications of TBRF are similar to those of LBRF but central nervous system (CNS)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 245, 'page_label': '246', 'id': 'data/guideline-170-en.pdf:245:1'}, page_content='involvement\\xa0(particularly\\xa0lymphocytic meningitis) is\\xa0more frequent than in LBRF and the number of relapses is higher.\\xa0The clinical diagnosis is difﬁcult, especially during the ﬁrst episode: cases occur sporadically rather than in outbreaks;\\nthe tick bite is painless and usually unnoticed by the patient; symptoms are very similar to those of malaria, typhoid\\nfever, leptospirosis, certain arbovirosis (yellow fever, dengue) or rickettsiosis, and meningitis.\\nLaboratory\\nTreatment\\nChildren under 45 kg: 2.2 mg/kg (max. 100 mg) 2 times daily\\xa0\\nChildren 45 kg and over and adults: 100 mg 2 times daily\\xa0\\nor\\nazithromycin PO\\xa0for 7 to 10 days (if doxycycline is contra-indicated or not available)\\nChildren: 10 mg/kg (max. 500 mg) once daily\\nAdults: 500 mg once daily\\nor'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 245, 'page_label': '246', 'id': 'data/guideline-170-en.pdf:245:2'}, page_content='Children: 10 mg/kg (max. 500 mg) once daily\\nAdults: 500 mg once daily\\nor\\nceftriaxone IV for 10 to 14 days (for pregnant women or in case of\\xa0CNS involvement)\\nChildren: 50 to 75 mg/kg (max. 2 g) once daily\\nAdults: 2 g once daily\\xa0\\n\\xa0\\xa0 Antibiotic treatment\\xa0can trigger a Jarisch-Herxheimer reaction with high fever, chills, fall in blood pressure and\\nsometimes shock. It is recommended to monitor the patient for 2 hours after the ﬁrst dose of antibiotic, for\\noccurrence and management of severe Jarisch-Herxheimer reaction (symptomatic treatment of shock).\\nJarisch-Herxheimer reaction appears to occur more frequently in LBRF than in TBRF.\\n\\xa0\\nAs for LBRF, the diagnosis is conﬁrmed by detection of\\xa0Borrelia\\xa0in the patient’s blood.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 245, 'page_label': '246', 'id': 'data/guideline-170-en.pdf:245:3'}, page_content='Repeat the examination if the ﬁrst smear is negative despite strong clinical suspicion.\\nIn all cases, rapid test for malaria in endemic regions (and antimalarial treatment if needed, see\\xa0Malaria, Chapter 6).\\nAntibiotic treatment:\\ndoxycycline PO\\xa0for 7 to 10 days\\n a \\nTreatment of pain and\\xa0fever\\xa0(paracetamol PO) and prevention or treatment of dehydration in the event of\\nassociated diarrhoea.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 246, 'page_label': '247', 'id': 'data/guideline-170-en.pdf:246:0'}, page_content='Page 247 / 409\\nFootnotes\\n(a) For IV administration of ceftriaxone, dilute with water for injection only.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 247, 'page_label': '248', 'id': 'data/guideline-170-en.pdf:247:0'}, page_content='Page 248 / 409\\nEruptive rickettsioses\\nLast update: October 2022\\n\\xa0\\n\\xa0\\nRickettsioses are eruptive fevers caused by bacteria of the genus\\xa0Rickettsia\\xa0and transmitted to man by an arthropod\\nvector. Three main groups are distinguished: typhus group, spotted fever group and scrub typhus group.\\nClinical features\\n\\xa0\\nCommon to all forms:\\nSudden onset of fever (temperature of over 39 °C) with severe headache and myalgias.\\n3 to 5 days later; onset of generalised cutaneous eruption (see below).\\nHypotension; non-dissociated rapid heart rate (variable).\\nTyphoid state: prostration, obnubilation, confusion and extreme asthenia, particularly marked in typhus forms.\\nInoculation eschar: painless, black crusted lesion surrounded by a erythematous halo at the site of the bite.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 247, 'page_label': '248', 'id': 'data/guideline-170-en.pdf:247:1'}, page_content='Always check for this signiﬁcant sign.\\nNon-cutaneous signs vary from one form to another, and are atypical and variable (see below).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 248, 'page_label': '249', 'id': 'data/guideline-170-en.pdf:248:0'}, page_content='Page 249 / 409\\n\\xa0\\nLaboratory\\nDetection of speciﬁc IgM of each group by indirect immunoﬂuorescence. The diagnosis is conﬁrmed by 2 serological\\ntests at an interval of 10 days. In practice, clinical signs and the epidemiological context are sufﬁcient to suggest the\\ndiagnosis and start treatment.\\nGroup Typhus Spotted fever Scrub\\ntyphus\\nForm Epidemic typhus Murine typhus Mediterranean \\nspotted fever\\nRocky\\nMountain\\nspotted fever\\nOther Old-\\nWorld tick-\\nborne fevers\\nScrub typhus\\nPathogen R. prowasekii R. typhi R. conorii R. rickettsii R. sibirica, R.\\naustralis\\nO.\\ntsutsugamushi\\nVector body lice rat ﬂeas ticks ticks ticks mites\\nReservoir man rats dogs rodents rodents, dogs,\\netc.\\nrodents\\nOccurence epidemic endemic endemic endemic endemic sporadic\\nGeographical\\ndistribution\\nworldwide,\\nconﬂicts; main'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 248, 'page_label': '249', 'id': 'data/guideline-170-en.pdf:248:1'}, page_content='Geographical\\ndistribution\\nworldwide,\\nconﬂicts; main\\nsites:\\nBurundi/Rwanda,\\nEthiopia\\nworldwide around the\\nmediterranean,\\nSub-Saharan\\nAfrica\\nNorth America, \\nCentral\\nAmerica,\\nColumbia,\\nBrazil\\nSouthern\\nAfrica,\\nAustralia,\\nSiberia\\nFar East, India,\\nSouth Paciﬁc\\nArea\\nRash maculopapular maculopapular maculopapular purpural maculopapular macular\\nEschar 0 0 black\\nnecrotic area\\nrare black\\nnecrotic area\\nblack\\nnecrotic area\\nTyphoid\\nstate\\n+++ +++ +/- +/- +/- +++\\nExtra-\\ncutaneous\\nsigns\\ncough, myalgia,\\nmeningeal signs\\ngastrointestinal\\nsigns\\nmeningeal\\nsigns\\ngastrointestinal\\nand\\nneurological\\nsigns,\\nhypotension\\nvariables meningeal\\nsigns\\nCase fatality\\n(%)\\n30 (without\\ntreatment)\\n5 2 5 1 0-30\\nComplications can be severe, and sometimes fatal: encephalitis, myocarditis, hepatitis, acute renal failure,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 248, 'page_label': '249', 'id': 'data/guideline-170-en.pdf:248:2'}, page_content='haemorrhage etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 249, 'page_label': '250', 'id': 'data/guideline-170-en.pdf:249:0'}, page_content='Page 250 / 409\\nTreatment\\n\\xa0\\nChildren under 45 kg: 2.2 mg/kg (max. 100 mg) 2 times daily\\nChildren 45 kg and over and adults: 100 mg 2 times daily\\nIn severe infections, a loading dose of doxycycline is recommended:\\nChildren under 45 kg: 4.4\\xa0mg/kg (max. 200 mg) on D1 then 2.2 mg /kg (max. 100 mg) 2 times daily\\nChildren 45 kg and over and adults: 200 mg on D1 then 100 mg 2 times daily\\xa0\\nPrevention\\n\\xa0\\nSymptomatic treatment:\\nHydration (PO or IV if the patient is unable to drink).\\nFever: paracetamol PO (Chapter 1). Acetylsalicylic acid (aspirin) is contra-indicated due to the risk of\\nhaemorrhage.\\nAntibiotic for 5 to 7 days or until 3 days after the fever has disappeared:\\ndoxycycline PO\\n a \\nIn a context of epidemic typhus, doxycycline PO is the choice treatment, but there is a risk of recurrence:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 249, 'page_label': '250', 'id': 'data/guideline-170-en.pdf:249:1'}, page_content='Children: 4 mg/kg\\xa0(max. 100 mg)\\xa0single dose\\xa0\\nAdults: 200 mg single dose\\nEpidemic typhus: control of body lice (see\\xa0Pediculosis, Chapter 4).\\nMurine typhus: control of ﬂeas and then rats.\\nSpotted fevers: avoid tick bites by wearing clothing and using repellents.\\nScrub typhus: use of repellents, chemoprophylaxis with\\xa0doxycycline\\xa0PO (200 mg once weekly in adults).\\nFootnotes\\n(a) Unlike borrelioses, antibiotic treatment of rickettsioses does not provoke a Jarisch-Herxheimer reaction. However, thegeographical distribution of borrelioses and rickettsioses may overlap, and thus a reaction may occur due to a possible co-infection (see Borreliosis).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 250, 'page_label': '251', 'id': 'data/guideline-170-en.pdf:250:0'}, page_content='Page 251 / 409\\nChapter 8: Viral diseases\\nMeasles\\nPoliomyelitis\\nRabies\\nViral hepatitis\\nDengue\\nViral haemorrhagic fevers\\nHIV infection and AIDS'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 251, 'page_label': '252', 'id': 'data/guideline-170-en.pdf:251:0'}, page_content='Page 252 / 409\\nMeasles\\nMeasles is a highly contagious acute viral infection, transmitted by the airborne route (inhalation of respiratory droplets\\nspread by infected individuals). The disease mainly affects children under 5 years of age and can be prevented by\\nimmunization.\\xa0For more information, refer to the guide\\xa0Management of a measles epidemic,\\xa0MSF.\\nClinical features\\nThe average incubation period is 10 days.\\xa0Prodromal or catarrhal phase\\xa0(2 to 4 days)\\n\\xa0Eruptive phase\\xa0(4 to 6 days)\\n\\xa0The eruptive phase is followed by skin desquamation during 1 to 2 weeks, very pronounced on pigmented skin (the skin\\ndevelops a striped appearance).\\xa0In practice, a patient presenting with fever and erythematous maculopapular rash and at least one of the following'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 251, 'page_label': '252', 'id': 'data/guideline-170-en.pdf:251:1'}, page_content=\"signs: cough or runny nose or conjunctivitis, is a clinical case of measles.\\nComplications\\nMost measles cases experience at least one complication:\\n\\xa0Pneumonia and dehydration are the most common immediate causes of death.\\nCase management\\nHigh fever (39-40 °C) with cough, coryza (nasal discharge) and/or conjunctivitis (red and watery eyes).\\nKoplik’s spots: tiny bluish-white spots on an erythematous base, found on the inside of the cheek. This sign is\\nspeciﬁc of measles infection, but may be absent at the time of examination. Observation of Koplik's spots is not\\nrequired for diagnosing measles.\\nOn average 3 days after the onset of symptoms: eruption of erythematous, non- pruritic maculopapules, which\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 251, 'page_label': '252', 'id': 'data/guideline-170-en.pdf:251:2'}, page_content='blanch with pressure. The rash begins on the forehead then spreads downward to the face, neck, trunk\\n(second\\xa0day), abdomen and lower limbs (third\\xa0and fourth\\xa0day).\\nAs the rash progresses, prodromal symptoms subside. In the absence of complications, the fever disappears once\\nthe rash reaches the feet.\\nThe rash fades around the ﬁfth\\xa0day in the same order that it appeared (from the head to the feet).\\nRespiratory and ENT: pneumonia, otitis media, laryngotracheobronchitis\\nOcular: purulent conjunctivitis, keratitis, xerophthalmia (risk of blindness)\\nGastrointestinal: diarrhoea with or without dehydration, benign or severe stomatitis\\nNeurological: febrile seizures; rarely, encephalitis\\nAcute malnutrition, provoked or aggravated by measles (post-measles period)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 251, 'page_label': '252', 'id': 'data/guideline-170-en.pdf:251:3'}, page_content='Acute malnutrition, provoked or aggravated by measles (post-measles period)\\nAdmit as inpatient children with at least one major complication:\\nInability to eat/drink/suck, or vomiting\\nAltered consciousness or seizures\\nDehydration\\nSevere pneumonia (pneumonia with respiratory distress or cyanosis or SpO\\xa0< 90%)2\\nAcute laryngotracheobronchitis (croup) a\\nCorneal lesions (pain, photophobia, erosion or opacity)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 252, 'page_label': '253', 'id': 'data/guideline-170-en.pdf:252:0'}, page_content='Page 253 / 409\\nIf in doubt, keep the child under observation for a few hours.\\nTreatment\\nSupportive and preventive treatment\\nTreatment of complications\\nSevere oral lesions that prevent eating\\nAcute malnutrition\\nTreat as outpatient children with no major complications, no complications or minor complications:\\nPneumonia without severe signs\\nAcute otitis media\\nPurulent conjunctivitis (no corneal lesions)\\nDiarrhoea without dehydration\\nOral candidiasis that does not interfere with eating\\nIsolation\\nIsolation of hospitalized patients\\nMeasles cases treated as outpatients should be kept at home during this period.\\nTreat fever: paracetamol (Fever, Chapter 1).\\nMake the child drink (high risk of dehydration).\\nGive smaller, more frequent meals or breastfeed more frequently (every 2 to 3 hours).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 252, 'page_label': '253', 'id': 'data/guideline-170-en.pdf:252:1'}, page_content='Clear the nasopharynx (nose-blowing or nasal lavages) to prevent secondary respiratory infection and improve the\\nchild’s comfort.\\nClean the eyes with clean water 2 times daily and administer retinol on D1 and D2 (see\\xa0Xerophthalmia,\\xa0Chapter 5) to\\nprevent ocular complications.\\nIn children under 5 years: amoxicillin PO for 5 days as a preventive measure (reduction of respiratory and ocular\\ninfections).\\nIn the event of watery diarrhoea without dehydration: oral rehydration according to WHO Plan A (see Dehydration,\\nChapter 1).\\nInsert a nasogastric tube for a few days if oral lesions prevent the child from drinking.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 253, 'page_label': '254', 'id': 'data/guideline-170-en.pdf:253:0'}, page_content='Page 254 / 409\\n\\xa0\\nPrevention\\n\\xa0\\n\\xa0 Treatment of complications\\nSevere pneumonia ceftriaxone IV or IM + cloxacillin IV then change to amoxicillin/clavulanic acid\\nPO (see Chapter 2)\\n+ oxygen if cyanosis or SpO < 90%\\n+ salbutamol if expiratory wheezing and sibilant rales on auscultation\\nIn all cases, close monitoring.\\n2\\nPneumonia without severe\\nsigns\\namoxicillin PO for 5 days\\nCroup Inpatient monitoring (risk of worsening). Keep the child calm. Agitation and crying\\nexacerbate the symptoms.\\nFor severe croup:\\ndexamethasone IM: 0.6 mg/kg single dose\\n+ nebulized epinephrine (adrenaline, 1 mg/ml ampoule): 0.5 ml/kg (max. 5 ml)\\n+ oxygen if cyanosis or SpO < 90%\\nIntensive monitoring until symptoms resolve.\\n2\\nAcute otitis media See Otitis, Chapter 2.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 253, 'page_label': '254', 'id': 'data/guideline-170-en.pdf:253:1'}, page_content='2\\nAcute otitis media See Otitis, Chapter 2.\\nDehydration Per oral route or IV depending on the degree of dehydration.\\nOral candidiasis See Stomatitis, Chapter 3.\\nPurulent conjunctivitis See Conjunctivitis, Chapter 5.\\nKeratitis/keratoconjunctivitis tetracycline 1% eye ointment 2 times daily for 7 days\\n+ retinol PO one dose on D1, D2 and D8 (see Xerophthalmia, Chapter 5)\\n+ eye protection and pain management (see Pain, Chapter 1).\\nNo topical corticosteroids.\\nXerophthalmia See Xerophthalmia, Chapter 5.\\nFebrile seizures See Seizures, Chapter 1.\\nNo chemoprophylaxis for contacts.\\nVaccination:\\nBetween\\xa09 and 12 months: one dose of 0.5 ml. The WHO recommends a second dose between 15 and 18\\nmonths. Respect an interval of at least 4 weeks between doses.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 253, 'page_label': '254', 'id': 'data/guideline-170-en.pdf:253:2'}, page_content='months. Respect an interval of at least 4 weeks between doses.\\nWhere\\xa0there is high risk of infection (overcrowding, epidemics, malnutrition, infants born to a mother with HIV\\ninfection, etc.), administer a supplementary dose from 6 months of age then continue vaccination schedule.\\nChildren\\xa0under 15 years who have missed\\xa0either one or both\\xa0doses of routine vaccination should be vaccinated\\nwhen they come in contact with health services. Check national recommendations.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 254, 'page_label': '255', 'id': 'data/guideline-170-en.pdf:254:0'}, page_content='Page 255 / 409\\nFootnotes\\n(a) Symptoms (hoarse crying or voice, difﬁculty breathing, a high-pitched inspiratory wheeze [inspiratory stridor], characteristic\"barking\" cough) are caused by inﬂammation and narrowing of the larynx. Croup is considered benign or “moderate” if thestridor occurs when the child is agitated or crying, but disappears when the child is calm. The child should be monitoredduring this period, however, because his general and respiratory status can deteriorate rapidly. Croup is severe when thestridor persists at rest or is associated with signs of respiratory distress.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 255, 'page_label': '256', 'id': 'data/guideline-170-en.pdf:255:0'}, page_content='Page 256 / 409\\nPoliomyelitis\\nPoliomyelitis is an acute viral infection due to a poliovirus (serotypes 1, 2 or 3). Human-to-human transmission is direct\\n(faecal-oral) or indirect (ingestion of food and water contaminated by stool). Humans are the only reservoir of the virus.\\nIn principle the disease can be eradicated by mass vaccination.\\xa0In endemic areas, poliomyelitis mainly affect children under 5 years not (or not fully) vaccinated, but the infection can\\naffect persons of any age, especially in areas where population immunity is low.\\nClinical features\\nLaboratory\\nLook for the polio virus in stool samples. The virus is excreted for one month after infection, but only intermittently;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 255, 'page_label': '256', 'id': 'data/guideline-170-en.pdf:255:1'}, page_content='therefore, 2 samples must be collected with an interval of 24-48 hours,\\xa0and within 14 days of onset of symptoms\\n.\\xa0Send the stool samples to a reference laboratory, with a clinical description of the patient. The stool samples must be\\nstored and transported between 0 °C and 8 °C.\\nTreatment\\nOutbreak control in case of acute ﬂaccid paralysis (AFP)\\nUp to 90% of cases are asymptomatic or present mild symptoms . [1] \\nNon-paralytic form: a non-speciﬁc febrile illness with muscle pain, headache, vomiting, backache; no neurological\\ninvolvement. As spontaneous recovery usually occurs within 10 days, diagnosis is rarely made outside epidemic\\ncontexts.\\nParalytic form: in less than 1% of cases, after the non-speciﬁc signs, the patient develops rapid onset (from the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 255, 'page_label': '256', 'id': 'data/guideline-170-en.pdf:255:2'}, page_content='morning to the evening) asymmetrical acute ﬂaccid paralysis, predominantly of the lower limbs, with ascending\\nprogression. The muscles become soft with diminished reﬂexes. Sensation is maintained. The disease is life\\nthreatening if paralysis involves the respiratory muscles or muscles of swallowing. Initial urinary retention is common.\\nGastrointestinal disturbances (nausea, vomiting, diarrhoea), muscle pain and meningeal symptoms may also occur.\\n [2]\\nHospitalise patients with the paralytic form: rest, prevent bed sores in bedridden patients, give analgesics (do not\\ngive IM injections to patients in the febrile phase), ventilate patients with respiratory paralysis.\\nPhysiotherapy once the lesions are stable to prevent muscle atrophy and contractures.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 255, 'page_label': '256', 'id': 'data/guideline-170-en.pdf:255:3'}, page_content='Care for sequelae: physiotherapy, surgery and prosthetics.\\nConsider any patient with AFP as a suspected case of poliomyelitis.\\nSend stool samples to a reference laboratory to conﬁrm the diagnosis. \\xa0\\nOrganize vaccination of all children under 5 years living in the area (from the same village or neighbouring villages)\\nirrespective of their vaccination status, within 14 days of laboratory conﬁrmation and with the available vaccine\\n(round 0) . [3] \\nOrganize two mass vaccination campaigns within 8 weeks of the laboratory conﬁrmation. The type of vaccine, the\\narea and the age groups are determined by epidemiological data.\\nOrganize a mop-up (door-to-door) vaccination campaign wherever monitoring suggests that children have been\\nmissed, to ensure interruption of transmission.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 255, 'page_label': '256', 'id': 'data/guideline-170-en.pdf:255:4'}, page_content='missed, to ensure interruption of transmission.\\nSurveillance: for each case of AFP there are between 100 and 200 subclinical cases. Therefore, active surveillance\\nto detect new cases is essential for epidemic control.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 256, 'page_label': '257', 'id': 'data/guideline-170-en.pdf:256:0'}, page_content='Page 257 / 409\\nPrevention\\nIn children who start routine vaccination late (after the age of 3 months), the dose of IPV is administered together with\\nthe ﬁrst\\xa0dose of bOPV, followed by 2 doses of bOPV alone administered 4 weeks apart.\\nThere is also an ‘IPV only’ schedule: 3 doses administered at least 4 weeks apart (e.g. at 6, 10 and 14 weeks) and a\\nbooster dose at least 6 months later.\\nIPV should eventually completely replace bOPV.\\n\\xa0\\nReferences\\n3 types of vaccines exist:\\na trivalent injectable inactivated poliovirus vaccine (IPV),\\na bivalent oral live attenuated poliovirus vaccine (bOPV),\\xa0containing serotypes 1 and 3,\\na monovalent oral type 2 vaccine (mOPV or nOPV) exclusively used for responding to epidemics.\\nVaccination schedule: depends on the epidemiology of the virus.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 256, 'page_label': '257', 'id': 'data/guideline-170-en.pdf:256:1'}, page_content='Vaccination schedule: depends on the epidemiology of the virus.\\nProtocols vary according to the country, follow national recommendations. For information, the WHO\\nrecommends:\\nSchedule\\nPrimary vaccination\\nEndemic or at risk zones (a) Other zones\\nBirth 1 dose bOPV (b) –\\n6 weeks 1 dose bOPV 1 dose bOPV\\n10 weeks 1 dose bOPV 1 dose bOPV\\n14 weeks 1 dose bOPV + 1 dose IPV 1 dose bOPV + 1 dose IPV\\n(a) Countries where poliomyelitis is endemic or zones at high risk of importation and subsequent spread of the virus.\\n(b) The ﬁrst\\xa0dose of bOPV is administered at birth, or as soon as possible, to optimise seroconversion rates after subsequentdoses and induce mucosal protection.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 256, 'page_label': '257', 'id': 'data/guideline-170-en.pdf:256:2'}, page_content='1. World Health Organization. Poliomyelitis (polio).https://www.who.int/health-topics/poliomyelitis#tab=tab_1\\xa0[Accessed 08 June 2021]\\n2. Centers for Disease Control and Prevention. Poliomyelitis. 2020.https://www.cdc.gov/vaccines/pubs/pinkbook/polio.html\\xa0[Accessed 08 June 2021]\\n3. Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus event or outbreak, version 3.1.World Health Organization. 2020.https://www.who.int/publications/i/item/9789240002999\\xa0[Accessed 08 June 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 257, 'page_label': '258', 'id': 'data/guideline-170-en.pdf:257:0'}, page_content='Page 258 / 409\\nRabies\\nRabies is a viral infection of wild and domestic mammals, transmitted to humans by the saliva of infected animals\\nthrough bites, scratches or licks on broken skin or mucous membranes.\\xa0\\xa0In endemic areas (Africa and Asia), 99% of cases are due to dog bites and\\xa040% of cases are children under 15 years of\\nage .\\xa0Before symptoms develop,\\xa0rabies can effectively be prevented by post-exposure prophylaxis.\\nOnce symptoms develop, rabies is fatal. There is no curative treatment; care is palliative.\\xa0\\nClinical features\\n\\xa0Diagnosis is often difﬁcult: there may be no history of scratch or bite (exposure through licking) or wounds may have\\nhealed; a reliable history may be difﬁcult to obtain.\\nPost-exposure prophylaxis\\nDeﬁnitions\\xa0of exposure categories\\xa0(WHO)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 257, 'page_label': '258', 'id': 'data/guideline-170-en.pdf:257:1'}, page_content='Post-exposure prophylaxis\\nDeﬁnitions\\xa0of exposure categories\\xa0(WHO)\\n\\xa0Post-exposure prophylaxis is carried out for Category II and III exposures.\\nTreatment of the wound\\nIn all cases\\n [1] \\nThe incubation period averages 20 to 90 days from exposure (75% of patients), but can be shorter (in severe\\nexposure, e.g. bites to face, head and hands; multiple bites), or longer (20% of patients develop symptoms\\nbetween 90 days and 1 year, and 5% more than 1 year after exposure).\\nProdromal phase: itching or paraesthesiae\\xa0or\\xa0neuropathic pain\\xa0around the site of exposure, and non-speciﬁc\\nsymptoms (fever, malaise, etc.).\\nNeurologic phase:\\nEncephalitic\\xa0form (furious form): psychomotor agitation or hydrophobia (throat spasms and panic, triggered by'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 257, 'page_label': '258', 'id': 'data/guideline-170-en.pdf:257:2'}, page_content='attempting to drink or sight/sound/touch of water) and aerophobia (similar response to a draft of air); sometimes\\nseizures. The patient is calm and lucid between episodes.\\xa0Infection evolves to\\xa0paralysis and coma.\\nParalytic form (less common, 20% of cases): progressive ascending paralysis resembling Guillain-Barré\\nsyndrome;\\xa0evolves to coma.\\nCategory I Contact with animal, or licks on intact skin No exposure\\nCategory II Nibbles on exposed skin\\nMinor bite(s) or scratch(es) without bleeding Minor exposure\\nCategory III\\nTransdermal bite(s) or scratch(es)\\nLicks on broken skin\\nContamination of mucous membranes by animal’s saliva (licks)\\nDirect contact with bats a\\nSevere exposure'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 258, 'page_label': '259', 'id': 'data/guideline-170-en.pdf:258:0'}, page_content='Page 259 / 409\\nProlonged cleansing of the wound or contact site\\xa0for 15 minutes\\xa0to eliminate the virus, as soon as possible after\\nexposure, is of critical importance. For skin: use soap, rinse copiously with running water, remove all foreign material;\\napplication of\\xa0a disinfectant (povidone iodine 10%\\xa0or other)\\xa0is an additional precaution which does not take the place\\nof\\xa0thorough\\xa0wound washing. For mucous membranes (eye, mouth, etc.): rinse thoroughly with water or 0.9% sodium\\nchloride. Local cleansing is indicated even if the patient presents late.\\nAccording to condition/type of wound\\nIn order to avoid inoculating virus deeper into the tissues, wounds are either not sutured at all (e.g. superﬁcial, non-'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 258, 'page_label': '259', 'id': 'data/guideline-170-en.pdf:258:1'}, page_content='mutilating or puncture wounds), or are left open and re-evaluated in 48-72 hours, with a view to possible closure. Highly\\ncontaminated wounds, or wounds that may compromise function, require surgical management (exploration, removal\\nof foreign material, excision of necrotic tissue, copious irrigation with\\xa0sterile\\xa00.9% sodium chloride or Ringer lactate,\\nwith local or general anaesthesia). When suturing is\\xa0indicated (face), rabies immunoglobulin should be administered\\nseveral hours\\xa0before wound closure (see below). Infected wounds are not sutured and reassessed daily.\\nPassive and active immunisation\\nGiven the duration of incubation, administration of vaccine/immunoglobulin\\xa0is always\\xa0a priority, even for patients\\nexposed several months previously.\\nAnti-rabies serotherapy'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 258, 'page_label': '259', 'id': 'data/guideline-170-en.pdf:258:2'}, page_content=\"exposed several months previously.\\nAnti-rabies serotherapy\\nRabies immunoglobulin is indicated\\xa0after:\\n\\xa0It\\xa0is intended to neutralize virus in the exposure site. It is given as a single dose on D0, with the ﬁrst dose of rabies\\nvaccine.\\nhuman rabies immunoglobulin:\\nChildren and adults: 20 IU/kg\\nor\\nhighly puriﬁed\\xa0rabies\\xa0immunoglobulin\\xa0F(ab')2 fragments:\\nChildren and adults:\\xa040 IU/kg\\xa0Inﬁltrate\\xa0rabies immunoglobulin\\xa0into and around the previously washed\\xa0wound(s).\\xa0Ensure it is not injected into a blood\\nvessel\\xa0(risk of shock).\\nFor ﬁnger wounds, inﬁltrate very cautiously to avoid\\xa0increased pressure\\xa0in the\\xa0tissue compartment\\xa0(compartment\\nsyndrome).\\nIn the event of multiple wounds, dilute the dose 2- to 3-fold with sterile 0.9% sodium chloride to obtain a sufﬁcient\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 258, 'page_label': '259', 'id': 'data/guideline-170-en.pdf:258:3'}, page_content='quantity to inﬁltrate all the sites exposed.\\nInﬁltrate\\xa0rabies immunoglobulin\\xa0into the wound even if it has already healed.\\xa0\\nFor mucosal exposures with no wound, rinse with rabies\\xa0immunoglobulin\\xa0diluted\\xa0in\\xa0sterile 0.9% sodium chloride.\\xa0Monitor the patient\\xa0during and after the\\xa0injection\\xa0(low risk of anaphylactic reaction).\\xa0If rabies\\xa0immunoglobulin\\xa0is not available on D0, the ﬁrst dose of rabies vaccine is administered alone. Administer rabies\\nimmunoglobulin\\xa0as soon as possible\\xa0between D0 and D7;\\xa0from\\xa0D8,\\xa0it is not necessary to\\nadminister\\xa0rabies\\xa0immunoglobulin\\xa0as vaccine-induced antibodies\\xa0begin to appear.\\nPost-exposure rabies\\xa0prophylaxis\\xa0\\nCategory III exposures\\xa0(except in patients who have received a full course of pre-exposure prophylaxis\\xa0against\\nrabies,\\xa0see\\xa0Prevention);'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 258, 'page_label': '259', 'id': 'data/guideline-170-en.pdf:258:4'}, page_content='rabies,\\xa0see\\xa0Prevention);\\xa0\\nCategory II and III exposures\\xa0in\\xa0immunocompromised patients (even in patients who have received a\\xa0full course\\xa0of\\npre-exposure\\xa0prophylaxis\\xa0against rabies).\\n b \\n [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 259, 'page_label': '260', 'id': 'data/guideline-170-en.pdf:259:0'}, page_content='Page 260 / 409\\nA complete prophylaxis\\xa0series is indicated for Category II and III exposures. It should be started on D0\\xa0and continued to\\ncompletion if the risk of rabies has not been excluded .\\xa0Several different types of rabies vaccines prepared from cell\\ncultures (CCEEV) exist.\\xa0 These vaccines must replace nerve tissue vaccines (NTV).\\xa0\\nProphylaxis\\xa0schedules may vary from country to country, check national recommendations.\\xa0The patient must be\\nadministered the full course of doses indicated.\\xa0\\nMain\\xa0post-exposure\\xa0prophylaxis\\xa0regimens\\nNotes:\\nOther measures\\nAntibiotherapy/antibiotic prophylaxis\\n c \\n [1]\\nDate\\nNo pre-exposure prophylaxis or unknown prophylaxis status \\nor incomplete pre-exposure prophylaxis or complete pre-exposure prophylaxis with an NTV\\nIM route'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 259, 'page_label': '260', 'id': 'data/guideline-170-en.pdf:259:1'}, page_content='IM route\\n1 dose = 0.5 or 1 ml depending on the\\nmanufacturer\\n (a) ID route\\n1 dose = 0.1 ml\\n (b) \\nD0 2 doses\\n(1 dose in each arm or thigh)\\n (c) 1 dose (c) 2 doses\\n(1 dose in each arm)\\n (c) \\nD3 \\xa0 1 dose 2 doses \\n(1 dose in each arm)\\nD7 1 dose 1 dose 2 doses \\n(1 dose in each arm)\\nD14 \\xa0 1 dose (d) \\xa0\\nD21 1 dose \\xa0 \\xa0\\n(a) IM route: there are two possible schedules, the Zagreb regimen (2-0-1-0-1) over 21 days or the 4-dose Essen regimen (1-1-1-1-0) over 14 to 28 days. The IM injection is administered into the anterolateral part of the thigh in children < 2 years; intothe deltoid muscle (arm) in children ≥ 2 years and adults; do not administer into the gluteal muscle.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 259, 'page_label': '260', 'id': 'data/guideline-170-en.pdf:259:2'}, page_content='(b) ID route: inject into the deltoid muscle\\xa0(or the\\xa0suprascapular region or the anterolateral part of the thigh). Incorrect IDtechnique results in failure of post-exposure prophylaxis.\\xa0If correct ID technique cannot be assured, use IM route.\\n(c) As well as a single dose of rabies immunoglobulin on D0 if indicated.\\n(d) The last\\xa0injection can be administered between D14 and D28.\\nIn immunocompromised patients: 1 dose on D0, 1 dose on D7 and 1 dose between D21 and D28. [1]\\nIn patients that have received a full course of\\xa0pre-exposure prophylaxis\\xa0(see\\xa0\\xa0Prevention),\\xa0the post-exposure\\nregimen is:\\xa01\\xa0dose\\xa0on D0 and 1 dose D3\\xa0by IM or ID route or 4 doses by ID route on D0.\\n [2]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 260, 'page_label': '261', 'id': 'data/guideline-170-en.pdf:260:0'}, page_content='Page 261 / 409\\n\\xa0The same dosage is used for both treatment and prophylaxis:\\nThe treatment of choice is\\xa0amoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO\\nUse formulations in a ratio of 8:1 or 7:1.\\xa0The dose is expressed in amoxicillin:\\nChildren < 40 kg: 25 mg/kg 2 times daily\\xa0\\nChildren ≥ 40 kg and adults:\\xa0\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times daily)\\nTetanus vaccination and serotherapy\\nCheck prophylaxis\\xa0status. If unknown or not up-to-date, see\\xa0Tetanus, Chapter 7.\\nPrevention\\nPre-exposure prophylaxis with a CCEEV\\xa0for people at risk (prolonged stay in rabies endemic areas, professionals in\\ncontact with animals\\xa0susceptible of carrying the virus, etc):\\xa01 dose by IM route or 2 doses by ID route on D0 and D7.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 260, 'page_label': '261', 'id': 'data/guideline-170-en.pdf:260:1'}, page_content='Infection present No infection\\nand\\nNo infection \\nand\\nlocal: redness,\\noedema,\\xa0serosanguinous\\nor\\xa0purulent\\xa0drainage\\nlocoregional or general:\\nlymphangitis, lymphadenopathy,\\nlocalised cellulitis, bone or joint\\ninfection, fever\\nwounds on the face or hands\\xa0or\\ngenital region\\nwounds involving joint, tendon,\\nligament or fracture\\ndeep puncture wounds\\nwounds with crush injury\\nwounds very contaminated or\\nrequiring debridement\\nwounds where correct debridement\\nis not possible\\nimmunocompromised patients\\nno criteria requiring antibiotic\\nprophylaxis\\nwounds more than 24-48\\nhours old\\nAntibiotherapy PO 7 days in the event\\nof local non severe infection;\\n14 days in the event of severe local\\ninfection, or widespread generalised\\ninfection.\\nAntibiotic prophylaxis PO 5 to 7 days No antibiotic prophylaxis\\n d'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 260, 'page_label': '261', 'id': 'data/guideline-170-en.pdf:260:2'}, page_content='infection.\\nAntibiotic prophylaxis PO 5 to 7 days No antibiotic prophylaxis\\n d \\nFootnotes\\n(a) In the event of direct contact with bats, check national recommendations.\\n(b) For example, for HIV-infected patients: CD4\\xa0≤ 25% in children < 5 years and < 200 cells/mm³ in children ≥ 5 years and adults.(http://apps.who.int/iris/bitstream/handle/10665/272371/WER9316.pdf?ua=1)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 260, 'page_label': '261', 'id': 'data/guideline-170-en.pdf:260:3'}, page_content='(c) Either through observation of the captured animal (if domestic) or through laboratory diagnosis of the animal (killed). TheWHO recommends a 10-day observation period of the animal, if captured. If no signs of rabies develop during theobservation period, the risk of rabies is excluded, and post-exposure prophylaxis is discontinued. Laboratory diagnosis ofthe dead animal involves sending the head to a specialised laboratory, which conﬁrms or excludes rabies in the animal. Iflaboratory diagnosis is negative, risk of rabies is excluded, and post-exposure prophylaxis is discontinued.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 261, 'page_label': '262', 'id': 'data/guideline-170-en.pdf:261:0'}, page_content='Page 262 / 409\\nReferences\\n(d) In penicillin-allergic patients:\\xa0•\\xa0Children:\\xa0co-trimoxazole\\xa0(30 mg SMX + 6 mg TMP/kg 2 times daily) +\\xa0clindamycin\\xa0(10 mg/kg\\xa03 times daily)\\xa0• Adults:\\xa0co-trimoxazole\\xa0(800 mg SMX + 160 mg TMP\\xa02 times daily) or\\xa0doxycycline\\xa0(100 mg\\xa02 times daily\\xa0or 200 mg oncedaily,\\xa0except in pregnant and lactating women)\\xa0+\\xa0metronidazole\\xa0(500 mg\\xa03 times daily).\\n1. Weekly epidemiological record/Relevé épidémiologique hebdomadaire, 20 April 2018, 93th\\xa0year/20 avril 2018, 93e\\xa0année.No\\xa016, 2018, 93, 201–220.http://apps.who.int/iris/bitstream/handle/10665/272371/WER9316.pdf?ua=1\\xa0[Accessed 25 october 2018]\\n2. Spencer\\xa0O,\\xa0Banerjee\\xa0S.\\xa0Animal bites. BMJ Best practice 2018\\xa0[Accessed 25 october 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 262, 'page_label': '263', 'id': 'data/guideline-170-en.pdf:262:0'}, page_content='Page 263 / 409\\nViral hepatitis\\nLast updated: October 2021\\n\\xa0\\nSeveral viral infections of the liver are grouped under the heading of viral hepatitis: hepatitis A, B, C, D (delta) and E.\\nThe different hepatitis viruses are present throughout the world, but their prevalence varies by country. Hepatitis A and\\nB are common in developing countries where\\xa0the vast majority of infections occur during childhood.\\xa0The clinical characteristics of all ﬁve diseases are similar enough to make differential diagnosis difﬁcult; however, there\\nare epidemiological, immunological and pathological differences. Patients with hepatitis B, C and D may later develop\\nchronic liver disease.\\nThe main characteristics of each type of viral hepatitis are summarized in the table below.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 262, 'page_label': '263', 'id': 'data/guideline-170-en.pdf:262:1'}, page_content='Clinical features\\n\\xa0The various forms of viral hepatitis\\nAsymptomatic forms\\nMild or anicteric forms are the most common, irrespective of the causal virus.\\xa0\\nIcteric\\xa0forms\\nInsidious or sudden onset with symptoms of varying intensity: fever, fatigue, nausea, gastrointestinal disturbance,\\nfollowed by jaundice, dark coloured urine and more or less claycoloured stool.\\nFulminant forms\\nHepatocellular failure with severe\\xa0cytolysis that can be fatal. This form is most frequent in hepatitis B patients with\\nsecondary infection with the D virus, and in the event of pregnant women infected with hepatitis E during their third\\ntrimester.\\nChronic hepatitis\\nHepatitis B, C and D may lead to cirrhosis and/or hepatocellular carcinoma (HCC).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 263, 'page_label': '264', 'id': 'data/guideline-170-en.pdf:263:0'}, page_content='Page 264 / 409\\n\\xa0 Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E\\nAge group\\nmost at risk\\nChildren Children Young adults Young adults Young adults\\nTransmission Faecal-oral\\nContaminated\\nfood and\\nwater\\nTransfusion\\n(rare)\\nVertical\\nClose contact with infected\\nperson (especially intra-\\nfamilial).\\nExposure to blood\\n(transfusion; material\\ncontaminated with blood)\\nSexual\\n (a) Exposure to\\nblood\\n(transfusion;\\nmaterial\\ncontaminated\\nwith blood)\\nSexual (low)\\nIntranasal\\n(implements\\nshared by\\nintranasal drug\\nusers)\\nVertical (a)\\nExposure to\\nblood\\n(transfusion;\\nmaterial\\ncontaminated\\nwith blood)\\nSexual\\nPossibly\\nvertical (a)\\nFaecal-oral\\nContaminated\\nfood and water\\nIncubation\\nperiod\\n2 to 6 weeks 4 to 30 weeks (average 10\\nweeks)\\n2 to 25 weeks Co-infection\\nB/D: as for\\nhepatitis B\\nSecondary'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 263, 'page_label': '264', 'id': 'data/guideline-170-en.pdf:263:1'}, page_content='weeks)\\n2 to 25 weeks Co-infection\\nB/D: as for\\nhepatitis B\\nSecondary\\ninfection of\\nhepatitis B:\\napproximately\\n5 weeks\\n2 to 8 weeks\\nFulminant\\nforms\\n0.2 to 0.4% 1 to 3% More rare than\\nin hepatitis B\\nMuch more\\ncommon in\\npatients with\\nsecondary\\ninfection of\\nhepatitis B\\nthan in patients\\nwith B/D co-\\ninfection\\n20% mortality\\nin pregnant\\nwomen\\nPrognosis No chronic\\nforms\\nChronicity: 0.2 to 10% (risk\\nis inversely related to age,\\ne.g. up to 90% if infected\\nbefore the age of 1 year) of\\nwhich 5 to 15% progress to\\ncirrhosis.\\nHCC possible\\nChronicity: up\\nto 50%, of\\nwhich 10 to\\n25% progress\\nto cirrhosis.\\nHCC possible\\nChronicity: <\\n5% for\\npatients with\\nB/D co-\\ninfection; >\\n90% if\\nsecondary\\ninfection of\\nhepatitis B\\n(rapid cirrhosis)\\nNo chronic\\nforms'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 264, 'page_label': '265', 'id': 'data/guideline-170-en.pdf:264:0'}, page_content='Page 265 / 409\\nLaboratory\\nDiagnosis\\nOther tests\\nOther investigations\\nElastography (Fibroscan®): measures the elasticity of the liver to determine stage of liver ﬁbrosis, scored from\\nF0\\xa0(absence of ﬁbrosis) to F4\\xa0(cirrhosis).\\nTreatment\\nTreatment of chronic active hepatitis B\\xa0\\nThe goal of treatment is to reduce the risk of cirrhosis and HCC.\\xa0\\nIndividual\\nprevention\\nPolyvalent\\nimmunoglobulin\\nSpeciﬁc anti-HBs\\nimmunoglobulin\\nSafe sex (condoms)\\nSpeciﬁc anti-\\nHBs\\nimmunoglobulin\\nmay be\\neffective\\nAs for hepatitis\\nB (the D virus\\ncan only\\ndevelop with\\nB)\\nCook meat\\n(pork)\\nVaccination Anti-hepatitis\\nA\\nAnti-hepatitis B Does not exist Anti-hepatitis\\nB\\nDoes not exist\\nCollective\\nprevention\\nHygiene,\\nsanitation\\nLimit transfusion, screen blood prior to transfusion\\nSingle use of disposable material\\nHygiene,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 264, 'page_label': '265', 'id': 'data/guideline-170-en.pdf:264:1'}, page_content='Single use of disposable material\\nHygiene,\\nsanitation\\n(a) Vertical transmission: transmission of the virus from the mother to the child during pregnancy, at the time of delivery, orduring the ﬁrst 28 days after birth.\\nHAV, HDV and\\xa0HEV infection: detection of IgM anti-HAV,\\xa0anti-HDV\\xa0and\\xa0anti-HEV antibodies, respectively.\\nHBV\\xa0infection: detection of HBsAg; chronic hepatitis B: presence of HBsAG for longer 6 months; chronic\\xa0active\\nhepatitis B: detection of HBeAg and/or HBV DNA.\\nHCV infection: detection of\\xa0anti-HCV antibodies\\xa0and HCV RNA; chronic hepatitis C: viraemia\\xa0persists\\xa0for longer\\nthan 6 months.\\nALT (or AST) level, platelet count, creatinine, HCV diagnosis and HBV viral load to decide treatment of chronic\\nactive hepatitis B.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 264, 'page_label': '265', 'id': 'data/guideline-170-en.pdf:264:2'}, page_content=\"active hepatitis B.\\nAPRI score (evaluation of liver ﬁbrosis in chronic hepatitis):\\xa0[(patient's AST level/normal AST level) x 100]/platelet\\ncount (10\\xa0platelets/litre).\\xa0An APRI score > 1 indicates probable severe ﬁbrosis.9\\nHIV test.\\nRest, hydration, no special diet.\\nDo not administer drug therapy for symptomatic treatment (analgesics, antipyretics, antidiarrhoeals, antiemetics\\netc.) during the acute phase as it may aggravate symptoms and the evolution of hepatitis. Corticosteroids are not\\nindicated.\\nStop or reduce alcohol consumption.\\nPatients with HIV co-infection\\xa0\\nLifelong antiretroviral therapy of HIV that includes tenofovir.\\xa0Do not administer tenofovir monotherapy or tenofovir\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 265, 'page_label': '266', 'id': 'data/guideline-170-en.pdf:265:0'}, page_content='Page 266 / 409\\nTreatment of chronic hepatitis C\\n\\xa0In case of decompensated cirrhosis\\xa0(presence of ascites\\xa0or jaundice or mental confusion or signs of gastrointestinal\\nhaemorrhage): same treatment but for 24 weeks.\\xa0Treatment is contra-indicated during pregnancy and breastfeeding.\\nFor women of childbearing age: provide a contraceptive; do not start treatment in women who do not want\\ncontraception.\\nVaccination\\n\\xa0\\n\\xa0\\ndual therapy with lamivudine or emtricitabine (risk of developing HIV drug resistance).\\xa0\\nPatients\\xa0without HIV co-infection\\xa0\\nTreatment is indicated in the event of cirrhosis or advanced hepatic ﬁbrosis (APRI score > 1.5 or Fibroscan F3-F4 >\\n10 kPa); HBsAg positive with persistently elevated ALT or AST > 2 times the normal values in 2 samples taken 3 or'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 265, 'page_label': '266', 'id': 'data/guideline-170-en.pdf:265:1'}, page_content='6 months apart; or persistently elevated ALT or AST with a high viral load (> 20 000 IU/ml).\\ntenofovir\\xa0PO (300 mg tab, equivalent to 245 mg of tenofovir disoproxil),\\xa0lifelong therapy:\\nChildren ≥ 12 years and adults, including pregnant women: one tablet once daily taken with a meal\\n [1]\\nGenotypes 1, 2, 3, 4, 5, 6\\xa0without cirrhosis\\nor with compensated cirrhosis\\nsofosbuvir/velpatasvir\\xa0PO (400 mg SOF/100 mg VEL tablet)\\n1 tablet once daily for 12 weeks\\nGenotypes 1, 2,\\xa04, 5, 6\\xa0without cirrhosis\\nor with compensated cirrhosis\\nGenotype 3 without cirrhosis\\nsofosbuvir/daclatasvir PO (400 mg SOF/60 mg DCV tablet)\\xa0\\n1 tablet once daily for 12 weeks\\nGenotype 3 with compensated cirrhosis sofosbuvir/daclatasvir PO (400 mg SOF/60 mg DCV tablet)\\n1 tablet once daily for\\xa024 weeks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 265, 'page_label': '266', 'id': 'data/guideline-170-en.pdf:265:2'}, page_content='1 tablet once daily for\\xa024 weeks\\nRoutine vaccination of neonates and infants \\xa0(according to national vaccination schedule):\\xa0 [2] \\n3 dose schedule: one dose as soon as possible after birth, preferably within the ﬁrst 24 hours of life,\\xa0then one\\ndose at 6 weeks and one dose\\xa0at 14 weeks a\\n4 dose schedule: one dose as soon as possible after birth,\\xa0preferably within the ﬁrst 24 hours of life,\\xa0then one\\ndose at 6 weeks, one dose at 10 weeks and one dose\\xa0at 14 weeks a\\nCatch-up vaccination\\xa0(unvaccinated individuals):\\n3 dose schedule\\xa0(0-1-6):\\xa02 doses 4 weeks apart, then a third\\xa0dose 6 months after the ﬁrst dose\\nPost-exposure prophylaxis:\\nOne dose on D0, one dose on D7 and one dose between D21 and D30 then a booster dose 12 months after the\\nﬁrst dose\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 265, 'page_label': '266', 'id': 'data/guideline-170-en.pdf:265:3'}, page_content='ﬁrst dose\\nFootnotes\\n(a) At birth, only the monovalent hepatitis B vaccine can be used.For the following doses, a monovalent or tetravalent (diphtheria, tetanus, pertussis,\\xa0hepatitis B) or\\xa0pentavalent (diphtheria,tetanus, pertussis, hepatitis B\\xa0and\\xa0Haemophilus inﬂuenzae) vaccine can be used, depending on national recommendations.If an infant was not administered the birth dose, this dose can be administered at anytime during the ﬁrst contact withhealth-care providers, up to the time of the next dose of the primary schedule.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 266, 'page_label': '267', 'id': 'data/guideline-170-en.pdf:266:0'}, page_content='Page 267 / 409\\nReferences\\n1. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virusinfection. July 2018.http://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1\\xa0[Accessed\\xa021 December 2018]\\n2. Weekly epidemiological record/Relevé épidémiologique hebdomadaire 7 JULY 2017, 92th\\xa0YEAR / 7 JUILLET 2017, 92e\\xa0ANNÉENo 27, 2017, 92, 369–392\\xa0http://apps.who.int/iris/bitstream/handle/10665/255841/WER9227.pdf?sequence=1\\xa0[Accessed 22 November 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 267, 'page_label': '268', 'id': 'data/guideline-170-en.pdf:267:0'}, page_content='Page 268 / 409\\nDengue\\nLast update: October 2022\\n\\xa0\\n\\xa0\\nDengue fever is an arbovirus transmitted to humans by the bite of a mosquito (Aedes). Transmission by transfusion of\\ncontaminated blood and transplacental transmission to the foetus have also been reported.\\nFour different serotypes of dengue have been described. Infection with one serotype provides a lifelong immunity to\\nthat speciﬁc serotype, but only partial, short-term immunity to other serotypes. There is no speciﬁc antiviral treatment.\\xa0Dengue is a mainly urban disease, present in tropical and subtropical regions , in particular in Asia, Central and South'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 267, 'page_label': '268', 'id': 'data/guideline-170-en.pdf:267:1'}, page_content='America and the Caribbean. Outbreaks have been described in Eastern Africa.\\xa0Primary infection may be asymptomatic or present as mild or occasionally severe dengue fever. Subsequent infections\\nincrease the risk of severe dengue.\\nClinical features\\nAfter the incubation period (4 to 10 days), the illness occurs in 3 phases:\\n\\xa0\\n a \\nFebrile phase: high fever (39 to 40 °C) lasting 2 to 7 days, often accompanied by generalized aches, a\\nmaculopapular rash and mild haemorrhagic manifestations.\\xa0\\nCritical phase\\xa0(between the third\\xa0and seventh\\xa0day): at the end of the febrile phase, temperature decreases. The\\nmajority of patients will have dengue without warning signs and proceed to the recovery phase. Certain patients will'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 267, 'page_label': '268', 'id': 'data/guideline-170-en.pdf:267:2'}, page_content='develop dengue with warning sign(s) at this stage.\\xa0These patients are at higher risk for developing severe dengue.\\nRecovery phase: patient improves, vital signs normalise, gastrointestinal symptoms subside and appetite returns.\\nAt times, bradycardia and generalized pruritus.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 268, 'page_label': '269', 'id': 'data/guideline-170-en.pdf:268:0'}, page_content='Page 269 / 409\\nMajor differential diagnoses\\nOther conditions to consider include a wide range of acute febrile illnesses, e.g.:\\xa0\\xa0\\nLaboratory\\nDiagnosis\\nSymptoms according to severity\\xa0(adapted from PAHO ) [1] \\nDengue\\nwithout warning\\nsigns\\nFever + 2 of the following symptoms:\\nNausea, vomiting\\nRash resembling measles\\nGeneralized aches (headache, retro-orbital pain, myalgias, arthralgias)\\nBenign mucocutaneous bleeding (petechiae, positive tourniquet test , epistaxis, gingival\\nbleeding)\\n (a) \\nLeucopenia\\nDengue\\nwith warning signs\\nPresence of at least one of these symptoms:\\nIntense abdominal pain\\nPersistent vomiting\\nFluid accumulation (ascites, pleural effusion)\\nMucosal bleeding\\nHepatomegaly (> 2 cm)\\nPostural hypotension\\nAgitation or lethargy\\nIncreasing haematocrit'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 268, 'page_label': '269', 'id': 'data/guideline-170-en.pdf:268:1'}, page_content='Postural hypotension\\nAgitation or lethargy\\nIncreasing haematocrit\\nSevere dengue Severe ﬂuid accumulation (ascites, pleural effusion) with respiratory distress and/or shock\\nSevere mucocutaneous bleeding\\nSevere organ involvement (e.g.: transaminases > 1000 IU/litre, myocarditis, altered mental\\nstatus)\\n(a) Tourniquet test: inﬂate a blood pressure cuff on the upper arm to a point midway between the systolic and diastolicpressure for 5 min. The test is positive when 20 or more petechiae per 2.5 cm square are observed.\\nChikungunya, Zika, inﬂuenza, mononucleosis, measles, rubella, viral haemorrhagic fevers\\xa0\\nMalaria\\xa0\\xa0\\nMeningococcemia, typhoid fever, leptospirosis, rickettsioses, other causes of sepsis\\xa0\\nLeukaemia'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 268, 'page_label': '269', 'id': 'data/guideline-170-en.pdf:268:2'}, page_content='Leukaemia\\xa0\\xa0\\xa0\\nNS-1 antigen detection during febrile phase with rapid diagnostic test or ELISA (serum, plasma or blood).\\xa0\\nAntibody detection (complex interpretation):\\xa0\\nIgM detection 5 to 6 days after onset of illness may support (but does not conﬁrm) a diagnosis of recent\\ninfection;\\nIgG detection may indicate prior infection by, or vaccination against, dengue virus or a closely related virus (e.g.\\nchikungunya, Zika, Japanese encephalitis, yellow fever).\\nPCR may also be available in reference laboratories.\\xa0\\nIn all cases, rapid test for malaria in endemic regions (and antimalarial treatment if needed, see Malaria, Chapter 6).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 269, 'page_label': '270', 'id': 'data/guideline-170-en.pdf:269:0'}, page_content='Page 270 / 409\\nMonitoring disease course\\nTreatment\\nPatients in Group A (outpatients)\\nPatients with no warning signs, able to drink sufﬁciently and with a normal urine output.\\nPatients in Group B (inpatients)\\nPatients with any of the following:\\n\\xa0In all cases:\\n\\xa0If poor\\xa0oral intake:\\n\\xa0If warning signs:\\nHaematocrit (Hct) or if available full blood count (FBC) at baseline, then daily if possible.\\nA progressive increase in Hct is a warning sign. It indicates haemoconcentration due to increased vascular\\npermeability (plasma leakage). Hct should be monitored frequently (before and after ﬂuid administration)\\xa0in\\npatients with warning signs up to the end of the ﬂuid treatment.\\xa0\\nLeukopenia and thrombocytopenia are common and improve as the recovery phase begins. Leukocytosis may'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 269, 'page_label': '270', 'id': 'data/guideline-170-en.pdf:269:1'}, page_content='occur with severe bleeding.\\nLiver function tests if possible\\xa0at baseline, then according to results.\\nBed rest and good hydration.\\nFever and pain: paracetamol PO at the usual doses (see\\xa0Fever, Chapter 1), maintaining a 6 to 8 hour interval\\nbetween doses. Do not prescribe acetylsalicylic acid, ibuprofen or other NSAIDs.\\nSeek medical attention if: no clinical improvement, persistent vomiting, cold extremities, agitation or lethargy,\\nbreathing difﬁculties or absence of urine output.\\nIf follow-up is impossible or symptoms cannot be monitored at home (patients living far from the health care\\nfacility/living alone), hospitalise for observation.\\nWarning sign(s)\\xa0\\nAcute (e.g. severe dehydation or malaria) or chronic\\xa0(e.g. diabetes, cardiovascular, renal or haemolytic disease,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 269, 'page_label': '270', 'id': 'data/guideline-170-en.pdf:269:2'}, page_content='obesity)\\xa0co-morbidities\\nRisk factors for bleeding (e.g. anticoagulation, coagulopathy, peptic ulcer or gastritis, treatment with NSAIDs)\\xa0\\nPregnant women, patients under 1 year or 65 years and over or patients with difﬁculty drinking\\nPlace the patient under a mosquito net; encourage oral ﬂuid intake (including oral rehydration solution (ORS) if\\nneeded).\\nAvoid invasive procedures (nasogastric tube, IM injections) to minimize the risk of bleeding.\\nFever and pain:\\xa0paracetamol\\xa0PO \\xa0with caution and without exceeding: [2] \\nchildren: 10 mg/kg every 6 to 8 hours\\nadults: 500 mg every 6 to 8 hours\\nIn case of elevated transaminases ≥ 10 times the upper limit of normal, do not administer paracetamol. Use tepid\\nsponging for reducing fever.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 269, 'page_label': '270', 'id': 'data/guideline-170-en.pdf:269:3'}, page_content='sponging for reducing fever.\\nMonitor vital signs, ﬂuid intake (infusion and oral) and urine output every 4 hours . b \\nPlace an intravenous line and administer:\\nchildren:\\xa05% glucose +\\xa0Ringer lactate solution as maintenance ﬂuids, according to the Holliday-Segar\\nformula, i.e. 4 ml/kg/hour for ﬁrst 10 kg of body weight + 2 ml/kg/hour for next 10 kg + 1 ml/kg/hour for each\\nadditional kg above 20 kg.\\n c \\nadults: Ringer lactate,\\xa02 to 3 ml/kg/hour\\nEncourage oral intake as soon as possible.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 270, 'page_label': '271', 'id': 'data/guideline-170-en.pdf:270:0'}, page_content='Page 271 / 409\\nPatients in Group C (intensive care unit)\\nPatients with severe dengue requiring emergency treatment for managing shock and other complications (e.g. severe\\nbleeding, acidosis, coagulopathy).\\nPrevention\\n\\xa0\\nReferences\\nMonitor clinical status (warning signs, general symptoms, vital signs, capillary reﬁll time), IV and oral ﬂuid intake, urine\\noutput, hourly for at least 4 hours, then every 4 hours while the patient is on IV ﬂuid treatment.\\nPlace an intravenous line and administer a bolus of Ringer lactate:\\nchildren and adults: 10 ml/kg over one hour\\npatients 65 years and over or with co-morbidities\\xa0: 5 ml/kg over one hour\\n\\xa0Re-assess the patient:\\nIf no improvement after ﬁrst bolus: administer a second bolus as above. If necessary, a total of 3 boluses can'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 270, 'page_label': '271', 'id': 'data/guideline-170-en.pdf:270:1'}, page_content='be administered.\\xa0If still no improvement after 3 bolus, consider as severe dengue (patients in Group C) and\\ntransfer to intensive care unit.\\nIf improvement after the ﬁrst, second, or third bolus, reduce Ringer lactate:\\nchildren and adults: 5 to 7 ml/kg/hour over 2 to 4 hours\\npatients 65 years and over or with co-morbidities: 5 ml/kg/hour\\xa0over 2 to 4 hours\\nIf continuing improvement, reduce Ringer lactate (then stop as soon as possible to reduce the risk of ﬂuid\\noverload):\\nchildren and adults: 3 to 5 ml/kg/hour over\\xa02 to 4 hours, then 2 to 4 ml/kg/hour over 24 to 48 hours\\npatients 65 years and over or with co-morbidities: 3 ml/kg/hour\\xa0over 2 to 4 hours, then 2 ml/kg/hour over 24\\nto 48 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 270, 'page_label': '271', 'id': 'data/guideline-170-en.pdf:270:2'}, page_content='to 48 hours\\nIf the patient deteriorates after initial improvement, resume the bolus therapy with Ringer lactate (up to 3 bolus)\\nas above.\\nIndividual protection: long sleeves and trousers, repellents, mosquito net (Aedes\\xa0bites during the day).\\nElimination of mosquito breeding sites (small collections of water in discarded tires, ﬂower pots, and other\\ncontainers).\\nFootnotes\\n(a) For more information:http://gamapserver.who.int/mapLibrary/Files/Maps/Global_DengueTransmission_ITHRiskMap.png?ua=1\\n(b) Adequate urine output: at least 1 ml/kg/hour in children and 0.5 ml/kg/hour in adults. If unavailable, ensure that the patient isurinating at least every 4 hours.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 270, 'page_label': '271', 'id': 'data/guideline-170-en.pdf:270:3'}, page_content='(c) Remove 50 ml of Ringer lactate (RL) from a 500 ml RL bottle or bag, then add 50 ml of 50% glucose to the remaining 450 mlof RL to obtain 500 ml of 5%\\xa0glucose-RL solution.\\xa0\\n1. Pan American Health Organization. Dengue: guidelines for patient care in the Region of the Americas, 2nd edition.Washington, D.C.: PAHO, 2016.https://iris.paho.org/bitstream/handle/10665.2/31207/9789275118900-eng.pdf?sequence=1&isAllowed=y [Accessed 23 Aug2022]\\n2. Pan American Health Organization. Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 271, 'page_label': '272', 'id': 'data/guideline-170-en.pdf:271:0'}, page_content='Page 272 / 409\\nWashington, D.C. : PAHO; 2022. \\xa0https://iris.paho.org/handle/10665.2/55867\\xa0[Accessed 16 Aug 2022]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 272, 'page_label': '273', 'id': 'data/guideline-170-en.pdf:272:0'}, page_content='Page 273 / 409\\nViral haemorrhagic fevers\\nSeveral diseases with different aetiologies and different modes of transmission are grouped under this term as they\\npresent with common clinical signs.\\nDengue haemorrhagic fever is a\\xa0viral haemorrhagic fever\\xa0that is described in a speciﬁc chapter (see\\xa0Dengue, Chapter\\n8).\\nClinical features\\n\\xa0\\nCommon syndrome (CS):\\nFever higher than 38.5 °C;\\nHaemorrhagic symptoms (purpura, epistaxis, haematemesis, melaena, etc.).\\nThe clinical signs are often nonspeciﬁc; the severity varies depending on the aetiology.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 273, 'page_label': '274', 'id': 'data/guideline-170-en.pdf:273:0'}, page_content='Page 274 / 409\\nLaboratory\\n\\xa0\\nReservoir/ Vector\\nGeographical\\ndistribution\\nIsolation\\nof\\npatients\\nClinical features\\nEstimated\\ncase\\nfatality\\nrate\\nEbola Marburg (a) Bats (?)\\nAfrica\\nStrict\\nisolation\\nCS + sudden onset general malaise,\\nvomiting and diarrhoea 60-80%\\nLassa (a) Rodents \\nWest Africa (b)\\nStrict\\nisolation\\nCS + general malaise, headache, muscle\\npain, facial oedema, pharyngitis, proteinuria\\non reagent strip\\n15-20%\\nJunin and\\nMachupo (a)\\nRodents \\nSouth America Isolation CS + vomiting, erythema of the face and,\\ndepending on the aetiology:\\nperiorbital oedema, cervical\\nadenopathy, pharyngitis\\npharyngitis, reddened conjunctivae\\noedema of the soft palate, generalised\\npetechial rash\\nproteinuria on reagent strip\\n15-30%\\nOmsk Ticks \\nEurope, Asia None 2-5%\\nCrimean\\nCongo (a)\\nLivestock/Ticks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 273, 'page_label': '274', 'id': 'data/guideline-170-en.pdf:273:1'}, page_content='15-30%\\nOmsk Ticks \\nEurope, Asia None 2-5%\\nCrimean\\nCongo (a)\\nLivestock/Ticks\\nAfrica, Asia\\nStrict\\nisolation 5-20%\\nFHSR\\n(hantavirus) (a)\\nRodents \\nAsia and Europe None < 1%\\nKyasanur Small mammals/Ticks \\nIndia None CS + headache, muscle pain, prostration 2-10%\\nRift Valley (a) Livestock/Mosquitoes\\nAfrica\\nMosquito\\nnets\\nClinical signs:\\nisolated fever\\nSC\\nencephalitis\\nretinitis and blindness\\n30-50%\\nYellow fever (a) Primates/Mosquitoes\\nAfrica, South America\\nMosquito\\nnets\\nCS + jaundice, proteinuria on reagent strip,\\noliguria, headache 10-30%\\n(a) Viral haemorrhagic fever\\xa0with epidemic potential.\\n(b) For more information on geographic distribution of Lassa fever:\\xa0https://www.who.int/emergencies/diseases/lassa-fever/geographic-distribution.png?ua=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 273, 'page_label': '274', 'id': 'data/guideline-170-en.pdf:273:2'}, page_content='A sample of whole blood must be send to a reference laboratory for serological diagnosis, with a clinical description\\nof the patient. The sample may also be sent on ﬁlter paper. It is easier to transport, but the small volume of blood\\nonly allows a limited number of aetiologies to be tested.\\nProtective clothing must be worn while taking or handling the sample (gown, gloves, glasses, mask, etc.).\\nThe sample must be sent in a triple packaging system for Category A infectious substances.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 274, 'page_label': '275', 'id': 'data/guideline-170-en.pdf:274:0'}, page_content='Page 275 / 409\\nManagement\\nSuspicion of haemorrhagic fever\\nIsolated case of fever with haemorrhagic symptoms in an endemic area\\xa0\\nConﬁrmed cases of Ebola, Marburg, Lassa, Crimean-Congo fevers or epidemics of unknown origin\\nPLUS\\nConﬁrmed cases of Yellow fever or Rift Valley fever\\nFor all patients\\nReport to the Ministry of Health of the country.\\nTreatment\\nIsolation: isolation room (or if not available, use screens/partitions); restrict visitors (if a carer is strictly necessary,\\ns/he must be protected with gown, gloves, mask).\\nStandard precautions:\\nThe majority of hospital-acquired infections have occurred due to a lack of respect for these precautions:\\nHand washing;\\nGloves for patient examination and when touching blood, body ﬂuids, secretions, excretions, mucous\\nmembranes, non-intact skin;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 274, 'page_label': '275', 'id': 'data/guideline-170-en.pdf:274:1'}, page_content='membranes, non-intact skin;\\nGowns to protect skin and prevent soiling of clothing during consultations and activities that are likely to\\ngenerate splashes or sprays of blood, body ﬂuids, secretions, or excretions;\\nSurgical mask and goggles, or face shield, to protect mucous membranes of the eyes, nose, and mouth during\\nactivities that may generate splashes of blood, body ﬂuids, secretions, and excretions;\\nAdequate procedures for the routine cleaning and disinfection of objects and surfaces;\\nRubber gloves to handle soiled laundry;\\nSafe waste management;\\nSafe injection practices.\\nStrict isolation in a reserved area separate from other patient areas, with a deﬁned circuit for entrance/exit and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 274, 'page_label': '275', 'id': 'data/guideline-170-en.pdf:274:2'}, page_content='changing room at the entrance/exit; dedicated staff and equipment/supplies; use of disposable material if possible.\\nStandard precautions (as above)\\nDroplet precautions AND contact precautions including personal protective equipment (PPE).\\nThe PPE is to be worn systematically prior to entry into isolation area, regardless the tasks to be performed (care,\\ncleaning, distribution of meals, etc.) and to be removed before leaving the isolation area:\\ntwo pairs of gloves,\\ndouble gown or coverall suit,\\nsurgical cap or hood, mask, protective glasses,\\nimpermeable apron,\\nrubber boots.\\nDisinfection of surfaces, objects, clothing and bedding with chlorine solution; safe handling and on site disposal of\\nwaste and excreta, etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 274, 'page_label': '275', 'id': 'data/guideline-170-en.pdf:274:3'}, page_content='waste and excreta, etc.\\nIn the event of a death, do not wash the body. Prompt and safe burial of the dead as quickly as possible, using a\\nbody bag.\\nStandard precautions.\\nPatient under a mosquito net to prevent transmission.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 275, 'page_label': '276', 'id': 'data/guideline-170-en.pdf:275:0'}, page_content='Page 276 / 409\\nPrevention\\n\\xa0\\nReferences\\nAetiological treatment: ribavirine for Lassa fever and Crimean-Congo fever.\\nSymptomatic treatment:\\nFever: paracetamol (Chapter 1). Acetylsalicylic acid (aspirin) is contra-indicated.\\nPain: mild (paracetamol), moderate (tramadol), severe (sublingual morphine): see\\xa0Pain, Chapter 1.\\nDehydration: oral rehydration salts and/or IV rehydration with Ringer lactate, see Dehydration, Chapter 1.\\nSeizures\\xa0(Chapter 1).\\nVomiting:\\xa0ondansetron\\xa0PO\\nChildren 6 months to < 2 years: 2 mg once daily\\nChildren 2 to < 4 years: 2 mg 2 times daily\\nChildren 4 to < 12 years: 4 mg\\xa02 times daily\\nChildren ≥ 12 years and adults: 4 to 8 mg\\xa02 times daily\\n [1] \\nFor Ebola and Marburg haemorrhagic fevers: invasive procedures must be strictly limited. Health care staff is at risk'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 275, 'page_label': '276', 'id': 'data/guideline-170-en.pdf:275:1'}, page_content='of contamination when inserting and maintaining IV lines. An IV line must be well secured so that the patient, often\\nconfused, cannot pull it out.\\nVaccination against yellow fever :\\nChildren\\xa0and adults: 0.5 ml single dose\\xa0\\n [2] \\nRoutine vaccination\\xa0:\\xa0children\\xa0from 9 months of age, along with the measles vaccine.\\nMass vaccination campaign during an epidemic:\\xa0children from 6 months and adults ; for pregnant women, only\\nadminister during an epidemic.\\nVaccination against Rift Valley fever: only during an epidemic.\\nVector control programmes for known vectors.\\nInfection control measures are essential in all cases.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 275, 'page_label': '276', 'id': 'data/guideline-170-en.pdf:275:2'}, page_content='Infection control measures are essential in all cases.\\n1. World Health Organization. Clinical management of patients with viral haemorrhagic fever. A pocket guide for front-linehealth workers. Interim emergency guidance for country adaptation, February 2016.http://apps.who.int/iris/bitstream/handle/10665/205570/9789241549608_eng.pdf;jsessionid=15E17DE39631519C2051413DDCBBC8A7?sequence=1\\xa0[Accessed 11 January 2019]\\n2. Weekly epidemiological record-Relevé épidémiologique hebdomadaire 5 july 2013, 88th\\xa0year / 5 juillet 2013, 88e\\xa0année No. 27,2013, 88, 269–284.https://www.who.int/wer/2013/wer8827.pdf?ua=1\\xa0[Accessed 10 december 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 276, 'page_label': '277', 'id': 'data/guideline-170-en.pdf:276:0'}, page_content='Page 277 / 409\\nHIV infection and AIDS\\nLast updated: January 2024\\n\\xa0\\nAcquired immune deﬁciency syndrome (AIDS) is the most advanced stage of infection with human immunodeﬁciency\\nvirus (HIV).\\nTwo subtypes of HIV have been identiﬁed. HIV-1 is more widespread than HIV-2, the latter mainly being found in West\\nAfrica. HIV-2 is less virulent and less transmissible than HIV-1.\\nHIV weakens the immune system by causing a deﬁcit in CD4 T lymphocytes.\\nEvolution of the disease\\n\\xa0The World Health Organization (WHO) has proposed a clinical classiﬁcation of HIV infection in 4 stages of severity for\\nadults and adolescents and for children.\\nLaboratory\\nDiagnosis of HIV infection\\nCD4 lymphocyte counts'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 276, 'page_label': '277', 'id': 'data/guideline-170-en.pdf:276:1'}, page_content='Laboratory\\nDiagnosis of HIV infection\\nCD4 lymphocyte counts\\nCD4 cell depletion is a marker of the progression of immune depression. The level of the CD4 cell count is a predictor\\nof the development of opportunistic infections or neoplasms and can be used to orient their diagnosis, e.g. cerebral\\ntoxoplasmosis or cryptococcal meningitis appear when the CD4 count is below 100 cells/mm\\xa0in adults. If clinical\\nsymptoms/signs are present suggesting one of these infections, but the CD4 count is greater than or equal to 200\\ncells/mm, it is unlikely that that particular infection is present.\\nOpportunistic infections\\nPrimary infection or acute retroviral syndrome: 50 to 70% of newly infected individuals develop during'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 276, 'page_label': '277', 'id': 'data/guideline-170-en.pdf:276:2'}, page_content='seroconversion (from 15 days to 3 months post exposure), a viral syndrome with fever, malaise, and\\nlymphadenopathy.\\nAsymptomatic HIV infection\\xa0(after seroconversion): a period of clinical latency, but not viral latency. The time\\nperiod for progression from HIV infection to the development of severe immune deﬁciency in western countries is\\napproximately 10 years. This period appears to be shorter in developing countries.\\nSymptomatic HIV infection: with progressive destruction of the immune system, common and more severe\\ndiseases occur more frequently, and with higher mortality, in seropositive individuals.\\nAIDS: this stage corresponds to the development of severe opportunistic infections and neoplasms. From a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 276, 'page_label': '277', 'id': 'data/guideline-170-en.pdf:276:3'}, page_content='biological point of view, AIDS is deﬁned as a CD4 count < 200 cells/mm. Without treatment the disease\\nprogresses rapidly towards death.\\n3\\n [1]\\nThe diagnosis is made with serological (detection of antibodies against the virus) or virological (especially in infants)\\ntesting.\\nTesting should always be done\\xa0voluntarily with informed consent.\\nAll HIV test results must be strictly\\xa0conﬁdential\\xa0in order to avoid discrimination.\\nThe individual should have access to services offering pre-test and post-test counselling, treatment and support.\\nA diagnosis of HIV infection can be made only after at least 2 different test results (2 different brands) are clearly\\npositive: the positive result of an initial (highly sensitive) test must be conﬁrmed through use of a second (highly'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 276, 'page_label': '277', 'id': 'data/guideline-170-en.pdf:276:4'}, page_content='speciﬁc) test.\\xa0In areas where HIV prevalence is low, diagnosis is conﬁrmed after 3 positive test results.\\n3\\n3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 277, 'page_label': '278', 'id': 'data/guideline-170-en.pdf:277:0'}, page_content='Page 278 / 409\\nIt is important to screen for serious opportunistic infections in those at risk (e.g. testing for cryptococcal antigen for all\\nadults with a CD4 count < 100 cells/mm\\xa0regardless of symptoms).\\nTreatment of HIV infection\\nAntiretroviral (ARV) treatment\\nA multi-drug (at least 3) antiretroviral therapy (ART) is the reference treatment. It does not eradicate the virus, but\\nslows the progression of the disease and improves the patient’s clinical state by reducing viral replication and\\nconsequently increasing the CD4 cell count to levels beyond the threshold of opportunistic infections.\\nTherapeutic classes\\nFour major classes ARV are used:\\nPrinciples of ARV treatment\\nOther possible combinations exist which are less commonly used or more difﬁcult to manage.\\nCriteria for ARV treatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 277, 'page_label': '278', 'id': 'data/guideline-170-en.pdf:277:1'}, page_content='Criteria for ARV treatment\\nAs a priority ART should be initiated in all patients with WHO clinical stage 3 or 4 and patients with CD4 < 350 /mm.\\nHowever, those with higher CD4 counts can initiate ART.\\nMonitoring of ARV treatment\\nHIV viral load is an essential tool for monitoring the effectiveness of ARV. CD4 count is useful for identifying severely\\nimmunosuppressed. Other tests such as blood count, tests for liver (ALAT) and renal function (creatinine clearance) are\\nnot essential, but can be useful in detecting adverse effects.\\nTreatment of opportunistic and other infections\\nWith progressive immunosuppression, HIV-infected patients who are not receiving triple therapy (or patients on ART'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 277, 'page_label': '278', 'id': 'data/guideline-170-en.pdf:277:2'}, page_content='but with poor adherence) become increasingly susceptible to infections. For conditions of clinical stages 2 and 3,\\nstandard treatments are usually effective. Patients may beneﬁt from primary prophylaxis against opportunistic\\ninfections (see\\xa0Primary prophylaxis). Tuberculosis (TB) is the most common serious opportunistic infection. It can be\\ndifﬁcult to diagnose in HIV-infected patients however.\\nTreatment of pain\\nTreat all patients for associated pain (see\\xa0Pain, Chapter 1).\\nPrevention of HIV infection\\n3\\n a\\nNRTI (nucleoside/nucleotide reverse transcriptase inhibitors): zidovudine (AZT), lamivudine (3TC), abacavir (ABC),\\ntenofovir (TDF), emtricitabine (FTC).\\nNNRTI (non-nucleoside reverse transcriptase inhibitors): efavirenz (EFV), nevirapine (NVP), etravirine (ETR). HIV-2 is'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 277, 'page_label': '278', 'id': 'data/guideline-170-en.pdf:277:3'}, page_content='naturally resistant to NNRTIs.\\nPI (protease inhibitors): atazanavir (ATV), lopinavir (LPV), ritonavir (RTV), darunavir (DRV).\\nINI (integrase inhibitors): dolutegravir, raltegravir.\\nDaily triple therapy must be taken for life to prevent the rapid development of resistance. It is important that the\\npatient understands this and that adherence to treatment is optimal.\\nFollow the ART protocols recommended by national HIV program.\\nThe most widely used and easiest regimens to administer are 2 NRTI + 1 NNRTI: e.g. TDF/3TC/EFV.\\nIn the event of treatment failure, all 3 drugs should be replaced with a second-line regimen: 2 other NRTIs + 1 PI.\\n3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 278, 'page_label': '279', 'id': 'data/guideline-170-en.pdf:278:0'}, page_content='Page 279 / 409\\nSexual transmission\\nThe most reliable method of prevention is the use of male or female condoms.\\nMale circumcision decreases signiﬁcantly the risk of HIV transmission.\\nEarly diagnosis and treatment of sexually transmitted infections is essential as they increase the transmission of HIV\\n(see\\xa0Chapter 9).\\nART to HIV positive and adherent partner does protect the negative partner from HIV infection.\\nOccupational transmission\\n(accidental needle stick injuries or injuries with contaminated objects, contact between a patient’s blood and\\nunprotected broken skin or mucous membranes)\\nPrevention is based on use of standard precautions to avoid contamination with soiled material or potentially infected\\nbody ﬂuids.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 278, 'page_label': '279', 'id': 'data/guideline-170-en.pdf:278:1'}, page_content='body ﬂuids.\\nPost-exposure prophylaxis (PEP): e.g. in the event of rape or occupational accidental exposure to blood, ARV\\ntreatment initiated as soon as possible within 72 hours of exposure for a duration of 1 month may reduce the risk of\\ninfection.\\nNosocomial transmission\\nPrevention of nosocomial HIV infection is based on the rational use of injections and strict respect for hygiene and\\nsterilization and disinfection procedures for medical material.\\nFor transfusion: strict respect of indications for transfusion and systematic serological screening of the donor’s blood\\nare the two indispensable precautions in the prevention of HIV transmission through transfusions.\\nTransmission in injection drug users'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 278, 'page_label': '279', 'id': 'data/guideline-170-en.pdf:278:2'}, page_content='Transmission in injection drug users\\nNeedle and syringe exchange programs with disposable needles and syringes for users can reduce the risk.\\nMother-to-child transmission (MTCT)\\nThe global rate of vertical transmission varies from 20 to 40%. The risk of transmission through breast-feeding is\\nevaluated at approximately 12% and persists for the duration of breast-feeding.\\nPrevention of opportunistic infections\\nIn the absence of ARV treatment, all HIV-infected individuals become symptomatic and evolve towards AIDS.\\nHowever, some opportunistic infections can be prevented.\\nPrimary prophylaxis\\nFor HIV infected patients who have not previously contracted an opportunistic infection, in order to prevent the\\ndevelopment of some opportunistic infections.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 278, 'page_label': '279', 'id': 'data/guideline-170-en.pdf:278:3'}, page_content='development of some opportunistic infections.\\xa0\\nIn pregnant women: HIV transmission from mother-to-child may be reduced by ART. The protocol called Option\\nB+ is the internationally preferred protocol. All HIV-infected pregnant women receive lifelong triple-drug therapy,\\nregardless of the CD4 count or clinical stage, both for their own health and to prevent transmission to the child. The\\nmost commonly recommended ART is TDF/3TC/EFV or TDF/FTC/EFV. Check national recommendations. In\\naddition, ARVs are administered to the newborn.\\nPrograms targeting pregnant women also include other preventive measures such as avoiding artiﬁcial rupture of\\nthe membranes and systematic episiotomy.\\nIn breast-feeding women: exclusive breast-feeding for the ﬁrst 6 months of life, introduction of complementary'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 278, 'page_label': '279', 'id': 'data/guideline-170-en.pdf:278:4'}, page_content='(solid) foods at 6 months, gradual cessation of breast-feeding to the age of 12 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 279, 'page_label': '280', 'id': 'data/guideline-170-en.pdf:279:0'}, page_content='Page 280 / 409\\n\\xa0\\nSecondary prophylaxis\\nFor patients who develop a speciﬁc opportunistic infection, in order to prevent recurrence once treatment for the\\ninfection is completed.\\xa0\\n\\xa0\\nInfections Primary prophylaxis\\nPneumocystosis\\nCerebral toxoplasmosis\\nIsosporiasis\\nVarious bacterial infections\\nMalaria\\nco-trimoxazole PO\\nChildren: 50 mg SMX + 10 mg TMP/kg once daily\\nAdults: 800 mg SMX + 160 mg TMP once daily\\nInfections Secondary prophylaxis Comments\\nPneumocystosis\\nco-trimoxazole PO\\nChildren: 50 mg SMX + 10 mg TMP/kg once\\ndaily\\nAdults: 800 mg SMX + 160 mg TMP once\\ndaily\\nAlternative\\ndapsone PO\\nChildren: 2 mg/kg once daily (max. 100 mg\\ndaily)\\nAdults: 100 mg once daily\\nToxoplasmosis Alternative\\nAdults:\\ndapsone PO: 200 mg once weekly or 50\\nmg once daily\\n+ pyrimethamine PO: 75 mg once weekly'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 279, 'page_label': '280', 'id': 'data/guideline-170-en.pdf:279:1'}, page_content='mg once daily\\n+ pyrimethamine PO: 75 mg once weekly\\n+ folinic acid PO: 25 to 30 mg once\\nweekly\\nIsosporiasis –\\nPenicilliosis\\nHistoplasmosis\\nitraconazole PO\\nAdults: 200 mg once daily –\\nCryptococcal meningitis ﬂuconazole PO\\nChildren: 6 mg/kg once daily\\nAdults: 200 mg once daily\\n–\\nOral or oesophageal\\ncandidiasis\\nﬂuconazole PO\\nChildren: 3 to 6 mg/kg once daily\\nAdults: 100 to 200 mg once daily\\nOnly for frequent and severe recurrences\\nHerpes simplex aciclovir PO\\nChildren under 2 years: 200 mg 2 times daily\\nChildren 2 years and over and adults: 400 mg\\n2 times daily\\nOnly for frequent and severe recurrences'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 280, 'page_label': '281', 'id': 'data/guideline-170-en.pdf:280:0'}, page_content='Page 281 / 409'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 281, 'page_label': '282', 'id': 'data/guideline-170-en.pdf:281:0'}, page_content='Page 282 / 409\\nSymptoms Deﬁnitions and\\naetiologies Diagnosis Treatment\\nDiarrhoea\\nwith or without blood\\n(also see\\nChapter 3)\\nDiarrhoea is deﬁned as at\\nleast 3 liquid stools per\\nday.\\nAetiologies:\\nParasitic infections\\n• Isospora belli\\n• Cryptosporidium\\n• Microsporidium\\n• Giardia lamblia\\n• Entamoeba histolytica\\nBacterial infections\\n• Shigella\\n• Salmonella enteritis\\n• Campylobacter\\nenteritis\\nMycobacterial\\ninfections\\n• Mycobacterium\\ntuberculosis\\n(gastrointestinal TB)\\n• Mycobacterium avium\\ncomplex\\nHelminthiasis\\n• Strongyloides\\nstercoralis\\nViral infections\\n• Cytomegalovirus (CMV)\\nOther causes\\n• Kaposi sarcoma\\n• Lymphoma\\n• Idiopathic (HIV\\ninfection)\\n• Antiretrovirals\\n(especially lopinavir and\\nritonavir)\\n1. History and clinical\\nexamination\\n2. Microscopic\\nexamination of stool for'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 281, 'page_label': '282', 'id': 'data/guideline-170-en.pdf:281:1'}, page_content='1. History and clinical\\nexamination\\n2. Microscopic\\nexamination of stool for\\nova and parasites (2 to 3\\nsamples)\\nNote:\\nI. belli, Cryptosporidium,\\nMicrosporidium, MAC\\nand CMV are unlikely if\\nCD4 count > 200 cells.\\n• Persistent (> 2 weeks) or chronic (>\\n4 weeks) diarrhoea is often\\nassociated with weight loss and\\ndehydration.\\n•\\xa0Prevention or treatment of\\ndehydration is critical (Dehydration,\\nChapter 1).\\n• Depending on the results of the\\nstool examinations: give appropriate\\ntreatment.\\n• If there is no laboratory support:\\nAcute bloody diarrhoea\\n• First-line treatment:\\nChildren: azithromycin PO: 20 mg/kg\\nonce daily for 5 days or\\nciproﬂoxacin PO: 15 mg/kg 2 times\\ndaily for 7 days\\nAdults: ciproﬂoxacin PO: 500 mg 2\\ntimes daily for 7 days\\n• If amoebiasis suspected:\\ntinidazole or metronidazole PO ('), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 281, 'page_label': '282', 'id': 'data/guideline-170-en.pdf:281:2'}, page_content='• If amoebiasis suspected:\\ntinidazole or metronidazole PO (\\nAmoebiasis, Chapter 3).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 282, 'page_label': '283', 'id': 'data/guideline-170-en.pdf:282:0'}, page_content='Page 283 / 409\\nNon-bloody persistent or chronic\\ndiarrhea\\nPersistent or chronic diarrhoea\\nsuggests advanced\\nimmunocompromised state. For\\npatients who qualify for ARVs by\\nCD4 count (or unknown CD4 count),\\nARV initiation is urgent and will\\nusually resolve symptoms in 14 to 28\\ndays.\\n• Isospora belli: co-trimoxazole PO\\nChildren: 40 mg SMX + 8 mg TMP/kg\\n2 times daily for 10 days then 25 mg\\nSMX + 5 mg TMP/kg 2 times daily\\nfor 3 weeks\\nAdults: 800 mg SMX + 160 mg TMP\\n2 times daily for 7 to 10 days then\\n400 mg SMX + 80 mg TMP 2 times\\ndaily for 3 weeks\\n• Cryptosporidium: no speciﬁc\\ntreatment in HIV-infected patients\\n• Microsporidium: albendazole PO\\n(limited efﬁcacy)\\nChildren: 10 mg/kg 2 times daily\\n(max. 800 mg daily) for 7 days\\nAdults: 400 mg 2 times daily for 2 to\\n4 weeks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 282, 'page_label': '283', 'id': 'data/guideline-170-en.pdf:282:1'}, page_content='(max. 800 mg daily) for 7 days\\nAdults: 400 mg 2 times daily for 2 to\\n4 weeks\\n• Helminthiasis: albendazole PO for\\n3 days\\nChildren > 6 months but ≤ 10 kg: 200\\nmg once daily\\nChildren > 6 months and adults: 400\\nmg once daily\\n• Giardiasis: tinidazole or\\nmetronidazole (\\nIntestinal protozoan infections,\\nChapter 6).\\n• If no improvement (and no contra-\\nindications such as bloody\\ndiarrhoea), symptomatic treatment\\nwith loperamide PO:\\nAdults: initial dose 4 mg then 2 mg\\nafter each liquid stool (max. 16 mg\\ndaily)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 283, 'page_label': '284', 'id': 'data/guideline-170-en.pdf:283:0'}, page_content='Page 284 / 409\\nNutrition ++++\\nChildren: continue to breastfeed;\\nincrease daily calorie intake:\\n6-11 months: add 150 kcal daily\\n12-23 months: add 200 kcal daily\\n2-5 years: add 250 kcal daily\\n6-9 years: add 350 kcal daily\\n10-14 years: add 400 kcal daily\\nEliminate fresh milk, give porridge\\nprepared with rice water or soup or\\nyoghurts. Give 2.5 ml of oil per meal.\\nAny child 0-5 years should receive\\nzinc sulfate (Acute diarrhoea,\\nChapter 3).\\nAdults: increase the calorie and\\nprotein intake (at least 2 g protein/kg\\ndaily). No food is excluded but avoid\\nraw food, fresh milk and foods high\\nin ﬁbre. Encourage small, frequent\\nmeals.\\nOral and\\noesophageal\\nlesions\\nFungal infections\\n• Oral candidiasis: see \\nStomatitis, Chapter 3.\\n• Oesophageal\\ncandidiasis: pain on\\nswallowing, dysphagia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 283, 'page_label': '284', 'id': 'data/guideline-170-en.pdf:283:1'}, page_content='• Oesophageal\\ncandidiasis: pain on\\nswallowing, dysphagia.\\nMay result in weight loss.\\nViral infections\\n• Oral hairy leukoplakia\\n(keratosis on the lateral\\nsides of the tongue due\\nto the Epstein-Barr virus)\\n• Oral and oesophageal\\nherpes\\nAphthous ulcers\\nClinical examination is\\nenough to make a\\ndiagnosis.\\nConsider all severe oral\\ncandidiasis (if the\\npharynx is involved) as\\noesophageal candidiasis\\neven in the absence of\\ndysphagia.\\n• Mild oral candidiasis\\nnystatin PO\\nChildren and adults: 100 000 IU (= 1\\nml) 4 times daily\\nor miconazole oral gel\\nChildren 6 months-2 years: 1.25 ml 4\\ntimes daily\\nChildren over 2 years and adults: 2.5\\nml 4 times daily\\nThe treatment lasts 7 to 14 days.\\n• Moderate to severe oral\\ncandidiasis and oesophageal\\ncandidiasis\\nﬂuconazole PO\\nChildren: 3 to 6 mg/kg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 283, 'page_label': '284', 'id': 'data/guideline-170-en.pdf:283:2'}, page_content='candidiasis\\nﬂuconazole PO\\nChildren: 3 to 6 mg/kg once daily\\nAdults: 50 to 200 mg once daily\\nup to 400 mg daily if necessary\\nThe treatment lasts 7 to 14 days for\\noral candidiasis and 14 to 21 days\\nfor oesophageal candidiasis.\\nCandidiasis is an indication for\\nprophylaxis with co-trimoxazole.\\n• Oral hairy leukoplakia: no treatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 284, 'page_label': '285', 'id': 'data/guideline-170-en.pdf:284:0'}, page_content='Page 285 / 409\\n• Oral herpes:\\nAnalgesics (paracetamol, ibuprofen).\\nFor recurrent or extensive forms\\naffecting the oesophagus, add:\\naciclovir PO for 7 days\\nChildren under 2 years: 200 mg 5\\ntimes daily\\nChildren 2 years and over and adults:\\n400 mg 5 times daily\\nSecondary prophylaxis only for\\npatients with frequent recurrences.\\nRespiratory\\nproblems\\n(also see\\nChapter 2)\\nCough and/or thoracic\\npain and/or dyspnoea in a\\nsymptomatic HIV\\ninfected patient.\\nAetiologies:\\nBacterial infections\\n• Streptococcus\\npneumoniae\\n• Haemophilus\\ninﬂuenzae\\n• Staphylococcus aureus\\nMycobacterial\\ninfections\\n• M. tuberculosis, MAC\\nProtozoal infections\\n• Pneumocystis jiroveci\\n(PCP)\\nFungal infections\\n• Cryptococcus\\nneoformans\\n• Histoplasma\\ncapsulatum\\n• Coccidioides immitis\\n• Aspergillus spp\\n• Penicillium marneffei'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 284, 'page_label': '285', 'id': 'data/guideline-170-en.pdf:284:1'}, page_content='capsulatum\\n• Coccidioides immitis\\n• Aspergillus spp\\n• Penicillium marneffei\\nViral infections\\n• CMV\\nNeoplasms\\n• Kaposi sarcoma\\n• Non-Hodgkin’s\\nlymphoma\\n1. History and clinical\\nexamination:\\nBlood in the sputum?\\nIf fever < 7 days,\\ndyspnoea: unlikely TB.\\nIf cough > 21 days,\\nweight loss, thoracic pain\\n> 15 days, no dyspnoea:\\nlikely TB.\\nPulmonary auscultation:\\nbilateral lobar\\npneumonia?\\n2. If possible:\\na) Look for AFB in\\nsputum\\nb) Chest x-ray\\n• PCP: bilateral interstitial\\ninﬁltrates\\n• TB: miliary shadowing,\\nlarge heart, pleural\\neffusion, enlarged lymph\\nnodes inside the chest.\\nNotes\\n• MAC, PCP, CMV and\\nfungal infections are\\nunlikely in patients with a\\nCD4 count > 200\\ncells/mm.\\n• Staphylococcal\\npneumonia is often\\nassociated with a\\npyomyositis or an\\nabscess.\\n3\\n• For the diagnosis and treatment of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 284, 'page_label': '285', 'id': 'data/guideline-170-en.pdf:284:2'}, page_content='pyomyositis or an\\nabscess.\\n3\\n• For the diagnosis and treatment of\\nupper respiratory tract infections,\\nparticularly pneumonia: see \\nChapter 2.\\n• If the chest x-ray is consistent with\\nstaphylococcal pneumonia:\\nChildren: see \\nStaphylococcal pneumonia, Chapter\\n2.\\nAdults: ceftriaxone IM or slow IV 1 g\\nonce daily + cloxacillin IV 2 g every\\n6 hours\\n• If the sputum examination is AFB+,\\ntreat for TB.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 285, 'page_label': '286', 'id': 'data/guideline-170-en.pdf:285:0'}, page_content='Page 286 / 409\\nOthers\\n• Lymphoid interstitial\\npneumonia\\n• Pleural effusion (often\\nTB)\\n• Pericardial effusion\\n(often TB)\\n• Pneumothorax (may be\\ndue to PCP)\\n• If the sputum examination is\\nnegative and the chest x-ray is\\nconsistent with PCP:\\nco-trimoxazole PO for 21 days\\nChildren: 50 mg SMX + 10 mg\\nTMP/kg 2 times daily\\nAdults: 1600 SMX + 320 TMP\\xa03\\ntimes daily\\nNote: the symptoms may become\\nworse during the ﬁrst phase of\\ntreatment, effectiveness can only be\\nevaluated after one week of\\ntreatment.\\nAdd prednisolone PO for patients\\nwith severe PCP with hypoxia:\\nChildren: start with 2 mg/kg daily\\nthen decrease the dose following\\nthe adult example\\nAdults: 40 mg 2 times daily for 5\\ndays, then 40 mg once daily for 5\\ndays then 20 mg once daily for 10\\ndays\\nSecondary prophylaxis is\\nrecommended.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 285, 'page_label': '286', 'id': 'data/guideline-170-en.pdf:285:1'}, page_content='days then 20 mg once daily for 10\\ndays\\nSecondary prophylaxis is\\nrecommended.\\n• Fungal infections (cryptococcosis,\\npenicilliosis, histoplasmosis):\\nAdults: amphotericin B IV: 0.7 to 1\\nmg/kg once daily for 2 weeks\\n(cryptococcosis, penicilliosis) or 1 to\\n2 weeks (histoplasmosis), then:\\nﬂuconazole PO: 400 mg daily for 8\\nweeks (cryptococcosis)\\nitraconazole PO: 200 mg 2 times\\ndaily for 10 weeks (penicilliosis)\\nitraconazole PO: 200 mg 3 times\\ndaily for 3 days then 200 to 400 mg\\ndaily for 12 weeks (histoplasmosis)\\nSecondary prophylaxis is\\nrecommended.\\nLymphadenopathy Enlarged lymph nodes in\\na symptomatic HIV-\\ninfected patient\\n1. Clinical examination:\\nlook for a local cause\\n(skin or dental infection\\netc.); TB or syphilis.\\n• Treat according to the aetiology or\\nempirical treatment with, for'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 285, 'page_label': '286', 'id': 'data/guideline-170-en.pdf:285:2'}, page_content='• Treat according to the aetiology or\\nempirical treatment with, for\\nexample doxycycline PO.\\n• TB: see the guide Tuberculosis,\\nMSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 286, 'page_label': '287', 'id': 'data/guideline-170-en.pdf:286:0'}, page_content='Page 287 / 409\\nPersistent generalised\\nlymphadenopathy (PGL):\\n• 2 or more extra-inguinal\\nsites\\n• lymph nodes > 1.5 cm\\n• enlarged for 3 or more\\nmonths PGL is usually\\ndue to HIV infection.\\nAetiologies:\\nHIV infection\\nInfections\\n• TB\\n• Syphilis\\n• Histoplasmosis\\n• Toxoplasmosis\\n• CMV\\nNeoplasms\\n• Kaposi sarcoma\\n• Lymphoma\\n2. Suspected TB: lymph\\nnode aspiration, look for\\nAFB, chest x-ray\\nNote: in HIV infected\\npatients, TB is often\\nextrapulmonary.\\n3. Suspected syphilis:\\nserology\\n4. If all examinations are\\nnegative: biopsy is useful\\nto exclude lymphoma,\\nKaposi’s sarcoma and\\nfungal or mycobacterial\\ninfections (see notes for\\npatients in stage 1).\\n• Early syphilis:\\nbenzathine benzylpenicillin IM\\nAdults: 2.4 MIU single dose (1.2 MIU\\nin each buttock)\\nor, if not available:\\nazithromycin PO'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 286, 'page_label': '287', 'id': 'data/guideline-170-en.pdf:286:1'}, page_content='in each buttock)\\nor, if not available:\\nazithromycin PO\\nAdults: 2 g single dose\\nNote: in patients in stage 1, no\\nfurther investigation (other than 1, 2\\nand 3 in this table) or treatment are\\nrequired.\\nSkin lesions\\n(also see\\nChapter 4)\\nBacterial infections\\n• Furunculosis\\n• Impetigo and pyoderma\\n• Axillary hidradenitis\\n• Pyomyositis\\n• Syphilis\\nViral infections\\n• Herpes zoster\\n• Herpes simplex\\n• Genital warts\\n• Molluscum\\ncontagiosum\\nFungal infections\\n• Candidiasis,\\ndermatophytoses and\\ndeep mycoses\\n(penicilliosis,\\ncryptococcosis,\\nhistoplasmosis, etc.)\\nNeoplasms\\n• Kaposi sarcoma\\n\\xa0 Bacterial infections\\n• Furunculosis, impetigo, chronic\\nfolliculitis: see \\nBacterial skin infections, Chapter 4.\\n• Suppurative axillary hidradenitis:\\nlocal treatment + doxycycline PO:\\n200 mg once daily for 6 weeks (in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 286, 'page_label': '287', 'id': 'data/guideline-170-en.pdf:286:2'}, page_content='local treatment + doxycycline PO:\\n200 mg once daily for 6 weeks (in\\nadults)\\n• Pyomyositis: antibiotics and\\nsurgical drainage, see Pyomyositis,\\nChapter 10.\\n• Primary and secondary syphilis: see\\nGenital ulcers, Chapter 9.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 287, 'page_label': '288', 'id': 'data/guideline-170-en.pdf:287:0'}, page_content='Page 288 / 409\\nOther skin infections\\n• Chronic prurigo or\\nurticaria\\n• Severe seborrhoeic\\ndermatitis\\n• Psoriasis\\n• Scabies\\n• Diffuse cutaneous\\nxerosis\\nRash caused by\\nmedication\\nBed sores\\nViral infections\\n• Herpes zoster: see \\nHerpes simplex and herpes zoster,\\nChapter 4.\\nFor necrotic, extensive forms,\\neruption on the face, ophthalmic\\nzoster, add aciclovir within 48 hours\\nof the onset of lesions:\\nChildren (IV route): 5 to 10 mg/kg\\nevery 8 hours for 7 days\\nAdults (oral route): 800 mg 5 times\\ndaily for 7 days\\n• Herpes simplex: see \\nHerpes simplex and herpes zoster,\\nChapter 4.\\n• Genital warts: see Venereal warts,\\nChapter 9.\\nFungal infections\\n• Candidiasis: 2% miconazole\\ncream, one application 2 times daily\\n• Dermatophytoses: see \\nSuperﬁcial fungal infections, Chapter\\n4.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 287, 'page_label': '288', 'id': 'data/guideline-170-en.pdf:287:1'}, page_content='• Dermatophytoses: see \\nSuperﬁcial fungal infections, Chapter\\n4.\\nTreatment of Kaposi sarcoma (KS)\\n• Start promptly ART.\\n• KS tumours with oedema or\\nulceration or presence of extensive\\noral or gastrointestinal or pulmonary\\nKS +/- systemic illness:\\nchemotherapy\\nOther skin infections\\n• Prurigo, urticaria: see \\nOther skin disorders, Chapter 4.\\n• Seborrhoeic dermatitis: Whitﬁeld’s\\nointment or 2% miconazole, one\\napplication 2 times daily. For severe\\ninﬂammation, use a topical\\ncorticosteroid in combination with\\nmiconazole.\\n• Xerosis: zinc oxide ointment or\\ncalamine lotion\\n• Psoriasis: corticosteroids and\\nzinc oxide ointment\\n• Scabies: local treatment. For\\ncrusted or profuse scabies, add\\nivermectin PO (see Scabies,\\nChapter 4).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 287, 'page_label': '288', 'id': 'data/guideline-170-en.pdf:287:2'}, page_content='crusted or profuse scabies, add\\nivermectin PO (see Scabies,\\nChapter 4).\\nNeurological Aetiologies: History and clinical Positive malaria test: see Malaria,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 288, 'page_label': '289', 'id': 'data/guideline-170-en.pdf:288:0'}, page_content='Page 289 / 409\\ndisorders in adults Infections\\n• TB meningitis\\n• Cryptococcal meningitis\\n• Cerebral toxoplasmosis\\n• Neurosyphilis\\n• CMV encephalitis\\n• HIV encephalopathy\\n• Progressive multifocal\\nleuko- encephalopathy\\n• Cerebral malaria\\nNeoplasms\\n• Primary CNS lymphoma\\nCommon causes of\\nheadache unrelated to\\nHIV infection:\\nsometimes more\\nfrequent in HIV infected\\npatients (sinusitis,\\nproblems with\\naccommodation etc.)\\nAdverse effects of\\nARVs\\nexamination:\\n• Change in mental state\\n• Focal deﬁcits\\n• Seizures\\n• Signs of meningeal\\nirritation\\n• Raised intercranial\\npressure\\n• Motor problems, ataxia\\nIn settings where\\ncryptococcal infection is\\ncommon, screen all\\nadults with CD4 < 100\\nprior to initiation of ART,\\nusing a rapid CrAg test\\non serum or plasma.\\nIn endemic areas: check\\nfor malaria (if febrile).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 288, 'page_label': '289', 'id': 'data/guideline-170-en.pdf:288:1'}, page_content='on serum or plasma.\\nIn endemic areas: check\\nfor malaria (if febrile).\\nLumbar puncture (LP) if\\nnot contra-indicated.\\nElements in favour of\\nneurosyphilis:\\n• VDRL positive in blood\\nand/or CSF\\n• cells in the CSF\\n• high protein in the CSF\\nChapter 6.\\nIf focal signs, treat for\\ntoxoplasmosis:\\nco-trimoxazole PO: 25 mg SMX + 5\\nmg TMP/kg 2 times daily for 4 to 6\\nweeks\\nor\\npyrimethamine PO: 100 mg morning\\nand evening on D1, then 75 to 100\\nmg daily + sulfadiazine PO: 2 g 2 to\\n3 times daily + folinic acid PO: 15\\nmg once daily, for 6 weeks\\nA secondary prophylaxis is\\nrecommended.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 289, 'page_label': '290', 'id': 'data/guideline-170-en.pdf:289:0'}, page_content='Page 290 / 409\\nIf the LP\\u2008is positive:\\n• Bacterial meningitis: see Chapter 7.\\n• TB meningitis: see the guide \\nTuberculosis, MSF.\\n• Cryptococcal meningitis :\\namphotericin B IV: 1 mg/kg once\\ndaily + ﬂucytosine PO: 25 mg/kg 4\\ntimes daily for 1 week\\nthen ﬂuconazole PO: 1200 mg once\\ndaily for 1 week then 800 mg once\\ndaily for 8 weeks\\nor, if not available\\namphotericin B IV: 1 mg/kg once\\ndaily + ﬂuconazole PO: 1200 mg\\nonce daily for 2 weeks\\nthen ﬂuconazole PO alone: 800 mg\\nonce daily for 8 weeks\\nor\\nﬂuconazole PO: 1200 mg once daily\\n+ ﬂucytosine PO: 25 mg/kg 4 times\\ndaily for 2 weeks\\nthen ﬂuconazole PO alone: 800 mg\\nonce daily for 8 weeks\\nDuring the induction phase: give\\nﬂuconazole IV (same doses) if the\\npatient cannot take oral treatment;\\nliposomal amphotericin B (3 mg/kg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 289, 'page_label': '290', 'id': 'data/guideline-170-en.pdf:289:1'}, page_content='patient cannot take oral treatment;\\nliposomal amphotericin B (3 mg/kg\\ndaily 2 weeks) may be used instead\\nof conventional amphotericin B in\\ncase of renal impairment.\\nA secondary prophylaxis is\\nrecommended.\\nNote: intracranial pressure (ICP) is\\noften raised in cryptococcal\\nmeningitis. To lower ICP, repeated\\n‘therapeutic’ punctures to drain CSF\\nmay be necessary at the beginning\\nof treatment.\\nNeurosyphilis:\\nbenzylpenicillin IV: 2 to 4 MIU (1.2\\nto 2.4 g)\\xa0every 4 hours for 14 days\\nor ceftriaxone IV or IM: 2 g once\\ndaily for 10 to 14 days\\nHeadache of unknown origin:\\nsymptomatic treatment starting with\\na step 1 analgesic (see Pain,\\nChapter 1).\\n [2] \\nNeurological Aetiologies: Good history taking as Positive malaria test: see Malaria,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 290, 'page_label': '291', 'id': 'data/guideline-170-en.pdf:290:0'}, page_content='Page 291 / 409\\ndisorders in\\nchildren\\n• Bacterial meningitis\\n• TB meningitis\\n• Cryptococcal meningitis\\n• Cerebral toxoplasmosis\\n• CMV meningo-\\nencephalitis\\n• Cerebral malaria\\nonly patients with acute\\nepisodes beneﬁt from\\nspeciﬁc aetiological\\ntreatment (seizures,\\nmeningeal syndrome,\\nfocal signs).\\nIn endemic areas, check\\nfor malaria (if febrile).\\nLumbar puncture (LP) if\\nnot contra-indicated.\\nChapter 6.\\nIf LP is not possible:\\n• Treat for bacterial meningitis if\\npatient febrile and/or meningeal\\nsyndrome (see Chapter 7).\\n• If focal signs, treat for\\ntoxoplasmosis:\\nco-trimoxazole PO: 25 mg SMX + 5\\nmg TMP/kg 2 times daily for 4 to 6\\nweeks\\nor \\npyrimethamine PO: 1 mg/kg 2 times\\ndaily for 2 days then 1 mg/kg once\\ndaily + sulfadiazine PO: 40 mg/kg 2\\ntimes daily + folinic acid PO: 10 mg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 290, 'page_label': '291', 'id': 'data/guideline-170-en.pdf:290:1'}, page_content='daily + sulfadiazine PO: 40 mg/kg 2\\ntimes daily + folinic acid PO: 10 mg\\nonce daily, for 8 weeks\\nA secondary prophylaxis is\\nrecommended.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 291, 'page_label': '292', 'id': 'data/guideline-170-en.pdf:291:0'}, page_content='Page 292 / 409\\nIf the LP is positive:\\n• Bacterial meningitis: see Chapter 7.\\n• TB meningitis: see the guide \\nTuberculosis, MSF.\\n• Cryptococcal meningitis (in order of\\npreference) :\\namphotericin B IV: 1 mg/kg once\\ndaily + ﬂucytosine PO: 25 mg/kg 4\\ntimes daily for 1 week then\\nﬂuconazole PO: 12 mg/kg once\\ndaily (max. 800 mg daily) for 1 week\\nthen 6-12 mg/kg once daily (max.\\n800 mg daily) for 8 weeks\\nor, if not available\\namphotericin B IV: 1 mg/kg once\\ndaily + ﬂuconazole PO: 12 mg/kg\\nonce daily (max. 800 mg daily) for 2\\nweeks then ﬂuconazole PO alone:\\n6-12 mg/kg once daily for 8 weeks\\n(max. 800 mg daily)\\nor\\nﬂuconazole PO: 12 mg/kg once\\ndaily (max. 800 mg daily) +\\nﬂucytosine PO: 25 mg/kg 4 times\\ndaily for 2 weeks then ﬂuconazole\\nPO alone: 6-12 mg/kg once daily\\n(max. 800 mg daily) for 8 weeks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 291, 'page_label': '292', 'id': 'data/guideline-170-en.pdf:291:1'}, page_content='PO alone: 6-12 mg/kg once daily\\n(max. 800 mg daily) for 8 weeks\\nDuring the induction phase: give\\nﬂuconazole IV (same doses) if the\\nchild cannot take oral treatment;\\nliposomal amphotericin B (3 mg/kg\\ndaily, 2 weeks) may be used instead\\nof conventional amphotericin B in\\ncase of renal impairment.\\nA secondary prophylaxis is\\nrecommended.\\n [2] \\nPersistent or\\nrecurrent fever\\nTemperature > 38 °C,\\nchronic (lasting more than\\n5 days) or recurrent\\n(multiple episodes in a\\nperiod of more than 5\\ndays)\\nAetiologies:\\n1. History and clinical\\nexamination: look for a\\nENT or urinary infection,\\nTB, skin infection,\\nenlarged lymph nodes\\netc.\\n2. In endemic areas,\\ncheck for malaria.\\n3. Suspected TB: look\\nfor AFB.\\nPositive malaria test: see Malaria,\\nChapter 6.\\nIf testing is not available: in endemic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 291, 'page_label': '292', 'id': 'data/guideline-170-en.pdf:291:2'}, page_content='Chapter 6.\\nIf testing is not available: in endemic\\nareas, treat malaria.\\nSuspected meningitis: treat\\naccording to the results of the LP.\\nIf LP is not available, treat for \\nbacterial meningitis, see Chapter 7.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 292, 'page_label': '293', 'id': 'data/guideline-170-en.pdf:292:0'}, page_content='Page 293 / 409\\n\\xa0\\nReferences\\nInfections\\n• Common childhood\\ndiseases\\n• Severe bacterial\\ninfections (TB,\\npneumonia, typhoid fever,\\nsepticaemia, meningitis,\\nendocarditis, etc.)\\n• Occult bacterial\\ninfections (sinusitis, otitis,\\nurinary tract infections)\\n• Opportunistic infections\\n(TB, mycosis,\\ntoxoplasmosis)\\n• Malaria\\nNeoplasms\\n• Non-Hodgkin’s\\nlymphoma\\nHIV infection\\nFever caused by\\nmedication\\n4. Chest x-ray, CBC,\\nblood cultures, urinalysis,\\nstool culture, serology,\\nlumbar puncture (LP).\\nIf the child is under\\ntreatment, consider\\nadverse effects of\\nmedication.\\nIdentiﬁed or suspected focus of\\ninfection:\\n• ENT: see Chapter 2; urinary: see \\nChapter 9, etc.\\n• TB: see the guide Tuberculosis,\\nMSF.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 292, 'page_label': '293', 'id': 'data/guideline-170-en.pdf:292:1'}, page_content='Chapter 9, etc.\\n• TB: see the guide Tuberculosis,\\nMSF.\\nFootnotes\\n(a) For more information: The use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for apublic health approach. World Health Organization, second edition, 2016.http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1\\n1. World Health Organization. WHO case deﬁnitions of HIV for surveillance and revised clinical staging and immunologicalclassiﬁcation de HIV-related disease in adults and children, 2007.http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf\\xa0[Accessed\\xa017\\xa0May\\xa02018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 292, 'page_label': '293', 'id': 'data/guideline-170-en.pdf:292:2'}, page_content='2. Word Health Organization. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, Geneva, 2018.http://apps.who.int/iris/bitstream/handle/10665/260399/9789241550277-eng.pdf?sequence=1 [Accessed\\xa017\\xa0May\\xa02018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 293, 'page_label': '294', 'id': 'data/guideline-170-en.pdf:293:0'}, page_content='Page 294 / 409\\nChapter 9: Genito-urinary diseases\\nNephrotic syndrome in children\\nUrolithiasis\\nAcute cystitis\\nAcute pyelonephritis\\nAcute prostatitis\\nGenital infections\\nUrethral discharge\\nAbnormal vaginal discharge\\nGenital ulcers\\nLower abdominal pain in women\\nUpper genital tract infections (UGTI)\\nVenereal warts\\nMajor genital infections (summary)\\nAbnormal uterine bleeding (in the absence of pregnancy)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 294, 'page_label': '295', 'id': 'data/guideline-170-en.pdf:294:0'}, page_content='Page 295 / 409\\nNephrotic syndrome in children\\nNephrotic syndrome (NS) is characterized by the presence of oedema, heavy proteinuria, hypoalbuminemia, and\\nhyperlipidaemia.\\nPrimary or idiopathic NS is the most common cause of NS in children between 1 and 10 years. It usually responds to\\ncorticosteroids.\\nSecondary NS is associated with infectious diseases (e.g. post-infectious glomerulonephritis, endocarditis, hepatitis B\\nand C, HIV infection, malaria, and schistosomiasis) and may respond to treatment of the underlying cause.\\xa0Children with NS are at increased risk of thromboembolism, severe bacterial infections (in particular, due to\\xa0S.\\npneumoniae) and malnutrition. Untreated NS may progress to renal failure.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 294, 'page_label': '295', 'id': 'data/guideline-170-en.pdf:294:1'}, page_content='Clinical features\\nAs oedema worsens, it may localize to the back or genitals, or become generalized with ascites and pleural\\neffusions.\\xa0\\n\\xa0\\nLaboratory\\nTreatment\\n\\xa0\\n\\xa0\\nTypically, the child presents with soft, pitting and painless oedema, which varies in location based on position and\\nactivity. Upon awaking, the child has periorbital or facial oedema, which over the day decreases as oedema of the\\nlegs increases.\\nThis oedema should be differentiated from the oedema of severe acute malnutrition (SAM): in SAM, the child\\npresents with bilateral pitting oedema of the feet and lower legs that does not vary with position. Oedema extends\\nupwards to hands and face in severe cases. It is usually associated with typical skin and hair changes (see\\nKwashiorkor:\\xa0Severe acute malnutrition, Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 294, 'page_label': '295', 'id': 'data/guideline-170-en.pdf:294:2'}, page_content='Kwashiorkor:\\xa0Severe acute malnutrition, Chapter 1).\\nOnce SAM is excluded, the following two criteria must be met to make a clinical diagnosis of primary NS:\\nPresence of heavy proteinuria,\\nand\\nAbsence of associated infections: see Hepatitis B and C and HIV infection (Chapter 8), Malaria and\\nSchistosomiases (Chapter 6).\\nUrine\\nMeasure protein with urinary dipstick on three separate voided urine samples (ﬁrst voided urine if possible). In NS,\\nproteinuria is equal or greater than +++ or equal or greater than 300 mg/dl or 30 g/litre . NS is excluded if heavy\\nproteinuria is not consistently present.\\n a \\nIn case of macroscopic haematuria, or microscopic haematuria ≥ +, consider glomerulonephritis.\\nBlood tests (if available)\\nSerum albumin concentration less than 30 g/litre and hyperlipidaemia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 294, 'page_label': '295', 'id': 'data/guideline-170-en.pdf:294:3'}, page_content='Serum albumin concentration less than 30 g/litre and hyperlipidaemia.\\nBlood urea nitrogen (BUN) and creatinine most often in the normal range.\\nPerform all necessary laboratory tests to exclude secondary NS.\\nHospitalize the child for initial therapy.\\nCorticosteroids (prednisolone or prednisone) are indicated in primary NS.\\nBefore starting corticosteroid treatment:\\nTreat any concomitant acute infections such as pneumonia, peritonitis, sepsis, pharyngitis, or cellulitis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 295, 'page_label': '296', 'id': 'data/guideline-170-en.pdf:295:0'}, page_content='Page 296 / 409\\n\\xa0\\nSee algorithm below. Total length of initial treatment is 2 to 4 months.\\n\\xa0\\n\\xa0\\nTreat infections as soon as they appear but do not routinely give prophylactic antibiotics.\\xa0\\nManagement of complications\\nExclude active tuberculosis and/or start antituberculous treatment.\\nCorticosteroid treatment\\nNutrition, ﬂuid intake, nursing and follow-up\\nNo salt-added diet.\\nDo not restrict ﬂuids (risk of thrombosis due to hypercoagulability). If oedema is very severe, ﬂuids may initially\\nbe restricted (e.g. 75% of usual intake) while monitoring urine output.\\nEncourage child to walk and play to prevent thromboembolism.\\nDischarge child when stable, follow-up at least monthly, more frequently if indicated, weight and urine dipstick at\\neach visit.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 295, 'page_label': '296', 'id': 'data/guideline-170-en.pdf:295:1'}, page_content='each visit.\\nInstruct the parent to continue no salt-added diet and to seek medical advice in case of fever, abdominal pain,\\nrespiratory distress or signs of thromboembolism.\\nManagement of infections\\nImmunization\\nChildren under 5 years: check that the child has received all EPI vaccines including\\xa0Haemophilus inﬂuenzae\\xa0type\\nB, conjugated pneumococcal vaccine and (if in an endemic area) meningococcal A conjugate vaccine. If not,\\nadminister catch-up vaccines.\\nChildren over 5 years: check that the child has received tetanus, measles, pneumococcal conjugate and (if in an\\nendemic area) meningococcal A conjugate vaccine. If not, administer catch-up vaccines.\\nIntravascular volume depletion potentially leading to shock, present despite oedematous appearance'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 296, 'page_label': '297', 'id': 'data/guideline-170-en.pdf:296:0'}, page_content='Page 297 / 409\\nSigns include decreased urine output with any one of the following: capillary reﬁll ≥ 3 seconds, poor skin\\nperfusion/mottling, cold extremities, low blood pressure.\\nIf signs are present, administer\\xa0human albumin 5%\\xa0IV: 1 g/kg. If albumin is not available, administer\\xa0Ringer\\nlactate\\xa0or\\xa00.9% sodium chloride: 10 ml/kg over 30 minutes.\\nIf signs of shock are present, see\\xa0Shock, Chapter 1.\\xa0\\nThis is the only situation in which diuretics should be used and only if there are no signs of intravascular volume\\ndepletion or after hypovolaemia has been corrected:\\nfurosemide\\xa0PO: 0.5 mg/kg 2 times daily\\nIf not effective, discontinue furosemide. If creatinine is normal, administer\\xa0spironolactone\\xa0PO: 1 mg/kg 2 times'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 296, 'page_label': '297', 'id': 'data/guideline-170-en.pdf:296:1'}, page_content='daily. The dose can be increased to 9 mg/kg daily in resistant cases of ascites.\\nWhile on diuretics, monitor for dehydration, thromboembolism and hypokalaemia.\\xa0Specialized advice and management (including further investigations such as renal biopsy) are required:\\n\\xa0In case of steroid-resistant NS, when referral is impossible and as a last resort, the following palliative measure may\\nreduce proteinuria and delay renal failure:\\nenalapril\\xa0PO: 0.1 to 0.3 mg/kg 2 times daily (start with the lowest dose and increase gradually if necessary until\\nreduction of proteinuria). If available, monitor for hyperkalaemia.\\nThis is a palliative measure and the prognosis\\xa0for steroid-resistant NS is poor in the absence of specialized treatment.\\n\\xa0\\nRespiratory distress due to severe oedema (rare)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 296, 'page_label': '297', 'id': 'data/guideline-170-en.pdf:296:2'}, page_content='Respiratory distress due to severe oedema (rare)\\nIn children less than 1 year or more than 10 years,\\nIn case of steroid resistant NS,\\n\\xa0In case of mixed nephrotic and nephritic clinical picture.\\nFootnotes\\n(a) Nephrotic range proteinuria in children is deﬁned as urinary protein excretion greater than 50 mg/kg daily. Quantitativemeasurement of protein excretion is normally based on a timed 24-hour urine collection. However, if this test cannot beperformed, urine dipstick measurements can be substituted.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 297, 'page_label': '298', 'id': 'data/guideline-170-en.pdf:297:0'}, page_content='Page 298 / 409\\nUrolithiasis\\nLast updated: December 2020\\n\\xa0\\nUrolithiasis is the formation and passage of calculi (stones) in the urinary tract.\\nClinical features\\n\\xa0Note: if available, ultrasound may demonstrate calculi and hydronephrosis.\\nTreatment\\n\\xa0Note: the majority of calculi pass spontaneously. If there are signs of signiﬁcant renal dysfunction or secondary\\ninfection that does not improve with antibiotic treatment, consider surgical referral.\\nMany calculi do not cause symptoms; they may be found incidentally through radiology exams.\\nSymptoms arise when calculi cause partial or complete obstruction and/or infection:\\nIntermittent, acute\\xa0ﬂank to pelvic pain (renal colic). Pain can be severe and typically causes nausea and vomiting.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 297, 'page_label': '298', 'id': 'data/guideline-170-en.pdf:297:1'}, page_content='Abdomen/ﬂank may be tender to palpation. Patients are typically restless, ﬁnding no comfortable position.\\nHaematuria\\xa0and/or gravel (calculi) passed in urine.\\nFever and signs of pyelonephritis if secondary infection\\xa0develops (see Acute pyelonephritis, Chapter 9).\\nEncourage the patient to drink ﬂuids.\\nAdminister analgesics according to the intensity of pain (see Pain, Chapter 1).\\nIn case of secondary infection: antibiotic treatment as for pyelonephritis. The effectiveness will depend on the\\npassage of calculi.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 298, 'page_label': '299', 'id': 'data/guideline-170-en.pdf:298:0'}, page_content=\"Page 299 / 409\\nAcute cystitis\\nLast updated: July 2021\\n\\xa0\\nCystitis is an infection of the bladder and urethra that affects mainly women and girls from 2 years of age. Escherichia\\ncoli is the causative pathogen in at least 70% of cases. Other pathogens include Proteus mirabilis, Enterococcus sp,\\nKlebsiella sp and in young women, Staphylococcus\\xa0saprophyticus.\\nClinical features\\nAND\\n\\xa0It is essential to rule out pyelonephritis.\\nThe symptom 'burning pain on urination' alone is insufﬁcient to make the diagnosis. See Abnormal vaginal discharge.\\nInvestigations\\xa0\\nPerform dipstick analysis for nitrites (which indicate the presence of enterobacteria) and leukocytes (which indicate\\nan inﬂammation) in the urine.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 298, 'page_label': '299', 'id': 'data/guideline-170-en.pdf:298:1'}, page_content='an inﬂammation) in the urine.\\n\\xa0\\nWhen urine microscopy is not feasible, an empirical antibiotherapy should be administered to patients with typical\\nsigns of cystitis and positive dipstick urinalysis (leukocytes and/or nitrites).\\xa0Note: aside of these results, in areas where urinary schistosomiasis is endemic, consider schistosomiasis in patients\\nwith macroscopic haematuria or microscopic haematuria detected by dipstick test, especially in children from 5 to 15\\nyears, even if the patient may suffer from concomitant bacterial cystitis.\\xa0\\nTreatment\\nCystitis in girls ≥ 2 years\\nceﬁxime PO: 8 mg/kg once daily for 3 days\\nor\\namoxicillin/clavulanic acid PO (dose expressed in amoxicillin): 12.5 mg/kg 2 times daily\\xa0for 3 days\\nCystitis in\\xa0young,\\xa0nonpregnant women'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 298, 'page_label': '299', 'id': 'data/guideline-170-en.pdf:298:2'}, page_content='Cystitis in\\xa0young,\\xa0nonpregnant women\\xa0\\nfosfomycin-trometamol PO: 3 g single dose\\nor\\nnitrofurantoin\\u202fPO:\\u202f100 mg 3 times daily for 5 days\\xa0\\xa0\\nBurning pain on urination and\\xa0urinary urgency and frequency; in children: crying when passing urine; involuntary loss of\\nurine.\\nNo fever (or mild fever), no ﬂank pain; no systemic signs and symptoms in children.\\nUrine dipstick test:\\nIf dipstick analysis is positive for nitrites and/or leukocytes, a urinary infection is likely.\\xa0\\nIn women, if dipstick analysis is negative for both nitrites and leukocytes, a urinary infection is excluded.\\xa0\\nMicroscopy/culture: when a dipstick analysis is positive, it is recommended to carry out urine microscopy/culture in'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 298, 'page_label': '299', 'id': 'data/guideline-170-en.pdf:298:3'}, page_content='order to conﬁrm the infection and identify the causative pathogen, particularly in children and pregnant women.\\nPOCUS :\\xa0in cases of recurrent\\xa0cystitis, perform FAST views to evaluate for signs of urinary tract pathologies.\\xa0 a \\nIf dipstick analysis is positive for both nitrites and leukocytes:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 299, 'page_label': '300', 'id': 'data/guideline-170-en.pdf:299:0'}, page_content='Page 300 / 409\\n\\xa0\\nCystitis in pregnant or lactating women\\nfosfomycin-trometamol PO:\\xa03 g single dose\\nor\\nnitrofurantoin\\xa0PO\\xa0(contraindicated\\xa0in the last month of pregnancy): 100 mg 3\\xa0times\\xa0daily for\\xa07\\xa0days\\xa0\\nor\\xa0\\nceﬁxime PO: 200 mg 2 times daily\\xa0for 5 days\\n\\xa0\\nIf dipstick analysis is negative for nitrites but positive for leukocytes, the infection may be due to S. saprophyticus.\\nFosfomycin is not active against this pathogen. Use nitrofurantoin\\xa0as above.\\nWhatever the antibiotic used, symptoms may persist for 2 to 3 days despite adequate treatment.\\nIn the event of treatment failure (or recurrent cystitis i.e. > 3-4 episodes per year), ciproﬂoxacin PO: 500 mg\\xa02\\ntimes daily for 3 days\\nFor patients with recurrent cystitis, consider bladder stones, urinary schistosomiasis, urinary tuberculosis or'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 299, 'page_label': '300', 'id': 'data/guideline-170-en.pdf:299:1'}, page_content='gonorrhoea (examine the partner).\\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 300, 'page_label': '301', 'id': 'data/guideline-170-en.pdf:300:0'}, page_content='Page 301 / 409\\nAcute pyelonephritis\\nPyelonephritis is\\xa0an infection of the renal parenchyma, more common in women than in men.\\nThe pathogens causing pyelonephritis are the same as those causing cystitis (see\\xa0Acute cystitis, Chapter 9).\\nPyelonephritis\\xa0is potentially severe, especially in pregnant women, neonates and infants.\\nManagement depends on the presence of signs of severity or complications or risk of complications.\\nClinical features\\nNeonates and infant\\n\\xa0In practice, a urinary tract infection should be suspected in children with unexplained fever or septic syndrome with no\\nobvious focus of infection.\\nOlder children and adults\\nAND\\nLaboratory\\nSee\\xa0Acute cystitis, Chapter 9.\\nTreatment'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 300, 'page_label': '301', 'id': 'data/guideline-170-en.pdf:300:1'}, page_content='AND\\nLaboratory\\nSee\\xa0Acute cystitis, Chapter 9.\\nTreatment\\n\\xa0\\n\\xa0\\nSymptoms are not speciﬁc: fever, irritability, vomiting, poor oral intake. Palpation of the lower abdomen may show\\nabdominal tenderness. The absence of fever does not rule out the diagnosis. On the other hand, fever –with no\\nobvious cause– may be the only manifestation.\\nNeonates may present with fever or hypothermia, altered general condition, altered conscious state, pale/grey\\ncolour, shock.\\nSigns of cystitis (burning pain on urination\\xa0and\\xa0urinary urgency and frequency, etc.)\\nFever >\\xa038 °C\\xa0and\\xa0unilateral ﬂank pain\\xa0or abdominal tenderness\\nNausea and/or vomiting are common.\\nCriteria for hospital admission:\\nPatients at risk of complications: children, pregnant women, men , functional or structural\\xa0abnormality of the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 300, 'page_label': '301', 'id': 'data/guideline-170-en.pdf:300:2'}, page_content='urinary tract\\xa0(lithiasis, malformation, etc.),\\xa0severe immunodeﬁciency;\\xa0\\n a \\nPatients with complicated pyelonephritis: urinary tract obstruction, renal abscess, emphysematous\\npyelonephritis in diabetic patients;\\nPatients with signs of severe infection:\\xa0sepsis (infection with signs of organ dysfunction) and septic shock,\\ndehydration or nausea/vomiting preventing hydration and oral treatment;\\nNo clinical improvement 24 hours after the start of oral antibiotherapy in women treated as outpatients.\\xa0\\nAntibiotherapy in children\\nChildren under one month\\xa0\\nampicillin slow IV (3 minutes) for 7 to 10 days\\nChildren 0 to 7 days (< 2 kg):\\xa050 mg/kg every 12 hours\\nChildren 0 to 7 days (≥ 2 kg):\\xa050 mg/kg every 8 hours\\nChildren 8 days to < 1 month:\\xa050 mg/kg every 8 hours'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 300, 'page_label': '301', 'id': 'data/guideline-170-en.pdf:300:3'}, page_content='Children 8 days to < 1 month:\\xa050 mg/kg every 8 hours\\n+ gentamicin slow IV (3 minutes) for 5 days\\nChildren 0 to 7 days (< 2 kg): 3 mg/kg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 301, 'page_label': '302', 'id': 'data/guideline-170-en.pdf:301:0'}, page_content=\"Page 302 / 409\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0Preferably use the combination ampicillin + gentamicin to cover\\xa0enterococci.\\xa0\\nPyelonephritis\\xa0with\\xa0abscess\\xa0formation\\xa0or\\xa0emphysematous pyelonephritis may require longer antibiotherapy.\\xa0\\n\\xa0\\nChildren 0 to 7 days (≥ 2 kg): 5 mg/kg once daily\\nChildren 8 days to < 1 month: 5 mg/kg once daily\\nor\\ncefotaxime\\xa0slow IV (3 minutes) for 7 to 10 days\\nChildren 0 to 7 days (< 2 kg): 50 mg/kg every 12 hours\\nChildren 0 to 7 days (≥ 2 kg):\\xa050 mg/kg every 8 hours\\nChildren 8 days to < 1 month:\\xa050 mg/kg every 8 hours\\nChildren one month and over\\nceftriaxone\\xa0IM or slow IV (3 minutes): 50 mg/kg once daily until the child's condition improves (at least 3 days)\\nthen change to oral route to complete 10 days of treatment\\xa0with:\\namoxicillin/clavulanic acid\\xa0PO (dose expressed in amoxicillin)\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 301, 'page_label': '302', 'id': 'data/guideline-170-en.pdf:301:1'}, page_content='amoxicillin/clavulanic acid\\xa0PO (dose expressed in amoxicillin)\\nChildren < 40 kg: 25 mg/kg 2 times daily\\xa0\\nChildren ≥ 40 kg:\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times\\xa0daily)\\xa0\\n b \\xa0\\nAntibiotherapy in adults [1]\\nUncomplicated\\xa0pyelonephritis\\xa0\\nceftriaxone\\xa0IM:\\xa01 g\\xa0single dose or\\xa0gentamicin\\xa0IM:\\xa05 mg/kg\\xa0single dose\\n+\\nciproﬂoxacin\\xa0PO: 500 mg 2\\xa0times daily for 7 days\\nor\\namoxicillin/clavulanic\\xa0acid\\xa0PO (dose expressed in amoxicillin)\\xa0for 10 to 14 days\\nRatio 8:1: 2000 mg daily (2 tablets of 500/62.5 mg 2 times daily)\\nRatio 7:1: 1750 mg daily (1 tablet of 875/125 mg 2 times\\xa0daily)\\xa0\\nor\\nceﬁxime\\xa0PO: 200 mg 2 times daily or 400 mg once daily for 10 to 14 days\\nPyelonephritis\\xa0with\\xa0criteria for hospital admission'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 301, 'page_label': '302', 'id': 'data/guideline-170-en.pdf:301:2'}, page_content='Pyelonephritis\\xa0with\\xa0criteria for hospital admission\\nampicillin\\xa0slow IV (3 minutes): 2 g every 6 hours for at least 3 days\\xa0+\\xa0gentamicin\\xa0IM:\\xa05 mg/kg once daily for 3\\ndays\\nthen change to amoxicillin/clavulanic\\xa0acid PO (or another antibiotic depending on the antibiotic susceptibility\\ntest)\\xa0to complete 10 to 14 days of treatment\\nor\\nceftriaxone\\xa0IV : 1 g once daily for at least 3 days\\xa0+\\xa0gentamicin\\xa0IM:\\xa05 mg/kg once daily for 3 days\\xa0in the event\\nof sepsis\\xa0then change to amoxicillin/clavulanic\\xa0acid\\xa0PO (or another antibiotic depending on the\\xa0antibiotic\\nsusceptibility test)\\xa0to complete 10 to 14 days of treatment\\n b \\xa0\\nTreatment of fever and pain:\\xa0do not administer\\xa0NSAID\\xa0(Fever, Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 301, 'page_label': '302', 'id': 'data/guideline-170-en.pdf:301:3'}, page_content='b \\xa0\\nTreatment of fever and pain:\\xa0do not administer\\xa0NSAID\\xa0(Fever, Chapter 1).\\nMaintain proper hydration (1.5 litres daily in adults), especially in children (risk of dehydration); treat dehydration if\\npresent (see Dehydration, Chapter 1).\\nManagement of septic shock if needed.\\nFootnotes\\n(a) Pyelonephritis is rare in men; bacterial prostatitis should be suspected in the event of febrile urinary tract infection.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 302, 'page_label': '303', 'id': 'data/guideline-170-en.pdf:302:0'}, page_content='Page 303 / 409\\nReferences\\n(b) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 302, 'page_label': '303', 'id': 'data/guideline-170-en.pdf:302:1'}, page_content='1. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, InfectiousDiseases Society of America, European Society for Microbiology and Infectious Diseases.\\xa0International clinical practiceguidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the InfectiousDiseases Society of America and the European Society for Microbiology and Infectious Diseases.\\xa0Clin Infect Dis.2011;52(5):e103.\\xa0https://academic.oup.com/cid/article/52/5/e103/388285\\xa0[Accessed 17 December 2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 303, 'page_label': '304', 'id': 'data/guideline-170-en.pdf:303:0'}, page_content='Page 304 / 409\\nAcute prostatitis\\nProstatitis is an acute bacterial infection of the prostate.\\nThe\\xa0most common\\xa0causative pathogen is Escherichia coli. Other pathogens include Proteus\\nmirabilis,\\xa0Klebsiella\\xa0sp,\\xa0Pseudomonas\\xa0aeruginosa and\\xa0Enterococcus\\xa0sp.\\nProgression to chronic prostatitis is possible.\\nClinical features\\n\\xa0On examination:\\nTreatment\\n\\xa0\\nReferences\\nFever (often high) and chills.\\nSigns of cystitis (burning on urination and urinary frequency).\\nPerineal, urethral, penile or rectal\\xa0pain.\\nUrinary retention.\\nVery\\xa0painful digital rectal examination. Fluctuant mass in case of prostatic abscess.\\nLeukocyturia, pyuria, possible\\xa0macroscopic\\xa0haematuria.\\nAntibiotic therapy:\\nciproﬂoxacin PO: 500 mg 2 times daily for 14 days then review the patient. Stop treatment if signs and symptoms'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 303, 'page_label': '304', 'id': 'data/guideline-170-en.pdf:303:1'}, page_content='have completely resolved. If signs and symptoms are ongoing continue the same treatment for a further 14 days. [1]\\nSymptomatic treatment:\\nEnsure adequate hydration (1.5 litres daily).\\nTreat fever (Chapter 1) and pain (Chapter 1).\\nRefer to a surgeon in case of suspected prostatic abscess.\\n1. National Institute for Health and Care Excellence. NICE guideline [NG110] Prostatitis (acute): antimicrobial prescribing, 2018.https://www.nice.org.uk/guidance/ng110/resources/visual-summary-pdf-6544018477 [Accessed 4 March 2020]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 304, 'page_label': '305', 'id': 'data/guideline-170-en.pdf:304:0'}, page_content='Page 305 / 409\\nGenital infections\\nLast updated: August 2021\\n\\xa0\\nThe diagnosis and treatment of genital infections (GI) present several difﬁculties: clinical features are not speciﬁc;\\nmany infections are asymptomatic; laboratory tests available in the ﬁeld are not always reliable; mixed infections are\\ncommon; sexual partners need to be treated simultaneously in case of sexually transmitted infections and the risk of\\nrecurrence or treatment failure is increased in HIV-infected patients.\\nThus, the WHO has introduced the syndromic management of GI and developed standardised case management\\nﬂowcharts: based on the identiﬁcation of consistent groups of signs and symptoms (syndromes), patients are treated\\nfor the pathogens/infections that may cause each syndrome.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 304, 'page_label': '305', 'id': 'data/guideline-170-en.pdf:304:1'}, page_content='for the pathogens/infections that may cause each syndrome.\\xa0\\n\\xa0\\nBasic principles of GI management\\nSpecial situation: sexual violence\\n a \\xa0\\n b \\xa0\\nLook for a GI if a patient complains of: See\\nUrethral discharge\\nPainful or difﬁcult urination (dysuria)\\nUrethral discharge\\nAbnormal vaginal discharge\\nVulvar itching/burning\\nPain with intercourse (dyspareunia)\\nPainful or difﬁcult urination (dysuria)\\nAbnormal vaginal discharge\\nGenital blisters or sores\\nBurning sensation in the vulva or perineum\\nGenital ulcers\\nSkin growths in the genital (or anal) area Venereal warts\\nLower abdominal pain (in women) Lower abdominal pain\\nUpper genital tract infections\\nThe patient can be effectively treated without laboratory testing. Some tests may help in diagnosing vaginal and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 304, 'page_label': '305', 'id': 'data/guideline-170-en.pdf:304:2'}, page_content='urethral discharge, but they should never delay treatment (results should be available within one hour).\\nThe patient should be treated at his/her ﬁrst encounter with the health care provider (no patient should be sent\\nhome without treatment, e.g. while waiting for laboratory results).\\nSingle dose regimens are preferred when indicated.\\nIn the case of urethral discharge, abnormal vaginal discharge (except candidiasis), genital ulcers (except herpes) and\\nsexually transmitted upper genital tract infection, the sexual partner should receive a treatment. In the case of\\ncandidiasis, genital herpes and venereal warts, the partner is treated only if symptomatic.\\nPatients with sexually transmitted infections should receive information on their disease(s) and treatment and be'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 304, 'page_label': '305', 'id': 'data/guideline-170-en.pdf:304:3'}, page_content='counselled on risk reduction and HIV testing. Condoms should be provided for the duration of treatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 305, 'page_label': '306', 'id': 'data/guideline-170-en.pdf:305:0'}, page_content='Page 306 / 409\\nTaking into consideration the physical, psychological, legal and social consequences of sexual violence,\\xa0medical\\ncare\\xa0is not limited to the diagnosis and treatment of genital lesions or infections.\\nCare includes listening to the victim’s story, a complete physical examination, laboratory tests if available, and\\ncompletion of a medical certiﬁcate.\\nDuring the consultation, prophylactic or curative treatments must be proposed to the patient.\\xa0\\n\\xa0\\n\\xa0Mental health care is necessary irrespective of any delay between the event and the patient arriving for a consultation.\\nCare is based on immediate attention (one-on-one reception and listening) and if necessary, follow-up care with a view'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 305, 'page_label': '306', 'id': 'data/guideline-170-en.pdf:305:1'}, page_content='to detecting and treating any psychological and/or psychiatric sequelae (anxiety, depression, post-traumatic stress\\ndisorder, etc.). See Chapter 11.\\n\\xa0\\nProphylactic treatment:\\npriority is given to:\\na) the risk of HIV transmission. Start antiretroviral therapy as early as possible if the patient is seen within 48-\\n72 hours after exposure (see HIV infection and AIDS, Chapter 8);\\nb) the risk of pregnancy resulting from rape. Administer emergency contraception as soon as possible, ideally\\nwithin 72 hours after the rape :\\nlevonorgestrel PO, one 1.5 mg tablet single dose (including in women receiving HIV post-exposure\\nprophylaxis); double the dose (3 mg) only\\xa0if the patient was\\xa0already\\xa0taking an enzyme-inducing drug\\xa0(e.g.\\nrifampicin, carbamazepine, certain antiretrovirals) before the rape;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 305, 'page_label': '306', 'id': 'data/guideline-170-en.pdf:305:2'}, page_content='rifampicin, carbamazepine, certain antiretrovirals) before the rape;\\nor ulipristal PO, one 30 mg tablet single dose;\\nor a copper intrauterine device (except in case of active genital infection);\\n c \\xa0\\nprevention of sexually transmitted infections: a single dose of\\xa0azithromycin PO 2 g + ceftriaxone IM 500\\xa0mg\\n(or, if ceftriaxone is not available, ceﬁxime PO 400 mg). If necessary, treatment of trichomoniasis may be\\nstarted later than the other treatments (tinidazole or metronidazole PO, 2 g single dose);\\ntetanus prophylaxis and/or vaccination (see Tetanus, Chapter 7) if there are any wounds;\\nvaccination against hepatitis B (accelerated vaccination schedule, see Viral hepatitis, Chapter 8).\\nCurative treatment:\\nof any related pathologies/infections if the assault is not recent.\\nof wounds,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 305, 'page_label': '306', 'id': 'data/guideline-170-en.pdf:305:3'}, page_content='of any related pathologies/infections if the assault is not recent.\\nof wounds,\\nFootnotes\\n(a) GI may be sexually transmitted (e.g. gonorrhoea, chlamydia) or not (e.g. most cases of candidiasis).\\n(b) Keep in mind that in Schistosoma haematobium endemic areas, genital symptoms may also be due to, or associated with,genitourinary schistosomiasis (see Schistosomiasis, Chapter 6).\\n(c) Nevertheless, between 72 and 120 hours (5 days) after the rape, emergency contraception is still sufﬁciently effective to beadministered.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 306, 'page_label': '307', 'id': 'data/guideline-170-en.pdf:306:0'}, page_content='Page 307 / 409\\nUrethral discharge\\nLast updated: August 2022\\n\\xa0\\nUrethral discharge is seen almost exclusively in men. The principal causative organisms are Neisseria gonorrhoeae\\n(gonorrhoea) and Chlamydia trachomatis (chlamydia).\\nAbnormal discharge should be conﬁrmed by performing a clinical examination . In males, the urethra should be milked\\ngently if no discharge is visible. Furthermore, speciﬁcally check for urethral discharge in patients complaining of painful\\nor difﬁcult urination (dysuria).\\nCase management\\nLaboratory\\nTreatment of the patient\\n a \\nC. trachomatis cannot easily be identiﬁed in a ﬁeld laboratory. In the absence of validated rapid diagnostic tests,\\nthe treatment is empiric.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 306, 'page_label': '307', 'id': 'data/guideline-170-en.pdf:306:1'}, page_content='the treatment is empiric.\\nIn men, a methylene blue or Gram stained smear from a urethral swab may be used to detect gonococci (Gram\\nnegative intracellular diplococci).\\nIn women: same treatment as cervicitis.\\nIn men:\\nIf microscopy of a urethral smear has been performed: in the absence of gonococci, treat for chlamydia alone;\\nin the presence of gonococci, treat for chlamydia AND gonorrhoea.\\nWhen no laboratory is available, treat for chlamydia AND gonorrhoea as below:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 307, 'page_label': '308', 'id': 'data/guideline-170-en.pdf:307:0'}, page_content='Page 308 / 409\\n\\xa0If urethral discharge persists or reappears after 7 days:\\nTreatment of the partner\\nThe sexual partner receives the same treatment as the patient, whether or not symptoms are present.\\n\\xa0\\nTreatment for chlamydia \\xa0 Treatment for gonorrhoea\\nazithromycin PO: 1 g single dose\\nor\\ndoxycycline PO: 100 mg 2 times daily for\\n7 days\\nPLUS ceftriaxone IM: 500 mg single dose\\nor, if ceftriaxone is not available,\\nceﬁxime PO: 400 mg single dose\\nVerify that the patient has received an effective treatment (i.e. one of the combinations above).\\nGonococcal resistance is a possibility if another treatment (e.g. co-trimoxazole or kanamycin) has been\\nadministered: re-treat for gonorrhoea as above (chlamydia is rarely resistant).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 307, 'page_label': '308', 'id': 'data/guideline-170-en.pdf:307:1'}, page_content='administered: re-treat for gonorrhoea as above (chlamydia is rarely resistant).\\nIf an effective antibiotic therapy has been given, consider trichomoniasis (tinidazole or metronidazole PO, 2 g\\nsingle dose); also consider reinfection.\\nFootnotes\\n(a) In areas where lymphatic ﬁlariasis is endemic, be careful not to confuse purulent urethral discharge with milky or rice-waterurine (chyluria) suggestive of lymphatic ﬁlariasis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 308, 'page_label': '309', 'id': 'data/guideline-170-en.pdf:308:0'}, page_content='Page 309 / 409\\nAbnormal vaginal discharge\\nLast updated: August 2022\\n\\xa0\\nAbnormal vaginal discharge is deﬁned as discharge that\\xa0is different\\xa0from usual with respect to\\ncolour/odour/consistency\\xa0(e.g. discoloured or purulent or malodorous).\\xa0Abnormal discharge is often associated with vulvar pruritus or pain with intercourse (dyspareunia), or painful or difﬁcult\\nurination (dysuria) or lower abdominal pain. Routinely check for abnormal vaginal discharge in women presenting with\\nthese symptoms.\\xa0Abnormal vaginal discharge may be a sign of infection of the vagina (vaginitis) and/or the cervix (cervicitis) or upper\\ngenital tract infection.\\nAbnormal discharge must be clinically conﬁrmed: inspection of the vulva, speculum exam checking for cervical/vaginal\\ninﬂammation or discharge.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 308, 'page_label': '309', 'id': 'data/guideline-170-en.pdf:308:1'}, page_content='inﬂammation or discharge.\\nAbdominal and bimanual pelvic examinations should be performed routinely in all women presenting with vaginal\\ndischarge to rule out upper genital tract infection (lower abdominal pain and cervical motion tenderness).\\xa0The principal causative organisms are:\\nCase management\\nIn vaginitis: Gardnerella vaginalis and other bacteria (bacterial vaginosis), Trichomonas vaginalis (trichomoniasis)\\nand Candida albicans (candidiasis).\\nIn cervicitis: Neisseria gonorrhoeae (gonorrhoea) and Chlamydia trachomatis (chlamydia).\\nIn upper genital tract infections: see Upper genital tract infections.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 309, 'page_label': '310', 'id': 'data/guideline-170-en.pdf:309:0'}, page_content='Page 310 / 409\\n\\xa0\\nCervicitis may be difﬁcult to diagnose. When in doubt, administer treatment for cervicitis to women with abnormal\\nvaginal discharge and any of the following risk factors:\\nLaboratory\\nTreatment of the patient\\nCervicitis\\nTreat for both chlamydia AND gonorrhoea.\\xa0\\nUrethral discharge in the partner\\nContext of sexual violence or prostitution\\nNew partner or more than one partner in the preceding 3 months\\nXpert\\xa0molecular (PCR) tests\\xa0are recommended\\xa0for the detection\\xa0of\\xa0C. trachomatis\\xa0and\\xa0N.\\xa0gonorrhoea.\\xa0\\nMicroscopic examination of a fresh wet smear may show mobile\\xa0T. vaginalis, yeast cells and hyphae in candidiasis,\\nand “clue cells” in bacterial vaginosis.\\xa0\\nIdentiﬁcation of\\xa0N. gonorrhoeae\\xa0by\\xa0Gram-stained\\xa0smear is not sensitive in women and is not recommended.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 310, 'page_label': '311', 'id': 'data/guideline-170-en.pdf:310:0'}, page_content='Page 311 / 409\\n\\xa0\\nBacterial vaginosis and trichomoniasis\\ntinidazole PO: 2 g single dose\\nor metronidazole PO: 2 g single dose\\xa0In the case of treatment failure:\\ntinidazole PO: 500 mg 2 times daily for 5 days\\nor metronidazole PO: 400 to 500 mg\\xa02 times daily\\xa0for 7 days\\nVulvovaginal candidiasis\\nclotrimazole (500 mg vaginal tab): 1 tablet inserted deep into the vagina at bedtime, single dose\\xa0If the patient has extensive vulvar involvement, miconazole 2% cream (one application to the vulva 2 times daily for 7\\ndays) may be used in combination with the intravaginal treatment above. Miconazole cream may complement, but\\ndoes not replace, treatment with clotrimazole.\\nTreatment of the partner'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 310, 'page_label': '311', 'id': 'data/guideline-170-en.pdf:310:1'}, page_content='does not replace, treatment with clotrimazole.\\nTreatment of the partner\\nWhen the patient is treated for vaginitis or cervicitis, the partner receives the same treatment as the patient, whether\\nor not symptoms are present.\\xa0In the case of vulvovaginal candidiasis, the partner is treated only if symptomatic (itching and redness of the\\nglans/prepuce): miconazole 2% cream, one application 2 times daily for 7 days.\\nTreatment for chlamydia \\xa0 Treatment for gonorrhoea\\nNon-pregnant women\\nazithromycin PO: 1 g single dose\\nor\\ndoxycycline PO: 100 mg 2 times daily\\nfor 7 days\\nPLUS ceftriaxone\\xa0IM:\\xa0500\\xa0mg single dose\\xa0\\nor, if not available,\\nceﬁxime PO: 400 mg single dose\\nPregnant women\\nazithromycin PO: 1 g single dose\\nor\\nerythromycin PO: 1 g 2 times daily\\nor 500 mg 4 times daily for 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 310, 'page_label': '311', 'id': 'data/guideline-170-en.pdf:310:2'}, page_content='or\\nerythromycin PO: 1 g 2 times daily\\nor 500 mg 4 times daily for 7 days\\nPLUS ceftriaxone\\xa0IM:\\xa0500\\xa0mg single dose\\nor, if not available,\\nceﬁxime PO: 400 mg single dose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 311, 'page_label': '312', 'id': 'data/guideline-170-en.pdf:311:0'}, page_content='Page 312 / 409\\nGenital ulcers\\nGenital ulcers, deﬁned as single or multiple vesicular, ulcerative or erosive lesions of the genital tract, with or without\\ninguinal lymphadenopathy, should lead to consideration of sexually transmitted infection.\\nThe principal causative organisms are\\xa0Treponema pallidum\\xa0(syphilis),\\xa0Haemophilus ducreyi\\xa0(chancroid) and\\xa0Herpes\\nsimplex\\xa0(genital herpes).\\xa0Chlamydia trachomatis\\xa0(lymphogranuloma venereum) and\\xa0Calymmatobacterium\\ngranulomatis\\xa0(donovanosis) are less frequent.\\nCase management\\nLaboratory\\nLaboratory testing available in the ﬁeld is of little value: e.g., in syphilis, a negative RPR or VDRL result does not\\nexclude primary syphilis in early stage, and a positive test may reﬂect previous infection in a successfully treated\\npatient.\\nTreatment of the patient'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 311, 'page_label': '312', 'id': 'data/guideline-170-en.pdf:311:1'}, page_content='patient.\\nTreatment of the patient\\nGenital herpes\\n a \\xa0\\nLocal treatment: clean the area with soap and water.\\nAntiviral treatment:\\xa0aciclovir\\xa0PO'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 312, 'page_label': '313', 'id': 'data/guideline-170-en.pdf:312:0'}, page_content='Page 313 / 409\\nIn patients with a ﬁrst episode, treatment may reduce the duration of symptoms when given within 5 days after the\\nonset of symptoms: 400 mg 3 times daily for 7 days.\\nIn patients with recurrence, give the same dose for 5 days, but treatment is only effective if initiated during the\\nprodromal phase or within 24 hours after the onset of symptoms.\\nIn patients with frequent recurrences (more than 6 episodes par year), see\\xa0HIV infection and AIDS, Chapter 8.\\nSyphilis\\nbenzathine benzylpenicillin\\xa0IM: 2.4 MUI per injection (half the dose in each buttock) .\\nEarly syphilis\\xa0(primary, secondary, or early latent infection of less than 12 months duration):\\xa0single dose\\nLate\\xa0latent\\xa0syphilis\\xa0(infection of more than 12 months duration or of unknown duration): one injection\\xa0weekly\\xa0for 3\\nweeks'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 312, 'page_label': '313', 'id': 'data/guideline-170-en.pdf:312:1'}, page_content='weeks\\nor, for penicillin-allergic patients\\xa0or if penicillin is not available:\\nerythromycin\\xa0PO: 1 g 2 times daily or 500 mg 4 times daily for 14 days\\xa0(early syphilis) or 30 days (late\\xa0latent\\xa0syphilis)\\nor\\ndoxycycline\\xa0PO: 100 mg 2 times daily for 14 days\\xa0(early syphilis) or 30 days (late\\xa0latent\\xa0syphilis)\\nor\\xa0\\nazithromycin\\xa0PO: 2 g single dose (only in cases of\\xa0early syphilis and only if the strain is sensitive)\\nChancroid\\nazithromycin\\xa0PO: 1 g single dose\\nor\\nceftriaxone\\xa0IM: 250 mg single dose\\nor\\nerythromycin\\xa0PO: 1 g 2 times daily or 500 mg 4 times daily\\xa0for 7 days\\xa0Fluctuant lymph nodes may be aspirated through healthy skin as required. Do not incise and drain lymph nodes.\\xa0Note: treat simultaneously for syphilis AND chancroid as both are frequent, and cannot be correctly distinguished on'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 312, 'page_label': '313', 'id': 'data/guideline-170-en.pdf:312:2'}, page_content='clinical grounds.\\nLymphogranuloma venereum\\nerythromycin\\xa0PO: 1 g 2 times daily or 500 mg 4 times daily\\xa0for 14 days\\nor\\ndoxycycline\\xa0PO: 100 mg 2 times daily\\xa0for 14 days\\xa0Fluctuant lymph nodes may be aspirated through healthy skin as required. Do not incise and drain lymph nodes.\\nDonovanosis\\nTreatment is given until the complete disappearance of the lesions (usually, several weeks; otherwise risk of\\nrecurrence):\\nazithromycin\\xa0PO: 1 g on D1 then 500 mg once daily\\nor\\nerythromycin\\xa0PO:\\xa01 g 2 times daily or 500 mg 4 times daily\\nor\\ndoxycycline\\xa0PO: 100 mg 2 times daily\\xa0In HIV infected patients, add\\xa0gentamicin\\xa0IM: 6 mg/kg once daily.\\nTreatment of the partner\\nTreatment of\\xa0pain: paracetamol PO (Chapter 1).\\n [1] \\n b \\n [2]\\n b\\n b'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 313, 'page_label': '314', 'id': 'data/guideline-170-en.pdf:313:0'}, page_content='Page 314 / 409\\nThe sexual partner receives the same treatment as the patient, whether or not symptoms are present, except in the\\ncase of genital herpes (the partner is treated only if symptomatic).\\n\\xa0\\nReferences\\nFootnotes\\n(a) Lymphogranuloma venereum is endemic in East and West Africa, India, Southeast Asia, South America and the Caribbean.Donovanosis is endemic in South Africa, Papua New Guinea, India, Brazil and the Caribbean.\\n(b) Doxycycline is contra-indicated in pregnant and breast-feeding women.\\n1. Centers for Disease Control and Prevention.\\xa0Syphilis Pocket Guide for Providers.\\xa02017.https://www.cdc.gov/std/syphilis/Syphilis-Pocket-Guide-FINAL-508.pdf'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 313, 'page_label': '314', 'id': 'data/guideline-170-en.pdf:313:1'}, page_content='2. World Health Organization.\\xa0WHO guidelines for the treatment of\\xa0Treponema pallidum\\xa0(syphilis), Geneva, 2016.http://apps.who.int/iris/bitstream/handle/10665/249572/9789241549806-eng.pdf?sequence=1'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 314, 'page_label': '315', 'id': 'data/guideline-170-en.pdf:314:0'}, page_content='Page 315 / 409\\nLower abdominal pain in women\\nUpper genital tract infection should be suspected in women with lower abdominal pain (see Upper genital tract\\ninfections).\\nGynaecological examination should be routinely performed:\\n\\xa0If available, POCUS : perform FAST views to evaluate for free ﬂuid and urological abnormalities. Perform pelvic views\\nto evaluate for uterine and adnexal pathologies. Consult a gynaecologist\\xa0(local or via\\xa0telemedicine\\xa0services).\\xa0\\nCase management\\n\\xa0\\nInspection of the vulva, speculum examination: check for purulent discharge or inﬂammation.\\nAbdominal exam and bimanual pelvic exam: check for pain on mobilising the cervix.\\xa0\\n a \\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 315, 'page_label': '316', 'id': 'data/guideline-170-en.pdf:315:0'}, page_content='Page 316 / 409\\nUpper genital tract infections (UGTI)\\nLast update: March 2023\\n\\xa0\\nUpper genital tract infections are bacterial infections of the uterus (endometritis) and/or the fallopian tubes (salpingitis),\\nwhich may be complicated by peritonitis, pelvic abscess or septicaemia.\\nUGTI may be sexually transmitted or arise after childbirth or abortion. Antibiotic choices are directed by the most\\ncommon pathogens in each scenario.\\nIf peritonitis or pelvic abscess is suspected, request a surgical opinion while initiating antibiotic therapy.\\nClinical features\\nSexually transmitted infections\\nDiagnosis may be difﬁcult, as clinical presentation is variable.\\nInfections after childbirth or abortion\\nTreatment\\nSexually transmitted infections'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 315, 'page_label': '316', 'id': 'data/guideline-170-en.pdf:315:1'}, page_content='Treatment\\nSexually transmitted infections\\nSuggestive symptoms are: abdominal pain, abnormal vaginal discharge, fever, dyspareunia, menometrorrhagia,\\ndysuria.\\nInfection is probable when one or more of the above symptoms are associated with one or more of the following\\nsigns: cervical motion tenderness, adnexal tenderness, tender abdominal mass.\\nMost cases present with a typical clinical picture, developing within 2 to 10 days after delivery (caesarean section\\nor vaginal delivery) or abortion (spontaneous or induced):\\nFever, generally high\\nAbdominal or pelvic pain\\nMalodorous or purulent lochia\\nEnlarged, soft and/or tender uterus\\nCheck for retained placenta.\\nIn the early stages, fever may be absent or moderate and abdominal pain may be mild.\\nCriteria for hospitalisation include:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 315, 'page_label': '316', 'id': 'data/guideline-170-en.pdf:315:2'}, page_content='Criteria for hospitalisation include:\\nClinical suspicion of severe or complicated infection (e.g. peritonitis, abscess, septicaemia)\\nDiagnostic uncertainty (e.g. suspicion of extra-uterine pregnancy, appendicitis)\\nSigniﬁcant obstacles to ambulatory oral treatment\\nNo improvement after 48 hours, or deterioration within 48 hours, of outpatient treatment\\nAll other patients may be treated on an ambulatory basis. They should be reassessed routinely on the third day of\\ntreatment to evaluate clinical improvement (decrease in pain, absence of fever). If it is difﬁcult to organise routine\\nfollow-up, advise patients to return to clinic if there is no improvement after 48 hours of treatment, or sooner if their\\ncondition is worsening.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 315, 'page_label': '316', 'id': 'data/guideline-170-en.pdf:315:3'}, page_content='condition is worsening.\\nAntibiotic therapy combines 3 antibiotics to cover the most frequent causative organisms: gonococci, chlamydiae,\\nand anaerobes.\\nAmbulatory treatment:\\nceﬁxime\\xa0PO: 400 mg single dose or\\xa0ceftriaxone\\xa0IM: 500 mg single dose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 316, 'page_label': '317', 'id': 'data/guideline-170-en.pdf:316:0'}, page_content='Page 317 / 409\\nInfections after childbirth or abortion\\n\\xa0\\n+\\xa0doxycycline\\xa0PO: 100 mg 2 times daily for 14 days\\n+\\xa0metronidazole\\xa0PO: 500 mg 2 times daily for 14 days\\n a \\nTreatment in hospital:\\nceftriaxone\\xa0IM or IV : 1 g once daily\\n+\\xa0doxycycline\\xa0PO: 100 mg 2 times daily\\xa0for 14 days\\n+\\xa0metronidazole\\xa0PO or IV infusion: 500 mg 2 times daily\\xa0for 14 days\\nContinue triple therapy for 24 to 48 hours after signs and symptoms have improved (resolution of fever,\\ndecrease in pain), then continue doxycycline (or erythromycin) + metronidazole to complete 14 days of\\ntreatment.\\n b \\n a \\nIf an IUD is in place, it should be removed (offer another method of contraception).\\nAnalgesic treatment according to pain intensity.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 316, 'page_label': '317', 'id': 'data/guideline-170-en.pdf:316:1'}, page_content='Analgesic treatment according to pain intensity.\\nTreatment of the partner: single dose treatment for both gonorrhoea AND chlamydia (as for\\xa0Urethral discharge),\\nwhether or not symptoms are present.\\nAntibiotic therapy: treatment must cover the most frequent causative organisms: anaerobes, Gram negatives and\\nstreptococci.\\nAmbulatory treatment\\xa0(early stages only):\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO for 7 days\\nUse formulations in a ratio of 8:1 or 7:1 exclusively.\\xa0The dose is expressed in amoxicillin:\\nRatio 8:1: 3000 mg daily (2 tablets of 500/62.5 mg 3 times daily)\\nRatio 7:1: 2625 mg daily (1 tablet of 875/125 mg 3 times daily)\\nor\\namoxicillin\\xa0PO: 1 g 3 times daily +\\xa0metronidazole\\xa0PO: 500 mg 3 times daily doses for 7 days\\nTreatment in hospital:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 316, 'page_label': '317', 'id': 'data/guideline-170-en.pdf:316:2'}, page_content='Treatment in hospital:\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) IV (dose expressed in amoxicillin): 1 g every 8 hours\\n+\\xa0gentamicin\\xa0IM: 5 mg/kg once daily\\nor\\nampicillin\\xa0IV:\\xa02 g every 8 hours\\n+\\xa0metronidazole\\xa0IV infusion:\\xa0500 mg every 8 hours\\n+\\xa0gentamicin\\xa0IM: as above\\nStop antibiotic therapy 48 hours after resolution of fever and clinical signs and symptoms.\\nIn penicillin-allergic patients, use\\xa0clindamycin\\xa0IV (900 mg every 8 hours) +\\xa0gentamicin\\xa0(as above).\\nIn case of placental retention: perform digital curettage or manual vacuum extraction (refer to the guide\\xa0Essential\\nobstetric and newborn care, MSF) 24 hours after initiation of antibiotic therapy.\\nAnalgesic treatment according to pain intensity.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 316, 'page_label': '317', 'id': 'data/guideline-170-en.pdf:316:3'}, page_content='Analgesic treatment according to pain intensity.\\nIf the patient’s condition deteriorates or if fever persists after 48-72 hours of treatment, consider the possibility of\\ncomplication requiring additional treatment (e.g. pelvic abscess drainage), otherwise change the antibiotic to\\nceftriaxone + doxycycline + metronidazole as in hospital-based treatment of sexually transmitted UGTI.\\nFootnotes\\n(a) In pregnant/breastfeeding women: erythromycin\\xa0PO: 1 g 2 times daily or 500 mg 4 times daily for 14 daysSingle dose azithromycin is not effective against chlamydia in the treatment of sexually transmitted UGTI.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 316, 'page_label': '317', 'id': 'data/guideline-170-en.pdf:316:4'}, page_content='(b) The solvent of ceftriaxone for IM injection contains lidocaine. Ceftriaxone reconstituted using this solvent must never beadministered by IV route. For IV administration, water for injection must always be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 317, 'page_label': '318', 'id': 'data/guideline-170-en.pdf:317:0'}, page_content='Page 318 / 409\\nVenereal warts\\nVenereal warts are benign tumours of the skin or mucous membranes due to certain papilloma viruses (HPV).\\nClinical features\\nTreatment\\nChoice of treatment depends on the size and location of the warts. Treatment may be less effective, and relapses\\nmore frequent, in HIV infected patients.\\nExternal warts < 3 cm and vaginal warts\\npodophyllotoxin\\xa00.5% solution may be self-applied by the patient, but in the event of vaginal warts, the treatment\\nmust be applied by medical staff.\\xa0Explain the procedure to the patient: apply the solution to the warts using an applicator or cotton bud, sparing the\\nsurrounding healthy skin, allow to air dry. On vaginal warts, the solution should be allowed to dry before the speculum is\\nwithdrawn.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 317, 'page_label': '318', 'id': 'data/guideline-170-en.pdf:317:1'}, page_content='withdrawn.\\nApply the solution 2 times daily, 3 consecutive days per week, for up to 4 weeks.\\xa0Podophyllum preparations are contra-indicated in pregnant or breastfeeding women. They should not be applied on\\ncervical, intra-urethral, rectal, oral or extensive warts. Improper use may result in painful ulceration.\\nExternal warts > 3 cm; cervical, intra-urethral, rectal and oral warts; warts in pregnant orbreastfeeding women\\nSurgical excision or cryotherapy or electrocoagulation.\\n\\xa0\\nVenereal warts are soft, raised, painless growths, sometimes clustered (cauliﬂower- like appearance) or macules\\n(ﬂat warts), which are more difﬁcult to discern. Warts can be external (vulva, penis, scrotum, perineum, anus) and/or\\ninternal (vagina, cervix, urethra, rectum; oral cavity in HIV infected patients).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 317, 'page_label': '318', 'id': 'data/guideline-170-en.pdf:317:2'}, page_content='In women, the presence of external warts is an indication for a speculum examination to exclude vaginal or cervical\\nwarts. Speculum exam may reveal a friable, fungating tumour on the cervix, suggestive of cancer associated with\\npapilloma virus . a \\n b \\xa0\\n c \\xa0\\nFootnotes\\n(a) Certain types of HPV may cause cancer. Presence of genital warts in women is an indication to screen for precancerouslesions of the cervix, if feasible in the context (visual inspection with acetic acid, or cervical smear, or other availabletechniques), and to treat any lesions identiﬁed (cryotherapy, conisation, etc., according to diagnosis).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 317, 'page_label': '318', 'id': 'data/guideline-170-en.pdf:317:3'}, page_content='(b) Podophyllum 10%, 15% or 25% resin is another preparation which is much more caustic, and should be applied only bymedical staff. Protect the surrounding skin (vaseline or zinc oxide ointment) before applying the resin. Wash off with soapand water after 1 to 4 hours. Apply once weekly for 4 weeks.\\n(c) Treatment of warts is not an emergency and may be deferred if alternatives to podophyllum preparations are not available.Genital warts are not an indication for caesarean section: it is uncommon for warts to interfere with delivery, and the risk ofmother-to-child transmission is very low.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 318, 'page_label': '319', 'id': 'data/guideline-170-en.pdf:318:0'}, page_content='Page 319 / 409\\nMajor genital infections (summary)\\n\\xa0\\nLast updated: July 2021'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 319, 'page_label': '320', 'id': 'data/guideline-170-en.pdf:319:0'}, page_content='Page 320 / 409\\nPathogens/\\nInfections Clinical features Investigations Treatment\\nNeisseria\\ngonorrhoeae\\n(gonorrhoea)\\nIn women:\\nvaginal discharge, cervicitis\\n(mucopurulent cervical discharge),\\ndysuria (50% of infections are\\nasymptomatic);\\nUGTI (salpingitis, endometritis).\\nIn men: purulent urethral discharge\\nand sometimes dysuria (5 to 50% of\\ninfections are asymptomatic).\\nBest method is PCR\\n(Xpert), if available.\\nIn men (not sensitive\\nenough in women): Gram\\nor methylene blue stain:\\nintracellular diplococci\\nand polymorphonuclear\\nleukocytes (more than 4\\nper ﬁeld).\\nceftriaxone IM: 500 mg\\nsingle dose\\nor, if not available,\\nceﬁxime PO: 400 mg\\nsingle dose\\nTreat also for\\nchlamydia.\\nIn case of upper genital\\ntract infection, see \\nUGTI.\\nChlamydia\\ntrachomatis\\n(chlamydia)\\nIn women:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 319, 'page_label': '320', 'id': 'data/guideline-170-en.pdf:319:1'}, page_content='tract infection, see \\nUGTI.\\nChlamydia\\ntrachomatis\\n(chlamydia)\\nIn women:\\nvaginal discharge, cervicitis, and\\nrarely dysuria (> 50% of\\ninfections are asymptomatic);\\nUGTI (salpingitis, endometritis).\\nIn men: mild urethral discharge and/or\\ndysuria but up to 90% of infections\\nare asymptomatic.\\nThe best method is PCR\\n(Xpert), if available.\\nazithromycin PO: 1 g\\nsingle dose\\nor doxycycline PO :\\n200 mg daily for 7 days\\nTreat also for\\ngonococcal infection\\n(except when a Gram\\nstain in males or PCR\\nshows no N.\\ngonorrhoeae).\\nIn case of upper genital\\ntract infection, see \\nUGTI.\\n (a) \\nTrichomonas\\nvaginalis\\n(trichomoniasis)\\nIn women: yellow-green vaginal\\ndischarge, sometimes foul smelling,\\nvulvar irritation (10 to 50% of\\ninfections are asymptomatic).\\nIn men: most infections are\\nasymptomatic. Can produce'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 319, 'page_label': '320', 'id': 'data/guideline-170-en.pdf:319:2'}, page_content='In men: most infections are\\nasymptomatic. Can produce\\nbalanitis, urethritis with mild discharge\\nand sometimes dysuria.\\nWet mount of fresh\\nvaginal ﬂuid shows motile\\ntrichomonas (low\\nsensitivity).\\npH of urethral/vaginal\\nﬂuid > 4.5.\\ntinidazole or\\nmetronidazole PO: 2 g\\nsingle dose\\nBacterial\\nvaginosis\\n(Gardnerella\\nvaginalis and\\nother\\nassociated\\nbacteria)\\nDiagnosis is made in the presence of 3 of the following 4 signs:\\nHomogenous grey-white adherent vaginal discharge\\npH of vaginal ﬂuid > 4.5\\nVaginal ﬂuid has an amine (ﬁshy) odour, especially when mixed with\\n10% KOH\\nPresence of clue cells in wet mount or Gram stain of vaginal ﬂuid\\ntinidazole or\\nmetronidazole PO: 2 g\\nsingle dose\\nCandida\\nalbicans\\n(candidiasis)\\nMainly seen in women: pruritus and\\nvulvovaginitis, frequently creamy-'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 319, 'page_label': '320', 'id': 'data/guideline-170-en.pdf:319:3'}, page_content='Mainly seen in women: pruritus and\\nvulvovaginitis, frequently creamy-\\nwhite vaginal discharge, sometimes\\ndysuria.\\nSaline of KOH wet mount\\nof fresh vaginal ﬂuid\\nshows budding yeast\\ncells and pseudohyphae.\\nIn women:\\nclotrimazole 500\\nmg: one vaginal\\ntablet single dose'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 320, 'page_label': '321', 'id': 'data/guideline-170-en.pdf:320:0'}, page_content='Page 321 / 409\\nIn men: balanitis/balanoposthitis\\n(inﬂammation of the glans/prepuce,\\nerythema, pruritus, white pustules)\\nand rarely urethritis\\npH of vaginal ﬂuid:\\nnormal\\nIn men:\\nmiconazole 2%\\ncream:\\xa01\\xa0application\\n2 times\\xa0daily\\xa0for 7\\ndays\\nHerpes\\nsimplex\\nvirus type 2\\n(genital herpes)\\nMany asymptomatic carriers. Multiple\\nvesicles on genitals leading to painful\\nulcerations. In women, affects vulva,\\nvagina and cervix; in males, penis and\\nsometimes urethra. In primary episodes,\\nfever (30%) and lymphadenopathy\\n(50%). Recurrences in 1/3 of infections\\nwith shorter and milder symptoms.\\nDiagnosis by culture,\\nserology and PCR done\\nexclusively at a reference\\nlaboratory.\\nAnalgesics, local\\ndisinfection.\\nIf available, aciclovir\\nPO:\\nPrimary episode:\\n1200 mg daily for 7\\ndays, given within 5'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 320, 'page_label': '321', 'id': 'data/guideline-170-en.pdf:320:1'}, page_content='PO:\\nPrimary episode:\\n1200 mg daily for 7\\ndays, given within 5\\ndays after onset of\\nlesions.\\nRecurrent\\ninfections: same\\ndose for 5 days,\\ngiven within 24\\nhours after onset of\\nlesions.\\nTreponema\\npallidum\\n(syphilis)\\nSingle ﬁrm painless genital ulcer, often\\nunnoticed.\\nRPR/VDRL lack sensitivity\\nand speciﬁcity, but may be\\nuseful for following\\ntreatment effectiveness\\n(decrease in titer) or\\nconﬁrming re-infection (rise\\nin titer).\\nTreponemal tests (TPHA,\\nFTA-ABS, rapid tests such\\nas SD Bioline®) are more\\nsensitive and speciﬁc.\\nbenzathine\\nbenzylpenicillin IM:\\n2.4 MIU per injection,\\nsingle dose (syphylis <\\n12 months) or once\\nweekly for 3 weeks\\n(syphilis > 12 months or\\nunknown duration)\\nor azithromycin PO: 2\\ng single dose\\nor erythromycin PO: 2\\ng daily for 14 days\\nor doxycycline PO :\\n200 mg daily for 14'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 320, 'page_label': '321', 'id': 'data/guideline-170-en.pdf:320:2'}, page_content='g daily for 14 days\\nor doxycycline PO :\\n200 mg daily for 14\\ndays\\nTreat also for\\nchancroid.\\n (a) \\nHaemophilus\\nducreyi\\n(chancroid)\\nPainful single (or multiple) genital ulcer\\n(soft chancre, bleeds easily when\\ntouched).\\nPainful and voluminous inguinal\\nlymphadenitis in 50%. Fistulae develop in\\n25% of cases.\\nH. ducreyi bacillus is difﬁcult\\nto identify on microscopy or\\nby culture.\\nazithromycin PO: 1 g\\nsingle dose\\nor ceftriaxone IM: 250\\nmg single dose\\nor ciproﬂoxacin PO :\\n1 g daily for 3 days\\nor erythromycin PO: 2\\ng daily\\xa0for 7 days\\nTreat also for syphillis.\\n (b)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 321, 'page_label': '322', 'id': 'data/guideline-170-en.pdf:321:0'}, page_content='Page 322 / 409\\nHuman\\npapillomavirus\\n(venereal\\nwarts)\\nSoft, raised, painless growths,\\nsometimes clustered (acuminate\\ncondyloma) or macules (ﬂat warts).\\nWarts can be external (vulva, penis,\\nscrotum, perineum, anus) and/or internal\\n(vagina, cervix, urethra, rectum; oral\\ncavity in HIV infected patients).\\nThe diagnosis is based on\\nclinical features.\\nIt feasible in the context, the\\npresence of genital warts in\\nwomen in an indication to\\nscreen for pre-cancerous\\nlesions of the cervix (visual\\ninspection with acetic acid,\\nor cervical smear, or other\\navailable techniques).\\nExternal warts < 3\\ncm and vaginal\\nwarts:\\npodophyllotoxin\\n0.5%\\nExternal warts > 3\\ncm; cervical, intra-\\nurethral, rectal and\\noral warts; warts in\\npregnant or\\nbreastfeeding\\nwomen: surgical\\nexcision or\\ncryotherapy or'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 321, 'page_label': '322', 'id': 'data/guideline-170-en.pdf:321:1'}, page_content='pregnant or\\nbreastfeeding\\nwomen: surgical\\nexcision or\\ncryotherapy or\\nelectrocoagulation.\\n(a) Doxycycline is contra-indicated in pregnant women. It should not be administered to breast-feeding women if the treatmentexceeds 7 days (use erythromycin).\\n(b) Ciproﬂoxacin should be avoided in pregnant women.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 322, 'page_label': '323', 'id': 'data/guideline-170-en.pdf:322:0'}, page_content='Page 323 / 409\\nAbnormal uterine bleeding (in the absence ofpregnancy)\\nLast updated: October 2021\\n\\xa0\\n\\xa0For the management of pregnancy-related bleeding, refer to the guide\\xa0Essential obstetric and newborn care, MSF.\\nIn all events\\nAccording to clinical examination\\nHeavy menstrual bleeding or intermenstrual genital bleeding\\nIn women of childbearing age:\\nassess if the bleeding is pregnancy-related;\\nperform a pregnancy test.\\nRapidly assess the severity of bleeding.\\nPerform a pelvic examination:\\nspeculum examination: determine the origin (vagina, cervix, uterine cavity) and cause of the bleeding; appearance\\nof the cervix; amount and intensity of bleeding;\\nbimanual examination: look for cervical motion tenderness, uterine enlargement or irregularity.\\nAssess for recent trauma or surgical history.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 322, 'page_label': '323', 'id': 'data/guideline-170-en.pdf:322:1'}, page_content='Assess for recent trauma or surgical history.\\nMeasure haemoglobin, if possible, to prevent or treat anaemia.\\nIn the event of signs of shock, see Shock, Chapter 1.\\nIn the event of heavy bleeding:\\nstart an IV infusion of Ringer lactate;\\nmonitor vital signs (heart rate, blood pressure);\\nadminister : \\ntranexamic acid IV: 10 mg/kg (max. 600 mg) every 8 hours. When bleeding has been reduced, switch to\\ntranexamic acid PO: 1 g 3 times daily, until bleeding stops (max. 5 days).\\n [1] \\nif bleeding persists and/or in case or contraindication to tranexamic acid, administer one of the following two\\ndrugs (except if suspicion of cervical or endometrial cancer):\\nethinylestradiol/levonorgestrel PO (0.03 mg/0.15 mg tab): one tablet 3 times daily for 7 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 322, 'page_label': '323', 'id': 'data/guideline-170-en.pdf:322:2'}, page_content='or medroxyprogesterone acetate PO: 20 mg 3 times daily for 7 days\\nIn case of massive haemorrhage and/or lack of response to medical management: surgical management (dilation\\nand curettage, intrauterine balloon, and as a last resort, hysterectomy).\\nIn the event of referral to a surgical facility, difﬁcult transport conditions may aggravate the bleeding: the patient\\nshould have an IV line and/or be accompanied by family members who are potential blood donors.\\nIf available, POCUS : perform FAST to evaluate for free ﬂuid and/or urological abnormalities; perform pelvic views\\nto evaluate for uterine and/or adnexal pathologies.\\n a \\nFriable, hard, ulcerated, hypertrophic mass on the cervix: possible cervical cancer; surgical treatment,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 322, 'page_label': '323', 'id': 'data/guideline-170-en.pdf:322:3'}, page_content='chemotherapy, radiation therapy or palliative care is required depending on the stage of the cancer. While waiting\\nfor appropriate treatment, tranexamic acid PO (1 g 3 times daily for 5 days max.) may be used to reduce bleeding.\\nInﬂammation of the cervix, light or moderate bleeding, purulent cervical discharge, pelvic pain: consider cervicitis\\n(see Abnormal vaginal discharge) or salpingitis (see Upper genital tract infections).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 323, 'page_label': '324', 'id': 'data/guideline-170-en.pdf:323:0'}, page_content='Page 324 / 409\\n\\xa0Note: rule out other causes of vaginal bleeding before diagnosing functional uterine bleeding. Consider for example\\npoorly tolerated contraceptive, endometrial cancer in postmenopausal women, genitourinary schistosomiasis in\\nendemic areas (see Schistosomiasis, Chapter 6).\\n\\xa0\\nReferences\\nEnlarged, irregular uterus: uterine ﬁbroids. In case of failure to respond to medical treatment, surgical management\\nis required. While waiting for surgery or if surgery is not indicated, treat as for functional uterine bleeding.\\nNormal uterus and cervix: possible functional uterine bleeding: tranexamic acid PO as above. In case of repeated\\nbleeding, it can be combined with an NSAID (ibuprofen PO for 3 to 5 days, see Pain, Chapter 1) and/or one of the\\nfollowing long-term treatments:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 323, 'page_label': '324', 'id': 'data/guideline-170-en.pdf:323:1'}, page_content='following long-term treatments:\\nlevonorgestrel intrauterine device\\nor ethinylestradiol/levonorgestrel PO (0.03 mg/0.15 mg tab): one tablet daily\\nor\\xa0medroxyprogesterone acetate IM: 150 mg every 3 months\\nor\\xa0medroxyprogesterone acetate PO : 10 mg once daily (up to 30 mg once daily if necessary) for 21 days\\nmonthly.\\n b \\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.\\n(b) Unlike the other treatments, this drug has no contraceptive effect.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 323, 'page_label': '324', 'id': 'data/guideline-170-en.pdf:323:2'}, page_content='(b) Unlike the other treatments, this drug has no contraceptive effect.\\n1. American College of Obstetricians and Gynecologists. Management of acute abnormal uterine bleeding in nonpregnantreproductive-aged women. Obstet Gynecol. 2013 Apr;121(4):891-6.\\xa0https://www.acog.org/-/media/project/acog/acogorg/clinical/ﬁles/committee-opinion/articles/2013/04/management-of-acute-abnormal-uterine-bleeding-in-nonpregnant-reproductive-aged-1.pdf'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 324, 'page_label': '325', 'id': 'data/guideline-170-en.pdf:324:0'}, page_content='Page 325 / 409\\nChapter 10: Medical and minor surgicalprocedures\\nDressings\\nTreatment of a simple wound\\nBurns\\nCutaneous abscess\\nPyomyositis\\nLeg ulcers\\nNecrotising infections of the skin and soft tissues\\nVenomous bites and stings\\nDental infections'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 325, 'page_label': '326', 'id': 'data/guideline-170-en.pdf:325:0'}, page_content='Page 326 / 409\\nDressings\\nThe objective of dressing wounds is to promote healing. The procedure includes cleaning, disinfection and protection\\nof the wound while respecting the rules of hygiene.\\nNot all wounds need to be covered by a dressing (e.g. a clean wound that has been sutured for several days; a small\\ndry wound not requiring sutures).\\nEquipment\\nSterile instruments\\n\\xa0Instruments for one dressing for one patient must be wrapped together in paper or fabric (or can be placed in a metallic\\nbox) and sterilised together to limit handling and breaks in asepsis. 5 to 10 compresses may be included in this set.\\nIf there are no sterile instruments, a dressing can be done using sterile gloves.\\nRenewable supplies\\nOrganisation of care'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 325, 'page_label': '326', 'id': 'data/guideline-170-en.pdf:325:1'}, page_content='Renewable supplies\\nOrganisation of care\\nProper organization of care helps maintain the rules of asepsis and decreases the risk of contamination of the wound\\nor transmission of organisms from one patient to another:\\nTechnique\\nOne Kocher or Pean forceps\\nOne dissecting forceps\\nOne pair of surgical scissors or one scalpel to excise necrotic tissue and to cut gauze or sutures\\nSterile compresses\\nNon-sterile disposable gloves\\nAdhesive tape and/or crepe or gauze bandage\\nSterile 0.9% sodium chloride or sterile water\\nDepending on the wound: antiseptic (7.5%\\xa0povidone iodine scrub solution,\\xa010%\\xa0povidone iodine dermal solution),\\nparafﬁn compresses, analgesics\\nAssign one room for dressings. It must be cleaned and the waste removed every day. The dressing table must be\\ndisinfected after each patient.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 325, 'page_label': '326', 'id': 'data/guideline-170-en.pdf:325:2'}, page_content='disinfected after each patient.\\nDressings may be applied at the bedside if the patient’s condition requires. Use a clean, disinfected dressing trolley\\nwith: on the upper tray, sterile and/or clean material (dressing set, extra compresses, etc.) and on the lower tray,\\nseptic material (container for contaminated instruments, sharps disposal container and a container or garbage bag\\nfor waste).\\nPrepare all the necessary material in a well lit area. If necessary, arrange for an assistant to be present.\\nWear protective glasses if there is a risk of projection from an oozing wound.\\nAlways proceed from clean to dirty: start with patients with uninfected wounds. If there are multiple dressings for\\none patient, start with the cleanest wound.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 325, 'page_label': '326', 'id': 'data/guideline-170-en.pdf:325:3'}, page_content='one patient, start with the cleanest wound.\\nIf the procedure may be painful, give an analgesic and wait the necessary time for the drug to take effect before\\nstarting the procedure.\\nSettle the patient comfortably in an area where his privacy is respected throughout the procedure.\\nExplain the procedure to the patient and obtain his co-operation.\\nInstruments (or sterile gloves) must be changed between patients.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 326, 'page_label': '327', 'id': 'data/guideline-170-en.pdf:326:0'}, page_content='Page 327 / 409\\nRemoval of an old dressing\\nObserve the wound\\n\\xa0\\n\\xa0In any case, if local signs of infection are observed, look for general signs of infection (fever, chills, changes in the\\noverall condition).\\nTechnique for cleaning and dressing of the wound\\nTo prevent drug interactions, use the same antiseptic for all care of one patient.\\nWash hands (ordinary soap) or disinfect them with an alcohol-based hand rub.\\nPut on non-sterile gloves and remove the adhesive tape, bandage and superﬁcial compresses.\\nProceed gently with the last compresses. If they stick to the wound, loosen them with 0.9% sodium chloride or\\nsterile water before removal.\\nObserve the soiled compresses. If there is signiﬁcant discharge, a greenish colour or a foul odour, a wound infection\\nis likely.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 326, 'page_label': '327', 'id': 'data/guideline-170-en.pdf:326:1'}, page_content='is likely.\\nDiscard the dressing and the non-sterile gloves in the waste container.\\nIn the case of an open wound, loss of cutaneous tissue or ulcer, the colour is an indicator of the stage in the healing\\nprocess:\\nblack\\xa0area = necrosis, wet or dry infected eschar\\nyellow\\xa0or\\xa0greenish\\xa0area = infected tissue and presence of pus\\nred\\xa0area = granulation, usually a sign of healing (unless there is hypertrophy), however, red edges indicate\\ninﬂammation or infection\\npink\\xa0area = process of epithelisation, the ﬁnal stage of healing that begins at the edges of the wound\\nIn the case of a sutured wound, the existence of local signs of suppuration and pain requires the removal of one or\\nmore sutures to avoid the infection spreading. Local signs include:\\nred, indurated and painful edges'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 326, 'page_label': '327', 'id': 'data/guideline-170-en.pdf:326:2'}, page_content='red, indurated and painful edges\\ndrainage of pus between the sutures, either spontaneously or when pressure is applied on either side of the\\nwound\\nlymphangitis\\nsub-cutaneous crepitations around the wound\\nWash hands again or disinfect them with an alcohol-based hand rub.\\nOpen the dressing set or box after checking the date of sterilisation and that the wrapping is intact.\\nPick up one of the sterile forceps being careful not to touch anything else.\\nPick up the second forceps with the help of the ﬁrst one.\\nMake a swab by folding a compress in 4 using the forceps.\\nClean sutured wound or clean open wound with red granulation:\\nclean with 0.9% sodium chloride or sterile water to remove any organic residue; work from the cleanest to the\\ndirtiest area (use a clean swab for each stroke);'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 326, 'page_label': '327', 'id': 'data/guideline-170-en.pdf:326:3'}, page_content='dirtiest area (use a clean swab for each stroke);\\ndab dry with a sterile compress;\\nre-cover a sutured wound with sterile compresses or an open wound with parafﬁn compresses; the dressing\\nshould extend a few cm beyond the edges of the wound;\\nkeep the dressing in place with adhesive tape or a bandage.\\nNecrotic or infected open wounds:\\nclean with\\xa0povidone\\xa0iodine (7.5% scrub solution, 1 part of solution + 4 parts of sterile 0.9% sodium chloride or\\nsterile water). Rinse thoroughly then dab dry with a sterile compress; or if not available, sterile 0.9% sodium\\nchloride or sterile water and apply an antiseptic (10%\\xa0povidone\\xa0iodine dermal solution).\\napply sterile vaseline and remove all necrotic tissue at each dressing change until the wound is clean.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 327, 'page_label': '328', 'id': 'data/guideline-170-en.pdf:327:0'}, page_content='Page 328 / 409\\n\\xa0The principles remain the same if the dressing is done using instruments or sterile gloves.\\nSubsequent dressings\\nDiscard any sharp materials used in an appropriate sharps container and the rest of the waste in a waste container.\\nAs quickly as possible, soak the instruments in disinfectant.\\nWash hands again or disinfect them with an alcohol-based hand rub.\\nClean, sutured wound: remove the initial dressing after 5 days if the wound remains painless and odourless, and if\\nthe dressing remains clean. The decision to re-cover or to leave the wound uncovered (if it is dry) often depends on\\nthe context and local practices.\\nInfected, sutured wound: remove one or more sutures and evacuate the pus. Change the dressing at least once\\ndaily.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 327, 'page_label': '328', 'id': 'data/guideline-170-en.pdf:327:1'}, page_content='daily.\\nOpen, dirty wound: daily cleaning and dressing change.\\nOpen granulating wound: change the dressing every 2 to 3 days, except if the granulation is hypertrophic (in this\\ncase, apply local corticosteroids).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 328, 'page_label': '329', 'id': 'data/guideline-170-en.pdf:328:0'}, page_content='Page 329 / 409\\nTreatment of a simple wound\\nA simple wound is a break in the continuity of the skin limited in depth at the sub-cutaneous fatty tissue, that does not\\naffect the underlying structures (muscle, bone, joints, major arteries, nerves, tendons) and without signiﬁcant loss of\\ntissue.\\xa0The goal of treatment is to assure rapid healing of the wound without complications or sequelae. Several basic rules\\napply:\\nEquipment\\nInstruments\\n(Figures 1a to 1d)\\xa0\\n\\xa0Instruments to suture one wound for one patient must be packaged and sterilised together (suture box or set) to limit\\nhandling and breaks in asepsis.\\nRenewable supplies\\nTechnique\\nInitial cleaning\\nrapidly treat wounds, while maintaining the rules of asepsis and the order of the initial procedures: cleaning-\\nexploration-excision;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 328, 'page_label': '329', 'id': 'data/guideline-170-en.pdf:328:1'}, page_content='exploration-excision;\\nidentify wounds that need to be sutured and those for which suturing would be harmful or dangerous;\\nimmediately suture recent, clean, simple wounds (less than 6 hours old) and delay suturing contaminated wounds\\nand/or those more than 6 hours old;\\nprevent local (abscess) or general (gas gangrene; tetanus) infections.\\nOne dissecting forceps, one needle-holder, one pair of surgical scissors and one Pean or Kocher forceps are\\nusually enough.\\nOne or two other artery forceps, a pair of Farabeuf retractors and a scalpel may be useful for a contused or deep\\nwound.\\nFor local anaesthesia: sterile syringe and needle; 1% lidocaine (without epinephrine)\\nSterile gloves, fenestrated sterile towel\\nSterile absorbable and non-absorbable sutures\\nAntiseptic and supplies for dressings'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 328, 'page_label': '329', 'id': 'data/guideline-170-en.pdf:328:2'}, page_content='Antiseptic and supplies for dressings\\nFor drainage: corrugated rubber drain or equivalent, nylon suture\\nSettle the patient comfortably in an area with good lighting and ensure all the necessary material is prepared.\\nExplain the procedure to the patient and ensure his co-operation.\\nIf the patient is a young child, arrange to have an assistant hold the child if necessary.\\nWear suitable clothing: sterile gloves for all wounds and a gown and protective glasses if there is a risk of projection\\nfrom a bleeding wound.\\nStart by washing the wound, prolong the cleaning if the wound is particularly soiled. Use ordinary soap\\nor\\xa07.5%\\xa0povidone iodine scrub solution and water and rinse.\\nIf necessary use a sterile brush. Cleaning with running water is preferable to cleaning by immersion.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 329, 'page_label': '330', 'id': 'data/guideline-170-en.pdf:329:0'}, page_content='Page 330 / 409\\nExploration\\nWound excision\\nImmediate suturing of a simple wound\\nDelayed suturing of a simple wound\\nHealing by second intention of infected wounds\\nIf the wound is infected and the patient has general signs of infection (fever, chills, changes in the overall condition)\\nsystemic antibiotic therapy may be required. Administer antibiotics at least one hour prior to starting care.\\nWash hands and put on sterile gloves.\\nDisinfect the wound and surrounding area with\\xa010% povidone iodine.\\nCover the wound with a fenestrated sterile towel.\\nLocal anaesthetic: inﬁltrate\\xa01% lidocaine\\xa0into the edges of the wound and wait at least 2 minutes for the\\nanaesthetic to take effect.\\nProceed carefully from the superﬁcial to the deepest parts of the wound to explore the extent of the wound, if'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 329, 'page_label': '330', 'id': 'data/guideline-170-en.pdf:329:1'}, page_content='necessary, aided by an assistant.\\nConsider the anatomical location of the wound and look for injury to any underlying structures (the clinical\\nexamination of a limb must include evaluation of sensitivity and motor functioning, as well as that of tendons in\\norder to orient surgical exploration):\\na wound that communicates with a fracture is an open fracture,\\na wound close to a joint may be a joint wound,\\na wound on the hands or feet may affect the nerves and/or tendons,\\na wound close to a major artery may be an arterial wound even if it is no longer bleeding.\\nLook for and remove any foreign bodies.\\nIn the event of signiﬁcant pain or bleeding, the exploration must be completed in an operating room.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 329, 'page_label': '330', 'id': 'data/guideline-170-en.pdf:329:2'}, page_content='The goal of the excision is to remove non-viable tissue, which favours the proliferation of bacteria and infection.\\nThe wound may require little or no excision if it is clean. The excision is more extensive if the wound is bruised,\\nirregular or extensive.\\nLimit excision of the skin around the wound, particularly in facial wounds.\\nSub-cutaneous fat and tissue of doubtful viability should be generously excised in order to leave only well\\nvascularised tissue.\\nImmediate suturing may have serious consequences for the patient if precautions to prevent infection and promote\\nhealing are not taken.\\nThe decision to suture immediately can only be taken after the cleaning, exploration and satisfactory excision, and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 329, 'page_label': '330', 'id': 'data/guideline-170-en.pdf:329:3'}, page_content='if the following conditions are met: simple wound, no more than 6 hours old with no devitalised or contused tissue\\n(the wound may be as long as 24 hours old if on the face, scalp, upper limbs or hands).\\nBites (for local treatment see\\xa0Rabies, Chapter 8) and bullet, shell or mine shrapnel wounds should not be\\nimmediately sutured.\\nWounds that do not ﬁll the above conditions should not be immediately sutured.\\nAfter cleaning, exploration and excision a simple dressing is applied to the open wound.\\nFurther cleaning and removal of any remaining necrotic tissue is completed with daily dressing changes.\\nIf after 72 hours there are no signs of local infection, the wound may be sutured.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 330, 'page_label': '331', 'id': 'data/guideline-170-en.pdf:330:0'}, page_content='Page 331 / 409\\nIf the wound does not meet the conditions of cleanliness described above, the wound cannot be sutured. It will heal\\neither spontaneously (healing by secondary intention), or will require a skin graft (once the wound is clean) if there is\\nsigniﬁcant loss of tissue.\\xa0Figures 1\\xa0:\\xa0Basic instruments\\nFigures 2\\xa0:\\xa0How to hold instruments\\nFigure 1a\\nKocher forceps, \\nstraight, toothed\\nFigure 1b\\nKelly forceps, \\ncurved, non-toothed\\nFigure 1c\\nSmall artery forceps,\\ncurved, non-toothed\\n \\nFigure 1d \\nFarabeuf retractors'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 331, 'page_label': '332', 'id': 'data/guideline-170-en.pdf:331:0'}, page_content='Page 332 / 409\\nFigures 3\\xa0:\\xa0Wound debridement\\nThis should be done sparingly, limited to excision of severely contused or lacerated tissue that is clearly becoming\\nnecrotic.\\nFigure 2a\\nAlways mount a surgical blade using a needle holder. \\nChange the blade for each new procedure.\\nFigure 2b \\nDissecting forceps should not be held in the palm of the hand,\\nbut rather between the thumb and index ﬁnger. \\nToothed dissecting forceps should only be used on skin.\\nFigure 2c\\nInsert the thumb and the ring ﬁnger into the handle of a needle holder (or scissors), and stabilize the instrument using\\nthe index ﬁnger.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 332, 'page_label': '333', 'id': 'data/guideline-170-en.pdf:332:0'}, page_content='Page 333 / 409\\nFigures 4\\xa0:\\xa0Practising making knots using forceps\\nFigure 3a\\nDebridement of a contused, ragged wound: straightening of the wound edges with a scalpel. Be conservative in\\nfacial wounds.\\nFigure 3b \\nExcision of edges of the aponeurosis to prevent necrosis.\\nFigure 3c\\nExcision of contused muscle.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 333, 'page_label': '334', 'id': 'data/guideline-170-en.pdf:333:0'}, page_content='Page 334 / 409\\nFigure 4a\\nLoop the suture around the needle holder in one direction and remember the direction of the loop. Grasp the loose\\nend with the needle holder\\nand pull it through the loop to make the ﬁrst knot.\\nLower the knot so that it closes the wound.\\nFigure 4b\\nThe second loop should be in the opposite direction. At least 3 knots are needed to make a suture, alternating form\\none direction to the other.\\nFigure 4c\\nIn principle the ﬁrst knot lies ﬂat. \\n\\xa0\\nFigure 4d\\nSecond knot in the opposite direction.\\nFigure 4e\\n Figure 4f'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 334, 'page_label': '335', 'id': 'data/guideline-170-en.pdf:334:0'}, page_content='Page 335 / 409\\nFigures 5\\xa0:\\xa0Particular problems\\nGrasp the loose end with the needle holder.\\nFigure 4g\\nFist ﬂat knot.\\nSlide the knot towards the wound using the hand holding \\nthe loose end while holding the other end with the needle holder.\\nTighten the knot without causing tissue ischaemia.\\nFigure 4h\\n Figure 4i\\nSecond knot in the opposite direction.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 335, 'page_label': '336', 'id': 'data/guideline-170-en.pdf:335:0'}, page_content='Page 336 / 409\\nFigure 6\\xa0:\\xa0Closing a corner\\nFigure 7\\xa0:\\xa0Closure of the skin, simple interrupted sutures with non-absorbable sutures\\nFigure 5a\\n Figure 5b\\nThe suture should be as deep as it is wide.\\nFigure 5c\\n Figure 5d\\nThe suture is too shallow, the edges are invaginated.\\nFigure 5e \\nPoor lining of the edges. \\n\\xa0\\nFigure 5f \\nDo not make the knot directly over the wound.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 336, 'page_label': '337', 'id': 'data/guideline-170-en.pdf:336:0'}, page_content='Page 337 / 409\\nBurns\\nLast updated: August 2022\\n\\xa0\\nBurns are cutaneous lesions caused by exposure to heat, electricity, chemicals or radiation. They cause signiﬁcant pain\\nand may threaten survival and/or compromise function.\\nClassiﬁcation of burns\\nSevere burns: one or more of the following parameters:\\n\\xa0Minor burns: involving less than 10% of the BSA in children and 15% in adults, in the absence of other risk factors\\nEvaluation of burns\\nExtent of burns\\nLund-Browder table – Percentage of body surface area according to age\\xa0\\nInvolving more than 10% of the body surface area (BSA) in children and 15% in adults\\nInhalation injury (smoke, hot air, particles, toxic gas, etc.)\\nMajor concomitant trauma (fracture, head injury, etc.)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 336, 'page_label': '337', 'id': 'data/guideline-170-en.pdf:336:1'}, page_content='Major concomitant trauma (fracture, head injury, etc.)\\nLocation: face, hands, neck, genitalia/perineum, joints (risk of functional deﬁcit)\\nElectrical and chemical burns or burns due to explosions\\nAge < 3 years or > 60 years or signiﬁcant co-morbidities (e.g. epilepsy, malnutrition)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 337, 'page_label': '338', 'id': 'data/guideline-170-en.pdf:337:0'}, page_content='Page 338 / 409\\n\\xa0This table helps to accurately calculate the % of BSA involved according to patient’s age: e.g. burn of the face,\\nanterior trunk, inner surface of the lower arm and circumferential burn of left upper arm in a child 2 years of age: 8.5 +\\n13 + 1.5 + 4 = 27% BSA.\\nDepth of burns\\nLocation < 1 year 1-4 years 5-9 years 10-15 years Adults\\nHead 19 17 13 10 7\\nNeck 2 2 2 2 2\\nAnterior trunk 13 13 13 13 13\\nPosterior trunk 13 13 13 13 13\\nRight buttock 2.5 2.5 2.5 2.5 2.5\\nLeft buttock 2.5 2.5 2.5 2.5 2.5\\nPerineum/genitalia 1 1 1 1 1\\nRight upper arm 4 4 4 4 4\\nLeft upper arm 4 4 4 4 4\\nRight lower arm 3 3 3 3 3\\nLeft lower arm 3 3 3 3 3\\nRight hand 2.5 2.5 2.5 2.5 2.5\\nLeft hand 2.5 2.5 2.5 2.5 2.5\\nRight thigh 5.5 6.5 8.5 8.5 9.5\\nLeft thigh 5.5 6.5 8.5 8.5 9.5\\nRight leg 5 5 5.5 6 7'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 337, 'page_label': '338', 'id': 'data/guideline-170-en.pdf:337:1'}, page_content='Left thigh 5.5 6.5 8.5 8.5 9.5\\nRight leg 5 5 5.5 6 7\\nLeft leg 5 5 5.5 6 7\\nRight foot 3.5 3.5 3.5 3.5 3.5\\nLeft foot 3.5 3.5 3.5 3.5 3.5'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 338, 'page_label': '339', 'id': 'data/guideline-170-en.pdf:338:0'}, page_content='Page 339 / 409\\nApart from ﬁrst-degree burns (painful erythema of the skin and absence of blisters) and very deep burns (third-degree\\nburns, carbonization), it is not possible, upon initial examination, to determine the depth of burns. Differentiation is\\npossible after D8-D10.\\xa0\\n\\xa0\\nEvaluation for the presence of inhalation injury\\nDyspnoea with chest wall indrawing, bronchospasm, soot in the nares or mouth, productive cough, carbonaceous\\nsputum, hoarseness, etc.\\nTreatment of severe burns\\nI. Initial management\\nOn admission\\nOnce the patient is stabilized\\n\\xa0 Superﬁcial burn on D8-D10 Deep burn on D8-D10\\nSensation Normal or pain Insensitive or diminished sensation\\nColour Pink, blanches with pressure White, red, brown or black\\nDoes not blanch with pressure\\nTexture Smooth and supple Firm and leathery'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 338, 'page_label': '339', 'id': 'data/guideline-170-en.pdf:338:1'}, page_content='Does not blanch with pressure\\nTexture Smooth and supple Firm and leathery\\nAppearance Minimal ﬁbrinous exudate\\nGranulation tissue evident\\nBleeds when incised\\nCovered with ﬁbrinous exudate\\nLittle or no bleeding when incised\\nHealing Heals spontaneously within 5-\\n15 days\\nVery deep burn: always requires surgery (no\\nspontaneous healing)\\nIntermediate burn: may heal spontaneously in 3 to 5\\nweeks; high risk of infection and permanent sequelae\\nEnsure airway is patent; high-ﬂow oxygen, even when\\xa0SpO\\xa0is normal.2\\nEstablish IV access, through unburned skin if possible (intraosseous access if IV access is not possible).\\nRinger lactate\\xa0(RL): 20 ml/kg during the ﬁrst hour, even if the patient is stable.\\nMorphine\\xa0SC: 0.2 mg/kg (Step 1 and Step 2 analgesics are not effective).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 338, 'page_label': '339', 'id': 'data/guideline-170-en.pdf:338:2'}, page_content='Morphine\\xa0SC: 0.2 mg/kg (Step 1 and Step 2 analgesics are not effective).\\nIn the event of chemical burns: ﬂush with copious amounts of water for 15 to 30 minutes, avoiding contamination of\\nhealthy skin; do not attempt to neutralize the chemical agent.\\nRemove clothes if they are not adherent to the burn.\\nTake history of the burn injury: mechanism, causative agent, time, etc.\\nAssess the burn injury: extent, depth, carbonization; ocular burns, burns at risk of secondary functional deﬁcits;\\ncircumferential burns of the extremities, chest or neck. Wear face mask and sterile gloves during the examination.\\nAssess for associated injuries (fractures, etc.).\\nProtect the patient and keep him warm: clean/sterile sheet, survival blanket.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 338, 'page_label': '339', 'id': 'data/guideline-170-en.pdf:338:3'}, page_content='Protect the patient and keep him warm: clean/sterile sheet, survival blanket.\\nInsert a urinary catheter if burns involve > 15% of BSA, and in the case of electrical burns or burns of the\\nperineum/genitalia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 339, 'page_label': '340', 'id': 'data/guideline-170-en.pdf:339:0'}, page_content='Page 340 / 409\\nNotes:\\nII. General measures during the ﬁrst 48 hours\\nResuscitative measures\\nIntravenous replacement ﬂuid to correct hypovolaemia:\\xa0Fluid and electrolyte requirements during the ﬁrst 48 hours according to age\\xa0\\nNote: increase replacement volumes by 50% (3 ml/kg x % BSA for the ﬁrst 8 hours) in the event of inhalation injury or\\nelectrical burn. For burns > 50% BSA, limit the calculation to 50% BSA.\\nThis formula provides a guide only and should be adjusted according to systolic arterial pressure (SAP) and urine\\noutput. Avoid ﬂuid overload. Reduce replacement ﬂuid volumes if urine output exceeds the upper limit.\\nTarget endpoints for IV replacement ﬂuids\\nInsert a nasogastric tube if burns involve > 20% of BSA (in the operating room while carrying out dressing\\nprocedure).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 339, 'page_label': '340', 'id': 'data/guideline-170-en.pdf:339:1'}, page_content='procedure).\\nCalculate and initiate ﬂuid and electrolyte requirements for the ﬁrst 24 hours.\\nIntensive monitoring: level of consciousness,\\xa0heart rate, blood pressure,\\xa0SpO, respiratory rate (RR) hourly;\\ntemperature and urine output every 4 hours.\\n2\\nAdditional testing: haemoglobin, blood group, urine dipstick test.\\nPrepare the patient for the ﬁrst dressing procedure in the operating room.\\nBurns do not bleed in the initial stage: check for haemorrhage if haemoglobin level is normal or low.\\nBurns alone do not alter the level of consciousness. In the case if altered consciousness, consider head injury,\\nintoxication, postictal state in epileptic patients.\\nClinical manifestations of electrical burns vary signiﬁcantly according to the type of current. Look for complications'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 339, 'page_label': '340', 'id': 'data/guideline-170-en.pdf:339:2'}, page_content='(arrhythmia, rhabdomyolysis, neurological disorders).\\n\\xa0 Children < 12 years Children ≥ 12 years and adults\\n0 - 8 h 2 ml/kg x % BSA of RL\\n+ maintenance ﬂuid per hour x 8 h (a) \\n2 ml/kg x % BSA of RL\\n8 - 24 h 2 ml/kg x % BSA of RL\\n+ maintenance ﬂuid per hour x 16 h (a) \\n2 ml/kg x % BSA of RL\\n24 - 48 h Daily maintenance IV ﬂuid requirements minus oral\\nﬂuids such as milk, broth, gavage feeds (do not\\ninclude drinking water in the calculation).\\n (a) 40 ml/kg RL minus oral ﬂuids (do not include\\ndrinking water in the calculation).\\n(a) Maintenance ﬂuid: alternate RL and 5% glucose: 4 ml/kg/h for ﬁrst 10 kg of body weight + 2 ml/kg/h for next 10 kg + 1ml/kg/h for each additional kg (over 20 kg, up to 30 kg)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 340, 'page_label': '341', 'id': 'data/guideline-170-en.pdf:340:0'}, page_content='Page 341 / 409\\n\\xa0In patients with oliguria despite adequate ﬂuid replacement:\\ndopamine\\xa0IV: 5 to 15 micrograms/kg/minute by IV pump\\nor\\nepinephrine\\xa0IV: 0.1 to 0.5 micrograms/kg/minute\\xa0by IV pump\\nStop the infusion after 48 hours, if ﬂuid requirements can be met by the oral route or gavage.\\nRespiratory care\\nAnalgesia\\nSee\\xa0Pain management\\nNutrition\\nStart feeding early, beginning at H8:\\nPatients at risk of rhabdomyolysis\\nIn the event of deep and extensive burns, electrical burns, crush injuries to the extremities:\\nInfection control\\xa0\\n\\xa0\\nNon-electrical burns Electrical burns\\nChildren\\n< 1 year\\nChildren \\n1-12 years\\nChildren \\n> 12 years/adults All ages\\nAP (mmHg) SAP ≥ 60 SAP 70 to 90 + (2 x age) SAP ≥ 100 Age appropriate SAP\\nUrine output 1 to 2 ml/kg/h 1 to 1.5 ml/kg/h 0.5 to 1 ml/kg/h 1 to 2 ml/kg/h'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 340, 'page_label': '341', 'id': 'data/guideline-170-en.pdf:340:1'}, page_content=\"Urine output 1 to 2 ml/kg/h 1 to 1.5 ml/kg/h 0.5 to 1 ml/kg/h 1 to 2 ml/kg/h\\nIn all cases: continuous inhalation of humidiﬁed oxygen, chest physiotherapy.\\nEmergency surgical intervention if necessary: tracheotomy, chest escharotomy.\\nDo not administer corticosteroids (no effect on oedema; predisposition to infection). No speciﬁc treatment for\\ndirect bronchopulmonary lesions.\\nDaily needs in adults\\ncalories: 25 kcal/kg + 40 kcal/% BSA\\nproteins: 1.5 to 2 g/kg\\nHigh energy foods (NRG5, Plumpy'nut, F100 milk) are necessary if the BSA is > 20% (normal food is inadequate).\\nNutritional requirements are administered according to the following distribution: carbohydrates 50%, lipids 30%,\\nproteins 20%.\\nProvide 5-10 times the recommended daily intake of vitamins and trace elements.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 340, 'page_label': '341', 'id': 'data/guideline-170-en.pdf:340:2'}, page_content='Provide 5-10 times the recommended daily intake of vitamins and trace elements.\\nEnteral feeds are preferred: oral route or nasogastric tube (necessary if BSA > 20%).\\nStart with small quantities on D1, then increase progressively to reach recommended energy requirements within 3\\ndays.\\nAssess nutritional status regularly (weigh 2 times weekly).\\nReduce energy loss: occlusive dressings, warm environment (28-33 °C), early grafting; management of pain,\\ninsomnia and depression.\\nMonitor for myoglobinuria: dark urine and urine dipstick tests.\\nIf present:\\xa0 induce alkaline diuresis for 48 hours (20 ml of\\xa08.4% sodium bicarbonate\\xa0per litre of RL) to obtain an\\noutput of 1 to 2 ml/kg/hour. Do not administer dopamine or furosemide.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 341, 'page_label': '342', 'id': 'data/guideline-170-en.pdf:341:0'}, page_content='Page 342 / 409\\nPrecautions against infection are of paramount importance until healing is complete. Infection is one of the most\\nfrequent and serious complications of burns:\\nOther treatments\\nIII. Local treatment\\nRegular dressing changes prevent infection, decrease heat and ﬂuid losses, reduce energy loss, and promote patient\\ncomfort. Dressings should be occlusive, assist in relieving pain, permit mobilisation, and prevent contractures.\\nBasic principles\\nTechnique\\nHygiene precautions (e.g. sterile gloves when handling patients).\\nRigorous wound management (dressing changes, early excision).\\nSeparate “new” patients (< 7 days from burn) from convalescent patients (≥ 7 days from burn).\\nDo not administer antibiotherapy in the absence of systemic infection.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 341, 'page_label': '342', 'id': 'data/guideline-170-en.pdf:341:1'}, page_content='Do not administer antibiotherapy in the absence of systemic infection.\\nInfection is deﬁned by the presence of at least 2 of 4 following signs: temperature > 38.5 °C or < 36 °C,\\ntachycardia, tachypnoea, elevation of white blood cell count by more than 100% (or substantial decrease in the\\nnumber of white blood cells).\\nIn the event of systemic infection, start empiric antibiotherapy:\\ncefazolin\\xa0IV\\nChildren > 1 month: 25 mg/kg every 8 hours\\xa0\\nAdults : 2 g\\xa0every 8 hours\\n+\\xa0ciproﬂoxacin\\xa0PO\\nChildren > 1 month: 15 mg/kg 2 times daily\\xa0\\nAdults: 500 mg 3 times daily\\xa0\\nLocal infection, in the absence of signs of systemic infection, requires topical treatment with silver sulfadiazine. Not\\nto be applied to children under 2 months.\\nOmeprazole\\xa0IV from D1\\nChildren: 1 mg/kg once daily\\nAdults: 40 mg once daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 341, 'page_label': '342', 'id': 'data/guideline-170-en.pdf:341:2'}, page_content='Omeprazole\\xa0IV from D1\\nChildren: 1 mg/kg once daily\\nAdults: 40 mg once daily\\nTetanus vaccination (see\\xa0Tetanus, Chapter 7).\\nThromboprophylaxis: low molecular weight heparin\\xa0SC beginning 48 to 72 hours post-injury.\\nPhysiotherapy from D1 (prevention of contractures), analgesia is necessary.\\nIntentional burns (suicide attempt, aggression): appropriate psychological follow-up.\\n a \\xa0\\nRigorous adherence to the principles of asepsis.\\nDressing changes require morphine administration in the non-anaesthetised patient.\\nThe ﬁrst dressing procedure is performed in the operating room under general anaesthesia, the following in an\\noperating room under general anaesthesia or at the bedside with morphine.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 341, 'page_label': '342', 'id': 'data/guideline-170-en.pdf:341:3'}, page_content='operating room under general anaesthesia or at the bedside with morphine.\\nAt the time of the ﬁrst dressing procedure, shave any hairy areas (armpit, groin, pubis) if burns involve the adjacent\\ntissues; scalp (anteriorly in the case of facial burns, entirely in the case of cranial burns). Cut nails.\\nClean the burn with povidone iodine scrub solution (1 volume of 7.5% povidone iodine\\xa0+ 4 volumes of 0.9% sodium\\nchloride or sterile water). Scrub gently with compresses, taking care to avoid bleeding.\\nRemove blisters with forceps and scissors.\\nRinse with 0.9% sodium chloride or sterile water.\\nDry the skin by blotting with sterile compresses.\\nApply silver sulfadiazine directly by hand (wear sterile gloves) in a uniform layer of 3-5 mm to all burned areas'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 341, 'page_label': '342', 'id': 'data/guideline-170-en.pdf:341:4'}, page_content='(except eyelids and lips) to children 2 months and over and adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 342, 'page_label': '343', 'id': 'data/guideline-170-en.pdf:342:0'}, page_content='Page 343 / 409\\nFrequency\\nMonitoring\\nIV. Surgical care\\nEmergency surgical interventions\\nBurn surgery\\nV. Pain management\\nAll burns require analgesic treatment. Pain intensity is not always predictable and regular assessment is paramount: use\\na simple verbal scale (SVS) in children > 5 years and adults and NFCS or FLACC scales in children < 5 years (see\\xa0Pain,\\nChapter 1).\\xa0Morphine is the treatment of choice for moderate to severe pain. Development of tolerance is common in burn\\npatients and requires dose augmentation. Adjuvant treatment may complement analgesic medication (e.g. massage\\ntherapy, psychotherapy).\\nContinuous pain (experienced at rest)\\nApply a greasy dressing (Jelonet® or petrolatum gauze) using a back and forth motion (do not use a circular\\nmovement).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 342, 'page_label': '343', 'id': 'data/guideline-170-en.pdf:342:1'}, page_content='movement).\\nCover with a sterile compresses, unfolded into a single layer. Never encircle a limb with a single compress.\\nWrap with a crepe bandage, loosely applied.\\nElevate extremities to prevent oedema; immobilise in extension.\\nRoutinely: every 48 hours.\\nDaily in the event of superinfection or in certain areas (e.g. perineum).\\nDistal ischaemia of the burned limb is the main complication during the ﬁrst 48 hours. Assess for signs of ischaemia:\\ncyanosis or pallor of the extremity, dysaesthesia, hyperalgia, impaired capillary reﬁll.\\nMonitor daily: pain, bleeding, progression of healing and infection.\\nEscharotomy: in the case of circumferential burns of arms, legs or ﬁngers, in order to avoid ischaemia, and\\ncircumferential burns of chest or neck that compromise respiratory movements.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 342, 'page_label': '343', 'id': 'data/guideline-170-en.pdf:342:2'}, page_content='circumferential burns of chest or neck that compromise respiratory movements.\\nTracheotomy: in the event of airway obstruction due to oedema (e.g. deep cervicofacial burns). Tracheotomy can\\nbe performed through a burned area.\\nTarsorrhaphy: in the event of ocular or deep eyelid burns.\\nSurgery for associated injuries (fractures, visceral lesions, etc.).\\nExcision-grafting of deep burns, in the operating room, under general anaesthesia, between D5 and D6: excision of\\nnecrotic tissue (eschar) with simultaneous grafting with autografts of thin skin. This intervention entails signiﬁcant\\nbleeding risk, do not involve more than 15% of BSA in the same surgery.\\nIf early excision-grafting is not feasible, default to the process of sloughing-granulation-reepithelisation. Sloughing'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 342, 'page_label': '343', 'id': 'data/guideline-170-en.pdf:342:3'}, page_content='occurs spontaneously due to the action of sulfadiazine/ petrolatum gauze dressings and, if necessary, by\\nmechanical surgical debridement of necrotic tissue. This is followed by granulation, which may require surgical\\nreduction in the case of hypertrophy. The risk of infection is high and the process is prolonged (> 1 month).\\nModerate pain:\\nparacetamol\\xa0PO +\\xa0tramadol\\xa0PO\\xa0(see\\xa0Pain, Chapter 1)\\xa0\\nModerate to severe pain:\\nparacetamol\\xa0PO +\\xa0sustained release morphine\\xa0PO\\xa0(see\\xa0Pain, Chapter 1)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 343, 'page_label': '344', 'id': 'data/guideline-170-en.pdf:343:0'}, page_content='Page 344 / 409\\nAcute pain experienced during care\\nAnalgesics are given in addition to those given for continuous pain.\\xa0\\nNote: these doses of morphine are for adults, dosing is the same in children > 1 year, should be halved in children\\nless than 1 year, and quartered in infants less than 3 months.\\nChronic pain (during the rehabilitation period)\\nMinor burns\\n\\xa0\\nIn patients with severe burns, oral drugs are poorly absorbed in the digestive tract during the ﬁrst 48 hours, morphine\\nis administered by SC route.\\nSigniﬁcant medical interventions and extensive burns: general anaesthesia in an operating room.\\nLimited non-surgical interventions (dressings, painful physiotherapy):\\nMild to moderate pain, 60 to 90 minutes before giving care:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 343, 'page_label': '344', 'id': 'data/guideline-170-en.pdf:343:1'}, page_content='Mild to moderate pain, 60 to 90 minutes before giving care:\\xa0\\ntramadol PO (see Pain, Chapter 1) rarely allows treatment to be completed comfortably. In the event of\\ntreatment failure, use morphine.\\nModerate or severe pain, 60 to 90 minutes before giving care:\\nimmediate release morphine\\xa0PO: initial dose of 0.5 to 1 mg/kg; the effective dose is usually around 1 mg/kg,\\nbut there is no maximum dose.\\nor\\xa0morphine\\xa0SC: initial dose of 0.2 to 0.5 mg/kg; the effective dose is usually around 0.5 mg/kg, but there is no\\nmaximum dose.\\nPain management using morphine during dressing changes at the bedside requires:\\nA trained nursing team.\\nAvailability of immediate release oral morphine and naloxone.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 343, 'page_label': '344', 'id': 'data/guideline-170-en.pdf:343:2'}, page_content='Availability of immediate release oral morphine and naloxone.\\nClose monitoring: level of consciousness, RR, heart rate, SpO, every 15 min for the ﬁrst hour following dressing\\nchange, then routine monitoring.\\n2\\nAssessment of pain intensity and sedation during the intervention and for 1 hour thereafter.\\nNecessary equipment for ventilation by mask and manual suction.\\nGentle handling of the patient at all times.\\nAdjustment of morphine doses for subsequent dressings:\\nIf pain intensity (SVS) is 0 or 1: continue with the same dose.\\nIf SVS score ≥ 2: increase the dose by 25 to 50%. If pain control remains inadequate, the dressing change\\nshould be carried out in the operating room under anaesthesia.\\nTake advantage of the residual analgesia following dressing changes to carry out physiotherapy.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 343, 'page_label': '344', 'id': 'data/guideline-170-en.pdf:343:3'}, page_content='As a last resort (morphine unavailable and no facilities to give general anaesthesia), in a safe setting (trained staff,\\nresuscitation equipment, recovery room), adding\\xa0ketamine\\xa0IM at analgesic doses (0.5 to 1 mg/kg) reinforces the\\nanalgesic effect of the paracetamol + tramadol combination given before a dressing change.\\nThe treatment is guided by self-evaluation of pain intensity, and utilises paracetamol and/or tramadol. Patients may\\ndevelop neuropathic pain (see\\xa0Pain, Chapter 1).\\nAll other associated pain (physiotherapy, mobilization) should be treated as acute pain.\\nTreat as outpatients.\\nWound care: dressings with silver sulfadiazine (to children 2 months and over and adults) or petrolatum gauze\\n(except for ﬁrst degree superﬁcial burns).\\nPain: paracetamol ± tramadol usually effective.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 344, 'page_label': '345', 'id': 'data/guideline-170-en.pdf:344:0'}, page_content='Page 345 / 409\\nFootnotes\\n(a) Open technique « naked burn patient under a mosquito net » and water immersion therapy are obsolete and should nolonger be used.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 345, 'page_label': '346', 'id': 'data/guideline-170-en.pdf:345:0'}, page_content='Page 346 / 409\\nCutaneous abscess\\nA cutaneous abscess is a collection of pus within the dermis or subcutaneous tissue.\\nIt is\\xa0most commonly due to Staphylococcus aureus.\\nClinical features\\nParaclinical investigations\\nRadiography in case of suspected osteomyelitis or septic arthritis.\\nTreatment\\nEquipment\\nAnaesthesia\\n\\xa0For analgesia, see Pain, Chapter 1.\\nTechnique\\nIncision\\n(Figure 8a)\\nPainful, red, shiny nodule with or without ﬂuctuance; suppuration or surrounding cellulitis (see Erysipelas and cellulitis,\\nChapter 4).\\nRegional adenopathy and fever may be present.\\nComplications: osteomyelitis, septic arthritis, septic shock (see Shock, Chapter 1).\\nTreatment is surgical incision and drainage, under aseptic conditions (i.e.\\xa0sterile consumables and instruments,\\nantiseptic skin preparation).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 345, 'page_label': '346', 'id': 'data/guideline-170-en.pdf:345:1'}, page_content='antiseptic skin preparation).\\nRefer to a surgeon any cutaneous abscess:\\nlocated in anterior and lateral neck, central triangle of the face, hand, perirectal region, breast, or\\nadjacent to major blood vessels (e.g. femoral artery), or\\ninvolving joint and bone.\\nAntibiotic therapy only if signs of systemic infection, extensive surrounding cellulitis or for individuals with risk\\nfactors e.g. immunosuppression or diabetes\\xa0(for antibiotic therapy, see Erysipelas and cellulitis,\\xa0Chapter 4).\\nSterile scalpel\\nSterile curved, non-toothed artery forceps (Kelly type)\\nSterile disposable gloves and compresses\\nAntiseptic solution and\\xa00.9% sodium chloride\\n5 or 10 ml syringe\\nFor small (approximately < 5 cm), well delineated abscess in adults: use local anaesthesia with 1%\\xa0lidocaine'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 345, 'page_label': '346', 'id': 'data/guideline-170-en.pdf:345:2'}, page_content='without epinephrine (10 mg/ml):\\xa015 to 20 ml.\\nFor larger (approximately > 5 cm), deep or poorly delineated abscess in adults or for abscess in children: consider\\nprocedural sedation or general anaesthesia (ketamine IM: 10 mg/kg).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 346, 'page_label': '347', 'id': 'data/guideline-170-en.pdf:346:0'}, page_content='Page 347 / 409\\nDigital exploration\\n(Figure 8b)\\nWashing\\nAbundant washing of the cavity using a syringe ﬁlled with 0.9% sodium chloride.\\nDrainage\\n(Figure 8c)\\nOnly necessary for deep abscesses.\\nInsert a drain (or, failing that a gauze wick) into the base of the cavity. If possible, ﬁx it to the edge of the incision with a\\nsingle suture. The drain is withdrawn progressively and then, after 3 to 5 days removed completely.\\nHold the scalpel between the thumb and middle ﬁnger of the dominant hand, the index ﬁnger presses on the handle.\\nHold the abscess between the thumb and index ﬁnger of the other hand. The scalpel blade should be perpendicular\\nto the skin.\\nThe incision is made in a single stroke along the long axis of the abscess. The incision must be long enough for a\\nﬁnger to be inserted.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 346, 'page_label': '347', 'id': 'data/guideline-170-en.pdf:346:1'}, page_content='ﬁnger to be inserted.\\n Figure 8a\\nIncision with a scalpel\\nExplore the cavity with the index ﬁnger, breaking down all loculi (a single cavity should remain), evacuate the pus (and\\nforeign body, if present) and explore to the edges of the cavity.\\nThe exploration also allows an assessment of the extent of the abscess, the depth, and location with respect to\\nunderlying structures (arterial pulsation) or any possible contact with underlying bone. In this last case, seek surgical\\nadvice.\\n\\xa0  Figure 8b \\nExploration of the cavity, \\nbreaking down any loculi'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 347, 'page_label': '348', 'id': 'data/guideline-170-en.pdf:347:0'}, page_content='Page 348 / 409\\nDressing\\nCover with sterile compresses.\\n\\xa0Figure 8c\\nDrain ﬁxed to the skin'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 348, 'page_label': '349', 'id': 'data/guideline-170-en.pdf:348:0'}, page_content='Page 349 / 409\\nPyomyositis\\nPyomyositis is an infection of the muscle, almost always due to Staphylococcus aureus. It most commonly affects the\\nmuscles of the limbs and torso. Infections may occur simultaneously in multiple sites.\\nRisk factors include immunosuppression, concurrent S. aureus\\xa0infection, malnutrition, trauma and injection drug use.\\nRisk of mortality is signiﬁcant if treatment is delayed.\\nClinical features\\nParaclinical investigations\\nTreatment\\nEquipment and anaesthesia\\nAs for Cutaneous\\xa0abscess, Chapter 10.\\nTechnique\\nSigns and symptoms:\\nlocal: exquisite muscle tenderness, oedema giving muscles \"woody\" texture on palpation.\\nsystemic: regional adenopathy and fever.\\npyomyositis of the psoas muscle: patient keeps hip ﬂexed and experiences pain on hip extension. If the abscess'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 348, 'page_label': '349', 'id': 'data/guideline-170-en.pdf:348:1'}, page_content='is on the right side, the clinical signs are the same as for appendicitis with pain in the right iliac fossa.\\nComplications: septic emboli, endocarditis and septic arthritis, septic shock (see Shock, Chapter 1).\\nPOCUS : assists in characterisation of abscess; can rule out deep venous thrombosis. a \\nRadiography: may demonstrate a foreign body, signs of osteomyelitis or osteosarcoma.\\nImmobilise the limb.\\nSystematic antibiotic therapy (see Erysipelas and cellulitis, Chapter 4).\\xa0\\nAdapt analgesics to the pain level (see Pain, Chapter 1).\\nApply compresses soaked in 70% alcohol 2 times daily (max. 3 times daily to prevent burns to the skin) until incision\\nand drainage.\\nTreatment is surgical incision and drainage, under aseptic conditions (sterile consumables and instruments,'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 348, 'page_label': '349', 'id': 'data/guideline-170-en.pdf:348:2'}, page_content='antiseptic skin preparation) following the rules for incision and drainage of abscesses (see\\xa0Cutaneous abscess,\\nChapter 10). Muscle abscesses are often deeper than other abscesses. As a result, aspiration with a large bore\\nneedle may be necessary to locate the abscess. Needle aspiration is insufﬁcient treatment even if pus is evacuated\\nand should be followed by surgical incision and drainage.\\nIn case of pyomyositis of the psoas muscle, start antibiotics and refer to a surgeon.\\nGenerous incision along the axis of the limb, over the site of the abscess and avoiding underlying neurovascular\\nstuctures; incise the skin, subcutaneous tissues and muscular fascia with a scalpel (Figure 9a).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 348, 'page_label': '349', 'id': 'data/guideline-170-en.pdf:348:3'}, page_content='Dissect the muscle ﬁbres with non-toothed forceps (Kelly type) or round tipped scissors. Insert the instrument or a\\nﬁnger into the muscle until the purulent cavity is reached. If an instrument is used, during insertion, keep the\\ninstrument closed and perpendicular to the muscle ﬁbres. Withdraw gently with the scissors or forceps slightly open,\\nkeeping instrument perpendicular to the ﬁbres (Figure 9b). If abscess is found to be very deep, it may be necessary\\nto refer to a surgeon.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 349, 'page_label': '350', 'id': 'data/guideline-170-en.pdf:349:0'}, page_content='Page 350 / 409\\n\\xa0\\nFigures 9: Surgical incision-drainage of a pyomyositis\\n\\xa0\\nUse a foreﬁnger to explore the cavity, break down any loculi and evacuate the pus (Figure 9c).\\nWash abundantly with 0.9% sodium chloride.\\nInsert a large drain.\\nFix the drain to the edge of the wound using a single suture. Remove the drain on about the 5  day (Figure 9d).th\\n Figure 9a \\nLong incision\\n\\xa0\\nFigure 9b\\nDissection of the muscle using\\xa0Kelly forceps, insert closed\\nthen withdraw\\xa0 \\nwith the instrument slightly open\\n Figure 9c \\nExploration and evacuation of pus\\xa0with the ﬁnger\\nFigure 9d\\nDrain ﬁxed to the skin\\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 350, 'page_label': '351', 'id': 'data/guideline-170-en.pdf:350:0'}, page_content='Page 351 / 409\\nLeg ulcers\\nDaily local treatment\\nSystemic treatment\\nLeg ulcers are chronic losses of cutaneous tissue. They are common in tropical regions, resulting from varied\\naetiologies:\\nvascular: venous and/or arterial insufﬁciency,\\nbacterial: leprosy, Buruli ulcer (Mycobacterium ulcerans), phagedenic ulcer, yaws, syphilis,\\nparasitic: dracunculiasis (Guinea-worm disease), leishmaniasis,\\nmetabolic: diabetes,\\ntraumatic: trauma is often a precipitating factor combined with another underlying cause.\\nThe history of the disease and a complete clinical examination (paying particular attention to the neurological\\nexamination to determine if there is a peripheral neuropathy caused by leprosy or diabetes) usually leads to an\\naetiological diagnosis.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 350, 'page_label': '351', 'id': 'data/guideline-170-en.pdf:350:1'}, page_content='aetiological diagnosis.\\nAll ulcers may become complicated with either local or regional secondary infections (abscess, lymphadenopathy,\\nadenitis, osteomyelitis, erysipela, pyodermitis), generalised infection (septicaemia), tetanus and after many years of\\nevolution, skin cancer.\\nBathe the leg for 10 to 15 minutes in\\xa0NaDCC\\xa0and rinse in boiled water.\\nRemove any necrotic (black) and ﬁbrinous (yellowish) tissue using compresses or excise the tissue with a scalpel.\\nApply:\\nto a clean ulcer, with little discharge: 10% povidone iodine and vaseline;\\nto a dirty ulcer, with little discharge: silver sulfadiazine to a limited area (monitor for systemic adverse effects);\\nto an oozing ulcer: 10% povidone iodine alone;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 350, 'page_label': '351', 'id': 'data/guideline-170-en.pdf:350:2'}, page_content='to an oozing ulcer: 10% povidone iodine alone;\\nto an extensive, oozing ulcer or multiple ulcers: diluted povidone iodine (1/4 of 10% povidone iodine + 3/4 of\\n0.9% sodium chloride or clean water) for one minute then rinse with 0.9% sodium chloride\\xa0or clean water to\\nreduce the risk of transcutaneous iodine absorption.\\nCover with a dry sterile dressing.\\nTreatment with analgesics in the event of pain: adapt the level and dosage to the individual (see\\xa0Pain, Chapter 1).\\nGive systemic antibiotics in case of:\\nSecondary infection (see\\xa0Bacterial skin infections, Chapter 4).\\nPhagedenic ulcer (in the early stages, antibiotics may be useful. They are often ineffective in the chronic\\nstages):\\ndoxycycline PO (except in children under 8 years and pregnant or lactating women)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 350, 'page_label': '351', 'id': 'data/guideline-170-en.pdf:350:3'}, page_content='Children\\xa08 years and over: 4 mg/kg once daily\\nAdults: 200 mg once daily\\nor\\nmetronidazole\\xa0PO\\nChildren: 10 mg/kg 3 times daily\\xa0\\nAdults: 500 mg\\xa03 times daily\\nIf after 7 days, antibiotherapy is effective,\\xa0continue with doxycycline or metronidazole as above. Treatment\\nduration varies according to the clinical evolution.\\nTreat the cause.\\nComplementary therapy:\\nElevate the legs in cases of venous and/or lymphatic insufﬁciency.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 351, 'page_label': '352', 'id': 'data/guideline-170-en.pdf:351:0'}, page_content='Page 352 / 409\\nTetanus prophylaxis if appropriate (see\\xa0Tetanus, Chapter 7).\\nSkin graft if the ulcer is extensive, clean, red and ﬂat. Skin grafts are often necessary after surgical excision to\\nheal phagedenic and Buruli ulcers.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 352, 'page_label': '353', 'id': 'data/guideline-170-en.pdf:352:0'}, page_content='Page 353 / 409\\nNecrotising infections of the skin and softtissues\\nInvasive infections of the soft tissues: skin, subcutaneous tissue, superﬁcial or deep fascia, muscles. They include\\nnecrotising cellulitis, necrotising fasciitis, myonecrosis, gas gangrene, etc.\\xa0Clinical presentation depends on the causative organism and the stage of progression. Group A streptococcus is\\nfrequently isolated, as are Staphylococcus aureus, enterobacteriaceae and anaerobic bacteria including Clostridium\\nsp.\\xa0Delay in treatment of a minor wound or certain types of wounds (gunshot wounds or stabbings, open fractures or non-\\nsterile intramuscular injections/circumcisions) or certain infections (varicella or omphalitis), favours the development of'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 352, 'page_label': '353', 'id': 'data/guideline-170-en.pdf:352:1'}, page_content='a necrotising infection. Patient risk factors include\\xa0immunosuppression, diabetes, malnutrition and advanced age.\\xa0A necrotising infection is a surgical emergency and has a high mortality rate.\\nClinical features\\nLaboratory\\nParaclinical investigations\\nRadiography: may demonstrate gas in muscles or along the fascia planes. Can rule out foreign body, osteomyelitis or\\nosteosarcoma.\\nTreatment\\nPrompt surgical management accompanied by IV antibiotic therapy is essential to reduce the high mortality. Refer\\nimmediately to a surgeon. Start resuscitation if necessary (see Shock, Chapter 1).\\xa0\\n\\xa0\\nInitial signs and symptoms include erythema, oedema and pain disproportionate to appearance of infection.\\nLocation depends on the portal of entry. It may be difﬁcult to differentiate necrotising infections from'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 352, 'page_label': '353', 'id': 'data/guideline-170-en.pdf:352:2'}, page_content='nonnecrotising infections (see Erysipelas and cellulitis, Chapter 4). Systemic signs of infection (fever, tachycardia\\netc.) may be present.\\nLesions progress rapidly despite antibiotic therapy, with the development of the typical signs of a necrotizing\\ninfection: haemorrhagic blisters and necrosis (cold bluish or blackish hypoaesthetic macules).\\nSigns of late infection: crepitus on palpation and fetid odour (gas gangrene) with signs of severe systemic infection\\n(see Shock, Chapter 1).\\nIf available, the following tests can help identify an early necrotising infection: white blood cell count > 15 000/mm³\\nor < 4000/mm³; serum creatinine > 141 micromol/litre; serum glucose > 10 mmol/litre (180 mg/dl) or < 3.3 mmol/litre'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 352, 'page_label': '353', 'id': 'data/guideline-170-en.pdf:352:3'}, page_content='(60 mg/dl). However, normal results do not exclude a necrotising infection.\\nObtain specimens for bacterial culture in the operating room and blood cultures if possible.\\xa0\\nEmergency surgical treatment:\\nDebridement, drainage, wide excision of necrotic tissue and rapid amputation if necessary.\\nSurgical re-evaluation within 24 to 36 hours to check for eventual progression of the necrosis and need for\\nfurther debridement.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 353, 'page_label': '354', 'id': 'data/guideline-170-en.pdf:353:0'}, page_content='Page 354 / 409\\n\\xa0 cloxacillin IV infusion (60 minutes)\\nChildren < 40 kg: 50 mg/kg every 6 hours\\nChildren ≥ 40 kg and adults: 3 g every 6 hours\\xa0 ceftriaxone slow IV (3 minutes) or IV infusion (30 minutes)\\nChildren 1 month and over: 100 mg/kg once daily\\nAdults: 2 g once daily\\xa0 clindamycin IV infusion (30 minutes)\\nNeonates 0 to 7 days (< 2 kg): 5 mg/kg every 12 hours\\nNeonates 0 to 7 days (≥ 2 kg): 5 mg/kg every 8 hours\\nNeonates 8 days to < 1 month (< 2 kg):\\xa05 mg/kg\\xa0every 8 hours\\nNeonates 8 days to < 1 month (≥ 2 kg): 10 mg/kg\\xa0every 8 hours\\nChildren 1 month and over: 10 to 13 mg/kg\\xa0every 8 hours\\xa0(max. 2700 mg daily)\\nAdults: 900 mg\\xa0every 8 hours\\xa0 amoxicillin/clavulanic acid (co-amoxiclav) slow IV injection (3 minutes) or IV infusion (30 minutes)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 353, 'page_label': '354', 'id': 'data/guideline-170-en.pdf:353:1'}, page_content='Children less than 3 months: 50 mg/kg every 12 hours\\xa0\\nChildren ≥ 3 months and < 40 kg: 50 mg/kg every 8 hours\\xa0(max. 6 g daily)\\nChildren ≥ 40 kg and adults: 2 g\\xa0every 8 hours\\xa0\\n\\xa0\\nIV antibiotic therapy for at least 14 days or more depending on clinical response:\\ncloxacillin + ceftriaxone + clindamycin\\xa0or amoxicillin/clavulanic acid + clindamycin. For doses, see below.\\n a \\n b \\n c \\n d \\nOther treatments:\\nDeep vein thrombosis prophylaxis;\\nAppropriate management of pain (see Pain, Chapter 1);\\nEarly nutritional support.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 353, 'page_label': '354', 'id': 'data/guideline-170-en.pdf:353:2'}, page_content='Early nutritional support.\\nFootnotes\\n(a) Cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. Then dilute each dose of cloxacillin in5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or5% glucose in children 20 kg and over and in adults.\\n(b) For administration by IV route, ceftriaxone powder should to be reconstituted in water for injection only. For administrationby IV infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kgand in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children 20 kg and over and in adults.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 353, 'page_label': '354', 'id': 'data/guideline-170-en.pdf:353:3'}, page_content='(c) Dilute each dose of clindamycin in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of100 ml of 0.9% sodium chloride or 5% glucose in children 20 kg and over and in adults.\\n(d) Dilute each dose of amoxicillin/clavulanic acid in 5 ml/kg of 0.9% sodium chloride in children less than 20 kg and in a bag of100 ml of 0.9% sodium chloride in children 20 kg and over and in adults. Do not dilute in glucose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 354, 'page_label': '355', 'id': 'data/guideline-170-en.pdf:354:0'}, page_content='Page 355 / 409\\nVenomous bites and stings\\nSnake bites and envenomation\\n\\xa0\\nClinical manifestations and management of bites and envenomations are described in the\\xa0table\\xa0below.\\xa0\\nIn the event of coagulation abnormalities, continue to monitor once daily until coagulation returns to normal.\\xa0\\nFor all patients, be prepared for an anaphylactic reaction, which, despite its potential severity (shock), is\\nusually more easily controlled than coagulation disorders or serious neurological disorders.\\xa0\\n\\xa0\\nClinical signs and treatment\\xa0\\nMore than 50% of the bites are dry bites, i.e. no envenomation occurred. In the event that venom is injected, the\\nseverity of envenomation depends on the species, the amount of venom injected, the location of the bite (bites on'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 354, 'page_label': '355', 'id': 'data/guideline-170-en.pdf:354:1'}, page_content='the head and neck are the most dangerous) and the weight, general condition and age of the individual (more serious\\nin children).\\nIt is rare that the snake involved is identiﬁed. However, observation of the clinical signs may orient diagnosis and\\nmanagement. Two major syndromes are identiﬁed:\\nneurological disorders that evolve towards respiratory muscle paralysis and coma are common manifestations\\nof elapid envenomation (cobra, mamba, etc.);\\nextensive local lesions (intense pain, inﬂammation with oedema and necrosis) and coagulation abnormalities are\\ncommon manifestations of viperid or crotalid (rattle snake) envenomation.\\nEarly diagnosis and monitoring of coagulation abnormalities is based on whole blood clotting tests performed in a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 354, 'page_label': '355', 'id': 'data/guideline-170-en.pdf:354:2'}, page_content='dry tube (at the patient’s arrival and then every 4 to 6 hours for the ﬁrst day).\\nTake 2 to 5 ml of whole blood, wait 30 minutes and examine the tube:\\nComplete clotting: no coagulation abnormality\\nIncomplete clotting or no clotting: coagulation abnormality, susceptibility to bleeding a\\nAetiological treatment is based on the administration of snake antivenom serum, only if there are clear\\xa0clinical\\nmanifestations of envenomation or coagulation abnormalities\\xa0are observed.\\nAntivenom sera are effective, but rarely available (verify local availability) and difﬁcult to store. Antivenom serum\\nshould be administered as early as possible: by IV infusion (in 0.9% sodium chloride) if using a poorly puriﬁed serum;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 354, 'page_label': '355', 'id': 'data/guideline-170-en.pdf:354:3'}, page_content='by slow IV in the event of severe envenomation if the serum is known to be well puriﬁed. Repeat antivenom serum\\nadministration after 4 or 6 hours if the symptoms of envenomation persist.\\n\\xa0\\n\\xa0\\nIn asymptomatic patients (bites without signs of envenomation and with normal coagulation), monitoring must\\ncontinue for at least 12 hours (24 hours preferred).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 355, 'page_label': '356', 'id': 'data/guideline-170-en.pdf:355:0'}, page_content='Page 356 / 409\\nTime\\nsince\\nbite\\nClinical manifestations Possible\\naggressor Treatment\\nBite\\n0 Fang marks\\nPain at the site of bite\\n? Strict rest, immobilisation of the limb with a\\nsplint to slow the diffusion of venom .\\nWound cleansing.\\nTetanus prophylaxis (Tetanus, Chapter 7).\\nObserve for manifestations of envenomation.\\nA the dispensary level, prepare patient\\nevacuation to a referral centre.\\n (a) \\nEnvenomation\\n10-30\\nminutes\\nHypotension, myosis, excessive\\nsalivation and sweating, dysphagia,\\ndyspnoea\\nLocal paraesthesia, paresis\\nElapids Insert a peripheral IV line.\\nIV antivenom serum as soon as possible.\\nInﬂammatory syndrome: intense pain,\\nextensive regional oedema\\nViperids\\nCrotalids\\nInsert a peripheral IV line.\\nIV antivenom serum as soon as possible.\\nAnalgesics .\\nIV or PO anti-inﬂammatories.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 355, 'page_label': '356', 'id': 'data/guideline-170-en.pdf:355:1'}, page_content='Analgesics .\\nIV or PO anti-inﬂammatories.\\n (b) \\n (b) \\xa0\\n30\\nminutes-\\n5 hours\\nCobra syndrome: bilateral eyelid drooping,\\ntrismus, respiratory muscle paralysis\\nShock\\nElapids Intubation and assisted ventilation.\\nSee Shock, Chapter 1.\\n30\\nminutes-\\n48 hours\\nHaemorrhagic syndome: epistaxis,\\npurpura, haemolysis or disseminated\\nintra-vascular coagulation\\nShock\\nViperids\\nCrotalids\\nMonitor coagulation (blood clotting test in a\\ndry tube).\\nTransfusion of fresh blood in the event of\\nsevere anaemia.\\nSee Shock, Chapter 1.\\n6 hours\\nor more\\nNo signs or changes in coagulation (non-\\nvenomous snakes or snake bite without\\nenvenomation)\\n? Reassure the patient.\\nSend him home after 12 hours.\\nTissue necrosis \\xa0 Remove blisters, clean; daily (non occlusive)\\ndressings.\\nSurgical intervention for necrosis, depending'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 355, 'page_label': '356', 'id': 'data/guideline-170-en.pdf:355:2'}, page_content='dressings.\\nSurgical intervention for necrosis, depending\\non the extent, after the lesions stabilise\\n(minimum 15 days).\\n(a) Tourniquets, incision-suction and cauterisation are ineffective and may be dangerous.\\n(b) Do not use acetylsalicylic acid (aspirin).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 356, 'page_label': '357', 'id': 'data/guideline-170-en.pdf:356:0'}, page_content='Page 357 / 409\\nScorpion stings and envenomation\\n\\xa0\\n\\xa0\\n\\xa0\\nSpider bites and envenomation\\n\\xa0\\n\\xa0As well as the general measures listed above, treatment includes administration of\\xa010% calcium gluconate\\xa0by slow IV\\nin the event of muscle spasms (children: 5 ml per injection, adults: 10 ml per injection, administered over 10 to 20\\nminutes).\\nIncision and debridement of necrotic tissue are not recommended (not useful; may impair healing).\\nHymenoptera stings (honeybees, wasps and hornets)\\nIn case of clinical evidence of infection only: drainage of any abscess; amoxicillin/clavulanic acid (co-amoxiclav) for\\n7 to 10 days in case of cellulitis.\\nInfections are relatively rare, and most often associated with traditional treatment or with nosocomial transmission\\nafter unnecessary or premature surgery.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 356, 'page_label': '357', 'id': 'data/guideline-170-en.pdf:356:1'}, page_content='after unnecessary or premature surgery.\\nIn most cases, the sting causes local effects including: pain, oedema, erythema. Management includes strict rest,\\nwound cleansing, analgesics PO, and tetanus prophylaxis (see\\xa0Tetanus, Chapter 7).\\nIn patients with signiﬁcant pain, inﬁltrate the area around the sting with local anaesthetic (1% lidocaine). Observe\\nfor 12 hours.\\nGeneral signs appear in the event of severe envenomation: hypertension, excessive salivation and sweating,\\nhyperthermia, vomiting, diarrhoea, muscle pain, respiratory difﬁculties, seizures; rarely, shock.\\nAetiological treatment:\\nThe use of scorpion antivenom sera is controversial (most of them are not very effective; they may be poorly\\ntolerated due to insufﬁcient puriﬁcation).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 356, 'page_label': '357', 'id': 'data/guideline-170-en.pdf:356:2'}, page_content='tolerated due to insufﬁcient puriﬁcation).\\nIn practice, in countries where scorpion envenomations are severe (North Africa, the Middle East, Central America\\nand Amazonia), check local availability of antivenom sera and follow national recommendations.\\nThe criteria for administration are the severity of the envenomation, the age of the patient (more severe in children)\\nand the time elapsed since the sting. This should not exceed 2 to 3 hours. If the time elapsed is more than 2 or 3\\nhours, the beneﬁt of antivenom serum is poor in comparison with the risk of anaphylaxis (in contrast to\\nenvenomation by snakes).\\nSymptomatic treatment:\\nIn the event of vomiting, diarrhoea or excessive sweating: prevention of dehydration (oral rehydration salts),\\nespecially in children.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 356, 'page_label': '357', 'id': 'data/guideline-170-en.pdf:356:3'}, page_content='especially in children.\\nIn the event of muscle pain:\\xa010% calcium gluconate\\xa0slow IV (children: 5 ml per injection, adults: 10 ml per\\ninjection, administered over 10 to 20 minutes).\\nIn the event of seizures: diazepam may be used with caution; the risk of respiratory depression is increased in\\nenvenomated patients (see\\xa0Seizures, Chapter 1).\\nTreatment is usually limited to wound cleansing, strict rest, analgesics PO and tetanus prophylaxis (see\\xa0Tetanus,\\nChapter 7).\\nSevere envenomations are rare. There are two main clinical syndromes:\\nNeurotoxic syndrome\\xa0(black widow spider): severe muscle pain, tachycardia, hypertension, nausea, vomiting,\\nheadache, excessive sweating. The signs develop for 24 hours and then resolve spontaneously over a few\\ndays.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 356, 'page_label': '357', 'id': 'data/guideline-170-en.pdf:356:4'}, page_content='days.\\nNecrotic syndrome\\xa0(recluse spider): local tissue lesions, possible necrosis and ulceration; mild general signs\\n(fever, chills, malaise and vomiting) which usually resolve over a few days. If present, haemolysis may sometimes\\nbe life threatening.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 357, 'page_label': '358', 'id': 'data/guideline-170-en.pdf:357:0'}, page_content='Page 358 / 409\\n\\xa0\\n\\xa0\\nFor children, if 1 ml syringe is not available, use a diluted solution, i.e. add 1 mg epinephine to 9 ml of 0.9% sodium\\nchloride to obtain a 0.1 mg/ml solution (1:10 000):\\nChildren under 6 years: 1.5 ml\\nChildren from 6 to 12 years: 3 ml\\nRepeat after 5 minutes if no clinical improvement.\\nIn patients with circulatory collapse or those who deteriorate despite receiving IM epinephrine, use IV epinephrine\\n(for doses, see\\xa0Anaphylactic shock, Chapter 1).\\n\\xa0\\nLocal care: remove the embedded sting (bee); clean with soap and water;\\xa0calamine\\xa0lotion if pruriginous (children and\\nadults: one application 3 to 4 times daily in a thin layer).\\nAnalgesics if necessary (paracetamol PO).\\nIn the event of an anaphylactic reaction:\\nepinephrine\\xa0(adrenaline) IM'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 357, 'page_label': '358', 'id': 'data/guideline-170-en.pdf:357:1'}, page_content='In the event of an anaphylactic reaction:\\nepinephrine\\xa0(adrenaline) IM\\nUse\\xa0undiluted\\xa0epinephrine solution (1:1000 = 1 mg/ml) and a 1 ml syringe graduated in\\xa00.01 ml in children:\\nChildren under 6 years: 0.15 ml\\nChildren from 6 to 12 years: 0.3 ml\\nChildren over 12 years and adults: 0.5 ml\\nFootnotes\\n(a) There can be a considerable delay between the decrease in coagulation factors (less than 30 minutes after the bite) andthe ﬁrst signs of bleeding (other than bleeding at the site of the bite and/or the development of sero-sanguinous blisters),which may appear only 3 days after the bite. Conversely, bleeding may resolve prior to normalization of coagulationparameters.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 358, 'page_label': '359', 'id': 'data/guideline-170-en.pdf:358:0'}, page_content='Page 359 / 409\\nDental infections\\nInfection arising as a secondary complication of an inﬂammation of the dental pulp. The severity and the treatment of\\ndental infections depend on their evolution: localised to the infected tooth, extended to adjacent anatomical\\nstructures or diffuse infections.\\nClinical features and treatment\\nInfection localised to a tooth and its surroundings (acute dental abscess)\\nInfections extending to adjacent anatomical structures (acute dento-alveolar abscess)\\nLocal spreading of an acute dental abscess into the surrounding bone and tissue.\\nNotes:\\nIf the dental procedure has to be delayed (local anaesthesia not possible due to inﬂammation, signiﬁcant\\ntrismus), start an antibiotherapy, but the dental procedure must be completed in the following days.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 358, 'page_label': '359', 'id': 'data/guideline-170-en.pdf:358:1'}, page_content='If there is no improvement within 48 to 72 hours after the dental procedure, do not change antibiotic, but start a\\nnew procedure on the tooth.\\nInfections extending into the cervico-facial tissues\\nIntense and continuous pain.\\nOn examination: swelling limited to the gum surrounding the infected tooth. Purulent exudate may be present\\ndraining either through the root canal, or through the periodontal ligament (loosening the tooth) or through a gingival\\nﬁstula. There are no signs of the infection extending to adjacent anatomical structures nor general signs of\\ninfection.\\nTreatment:\\nTreatment is only surgical (the source of infection is inaccessible to antibiotics): root canal therapy (disinfection\\nof the root canal) if possible or extraction of the tooth.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 358, 'page_label': '359', 'id': 'data/guideline-170-en.pdf:358:2'}, page_content='of the root canal) if possible or extraction of the tooth.\\nPain: paracetamol or ibuprofen PO (see\\xa0Pain, Chapter 1).\\nPainful gingival and buccal swelling with warm and tender skin, developing into a ripe abscess: intense pain, with\\ntrismus, particularly if the infection is in a posterior tooth, presence of general signs (fever, fatigue, cervical\\nlymphadenopathy).\\nIn patients with acute gangrenous cellulitis (crepitations on palpation), treat as an infection extending into the\\ncervico-facial tissues (see below).\\nTreatment:\\nFirst surgical: incision and drainage of the pus or extraction of the tooth.\\nThen antibiotic treatment for 5 days following the procedure:\\xa0\\namoxicillin\\xa0PO\\nChildren: 25 mg/kg 2 times daily\\xa0\\nAdults: 1 g\\xa02 times daily\\nPain: paracetamol or ibuprofen PO (see\\xa0Pain, Chapter 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 358, 'page_label': '359', 'id': 'data/guideline-170-en.pdf:358:3'}, page_content='Pain: paracetamol or ibuprofen PO (see\\xa0Pain, Chapter 1).\\nExtremely serious cellulitis, with rapidly spreading cervical or facial tissue necrosis and signs of septicaemia.\\nTreatment:\\ntreatment in an intensive care unit.\\nhigh dose antibiotic treatment (see\\xa0Necrotising infections of the skin and soft tissues).\\nextraction of the tooth.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 359, 'page_label': '360', 'id': 'data/guideline-170-en.pdf:359:0'}, page_content='Page 360 / 409\\nChapter 11: Mental disorders in adults\\nAnxiety\\nInsomnia\\nAgitation\\nAcute confusional state (delirium)\\nPost-traumatic stress disorder\\nDepression\\nPsychotic disorders\\nAcute psychotic episode\\nChronic psychoses\\nBipolar disorder'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 360, 'page_label': '361', 'id': 'data/guideline-170-en.pdf:360:0'}, page_content='Page 361 / 409\\nAnxiety\\nLast updated: November 2021\\n\\xa0\\nA patient suffering from anxiety has:\\n\\xa0Anxiety is a common feature in depression, post-traumatic stress disorder and psychosis. It can also occur in isolation,\\nnot associated with any other mental disorders. Anxiety symptoms often occur immediately after a difﬁcult life event.\\nMedically unexplained symptoms\\xa0are frequent in refugees and people exposed to adversity;\\xa0in certain cultures they may\\nbe the only expression of psychological\\xa0distress.\\xa0\\nManagement\\nTry to determine the source of the anxiety and reassure the patient (without minimising the distress or symptoms). If'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 360, 'page_label': '361', 'id': 'data/guideline-170-en.pdf:360:1'}, page_content='necessary, use simple relaxation techniques to alleviate the symptoms .\\xa0If symptoms are exacerbated (e.g., tachycardia, feeling of suffocation, fear of dying or “going crazy,” agitation, or\\nconversely, prostration), it may be necessary to administer diazepam: 5 to 10 mg PO or 10 mg IM, to be repeated\\nafter one hour if required.\\xa0Acute severe anxiety may justify a short course (max. 2 or 3 weeks) of:\\ndiazepam PO: 2.5 to 5 mg 2 times daily; reducing the dose by half in the last few days of treatment\\xa0Moderate anxiety lasting more than 2 weeks, administer as ﬁrst-line treatment:\\xa0\\nhydroxyzine PO: 25 to 50 mg 2 times daily\\xa0(max. 100 mg daily)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 360, 'page_label': '361', 'id': 'data/guideline-170-en.pdf:360:2'}, page_content='hydroxyzine PO: 25 to 50 mg 2 times daily\\xa0(max. 100 mg daily)\\nor, only if there is no improvement after 1 week, diazepam PO: 2.5 to 5 mg 2 times daily for max. 2 weeks.\\xa0If symptoms recur after treatment discontinuation, do not resume diazepam or hydroxyzine.\\xa0Re-evaluate for possible\\ndepression or post-traumatic stress disorder.\\xa0For generalised anxiety\\xa0that lasts more than 2 months, and does not improve with psychosocial interventions, an\\nantidepressant should be prescribed (ﬂuoxetine\\xa0or paroxetine PO: 20 mg once daily), to be continued for 2 to 3\\nmonths after symptoms resolve then, stop gradually over 2 weeks.\\npsychological\\xa0symptoms: pervasive worries, e.g. fear of having a serious illness, fear with no clearly-deﬁned object\\nor phobias;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 360, 'page_label': '361', 'id': 'data/guideline-170-en.pdf:360:3'}, page_content='or phobias;\\nbehavioural changes: nervousness, avoidance behaviour,\\xa0self-isolating tendency, irritability;\\nphysical symptoms: e.g. dry mouth, “lump in the throat”;\\xa0sometimes\\xa0medically unexplained symptoms\\xa0(e.g. feeling of\\nmalaise, hot ﬂashes or chills, diffuse pain);\\nconcentration difﬁculties, sleep problems (difﬁculty getting to sleep, recurrent nightmares).\\n a \\nFootnotes\\n(a) For example, in case of hyperventilation, use a technique that controls the respiratory rate: get the patient in a comfortableposition with his eyes closed. Help him focus on his breathing so that it becomes calmer and more regular, with three-phasebreathing cycles: inhalation (count to three), exhalation (count to three), pause (count to three), etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 361, 'page_label': '362', 'id': 'data/guideline-170-en.pdf:361:0'}, page_content='Page 362 / 409\\nInsomnia\\nLast updated: November 2021\\n\\xa0\\nComplaints may be: difﬁculty falling or remaining asleep, waking up too early in the morning, nightmares, or fatigue.\\nSymptoms occur at least three times a week for at least one month.\\nManagement\\nIf insomnia is related to an organic cause, treat the cause (e.g. administer analgesics for pain).\\xa0If insomnia is related to the use of alcohol, drugs or a medication, management depends on the substance involved.\\xa0If insomnia is related to a particular life event (e.g. bereavement), a short term treatment with a sedative may be useful:\\npromethazine\\xa0PO: 25 mg once daily at bedtime for 7 to 10 days\\nor, if promethazine is not available, hydroxyzine PO: 25 mg once daily at bedtime for 7 to 10 days'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 361, 'page_label': '362', 'id': 'data/guideline-170-en.pdf:361:1'}, page_content='or, as a last resort (risk of addiction), diazepam\\xa0PO: 2 to 5 mg once daily\\xa0at bedtime for 7 days max.\\xa0If insomnia persists, re-evaluate the patient. Insomnia is a common feature in\\xa0depression (Depression),\\xa0post-traumatic\\nstress disorder\\xa0(Post-traumatic stress disorder) and\\xa0anxiety\\xa0disorders (Anxiety). In such cases, the underlying disorder\\nshould be addressed.\\n\\xa0\\n a \\nFootnotes\\n(a) The main drugs known to cause sleep problems are corticosteroids, beta blockers, levodopa/carbidopa, ﬂuoxetine,levothyroxine, etc.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 362, 'page_label': '363', 'id': 'data/guideline-170-en.pdf:362:0'}, page_content='Page 363 / 409\\nAgitation\\nLast updated: November 2021\\n\\xa0\\nPeople who have recently experienced violent events, or with anxiety, depression, psychotic disorders or delirium, may\\nhave periods of psychomotor agitation.\\nAgitation is common in acute intoxication (alcohol/psychostimulant drugs) and withdrawal syndrome. Certain drugs may\\ncause agitation (selective serotonin reuptake inhibitors (SSRIs), levodopa, meﬂoquine, efavirenz, etc.).\\nAgitation may be accompanied by oppositional,\\xa0violent or ﬂeeing behaviour.\\nManagement\\nClinical evaluation is best performed in pairs, in a calm setting, with or without the person’s family/friends, depending on\\nthe situation.\\xa0It is essential to check for signs of delirium. If present, the priority is to identify the cause and treat it (see Acute'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 362, 'page_label': '363', 'id': 'data/guideline-170-en.pdf:362:1'}, page_content='confusional state).\\xa0It may be necessary to administer diazepam 10 mg PO to reduce the agitation and conduct the clinical exam, without\\nover-sedating the patient.\\xa0If the patient is violent or dangerous, urgent sedation is required: diazepam IM 10 mg, to be repeated after 30 to 60\\nminutes if necessary.\\nPhysical restraint should only be used in certain circumstances, strictly following the procedure in place.\\xa0\\xa0Avoid diazepam if agitation is related to acute alcohol intoxication or in case of delirium (risk of respiratory depression).\\nUse haloperidol (see Acute confusional state).\\xa0Alcoholic patients can experience withdrawal symptoms within 6 to 24 hours after they stop drinking. Withdrawal'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 362, 'page_label': '363', 'id': 'data/guideline-170-en.pdf:362:2'}, page_content='syndrome should be taken into consideration in patients who are hospitalised and therefore forced to stop drinking\\nabruptly. In the early phase (pre-delirium tremens), the symptoms include irritability, a general feeling of malaise, profuse\\nsweating and shaking. Treatment consists in:\\ndiazepam PO (10 mg every 6 hours for 1 to 3 days, then reduce and stop over 7 days)\\n+ oral hydration (3 litres of water daily)\\n+ thiamine IM or very slow IV (100 mg 3 times daily for at least 3 days)\\xa0If the agitation is associated with anxiety, see Anxiety; if associated with psychotic disorders, see Psychotic disorders.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 363, 'page_label': '364', 'id': 'data/guideline-170-en.pdf:363:0'}, page_content='Page 364 / 409\\nAcute confusional state (delirium)\\nLast updated: July 2022\\n\\xa0\\nClinical features\\nThe clinical picture includes:\\nThese symptoms develop rapidly (hours or days), and often ﬂuctuate during the course of the day.\\nAgitation, delusions, behavioural disorders and hallucinations (often visual) may be associated symptoms.\\nManagement\\nDelirium almost always has an organic cause:\\nAlso consider the use of drugs which may cause\\xa0delirium (opioid\\xa0analgesics, psychotropic drugs, ﬂuoroquinolones, etc.),\\nuse of toxic substances (alcohol/drugs), or withdrawal from these substances.\\xa0Delirium\\xa0requires hospitalisation.\\n\\xa0The administration of diazepam may increase delirium.\\xa0If it is absolutely necessary to sedate an agitated patient, use\\nlow dose haloperidol for a short time (7 days or less):'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 363, 'page_label': '364', 'id': 'data/guideline-170-en.pdf:363:1'}, page_content='low dose haloperidol for a short time (7 days or less):\\nhaloperidol PO: 0.5 to 1 mg 2 times daily\\nor haloperidol IM: 0.5 to 1 mg, to be repeated if the patient is still agitated 30 to 60 minutes after the ﬁrst injection. \\nIf necessary, administer additional doses every 4 hours, do not exceed a total dose of 5 mg daily.\\xa0In case of\\xa0delirium related to\\xa0alcohol withdrawal (delirium tremens):\\ndisorientation in time and space;\\nimpaired consciousness;\\nconcentration problems;\\nmemory impairment.\\nInfectious: meningitis,\\xa0severe malaria, encephalitis, septicaemia, syphilis, AIDS, etc.\\nMetabolic: hyper/hypoglycaemia, electrolyte imbalance, niacin (vitamin PP or B) or thiamine (vitamin B)\\ndeﬁciencies, etc.\\n3 1\\nEndocrine: thyroid disorders'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 363, 'page_label': '364', 'id': 'data/guideline-170-en.pdf:363:2'}, page_content='deﬁciencies, etc.\\n3 1\\nEndocrine: thyroid disorders\\nNeurological: epilepsy, raised intracranial pressure, head trauma, meningeal haemorrhage, brain tumour, etc.\\nTreat the underlying cause.\\nProvide\\xa0supportive\\xa0care\\xa0(i.e.\\xa0nutrition, ﬂuid, electrolyte balance); ensure bladder function.\\nEnsure that the patient receives only medications appropriate to their needs.\\nTreat pain if needed (see\\xa0Pain, Chapter 1);\\nEnsure adequate sensory\\xa0environment:\\xa0low lightening, limit noise.\\nAdmit the patient to an intensive care unit.\\nAdminister diazepam IV: 10 to 20 mg 4 to 6 times daily, under close supervision with ventilation equipment near at\\nhand.\\nThe goal is to achieve mild sedation without provoking respiratory depression. The doses and duration of the'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 363, 'page_label': '364', 'id': 'data/guideline-170-en.pdf:363:3'}, page_content='treatment are adjusted according to the clinical progress.\\nIV hydration: 2 to 4 litres 0.9% sodium chloride per\\xa024 hours.\\nAdminister thiamine IM or very slow IV (over 30 minutes): 100 mg 3 times daily for 3 to 5 days.\\nMonitor vital signs and blood glucose levels.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 364, 'page_label': '365', 'id': 'data/guideline-170-en.pdf:364:0'}, page_content='Page 365 / 409\\nPost-traumatic stress disorder\\nLast updated: November 2021\\n\\xa0\\nAn event is “traumatic” when someone has been directly confronted with death, either\\xa0by seeing another person being\\nkilled or seriously injured as the result of violence, or by experiencing serious harm, such as a threat to his/her life or\\nphysical integrity (e.g. rape, torture). Exposure to one or several of these events causes feelings of helplessness and\\nhorror.\\xa0Immediate, transitory symptoms (disorientation, anxiety, sadness, ﬂeeing,\\xa0etc.) are to be distinguished from secondary,\\nlong-lasting problems that appear and/or last several weeks or months after the event: post-traumatic stress, often\\nassociated with depression (Depression), or sometimes acute psychosis (Psychotic disorders), even in people with no'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 364, 'page_label': '365', 'id': 'data/guideline-170-en.pdf:364:1'}, page_content='history of psychotic symptoms.\\xa0Post-traumatic stress disorder is characterized by three types of psychological response, generally seen in\\ncombination .\\nHypervigilance\\xa0(constant state of alert), exaggerated startle reaction,\\xa0anxiety, insomnia, poor\\nconcentration;\\xa0sometimes somatic symptoms (sweating, shaking, tachycardia, headache, etc.).\\xa0Re-experiencing is highly distressing and causes disorders that may worsen over time; people isolate themselves,\\nbehave differently, stop fulﬁlling their family/social obligations, and experience diffuse pain and mental exhaustion.\\nManagement\\nPsychological intervention is essential to reduce the suffering, disabling symptoms and social handicaps resulting from'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 364, 'page_label': '365', 'id': 'data/guideline-170-en.pdf:364:2'}, page_content='PTSD.\\xa0It is important to reassure the patient that their\\xa0symptoms are a normal response to an abnormal event. Sessions\\nshould be conducted with tact. The patient should be listened to. Avoid intensely questioning the patient about their\\nemotions: leave it to the patient to decide how far they want to go.\\xa0Associated symptoms (anxiety or insomnia), if persistent, can be relieved by symptomatic treatment (see Anxiety and\\nInsomnia) for no more than two weeks.\\xa0If the patient has severe symptoms (obsessive thoughts, pronounced hypervigilance, comorbid\\xa0despression etc.), the\\npharmacological treatment is\\xa0ﬂuoxetine\\xa0PO\\xa0(20 mg once daily) or paroxetine PO\\xa0(10 to 20 mg once daily) or sertraline\\nPO (50 mg once daily), to be continued for 2 to 3 months after symptoms resolve then, stop gradually.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 364, 'page_label': '365', 'id': 'data/guideline-170-en.pdf:364:3'}, page_content='[1] \\nPersistent re-experiencing\\nThe patient describes:\\nimages, thoughts or perceptions related to the traumatic experience, which intrude despite efforts to block\\nthem out, including at night in the form of distressing dreams;\\nﬂashbacks during which the patient “relives” parts of the traumatic scene.\\nAvoidance\\xa0\\nThe patient tries to avoid:\\xa0\\nplaces, situations and people that might be associated with the trauma;\\nhaving thoughts or feelings related to the trauma; patients may use alcohol, drugs or any psychotropic agents\\nfor this purpose.\\nPersistent perceptions of heightened current threat'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 365, 'page_label': '366', 'id': 'data/guideline-170-en.pdf:365:0'}, page_content='Page 366 / 409\\nReferences\\n1. World Health Organization. Post traumatic stress disorder. International Classiﬁcation of Diseases for Mortality andMorbidity Statistics, Eleventh Revision (ICD-11).https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/2070699808\\xa0[Accessed 26 January 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 366, 'page_label': '367', 'id': 'data/guideline-170-en.pdf:366:0'}, page_content='Page 367 / 409\\nDepression\\nLast updated: July 2022\\n\\xa0\\nDepression is characterised by a set of symptoms that have been present at least two weeks and represent a change\\nfrom previous functioning.\\xa0The standard criteria for diagnosis of major depressive disorder are:\\n\\xa0The features of depression can vary according to the patient’s culture .\\xa0For example, the depressed patient may\\nexpress multiple somatic complaints rather than psychological distress. Depression may also manifest itself as an\\nacute psychotic disorder in a given cultural context.\\nManagement\\nWhen faced with symptoms of depression, consider an underlying organic cause (e.g. hypothyroidism or Parkinson’s\\ndisease) or adverse effects from medical treatment (corticosteroids, cycloserine, efavirenz, meﬂoquine, etc.). Look for'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 366, 'page_label': '367', 'id': 'data/guideline-170-en.pdf:366:1'}, page_content='a triggering event (e.g. sexual violence, recent childbirth and post-partum depression).\\xa0Depressive disorders are the most common mental disorders in patients with severe chronic infectious diseases such\\nas HIV infection or tuberculosis. These disorders should not be neglected, especially as they have a negative impact on\\nadherence to treatment.\\xa0Symptoms of depression are common after a major loss (bereavement, forced displacement, etc.). They gradually\\nsubside, in most cases, with social support. Psychological support may be useful.\\xa0Pharmacological treatment should always be offered, along with counseling, to patients with severe depression\\n(Patient Health Questionnaire-9 (PHQ-9) score > 19; severe functional impairment, psychotic symptoms, and/or'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 366, 'page_label': '367', 'id': 'data/guideline-170-en.pdf:366:2'}, page_content='suicidal risk).\\xa0\\xa0In patients with moderately severe depression (PHQ-9 score 15-19), pharmacological treatment should be considered\\nif there is no improvement after 3 counselling sessions, or from the outset\\u202fif patients express a personal preference for\\nit.\\xa0Before prescribing, make sure that 9-month treatment and follow-up (psychological support, adherence and response)\\nare possible.\\xa0\\nPervasive sadness and/or a lack of interest or pleasure in activities normally found pleasurable and\\nAt least four of the following signs:\\nSigniﬁcant change in appetite or weight\\nInsomnia, especially early waking (or, more rarely, hypersomnia)\\nPsychomotor agitation or retardation\\nSigniﬁcant fatigue, making it difﬁcult to carry out daily tasks\\nDiminished ability to make decisions or concentrate'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 366, 'page_label': '367', 'id': 'data/guideline-170-en.pdf:366:3'}, page_content='Diminished ability to make decisions or concentrate\\nFeelings of guilt or worthlessness, loss of self-conﬁdence or self-esteem\\nFeelings of despair\\nThoughts of death, suicidal ideation or attempt\\n a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 367, 'page_label': '368', 'id': 'data/guideline-170-en.pdf:367:0'}, page_content='Page 368 / 409\\nPreferably use a serotonin reuptake inhibitor (SRI), particularly in older patients.\\xa0Preferably use ﬂuoxetine, except during\\npregnancy when sertraline is preferred.\\nﬂuoxetine\\xa0PO: 20 mg on alternate days for one week, then once daily for 3 weeks, then increase the dose if necessary\\n(max. 40 mg daily); use with caution in patients with severe anxiety disorders or who are immobilised (e.g. wounded)\\nor\\nparoxetine\\xa0PO: 10 mg once daily for 3 days, then 20 mg once daily for 3 weeks, then increase the dose if necessary\\n(max. 40 mg daily), especially if the depression is accompanied by severe anxiety\\nor\\nsertraline\\xa0PO: 25 mg once daily for 3 days, then 50 mg once daily for 3 weeks, then increase the dose if necessary'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 367, 'page_label': '368', 'id': 'data/guideline-170-en.pdf:367:1'}, page_content='(max. 100 mg daily)\\xa0Assess tolerance and response every week for 4 weeks. If the response is inadequate after 4 weeks at optimal dose\\nor if the SRI is poorly tolerated, replace with another SRI (there is no need for a medication-free interval between the\\ntwo).\\nIf SRIs are not available,\\xa0amitriptyline\\xa0PO may be used as an alternative: start with 25 mg\\xa0once daily at bedtime and\\ngradually increase over 8 to 10 days to 75 mg\\xa0once daily (max. 150 mg daily). The therapeutic dose is close to the\\nlethal dose; in older patients, reduce the dose by half.\\xa0There is a delay of 2 to 3 weeks before the antidepressant effect of SRIs\\xa0occurs, at least 4 weeks for amitriptyline.\\nDuring this period, anxiety may be exacerbated and the risk of suicide may increase, especially with'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 367, 'page_label': '368', 'id': 'data/guideline-170-en.pdf:367:2'}, page_content=\"ﬂuoxetine.\\xa0Hydroxyzine PO (25 to 50 mg 2 times daily, max 100 mg daily) or promethazine PO (25 to 50 mg once daily\\nat bedtime) may be given for the ﬁrst 2 weeks of treatment. If there is no improvement after 1 week, change to\\ndiazepam PO (2.5 to 5 mg 2 times daily) for 2 weeks max.\\xa0\\xa0During the ﬁrst 2 to 4 weeks, do not give the patient more tablets than the quantity required for each week or entrust\\nthe treatment to someone in the patient's close entourage that can initially ensure administration of the drug.\\xa0Severe depression carries the risk of suicide. Talking to patients about this will not increase the risk of suicide attempt.\\nOn the contrary – depressed people are often anxious and ambivalent about suicide and feel relieved when able to talk\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 367, 'page_label': '368', 'id': 'data/guideline-170-en.pdf:367:3'}, page_content='about it.\\xa0If major symptoms have not improved after a month of treatment, increase to the maximum dose and assess\\u202fafter 2\\nweeks. If there is no improvement, refer the patient to a psychiatrist, if possible; if not, try a different antidepressant.\\xa0The treatment should always be stopped gradually over a 4-week period.\\xa0Inform the patient about problems\\nassociated with abrupt treatment discontinuation (very common with paroxetine).\\nSpecial situations: pregnant or breast-feeding women\\nRe-evaluate the need to continue treatment. If treatment is still necessary, it is best to continue a treatment that\\nhas been effective rather than switching to a different antidepressant. Nevertheless, if the woman plans to'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 367, 'page_label': '368', 'id': 'data/guideline-170-en.pdf:367:4'}, page_content='breastfeed and is taking ﬂuoxetine, consider switching to another SRI at least 3 weeks before expected delivery to\\nreduce adverse effects in the neonate during breastfeeding. Monitor the neonate the ﬁrst few days of life for signs\\nof toxicity or withdrawal symptoms.\\nDepression is more\\xa0frequent in the post-partum (breast-feeding) period\\xa0than in\\xa0pregnancy.\\xa0In case of severe post-\\npartum depression in a breast-feeding woman: use sertraline as ﬁrst-line option, or if not available, use paroxetine:\\ndo not administer ﬂuoxetine. In case of severe depression during pregnancy: use\\xa0sertraline, avoid\\xa0paroxetine.\\nPregnancy in a woman under antidepressants:\\nDepression occurring during pregnancy or during post-partum period:\\n\\xa0\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 368, 'page_label': '369', 'id': 'data/guideline-170-en.pdf:368:0'}, page_content='Page 369 / 409\\n(a) Hence the importance of working with an “informant” (in the anthropological sense of the word) when dealing withunfamiliar cultural contexts.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 369, 'page_label': '370', 'id': 'data/guideline-170-en.pdf:369:0'}, page_content='Page 370 / 409\\nPsychotic disorders\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nLast updated: July 2022\\n\\xa0\\nPsychoses are characterised by delusions (the patient is convinced of things that are not real and not accounted for by\\nthe person’s cultural background),\\xa0or hallucinations (the patient hears voices that do not exist) and behavioural\\nsymptoms (e.g. strange behaviour, agitation, mutism, opposition, ﬂeeing).\\xa0\\xa0Management includes psychosocial support and antipsychotic medication.\\nTreatment efﬁcacy and prognosis depend\\xa0largely on the quality of the therapeutic relationship established with the\\npatient and their\\xa0family.\\nKeeping the patient at home with outpatient follow-up is preferred if there is no risk of self-harm or harm to others,\\xa0and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 369, 'page_label': '370', 'id': 'data/guideline-170-en.pdf:369:1'}, page_content='if the family is capable of managing the disorder.\\xa0Interpretation of psychotic symptoms vary according to the cultural context . For example, psychotic disorders may\\nbe attributed to charms or to ancestor intervention. Therapeutic approach should take those beliefs into account.\\nPatients are usually already under “traditional” treatments, this should not be seen as an obstacle to conventional\\nmedical treatment.\\n\\xa0\\nAcute psychotic episode\\nChronic psychoses\\nBipolar disorder\\n a \\nFootnotes\\n(a) Hence the importance of working with an “informant” (in the anthropological sense of the word) when dealing withunfamiliar cultural contexts.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 370, 'page_label': '371', 'id': 'data/guideline-170-en.pdf:370:0'}, page_content='Page 371 / 409\\nAcute psychotic episode\\n\\xa0\\n\\xa0\\nLast updated: July 2022\\n\\xa0\\nAn acute psychotic episode can be a one-time occurrence, usually of sudden onset, or can occur repeatedly, or it may\\nbe the early phase of chronic psychosis. It can occur following an adverse life event (e.g. loss, acute stress or trauma).\\nIn postpartum psychosis,\\xa0delusions\\xa0are frequently related to the mother-child relationship.\\xa0Before prescribing antipsychotic medication, consider the possibility of an underlying organic cause (see\\xa0Acute\\nconfusional state (delirium)) or substance\\xa0use; check and record blood pressure, heart rate, weight.\\xa0Antipsychotic treatment is the same as for\\xa0chronic psychoses\\xa0(haloperidol or risperidone) and should last at least 3'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 370, 'page_label': '371', 'id': 'data/guideline-170-en.pdf:370:1'}, page_content='months. After 3 months, if the patient is stable, stop the treatment gradually over 4 weeks, monitoring for potential\\nrelapse.\\xa0If the acute episode lasted more than 3 months, continue antipsychotic treatment for at least 2 years.\\xa0\\xa0\\xa0For severe anxiety or agitation, a\\xa0short-course anxiolytic\\xa0or sedative treatment\\xa0may be added to the antipsychotic\\ntreatment, at the beginning of treatment.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 371, 'page_label': '372', 'id': 'data/guideline-170-en.pdf:371:0'}, page_content='Page 372 / 409\\nChronic psychoses\\n\\xa0\\n\\xa0\\nLast updated: July 2022\\n\\xa0\\nChronic psychoses (schizophrenia, paranoid psychosis, etc.) are deﬁned by speciﬁc clinical characteristics and their\\nlong-term nature.\\nSchizophrenia is characterized by delusions, disorganized thinking, hallucinations, depersonalisation, loss of motivation,\\ndiminished emotional expression, impaired cognition, abnormal behaviour and neglected hygiene.\\xa0Such patients are\\noften very anxious.\\xa0The goal of treatment is to reduce symptoms and improve social and occupational functioning. It offers real beneﬁts,\\neven if chronic symptoms persist (tendency toward social isolation, possible relapses and periods of increased'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 371, 'page_label': '372', 'id': 'data/guideline-170-en.pdf:371:1'}, page_content='behavioural problems, etc.).\\xa0Before prescribing antipsychotic medication, consider the possibility of an underlying organic cause (see Acute\\nconfusional state (delirium)) and use of substances. Check and record blood pressure, heart rate and weight.\\u202f\\xa0Treatment should last at least one year, possibly for life, particularly in\\xa0patients with schizophrenia.\\xa0Uncertainty about\\nthe possibility of follow-up at one year or beyond is no reason not to treat. However, it is better not to start\\npharmacological treatment for patients who have no family/social support (e.g. homeless), provided they do not have\\nsevere behavioural disorders.\\xa0Only prescribe one antipsychotic at a time. To limit the risk of adverse effects, start treatment at a low dose and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 371, 'page_label': '372', 'id': 'data/guideline-170-en.pdf:371:2'}, page_content='gradually increase until the minimum effective dose is reached.\\xa0In older patients, reduce the dose by half, whichever\\nmedication is used.\\xa0\\xa0Haloperidol is the ﬁrst-line antipsychotic.\\xa0Preferably use oral haloperidol with a view to switching to long-acting\\nhaloperidol (haloperidol\\xa0decanoate)\\xa0if the patient is likely to need long-term treatment (e.g. patients with schizophrenia).\\nhaloperidol\\xa0PO: start with 0.5 mg 2 times daily for 3 days then 1 mg 2 times daily until the end of the ﬁrst week;\\nincrease to 2.5 mg 2 times daily the second week. After 2 weeks, assess if the treatment is well tolerated and'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 371, 'page_label': '372', 'id': 'data/guideline-170-en.pdf:371:3'}, page_content='effective. If it is not effective, check adherence;\\xa0if necessary increase to 5 mg 2 times daily (max. 15 mg daily).\\xa0If haloperidol is not available, contraindicated or poorly tolerated, possible alternative are:\\nrisperidone\\xa0PO: 1 mg 2 times daily for one week, then 2 mg 2 times daily for one week; if necessary, increase to 3 mg\\n2 times daily as of the third\\xa0week (max. 10 mg daily).\\nor\\nchlorpromazine\\xa0PO (especially if a sedative effect is required):\\xa0\\n25 to 50 mg once daily in the evening for one week; if necessary, increase to 50 mg in the morning and 100 mg in the\\nevening for one week; if necessary, 100 mg 3 times daily as of the third\\xa0week.\\nor'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 371, 'page_label': '372', 'id': 'data/guideline-170-en.pdf:371:4'}, page_content='or\\xa0\\nolanzapine PO: 10 mg once daily; if necessary, increase by 5 mg every week (max. 20 mg daily).\\xa0In case of extrapyramidal symptoms,\\xa0try reducing the dose of antipsychotic or, if the\\xa0extrapyramidal symptoms are\\nsevere,\\xa0add\\xa0biperiden\\xa0PO: 2\\xa0mg once daily, increase if necessary up to 2 mg 2 to 3 times daily (if biperiden is not\\navailable, use\\xa0trihexyphenidyl\\xa0PO at the same dosage).\\xa0\\xa0For severe anxiety, it is possible to add a\\xa0short-course anxiolytic treatment (for a few days to max. 2 to 3 weeks) to\\nthe antipsychotic treatment:\\ndiazepam\\xa0PO: 2.5 to 5 mg\\xa02 times daily\\xa0For major agitation:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 372, 'page_label': '373', 'id': 'data/guideline-170-en.pdf:372:0'}, page_content='Page 373 / 409\\nhaloperidol\\xa0PO\\xa05 mg +\\xa0promethazine\\xa0PO 25 mg, to be repeated after 60 minutes if necessary. After a further 60\\nminutes, if necessary administer promethazine IM 50 mg.\\nIn case of hostile or agressive behaviour, use IM route (same dose), to be repeated after 30 minutes if necessary;\\nafter a further 30 minutes, if necessary, administer promethazine IM 50 mg.\\nHigh doses of haloperidol can induce extrapyramidal symptoms, add biperiden if necessary.\\ndiazepam\\xa0PO or\\xa0IM:\\xa010 mg to be repeated after 60 minutes if necessary\\nDo not combine two antipsychotics.\\xa0For long-term treatment (e.g. patients\\xa0with schizophrenia) a long-acting antipsychotic drug can be used once the\\npatient has been stabilised on oral treatment. The dosage depends on the oral dose the patient is taking.\\xa0The switch'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 372, 'page_label': '373', 'id': 'data/guideline-170-en.pdf:372:1'}, page_content='from oral to a long-acting antipsychotic should be gradual, according to a speciﬁc protocol. For information, at the\\nend of the transition period from oral to long-acting antipsychotic, the dose of haloperidol decanoate IM administered\\nevery 3 to 4 weeks is approximately:\\xa0\\nFor a patient on\\xa0risperidone\\xa0PO: gradually decrease the dose of risperidone by slowly introducing haloperidol PO then,\\nonce the patient is stabilised, change to haloperidol decanoate every 3 to 4 weeks as above.\\nSpecial situations: pregnant or breast-feeding women\\nIf the patient is not under antipsychotic treatment:\\nIf the patient is already under antipsychotic treatment:\\nDaily dose \\nof haloperidol PO\\nMonthly dose of\\nhaloperidol decanoate IM (a)\\n2.5 mg 25 mg\\n5 mg 50 mg\\n10 mg 100 mg\\n15 mg 150 mg'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 372, 'page_label': '373', 'id': 'data/guideline-170-en.pdf:372:2'}, page_content='haloperidol decanoate IM (a)\\n2.5 mg 25 mg\\n5 mg 50 mg\\n10 mg 100 mg\\n15 mg 150 mg\\n(a) If haloperidol decanoate is not available, ﬂuphenazine IM: 12.5 to 50 mg/injection every 3 to 4 weeks.\\nIn the event of pregnancy in a woman taking antipsychotics: re-evaluate the need to continue the treatment. If\\ntreatment is still necessary, administer the minimal effective dose and avoid combination with an anticholinergic\\n(biperiden or\\xa0trihexphenidyl).\\xa0Monitor the neonate for extrapyramidal symptoms during the ﬁrst few days of life.\\nFirst symptoms of psychosis during pregnancy: start with the lowest dose of haloperidol and only increase slowly if\\nnecessary.\\xa0\\nPost-partum psychosis: if the woman is breast-feeding,\\xa0haloperidol\\xa0should be preferred.\\nLong-acting\\xa0antipsychotics should not be administered.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 373, 'page_label': '374', 'id': 'data/guideline-170-en.pdf:373:0'}, page_content='Page 374 / 409\\nBipolar disorder\\n\\xa0\\n\\xa0\\nLast updated: July 2022\\n\\xa0\\nBipolar disorder is characterised by alternating manic and depressive episodes , generally separated by “normal”\\nperiods lasting several months or years.\\xa0Episodes of mania are characterised by elation, euphoria and hyperactivity accompanied by insomnia, grandiose ideas,\\nand loss of social inhibitions (sexual, in particular).\\nDepressive episodes are often severe, with signiﬁcant risk of suicide.\\nLook for family history\\xa0of similar symptoms (particularly suicide),\\xa0very frequent in bipolar patients.\\xa0Pharmacological treatment:\\nvalproic acid\\xa0PO: 200 mg 2 times daily (Week 1) then 400 mg 2 times daily (Week 2) then 500 mg 2 times daily'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 373, 'page_label': '374', 'id': 'data/guideline-170-en.pdf:373:1'}, page_content='(Week 3). This is usually sufﬁcient to stabilise the patient; if necessary the dose may be increased by 500 mg weekly\\n(max. 1000 mg 2 times daily).\\nor\\ncarbamazepine\\xa0PO: 100 mg 2 times daily (Week 1) then 200 mg 2 times daily (Week 2) then 200 mg 3 times daily\\n(Week 3). This is usually sufﬁcient to stabilise the patient; if necessary the dose may be increased\\xa0by 200 mg\\nweekly\\xa0(max. 1200 mg daily).\\xa0\\n\\xa0Long-term treatment for bipolar disorder is based on continuation of the treatment that led to the remission of the\\nmanic episode: antipsychotic, mood stabilizer, or a combination of both.\\nTreatment can be initiated by a physician trained in mental health, but a consultation should be set up as soon as\\npossible with a specialist.\\xa0\\xa0\\n a'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 373, 'page_label': '374', 'id': 'data/guideline-170-en.pdf:373:2'}, page_content='possible with a specialist.\\xa0\\xa0\\n a \\nEpisodes of mania\\xa0are treated with\\xa0haloperidol\\xa0PO:\\xa05 mg once daily for 3 days, then 7.5 mg for one week; if\\nnecessary, increase by increments of 2.5 mg per week (max. 15 mg daily).\\xa0\\nPossible alternatives:\\xa0\\nrisperidone PO: 2 mg once daily; if necessary, increase in increments of 1 mg per week (max. 6 mg daily).\\xa0\\nor\\xa0\\nolanzapine PO: 10 mg once daily for 3 days; if necessary, increase in increments of 5 mg per week (max. 20 mg\\ndaily).\\xa0\\nIf there is improvement after one week of treatment, continue with the same dose for at least 8 weeks after\\nremission of symptoms.\\nDiazepam\\xa0PO (5 to 10 mg daily) can be added during the ﬁrst 2 to 3 weeks.\\nIf symptoms do not resolve after 2 weeks of antipsychotic treatment at maximum tolerated dose (and 2 different'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 373, 'page_label': '374', 'id': 'data/guideline-170-en.pdf:373:3'}, page_content='antipsychotics have been tried), add a mood stabiliser:\\nTreatment should be continued until at least 8 weeks after complete remission of symptoms. Assess together with\\nthe patient the beneﬁts and risks of pursuing long-term treatment.\\xa0\\nIf is it decided to discontinue antipsychotic treatment,\\u202fmedication should be stopped gradually, monitoring for\\npossible relapse.\\xa0\\nDepressive episodes are treated as for depression (see Depression).\\xa0\\nIf the patient has an episode of mania while on antidepressants, immediately stop antidepressants and\\u202ftreat the\\nepisode of mania as above. An episode of mania while on antidepressants is indicative of bipolar disorder.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 374, 'page_label': '375', 'id': 'data/guideline-170-en.pdf:374:0'}, page_content='Page 375 / 409\\nValproic acid is not recommended in women of childbearing age. If it is necessary to start treatment, use\\ncarbamazepine.\\nIf a woman of childbearing age is already taking valproic acid, switch to carbamazepine by gradually decreasing the\\ndose of valproic acid over a period of 2 weeks (do not stop treatment abruptly) while gradually starting carbamazepine.\\nIf a woman becomes pregnant or is planning pregnancy it is essential to contact a specialist to re-evaluate whether the\\ntreatment is still necessary and adjust the dose if needed.\\n\\xa0\\nFootnotes\\n(a) “Unipolar forms” are characterized by recurring episodes of depression.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 375, 'page_label': '376', 'id': 'data/guideline-170-en.pdf:375:0'}, page_content='Page 376 / 409\\nChapter 12: Other conditions\\nSickle cell disease\\nEpilepsy\\nDiabetes type 2 in adults\\nEssential hypertension in adults\\nHeart failure in adults\\nChronic heart failure\\nAcute heart failure (acute pulmonary oedema)\\nEndemic goitre and iodine deﬁciency'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 376, 'page_label': '377', 'id': 'data/guideline-170-en.pdf:376:0'}, page_content='Page 377 / 409\\nSickle cell disease\\nHomozygous sickle cell disease (SCD) is a life-threatening genetic disorder of haemoglobin (Hb). The abnormal Hb\\n(HbS) results in the distortion of red blood cells into a sickle shape leading to increased destruction (haemolysis), an\\nincrease in blood viscosity and obstruction of capillaries (vaso-occlusion).\\nSCD is common in sub-Saharan Africa (1 to 3% of births), on the American continent, in India and in the Mediterranean\\nbasin.\\nClinical features\\nMajor acute manifestations\\nPainful vaso-occlusive crises (VOC)\\nFever\\nLook for infection: in particular pneumonia, cellulitis, meningitis, osteomyelitis and sepsis (patients are particularly\\nsusceptible to infections especially due to pneumococcus, meningococcus and\\xa0Haemophilus inﬂuenzae); malaria.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 376, 'page_label': '377', 'id': 'data/guideline-170-en.pdf:376:1'}, page_content='Acute severe anaemia\\nStroke\\nSymptoms generally begin after 6 months of age.\\nMajor signs: recurrent painful crises, chronic anaemia, splenomegaly and frequently, growth retardation and\\nmalnutrition in children.\\nSerious acute life threatening complications such as stroke, overwhelming infections and acute chest syndrome.\\nIn populations in whom the disease is frequent, diagnosis is suggested by a family history of similar clinical signs.\\nChildren under 2 years present with the hand-foot syndrome or dactylitis (acute pain and swelling in the hands or\\nfeet).\\nChildren older than 2 years and adults present with acute pain affecting the back, chest, abdomen (can resemble an\\nacute abdomen) and extremities.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 376, 'page_label': '377', 'id': 'data/guideline-170-en.pdf:376:2'}, page_content='acute abdomen) and extremities.\\nYoung children may have non-speciﬁc signs of a VOC: refusal to walk, irritability, lack of appetite, crying, whimpering\\nor moaning when touched, etc.\\nLook for an associated infection that might have precipitated the VOC.\\nIn case of bony pain in a single location, unresponsive to analgesics (or a persistent limp in a child) associated with\\nfever and erythema or swelling, consider an osteomyelitis.\\nThe chronic anaemia is often complicated by acute severe anaemia with gradually appearing fatigue, pallor of the\\nconjunctivae and palms, shortness of breath, tachycardia, syncope or heart failure.\\nThe acute anaemia can be due to:\\nAcute severe haemolysis often secondary to malaria: fever, haemoglobinuria (dark urine) and yellow\\nconjunctivae.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 376, 'page_label': '377', 'id': 'data/guideline-170-en.pdf:376:3'}, page_content='conjunctivae.\\nSplenic sequestration (trapping of blood cells in the spleen), mostly in children 1 to 4 years: sudden enlargement\\nof the spleen, severe left upper quadrant pain, thrombocytopenia. Can lead to shock.\\nAplastic crisis (transient suspension of red blood cell production by the bone marrow): impalpable spleen and\\nabsence of reticulocytes.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 377, 'page_label': '378', 'id': 'data/guideline-170-en.pdf:377:0'}, page_content='Page 378 / 409\\nAcute chest syndrome (ACS)\\nPriapism\\nPainful prolonged erection in the absence of sexual stimulation, also occurring in young boys. Risk of necrosis and\\nirreversible erectile dysfunction.\\nLaboratory and other investigations\\nDiagnosis\\nOther examinations\\n\\xa0\\nManagement of major acute manifestations\\nMost often ischaemic (due to vaso-occlusion in cerebral vessels) but a stroke can also be haemorrhagic.\\nSudden loss of motor function or aphasia, in children and in adults.\\nSigns can resemble meningitis and cerebral malaria: headache, photophobia, vomiting, stiff neck, alteration of\\nconsciousness and neurologic signs or rarely seizures.\\nChest pain, tachypnoea, respiratory distress, hypoxia; fever (more frequent in children); pulmonary inﬁltrate on chest\\nx-ray. Often proceeded by a VOC.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 377, 'page_label': '378', 'id': 'data/guideline-170-en.pdf:377:1'}, page_content='x-ray. Often proceeded by a VOC.\\nComplications: multiorgan failure (lung, liver, kidney).\\nHb electrophoresis conﬁrms the diagnosis but is often unavailable.\\nIf not available, a positive Emmel test (or sickling test) in the presence of clinical signs of sickle cell disease\\nsupports the diagnosis.\\nTests Indications\\nHaemoglobin • At the time of diagnosis and annually (frequently 7 to 9 g/dl).\\n• In case of VOC, fever, acute anaemia (≤ 5 g/dl or drop in Hb ≥ 2 g/dl below the\\npatient’s baseline), stroke, ACS.\\n• For monitoring of transfused patients.\\nPlatelets • At the time of diagnosis and annually.\\n• In case of acute anaemia (thrombocytopenia - platelet count ≤ 100 000/mm if\\nsplenic sequestration).\\n3\\nUrine dipstick • In case of fever: look for a urinary tract infection.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 377, 'page_label': '378', 'id': 'data/guideline-170-en.pdf:377:2'}, page_content='3\\nUrine dipstick • In case of fever: look for a urinary tract infection.\\n• In case of acute severe anaemia: look for haemoglobinuria.\\nMalaria test In case of VOC, fever, acute anaemia or stroke.\\nLumbar puncture In case of fever with meningeal signs or unexplained coma.\\nOther\\n(if available)\\n• Complete blood count and reticulocyte count.\\n• Blood culture in case of fever.\\n• X-ray if suspicion of pneumonia, osteomyelitis, ACS.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 378, 'page_label': '379', 'id': 'data/guideline-170-en.pdf:378:0'}, page_content='Page 379 / 409\\nPainful vaso-occlusive crisis (VOC)\\n\\xa0For the treatment of pain according to intensity, see\\xa0Pain\\xa0(Chapter 1).\\nFever and infection\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\n\\xa0\\nceftriaxone\\xa0slow IV injection (3 minutes) or IV infusion (30 minutes)\\nChildren < 40 kg: 50 mg/kg every 12 hours\\nChildren ≥ 40 kg and adults: 2 g\\xa0every 12 hours\\n+\\xa0cloxacillin\\xa0IV infusion (60 minutes)\\nChildren < 40 kg: 50 mg/kg every 6 hours\\xa0\\nChildren ≥ 40 kg and adults: 3 g\\xa0every 6 hours\\xa0\\nAdminister IV therapy for at least 14 days. Then if the patient has improved, change to the oral route for an\\nadditional 14 days of treatment with a combination of:\\nciproﬂoxacin\\xa0PO\\nChildren < 35 kg: 15 mg/kg 2 times daily\\nChildren ≥ 35 kg and adults: 500 mg\\xa02 times daily\\n+\\xa0amoxicillin/clavulanic acid\\xa0PO (see below)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 378, 'page_label': '379', 'id': 'data/guideline-170-en.pdf:378:1'}, page_content='+\\xa0amoxicillin/clavulanic acid\\xa0PO (see below)\\xa0\\xa0\\nceftriaxone\\xa0IM or slow IV \\xa0injection (3 minutes) or IV infusion (30 minutes)\\nChildren < 20 kg: 50 mg/kg once daily (max. 2 g/day)\\nChildren ≥ 20 kg and adults: 1 to 2 g once daily\\xa0After 48 hours re-evaluate the patient:\\namoxicillin/clavulanic acid\\xa0(co-amoxiclav) PO for 7 to 10 days.\\nUse formulations in a ratio of 8:1 or 7:1 exclusively. The dose is expressed in amoxicillin:\\nChildren < 40 kg: 50 mg/kg 2 times daily\\xa0\\nModerate pain (at home):\\nGenerous oral hydration (water, soup, juice, coconut water): minimum 100 ml/kg daily in children and 50 ml/kg\\ndaily in adults (2.5 to 3 litres daily);\\nWarm compresses (application of cold is contra-indicated);\\nLevel 1 (paracetamol and ibuprofen) and level 2 (tramadol) analgesics;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 378, 'page_label': '379', 'id': 'data/guideline-170-en.pdf:378:2'}, page_content='Level 1 (paracetamol and ibuprofen) and level 2 (tramadol) analgesics;\\nIf pain is not controlled at home within 24 hours, seek medical attention.\\nSevere pain or pain not controlled at home (in hospital):\\nPO hydration (as above); if the patient is unable to drink sufﬁciently, IV hydration (Appendix 1); in the event of\\ndehydration, treat according to the degree of dehydration (see Dehydration, Chapter 1);\\nLevel 3 analgesics (morphine);\\nDo not give routine antibiotics in the absence of fever; do not transfuse for VOC.\\nAdmit to hospital:\\nAll children less than 2 years;\\nChildren with fever ≥ 38.5 °C and adults\\xa0with fever ≥ 39.5 °C; patients who are critically ill appearing or have\\nacute anaemia.\\n a \\xa0\\nPO or IV hydration (Appendix 1).\\nTreat malaria if present.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 378, 'page_label': '379', 'id': 'data/guideline-170-en.pdf:378:3'}, page_content='acute anaemia.\\n a \\xa0\\nPO or IV hydration (Appendix 1).\\nTreat malaria if present.\\nTreat bacterial infections according to cause.\\nTreat all patients with respiratory symptoms for pneumonia and ACS.\\nIn case of osteomyelitis:\\n b \\n c\\nIf the source of infection is unknown:\\n b \\nIf the patient is improving (afebrile, can drink), change to:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 379, 'page_label': '380', 'id': 'data/guideline-170-en.pdf:379:0'}, page_content='Page 380 / 409\\nChildren ≥ 40 kg and adults:\\nRatio 8:1: 3000 mg daily (2 tab of 500/62.5 mg 3 times daily)\\nRatio 7:1: 2625 mg daily (1 tab of 875/125 mg 3 times\\xa0daily)\\nPatients over 2 years without acute anaemia can continue treatment as outpatients.\\nPatients under 2 years or with acute anaemia or who cannot be monitored and treated at home by their family\\nshould complete PO antibiotherapy in hospital.\\nAcute severe haemolysis\\nAplastic crisis\\nSplenic sequestration\\n\\xa0Note: splenectomy is contra-indicated (high operative mortality).\\nStroke\\nIf the patient is not improving, continue ceftriaxone until the patient is afebrile, then, change to PO treatment.\\nMonitor for acute anaemia.\\nAdmit to hospital.\\nTreat malaria if present.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 379, 'page_label': '380', 'id': 'data/guideline-170-en.pdf:379:1'}, page_content='Monitor for acute anaemia.\\nAdmit to hospital.\\nTreat malaria if present.\\nTransfuse packed red blood cells if Hb < 5 g/dl or drop of 2 g/dl below the patient’s baseline. Target a Hb level of\\n9 g/dl.\\n d e \\xa0\\nStart with 10 to 15 ml/kg in 3 to 4 hours. For information, 10 ml/kg of packed red blood cells usually raise the Hb\\nby 2.5 g/dl.\\nRepeat the Hb. If a second\\xa0transfusion is needed, check for signs of ﬂuid overload before starting the\\ntransfusion.\\nMeasure Hb and perform urine dipstick in the following days. Further transfusions may be necessary if\\nhaemolysis is ongoing.\\nAdmit to hospital.\\nTreat an associated bacterial infection if present.\\nTransfuse as for haemolysis. Repeat the Hb every other day. An increasing reticulocyte count and a gradual'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 379, 'page_label': '380', 'id': 'data/guideline-170-en.pdf:379:2'}, page_content='increase of the Hb indicate improvement. Follow patient until they have reached their baseline Hb.\\nAdmit to hospital.\\nTreat hypovolaemic shock if present.\\nMonitor the size of the spleen.\\nTransfuse if Hb < 5 g/dl, target a Hb level of 7 to 8 g/dl maximum.\\nAdminister ceftriaxone as above.\\nAfter clinical improvement, monitor for relapse (follow the size of the spleen).\\nAdmit to hospital.\\nThe treatment of choice for ischaemic stroke is an exchange transfusion to lower the concentration of HbS.\\nTransfer the patient to a specialized facility for further management (including prophylactic therapy to prevent\\nrecurrences with transfusion program, hydroxyurea).\\nIf the patient is awaiting transfer or if transfer is not possible:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 379, 'page_label': '380', 'id': 'data/guideline-170-en.pdf:379:3'}, page_content='If the patient is awaiting transfer or if transfer is not possible:\\nOxygen continuously, at least 5 litres/minute or to maintain the SpO\\xa0between 94 and 98%.2\\nTreat seizures if present.\\nTransfuse if the Hb ≤ 9 g/dl. Target Hb of 10 g/dl.\\nAfter the transfusion provide IV hydration (Appendix 1).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 380, 'page_label': '381', 'id': 'data/guideline-170-en.pdf:380:0'}, page_content='Page 381 / 409\\nAcute chest syndrome\\nceftriaxone\\xa0slow IV \\xa0injection (3 minutes) or IV infusion (30 minutes) for 7 to 10 days\\nChildren < 20 kg: 50 mg/kg once daily (max. 2 g daily)\\nChildren ≥ 20 kg and adults: 1 to 2 g once daily\\n+\\xa0azithromycin\\xa0PO for 5 days\\nChildren: 10 mg/kg once daily (max. 500 mg daily)\\nAdults: 500 mg on D1 then 250 mg once daily from D2 to D5\\n\\xa0salbutamol\\xa0aerosol (100 micrograms/puff)\\nChildren and adults: 2 to 4 puffs with a spacer every 10 to 30 minutes as needed\\nPriapism\\nPrevention of complications\\nCertain complications can be avoided with appropriate health education of patients/families, routine preventive care\\nand regular follow-up.\\nEducation of patients (including children) and families\\nAdmit to hospital.\\nMeasure SpO\\xa0and administer oxygen as in stroke.2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 380, 'page_label': '381', 'id': 'data/guideline-170-en.pdf:380:1'}, page_content='Admit to hospital.\\nMeasure SpO\\xa0and administer oxygen as in stroke.2\\nPO hydration as for a VOC;\\xa0if the patient is unable to drink sufﬁciently, IV hydration (Appendix 1) while monitoring for\\nﬂuid overload; in the event of ﬂuid overload, administer one dose of furosemide IV (see Dehydration, Chapter 1).\\nAntibiotics:\\n b \\nTransfuse if symptoms are unresponsive to antibiotics and Hb < 9 g/dl.\\nIf wheezing is present treat with:\\nEncourage deep breathing (incentive spirometry hourly).\\nTreat pain (see\\xa0Pain, Chapter 1).\\nPO hydration as for a VOC; IV hydration if necessary (Appendix 1) and treat dehydration if present (see\\xa0Dehydration,\\nChapter 1).\\nEncourage urination, apply warm compresses, treat pain.\\nErection > 4 hours: consider transfusion and refer to surgery.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 381, 'page_label': '382', 'id': 'data/guideline-170-en.pdf:381:0'}, page_content='Page 382 / 409\\n\\xa0\\nRoutine preventive care\\nphenoxymethylpenicillin\\xa0(penicillin V) PO until age 15 years (at least until 5 years):\\nChildren < 1 year: 62.5 mg 2 times daily\\nChildren 1 to < 5 years: 125 mg\\xa02 times daily\\nChildren 5 to 15 years: 250 mg\\xa02 times daily\\xa0\\nEnsure that the child’s immunisations are up to date; if not, administer catch up vaccines:\\n\\xa0\\nfolic acid\\xa0PO(life-long treatment)\\nChildren < 1 year: 2.5 mg once daily\\nBasic knowledge\\nDisease\\nTreatment\\nMonitoring\\nChronic, necessarily transmitted by both parents, non-contagious.\\nRoutine (see below) and symptomatic (pain).\\nSize of the spleen, temperature, baseline Hb.\\nMajor precipitating factors of a painful crisis and how to prevent them\\nCold\\nExcessive heat\\nTight clothing\\nDehydration\\nExcessive effort\\nInfections'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 381, 'page_label': '382', 'id': 'data/guideline-170-en.pdf:381:1'}, page_content='Cold\\nExcessive heat\\nTight clothing\\nDehydration\\nExcessive effort\\nInfections\\nWear warm clothing, avoid bathing in cold water.\\nFor example, avoid going out at mid-day.\\nWear wide comfortable clothing without elastics.\\nDrink plenty of ﬂuids.\\nModerate physical activity is beneﬁcial.\\nFollow routine treatments (including vaccination).\\nPrincipal complications requiring the patient to seek urgent medical advice\\nPain unresponsive to analgesia after 24 hours or severe from the start.\\nAny fever (do not treat at home).\\nRespiratory problems (cough, difﬁculty breathing, chest pain).\\nDiarrhoea/vomiting and inability to drink.\\nDehydration (dark, infrequent urine).\\nAnaemia (pale or yellow conjunctivae, pale palms, enlarged spleen).\\nPrevention of pneumococcal infections\\nImmunization\\nChildren \\n< 5 years'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 381, 'page_label': '382', 'id': 'data/guideline-170-en.pdf:381:2'}, page_content='Prevention of pneumococcal infections\\nImmunization\\nChildren \\n< 5 years\\nDTP, hepatitis B, polio, measles, H. inﬂuenzae type B vaccines\\nPneumococcal conjugate vaccine (PCV13 or, if not available, PCV10)\\nMeningococcal conjugate vaccine in endemic areas\\nAt 2 years: pneumococcal 23-valent polysaccharide vaccine, at least 8 weeks after the last\\nPCV13 or 10\\nChildren \\n> 5 years\\nDTP or Td, hepatitis B, polio, measles, H. inﬂuenzae type B vaccines\\nPneumococcal conjugate vaccine PCV13 (or PCV10)\\nMeningococcal conjugate vaccine in endemic areas\\nTo support red blood cell production\\n f'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 382, 'page_label': '383', 'id': 'data/guideline-170-en.pdf:382:0'}, page_content='Page 383 / 409\\nChildren ≥ 1 year and adults: 5 mg once daily\\xa0\\nmeﬂoquine\\xa0PO\\nChildren 6 months to 5 years and > 5 kg: 5 mg base/kg once weekly\\nDo not use to treat malaria.\\xa0\\nRoutine follow-up of patients\\nChildren < 5 years: every 1 to 3 months;\\nChildren ≥ 5 years and adults: every 3 to 6 months.\\n\\xa0\\nMalaria chemoprophylaxis (if malaria prevalence ≥ 5%)\\nProvide nutritional support at hospital discharge.\\nBetween crises, for information:\\nAfter a crisis: as often as necessary, according to the clinical course.\\nFootnotes\\n(a) Critically ill appearing child: weak grunting or crying, drowsy and difﬁcult to arouse, does not smile, disconjugate or anxiousgaze, pallor or cyanosis, general hypotonia.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 382, 'page_label': '383', 'id': 'data/guideline-170-en.pdf:382:1'}, page_content='(b) For administration by IV route, ceftriaxone powder should to be reconstituted in water for injection only. For administrationby IV infusion, dilute each dose of ceftriaxone in 5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kgand in a bag of 100 ml of 0.9% sodium chloride or 5% glucose in children 20 kg and over and in adults.\\n(c) Cloxacillin powder for injection should be reconstituted in 4 ml of water for injection. Then dilute each dose of cloxacillin in5 ml/kg of 0.9% sodium chloride or 5% glucose in children less than 20 kg and in a bag of 100 ml of 0.9% sodium chloride or5% glucose in children 20 kg and over and in adults.\\n(d) Always inquire how many transfusions a patient has previously received (risk of iron overload).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 382, 'page_label': '383', 'id': 'data/guideline-170-en.pdf:382:2'}, page_content='(e) Do not transfuse whole blood if possible (risk of ﬂuid overload).\\n(f) Iron is contraindicated in patients who have received multiple transfusions. Avoid combined preparations of iron and folicacid.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 383, 'page_label': '384', 'id': 'data/guideline-170-en.pdf:383:0'}, page_content='Page 384 / 409\\nEpilepsy\\nLast updated: October 2024\\n\\xa0\\nEpilepsy is a chronic neurological disorder characterized by recurrent seizures.\\xa0People with epilepsy frequently face discrimination and stigma as well as social and economic difﬁculties. They are\\nalso at risk of mental, behavioural or cognitive disorders as well as seizure-related injuries. Management of\\ncomorbidities and patient/family education and support are essential.\\xa0Seizures are usually short episodes. A seizure lasting longer than\\xa05\\xa0minutes (or 2 or more seizures in 5 minutes without\\ncomplete restoration of baseline consciousness\\xa0between seizures) is a medical emergency, see\\xa0Generalised tonic-\\nclonic seizures and convulsive status epilepticus, Chapter 1.\\nClinical features'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 383, 'page_label': '384', 'id': 'data/guideline-170-en.pdf:383:1'}, page_content='clonic seizures and convulsive status epilepticus, Chapter 1.\\nClinical features\\nManifestations of epilepsy (i.e. seizures) are varied. It is critical to recognize the type of seizure to determine patient\\nmanagement.\\nSeizures are classiﬁed as follows :\\xa0Generalized onset seizures\\n\\xa0Focal onset seizures\\n\\xa0Epilepsy is clinically diagnosed when 2 or more \"unprovoked\" seizures (i.e. seizures not caused by a temporary\\nreversible condition) of any type occur more than 24 hours apart .\\nTreatment principles\\nRarely, ASMs may cause a paradoxical increase in seizure frequency, mainly at the start of treatment or after an\\nincrease in dose.\\n [1] \\nTonic-clonic seizures:\\xa0contraction of muscles, including respiratory muscles (tonic phase), followed by rhythmic'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 383, 'page_label': '384', 'id': 'data/guideline-170-en.pdf:383:2'}, page_content='jerking of the arms and legs (clonic phase) and\\xa0loss of consciousness;\\nMyoclonic seizures: sudden and brief contractions of a muscle or group of muscles;\\nAtonic seizures: sudden loss of muscle tone, frequently resulting in falls;\\nAbsence seizures:\\xa0brief (a few seconds) impairment of consciousness and cessation of activity; most common in\\nchildren from 4 years of age.\\nStart with localised symptoms (e.g.\\xa0jerking movements of one body part or repetitive lips smacking) and sometimes\\nspread to\\xa0the rest of the body, becoming generalised.\\n [2] [3] \\nOnce the diagnosis of epilepsy (or seizures requiring long-term treatment) has been made, an antiseizure medication\\n(ASM) is prescribed to prevent the occurrence of new seizures.\\nThe treatment prescribed should be a monotherapy (i.e. a single ASM).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 383, 'page_label': '384', 'id': 'data/guideline-170-en.pdf:383:3'}, page_content='The treatment prescribed should be a monotherapy (i.e. a single ASM).\\nFor choosing an ASM, see\\xa0Choice of an antiseizure medication. The likelihood of continued ASM availability should\\nalso be considered when making the choice.\\nTreatment should be taken daily without interruption for the long term. Abruptly stopping or reducing an ASM dose is\\nlikely to provoke seizures.\\nLong-term patient follow-up is required, see\\xa0Patient follow-up. Any change in treatment (dose increments, ASM\\nsubstitution or discontinuation) requires close clinical monitoring.\\nIf seizures are not controlled, assess adherence to treatment, consider increasing the dose if tolerated, up to the\\nmaximum dose if necessary.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 384, 'page_label': '385', 'id': 'data/guideline-170-en.pdf:384:0'}, page_content='Page 385 / 409\\nChoice of an antiseizure medication\\nAn ASM is selected according to:\\n\\xa0\\nIf seizures are still not controlled or treatment is not tolerated, gradually change to another ASM\\xa0(slowly increase\\nthe dose of the new ASM\\xa0then slowly decrease the dose of the ﬁrst ASM until complete substitution).\\nCombination therapy should be considered only if two different ASMs used in monotherapy have failed.\\nStopping an antiseizure treatment may be considered when the patient has been seizure-free for at least 2 years\\n. The beneﬁts/risks of stopping the ASM should be discussed with the patient (seizures may recur after stopping\\ntreatment). The dose should be slowly tapered (e.g. by 10% every 2 weeks)\\xa0over a period of at least 3 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 384, 'page_label': '385', 'id': 'data/guideline-170-en.pdf:384:1'}, page_content='Patients should seek medical attention if seizures recur during or after stopping treatment.\\n [4]\\nPatient and family education is essential.\\xa0 Provide information about epilepsy as a disease, the beneﬁts of\\ntreatment, ways to maximize control (including adherence to treatment) and ﬁrst aid for seizures. Explain that\\npeople with epilepsy can lead normal lives when certain safety measures\\xa0are taken (e.g. not swimming alone, not\\ncooking over open ﬂames) . [4] [5] \\nthe type of seizure: some ASMs may exacerbate some symptoms,\\xa0\\nthe patient’s characteristics: age, sex, pregnancy or breastfeeding status, comorbidities, and related treatments,\\nthe ASM’s adverse effect proﬁle: in general, newer ASMs (e.g. levetiracetam) are safer, better tolerated, and have'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 384, 'page_label': '385', 'id': 'data/guideline-170-en.pdf:384:2'}, page_content='fewer drug interactions than older ASMs (e.g. carbamazepine, phenobarbital, phenytoin, valproic acid).\\nAge/Type of seizures First choice Second choice Third choice\\nChildren 1 month to < 2 years\\nMotor, generalised\\n(tonic-clonic, myoclonic , atonic ) (a)  (b) levetiracetam (LEV) phenobarbital (PB) carbamazepine (CBZ)\\nor phenytoin\\xa0(PHT)\\nNon-motor, generalised (absence) – – –\\nFocal\\xa0(partial) LEV or CBZ PB or PHT –\\nGirls 2 to < 10 years, boys ≥ 2 years and men\\nMotor, generalised\\n(tonic-clonic, myoclonic , atonic ) (a)  (b) \\nLEV or\\nvalproic acid\\xa0(VPA)\\nCBZ or PB\\nor PHT –\\nNon-motor, generalised (absence ) (c) LEV or VPA – –\\nFocal\\xa0(partial) LEV or CBZ VPA PB or PHT\\nGirls ≥ 10 years and women\\nMotor, generalised\\n(tonic-clonic, myoclonics , atonic ) (a)  (b) LEV CBZ or PHT PB'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 384, 'page_label': '385', 'id': 'data/guideline-170-en.pdf:384:3'}, page_content='(tonic-clonic, myoclonics , atonic ) (a)  (b) LEV CBZ or PHT PB\\nNon-motoras, generalised (absence ) (c) LEV – –\\nFocal\\xa0(partial) LEV CBZ or PHT PB'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 385, 'page_label': '386', 'id': 'data/guideline-170-en.pdf:385:0'}, page_content='Page 386 / 409\\nChildren\\nPatients over 65 years\\nPregnant women and girls\\n\\xa0In all cases:\\nWomen and girls of childbearing age\\n(a) For myoclonic seizures:\\xa0CBZ and PHT are not recommended (risk of worsening symptoms).\\n(b) For atonic seizures:\\xa0CBZ is not recommended (risk of worsening symptoms).\\n(c) For absence seizures: CBZ, PB and PHT are not recommended (risk of worsening symptoms).\\nVPA is contraindicated in children less than 2 years (increased risk of hepatotoxicity).\\nLEV is preferred in older patients . [6] \\nThe risk of major congenital malformations (MCM) is lower with monotherapy than with combined therapy .\\xa0 [7] \\nASMs that can be used during pregnancy include:\\nLEV: ﬁrst-line, safest ASM with the lowest risk of MCM .\\xa0 [7] [8] \\nASMs other than LEV (only if LEV is not available):'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 385, 'page_label': '386', 'id': 'data/guideline-170-en.pdf:385:1'}, page_content='ASMs other than LEV (only if LEV is not available):\\nCBZ and PHT:\\xa0associated with an intermediate risk of MCM ;\\xa0 [7] [8] \\nPB: associated with a high risk of MCM \\xa0and small for gestational age. [7] [8] \\nIf taking ASM treatment before pregnancy:\\nLEV: continue treatment under closer monitoring.\\nASMs other than LEV:\\nThe beneﬁts/risks of substitution for a safer ASM should be discussed with patients.\\xa0\\nSubstitution may be beneﬁcial for the foetus but may also be a risk for the mother and the foetus if it results\\nin loss of seizure control. The term of pregnancy should be taken into account. For substitution with a safer\\nASM, see\\xa0Treatment principles. A substitution frequently takes 2 to 3 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 385, 'page_label': '386', 'id': 'data/guideline-170-en.pdf:385:2'}, page_content='ASM, see\\xa0Treatment principles. A substitution frequently takes 2 to 3 months.\\nVPA must not be prescribed in pregnant women and girls. It is associated with the highest risk of MCM and\\nneurodevelopmental disorders in children exposed in utero . In situations where VPA would be the only option,\\ndivide\\xa0doses over the day\\xa0to minimize peaks in VPA plasma concentrations.\\n [7] [8] \\nThe parents should be informed of current knowledge in terms of risks for the unborn child, in particular when the risk\\nof foetotoxicity is high.\\nAdminister the lower effective dose (foetal harms are mainly dose-dependent).\\nASM plasma concentrations may decrease during pregnancy. If the dose needs to be increased antepartum,\\xa0start'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 385, 'page_label': '386', 'id': 'data/guideline-170-en.pdf:385:3'}, page_content='reducing it from D3-D4 postpartum\\xa0to gradually return to the dose effective before pregnancy.\\nStart taking high dose folic acid to reduce the risk of MCM (5 mg daily for the ﬁrst trimester ). [9] a \\nAfter pregnancy, the beneﬁts of breastfeeding are considered to outweigh the risk of adverse effects of ASMs . [10] \\nThe choice of an ASM is based on the same criteria as per pregnant women and girls due to the possibility of\\nundiagnosed or future pregnancies.\\nPreconception and/or contraception counselling should be offered.\\xa0\\nIf considering pregnancy, depending on the ASM currently taken, consider a safer ASM.\\xa0\\nWhen planning pregnancy, start taking folic acid before conception to reduce the risk of MCM.\\nIf no pregnancy is planned, effective contraception should be provided:'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 385, 'page_label': '386', 'id': 'data/guideline-170-en.pdf:385:4'}, page_content='If no pregnancy is planned, effective contraception should be provided:\\nPatient taking CBZ, PB or PHT: injectable medroxyprogesterone (DMPA) or levonorgestrel-containing or\\ncopper intrauterine device . [7] \\nPatient taking LEV or VPA: as above, but contraceptive implants and oral contraceptives can also be used .\\xa0 [7]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 386, 'page_label': '387', 'id': 'data/guideline-170-en.pdf:386:0'}, page_content=\"Page 387 / 409\\nDosage of antiseizure medications\\nStart with a low dose then increase gradually based on patient's response (seizure control) and tolerance (occurrence\\nof adverse effects). The following doses are given as a guide and should be ajusted individually.\\xa0carbamazepine\\xa0PO:\\n\\xa0levetiracetam\\xa0PO:\\n\\xa0phenobarbital\\xa0PO:\\n\\xa0phenytoin PO:\\n\\xa0valproic acid\\xa0(sodium valproate) PO:\\nPatient follow-up\\nIn situations where VPA would be the only effective option (i.e. after conﬁrmation that other ASMs are ineffective\\nor poorly tolerated), a blood pregnancy test should be performed before starting the treatment, then regularly if the\\npatient is not on effective contraception.\\nIf pregnancy occurs, see\\xa0Pregnant women and girls.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 386, 'page_label': '387', 'id': 'data/guideline-170-en.pdf:386:1'}, page_content='If pregnancy occurs, see\\xa0Pregnant women and girls.\\nChildren 1 month\\xa0to 11 years:\\xa0start with\\xa05 mg/kg once daily\\xa0or 2.5 mg/kg 2 times daily;\\xa0increase\\xa0the daily dose\\xa0by\\nincrements\\xa0of\\xa02.5 to 5 mg/kg\\xa0every 3 to 7 days, up to\\xa05 mg/kg 2 or 3 times daily\\xa0if necessary\\xa0(max. 20 mg/kg daily).\\nChildren 12 years and over: start with 100 to 200 mg once daily or 50 to 100 mg 2 times daily; increase\\xa0the daily\\ndose by increments of 100 to 200 mg every week, up to 200 to 400 mg 2 or 3 times daily if necessary (max. 1800\\nmg daily).\\nAdults:\\xa0start with\\xa0100 to 200 mg once daily or\\xa050 to 100 mg\\xa02 times\\xa0daily;\\xa0increase\\xa0the daily dose\\xa0by\\nincrements\\xa0of\\xa0100 to 200 mg\\xa0every week,\\xa0up to\\xa0400 mg 2\\xa0or\\xa03 times daily\\xa0if necessary (max. 2 g daily).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 386, 'page_label': '387', 'id': 'data/guideline-170-en.pdf:386:2'}, page_content='Children 1 to 5 months: start with 7 mg/kg once daily; increase to 7 mg/kg 2 times daily after 2 weeks, then by\\nincrements of 7 mg/kg\\xa02 times daily\\xa0every 2 weeks if necessary (max. 21 mg/kg 2 times daily).\\nChildren 6 months to 17 years (< 50 kg): start with 10 mg/kg once daily; increase\\xa0to\\xa010 mg/kg 2 times daily after\\xa02\\nweeks, then\\xa0by increments of 10 mg/kg 2 times daily every 2 weeks if necessary (max. 30 mg/kg 2 times daily).\\nChildren 50 kg and over\\xa0and adult: start with 250 mg 2 times daily; increase\\xa0to 500 mg 2 times daily after\\xa02 to 4\\nweeks,\\xa0then\\xa0by increments of 500 mg 2 times daily every 2 to 4 weeks if necessary (max. 1.5 g\\xa02 times daily).\\nChildren\\xa01 month to 11 years: start with 2 to 3 mg/kg once daily at bedtime or 1 to 1.5 mg/kg 2 times daily for 2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 386, 'page_label': '387', 'id': 'data/guideline-170-en.pdf:386:3'}, page_content='weeks; increase the daily dose by increments of 1 to 2 mg/kg every week, up to\\xa02 to 6\\xa0mg/kg\\xa0once daily if\\nnecessary.\\nChildren 12 years and over and adults: start with 1 mg/kg (max. 60 mg) once daily at bedtime\\xa0for 2 weeks; increase\\nthe daily dose\\xa0by increments of 15 to 30 mg every week, up to 3 mg/kg once daily if needed (max. 180 mg daily).\\nChildren\\xa01 month to 11 years: start with 1.5 to 2.5\\xa0mg/kg 2 times\\xa0daily; increase\\xa0the daily dose by increments of 5\\nmg/kg every 3 to 4 weeks, up to 2.5 to 5 mg/kg 2 times daily if necessary\\xa0(max.\\xa07.5 mg/kg 2 times daily\\xa0or 300 mg\\ndaily).\\nChildren\\xa012 years and over: start with 75 to 150 mg 2 times daily; increase\\xa0the daily dose by increments of 25\\xa0mg\\nevery 3 to 4\\xa0weeks, up to 150 to 200 mg 2 times daily\\xa0if necessary\\xa0(max. 300 mg 2 times daily).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 386, 'page_label': '387', 'id': 'data/guideline-170-en.pdf:386:4'}, page_content='Adults:\\xa0start with 150 to 300 mg once daily or 75 to 150 mg 2 times daily; increase\\xa0the daily dose by increments of\\n50\\xa0mg every 3 to 4 weeks, up to 200 to 400 mg once daily or 100 to 250 mg 2 times daily if necessary (max. 400 mg\\nonce daily or 300 mg 2 times daily).\\nChildren 2\\xa0to 11 years:\\xa0start with 10 to 15 mg/kg once daily or 5 to 7.5 mg/kg\\xa02 times daily;\\xa0increase\\xa0the daily dose\\nby increments of 5\\xa0to 10\\xa0mg/kg every\\xa0week, up to 12.5 to 15 mg/kg 2 times daily if necessary (max. 600 mg 2 times\\ndaily).\\nChildren 12 years and over and adults:\\xa0start with 500 to 600 mg once daily;\\xa0increase\\xa0the daily dose by increments of\\n200 mg every 3 days, up to 500 mg to 1 g 2 times daily if necessary (max. 2.5 g daily).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 387, 'page_label': '388', 'id': 'data/guideline-170-en.pdf:387:0'}, page_content='Page 388 / 409\\nThe initial follow-up schedule is guided by titration of the prescribed ASM.\\nOnce seizures are controlled for at least 1 month, follow-up can be spaced out to 3 months, then every 6 months if the\\npatient is stable.\\xa0Encourage maintaining a seizure diary if possible.\\xa0At each consultation:\\n\\xa0\\nReferences\\nAssess:\\nGrowth and development in children.\\nTreatment :\\nresponse (seizure frequency) and tolerance (adverse effects),\\nimpact on daily life (e.g. time off school or work).\\nAdherence to treatment.\\nCo-morbidities, including associated anxiety or depression.\\nAdjust the dose of the ASM if necessary. In\\xa0this case, review patient as needed but in any case within one month\\nfollowing any change in dose.\\nProvide treatment\\xa0until the next consultation or the facility’s dispensing schedule.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 387, 'page_label': '388', 'id': 'data/guideline-170-en.pdf:387:1'}, page_content='Answer questions, discuss problems, and try to ﬁnd solutions with the patient.\\nFootnotes\\n(a) The optimal dose of folic acid to prevent MCM is not established. After the ﬁrst trimester, the dose should be reduced (usethe ﬁxed-dose combination 60 mg of elemental iron/400 micrograms folic acid).\\n1. Fisher RS, Cross JH, French JA, et al. Operational classiﬁcation of seizure types by the International League Against Epilepsy:Position Paper of the ILAE Commission for Classiﬁcation and Terminology.\\xa0Epilepsia. 2017;58(4):522-530.\\xa0https://doi.org/10.1111/epi.13670'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 387, 'page_label': '388', 'id': 'data/guideline-170-en.pdf:387:2'}, page_content='2. World Health Organization. Pocket book of primary health care for children and adolescents: guidelines for healthpromotion, disease prevention and management from the newborn period to adolescence. Copenhagen: WHO RegionalOfﬁce for Europe; 2022.https://www.who.int/europe/publications/i/item/9789289057622\\n3. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE Ofﬁcial Report: A practical clinical deﬁnition of epilepsy. Epilepsia.2014;55(4):475-482.https://doi.org/10.1111/epi.12550\\n4. World Health Organization. mhGAP Intervention Guide for Mental, Neurological and Substance Use Disorders in Non-Specialized Health Settings: Mental Health Gap Action Programme (mhGAP). version 2.0. World Health Organization; 2016.\\xa0https://www.who.int/publications/i/item/9789241549790'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 387, 'page_label': '388', 'id': 'data/guideline-170-en.pdf:387:3'}, page_content='5. NICE. Epilepsies in children, young people and adults. Published online April 27, 2022.https://www.nice.org.uk/guidance/ng217\\n6. Piccenna L, O’Dwyer R, Leppik I, et al. Management of epilepsy in older adults: A critical review by the ILAE Task Force onEpilepsy in the elderly. Epilepsia. 2023;64(3):567-585.\\xa0https://doi.org/10.1111/epi.17426\\n7. American College of Obstetricians and Gynecologists. Gynecologic management of adolescents and young women withseizure disorders. ACOG Committee Opinion No. 806. Obstet Gynecol 2020;135:e213–20.https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2020/05/gynecologic-management-of-adolescents-and-young-women-with-seizure-disorders'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 387, 'page_label': '388', 'id': 'data/guideline-170-en.pdf:387:4'}, page_content='8. Meador KJ. Effects of Maternal Use of Antiseizure Medications on Child Development. Neurol Clin. 2022 Nov;40(4):755-768.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589915/'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 388, 'page_label': '389', 'id': 'data/guideline-170-en.pdf:388:0'}, page_content='Page 389 / 409\\n9. Royal College of Obstetricians and Gynaecologists (UK). Epilepsy in Pregnancy. Published online June 2016.https://www.rcog.org.uk/media/rzldnacf/gtg68_epilepsy.pdf\\n10.Pennell PB. Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts. Neurotherapeutics. 2016 Oct;13(4):811-820.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081129/'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 389, 'page_label': '390', 'id': 'data/guideline-170-en.pdf:389:0'}, page_content='Page 390 / 409\\nDiabetes type 2 in adults\\nLast update: November 2023\\n\\xa0\\nDiabetes is a metabolic disorder that leads to hyperglycaemia.\\nType 2 diabetes usually occurs in adults and accounts for 90 to 95% of diabetes cases worldwide.\\nType 2 diabetes can lead to acute complications, as well as chronic complications that result in serious organ damage\\n(cardiovascular\\xa0events; diabetic retinopathy, neuropathy, nephropathy).\\nClinical features\\nDiagnosis\\n [1] \\nFew or no symptoms; symptoms of hyperglycaemia may be present: polyuria (frequent urination) and polydypsia\\n(excessive thirst and drinking).\\nIn rare cases, patients may present with severe hyperglycaemia (impaired consciousness, coma or acute\\ndehydration).\\nLook for diabetes in the event of:\\nsymptoms of hyperglycaemia;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 389, 'page_label': '390', 'id': 'data/guideline-170-en.pdf:389:1'}, page_content='dehydration).\\nLook for diabetes in the event of:\\nsymptoms of hyperglycaemia;\\ncardiovascular disorders: stroke, myocardial infarction, hypertension;\\nperipheral neuropathies,\\xa0foot ulcers, absence of tendon reﬂexes or peripheral pulse.\\nDiagnosis is made on one of the following results : a [1] [2] \\nTests Symptomatic patient Asymptomatic patient\\nFasting blood glucose (a) 1 fasting blood glucose\\n≥ 7 mmol/litre\\xa0 (≥ 126 mg/dl)\\n2 fasting blood glucose\\n≥ 7 mmol/litre\\xa0(≥ 126 mg/dl)\\nRandom blood glucose (b) 1 random blood glucose\\n≥ 11 mmol/litre\\xa0(≥ 200 mg/dl)\\nSee tablenote\\xa0 (b)\\nPost-load blood glucose (c) 1 post-load blood glucose:\\xa0\\non venous blood\\n≥ 11 mmol/litre\\xa0(≥ 200 mg/dl)\\n2 post-load blood glucose:\\non venous blood\\xa0\\n≥ 11 mmol/litre (≥ 200 mg/dl)\\nor\\non capillary blood'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 389, 'page_label': '390', 'id': 'data/guideline-170-en.pdf:389:2'}, page_content='on venous blood\\xa0\\n≥ 11 mmol/litre (≥ 200 mg/dl)\\nor\\non capillary blood\\xa0\\n≥ 12.2 mmol/litre (≥ 220 mg/dl)\\nor\\non capillary blood\\xa0\\xa0\\n≥ 12.2 mmol/litre (≥ 220 mg/dl)\\nGlycated Hb (HbA1c) (d) 1 HbA1c\\xa0≥ 6.5% 2 HbA1c\\xa0≥ 6.5%\\n(a) Fasting blood glucose test: performed on patient that has fasted at least 8 hours. Values are the same for venous andcapillary blood.\\n(b) Random blood glucose test: performed at any moment of the day.\\xa0Values are for venous blood only.\\xa0For asymptomatic patients, it is not recommended to perform 2 random blood glucose tests. If the ﬁrst test is a randomblood glucose,\\xa0the second test should be a fasting blood glucose.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 389, 'page_label': '390', 'id': 'data/guideline-170-en.pdf:389:3'}, page_content='(c) Post-load blood glucose test: performed 2 hours after oral ingestion of 75 g glucose (one sachet of 75 g anhydrousglucose powder dissolved in 200 to 300 ml of water, to be drunk within 10 minutes).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 390, 'page_label': '391', 'id': 'data/guideline-170-en.pdf:390:0'}, page_content='Page 391 / 409\\nor\\nTreatment\\xa0\\nGlycaemic targets\\nFasting blood glucose ≤ 7 mmol/litre (≤ 126 mg/dl) or HbA1c of 7%.\\nThe closer blood glucose levels remain to these values, the more cardiovascular complications are prevented or\\ndelayed.\\nDepending on the context (healthcare provision) or patient proﬁle (older patient, history of severe hypoglycaemia or\\nlong-standing poorly controlled diabetes), HbA1c\\xa0≤\\xa08% \\xa0is acceptable.\\nBlood glucose should not fall < 4.5 mmol/litre (or < 80 mg/dl) or HbA1c < 6.5%.\\nLifestyle and dietary advice\\nPharmacological treatment\\nFirst-line treatment\\xa0metformin\\xa0PO .\\nThe usual dose is 1 to 2 g daily.\\xa0For information:\\nWeek 1: 500 mg once daily in the morning at breakfast\\nWeek 2: 500 mg 2 times daily (morning and evening) during meals'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 390, 'page_label': '391', 'id': 'data/guideline-170-en.pdf:390:1'}, page_content='Week 2: 500 mg 2 times daily (morning and evening) during meals\\nIncrease in increments of 500 mg per week as long as the drug is well tolerated (max. 2 g daily, i.e. 1 g morning and\\nevening).\\xa0If glycaemic control is not acheived, administer metformin in combination with a\\xa0sulfonylurea.\\xa0\\nSulfonylurea\\xa0doses are adjusted in increments to avoid the risk of hypoglycaemia, based on blood glucose results.\\nThe usual dose is 5 mg 2 times daily. For information:\\nWeek 1: 2.5 mg once daily in the morning at breakfast\\nWeek 2: 5 mg once daily in the morning at breakfast\\nIncrease in increments of 2.5 mg weekly until fasting blood glucose reaches target levels (max.15 mg daily).\\nThe usual dose is 40 to 80 mg 2 times daily. For information:\\nWeeks 1 and 2: 40 mg once daily in the morning at breakfast'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 390, 'page_label': '391', 'id': 'data/guideline-170-en.pdf:390:2'}, page_content='Weeks 1 and 2: 40 mg once daily in the morning at breakfast\\nIncrease in increments of 40 mg every 2 weeks (weeks 3 and 4: 80 mg once daily in the morning at breakfast) until\\nfasting blood glucose reaches target levels (max. 240 mg daily, i.e. 120 mg morning and evening).\\xa0\\n(d) Glycated haemoglobin (HbA1c): reﬂects average glycaemia over around 3 months.\\nPerform urine dipstick analysis for ketones if:\\nfasting blood glucose ≥ 15 mmol/litre (≥ 270 mg/dl) and symptoms of hyperglycemia,\\nfasting or random blood glucose ≥ 18 mmol/litre (≥ 325 mg/dl) even without symptoms.\\nRefer the patient if acute complications (such as hyperosmolar hyperglycaemia or ketoacidosis) are present.\\n [3] \\n [2] \\n b\\nAvoid sugared foods and drinks (but no excessive restriction of carbohydrates).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 390, 'page_label': '391', 'id': 'data/guideline-170-en.pdf:390:3'}, page_content='High ﬁbre intake; limit animal fats and alcohol.\\nPhysical activity.\\nWeight control. If BMI ≥ 25, try to reduce weight by 5 to 10%.\\nStop smoking.\\n c \\nIn patients under 60,\\xa0glibenclamide\\xa0PO:\\xa0\\nIn patients over 60,\\xa0gliclazide\\xa0PO (immediate release tablet):'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 391, 'page_label': '392', 'id': 'data/guideline-170-en.pdf:391:0'}, page_content='Page 392 / 409\\nIf glycaemic control is not acheived with the combination of metformin + a\\xa0sulfonylurea, continue metformin but\\nreplace the sulfonylurea\\xa0with\\xa0intermediate-acting\\xa0insulin\\xa0SC: start with 0.2 IU/kg at bedtime. The dose is adjusted\\nafter measuring fasting blood glucose in the morning. Once blood glucose levels have stabilized, test levels once\\nweekly then after each consultation. Doses of 1 IU/kg/day or more may be necessary to reach glycaemic\\xa0targets. If\\nthe necessary dose is over 0.5 IU/kg/day, administer in 2 injections daily.\\nAdjustment of intermediate-acting insulin dosage based on blood glucose levels\\n\\xa0Example for a man weighing 79 kg:\\nStart with 16 IU per day (79 kg x 0.2 IU).\\nOn D4, blood glucose is 14.6 mmol/litre. Add 4 IU (daily dose of insulin is 20 IU).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 391, 'page_label': '392', 'id': 'data/guideline-170-en.pdf:391:1'}, page_content='On D8, blood glucose is 10.4 mmol/litre. Add 2 IU (daily dose of insulin is 22 IU).\\xa0\\nOn D12, blood glucose is 6.1 mmol/litre. Glycaemic target\\xa0is reached.\\xa0\\nSurveillance and monitoring\\nLaboratory surveillance\\nMorning blood glucose\\xa0 Action\\n< 4 mmol/litre\\n(< 70 mg/dl)\\nTreat hypoglycaemia (see Hypoglycaemia, Chapter 1).\\nReduce daily dose of insulin by 2 to 4 units.\\nMaintain new dose for 4 days.\\nCheck blood glucose after 4 days, readjust dose if glycaemic target has not\\nbeen not reached.\\nCheck blood glucose again after 4 days and repeat the process until\\nglycaemic target is reached.\\n≥ 4 and < 7.2 mmol/litre\\n(≥ 70 and < 130\\xa0mg/dl)\\nDo not change dose.\\n≥ 7.2 and < 11 mmol/litre\\n(≥ 130\\xa0and < 200 mg/dl)\\nIncrease daily dose of insulin by 2 units.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 391, 'page_label': '392', 'id': 'data/guideline-170-en.pdf:391:2'}, page_content='(≥ 130\\xa0and < 200 mg/dl)\\nIncrease daily dose of insulin by 2 units.\\nCheck blood glucose after 4 days, readjust dose if glycaemic target has not\\nbeen not reached.\\nCheck blood glucose again after 4 days and repeat the process until\\nglycaemic target is reached.\\n≥ 11 mmol/litre\\n(≥ 200 mg/dl)\\nIncrease daily dose of insulin by 4 units.\\nCheck blood glucose after 4 days, readjust dose if glycaemic target has not\\nbeen not reached.\\nCheck blood glucose again after 4 days and repeat the process until\\nglycaemic target is reached.\\nPerform urine dipstick analysis for ketones according to the criteria deﬁned in\\nthe Diagnosis section.\\xa0\\nPatients on oral hypoglycemic agents: blood glucose test once a month to begin with, then during monitoring visits.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 391, 'page_label': '392', 'id': 'data/guideline-170-en.pdf:391:3'}, page_content='Patients on insulin: fasting blood glucose test during the dose adjustment phase then, if possible, once weekly, once\\nthe insulin dose stabilised.\\xa0\\nHbA1c if available: every 3 months, then every 6 months if well stabilised.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 392, 'page_label': '393', 'id': 'data/guideline-170-en.pdf:392:0'}, page_content=\"Page 393 / 409\\nClinical monitoring\\nPatient education\\n\\xa0\\nReferences\\nOther necessary tests according to comorbidities and chronic complications.\\nRoutine consultations: check blood pressure (should remain < 140/80 mmHg) and weight, examine feet.\\nConsultations once a month for the ﬁrst 6 months, then individualised frequency of consultations depending on the\\npatient's characteristics (e.g.\\xa0every 6 months if\\xa0the diabetes is well controlled).\\nAnnual check-up: check for cardiovascular and neurological complications, evaluate renal function (serum creatinine\\nand proteinuria dipstick test), examination of teeth and gums.\\nManagement of diabetes complications.\\n b\\nLifestyle and dietary measures (diet, physical activity, etc.).\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 392, 'page_label': '393', 'id': 'data/guideline-170-en.pdf:392:1'}, page_content='b\\nLifestyle and dietary measures (diet, physical activity, etc.).\\nPatients on sulfonylurea\\xa0or insulin therapy: signs of hypoglycaemia/hyperglycaemia and\\xa0management.\\nPatients on insulin therapy: auto-administration (schedule, injection sites and techniques); storage of insulin.\\nPatients on insulin therapy\\xa0or\\xa0presenting hypoglycaemic episodes : self-monitoring of blood glucose and\\nadjustment of doses at home using a glucometer.\\n [3] \\nPatients with sensory\\xa0neuropathy or peripheral arterial disease:\\xa0autoexamination of feet; prevention of foot lesions.\\nFootnotes\\n(a) Even in symptomatic patients, it is preferable to perform a second blood glucose test to conﬁrm the result.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 392, 'page_label': '393', 'id': 'data/guideline-170-en.pdf:392:2'}, page_content='(b) These measures concern all patients regardless of medication prescribed. They can be sufﬁcient alone to normalize bloodglucose levels in certain patients.\\n(c) If metformin is contraindicated or not tolerated, replace with a\\xa0sulfonylurea.\\n1. World Health Organization. Classiﬁcation of Diabetes Mellitus. World Health Organization; 2019 [Accessed October 19, 2023].https://iris.who.int/handle/10665/325182\\n2. HEARTS D: diagnosis and management of type 2 diabetes [Accessed October 19, 2023].https://www.who.int/publications-detail-redirect/who-ucn-ncd-20.1\\n3. Type 2 diabetes in adults: management | Guidance | NICE. Published December 2, 2015 [Accessed October 19, 2023].https://www.nice.org.uk/guidance/ng28'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 393, 'page_label': '394', 'id': 'data/guideline-170-en.pdf:393:0'}, page_content='Page 394 / 409\\nEssential hypertension in adults\\nHypertension (or high blood pressure - HBP) is deﬁned as elevated blood pressure (BP) at rest that persists over time\\ni.e. measured 3 times during 3 separate consultations over a period of three months.\\nEssential hypertension is deﬁned as HBP of undetermined cause (the large majority of cases).\\xa0The global overall prevalence of HBP in adults aged 25 and over is around 40%.\\xa0Serious complications of HBP can be acute (hypertensive encephalopathy, left-sided heart failure, acute renal failure)\\nor delayed i.e. occur after a long period during which HBP has not been controlled (stroke, ischaemic heart disease,\\nperipheral arterial disease, chronic renal impairment).\\xa0For pregnancy-induced hypertension, see\\xa0Essential obstetric and newborn care, MSF.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 393, 'page_label': '394', 'id': 'data/guideline-170-en.pdf:393:1'}, page_content='Clinical features\\n\\xa0\\n\\xa0\\nSBP\\xa0≥ 180 and/or DBP ≥\\xa0110 and some symptoms (moderate headaches, epistaxis, dizziness, tinnitus,\\xa0eye\\nﬂoaters) but no signs of end-organ damage;\\nSBP ≥\\xa0180 and/or DBP ≥\\xa0110 and signs of\\xa0end-organ damage:\\nParaclinical investigations\\n [1]\\nHBP thresholds:\\nHBP classiﬁcation\\nBlood pressure (BP) in mmHg\\nSystolic (SBP) Diastolic (DBP)\\nMild 140 or over 90 or over\\nModerate 160 or over 100 or over\\nSevere 180 or over 110 or over\\nSevere\\xa0HBP is deﬁned more by the presence of serious end-organ damage\\xa0than the blood pressure reading:\\nUncomplicated hypertensive crisis:\\nHypertensive emergency:\\nintense headaches, nausea/vomitting, confusion, seizures, coma in the event of hypertensive\\nencephalopathy;\\ndyspnoea, chest pain in the event of heart failure or cardiac ischaemia;'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 393, 'page_label': '394', 'id': 'data/guideline-170-en.pdf:393:2'}, page_content='dyspnoea, chest pain in the event of heart failure or cardiac ischaemia;\\nrapid and/or irregular heart rate in the event of heart failure;\\nanuria, oliguria in the event of renal\\xa0impairment.\\nHistory and clinical examination should look for:\\xa0\\nmedications being taken that can cause or aggravate HBP; a\\nfocal neurological\\xa0sign(s) suggestive of stroke;\\ncomorbidities and risk factors: heart failure, diabetes, renal impairment; excessive smoking or consumption of\\nalcohol, excess weight (BMI ≥ 25), etc.\\nBlood test: ionogram (particularly serum potassium levels), serum creatinine.\\xa0\\nOther necessary laboratory tests according to comorbidities (e.g. diabetes).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 394, 'page_label': '395', 'id': 'data/guideline-170-en.pdf:394:0'}, page_content='Page 395 / 409\\nLong-term treatment\\nLifestyle and dietary advice\\nRecommended for all hypertensive patients:\\nPharmacological treatment\\xa0\\nStart with a monotherapy. One of\\xa0four classes\\xa0of antihypertensive drugs can be chosen as ﬁrst line treatment,\\naccording to the patient’s characteristics (e.g. age, contra-indications, etc.). For information:\\xa0\\xa0\\nECG and\\xa0echocardiogram\\xa0to look for signs of\\xa0heart failure,\\xa0coronary disease, or arrhythmia.\\nThe goal of treatment is to lower BP. Target BP are:\\nSBP < 140 and/or DBP < 90\\nSBP < 140 and/or DBP < 80 in diabetic patients\\nSBP < 150 and/or DBP < 90 in patients aged > 80 years\\nIn patients with mild HBP (SBP ≥ 140 and/or DBP ≥ 90) without associated cardiovascular disorders or stroke or\\ndiabetes, start with lifestyle and dietary advice.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 394, 'page_label': '395', 'id': 'data/guideline-170-en.pdf:394:1'}, page_content='diabetes, start with lifestyle and dietary advice.\\xa0\\nPharmacological treatment is indicated in the following cases:\\nSBP ≥ 160 and/or DBP ≥ 100;\\nHBP associated with cardiovascular disorder, stroke or diabetes;\\nHBP not controlled by lifestyle and dietary changes alone.\\nReduce calorie and salt intake.\\nRegular physical activity.\\nWeight loss if BMI ≥ 25.\\nStop smoking and alcohol consumption.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 395, 'page_label': '396', 'id': 'data/guideline-170-en.pdf:395:0'}, page_content='Page 396 / 409\\n\\xa0In patients with no comorbidity start with a thiazide diuretic and check BP after 4 weeks of treatment.\\xa0\\nIf the treatment has been correctly taken but there is no improvement after 4 weeks, add a second antihypertensive\\ndrug.\\nAfter 4 weeks of\\xa0bitherapy,\\xa0reevaluate. If the patient’s BP remains too high, consider\\xa0triple-therapy.\\xa0In diabetic patients, if there is no improvement after 4 weeks of AEC inhibitor treatment taken correctly, add a calcium\\nchannel blocker.\\xa0In patients with a cardiac disorder (heart failure or coronary heart disease), bitherapy is usually necessary from the start\\n(AEC inhibitor + beta-blocker).\\nSurveillance and monitoring\\nLaboratory surveillance\\nAccording to treatment (diuretic, AEC inhibitor, etc.): ionogram\\xa0and serum creatinine every 6 to 12 months.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 395, 'page_label': '396', 'id': 'data/guideline-170-en.pdf:395:1'}, page_content='Clinical monitoring\\nPatient education\\nPatient with no comorbidities Patient with comorbidities\\nThiazide diuretic After a stroke: thiazide diuretic\\nPatient > 65 years: thiazide diuretic or calcium\\nchannel blocker\\xa0\\nDiabetic patient:\\nangiotensin converting enzyme (ACE) inhibitor\\nor beta blocker if concomitant cardiovascular disorder\\nPatient with black skin: thiazide diuretic or calcium\\nchannel blocker (avoid ACE inhibitors)\\nRenal impairment: ACE inhibitor\\nThiazide diuretic:\\nhydrochlorothiazide PO: 12.5 to 25 mg once daily in the morning (max. 25 mg daily)\\n\\xa0\\nAngiotensin converting enzyme inhibitor:\\nenalapril PO: start with 5 mg once daily. Gradually increase, every 1 to 2 weeks, according to BP, up to 10 to 20 mg\\nonce daily (max. 40 mg daily).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 395, 'page_label': '396', 'id': 'data/guideline-170-en.pdf:395:2'}, page_content=\"once daily (max. 40 mg daily).\\nIn elderly patients or patients taking a diuretic or patients with renal impairment: start with 2.5 mg once daily.\\n\\xa0\\nCalcium channel blocker:\\namlodipine PO: 5 mg once daily. Increase to 10 mg once daily if necessary (max. 10 mg daily).\\xa0\\nIn elderly patients or patients with hepatic impairment: start with 2.5 mg once daily.\\n\\xa0\\nBeta-blocker:\\xa0\\xa0(contra-indicated in patients with asthma)\\nbisoprolol PO: 5 to 10 mg once daily in the morning\\nDo not stop treatment abruptly (risk of malaise, angina).\\nConsultations every 3 months (BP, weight), then every 6 months, then individualised frequency of consultations\\ndepending on the patient's characteristics.\\nManagement of comorbidities (e.g. diabetes).\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 396, 'page_label': '397', 'id': 'data/guideline-170-en.pdf:396:0'}, page_content='Page 397 / 409\\nTreatment of\\xa0hypertensive crisis\\nUncomplicated\\xa0hypertensive crisis\\xa0\\nMost frequent. Reassure the patient\\xa0and prescribe rest.\\xa0Check BP a few days later to start or adapt treatment.\\nHypertensive emergency\\nTreat in an intensive care unit.\\nThe aim is to reduce BP by 10 to 15% within the ﬁrst hour and to not reduce it more than 25% during the ﬁrst 24\\nhours.\\xa0\\nlabetalol\\xa0IV (contra-indicated in patients with asthma :\\n20 mg over at least 1 minute. Administer another dose after 10 minutes if BP has not decreased. If necessary, 40\\nmg doses are administered every 10 minutes until hypertension is controlled (max. 300 mg total dose).\\n\\xa0\\nReferences\\nLifestyle and dietary advice.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 396, 'page_label': '397', 'id': 'data/guideline-170-en.pdf:396:1'}, page_content='References\\nLifestyle and dietary advice.\\nTreatment observance: do not stop treatment abruptly, particularly if taking beta blockers (risk of malaise, angina).\\nConsultation in the event of epistaxis, tinnitus, eye ﬂoaters; adverse effects of treatment (e.g. cough with AEC\\ninhibitors, erectile dysfunction with beta blockers, oedema with calcium channel blockers).\\nHypertensive encephalopathy:\\xa0\\n b \\nStroke: do not try to decrease BP during the ﬁrst 3 days unless SBP is ≥ 220 and/or DBP ≥ 120 (in this event\\nadminister labetalol).\\xa0\\nAcute pulmonary oedema: see\\xa0Acute heart failure.\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 396, 'page_label': '397', 'id': 'data/guideline-170-en.pdf:396:2'}, page_content='Acute pulmonary oedema: see\\xa0Acute heart failure.\\nFootnotes\\n(a) Consider secondary hypertension caused by medications being taken, mainly NSAID, corticosteroids, opioids, oralestroprogestogens, etc. Treatment, in this event, consists in stopping or replacing the causative drug.\\n(b) In patient with asthma, hydralazine IV: 5 to 10 mg diluted in 10 ml of 0,9% sodium chloride administered by slow IV, to berepeated after 20 to 30 minutes if necessary.\\n1. World Health Organization. Media center. High blood pressure: a public health problem, 2018.http://www.emro.who.int/media/world-health-day/public-health-problem-factsheet-2013.html [Accessed 12 September2018]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 397, 'page_label': '398', 'id': 'data/guideline-170-en.pdf:397:0'}, page_content='Page 398 / 409\\nHeart failure in adults\\n\\xa0\\n\\xa0\\nHeart failure (HF) is deﬁned as the inability of the heart to maintain adequate\\xa0cardiac\\xa0output.\\xa0\\nIt is a serious condition, particularly frequent in people over 70 years.\\xa0\\nThere are two types:\\n\\xa0\\n\\xa0\\n\\xa0\\nchronic HF: gradual onset of signs of HF;\\nacute HF: sudden onset of\\xa0life-threatening\\xa0HF (cardiogenic acute pulmonary oedema or shock), in most cases in\\npatients with known\\xa0cardiopathy.\\nChronic heart failure\\nAcute heart failure (acute pulmonary oedema)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 398, 'page_label': '399', 'id': 'data/guideline-170-en.pdf:398:0'}, page_content='Page 399 / 409\\nChronic heart failure\\nClinical features\\nFatigue\\xa0 and/or progressive onset of dyspnoea, occurs on exertion and then at rest, accentuated by the decubitus\\nposition, preventing the patient from lying down; peripheral oedema.\\nOedema of the lower limbs, hepatomegaly, jugular vein distention, hepatojugular reﬂux; ascites in advanced stages.\\nLeft and right-sided signs; right-sided signs are often the most prominent.\\xa0\\nEvaluate severity of HF :\\xa0\\nIdentify causative or aggravating factors:\\nParaclinical\\xa0investigations\\nTreatment\\nLifestyle and dietary advice\\nLeft-sided HF (left ventricle failure; most frequent form)\\nRight-sided HF (right ventricle failure)\\nGlobal HF (failure of both ventricles)\\n [1]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 398, 'page_label': '399', 'id': 'data/guideline-170-en.pdf:398:1'}, page_content='Global HF (failure of both ventricles)\\n [1] \\nClass I No limitation of physical activity. No symptoms during ordinary physical activity.\\nClass II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue,\\npalpitation, dyspnoea.\\nClass III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue,\\npalpitation, or dyspnoea.\\nClass IV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.\\nCoronary or valvular heart disease, hypertension, viral or toxic cardiopathy, pericarditis.\\nAnaemia, American trypanosomiasis, rheumatic fever, diabetes, thyroid disorder, drug/alcohol addiction.\\nCardiac ultrasound: if available, method of choice to conﬁrm cardiopathy.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 398, 'page_label': '399', 'id': 'data/guideline-170-en.pdf:398:2'}, page_content='Cardiac ultrasound: if available, method of choice to conﬁrm cardiopathy.\\nElectrocardiogram (ECG): can diagnose left ventricular cardiomyopathy (left ventricular hypertrophy and/or left\\nbundle branch block) or arrhythmia and particularly atrial ﬁbrillation (AF or Aﬁb) or signs of myocardial ischemia or\\ninfarction.\\nChest x-ray: can exclude lung disease in patients with dyspnoea or can show cardiomegaly or pleural effusion (often\\nbilateral) and alveolar-interstitial syndrome.\\nBlood test: full blood count, ionogram, serum creatinine.\\nOther necessary laboratory tests according to comorbidities (e.g. diabetes, thyroid disorder).\\nReduce salt intake to limit ﬂuid retention.\\nNormal ﬂuid intake except in cases of very severe oedema.\\nStop smoking.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 398, 'page_label': '399', 'id': 'data/guideline-170-en.pdf:398:3'}, page_content='Normal ﬂuid intake except in cases of very severe oedema.\\nStop smoking.\\nPhysical activity adapted to the patient’s capacity.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 399, 'page_label': '400', 'id': 'data/guideline-170-en.pdf:399:0'}, page_content='Page 400 / 409\\nTreatment of ﬂuid retention\\nfurosemide\\xa0PO: start with 20 mg once daily; increase if necessary, according to clinical response (certain patients\\nneed doses of 80 mg 1 to 2 times daily) then reduce once oedema\\xa0decrease\\xa0(20 to 40 mg once daily).\\xa0The reabsorption of oedema can sometimes be slow, taking up to 2 to 3 weeks.\\nThe gradual worsening of HF may require\\xa0an increase in dosage. Lifelong\\xa0treatment with diuretics is not always\\nnecessary.\\xa0\\xa0In\\xa0the event of resistant oedema, add\\xa0hydrochlorothiazide\\xa0PO (25 mg 1 to 2 times daily for a few days) but only in\\nhospital settings and monitoring renal function.\\nLong-term (lifelong) treatment\\nOther treatments\\nWeight loss if BMI ≥ 25.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 399, 'page_label': '400', 'id': 'data/guideline-170-en.pdf:399:1'}, page_content='Long-term (lifelong) treatment\\nOther treatments\\nWeight loss if BMI ≥ 25.\\nACE inhibitors are the ﬁrst line treatment. Start with low doses, especially in patients with\\xa0hypotension, renal\\nimpairment, hyponatraemia.\\xa0\\nWhile increasing the dose monitor: drug tolerance (dry cough), blood pressure (the systolic BP should remain above\\n> 90 mmHg), serum potassium and creatinine levels.\\nIn patients taking diuretics, reduce the dose of the diuretic if possible while introducing ACE inhibitors (risk of\\nhypotension if the patient is on high doses of diuretics).\\nenalapril\\xa0PO:\\nWeek 1: 2.5 mg once daily for 3 days then 5 mg once daily\\xa0\\nWeek 2: 10 mg once daily for 3 days then 20 mg once daily\\nThe effective dose is usually 20 mg once daily (or 10 mg 2 times daily). Doses of 10 mg daily are sometimes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 399, 'page_label': '400', 'id': 'data/guideline-170-en.pdf:399:2'}, page_content='enough; conversely, doses of 40 mg daily (maximum) are sometimes necessary.\\nOnce the patient has been stable for at least 2 weeks taking ACE inhibitors and in the absence of any contra-\\nindications (asthma, hypotension, bradycardia, conduction disorders, particularly atrio-ventricular heart blocks), add\\na beta blocker.\\nbisoprolol\\xa0PO: start with a low dose and gradually increase as long as the drug is well tolerated (monitor for signs\\nof worsening HF, blood pressure, heart rate).\\nWeek 1: 1.25 mg once daily\\xa0\\nWeek 2: 2.5 mg once daily\\nWeek 3: 3.75 mg once daily\\nWeeks 4 to 8: 5 mg once daily\\nIf insufﬁcient:\\nWeeks 9 to 12: 7.5 mg once daily\\nAs from week 13: 10 mg once daily (max. 10 mg daily)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 399, 'page_label': '400', 'id': 'data/guideline-170-en.pdf:399:3'}, page_content='As from week 13: 10 mg once daily (max. 10 mg daily)\\nIn the event of temporarily worsening HF, hypotension or bradycardia, readjust doses of associated treatments and\\nreduce the dose of bisoprolol or gradually stop treatment (stopping abruptly can lead to acute deterioration of the\\npatient’s condition). Once the patient is stabilized, re-increase/recommence bisoprolol.\\nAntagonist of aldosterone: only if serum potassium levels and ECG can be monitored (risk of severe hyperkalaemia),\\nadd\\xa0spironolactone\\xa0PO (25 mg once daily) to long-term treatment, particularly in cases of severe HF (Classes III\\nand IV).\\nNitrates: can be used in left-sided or global HF in patients with intolerance to ACE inhibitors (cough is not tolerated,\\nrenal impairment, severe hypotension).'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 399, 'page_label': '400', 'id': 'data/guideline-170-en.pdf:399:4'}, page_content='renal impairment, severe hypotension).\\nisosorbide dinitrate\\xa0PO: start with 5 to 40 mg 2 to 3 times daily and increase up to the effective dose, usually 15\\nto 120 mg daily.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 400, 'page_label': '401', 'id': 'data/guideline-170-en.pdf:400:0'}, page_content=\"Page 401 / 409\\nTreatment of causative or aggravating factors\\nAccording to the cause.\\nSurveillance and monitoring\\nLaboratory surveillance\\xa0\\nAccording to treatment (ACE, diuretic, etc.).\\nClinical monitoring\\nPatient education\\n\\xa0\\nReferences\\nDigitalis glycosides: administer with caution, in intensive care unit (the therapeutic dose is close to the toxic dose),\\nonly in patients with AF with rapid ventricular response conﬁrmed by ECG: no visible P waves, irregularly irregular\\nQRS complex (120-160).\\nOnce stabilised,\\xa0consultations once a month for the ﬁrst 6 months, then individualised frequency of consultations\\ndepending on the patient's characteristics.\\nRoutine consultations:\\xa0weight curve, BP, progress of signs\\xa0(dyspnoea, oedema, etc.).\\nMonitoring of comorbidities and causative or aggravating.\"), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 400, 'page_label': '401', 'id': 'data/guideline-170-en.pdf:400:1'}, page_content='Monitoring of comorbidities and causative or aggravating.\\nLifestyle and dietary measures (diet, weight control, physical activity adapted to the patient’s capacity, etc.).\\nWarning signs (shortness of breath\\xa0or oedema of the lower limbs, serious adverse effects of treatment) and\\nmanagement (timely/urgent medical consultation).\\n1. Chop WM, Jr. Extending the New York Heart Association classiﬁcation system. JAMA. 1985;254:505.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 401, 'page_label': '402', 'id': 'data/guideline-170-en.pdf:401:0'}, page_content='Page 402 / 409\\nAcute heart failure (acute pulmonary oedema)\\nLast updated: April 2021\\n\\xa0\\nClinical features\\n\\xa0Signs of severity:\\nParaclinical\\xa0investigations\\nDiagnosis is mainly clinical.\\n\\xa0If available:\\nTreatment\\nSystolic blood pressure\\xa0is\\xa0< 90 mmHg\\nSee\\xa0Shock, Chapter 1.\\nSystolic blood pressure\\xa0is\\xa0≥ 90 mmHg\\nSudden onset or exacerbation of dyspnoea\\nFatigue, increased time to recover after exercise\\nBilateral peripheral oedema\\nCold extremities\\nElevated jugular venous pressure\\nOn auscultation: bilateral pulmonary crepitations and/or extra heart sound (gallop rhythm)\\nSevere respiratory distress (intercostal\\xa0retractions,\\xa0nasal ﬂaring,\\xa0see-saw breathing,\\xa0SpO\\xa0< 90%,\\netc.),\\xa0cyanosis,\\xa0profuse sweating,\\xa0confusion\\n2\\nSystolic blood pressure\\xa0< 90 mmHg\\xa0(cardiogenic shock)'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 401, 'page_label': '402', 'id': 'data/guideline-170-en.pdf:401:1'}, page_content='2\\nSystolic blood pressure\\xa0< 90 mmHg\\xa0(cardiogenic shock)\\xa0\\nRapid and excessive increase in arterial blood pressure (hypertensive emergency)\\nHeart rate (HR) > 130/minute or < 40/minute\\nRespiratory rate\\xa0(RR) > 30/minute or < 12/minute\\xa0\\nChest pain if underlying cardiac ischemia\\nECG:\\xa0look for signs of myocardial ischemia or\\xa0arrhythmia.\\nChest x-ray: signs vary depending on the\\xa0severity\\xa0of pulmonary oedema. In early stage, dilation of vessels in upper\\nlobes then perihilar haze\\xa0and thickening of septa.\\xa0In advanced stage, prominent opacities in hilar and perihilar regions\\nand pleural effusion. Can exclude\\xa0other lung disease, such as pulmonary infection.\\nPOCUS : a \\nPerform 12-zone lung exam to evaluate for signs of bilateral pulmonary oedema and/or pleural effusions.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 401, 'page_label': '402', 'id': 'data/guideline-170-en.pdf:401:2'}, page_content='Perform 5-view cardiac exam to evaluate for signs of acute volume overload and/or decreased cardiac\\nfunction.\\nMonitoring: full blood count, electrolytes, serum creatinine; cardiac troponins if available.\\n [1] [2]\\nThe patient must be hospitalised.\\nPlace patient in semi-seated position, legs down.\\nIn patients with SpO < 90%, administer oxygen with a mask at the necessary ﬂow rate to maintain SpO ≥ 95%. If\\npulse oximetry is not available, administer oxygen at a ﬂow rate of\\xa06 to 10 litres/minute to patients with signs of\\n2 2'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 402, 'page_label': '403', 'id': 'data/guideline-170-en.pdf:402:0'}, page_content='Page 403 / 409\\nisosorbide dinitrate sublingual (5 mg tablet)\\n\\xa05 mg per dose; if necessary up to 2 doses taken 10 minutes apart\\nor\\nisosorbide dinitrate IV (10 ml ampoule, 1 mg/ml)\\n\\xa02 mg (= 2 ml) by slow IV injection (over 2 minutes) then if necessary 2 to 10 mg/hour by continuous\\xa0 \\xa0 \\xa0 infusion with\\nan electric syringe pump\\nor\\xa0\\nglyceryl trinitrate\\xa0sublingual (0.5 mg tablet)\\n0.5 mg per dose; if necessary up to 3 doses taken 5 minutes apart\\n\\xa0Subsequent treatment depends on the underlying pathology (chronic heart failure,\\xa0hypertension,\\xa0acute coronary\\nsyndrome, etc.).\\nReferences\\nhypoxia.\\nInsert an IV line.\\nIf there are signs of volume overload (and/or in case of hypertensive emergency): furosemide IV, 40 to 80 mg, may'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 402, 'page_label': '403', 'id': 'data/guideline-170-en.pdf:402:1'}, page_content='be repeated if necessary according to urine output, signs of respiratory distress and SpO. If the patient was\\nalready taking furosemide at doses of > 40 mg, administer pre-existing dose by IV route.\\n2\\nAdd a short-acting nitrate (vasodilator) if systolic blood pressure is > 100 mmHg. The aim is to gradually lower\\nsystolic blood pressure to near-baseline value. If the patient’s baseline value is unknown, for information, lower\\nsystolic blood pressure to 120-150 mmHg and the diastolic pressure to under 110 mmHg.\\nNon-invasive ventilation using continuous positive airway pressure (CPAP) is recommended in patients with\\npersistent hypoxaemia, unless contraindicated (e.g. impaired consciousness) and on condition that appropriate\\nmonitoring is available.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 402, 'page_label': '403', 'id': 'data/guideline-170-en.pdf:402:2'}, page_content='monitoring is available.\\nMonitoring: HR, RR, BP, SpO, mental status, urine output.2\\nFootnotes\\n(a) POCUS should only be performed and interpreted by trained clinicians.\\n1. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Forcefor the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developedwith the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.https://academic.oup.com/eurheartj/article/37/27/2129/1748921 [Accessed 23 March 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 402, 'page_label': '403', 'id': 'data/guideline-170-en.pdf:402:3'}, page_content='2. Ezekowitz, Justin A. et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for theManagement of Heart Failure. Can J Cardiol 2017;33:1342-1433.https://www.onlinecjc.ca/action/showPdf?pii=S0828-282X%2817%2930973-X [Accessed 23 March 2021]'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 403, 'page_label': '404', 'id': 'data/guideline-170-en.pdf:403:0'}, page_content='Page 404 / 409\\nEndemic goitre and iodine deﬁciency\\nGoitre is an enlargement of the thyroid gland. Endemic goitre occurs in iodine-deﬁcient areas. Goitre can also be\\ncaused or aggravated by the regular consumption of goitrogens such as manioc, cabbage, turnips, millet etc.\\xa0Goitre is an adaptive process: iodine is essential for the production of thyroid hormones; iodine deﬁciency impairs\\nthyroid hormone synthesis; to compensate, the thyroid gland increases in volume. Thyroid function usually remains\\nnormal.\\xa0As well as the development of goitre, iodine deﬁciency in pregnant women has serious consequences for the child\\n(foetal and perinatal mortality, physical and mental retardation, cretinism). These risks must be prevented by providing\\niodine supplementation in iodinedeﬁcient areas.'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 403, 'page_label': '404', 'id': 'data/guideline-170-en.pdf:403:1'}, page_content='iodine supplementation in iodinedeﬁcient areas.\\nClinical features\\nPrevention and treatment\\nThe objective of prevention is to reduce the consequences of iodine deﬁciency in neonates and children. Supplying\\niodised salt through national programmes is the recommended method of prevention.\\xa0For prevention in populations living in iodine deﬁcient areas where iodised salt is not available and for curative\\ntreatment of patients with goitre: use\\xa0iodised oil, according to national protocols. For information (according to the\\nWHO):\\xa0\\n\\xa0Curative and preventive single-doses are the same. Oral treatment is preferred. The target populations are pregnant'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 403, 'page_label': '404', 'id': 'data/guideline-170-en.pdf:403:2'}, page_content='and breastfeeding women, women of childbearing age and children.\\xa0In children, goitre disappears after several months. It disappears more slowly (or never) in adults despite restoration of\\nnormal thyroid function in 2 weeks. Surgery is only indicated for patients with local mechanical dysfunction.\\nThe WHO proposes a simpliﬁed classiﬁcation based on the signiﬁcance of goitre:\\nGroup 0: normal thyroid, no palpable or visible goitre\\nGroup 1: enlarged thyroid, palpable but not visible when the neck is in the normal position\\nGroup 2: thyroid clearly visible when the neck is in the normal position\\nPossible mechanical complications (rare): compression, deviation of the trachea or of the oesophagus.\\nPopulation\\nIodised oil PO\\nonce yearly \\n(190 mg capsule)\\nChildren under 1 year 1 capsule'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 403, 'page_label': '404', 'id': 'data/guideline-170-en.pdf:403:3'}, page_content='Iodised oil PO\\nonce yearly \\n(190 mg capsule)\\nChildren under 1 year 1 capsule\\nChildren from 1 to < 6 years 2 capsules\\nChildren from 6 to 15 years 3 capsules\\nPregnant or lactating women\\nor women of childbearing age 2 capsules'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 404, 'page_label': '405', 'id': 'data/guideline-170-en.pdf:404:0'}, page_content='Page 405 / 409\\nAppendices\\nAppendix 1. Normal daily maintenance IV ﬂuids in children > 1 month'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 405, 'page_label': '406', 'id': 'data/guideline-170-en.pdf:405:0'}, page_content='Page 406 / 409\\nAppendix 1. Normal daily maintenance IV ﬂuidsin children > 1 month\\nLast updated: January 2021\\n\\xa0\\nIndications\\nBasic hydration needs for patients unable to drink sufﬁciently. After 48 hours, it is essential to provide nutrition to the\\npatient orally or by nasogastric tube and to gradually reduce IV ﬂuids.\\xa0 This protocol should not be used for surgical or burns patients, those with renal, cardiac disease or diabetic\\nketoacidosis.\\nFluid to be administered\\nThe ﬂuid of choice in children is Ringer lactate-Glucose 5% (RL-G5%). Use a premixed solution if available. If not,\\nadd 50 ml of G50% to 500 ml of RL or 100 ml of G50% to 1000 ml of RL. If RL is not available, use 0.9% sodium'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 405, 'page_label': '406', 'id': 'data/guideline-170-en.pdf:405:1'}, page_content='chloride instead.\\xa0For ease of prescription and administration, the daily volumes and rates in drops per minute have been rounded off.\\xa0\\n a \\xa0\\n\\xa0\\n\\xa0\\nWeight Volume\\n/24 hours\\nRate\\n(paediatric infusion set 1 ml = 60 drops)\\n (*) \\n3 to < 4 kg 350 ml/24 h 15 drops/min\\n4 to < 5 kg 450 ml/24 h 19 drops/min\\n5 to < 6 kg 550 ml/24 h 23 drops/min\\n6 to < 7 kg 650 ml/24 h 27 drops/min\\n7 to < 8 kg 750 ml/24 h 31 drops/min\\n8 to < 9 kg 850 ml/24 h 35 drops/min\\n9 to < 11 kg 950 ml/24 h 40 drops/min\\n11 to < 14 kg 1100 ml/24 h 46 drops/min\\n14 to < 16 kg 1200 ml/24 h 50 drops/min\\n16 to < 18 kg 1300 ml/24 h 54 drops/min\\n18 to < 20 kg 1400 ml/24 h 58 drops/min'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 406, 'page_label': '407', 'id': 'data/guideline-170-en.pdf:406:0'}, page_content='Page 407 / 409\\n\\xa0\\nWeight Volume \\n/24 hours\\nRate\\n(paediatric infusion set\\n1 ml = 60 drops)\\n (*) Rate \\n(standard infusion set \\n1 ml = 20 drops)\\n20 to < 22 kg 1500 ml/24 h 63 drops/min 21 drops/min\\n22 to < 26 kg 1600 ml/24 h 67 drops/min 22 drops/min\\n26 to < 30 kg 1700 ml/24 h 71 drops/min 24 drops/min\\n30 to < 35 kg 1800 ml/24 h 75 drops/min 25 drops/min\\n≥ 35 kg 2000 ml/24 h 83 drops/min 28 drops/min\\n(*) In a paediatric infusion set, the number of drops per minute is equal to the number of ml per hour.For example: 15 drops/min = 15 ml/hour\\nFootnotes'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 406, 'page_label': '407', 'id': 'data/guideline-170-en.pdf:406:1'}, page_content='Footnotes\\n(a) Daily needs are calculated according the following formula:Children 0-10 kg: 100 ml/kg per dayChildren 11-20 kg: 1000 ml + (50 ml/kg for every kg over 10 kg) per dayChildren > 20 kg: 1500 ml + (20-25 ml/kg for every kg over 20 kg) per dayAdults: 2 litres per day'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 407, 'page_label': '408', 'id': 'data/guideline-170-en.pdf:407:0'}, page_content='Page 408 / 409\\nMain references\\n\\xa0\\nWebsites consulted between June 2019 and December 2022\\nBritish National Formulary\\xa0(BNF) and\\xa0British National Formulary for Children\\xa0(BNFc)\\nMedicinesComplete\\xa0Martindale.\\xa0The Complete Drug Reference\\nMedicinesComplete\\xa0UpToDate. Evidence-based clinical decision support resource\\xa0BMJ Group. BMJ Best Practice.\\xa0La revue\\xa0Prescrire\\xa0Centre belge d’information pharmacothérapeutique (CBIP)\\nhttp://www.cbip.be/fr/start\\xa0Centers for Disease Control and Prevention\\nhttp://www.cdc.gov/DiseasesConditions/\\xa0Cochrane Library\\xa0World Health Organization\\nhttp://www.who.int/publications/en/'), Document(metadata={'producer': 'Skia/PDF m91', 'creator': 'Chromium', 'creationdate': '2025-01-30T11:41:24+00:00', 'moddate': '2025-01-30T11:41:24+00:00', 'source': 'data/guideline-170-en.pdf', 'total_pages': 409, 'page': 408, 'page_label': '409', 'id': 'data/guideline-170-en.pdf:408:0'}, page_content='Page 409 / 409')]\n"
     ]
    }
   ],
   "source": [
    "print(chunked_docs)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "rag_env",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.19"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
